{"LEVEL_4":[{"id":2083,"uuid":"1fd2d2b7-b69a-4e58-b205-81ef99c8c2e9","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"L597","name":"L597","refResidues":"L","proteinStart":597,"proteinEnd":597,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C113330","drugName":"PLX8394","uuid":"44faeeae-ad6d-4370-8c99-97955f9e0feb","synonyms":["BRAF Inhibitor PLX8394"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1571713943000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"LEVEL_4","liquidPropagationLevel":"NO","articles":[{"pmid":"26466569","title":"RAF inhibitors that evade paradoxical MAPK pathway activation.","journal":"Nature","pubDate":"2015 Oct 22","volume":"526","issue":"7574","pages":"583-6","authors":"Zhang C et al","elocationId":"doi: 10.1038/nature14982","link":null,"reference":"Zhang C et al. Nature. 2015 Oct 22;526(7574)583-6.","abstract":null},{"pmid":"28659148","title":"PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.","journal":"Molecular cancer","pubDate":"2017 Jun 28","volume":"16","issue":"1","pages":"112","authors":"Tutuka CSA et al","elocationId":"doi: 10.1186/s12943-017-0684-x","link":null,"reference":"Tutuka CSA et al. Molecular cancer. 2017 Jun 28;16(1)112.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://mct.aacrjournals.org/content/17/1_Supplement/B176","reference":"null. null. .","abstract":"Janku et al. Abstract# B176, AACR-NCI-EORTC 2017"},{"pmid":"28783719","title":"Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.","journal":"Nature","pubDate":"2017 Aug 10","volume":"548","issue":"7666","pages":"234-238","authors":"Yao Z et al","elocationId":"doi: 10.1038/nature23291","link":null,"reference":"Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.","abstract":null},{"pmid":"30559419","title":"RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.","journal":"Nature medicine","pubDate":"2019 Feb","volume":"25","issue":"2","pages":"284-291","authors":"Yao Z et al","elocationId":"doi: 10.1038/s41591-018-0274-5","link":null,"reference":"Yao Z et al. Nature medicine. 2019 Feb;25(2)284-291.","abstract":null}]},{"id":22244,"uuid":"4004fb3c-149d-47ce-adf0-f1d55fe70c62","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":224,"subtype":"Chronic Myelomonocytic Leukemia","code":"CMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C129546","drugName":"H3B-8800","uuid":"1cb40d2d-b6ee-4935-8e7e-131de7e3d5ea","synonyms":["Splicing Modulator H3B-8800","H3B 8800","Splicing Inhibitor H3B-8800","Splicing Factor Inhibitor H3B-8800"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572235178000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29457796","title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.","journal":"Nature medicine","pubDate":"2018 May","volume":"24","issue":"4","pages":"497-504","authors":"Seiler M et al","elocationId":"doi: 10.1038/nm.4493","link":null,"reference":"Seiler M et al. Nature medicine. 2018 May;24(4)497-504.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/128/22/966?sso-checked=true","reference":"null. null. .","abstract":"Buonamici, S. et al. Abstract# Blood 128:966, 2016"}]},{"id":10919,"uuid":"0d03b7c1-523d-40b1-8050-f9aee2be42ed","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":551,"subtype":"Ewing Sarcoma","code":"ES","color":"White","mainType":"Bone Cancer","level":2,"tissue":"Bone","tumorForm":"SOLID"},{"id":284,"subtype":"Ewing Sarcoma of Soft Tissue","code":"ESST","color":"LightYellow","mainType":"Soft Tissue Sarcoma","level":2,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2313,"hugoSymbol":"FLI1","oncogene":true,"grch37Isoform":"ENST00000527786","grch37RefSeq":"NM_002017.4","grch38Isoform":"ENST00000527786","grch38RefSeq":"NM_002017.4","geneAliases":["SIC-1","EWSR2","BDPLT21"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2313,"hugoSymbol":"FLI1","oncogene":true,"grch37Isoform":"ENST00000527786","grch37RefSeq":"NM_002017.4","grch38Isoform":"ENST00000527786","grch38RefSeq":"NM_002017.4","geneAliases":["SIC-1","EWSR2","BDPLT21"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"EWSR1-FLI1 Fusion","name":"EWSR1-FLI1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C125657","drugName":"TK216","uuid":"af85c77d-1ae7-4dc5-a4a1-ccc7df58f0a6","synonyms":["Ets-family Transcription Factor Inhibitor TK216","TK-216"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572236384000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://cancerres.aacrjournals.org/content/77/13_Supplement/694","reference":"null. null. .","abstract":"Selvanathan et al. Abstract# 694, AACR 2017"},{"pmid":"19584866","title":"A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma.","journal":"Nature medicine","pubDate":"2009 Jul","volume":"15","issue":"7","pages":"750-6","authors":"Erkizan HV et al","elocationId":"doi: 10.1038/nm.1983","link":null,"reference":"Erkizan HV et al. Nature medicine. 2009 Jul;15(7)750-6.","abstract":null}]},{"id":2087,"uuid":"690ed068-5612-438a-ac07-948a18228375","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"K601","name":"K601","refResidues":"K","proteinStart":601,"proteinEnd":601,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C113330","drugName":"PLX8394","uuid":"44faeeae-ad6d-4370-8c99-97955f9e0feb","synonyms":["BRAF Inhibitor PLX8394"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1571713975000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"LEVEL_4","liquidPropagationLevel":"NO","articles":[{"pmid":"26466569","title":"RAF inhibitors that evade paradoxical MAPK pathway activation.","journal":"Nature","pubDate":"2015 Oct 22","volume":"526","issue":"7574","pages":"583-6","authors":"Zhang C et al","elocationId":"doi: 10.1038/nature14982","link":null,"reference":"Zhang C et al. Nature. 2015 Oct 22;526(7574)583-6.","abstract":null},{"pmid":"28659148","title":"PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.","journal":"Molecular cancer","pubDate":"2017 Jun 28","volume":"16","issue":"1","pages":"112","authors":"Tutuka CSA et al","elocationId":"doi: 10.1186/s12943-017-0684-x","link":null,"reference":"Tutuka CSA et al. Molecular cancer. 2017 Jun 28;16(1)112.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://mct.aacrjournals.org/content/17/1_Supplement/B176","reference":"null. null. .","abstract":"Janku et al. Abstract# B176, AACR-NCI-EORTC 2017"},{"pmid":"28783719","title":"Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.","journal":"Nature","pubDate":"2017 Aug 10","volume":"548","issue":"7666","pages":"234-238","authors":"Yao Z et al","elocationId":"doi: 10.1038/nature23291","link":null,"reference":"Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.","abstract":null},{"pmid":"30559419","title":"RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.","journal":"Nature medicine","pubDate":"2019 Feb","volume":"25","issue":"2","pages":"284-291","authors":"Yao Z et al","elocationId":"doi: 10.1038/s41591-018-0274-5","link":null,"reference":"Yao Z et al. Nature medicine. 2019 Feb;25(2)284-291.","abstract":null}]},{"id":22248,"uuid":"9a6633da-131d-442e-8d16-3355778b8680","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C129546","drugName":"H3B-8800","uuid":"1cb40d2d-b6ee-4935-8e7e-131de7e3d5ea","synonyms":["Splicing Modulator H3B-8800","H3B 8800","Splicing Inhibitor H3B-8800","Splicing Factor Inhibitor H3B-8800"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572235203000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29457796","title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.","journal":"Nature medicine","pubDate":"2018 May","volume":"24","issue":"4","pages":"497-504","authors":"Seiler M et al","elocationId":"doi: 10.1038/nm.4493","link":null,"reference":"Seiler M et al. Nature medicine. 2018 May;24(4)497-504.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/128/22/966?sso-checked=true","reference":"null. null. .","abstract":"Buonamici, S. et al. Abstract# Blood 128:966, 2016"}]},{"id":12266,"uuid":"c72dffd4-0e99-40a0-822d-be2a58faa5df","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":900,"subtype":"","code":"","color":"Yellow","mainType":"Bladder Cancer","level":0,"tissue":"Bladder/Urinary Tract","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7403,"hugoSymbol":"KDM6A","oncogene":false,"grch37Isoform":"ENST00000377967","grch37RefSeq":"NM_021140.2","grch38Isoform":"ENST00000377967","grch38RefSeq":"NM_021140.2","geneAliases":["UTX","bA386N14.2","KABUK2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":7403,"hugoSymbol":"KDM6A","oncogene":false,"grch37Isoform":"ENST00000377967","grch37RefSeq":"NM_021140.2","grch38Isoform":"ENST00000377967","grch38RefSeq":"NM_021140.2","geneAliases":["UTX","bA386N14.2","KABUK2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C107506","drugName":"Tazemetostat","uuid":"49e07d49-ee64-4049-c09d-37c6ce612cad","synonyms":["TAZEMETOSTAT","N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide","Tazemetostat","Tazemetostat\"","EPZ-6438","EPZ6438","N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide","\"E7438"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572236086000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"24123378","title":"EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification.","journal":"Stem cells (Dayton, Ohio)","pubDate":"2014 Mar","volume":"32","issue":"3","pages":"802-15","authors":"Hemming S et al","elocationId":"doi: 10.1002/stem.1573","link":null,"reference":"Hemming S et al. Stem cells (Dayton, Ohio). 2014 Mar;32(3)802-15.","abstract":null},{"pmid":"28228601","title":"Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.","journal":"Science translational medicine","pubDate":"2017 Feb 22","volume":"9","issue":"378","pages":"","authors":"Ler LD et al","elocationId":"pii: eaai8312. doi: 10.1126/scitranslmed.aai8312","link":null,"reference":"Ler LD et al. Science translational medicine. 2017 Feb 22;9(378).","abstract":null},{"pmid":"29045832","title":"UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.","journal":"Cell reports","pubDate":"2017 Oct 17","volume":"21","issue":"3","pages":"628-640","authors":"Ezponda T et al","elocationId":"doi: 10.1016/j.celrep.2017.09.078","link":null,"reference":"Ezponda T et al. Cell reports. 2017 Oct 17;21(3)628-640.","abstract":null}]},{"id":21358,"uuid":"481a4855-6ff7-4a13-8a13-fd011931fcc1","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C129546","drugName":"H3B-8800","uuid":"1cb40d2d-b6ee-4935-8e7e-131de7e3d5ea","synonyms":["Splicing Modulator H3B-8800","H3B 8800","Splicing Inhibitor H3B-8800","Splicing Factor Inhibitor H3B-8800"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572235398000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29457796","title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.","journal":"Nature medicine","pubDate":"2018 May","volume":"24","issue":"4","pages":"497-504","authors":"Seiler M et al","elocationId":"doi: 10.1038/nm.4493","link":null,"reference":"Seiler M et al. Nature medicine. 2018 May;24(4)497-504.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/128/22/966?sso-checked=true","reference":"null. null. .","abstract":"Buonamici, S. et al. Abstract# Blood 128:966, 2016"}]},{"id":21360,"uuid":"e17ab341-faa3-40ca-a4f0-ce76c6bc319d","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":224,"subtype":"Chronic Myelomonocytic Leukemia","code":"CMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C129546","drugName":"H3B-8800","uuid":"1cb40d2d-b6ee-4935-8e7e-131de7e3d5ea","synonyms":["Splicing Modulator H3B-8800","H3B 8800","Splicing Inhibitor H3B-8800","Splicing Factor Inhibitor H3B-8800"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572235422000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29457796","title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.","journal":"Nature medicine","pubDate":"2018 May","volume":"24","issue":"4","pages":"497-504","authors":"Seiler M et al","elocationId":"doi: 10.1038/nm.4493","link":null,"reference":"Seiler M et al. Nature medicine. 2018 May;24(4)497-504.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/128/22/966?sso-checked=true","reference":"null. null. .","abstract":"Buonamici, S. et al. Abstract# Blood 128:966, 2016"}]},{"id":14770,"uuid":"9b6b5cac-d120-442f-bba9-84d0d62e588d","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C74061","drugName":"Crizotinib","uuid":"f05d12ab-6204-4a1c-803f-f3a7f6e30af2","synonyms":["MET Tyrosine Kinase Inhibitor PF-02341066","Crizotinib","2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-","Xalkori\"","PF-02341066","CRIZOTINIB","PF-2341066","\"(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine","MET tyrosine kinase inhibitor PF-02341066"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572235738000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29284707","title":"Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2018 Mar 15","volume":"24","issue":"6","pages":"1337-1343","authors":"Plenker D et al","elocationId":"doi: 10.1158/1078-0432.CCR-17-3001","link":null,"reference":"Plenker D et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Mar 15;24(6)1337-1343.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539","reference":"null. null. .","abstract":"Wang et al. Abstract#e13539, ASCO 2018"},{"pmid":"29527595","title":"Dramatic Response to Crizotinib in a Patient with Lung Cancer Positive for an <i>HLA-DRB1-MET</i> Gene Fusion.","journal":"JCO precision oncology","pubDate":"2017","volume":"2017","issue":"1","pages":"","authors":"Davies KD et al","elocationId":"doi: 10.1200/PO.17.00117","link":null,"reference":"Davies KD et al. JCO precision oncology. 2017;2017(1).","abstract":null},{"pmid":"29102694","title":"KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2018 Mar","volume":"13","issue":"3","pages":"e29-e31","authors":"Cho JH et al","elocationId":"doi: 10.1016/j.jtho.2017.10.014","link":null,"reference":"Cho JH et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Mar;13(3)e29-e31.","abstract":null}]},{"id":6644,"uuid":"0af627f2-7d34-4bf7-b6a2-febf073c38b2","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"A763_Y764insFQEA","name":"A763_Y764insFQEA","refResidues":null,"proteinStart":763,"proteinEnd":764,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C66940","drugName":"Afatinib","uuid":"e1f45ae7-33ae-428c-9e77-da4a9b7270b6","synonyms":["BIBW 2992","Afatinib","BIBW2992","AFATINIB","(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1584639054000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"26515464","title":"In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.","journal":"Oncotarget","pubDate":"2015 Nov 17","volume":"6","issue":"36","pages":"38789-803","authors":"Hirano T et al","elocationId":"doi: 10.18632/oncotarget.5887","link":null,"reference":"Hirano T et al. Oncotarget. 2015 Nov 17;6(36)38789-803.","abstract":null}]},{"id":21366,"uuid":"38ba6dc6-6954-4e06-931e-d3ba972b67b7","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C129546","drugName":"H3B-8800","uuid":"1cb40d2d-b6ee-4935-8e7e-131de7e3d5ea","synonyms":["Splicing Modulator H3B-8800","H3B 8800","Splicing Inhibitor H3B-8800","Splicing Factor Inhibitor H3B-8800"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572235439000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29457796","title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.","journal":"Nature medicine","pubDate":"2018 May","volume":"24","issue":"4","pages":"497-504","authors":"Seiler M et al","elocationId":"doi: 10.1038/nm.4493","link":null,"reference":"Seiler M et al. Nature medicine. 2018 May;24(4)497-504.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/128/22/966?sso-checked=true","reference":"null. null. .","abstract":"Buonamici, S. et al. Abstract# Blood 128:966, 2016"}]},{"id":6582,"uuid":"a3395a23-e4dd-4e9e-8abd-9e1fe8599f1d","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L747P","name":"L747P","refResidues":"L","proteinStart":747,"proteinEnd":747,"variantResidues":"P","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C66940","drugName":"Afatinib","uuid":"e1f45ae7-33ae-428c-9e77-da4a9b7270b6","synonyms":["BIBW 2992","Afatinib","BIBW2992","AFATINIB","(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1582153652000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"31279301","title":"Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.","journal":"European journal of cancer (Oxford, England : 1990)","pubDate":"2019 Aug","volume":"117","issue":"","pages":"107-115","authors":"Yao ZH et al","elocationId":"doi: 10.1016/j.ejca.2019.05.032","link":null,"reference":"Yao ZH et al. European journal of cancer (Oxford, England : 1990). 2019 Aug;117()107-115.","abstract":null},{"pmid":"31200815","title":"Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.","journal":"Lung cancer (Amsterdam, Netherlands)","pubDate":"2019 Jul","volume":"133","issue":"","pages":"103-109","authors":"Liang SK et al","elocationId":"doi: 10.1016/j.lungcan.2019.05.019","link":null,"reference":"Liang SK et al. Lung cancer (Amsterdam, Netherlands). 2019 Jul;133()103-109.","abstract":null},{"pmid":"30746257","title":"EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report.","journal":"Journal of thoracic disease","pubDate":"2018 Dec","volume":"10","issue":"12","pages":"E802-E805","authors":"Zhou T et al","elocationId":"doi: 10.21037/jtd.2018.12.26","link":null,"reference":"Zhou T et al. Journal of thoracic disease. 2018 Dec;10(12)E802-E805.","abstract":null}]},{"id":6649,"uuid":"5acef079-01be-4ca7-bca2-47bf7866c6d8","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Kinase Domain Duplication","name":"Kinase Domain Duplication","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C65530","drugName":"Erlotinib","uuid":"83754311-3f3b-4782-bfbf-08e71c790b9a","synonyms":["Erlotinib","erlotinib","ERLOTINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1582154566000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"30255937","title":"Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC.","journal":"International journal of cancer","pubDate":"2019 Jun 1","volume":"144","issue":"11","pages":"2677-2682","authors":"Wang J et al","elocationId":"doi: 10.1002/ijc.31895","link":null,"reference":"Wang J et al. International journal of cancer. 2019 Jun 1;144(11)2677-2682.","abstract":null},{"pmid":"28336552","title":"Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.","journal":"Cancer discovery","pubDate":"2017 Jun","volume":"7","issue":"6","pages":"596-609","authors":"Jordan EJ et al","elocationId":"doi: 10.1158/2159-8290.CD-16-1337","link":null,"reference":"Jordan EJ et al. Cancer discovery. 2017 Jun;7(6)596-609.","abstract":null},{"pmid":"26398831","title":"Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2015 Oct","volume":"10","issue":"10","pages":"e97-9","authors":"Baik CS et al","elocationId":"doi: 10.1097/JTO.0000000000000586","link":null,"reference":"Baik CS et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Oct;10(10)e97-9.","abstract":null},{"pmid":"26286086","title":"EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.","journal":"Cancer discovery","pubDate":"2015 Nov","volume":"5","issue":"11","pages":"1155-63","authors":"Gallant JN et al","elocationId":"doi: 10.1158/2159-8290.CD-15-0654","link":null,"reference":"Gallant JN et al. Cancer discovery. 2015 Nov;5(11)1155-63.","abstract":null}]},{"id":10298,"uuid":"ee5ca991-75a6-499f-95b2-faff66e94d9f","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2263,"hugoSymbol":"FGFR2","oncogene":true,"grch37Isoform":"ENST00000358487","grch37RefSeq":"NM_000141.4","grch38Isoform":"ENST00000358487","grch38RefSeq":"NM_000141.4","geneAliases":["BBDS","BFR-1","CEK3","JWS","BEK","ECT1","K-SAM","KGFR","TK14","TK25","CD332","CFD1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2263,"hugoSymbol":"FGFR2","oncogene":true,"grch37Isoform":"ENST00000358487","grch37RefSeq":"NM_000141.4","grch38Isoform":"ENST00000358487","grch38RefSeq":"NM_000141.4","geneAliases":["BBDS","BFR-1","CEK3","JWS","BEK","ECT1","K-SAM","KGFR","TK14","TK25","CD332","CFD1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C88302","drugName":"BGJ398","uuid":"dcbc3088-5056-487b-bc2f-da930840dfff","synonyms":["\"3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea","BGJ-398","Infigratinib\"","INFIGRATINIB","Infigratinib"],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C111988","drugName":"Debio1347","uuid":"91859b88-74e8-4c71-98ce-70746997d61b","synonyms":["CH5183284","Debiopharm 1347","FF284","FGFR Inhibitor Debio 1347","debio 1347","debio 1347-101"],"priority":1}]},{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C103273","drugName":"Erdafitinib","uuid":"f2e41d69-c383-4e33-ba25-0bf5f837db11","synonyms":["\"1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-","Balversa","Erdafitinib","JNJ-42756493\"","ERDAFITINIB"],"priority":1}]},{"approvedIndications":[],"priority":4,"drugs":[{"ncitCode":"C88272","drugName":"AZD4547","uuid":"ea736f8d-c242-45d0-96d2-225a6553bd89","synonyms":["FGFR Inhibitor AZD4547"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572237538000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"LEVEL_4","liquidPropagationLevel":"NO","articles":[{"pmid":"23082000","title":"Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2012 Dec 15","volume":"18","issue":"24","pages":"6658-67","authors":"Zhang J et al","elocationId":"doi: 10.1158/1078-0432.CCR-12-2694","link":null,"reference":"Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.","abstract":null},{"pmid":"25169980","title":"The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.","journal":"Molecular cancer therapeutics","pubDate":"2014 Nov","volume":"13","issue":"11","pages":"2547-58","authors":"Nakanishi Y et al","elocationId":"doi: 10.1158/1535-7163.MCT-14-0248","link":null,"reference":"Nakanishi Y et al. Molecular cancer therapeutics. 2014 Nov;13(11)2547-58.","abstract":null},{"pmid":"27870574","title":"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Jan 10","volume":"35","issue":"2","pages":"157-165","authors":"Nogova L et al","elocationId":"","link":null,"reference":"Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.","abstract":null},{"pmid":"26438159","title":"ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.","journal":"Molecular cancer therapeutics","pubDate":"2015 Dec","volume":"14","issue":"12","pages":"2831-9","authors":"Nakanishi Y et al","elocationId":"doi: 10.1158/1535-7163.MCT-15-0497","link":null,"reference":"Nakanishi Y et al. Molecular cancer therapeutics. 2015 Dec;14(12)2831-9.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://cancerres.aacrjournals.org/content/77/13_Supplement/2088","reference":"null. null. .","abstract":"Brichory F et al. Abstract# 2088, AACR 2017"},{"pmid":"31340094","title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.","journal":"The New England journal of medicine","pubDate":"2019 Jul 25","volume":"381","issue":"4","pages":"338-348","authors":"Loriot Y et al","elocationId":"doi: 10.1056/NEJMoa1817323","link":null,"reference":"Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.","abstract":null},{"pmid":"30745300","title":"A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 May 1","volume":"25","issue":"9","pages":"2699-2707","authors":"Voss MH et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-1959","link":null,"reference":"Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.","abstract":null},{"pmid":"31088831","title":"Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 Aug 15","volume":"25","issue":"16","pages":"4888-4897","authors":"Bahleda R et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-3334","link":null,"reference":"Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.","abstract":null}]},{"id":6650,"uuid":"cbe10f3b-e2fb-4c65-a685-e344bc25c471","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Kinase Domain Duplication","name":"Kinase Domain Duplication","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C1855","drugName":"Gefitinib","uuid":"b76d7b2b-b5fb-4561-892f-6b00bfaf0dfa","synonyms":["GEFITINIB","Iressa","N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine","ZD 1839","gefitinib","Gefitinib","4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline","ZD1839"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1582154825000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"30255937","title":"Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC.","journal":"International journal of cancer","pubDate":"2019 Jun 1","volume":"144","issue":"11","pages":"2677-2682","authors":"Wang J et al","elocationId":"doi: 10.1002/ijc.31895","link":null,"reference":"Wang J et al. International journal of cancer. 2019 Jun 1;144(11)2677-2682.","abstract":null},{"pmid":"26398831","title":"Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2015 Oct","volume":"10","issue":"10","pages":"e97-9","authors":"Baik CS et al","elocationId":"doi: 10.1097/JTO.0000000000000586","link":null,"reference":"Baik CS et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Oct;10(10)e97-9.","abstract":null},{"pmid":"26286086","title":"EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.","journal":"Cancer discovery","pubDate":"2015 Nov","volume":"5","issue":"11","pages":"1155-63","authors":"Gallant JN et al","elocationId":"doi: 10.1158/2159-8290.CD-15-0654","link":null,"reference":"Gallant JN et al. Cancer discovery. 2015 Nov;5(11)1155-63.","abstract":null}]},{"id":24315,"uuid":"5a1fa811-7a4e-417f-a06e-d6ff483c2cf9","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8233,"hugoSymbol":"ZRSR2","oncogene":false,"grch37Isoform":"ENST00000307771","grch37RefSeq":"NM_005089.3","grch38Isoform":"ENST00000307771","grch38RefSeq":"NM_005089.3","geneAliases":["URP","ZC3H22","U2AF1-RS2","U2AF1RS2","U2AF1L2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":8233,"hugoSymbol":"ZRSR2","oncogene":false,"grch37Isoform":"ENST00000307771","grch37RefSeq":"NM_005089.3","grch38Isoform":"ENST00000307771","grch38RefSeq":"NM_005089.3","geneAliases":["URP","ZC3H22","U2AF1-RS2","U2AF1RS2","U2AF1L2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C129546","drugName":"H3B-8800","uuid":"1cb40d2d-b6ee-4935-8e7e-131de7e3d5ea","synonyms":["Splicing Modulator H3B-8800","H3B 8800","Splicing Inhibitor H3B-8800","Splicing Factor Inhibitor H3B-8800"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572234888000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29457796","title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.","journal":"Nature medicine","pubDate":"2018 May","volume":"24","issue":"4","pages":"497-504","authors":"Seiler M et al","elocationId":"doi: 10.1038/nm.4493","link":null,"reference":"Seiler M et al. Nature medicine. 2018 May;24(4)497-504.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/128/22/966?sso-checked=true","reference":"null. null. .","abstract":"Buonamici, S. et al. Abstract# Blood 128:966, 2016"}]},{"id":24317,"uuid":"31ea9bd1-0c72-4fe2-af00-11ee2a21f04d","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":224,"subtype":"Chronic Myelomonocytic Leukemia","code":"CMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8233,"hugoSymbol":"ZRSR2","oncogene":false,"grch37Isoform":"ENST00000307771","grch37RefSeq":"NM_005089.3","grch38Isoform":"ENST00000307771","grch38RefSeq":"NM_005089.3","geneAliases":["URP","ZC3H22","U2AF1-RS2","U2AF1RS2","U2AF1L2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":8233,"hugoSymbol":"ZRSR2","oncogene":false,"grch37Isoform":"ENST00000307771","grch37RefSeq":"NM_005089.3","grch38Isoform":"ENST00000307771","grch38RefSeq":"NM_005089.3","geneAliases":["URP","ZC3H22","U2AF1-RS2","U2AF1RS2","U2AF1L2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C129546","drugName":"H3B-8800","uuid":"1cb40d2d-b6ee-4935-8e7e-131de7e3d5ea","synonyms":["Splicing Modulator H3B-8800","H3B 8800","Splicing Inhibitor H3B-8800","Splicing Factor Inhibitor H3B-8800"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572234941000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29457796","title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.","journal":"Nature medicine","pubDate":"2018 May","volume":"24","issue":"4","pages":"497-504","authors":"Seiler M et al","elocationId":"doi: 10.1038/nm.4493","link":null,"reference":"Seiler M et al. Nature medicine. 2018 May;24(4)497-504.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/128/22/966?sso-checked=true","reference":"null. null. .","abstract":"Buonamici, S. et al. Abstract# Blood 128:966, 2016"}]},{"id":6847,"uuid":"cc7cd9de-d764-4c14-8e5a-2261fa3b0ad3","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":882,"subtype":"","code":"","color":"Gray","mainType":"Glioma","level":0,"tissue":"CNS/Brain","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C26653","drugName":"Lapatinib","uuid":"6b1eee04-b74c-46d3-bdd3-1c68d1ec11b0","synonyms":["LAPATINIB","GW572016","lapatinib","GW 2016","GW2016","GSK572016","Lapatinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1571714651000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22588883","title":"Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.","journal":"Cancer discovery","pubDate":"2012 May","volume":"2","issue":"5","pages":"458-71","authors":"Vivanco I et al","elocationId":"doi: 10.1158/2159-8290.CD-11-0284","link":null,"reference":"Vivanco I et al. Cancer discovery. 2012 May;2(5)458-71.","abstract":null},{"pmid":"20459769","title":"Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.","journal":"BMC cancer","pubDate":"2010 May 11","volume":"10","issue":"","pages":"188","authors":"Diaz R et al","elocationId":"doi: 10.1186/1471-2407-10-188","link":null,"reference":"Diaz R et al. BMC cancer. 2010 May 11;10()188.","abstract":null},{"pmid":"18334972","title":"Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.","journal":"British journal of cancer","pubDate":"2008 Mar 25","volume":"98","issue":"6","pages":"1076-84","authors":"Konecny GE et al","elocationId":"doi: 10.1038/sj.bjc.6604278","link":null,"reference":"Konecny GE et al. British journal of cancer. 2008 Mar 25;98(6)1076-84.","abstract":null}]},{"id":24321,"uuid":"2a733d3d-a74a-4f5f-b6c9-315efa66398e","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8233,"hugoSymbol":"ZRSR2","oncogene":false,"grch37Isoform":"ENST00000307771","grch37RefSeq":"NM_005089.3","grch38Isoform":"ENST00000307771","grch38RefSeq":"NM_005089.3","geneAliases":["URP","ZC3H22","U2AF1-RS2","U2AF1RS2","U2AF1L2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":8233,"hugoSymbol":"ZRSR2","oncogene":false,"grch37Isoform":"ENST00000307771","grch37RefSeq":"NM_005089.3","grch38Isoform":"ENST00000307771","grch38RefSeq":"NM_005089.3","geneAliases":["URP","ZC3H22","U2AF1-RS2","U2AF1RS2","U2AF1L2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C129546","drugName":"H3B-8800","uuid":"1cb40d2d-b6ee-4935-8e7e-131de7e3d5ea","synonyms":["Splicing Modulator H3B-8800","H3B 8800","Splicing Inhibitor H3B-8800","Splicing Factor Inhibitor H3B-8800"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572234994000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29457796","title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.","journal":"Nature medicine","pubDate":"2018 May","volume":"24","issue":"4","pages":"497-504","authors":"Seiler M et al","elocationId":"doi: 10.1038/nm.4493","link":null,"reference":"Seiler M et al. Nature medicine. 2018 May;24(4)497-504.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/128/22/966?sso-checked=true","reference":"null. null. .","abstract":"Buonamici, S. et al. Abstract# Blood 128:966, 2016"}]},{"id":5570,"uuid":"af6dbcbc-2e31-48b8-aab0-d14b6f79f4d7","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1029,"hugoSymbol":"CDKN2A","oncogene":false,"grch37Isoform":"ENST00000304494","grch37RefSeq":"NM_000077.4","grch38Isoform":"ENST00000304494","grch38RefSeq":"NM_000077.4","geneAliases":["P16INK4A","CDKN2Ap14ARF","MTS1","TP16","P16INK4","CDKN2Ap14IRF","INK4","P14ARF","P19ARF","MLM","CMM2","P14","MTS-1","P16","ARF","P19","INK4A","P16-INK4A","CDKN2","CDKN2Ap16INK4A"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":1029,"hugoSymbol":"CDKN2A","oncogene":false,"grch37Isoform":"ENST00000304494","grch37RefSeq":"NM_000077.4","grch38Isoform":"ENST00000304494","grch38RefSeq":"NM_000077.4","geneAliases":["P16INK4A","CDKN2Ap14ARF","MTS1","TP16","P16INK4","CDKN2Ap14IRF","INK4","P14ARF","P19ARF","MLM","CMM2","P14","MTS-1","P16","ARF","P19","INK4A","P16-INK4A","CDKN2","CDKN2Ap16INK4A"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C95701","drugName":"Ribociclib","uuid":"b7734d8a-b096-4b64-9558-2fcfd63dd6ad","synonyms":["RIBOCICLIB","LEE-011","Ribociclib\"","LEE011","Ribociclib","Kisqali","\"7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide"],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C49176","drugName":"Palbociclib","uuid":"9b59ba48-b340-4e20-8d01-c50dd438e731","synonyms":["PALBOCICLIB","\"6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one","PD 991","Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-\"","Palbociclib","PD-0332991","PD 332991","PD 0332991","Ibrance"],"priority":1}]},{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C97660","drugName":"Abemaciclib","uuid":"d65def80-26cb-4af0-b87b-f9a6b498b2a4","synonyms":["Verzenio\"","Abemaciclib","\"2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)","LY-2835219","ABEMACICLIB","LY2835219"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1571714267000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"LEVEL_4","liquidPropagationLevel":"NO","articles":[{"pmid":"24495407","title":"Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.","journal":"Pigment cell & melanoma research","pubDate":"2014 Jul","volume":"27","issue":"4","pages":"590-600","authors":"Young RJ et al","elocationId":"doi: 10.1111/pcmr.12228","link":null,"reference":"Young RJ et al. Pigment cell & melanoma research. 2014 Jul;27(4)590-600.","abstract":null},{"pmid":"19874578","title":"PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially   inhibits proliferation of luminal estrogen receptor-positive human   breast cancer cell lines in vitro.","journal":"Breast cancer research : BCR","pubDate":"2009","volume":"11","issue":"5","pages":"R77","authors":"Finn RS et al","elocationId":"doi: 10.1186/bcr2419","link":null,"reference":"Finn RS et al. Breast cancer research : BCR. 2009;11(5)R77.","abstract":null},{"pmid":"28283584","title":"Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common <i>CDKN2A</i> Alteration.","journal":"The oncologist","pubDate":"2017 Apr","volume":"22","issue":"4","pages":"416-421","authors":"Elvin JA et al","elocationId":"doi: 10.1634/theoncologist.2016-0310","link":null,"reference":"Elvin JA et al. The oncologist. 2017 Apr;22(4)416-421.","abstract":null},{"pmid":"29232554","title":"Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.","journal":"Cancer cell","pubDate":"2017 Dec 11","volume":"32","issue":"6","pages":"761-776.e6","authors":"Gong X et al","elocationId":"doi: 10.1016/j.ccell.2017.11.006","link":null,"reference":"Gong X et al. Cancer cell. 2017 Dec 11;32(6)761-776.e6.","abstract":null},{"pmid":"25941111","title":"Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2015 Jul 1","volume":"21","issue":"13","pages":"2905-10","authors":"VanArsdale T et al","elocationId":"doi: 10.1158/1078-0432.CCR-14-0816","link":null,"reference":"VanArsdale T et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jul 1;21(13)2905-10.","abstract":null}]},{"id":19714,"uuid":"7365234d-a84f-4499-9fe5-b1e3d1ea6c3d","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5728,"hugoSymbol":"PTEN","oncogene":false,"grch37Isoform":"ENST00000371953","grch37RefSeq":"NM_000314.4","grch38Isoform":"ENST00000371953","grch38RefSeq":"NM_000314.4","geneAliases":["DEC","MHAM","TEP1","BZS","PTEN1","GLM2","PTENbeta","CWS1","MMAC1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":5728,"hugoSymbol":"PTEN","oncogene":false,"grch37Isoform":"ENST00000371953","grch37RefSeq":"NM_000314.4","grch38Isoform":"ENST00000371953","grch38RefSeq":"NM_000314.4","geneAliases":["DEC","MHAM","TEP1","BZS","PTEN1","GLM2","PTENbeta","CWS1","MMAC1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C107684","drugName":"AZD8186","uuid":"4d91e491-7d0f-4a6b-8547-e87449b2fc3a","synonyms":["AZD-8186","PI3Kbeta Inhibitor AZD8186"],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C106261","drugName":"GSK2636771","uuid":"766b6fee-ce4d-4241-b086-4a0fe3c63964","synonyms":["PI3K-beta Inhibitor GSK2636771"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1579725096000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"LEVEL_4","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2570","reference":"null. null. .","abstract":"Hansen et al. Abstract# 2570, ASCO 2017"},{"pmid":"28645941","title":"A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2017 Oct 1","volume":"23","issue":"19","pages":"5981-5992","authors":"Mateo J et al","elocationId":"doi: 10.1158/1078-0432.CCR-17-0725","link":null,"reference":"Mateo J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Oct 1;23(19)5981-5992.","abstract":null}]},{"id":2308,"uuid":"96034660-351c-4fce-9f82-cdfe98f7a0d2","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"G469R","name":"G469R","refResidues":"G","proteinStart":469,"proteinEnd":469,"variantResidues":"R","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"G464","name":"G464","refResidues":"G","proteinStart":464,"proteinEnd":464,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"G469A","name":"G469A","refResidues":"G","proteinStart":469,"proteinEnd":469,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"G469V","name":"G469V","refResidues":"G","proteinStart":469,"proteinEnd":469,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C113330","drugName":"PLX8394","uuid":"44faeeae-ad6d-4370-8c99-97955f9e0feb","synonyms":["BRAF Inhibitor PLX8394"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1571714073000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"LEVEL_4","liquidPropagationLevel":"NO","articles":[{"pmid":"26466569","title":"RAF inhibitors that evade paradoxical MAPK pathway activation.","journal":"Nature","pubDate":"2015 Oct 22","volume":"526","issue":"7574","pages":"583-6","authors":"Zhang C et al","elocationId":"doi: 10.1038/nature14982","link":null,"reference":"Zhang C et al. Nature. 2015 Oct 22;526(7574)583-6.","abstract":null},{"pmid":"28659148","title":"PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.","journal":"Molecular cancer","pubDate":"2017 Jun 28","volume":"16","issue":"1","pages":"112","authors":"Tutuka CSA et al","elocationId":"doi: 10.1186/s12943-017-0684-x","link":null,"reference":"Tutuka CSA et al. Molecular cancer. 2017 Jun 28;16(1)112.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://mct.aacrjournals.org/content/17/1_Supplement/B176","reference":"null. null. .","abstract":"Janku et al. Abstract# B176, AACR-NCI-EORTC 2017"},{"pmid":"28783719","title":"Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.","journal":"Nature","pubDate":"2017 Aug 10","volume":"548","issue":"7666","pages":"234-238","authors":"Yao Z et al","elocationId":"doi: 10.1038/nature23291","link":null,"reference":"Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.","abstract":null},{"pmid":"30559419","title":"RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.","journal":"Nature medicine","pubDate":"2019 Feb","volume":"25","issue":"2","pages":"284-291","authors":"Yao Z et al","elocationId":"doi: 10.1038/s41591-018-0274-5","link":null,"reference":"Yao Z et al. Nature medicine. 2019 Feb;25(2)284-291.","abstract":null}]},{"id":7045,"uuid":"7b0bdbd4-9fc1-4db2-a101-2730379b51ae","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":83,"subtype":"Non-Small Cell Lung Cancer","code":"NSCLC","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":2,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L718V","name":"L718V","refResidues":"L","proteinStart":718,"proteinEnd":718,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C66940","drugName":"Afatinib","uuid":"e1f45ae7-33ae-428c-9e77-da4a9b7270b6","synonyms":["BIBW 2992","Afatinib","BIBW2992","AFATINIB","(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1577753523000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"31757379","title":"Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2019 Dec","volume":"14","issue":"12","pages":"e274-e275","authors":"Fang W et al","elocationId":"doi: 10.1016/j.jtho.2019.07.018","link":null,"reference":"Fang W et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Dec;14(12)e274-e275.","abstract":null},{"pmid":"29571986","title":"Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.","journal":"Lung cancer (Amsterdam, Netherlands)","pubDate":"2018 Apr","volume":"118","issue":"","pages":"1-5","authors":"Liu Y et al","elocationId":"doi: 10.1016/j.lungcan.2018.01.015","link":null,"reference":"Liu Y et al. Lung cancer (Amsterdam, Netherlands). 2018 Apr;118()1-5.","abstract":null}]},{"id":13190,"uuid":"9dd8fdcd-b6d9-4f6d-b1d0-ceb80f6c0519","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C68923","drugName":"Cobimetinib","uuid":"eb357145-3b18-4aca-b75a-5e18dd2bf4f9","synonyms":["Cotellic","Cobimetinib","XL518","COBIMETINIB","GDC-0973","MEK Inhibitor GDC-0973"],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C77908","drugName":"Trametinib","uuid":"fb2bb01c-c0ec-4641-abf7-87f486075022","synonyms":["Mekinist","\"GSK1120212","Trametinib\"","TRAMETINIB","JTP-74057","MEK Inhibitor GSK1120212","N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","Trametinib"],"priority":1}]},{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C84865","drugName":"Binimetinib","uuid":"feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677","synonyms":["ARRY-438162","Mektovi","Binimetinib","ARRY-162","MEK162","BINIMETINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1571718825000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"LEVEL_4","liquidPropagationLevel":"NO","articles":[{"pmid":"29247021","title":"First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.","journal":"Cancer discovery","pubDate":"2018 Feb","volume":"8","issue":"2","pages":"184-195","authors":"Sullivan RJ et al","elocationId":"doi: 10.1158/2159-8290.CD-17-1119","link":null,"reference":"Sullivan RJ et al. Cancer discovery. 2018 Feb;8(2)184-195.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://cancerres.aacrjournals.org/content/77/13_Supplement/4973","reference":"null. null. .","abstract":"Bhagwat et al. Abstract# 4973, AACR 2017"},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://cancerres.aacrjournals.org/content/74/19_Supplement/DDT02-03","reference":"null. null. .","abstract":"Robarge et al. Abstract# DDT02-03, AACR 2014"},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://cancerres.aacrjournals.org/content/77/13_Supplement/5168","reference":"null. null. .","abstract":"Burrows et al. Abstract# 5168, AACR 2017"},{"pmid":"23200175","title":"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.","journal":"The Lancet. Oncology","pubDate":"2013 Jan","volume":"14","issue":"1","pages":"38-47","authors":"Jänne PA et al","elocationId":"doi: 10.1016/S1470-2045(12)70489-8","link":null,"reference":"Jänne PA et al. The Lancet. Oncology. 2013 Jan;14(1)38-47.","abstract":null},{"pmid":"24746704","title":"Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.","journal":"Cancer cell","pubDate":"2014 May 12","volume":"25","issue":"5","pages":"697-710","authors":"Lito P et al","elocationId":"doi: 10.1016/j.ccr.2014.03.011","link":null,"reference":"Lito P et al. Cancer cell. 2014 May 12;25(5)697-710.","abstract":null},{"pmid":"28783719","title":"Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.","journal":"Nature","pubDate":"2017 Aug 10","volume":"548","issue":"7666","pages":"234-238","authors":"Yao Z et al","elocationId":"doi: 10.1038/nature23291","link":null,"reference":"Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.","abstract":null},{"pmid":"25435214","title":"Targeting RAS-ERK signalling in cancer: promises and challenges.","journal":"Nature reviews. Drug discovery","pubDate":"2014 Dec","volume":"13","issue":"12","pages":"928-42","authors":"Samatar AA et al","elocationId":"doi: 10.1038/nrd4281","link":null,"reference":"Samatar AA et al. Nature reviews. Drug discovery. 2014 Dec;13(12)928-42.","abstract":null}]},{"id":23944,"uuid":"1b058d93-7357-499d-82f7-d18fcab37ae0","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7307,"hugoSymbol":"U2AF1","oncogene":true,"grch37Isoform":"ENST00000291552","grch37RefSeq":"NM_006758.2","grch38Isoform":"ENST00000291552","grch38RefSeq":"NM_006758.2","geneAliases":["FP793","U2AFBP","RN","RNU2AF1","U2AF35"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":7307,"hugoSymbol":"U2AF1","oncogene":true,"grch37Isoform":"ENST00000291552","grch37RefSeq":"NM_006758.2","grch38Isoform":"ENST00000291552","grch38RefSeq":"NM_006758.2","geneAliases":["FP793","U2AFBP","RN","RNU2AF1","U2AF35"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C129546","drugName":"H3B-8800","uuid":"1cb40d2d-b6ee-4935-8e7e-131de7e3d5ea","synonyms":["Splicing Modulator H3B-8800","H3B 8800","Splicing Inhibitor H3B-8800","Splicing Factor Inhibitor H3B-8800"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572235038000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29457796","title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.","journal":"Nature medicine","pubDate":"2018 May","volume":"24","issue":"4","pages":"497-504","authors":"Seiler M et al","elocationId":"doi: 10.1038/nm.4493","link":null,"reference":"Seiler M et al. Nature medicine. 2018 May;24(4)497-504.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/128/22/966?sso-checked=true","reference":"null. null. .","abstract":"Buonamici, S. et al. Abstract# Blood 128:966, 2016"}]},{"id":23946,"uuid":"c3d38353-2e18-42f4-9c8c-2cee92f04b50","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":224,"subtype":"Chronic Myelomonocytic Leukemia","code":"CMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7307,"hugoSymbol":"U2AF1","oncogene":true,"grch37Isoform":"ENST00000291552","grch37RefSeq":"NM_006758.2","grch38Isoform":"ENST00000291552","grch38RefSeq":"NM_006758.2","geneAliases":["FP793","U2AFBP","RN","RNU2AF1","U2AF35"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":7307,"hugoSymbol":"U2AF1","oncogene":true,"grch37Isoform":"ENST00000291552","grch37RefSeq":"NM_006758.2","grch38Isoform":"ENST00000291552","grch38RefSeq":"NM_006758.2","geneAliases":["FP793","U2AFBP","RN","RNU2AF1","U2AF35"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C129546","drugName":"H3B-8800","uuid":"1cb40d2d-b6ee-4935-8e7e-131de7e3d5ea","synonyms":["Splicing Modulator H3B-8800","H3B 8800","Splicing Inhibitor H3B-8800","Splicing Factor Inhibitor H3B-8800"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572235072000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29457796","title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.","journal":"Nature medicine","pubDate":"2018 May","volume":"24","issue":"4","pages":"497-504","authors":"Seiler M et al","elocationId":"doi: 10.1038/nm.4493","link":null,"reference":"Seiler M et al. Nature medicine. 2018 May;24(4)497-504.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/128/22/966?sso-checked=true","reference":"null. null. .","abstract":"Buonamici, S. et al. Abstract# Blood 128:966, 2016"}]},{"id":16331,"uuid":"89e907f7-e8be-404f-984e-810e9d097fc2","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4763,"hugoSymbol":"NF1","oncogene":false,"grch37Isoform":"ENST00000356175","grch37RefSeq":"NM_000267","grch38Isoform":"ENST00000356175","grch38RefSeq":"NM_000267","geneAliases":["WSS","NFNS","VRNF"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4763,"hugoSymbol":"NF1","oncogene":false,"grch37Isoform":"ENST00000356175","grch37RefSeq":"NM_000267","grch38Isoform":"ENST00000356175","grch38RefSeq":"NM_000267","geneAliases":["WSS","NFNS","VRNF"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C68923","drugName":"Cobimetinib","uuid":"eb357145-3b18-4aca-b75a-5e18dd2bf4f9","synonyms":["Cotellic","Cobimetinib","XL518","COBIMETINIB","GDC-0973","MEK Inhibitor GDC-0973"],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C77908","drugName":"Trametinib","uuid":"fb2bb01c-c0ec-4641-abf7-87f486075022","synonyms":["Mekinist","\"GSK1120212","Trametinib\"","TRAMETINIB","JTP-74057","MEK Inhibitor GSK1120212","N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","Trametinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572229871000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"LEVEL_4","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e13562","reference":"null. null. .","abstract":"Romo et al. Abstract# e13562, ASCO 2019"},{"pmid":"24576830","title":"Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.","journal":"Cancer research","pubDate":"2014 Apr 15","volume":"74","issue":"8","pages":"2340-50","authors":"Nissan MH et al","elocationId":"doi: 10.1158/0008-5472.CAN-13-2625","link":null,"reference":"Nissan MH et al. Cancer research. 2014 Apr 15;74(8)2340-50.","abstract":null},{"pmid":"24535670","title":"Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.","journal":"Cancer discovery","pubDate":"2014 May","volume":"4","issue":"5","pages":"606-19","authors":"de Bruin EC et al","elocationId":"doi: 10.1158/2159-8290.CD-13-0741","link":null,"reference":"de Bruin EC et al. Cancer discovery. 2014 May;4(5)606-19.","abstract":null},{"pmid":"31151904","title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2019 Jul","volume":"20","issue":"7","pages":"1011-1022","authors":"Fangusaro J et al","elocationId":"doi: 10.1016/S1470-2045(19)30277-3","link":null,"reference":"Fangusaro J et al. The Lancet. Oncology. 2019 Jul;20(7)1011-1022.","abstract":null},{"pmid":"26936308","title":"Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma.","journal":"Journal of clinical pharmacy and therapeutics","pubDate":"2016 Jun","volume":"41","issue":"3","pages":"357-359","authors":"Ameratunga M et al","elocationId":"doi: 10.1111/jcpt.12378","link":null,"reference":"Ameratunga M et al. Journal of clinical pharmacy and therapeutics. 2016 Jun;41(3)357-359.","abstract":null}]},{"id":5324,"uuid":"56df1fb2-b352-4f77-affd-9cc1ca244f37","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":51755,"hugoSymbol":"CDK12","oncogene":false,"grch37Isoform":"ENST00000447079","grch37RefSeq":"NM_016507.2","grch38Isoform":"ENST00000447079","grch38RefSeq":"NM_016507.2","geneAliases":["CRK7","CRKR","CRKRS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":51755,"hugoSymbol":"CDK12","oncogene":false,"grch37Isoform":"ENST00000447079","grch37RefSeq":"NM_016507.2","grch38Isoform":"ENST00000447079","grch38RefSeq":"NM_016507.2","geneAliases":["CRK7","CRKR","CRKRS"],"genesets":[],"tsg":true},"consequence":{"term":"feature_truncation","isGenerallyTruncating":true,"description":"A sequence variant that causes the reduction of a genomic feature, with regard to the reference sequence"},"alteration":"Truncating Mutations","name":"Truncating Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C68814","drugName":"Nivolumab","uuid":"e5402b72-1dbf-4735-97a1-3c86f27e8799","synonyms":["NIVO","Nivolumab","ONO-4538","Opdivo","BMS-936558","NIVOLUMAB","MDX-1106"],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C106432","drugName":"Pembrolizumab","uuid":"0746dd92-8f4d-4bf7-9161-57a223cb67d5","synonyms":["Pembrolizumab","MK-3475","PEMBROLIZUMAB","Keytruda","Lambrolizumab","SCH 900475\"","\"Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide"],"priority":1}]},{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C121540","drugName":"Cemiplimab","uuid":"9d83b717-7bf3-489b-b457-005b6f77f7ac","synonyms":["\"CEMIPLIMAB","Cemiplimab","REGN2810\"","Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal REGN2810 Heavy Chain), Disulfide with Human Monoclonal REGN2810 kappa-chain, Dimer"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572238195000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29906450","title":"Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.","journal":"Cell","pubDate":"2018 Jun 14","volume":"173","issue":"7","pages":"1770-1782.e14","authors":"Wu YM et al","elocationId":"doi: 10.1016/j.cell.2018.04.034","link":null,"reference":"Wu YM et al. Cell. 2018 Jun 14;173(7)1770-1782.e14.","abstract":null}]},{"id":23950,"uuid":"8bb54806-96f1-40b1-bef8-3976b042f220","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7307,"hugoSymbol":"U2AF1","oncogene":true,"grch37Isoform":"ENST00000291552","grch37RefSeq":"NM_006758.2","grch38Isoform":"ENST00000291552","grch38RefSeq":"NM_006758.2","geneAliases":["FP793","U2AFBP","RN","RNU2AF1","U2AF35"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":7307,"hugoSymbol":"U2AF1","oncogene":true,"grch37Isoform":"ENST00000291552","grch37RefSeq":"NM_006758.2","grch38Isoform":"ENST00000291552","grch38RefSeq":"NM_006758.2","geneAliases":["FP793","U2AFBP","RN","RNU2AF1","U2AF35"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C129546","drugName":"H3B-8800","uuid":"1cb40d2d-b6ee-4935-8e7e-131de7e3d5ea","synonyms":["Splicing Modulator H3B-8800","H3B 8800","Splicing Inhibitor H3B-8800","Splicing Factor Inhibitor H3B-8800"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572235093000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29457796","title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.","journal":"Nature medicine","pubDate":"2018 May","volume":"24","issue":"4","pages":"497-504","authors":"Seiler M et al","elocationId":"doi: 10.1038/nm.4493","link":null,"reference":"Seiler M et al. Nature medicine. 2018 May;24(4)497-504.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/128/22/966?sso-checked=true","reference":"null. null. .","abstract":"Buonamici, S. et al. Abstract# Blood 128:966, 2016"}]},{"id":6672,"uuid":"1d060c40-1441-453f-b91b-e358bc8fd041","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"D761Y","name":"D761Y","refResidues":"D","proteinStart":761,"proteinEnd":761,"variantResidues":"Y","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C116377","drugName":"Osimertinib","uuid":"4c2c1261-bfc3-4180-8113-127194366320","synonyms":["OSIMERTINIB","AZD-9291","Osimertinib","\"2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-","Tagrisso\"","Mereletinib","AZD9291"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1571714506000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"17085664","title":"Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2006 Nov 1","volume":"12","issue":"21","pages":"6494-501","authors":"Balak MN et al","elocationId":"","link":null,"reference":"Balak MN et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Nov 1;12(21)6494-501.","abstract":null},{"pmid":"28424065","title":"Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.","journal":"BMC cancer","pubDate":"2017 Apr 19","volume":"17","issue":"1","pages":"281","authors":"Chiba M et al","elocationId":"doi: 10.1186/s12885-017-3263-z","link":null,"reference":"Chiba M et al. BMC cancer. 2017 Apr 19;17(1)281.","abstract":null}]},{"id":10065,"uuid":"c7a1419f-affe-4706-8e92-711bf496d9d4","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2260,"hugoSymbol":"FGFR1","oncogene":true,"grch37Isoform":"ENST00000425967","grch37RefSeq":"NM_001174067.1","grch38Isoform":"ENST00000425967","grch38RefSeq":"NM_001174067.1","geneAliases":["FLG","N-SAM","FLT2","ECCL","CEK","HBGFR","HRTFDS","BFGFR","FGFR-1","FLT-2","OGD","FGFBR","HH2","bFGF-R-1","CD331","KAL2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2260,"hugoSymbol":"FGFR1","oncogene":true,"grch37Isoform":"ENST00000425967","grch37RefSeq":"NM_001174067.1","grch38Isoform":"ENST00000425967","grch38RefSeq":"NM_001174067.1","geneAliases":["FLG","N-SAM","FLT2","ECCL","CEK","HBGFR","HRTFDS","BFGFR","FGFR-1","FLT-2","OGD","FGFBR","HH2","bFGF-R-1","CD331","KAL2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C103273","drugName":"Erdafitinib","uuid":"f2e41d69-c383-4e33-ba25-0bf5f837db11","synonyms":["\"1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-","Balversa","Erdafitinib","JNJ-42756493\"","ERDAFITINIB"],"priority":1}]},{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C88302","drugName":"BGJ398","uuid":"dcbc3088-5056-487b-bc2f-da930840dfff","synonyms":["\"3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea","BGJ-398","Infigratinib\"","INFIGRATINIB","Infigratinib"],"priority":1}]},{"approvedIndications":[],"priority":4,"drugs":[{"ncitCode":"C88272","drugName":"AZD4547","uuid":"ea736f8d-c242-45d0-96d2-225a6553bd89","synonyms":["FGFR Inhibitor AZD4547"],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C111988","drugName":"Debio1347","uuid":"91859b88-74e8-4c71-98ce-70746997d61b","synonyms":["CH5183284","Debiopharm 1347","FF284","FGFR Inhibitor Debio 1347","debio 1347","debio 1347-101"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1571714779000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"LEVEL_4","liquidPropagationLevel":"NO","articles":[{"pmid":"23082000","title":"Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2012 Dec 15","volume":"18","issue":"24","pages":"6658-67","authors":"Zhang J et al","elocationId":"doi: 10.1158/1078-0432.CCR-12-2694","link":null,"reference":"Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.","abstract":null},{"pmid":"25169980","title":"The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.","journal":"Molecular cancer therapeutics","pubDate":"2014 Nov","volume":"13","issue":"11","pages":"2547-58","authors":"Nakanishi Y et al","elocationId":"doi: 10.1158/1535-7163.MCT-14-0248","link":null,"reference":"Nakanishi Y et al. Molecular cancer therapeutics. 2014 Nov;13(11)2547-58.","abstract":null},{"pmid":"27870574","title":"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Jan 10","volume":"35","issue":"2","pages":"157-165","authors":"Nogova L et al","elocationId":"","link":null,"reference":"Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.","abstract":null},{"pmid":"26438159","title":"ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.","journal":"Molecular cancer therapeutics","pubDate":"2015 Dec","volume":"14","issue":"12","pages":"2831-9","authors":"Nakanishi Y et al","elocationId":"doi: 10.1158/1535-7163.MCT-15-0497","link":null,"reference":"Nakanishi Y et al. Molecular cancer therapeutics. 2015 Dec;14(12)2831-9.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://cancerres.aacrjournals.org/content/77/13_Supplement/2088","reference":"null. null. .","abstract":"Brichory F et al. Abstract# 2088, AACR 2017"},{"pmid":"31340094","title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.","journal":"The New England journal of medicine","pubDate":"2019 Jul 25","volume":"381","issue":"4","pages":"338-348","authors":"Loriot Y et al","elocationId":"doi: 10.1056/NEJMoa1817323","link":null,"reference":"Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.","abstract":null},{"pmid":"30745300","title":"A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 May 1","volume":"25","issue":"9","pages":"2699-2707","authors":"Voss MH et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-1959","link":null,"reference":"Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.","abstract":null},{"pmid":"31088831","title":"Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 Aug 15","volume":"25","issue":"16","pages":"4888-4897","authors":"Bahleda R et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-3334","link":null,"reference":"Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.","abstract":null}]},{"id":6610,"uuid":"13e31e74-a398-4f0e-84df-b24bc70720e6","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"729_761ins","name":"Exon 19 insertion","refResidues":null,"proteinStart":729,"proteinEnd":761,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C66940","drugName":"Afatinib","uuid":"e1f45ae7-33ae-428c-9e77-da4a9b7270b6","synonyms":["BIBW 2992","Afatinib","BIBW2992","AFATINIB","(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1584634567000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22190593","title":"EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2012 Mar 15","volume":"18","issue":"6","pages":"1790-7","authors":"He M et al","elocationId":"doi: 10.1158/1078-0432.CCR-11-2361","link":null,"reference":"He M et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Mar 15;18(6)1790-7.","abstract":null}]},{"id":6675,"uuid":"c0d38860-a024-4ebf-948e-10947f68f720","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":882,"subtype":"","code":"","color":"Gray","mainType":"Glioma","level":0,"tissue":"CNS/Brain","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"R108K","name":"R108K","refResidues":"R","proteinStart":108,"proteinEnd":108,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"A289V","name":"A289V","refResidues":"A","proteinStart":289,"proteinEnd":289,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T263P","name":"T263P","refResidues":"T","proteinStart":263,"proteinEnd":263,"variantResidues":"P","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C26653","drugName":"Lapatinib","uuid":"6b1eee04-b74c-46d3-bdd3-1c68d1ec11b0","synonyms":["LAPATINIB","GW572016","lapatinib","GW 2016","GW2016","GSK572016","Lapatinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572228978000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22588883","title":"Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.","journal":"Cancer discovery","pubDate":"2012 May","volume":"2","issue":"5","pages":"458-71","authors":"Vivanco I et al","elocationId":"doi: 10.1158/2159-8290.CD-11-0284","link":null,"reference":"Vivanco I et al. Cancer discovery. 2012 May;2(5)458-71.","abstract":null},{"pmid":"20459769","title":"Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.","journal":"BMC cancer","pubDate":"2010 May 11","volume":"10","issue":"","pages":"188","authors":"Diaz R et al","elocationId":"doi: 10.1186/1471-2407-10-188","link":null,"reference":"Diaz R et al. BMC cancer. 2010 May 11;10()188.","abstract":null},{"pmid":"18334972","title":"Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.","journal":"British journal of cancer","pubDate":"2008 Mar 25","volume":"98","issue":"6","pages":"1076-84","authors":"Konecny GE et al","elocationId":"doi: 10.1038/sj.bjc.6604278","link":null,"reference":"Konecny GE et al. British journal of cancer. 2008 Mar 25;98(6)1076-84.","abstract":null}]},{"id":21848,"uuid":"a7e5c728-5ac0-4048-96eb-dd61c3498249","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":983,"subtype":"","code":"","color":"","mainType":"All Liquid Tumors","level":-1,"tissue":"","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6598,"hugoSymbol":"SMARCB1","oncogene":false,"grch37Isoform":"ENST00000263121","grch37RefSeq":"NM_003073.3","grch38Isoform":"ENST00000618915","grch38RefSeq":"NM_003073.3","geneAliases":["MRD15","SNF5L1","RDT","RTPS1","BAF47","PPP1R144","SNF5","CSS3","INI1","hSNFS","Sfh1p","SWNTS1","Snr1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":6598,"hugoSymbol":"SMARCB1","oncogene":false,"grch37Isoform":"ENST00000263121","grch37RefSeq":"NM_003073.3","grch38Isoform":"ENST00000618915","grch38RefSeq":"NM_003073.3","geneAliases":["MRD15","SNF5L1","RDT","RTPS1","BAF47","PPP1R144","SNF5","CSS3","INI1","hSNFS","Sfh1p","SWNTS1","Snr1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C107506","drugName":"Tazemetostat","uuid":"49e07d49-ee64-4049-c09d-37c6ce612cad","synonyms":["TAZEMETOSTAT","N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide","Tazemetostat","Tazemetostat\"","EPZ-6438","EPZ6438","N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide","\"E7438"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572235326000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"LEVEL_4","liquidPropagationLevel":"NO","articles":[{"pmid":"27391784","title":"Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.","journal":"PloS one","pubDate":"2016","volume":"11","issue":"7","pages":"e0158888","authors":"Kawano S et al","elocationId":"doi: 10.1371/journal.pone.0158888","link":null,"reference":"Kawano S et al. PloS one. 2016;11(7)e0158888.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.abstractsonline.com/pp8/#!/4557/presentation/616","reference":"null. null. .","abstract":"Chi et al. Abstract# A175, AACR-NCI-EORTC 2017"},{"pmid":"20951942","title":"Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation.","journal":"Cancer cell","pubDate":"2010 Oct 19","volume":"18","issue":"4","pages":"316-28","authors":"Wilson BG et al","elocationId":"doi: 10.1016/j.ccr.2010.09.006","link":null,"reference":"Wilson BG et al. Cancer cell. 2010 Oct 19;18(4)316-28.","abstract":null},{"pmid":"23620515","title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.","journal":"Proceedings of the National Academy of Sciences of the United States of America","pubDate":"2013 May 7","volume":"110","issue":"19","pages":"7922-7","authors":"Knutson SK et al","elocationId":"doi: 10.1073/pnas.1303800110","link":null,"reference":"Knutson SK et al. Proceedings of the National Academy of Sciences of the United States of America. 2013 May 7;110(19)7922-7.","abstract":null},{"pmid":"29650362","title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.","journal":"The Lancet. Oncology","pubDate":"2018 May","volume":"19","issue":"5","pages":"649-659","authors":"Italiano A et al","elocationId":"doi: 10.1016/S1470-2045(18)30145-1","link":null,"reference":"Italiano A et al. The Lancet. Oncology. 2018 May;19(5)649-659.","abstract":null}]},{"id":15962,"uuid":"0899acf0-1f4e-4660-bcbd-4bf48d53d208","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2475,"hugoSymbol":"MTOR","oncogene":true,"grch37Isoform":"ENST00000361445","grch37RefSeq":"NM_004958.3","grch38Isoform":"ENST00000361445","grch38RefSeq":"NM_004958.3","geneAliases":["FRAP1","RAFT1","FRAP2","FRAP","SKS","RAPT1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2475,"hugoSymbol":"MTOR","oncogene":true,"grch37Isoform":"ENST00000361445","grch37RefSeq":"NM_004958.3","grch38Isoform":"ENST00000361445","grch38RefSeq":"NM_004958.3","geneAliases":["FRAP1","RAFT1","FRAP2","FRAP","SKS","RAPT1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C48387","drugName":"Everolimus","uuid":"dacd7256-8305-466d-af04-bfd1c4e5dad5","synonyms":["RAD 001","everolimus\"","EVEROLIMUS","42-O-(2-Hydroxy)ethyl Rapamycin","Zortress","\"(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone","Certican","Votubia","Afinitor","RAD001","Everolimus"],"priority":1}]},{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C1844","drugName":"Temsirolimus","uuid":"234f5a9c-00e4-4447-8389-53e9b3fe4a26","synonyms":["CCI-779 Rapamycin Analog","temsirolimus","42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin","CCI-779","Torisel","TEMSIROLIMUS","Rapamycin Analog CCI-779","Temsirolimus","Rapamycin Analog","Cell Cycle Inhibitor 779"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572235625000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"LEVEL_4","liquidPropagationLevel":"NO","articles":[{"pmid":"26831717","title":"Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2016 May 15","volume":"22","issue":"10","pages":"2445-2452","authors":"Kwiatkowski DJ et al","elocationId":"doi: 10.1158/1078-0432.CCR-15-2631","link":null,"reference":"Kwiatkowski DJ et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 May 15;22(10)2445-2452.","abstract":null},{"pmid":"30327302","title":"PTEN Expression, Not Mutation Status in <i>TSC1, TSC2</i>, or <i>mTOR</i>, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 Jan 15","volume":"25","issue":"2","pages":"506-514","authors":"Voss MH et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-1833","link":null,"reference":"Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Jan 15;25(2)506-514.","abstract":null},{"pmid":"24631838","title":"A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.","journal":"Cancer discovery","pubDate":"2014 May","volume":"4","issue":"5","pages":"554-63","authors":"Grabiner BC et al","elocationId":"doi: 10.1158/2159-8290.CD-13-0929","link":null,"reference":"Grabiner BC et al. Cancer discovery. 2014 May;4(5)554-63.","abstract":null},{"pmid":"27482884","title":"Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.","journal":"The Journal of clinical investigation","pubDate":"2016 Sep 1","volume":"126","issue":"9","pages":"3526-40","authors":"Xu J et al","elocationId":"doi: 10.1172/JCI86120","link":null,"reference":"Xu J et al. The Journal of clinical investigation. 2016 Sep 1;126(9)3526-40.","abstract":null},{"pmid":"24622468","title":"Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2014 Apr 1","volume":"20","issue":"7","pages":"1955-64","authors":"Voss MH et al","elocationId":"doi: 10.1158/1078-0432.CCR-13-2345","link":null,"reference":"Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Apr 1;20(7)1955-64.","abstract":null}]},{"id":10525,"uuid":"cab46b19-5c8e-4898-a201-96aba3cc81f5","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2261,"hugoSymbol":"FGFR3","oncogene":true,"grch37Isoform":"ENST00000260795","grch37RefSeq":"NM_000142.4","grch38Isoform":"ENST00000440486","grch38RefSeq":"NM_000142.4","geneAliases":["JTK4","HSFGFR3EX","ACH","CEK2","CD333"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2261,"hugoSymbol":"FGFR3","oncogene":true,"grch37Isoform":"ENST00000260795","grch37RefSeq":"NM_000142.4","grch38Isoform":"ENST00000440486","grch38RefSeq":"NM_000142.4","geneAliases":["JTK4","HSFGFR3EX","ACH","CEK2","CD333"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":4,"drugs":[{"ncitCode":"C88272","drugName":"AZD4547","uuid":"ea736f8d-c242-45d0-96d2-225a6553bd89","synonyms":["FGFR Inhibitor AZD4547"],"priority":1}]},{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C88302","drugName":"BGJ398","uuid":"dcbc3088-5056-487b-bc2f-da930840dfff","synonyms":["\"3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea","BGJ-398","Infigratinib\"","INFIGRATINIB","Infigratinib"],"priority":1}]},{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C103273","drugName":"Erdafitinib","uuid":"f2e41d69-c383-4e33-ba25-0bf5f837db11","synonyms":["\"1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-","Balversa","Erdafitinib","JNJ-42756493\"","ERDAFITINIB"],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C111988","drugName":"Debio1347","uuid":"91859b88-74e8-4c71-98ce-70746997d61b","synonyms":["CH5183284","Debiopharm 1347","FF284","FGFR Inhibitor Debio 1347","debio 1347","debio 1347-101"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1571714859000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"LEVEL_4","liquidPropagationLevel":"NO","articles":[{"pmid":"23082000","title":"Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2012 Dec 15","volume":"18","issue":"24","pages":"6658-67","authors":"Zhang J et al","elocationId":"doi: 10.1158/1078-0432.CCR-12-2694","link":null,"reference":"Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.","abstract":null},{"pmid":"25169980","title":"The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.","journal":"Molecular cancer therapeutics","pubDate":"2014 Nov","volume":"13","issue":"11","pages":"2547-58","authors":"Nakanishi Y et al","elocationId":"doi: 10.1158/1535-7163.MCT-14-0248","link":null,"reference":"Nakanishi Y et al. Molecular cancer therapeutics. 2014 Nov;13(11)2547-58.","abstract":null},{"pmid":"27870574","title":"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Jan 10","volume":"35","issue":"2","pages":"157-165","authors":"Nogova L et al","elocationId":"","link":null,"reference":"Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.","abstract":null},{"pmid":"26438159","title":"ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.","journal":"Molecular cancer therapeutics","pubDate":"2015 Dec","volume":"14","issue":"12","pages":"2831-9","authors":"Nakanishi Y et al","elocationId":"doi: 10.1158/1535-7163.MCT-15-0497","link":null,"reference":"Nakanishi Y et al. Molecular cancer therapeutics. 2015 Dec;14(12)2831-9.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://cancerres.aacrjournals.org/content/77/13_Supplement/2088","reference":"null. null. .","abstract":"Brichory F et al. Abstract# 2088, AACR 2017"},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://meetinglibrary.asco.org/record/160559/abstract","reference":"null. null. .","abstract":"Siefker-Radtke et al. Abstract#4503, ASCO 2018"},{"pmid":"31340094","title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.","journal":"The New England journal of medicine","pubDate":"2019 Jul 25","volume":"381","issue":"4","pages":"338-348","authors":"Loriot Y et al","elocationId":"doi: 10.1056/NEJMoa1817323","link":null,"reference":"Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.","abstract":null},{"pmid":"30745300","title":"A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 May 1","volume":"25","issue":"9","pages":"2699-2707","authors":"Voss MH et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-1959","link":null,"reference":"Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.","abstract":null},{"pmid":"21119661","title":"Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.","journal":"British journal of cancer","pubDate":"2011 Jan 4","volume":"104","issue":"1","pages":"75-82","authors":"Lamont FR et al","elocationId":"doi: 10.1038/sj.bjc.6606016","link":null,"reference":"Lamont FR et al. British journal of cancer. 2011 Jan 4;104(1)75-82.","abstract":null},{"pmid":"31088831","title":"Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 Aug 15","volume":"25","issue":"16","pages":"4888-4897","authors":"Bahleda R et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-3334","link":null,"reference":"Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.","abstract":null},{"pmid":"26324363","title":"Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2015 Oct 20","volume":"33","issue":"30","pages":"3401-8","authors":"Tabernero J et al","elocationId":"doi: 10.1200/JCO.2014.60.7341","link":null,"reference":"Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.","abstract":null},{"pmid":"29848605","title":"Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations.","journal":"Cancer discovery","pubDate":"2018 Jul","volume":"8","issue":"7","pages":"812-821","authors":"Pal SK et al","elocationId":"doi: 10.1158/2159-8290.CD-18-0229","link":null,"reference":"Pal SK et al. Cancer discovery. 2018 Jul;8(7)812-821.","abstract":null}]},{"id":22240,"uuid":"f96134dc-3e3d-4830-a825-9392f022a51a","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C129546","drugName":"H3B-8800","uuid":"1cb40d2d-b6ee-4935-8e7e-131de7e3d5ea","synonyms":["Splicing Modulator H3B-8800","H3B 8800","Splicing Inhibitor H3B-8800","Splicing Factor Inhibitor H3B-8800"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572235153000,"lastReview":null,"levelOfEvidence":"LEVEL_4","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29457796","title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.","journal":"Nature medicine","pubDate":"2018 May","volume":"24","issue":"4","pages":"497-504","authors":"Seiler M et al","elocationId":"doi: 10.1038/nm.4493","link":null,"reference":"Seiler M et al. Nature medicine. 2018 May;24(4)497-504.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/128/22/966?sso-checked=true","reference":"null. null. .","abstract":"Buonamici, S. et al. Abstract# Blood 128:966, 2016"}]}],"LEVEL_1":[{"id":20325,"uuid":"83ba219f-de98-4e01-9555-354b9cc16bb9","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":936,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer","level":0,"tissue":"Prostate","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5892,"hugoSymbol":"RAD51D","oncogene":false,"grch37Isoform":"ENST00000345365","grch37RefSeq":"NM_002878","grch38Isoform":"ENST00000345365","grch38RefSeq":"","geneAliases":["BROVCA4","TRAD","RAD51L3"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":5892,"hugoSymbol":"RAD51D","oncogene":false,"grch37Isoform":"ENST00000345365","grch37RefSeq":"NM_002878","grch38Isoform":"ENST00000345365","grch38RefSeq":"","geneAliases":["BROVCA4","TRAD","RAD51L3"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1591160860000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32343890","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer.","journal":"The New England journal of medicine","pubDate":"2020 May 28","volume":"382","issue":"22","pages":"2091-2102","authors":"de Bono J et al","elocationId":"doi: 10.1056/NEJMoa1911440","link":null,"reference":"de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.","abstract":null}]},{"id":4717,"uuid":"fbc4412e-2aec-45af-b8f9-8eca4b193205","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":936,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer","level":0,"tissue":"Prostate","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":83990,"hugoSymbol":"BRIP1","oncogene":false,"grch37Isoform":"ENST00000259008","grch37RefSeq":"NM_032043.2","grch38Isoform":"ENST00000259008","grch38RefSeq":"NM_032043.2","geneAliases":["FANCJ","OF","BACH1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":83990,"hugoSymbol":"BRIP1","oncogene":false,"grch37Isoform":"ENST00000259008","grch37RefSeq":"NM_032043.2","grch38Isoform":"ENST00000259008","grch38RefSeq":"NM_032043.2","geneAliases":["FANCJ","OF","BACH1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1591158407000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32343890","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer.","journal":"The New England journal of medicine","pubDate":"2020 May 28","volume":"382","issue":"22","pages":"2091-2102","authors":"de Bono J et al","elocationId":"doi: 10.1056/NEJMoa1911440","link":null,"reference":"de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.","abstract":null}]},{"id":20339,"uuid":"8079b1c2-bd36-4d2a-951c-32b30f0c3db9","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":936,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer","level":0,"tissue":"Prostate","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8438,"hugoSymbol":"RAD54L","oncogene":false,"grch37Isoform":"ENST00000371975","grch37RefSeq":"NM_001142548.1","grch38Isoform":"ENST00000371975","grch38RefSeq":"NM_001142548.1","geneAliases":["hRAD54","HR54","hHR54","RAD54A"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":8438,"hugoSymbol":"RAD54L","oncogene":false,"grch37Isoform":"ENST00000371975","grch37RefSeq":"NM_001142548.1","grch38Isoform":"ENST00000371975","grch38RefSeq":"NM_001142548.1","geneAliases":["hRAD54","HR54","hHR54","RAD54A"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1591160986000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32343890","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer.","journal":"The New England journal of medicine","pubDate":"2020 May 28","volume":"382","issue":"22","pages":"2091-2102","authors":"de Bono J et al","elocationId":"doi: 10.1056/NEJMoa1911440","link":null,"reference":"de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.","abstract":null}]},{"id":17525,"uuid":"c01f87fb-ee57-48a9-b97f-93609fe157f1","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"D842_H845insV","name":"D842_H845insV","refResidues":null,"proteinStart":842,"proteinEnd":845,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"D842V","name":"D842V","refResidues":"D","proteinStart":842,"proteinEnd":842,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"D842Y","name":"D842Y","refResidues":"D","proteinStart":842,"proteinEnd":842,"variantResidues":"Y","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"D842_H845del","name":"D842_H845del","refResidues":null,"proteinStart":842,"proteinEnd":845,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C123827","drugName":"Avapritinib","uuid":"3d49e386-0cc4-401e-9acd-d2d33b2923a3","synonyms":["PDGFR alpha/KIT Mutant-specific Inhibitor BLU-285","BLU-285","Avapritinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1595393250000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.11022","reference":"null. null. .","abstract":"Heinrich et al. Abstract# 11022, ASCO 2019"},{"pmid":"32615108","title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.","journal":"The Lancet. Oncology","pubDate":"2020 Jul","volume":"21","issue":"7","pages":"935-946","authors":"Heinrich MC et al","elocationId":"doi: 10.1016/S1470-2045(20)30269-2","link":null,"reference":"Heinrich MC et al. The Lancet. Oncology. 2020 Jul;21(7)935-946.","abstract":null}]},{"id":17285,"uuid":"140a8f3a-ace7-4426-8ff7-c8147e41d7c8","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":936,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer","level":0,"tissue":"Prostate","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":79728,"hugoSymbol":"PALB2","oncogene":false,"grch37Isoform":"ENST00000261584","grch37RefSeq":"NM_024675.3","grch38Isoform":"ENST00000261584","grch38RefSeq":"NM_024675.3","geneAliases":["FANCN","PNCA3"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":79728,"hugoSymbol":"PALB2","oncogene":false,"grch37Isoform":"ENST00000261584","grch37RefSeq":"NM_024675.3","grch38Isoform":"ENST00000261584","grch38RefSeq":"NM_024675.3","geneAliases":["FANCN","PNCA3"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1591160322000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32343890","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer.","journal":"The New England journal of medicine","pubDate":"2020 May 28","volume":"382","issue":"22","pages":"2091-2102","authors":"de Bono J et al","elocationId":"doi: 10.1056/NEJMoa1911440","link":null,"reference":"de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.","abstract":null}]},{"id":23686,"uuid":"d7697c91-2f3f-4223-b917-a39df9a7af69","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":889,"subtype":"","code":"","color":"Gray","mainType":"CNS Cancer","level":0,"tissue":"CNS/Brain","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7248,"hugoSymbol":"TSC1","oncogene":false,"grch37Isoform":"ENST00000298552","grch37RefSeq":"NM_000368.4","grch38Isoform":"ENST00000298552","grch38RefSeq":"NM_000368.4","geneAliases":["TSC"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":7248,"hugoSymbol":"TSC1","oncogene":false,"grch37Isoform":"ENST00000298552","grch37RefSeq":"NM_000368.4","grch38Isoform":"ENST00000298552","grch38RefSeq":"NM_000368.4","geneAliases":["TSC"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Everolimus is FDA-approved for the treatment of pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected."],"priority":1,"drugs":[{"ncitCode":"C48387","drugName":"Everolimus","uuid":"dacd7256-8305-466d-af04-bfd1c4e5dad5","synonyms":["RAD 001","everolimus\"","EVEROLIMUS","42-O-(2-Hydroxy)ethyl Rapamycin","Zortress","\"(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone","Certican","Votubia","Afinitor","RAD001","Everolimus"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1530815547000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"23158522","title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.","journal":"Lancet (London, England)","pubDate":"2013 Jan 12","volume":"381","issue":"9861","pages":"125-32","authors":"Franz DN et al","elocationId":"doi: 10.1016/S0140-6736(12)61134-9","link":null,"reference":"Franz DN et al. Lancet (London, England). 2013 Jan 12;381(9861)125-32.","abstract":null}]},{"id":12678,"uuid":"29209b1a-05d9-459a-a0f4-e63ce70ba208","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"S501_A502dup","name":"S501_A502dup","refResidues":null,"proteinStart":501,"proteinEnd":502,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"N505I","name":"N505I","refResidues":"N","proteinStart":505,"proteinEnd":505,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"A502_Y503dup","name":"A502_Y503dup","refResidues":null,"proteinStart":502,"proteinEnd":503,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"K509I","name":"K509I","refResidues":"K","proteinStart":509,"proteinEnd":509,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"S476I","name":"S476I","refResidues":"S","proteinStart":476,"proteinEnd":476,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[" (2) adjuvant treatment of adult patients following complete gross resection of KIT-positive GIST.","Imatinib is FDA-approved for the treatment of (1) patients with KIT-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs)"],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580401519000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"28196207","title":"Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.","journal":"JAMA oncology","pubDate":"2017 Jul 1","volume":"3","issue":"7","pages":"944-952","authors":"Heinrich MC et al","elocationId":"doi: 10.1001/jamaoncol.2016.6728","link":null,"reference":"Heinrich MC et al. JAMA oncology. 2017 Jul 1;3(7)944-952.","abstract":null},{"pmid":"18235122","title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Feb 1","volume":"26","issue":"4","pages":"626-32","authors":"Blanke CD et al","elocationId":"doi: 10.1200/JCO.2007.13.4452","link":null,"reference":"Blanke CD et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Feb 1;26(4)626-32.","abstract":null},{"pmid":"12181401","title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.","journal":"The New England journal of medicine","pubDate":"2002 Aug 15","volume":"347","issue":"7","pages":"472-80","authors":"Demetri GD et al","elocationId":"","link":null,"reference":"Demetri GD et al. The New England journal of medicine. 2002 Aug 15;347(7)472-80.","abstract":null},{"pmid":"18955451","title":"Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5360-7","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2008.17.4284","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5360-7.","abstract":null}]},{"id":12679,"uuid":"4167b055-f42c-46b7-b845-85461819a1d7","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"S501_A502dup","name":"S501_A502dup","refResidues":null,"proteinStart":501,"proteinEnd":502,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"N505I","name":"N505I","refResidues":"N","proteinStart":505,"proteinEnd":505,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"A502_Y503dup","name":"A502_Y503dup","refResidues":null,"proteinStart":502,"proteinEnd":503,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"K509I","name":"K509I","refResidues":"K","proteinStart":509,"proteinEnd":509,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"S476I","name":"S476I","refResidues":"S","proteinStart":476,"proteinEnd":476,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Sunitinib is FDA-approved for gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate."],"priority":2,"drugs":[{"ncitCode":"C71622","drugName":"Sunitinib","uuid":"5b548883-0142-4d15-a324-22d7b29800b2","synonyms":["\"1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-","Sunitinib","SUNITINIB","sunitinib\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580401586000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"17046465","title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.","journal":"Lancet (London, England)","pubDate":"2006 Oct 14","volume":"368","issue":"9544","pages":"1329-38","authors":"Demetri GD et al","elocationId":"","link":null,"reference":"Demetri GD et al. Lancet (London, England). 2006 Oct 14;368(9544)1329-38.","abstract":null}]},{"id":12680,"uuid":"dbc14df5-cbfb-46e1-a4f7-0f3d1513fc19","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"S501_A502dup","name":"S501_A502dup","refResidues":null,"proteinStart":501,"proteinEnd":502,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"N505I","name":"N505I","refResidues":"N","proteinStart":505,"proteinEnd":505,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"A502_Y503dup","name":"A502_Y503dup","refResidues":null,"proteinStart":502,"proteinEnd":503,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"K509I","name":"K509I","refResidues":"K","proteinStart":509,"proteinEnd":509,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"S476I","name":"S476I","refResidues":"S","proteinStart":476,"proteinEnd":476,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Regorafenib is FDA-approved for patients with advanced, unresectable gastrointestinal stromal tumors (GIST) that no longer respond to imatinib and sunitinib."],"priority":3,"drugs":[{"ncitCode":"C78204","drugName":"Regorafenib","uuid":"e0d0786c-307a-4a7a-bfff-036cfa7f9df5","synonyms":["Regorafenib","Stivarga","REGORAFENIB","BAY 73-4506","4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580401631000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"23177515","title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.","journal":"Lancet (London, England)","pubDate":"2013 Jan 26","volume":"381","issue":"9863","pages":"295-302","authors":"Demetri GD et al","elocationId":"doi: 10.1016/S0140-6736(12)61857-1","link":null,"reference":"Demetri GD et al. Lancet (London, England). 2013 Jan 26;381(9863)295-302.","abstract":null}]},{"id":12681,"uuid":"ae3b2aa2-2e11-48a2-bd59-5d127cd9bc2c","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"S501_A502dup","name":"S501_A502dup","refResidues":null,"proteinStart":501,"proteinEnd":502,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"N505I","name":"N505I","refResidues":"N","proteinStart":505,"proteinEnd":505,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"A502_Y503dup","name":"A502_Y503dup","refResidues":null,"proteinStart":502,"proteinEnd":503,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"K509I","name":"K509I","refResidues":"K","proteinStart":509,"proteinEnd":509,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"S476I","name":"S476I","refResidues":"S","proteinStart":476,"proteinEnd":476,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":4,"drugs":[{"ncitCode":null,"drugName":"Ripretinib","uuid":"2841f955-5295-416c-a7a3-3dd39962bfae","synonyms":[],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1597941791000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32511981","title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2020 Jul","volume":"21","issue":"7","pages":"923-934","authors":"Blay JY et al","elocationId":"doi: 10.1016/S1470-2045(20)30168-6","link":null,"reference":"Blay JY et al. The Lancet. Oncology. 2020 Jul;21(7)923-934.","abstract":null}]},{"id":12684,"uuid":"b23669c9-57cd-4210-b43d-ba9a4e063ee5","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"W557C","name":"W557C","refResidues":"W","proteinStart":557,"proteinEnd":557,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"N564_Y578del","name":"N564_Y578del","refResidues":null,"proteinStart":564,"proteinEnd":578,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L576P","name":"L576P","refResidues":"L","proteinStart":576,"proteinEnd":576,"variantResidues":"P","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K550_G592del","name":"Exon 11 deletion","refResidues":null,"proteinStart":550,"proteinEnd":592,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K558_E562del","name":"K558_E562del","refResidues":null,"proteinStart":558,"proteinEnd":562,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"Y578_D579insEQQLPY","name":"Y578_D579insEQQLPY","refResidues":null,"proteinStart":578,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"Y553_Q556del","name":"Y553_Q556del","refResidues":null,"proteinStart":553,"proteinEnd":556,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"I563_L576del","name":"I563_L576del","refResidues":null,"proteinStart":563,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"D579_H580insFNPTQLPYD","name":"D579_H580insFNPTQLPYD","refResidues":null,"proteinStart":579,"proteinEnd":580,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V560E","name":"V560E","refResidues":"V","proteinStart":560,"proteinEnd":560,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"E554_I571del","name":"E554_I571del","refResidues":null,"proteinStart":554,"proteinEnd":571,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y578C","name":"Y578C","refResidues":"Y","proteinStart":578,"proteinEnd":578,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"D579_H580insLPCD","name":"D579_H580insLPCD","refResidues":null,"proteinStart":579,"proteinEnd":580,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"Y553_K558del","name":"Y553_K558del","refResidues":null,"proteinStart":553,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V559_G565del","name":"V559_G565del","refResidues":null,"proteinStart":559,"proteinEnd":565,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"M552_W557del","name":"M552_W557del","refResidues":null,"proteinStart":552,"proteinEnd":557,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V555_L576del","name":"V555_L576del","refResidues":null,"proteinStart":555,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559G","name":"V559G","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V559_V560del","name":"V559_V560del","refResidues":null,"proteinStart":559,"proteinEnd":560,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V559del","name":"V559del","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"P573Q","name":"P573Q","refResidues":"P","proteinStart":573,"proteinEnd":573,"variantResidues":"Q","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V569_L576del","name":"V569_L576del","refResidues":null,"proteinStart":569,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559F","name":"V559F","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"F","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"E554_K558del","name":"E554_K558del","refResidues":null,"proteinStart":554,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V560G","name":"V560G","refResidues":"V","proteinStart":560,"proteinEnd":560,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"Y578_D579dup","name":"Y578_D579dup","refResidues":null,"proteinStart":578,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P577_W582delinsPYD","name":"P577_W582delinsPYD","refResidues":null,"proteinStart":577,"proteinEnd":582,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559A","name":"V559A","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K558_V560del","name":"K558_V560del","refResidues":null,"proteinStart":558,"proteinEnd":560,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"T574insTQLPYD","name":"T574insTQLPYD","refResidues":null,"proteinStart":574,"proteinEnd":574,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"Q575_P585dup","name":"Q575_P585dup","refResidues":null,"proteinStart":575,"proteinEnd":585,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559C","name":"V559C","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"W557_V560del","name":"W557_V560del","refResidues":null,"proteinStart":557,"proteinEnd":560,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"P577_R588dup","name":"P577_R588dup","refResidues":null,"proteinStart":577,"proteinEnd":588,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P551_E554del","name":"P551_E554del","refResidues":null,"proteinStart":551,"proteinEnd":554,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"E554_V559del","name":"E554_V559del","refResidues":null,"proteinStart":554,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"K558delinsNP","name":"K558delinsNP","refResidues":null,"proteinStart":558,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"W557_K558del","name":"W557_K558del","refResidues":null,"proteinStart":557,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P551_W557delinsL","name":"P551_W557delinsL","refResidues":null,"proteinStart":551,"proteinEnd":557,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P551_V555del","name":"P551_V555del","refResidues":null,"proteinStart":551,"proteinEnd":555,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"M552_K558del","name":"M552_K558del","refResidues":null,"proteinStart":552,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"D572_P573dup","name":"D572_P573dup","refResidues":null,"proteinStart":572,"proteinEnd":573,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"D579del","name":"D579del","refResidues":"D","proteinStart":579,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"W557R","name":"W557R","refResidues":"W","proteinStart":557,"proteinEnd":557,"variantResidues":"R","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P573_D579del","name":"P573_D579del","refResidues":null,"proteinStart":573,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"W557_V559delinsC","name":"W557_V559delinsC","refResidues":null,"proteinStart":557,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"W557G","name":"W557G","refResidues":"W","proteinStart":557,"proteinEnd":557,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P551_M552del","name":"P551_M552del","refResidues":null,"proteinStart":551,"proteinEnd":552,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559D","name":"V559D","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"D","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"L576del","name":"L576del","refResidues":"L","proteinStart":576,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K550_V555delinsI","name":"K550_V555delinsI","refResidues":null,"proteinStart":550,"proteinEnd":555,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"Y568_L576delinsVN","name":"Y568_L576delinsVN","refResidues":null,"proteinStart":568,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V555_V559del","name":"V555_V559del","refResidues":null,"proteinStart":555,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K558_V559del","name":"K558_V559del","refResidues":null,"proteinStart":558,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V560D","name":"V560D","refResidues":"V","proteinStart":560,"proteinEnd":560,"variantResidues":"D","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K550_W557del","name":"K550_W557del","refResidues":null,"proteinStart":550,"proteinEnd":557,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"D572A","name":"D572A","refResidues":"D","proteinStart":572,"proteinEnd":572,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559I","name":"V559I","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V560del","name":"V560del","refResidues":"V","proteinStart":560,"proteinEnd":560,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K550_K558del","name":"K550_K558del","refResidues":null,"proteinStart":550,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"Q556_K558del","name":"Q556_K558del","refResidues":null,"proteinStart":556,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"Q575_L576dup","name":"Q575_L576dup","refResidues":null,"proteinStart":575,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P577_D579del","name":"P577_D579del","refResidues":null,"proteinStart":577,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"K558N","name":"K558N","refResidues":"K","proteinStart":558,"proteinEnd":558,"variantResidues":"N","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"T574_R588delinsL","name":"T574_R588delinsL","refResidues":null,"proteinStart":574,"proteinEnd":588,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[" (2) adjuvant treatment of adult patients following complete gross resection of KIT-positive GIST.","Imatinib is FDA-approved for the treatment of (1) patients with KIT-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs)"],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580402717000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"28196207","title":"Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.","journal":"JAMA oncology","pubDate":"2017 Jul 1","volume":"3","issue":"7","pages":"944-952","authors":"Heinrich MC et al","elocationId":"doi: 10.1001/jamaoncol.2016.6728","link":null,"reference":"Heinrich MC et al. JAMA oncology. 2017 Jul 1;3(7)944-952.","abstract":null},{"pmid":"18235122","title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Feb 1","volume":"26","issue":"4","pages":"626-32","authors":"Blanke CD et al","elocationId":"doi: 10.1200/JCO.2007.13.4452","link":null,"reference":"Blanke CD et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Feb 1;26(4)626-32.","abstract":null},{"pmid":"12181401","title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.","journal":"The New England journal of medicine","pubDate":"2002 Aug 15","volume":"347","issue":"7","pages":"472-80","authors":"Demetri GD et al","elocationId":"","link":null,"reference":"Demetri GD et al. The New England journal of medicine. 2002 Aug 15;347(7)472-80.","abstract":null},{"pmid":"18955451","title":"Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5360-7","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2008.17.4284","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5360-7.","abstract":null}]},{"id":12685,"uuid":"3adcb23d-e1d1-457e-8ca3-6b963ccc44b0","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"W557C","name":"W557C","refResidues":"W","proteinStart":557,"proteinEnd":557,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"N564_Y578del","name":"N564_Y578del","refResidues":null,"proteinStart":564,"proteinEnd":578,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L576P","name":"L576P","refResidues":"L","proteinStart":576,"proteinEnd":576,"variantResidues":"P","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K550_G592del","name":"Exon 11 deletion","refResidues":null,"proteinStart":550,"proteinEnd":592,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K558_E562del","name":"K558_E562del","refResidues":null,"proteinStart":558,"proteinEnd":562,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"Y578_D579insEQQLPY","name":"Y578_D579insEQQLPY","refResidues":null,"proteinStart":578,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"Y553_Q556del","name":"Y553_Q556del","refResidues":null,"proteinStart":553,"proteinEnd":556,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"I563_L576del","name":"I563_L576del","refResidues":null,"proteinStart":563,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"D579_H580insFNPTQLPYD","name":"D579_H580insFNPTQLPYD","refResidues":null,"proteinStart":579,"proteinEnd":580,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V560E","name":"V560E","refResidues":"V","proteinStart":560,"proteinEnd":560,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"E554_I571del","name":"E554_I571del","refResidues":null,"proteinStart":554,"proteinEnd":571,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y578C","name":"Y578C","refResidues":"Y","proteinStart":578,"proteinEnd":578,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"D579_H580insLPCD","name":"D579_H580insLPCD","refResidues":null,"proteinStart":579,"proteinEnd":580,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"Y553_K558del","name":"Y553_K558del","refResidues":null,"proteinStart":553,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V559_G565del","name":"V559_G565del","refResidues":null,"proteinStart":559,"proteinEnd":565,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"M552_W557del","name":"M552_W557del","refResidues":null,"proteinStart":552,"proteinEnd":557,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V555_L576del","name":"V555_L576del","refResidues":null,"proteinStart":555,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559G","name":"V559G","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V559_V560del","name":"V559_V560del","refResidues":null,"proteinStart":559,"proteinEnd":560,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V559del","name":"V559del","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"P573Q","name":"P573Q","refResidues":"P","proteinStart":573,"proteinEnd":573,"variantResidues":"Q","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V569_L576del","name":"V569_L576del","refResidues":null,"proteinStart":569,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559F","name":"V559F","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"F","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"E554_K558del","name":"E554_K558del","refResidues":null,"proteinStart":554,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V560G","name":"V560G","refResidues":"V","proteinStart":560,"proteinEnd":560,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"Y578_D579dup","name":"Y578_D579dup","refResidues":null,"proteinStart":578,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P577_W582delinsPYD","name":"P577_W582delinsPYD","refResidues":null,"proteinStart":577,"proteinEnd":582,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559A","name":"V559A","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K558_V560del","name":"K558_V560del","refResidues":null,"proteinStart":558,"proteinEnd":560,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"T574insTQLPYD","name":"T574insTQLPYD","refResidues":null,"proteinStart":574,"proteinEnd":574,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"Q575_P585dup","name":"Q575_P585dup","refResidues":null,"proteinStart":575,"proteinEnd":585,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559C","name":"V559C","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"W557_V560del","name":"W557_V560del","refResidues":null,"proteinStart":557,"proteinEnd":560,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"P577_R588dup","name":"P577_R588dup","refResidues":null,"proteinStart":577,"proteinEnd":588,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P551_E554del","name":"P551_E554del","refResidues":null,"proteinStart":551,"proteinEnd":554,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"E554_V559del","name":"E554_V559del","refResidues":null,"proteinStart":554,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"K558delinsNP","name":"K558delinsNP","refResidues":null,"proteinStart":558,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"W557_K558del","name":"W557_K558del","refResidues":null,"proteinStart":557,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P551_W557delinsL","name":"P551_W557delinsL","refResidues":null,"proteinStart":551,"proteinEnd":557,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P551_V555del","name":"P551_V555del","refResidues":null,"proteinStart":551,"proteinEnd":555,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"M552_K558del","name":"M552_K558del","refResidues":null,"proteinStart":552,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"D572_P573dup","name":"D572_P573dup","refResidues":null,"proteinStart":572,"proteinEnd":573,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"D579del","name":"D579del","refResidues":"D","proteinStart":579,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"W557R","name":"W557R","refResidues":"W","proteinStart":557,"proteinEnd":557,"variantResidues":"R","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P573_D579del","name":"P573_D579del","refResidues":null,"proteinStart":573,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"W557_V559delinsC","name":"W557_V559delinsC","refResidues":null,"proteinStart":557,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"W557G","name":"W557G","refResidues":"W","proteinStart":557,"proteinEnd":557,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P551_M552del","name":"P551_M552del","refResidues":null,"proteinStart":551,"proteinEnd":552,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559D","name":"V559D","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"D","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"L576del","name":"L576del","refResidues":"L","proteinStart":576,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K550_V555delinsI","name":"K550_V555delinsI","refResidues":null,"proteinStart":550,"proteinEnd":555,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"Y568_L576delinsVN","name":"Y568_L576delinsVN","refResidues":null,"proteinStart":568,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V555_V559del","name":"V555_V559del","refResidues":null,"proteinStart":555,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K558_V559del","name":"K558_V559del","refResidues":null,"proteinStart":558,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V560D","name":"V560D","refResidues":"V","proteinStart":560,"proteinEnd":560,"variantResidues":"D","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K550_W557del","name":"K550_W557del","refResidues":null,"proteinStart":550,"proteinEnd":557,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"D572A","name":"D572A","refResidues":"D","proteinStart":572,"proteinEnd":572,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559I","name":"V559I","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V560del","name":"V560del","refResidues":"V","proteinStart":560,"proteinEnd":560,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K550_K558del","name":"K550_K558del","refResidues":null,"proteinStart":550,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"Q556_K558del","name":"Q556_K558del","refResidues":null,"proteinStart":556,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"Q575_L576dup","name":"Q575_L576dup","refResidues":null,"proteinStart":575,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P577_D579del","name":"P577_D579del","refResidues":null,"proteinStart":577,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"K558N","name":"K558N","refResidues":"K","proteinStart":558,"proteinEnd":558,"variantResidues":"N","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"T574_R588delinsL","name":"T574_R588delinsL","refResidues":null,"proteinStart":574,"proteinEnd":588,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Sunitinib is FDA-approved for gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate."],"priority":2,"drugs":[{"ncitCode":"C71622","drugName":"Sunitinib","uuid":"5b548883-0142-4d15-a324-22d7b29800b2","synonyms":["\"1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-","Sunitinib","SUNITINIB","sunitinib\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580402744000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"17046465","title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.","journal":"Lancet (London, England)","pubDate":"2006 Oct 14","volume":"368","issue":"9544","pages":"1329-38","authors":"Demetri GD et al","elocationId":"","link":null,"reference":"Demetri GD et al. Lancet (London, England). 2006 Oct 14;368(9544)1329-38.","abstract":null}]},{"id":12686,"uuid":"59b429c7-dd7a-464d-8a86-b3778c0402c9","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"W557C","name":"W557C","refResidues":"W","proteinStart":557,"proteinEnd":557,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"N564_Y578del","name":"N564_Y578del","refResidues":null,"proteinStart":564,"proteinEnd":578,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L576P","name":"L576P","refResidues":"L","proteinStart":576,"proteinEnd":576,"variantResidues":"P","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K550_G592del","name":"Exon 11 deletion","refResidues":null,"proteinStart":550,"proteinEnd":592,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K558_E562del","name":"K558_E562del","refResidues":null,"proteinStart":558,"proteinEnd":562,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"Y578_D579insEQQLPY","name":"Y578_D579insEQQLPY","refResidues":null,"proteinStart":578,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"Y553_Q556del","name":"Y553_Q556del","refResidues":null,"proteinStart":553,"proteinEnd":556,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"I563_L576del","name":"I563_L576del","refResidues":null,"proteinStart":563,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"D579_H580insFNPTQLPYD","name":"D579_H580insFNPTQLPYD","refResidues":null,"proteinStart":579,"proteinEnd":580,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V560E","name":"V560E","refResidues":"V","proteinStart":560,"proteinEnd":560,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"E554_I571del","name":"E554_I571del","refResidues":null,"proteinStart":554,"proteinEnd":571,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y578C","name":"Y578C","refResidues":"Y","proteinStart":578,"proteinEnd":578,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"D579_H580insLPCD","name":"D579_H580insLPCD","refResidues":null,"proteinStart":579,"proteinEnd":580,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"Y553_K558del","name":"Y553_K558del","refResidues":null,"proteinStart":553,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V559_G565del","name":"V559_G565del","refResidues":null,"proteinStart":559,"proteinEnd":565,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"M552_W557del","name":"M552_W557del","refResidues":null,"proteinStart":552,"proteinEnd":557,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V555_L576del","name":"V555_L576del","refResidues":null,"proteinStart":555,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559G","name":"V559G","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V559_V560del","name":"V559_V560del","refResidues":null,"proteinStart":559,"proteinEnd":560,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V559del","name":"V559del","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"P573Q","name":"P573Q","refResidues":"P","proteinStart":573,"proteinEnd":573,"variantResidues":"Q","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V569_L576del","name":"V569_L576del","refResidues":null,"proteinStart":569,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559F","name":"V559F","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"F","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"E554_K558del","name":"E554_K558del","refResidues":null,"proteinStart":554,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V560G","name":"V560G","refResidues":"V","proteinStart":560,"proteinEnd":560,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"Y578_D579dup","name":"Y578_D579dup","refResidues":null,"proteinStart":578,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P577_W582delinsPYD","name":"P577_W582delinsPYD","refResidues":null,"proteinStart":577,"proteinEnd":582,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559A","name":"V559A","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K558_V560del","name":"K558_V560del","refResidues":null,"proteinStart":558,"proteinEnd":560,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"T574insTQLPYD","name":"T574insTQLPYD","refResidues":null,"proteinStart":574,"proteinEnd":574,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"Q575_P585dup","name":"Q575_P585dup","refResidues":null,"proteinStart":575,"proteinEnd":585,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559C","name":"V559C","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"W557_V560del","name":"W557_V560del","refResidues":null,"proteinStart":557,"proteinEnd":560,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"P577_R588dup","name":"P577_R588dup","refResidues":null,"proteinStart":577,"proteinEnd":588,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P551_E554del","name":"P551_E554del","refResidues":null,"proteinStart":551,"proteinEnd":554,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"E554_V559del","name":"E554_V559del","refResidues":null,"proteinStart":554,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"K558delinsNP","name":"K558delinsNP","refResidues":null,"proteinStart":558,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"W557_K558del","name":"W557_K558del","refResidues":null,"proteinStart":557,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P551_W557delinsL","name":"P551_W557delinsL","refResidues":null,"proteinStart":551,"proteinEnd":557,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P551_V555del","name":"P551_V555del","refResidues":null,"proteinStart":551,"proteinEnd":555,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"M552_K558del","name":"M552_K558del","refResidues":null,"proteinStart":552,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"D572_P573dup","name":"D572_P573dup","refResidues":null,"proteinStart":572,"proteinEnd":573,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"D579del","name":"D579del","refResidues":"D","proteinStart":579,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"W557R","name":"W557R","refResidues":"W","proteinStart":557,"proteinEnd":557,"variantResidues":"R","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P573_D579del","name":"P573_D579del","refResidues":null,"proteinStart":573,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"W557_V559delinsC","name":"W557_V559delinsC","refResidues":null,"proteinStart":557,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"W557G","name":"W557G","refResidues":"W","proteinStart":557,"proteinEnd":557,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P551_M552del","name":"P551_M552del","refResidues":null,"proteinStart":551,"proteinEnd":552,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559D","name":"V559D","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"D","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"L576del","name":"L576del","refResidues":"L","proteinStart":576,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K550_V555delinsI","name":"K550_V555delinsI","refResidues":null,"proteinStart":550,"proteinEnd":555,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"Y568_L576delinsVN","name":"Y568_L576delinsVN","refResidues":null,"proteinStart":568,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V555_V559del","name":"V555_V559del","refResidues":null,"proteinStart":555,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K558_V559del","name":"K558_V559del","refResidues":null,"proteinStart":558,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V560D","name":"V560D","refResidues":"V","proteinStart":560,"proteinEnd":560,"variantResidues":"D","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K550_W557del","name":"K550_W557del","refResidues":null,"proteinStart":550,"proteinEnd":557,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"D572A","name":"D572A","refResidues":"D","proteinStart":572,"proteinEnd":572,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559I","name":"V559I","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V560del","name":"V560del","refResidues":"V","proteinStart":560,"proteinEnd":560,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K550_K558del","name":"K550_K558del","refResidues":null,"proteinStart":550,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"Q556_K558del","name":"Q556_K558del","refResidues":null,"proteinStart":556,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"Q575_L576dup","name":"Q575_L576dup","refResidues":null,"proteinStart":575,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P577_D579del","name":"P577_D579del","refResidues":null,"proteinStart":577,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"K558N","name":"K558N","refResidues":"K","proteinStart":558,"proteinEnd":558,"variantResidues":"N","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"T574_R588delinsL","name":"T574_R588delinsL","refResidues":null,"proteinStart":574,"proteinEnd":588,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Regorafenib is FDA-approved for patients with advanced, unresectable gastrointestinal stromal tumors (GIST) that no longer respond to imatinib and sunitinib."],"priority":3,"drugs":[{"ncitCode":"C78204","drugName":"Regorafenib","uuid":"e0d0786c-307a-4a7a-bfff-036cfa7f9df5","synonyms":["Regorafenib","Stivarga","REGORAFENIB","BAY 73-4506","4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580402775000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"23177515","title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.","journal":"Lancet (London, England)","pubDate":"2013 Jan 26","volume":"381","issue":"9863","pages":"295-302","authors":"Demetri GD et al","elocationId":"doi: 10.1016/S0140-6736(12)61857-1","link":null,"reference":"Demetri GD et al. Lancet (London, England). 2013 Jan 26;381(9863)295-302.","abstract":null}]},{"id":12687,"uuid":"65a52219-33ea-4904-8a43-0f0c57223e9c","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"W557C","name":"W557C","refResidues":"W","proteinStart":557,"proteinEnd":557,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"N564_Y578del","name":"N564_Y578del","refResidues":null,"proteinStart":564,"proteinEnd":578,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L576P","name":"L576P","refResidues":"L","proteinStart":576,"proteinEnd":576,"variantResidues":"P","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K550_G592del","name":"Exon 11 deletion","refResidues":null,"proteinStart":550,"proteinEnd":592,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K558_E562del","name":"K558_E562del","refResidues":null,"proteinStart":558,"proteinEnd":562,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"Y578_D579insEQQLPY","name":"Y578_D579insEQQLPY","refResidues":null,"proteinStart":578,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"Y553_Q556del","name":"Y553_Q556del","refResidues":null,"proteinStart":553,"proteinEnd":556,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"I563_L576del","name":"I563_L576del","refResidues":null,"proteinStart":563,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"D579_H580insFNPTQLPYD","name":"D579_H580insFNPTQLPYD","refResidues":null,"proteinStart":579,"proteinEnd":580,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V560E","name":"V560E","refResidues":"V","proteinStart":560,"proteinEnd":560,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"E554_I571del","name":"E554_I571del","refResidues":null,"proteinStart":554,"proteinEnd":571,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y578C","name":"Y578C","refResidues":"Y","proteinStart":578,"proteinEnd":578,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"D579_H580insLPCD","name":"D579_H580insLPCD","refResidues":null,"proteinStart":579,"proteinEnd":580,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"Y553_K558del","name":"Y553_K558del","refResidues":null,"proteinStart":553,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V559_G565del","name":"V559_G565del","refResidues":null,"proteinStart":559,"proteinEnd":565,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"M552_W557del","name":"M552_W557del","refResidues":null,"proteinStart":552,"proteinEnd":557,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V555_L576del","name":"V555_L576del","refResidues":null,"proteinStart":555,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559G","name":"V559G","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V559_V560del","name":"V559_V560del","refResidues":null,"proteinStart":559,"proteinEnd":560,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V559del","name":"V559del","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"P573Q","name":"P573Q","refResidues":"P","proteinStart":573,"proteinEnd":573,"variantResidues":"Q","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V569_L576del","name":"V569_L576del","refResidues":null,"proteinStart":569,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559F","name":"V559F","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"F","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"E554_K558del","name":"E554_K558del","refResidues":null,"proteinStart":554,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V560G","name":"V560G","refResidues":"V","proteinStart":560,"proteinEnd":560,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"Y578_D579dup","name":"Y578_D579dup","refResidues":null,"proteinStart":578,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P577_W582delinsPYD","name":"P577_W582delinsPYD","refResidues":null,"proteinStart":577,"proteinEnd":582,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559A","name":"V559A","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K558_V560del","name":"K558_V560del","refResidues":null,"proteinStart":558,"proteinEnd":560,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"T574insTQLPYD","name":"T574insTQLPYD","refResidues":null,"proteinStart":574,"proteinEnd":574,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"Q575_P585dup","name":"Q575_P585dup","refResidues":null,"proteinStart":575,"proteinEnd":585,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559C","name":"V559C","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"W557_V560del","name":"W557_V560del","refResidues":null,"proteinStart":557,"proteinEnd":560,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"P577_R588dup","name":"P577_R588dup","refResidues":null,"proteinStart":577,"proteinEnd":588,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P551_E554del","name":"P551_E554del","refResidues":null,"proteinStart":551,"proteinEnd":554,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"E554_V559del","name":"E554_V559del","refResidues":null,"proteinStart":554,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"K558delinsNP","name":"K558delinsNP","refResidues":null,"proteinStart":558,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"W557_K558del","name":"W557_K558del","refResidues":null,"proteinStart":557,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P551_W557delinsL","name":"P551_W557delinsL","refResidues":null,"proteinStart":551,"proteinEnd":557,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P551_V555del","name":"P551_V555del","refResidues":null,"proteinStart":551,"proteinEnd":555,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"M552_K558del","name":"M552_K558del","refResidues":null,"proteinStart":552,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"D572_P573dup","name":"D572_P573dup","refResidues":null,"proteinStart":572,"proteinEnd":573,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"D579del","name":"D579del","refResidues":"D","proteinStart":579,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"W557R","name":"W557R","refResidues":"W","proteinStart":557,"proteinEnd":557,"variantResidues":"R","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P573_D579del","name":"P573_D579del","refResidues":null,"proteinStart":573,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"W557_V559delinsC","name":"W557_V559delinsC","refResidues":null,"proteinStart":557,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"W557G","name":"W557G","refResidues":"W","proteinStart":557,"proteinEnd":557,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P551_M552del","name":"P551_M552del","refResidues":null,"proteinStart":551,"proteinEnd":552,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559D","name":"V559D","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"D","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"L576del","name":"L576del","refResidues":"L","proteinStart":576,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K550_V555delinsI","name":"K550_V555delinsI","refResidues":null,"proteinStart":550,"proteinEnd":555,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"Y568_L576delinsVN","name":"Y568_L576delinsVN","refResidues":null,"proteinStart":568,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V555_V559del","name":"V555_V559del","refResidues":null,"proteinStart":555,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K558_V559del","name":"K558_V559del","refResidues":null,"proteinStart":558,"proteinEnd":559,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V560D","name":"V560D","refResidues":"V","proteinStart":560,"proteinEnd":560,"variantResidues":"D","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K550_W557del","name":"K550_W557del","refResidues":null,"proteinStart":550,"proteinEnd":557,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"D572A","name":"D572A","refResidues":"D","proteinStart":572,"proteinEnd":572,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V559I","name":"V559I","refResidues":"V","proteinStart":559,"proteinEnd":559,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"V560del","name":"V560del","refResidues":"V","proteinStart":560,"proteinEnd":560,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"K550_K558del","name":"K550_K558del","refResidues":null,"proteinStart":550,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"Q556_K558del","name":"Q556_K558del","refResidues":null,"proteinStart":556,"proteinEnd":558,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"Q575_L576dup","name":"Q575_L576dup","refResidues":null,"proteinStart":575,"proteinEnd":576,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"P577_D579del","name":"P577_D579del","refResidues":null,"proteinStart":577,"proteinEnd":579,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"K558N","name":"K558N","refResidues":"K","proteinStart":558,"proteinEnd":558,"variantResidues":"N","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"T574_R588delinsL","name":"T574_R588delinsL","refResidues":null,"proteinStart":574,"proteinEnd":588,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":4,"drugs":[{"ncitCode":null,"drugName":"Ripretinib","uuid":"2841f955-5295-416c-a7a3-3dd39962bfae","synonyms":[],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1597941741000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32511981","title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2020 Jul","volume":"21","issue":"7","pages":"923-934","authors":"Blay JY et al","elocationId":"doi: 10.1016/S1470-2045(20)30168-6","link":null,"reference":"Blay JY et al. The Lancet. Oncology. 2020 Jul;21(7)923-934.","abstract":null}]},{"id":13199,"uuid":"ae38bb50-3f09-4939-8a45-6af9eb4a7a35","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":935,"subtype":"","code":"","color":"SaddleBrown","mainType":"Colorectal Cancer","level":0,"tissue":"Bowel","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Wildtype","name":"Wildtype","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Cetuximab is FDA-approved for treatment of KRAS wildtype, EGFR-expressing, metastatic colorectal cancer (mCRC): 1) In combination with FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) as first-line treatment 2) In combination with irinotecan (for patients unresponsive to irinotecan-based chemotherapy) 3) As monotherapy for patients who have failed oxaliplatin- and irinotecan-based chemotherapy or are intolerant to irinotecan."],"priority":1,"drugs":[{"ncitCode":"C1723","drugName":"Cetuximab","uuid":"5fce3074-e420-4c36-9603-2423daf20118","synonyms":["CETUXIMAB","Cetuximab Biosimilar CMAB009","IMC-C225","Chimeric Anti-EGFR Monoclonal Antibody","Cetuximab Biosimilar KL 140","cetuximab","Cetuximab Biosimilar CDP-1","Chimeric Monoclonal Antibody C225","Cetuximab","Chimeric MoAb C225","Erbitux"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1535230547000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"15677699","title":"Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2005 Mar 20","volume":"23","issue":"9","pages":"1803-10","authors":"Chung KY et al","elocationId":"","link":null,"reference":"Chung KY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Mar 20;23(9)1803-10.","abstract":null},{"pmid":"19339720","title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.","journal":"The New England journal of medicine","pubDate":"2009 Apr 2","volume":"360","issue":"14","pages":"1408-17","authors":"Van Cutsem E et al","elocationId":"doi: 10.1056/NEJMoa0805019","link":null,"reference":"Van Cutsem E et al. The New England journal of medicine. 2009 Apr 2;360(14)1408-17.","abstract":null},{"pmid":"24739896","title":"Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.","journal":"The Lancet. Oncology","pubDate":"2014 May","volume":"15","issue":"6","pages":"569-79","authors":"Price TJ et al","elocationId":"doi: 10.1016/S1470-2045(14)70118-4","link":null,"reference":"Price TJ et al. The Lancet. Oncology. 2014 May;15(6)569-79.","abstract":null}]},{"id":13200,"uuid":"f4523975-a34f-4dab-bf77-d91f7e10fee4","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":935,"subtype":"","code":"","color":"SaddleBrown","mainType":"Colorectal Cancer","level":0,"tissue":"Bowel","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Wildtype","name":"Wildtype","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Panitumumab is FDA-approved for KRAS wildtype, EGFR-expressing metastatic colorectal cancer, either in combination with FOLFOX (first-line) or as monotherapy following disease progression after treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens."],"priority":2,"drugs":[{"ncitCode":"C1857","drugName":"Panitumumab","uuid":"d7b1d12a-e942-4801-bb64-916c9bdfaaf3","synonyms":["ABX-EGF, Clone E7.6.3","PANITUMUMAB","\"ABX-EGF","Panitumumab","Vectibix","MoAb ABX-EGF","ABX-EGF","panitumumab","panitumumab\"","ABX-EGF Monoclonal Antibody","Monoclonal Antibody ABX-EGF"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1608173588000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"27736842","title":"A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.","journal":"British journal of cancer","pubDate":"2016 Nov 8","volume":"115","issue":"10","pages":"1206-1214","authors":"Kim TW et al","elocationId":"doi: 10.1038/bjc.2016.309","link":null,"reference":"Kim TW et al. British journal of cancer. 2016 Nov 8;115(10)1206-1214.","abstract":null},{"pmid":"20921462","title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2010 Nov 1","volume":"28","issue":"31","pages":"4706-13","authors":"Peeters M et al","elocationId":"doi: 10.1200/JCO.2009.27.6055","link":null,"reference":"Peeters M et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Nov 1;28(31)4706-13.","abstract":null},{"pmid":"31609637","title":"FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2019 Dec 10","volume":"37","issue":"35","pages":"3401-3411","authors":"Modest DP et al","elocationId":"doi: 10.1200/JCO.19.01340","link":null,"reference":"Modest DP et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Dec 10;37(35)3401-3411.","abstract":null},{"pmid":"24739896","title":"Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.","journal":"The Lancet. Oncology","pubDate":"2014 May","volume":"15","issue":"6","pages":"569-79","authors":"Price TJ et al","elocationId":"doi: 10.1016/S1470-2045(14)70118-4","link":null,"reference":"Price TJ et al. The Lancet. Oncology. 2014 May;15(6)569-79.","abstract":null},{"pmid":"31268481","title":"Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.","journal":"JAMA oncology","pubDate":"2019 Jul 3","volume":"","issue":"","pages":"","authors":"Pietrantonio F et al","elocationId":"doi: 10.1001/jamaoncol.2019.1467","link":null,"reference":"Pietrantonio F et al. JAMA oncology. 2019 Jul 3;().","abstract":null},{"pmid":"20921465","title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2010 Nov 1","volume":"28","issue":"31","pages":"4697-705","authors":"Douillard JY et al","elocationId":"doi: 10.1200/JCO.2009.27.4860","link":null,"reference":"Douillard JY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Nov 1;28(31)4697-705.","abstract":null}]},{"id":13201,"uuid":"808c89d5-2ba9-4800-8f4a-c3d3f5a1a37f","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":935,"subtype":"","code":"","color":"SaddleBrown","mainType":"Colorectal Cancer","level":0,"tissue":"Bowel","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Wildtype","name":"Wildtype","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Regorafenib is FDA-approved for patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, or anti-VEGF therapy. Patients who are KRAS wild type also have to have had prior anti-EGFR therapy."],"priority":3,"drugs":[{"ncitCode":"C78204","drugName":"Regorafenib","uuid":"e0d0786c-307a-4a7a-bfff-036cfa7f9df5","synonyms":["Regorafenib","Stivarga","REGORAFENIB","BAY 73-4506","4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1548779186000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"23177514","title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.","journal":"Lancet (London, England)","pubDate":"2013 Jan 26","volume":"381","issue":"9863","pages":"303-12","authors":"Grothey A et al","elocationId":"doi: 10.1016/S0140-6736(12)61900-X","link":null,"reference":"Grothey A et al. Lancet (London, England). 2013 Jan 26;381(9863)303-12.","abstract":null}]},{"id":20626,"uuid":"2338cc82-0d24-46c5-adf2-409b397f79d3","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":495,"subtype":"Medullary Thyroid Cancer","code":"THME","color":"Teal","mainType":"Thyroid Cancer","level":2,"tissue":"Thyroid","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5979,"hugoSymbol":"RET","oncogene":true,"grch37Isoform":"ENST00000355710","grch37RefSeq":"NM_020975.4","grch38Isoform":"ENST00000355710","grch38RefSeq":"NM_020975.4","geneAliases":["MTC1","CDHF12","CDHR16","MEN2A","HSCR1","MEN2B","RET-ELE1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5979,"hugoSymbol":"RET","oncogene":true,"grch37Isoform":"ENST00000355710","grch37RefSeq":"NM_020975.4","grch38Isoform":"ENST00000355710","grch38RefSeq":"NM_020975.4","geneAliases":["MTC1","CDHF12","CDHR16","MEN2A","HSCR1","MEN2B","RET-ELE1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C134987","drugName":"Selpercatinib","uuid":"f495e1be-c45d-4858-99bd-eac4a7eead23","synonyms":["RET Inhibitor LOXO-292","RET Kinase Inhibitor LOXO-292","LOXO-292"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1589232375000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://www.sciencedirect.com/science/article/pii/S0923753419604539","reference":"null. null. .","abstract":"Wirth et al. Abstract# LBA93, ESMO2019"}]},{"id":20627,"uuid":"7becdb72-bdff-4d94-a59d-c78df7c6d06b","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":495,"subtype":"Medullary Thyroid Cancer","code":"THME","color":"Teal","mainType":"Thyroid Cancer","level":2,"tissue":"Thyroid","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5979,"hugoSymbol":"RET","oncogene":true,"grch37Isoform":"ENST00000355710","grch37RefSeq":"NM_020975.4","grch38Isoform":"ENST00000355710","grch38RefSeq":"NM_020975.4","geneAliases":["MTC1","CDHF12","CDHR16","MEN2A","HSCR1","MEN2B","RET-ELE1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5979,"hugoSymbol":"RET","oncogene":true,"grch37Isoform":"ENST00000355710","grch37RefSeq":"NM_020975.4","grch38Isoform":"ENST00000355710","grch38RefSeq":"NM_020975.4","geneAliases":["MTC1","CDHF12","CDHR16","MEN2A","HSCR1","MEN2B","RET-ELE1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":null,"drugName":"Pralsetinib","uuid":"9fea34f7-1977-4434-88e8-551b093a2e69","synonyms":[],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1608081991000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://meetinglibrary.asco.org/record/174787/abstract","reference":"null. null. .","abstract":"Taylor et al. Abstract# 6018, ASCO 2019"},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy","reference":"null. null. .","abstract":"Hu et al. Abstract# 19130, ESMO 2020"},{"pmid":"29657135","title":"Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers.","journal":"Cancer discovery","pubDate":"2018 Jul","volume":"8","issue":"7","pages":"836-849","authors":"Subbiah V et al","elocationId":"doi: 10.1158/2159-8290.CD-18-0338","link":null,"reference":"Subbiah V et al. Cancer discovery. 2018 Jul;8(7)836-849.","abstract":null}]},{"id":9875,"uuid":"cc78db12-a3f5-41ab-8c76-a9a35ff60292","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":936,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer","level":0,"tissue":"Prostate","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":55120,"hugoSymbol":"FANCL","oncogene":false,"grch37Isoform":"ENST00000233741","grch37RefSeq":"NM_018062.3","grch38Isoform":"ENST00000233741","grch38RefSeq":"NM_018062.3","geneAliases":["POG","FAAP43","PHF9"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":55120,"hugoSymbol":"FANCL","oncogene":false,"grch37Isoform":"ENST00000233741","grch37RefSeq":"NM_018062.3","grch38Isoform":"ENST00000233741","grch38RefSeq":"NM_018062.3","geneAliases":["POG","FAAP43","PHF9"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1591338359000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32343890","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer.","journal":"The New England journal of medicine","pubDate":"2020 May 28","volume":"382","issue":"22","pages":"2091-2102","authors":"de Bono J et al","elocationId":"doi: 10.1056/NEJMoa1911440","link":null,"reference":"de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.","abstract":null}]},{"id":12692,"uuid":"0807f7f9-a969-4730-bfdd-18ba9c0f44ab","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V654A","name":"V654A","refResidues":"V","proteinStart":654,"proteinEnd":654,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580403340000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"28196207","title":"Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.","journal":"JAMA oncology","pubDate":"2017 Jul 1","volume":"3","issue":"7","pages":"944-952","authors":"Heinrich MC et al","elocationId":"doi: 10.1001/jamaoncol.2016.6728","link":null,"reference":"Heinrich MC et al. JAMA oncology. 2017 Jul 1;3(7)944-952.","abstract":null},{"pmid":"18235122","title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Feb 1","volume":"26","issue":"4","pages":"626-32","authors":"Blanke CD et al","elocationId":"doi: 10.1200/JCO.2007.13.4452","link":null,"reference":"Blanke CD et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Feb 1;26(4)626-32.","abstract":null},{"pmid":"12181401","title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.","journal":"The New England journal of medicine","pubDate":"2002 Aug 15","volume":"347","issue":"7","pages":"472-80","authors":"Demetri GD et al","elocationId":"","link":null,"reference":"Demetri GD et al. The New England journal of medicine. 2002 Aug 15;347(7)472-80.","abstract":null},{"pmid":"18955451","title":"Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5360-7","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2008.17.4284","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5360-7.","abstract":null}]},{"id":12693,"uuid":"74bee5b3-8051-43fd-b2e0-f5354760469a","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V654A","name":"V654A","refResidues":"V","proteinStart":654,"proteinEnd":654,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C71622","drugName":"Sunitinib","uuid":"5b548883-0142-4d15-a324-22d7b29800b2","synonyms":["\"1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-","Sunitinib","SUNITINIB","sunitinib\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580404408000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"17046465","title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.","journal":"Lancet (London, England)","pubDate":"2006 Oct 14","volume":"368","issue":"9544","pages":"1329-38","authors":"Demetri GD et al","elocationId":"","link":null,"reference":"Demetri GD et al. Lancet (London, England). 2006 Oct 14;368(9544)1329-38.","abstract":null}]},{"id":17045,"uuid":"5143ddc9-fad3-42d8-9102-971ec9f9a531","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4914,"hugoSymbol":"NTRK1","oncogene":true,"grch37Isoform":"ENST00000524377","grch37RefSeq":"NM_002529.3","grch38Isoform":"ENST00000524377","grch38RefSeq":"NM_002529.3","geneAliases":["TRK1","TRKA","Trk-A","TRK","p140-TrkA","MTC"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4914,"hugoSymbol":"NTRK1","oncogene":true,"grch37Isoform":"ENST00000524377","grch37RefSeq":"NM_002529.3","grch38Isoform":"ENST00000524377","grch38RefSeq":"NM_002529.3","geneAliases":["TRK1","TRKA","Trk-A","TRK","p140-TrkA","MTC"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C115977","drugName":"Larotrectinib","uuid":"b0b3d8ee-86a5-4421-b4a9-053d3c1ff544","synonyms":["LAROTRECTINIB","LOXO-101","Larotrectinib","LOXO 101","\"1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-","ARRY 470","3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide","Larotrectinib\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1544567951000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"26216294","title":"An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.","journal":"Cancer discovery","pubDate":"2015 Oct","volume":"5","issue":"10","pages":"1049-57","authors":"Doebele RC et al","elocationId":"doi: 10.1158/2159-8290.CD-15-0443","link":null,"reference":"Doebele RC et al. Cancer discovery. 2015 Oct;5(10)1049-57.","abstract":null},{"pmid":"29466156","title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.","journal":"The New England journal of medicine","pubDate":"2018 Feb 22","volume":"378","issue":"8","pages":"731-739","authors":"Drilon A et al","elocationId":"doi: 10.1056/NEJMoa1714448","link":null,"reference":"Drilon A et al. The New England journal of medicine. 2018 Feb 22;378(8)731-739.","abstract":null}]},{"id":12694,"uuid":"aaa2b6a7-07f0-408a-8dc1-af9181d45e79","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V654A","name":"V654A","refResidues":"V","proteinStart":654,"proteinEnd":654,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C78204","drugName":"Regorafenib","uuid":"e0d0786c-307a-4a7a-bfff-036cfa7f9df5","synonyms":["Regorafenib","Stivarga","REGORAFENIB","BAY 73-4506","4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580403363000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"23177515","title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.","journal":"Lancet (London, England)","pubDate":"2013 Jan 26","volume":"381","issue":"9863","pages":"295-302","authors":"Demetri GD et al","elocationId":"doi: 10.1016/S0140-6736(12)61857-1","link":null,"reference":"Demetri GD et al. Lancet (London, England). 2013 Jan 26;381(9863)295-302.","abstract":null}]},{"id":17046,"uuid":"20886f10-2f04-4af6-97b3-dbf1d1e49c54","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4914,"hugoSymbol":"NTRK1","oncogene":true,"grch37Isoform":"ENST00000524377","grch37RefSeq":"NM_002529.3","grch38Isoform":"ENST00000524377","grch38RefSeq":"NM_002529.3","geneAliases":["TRK1","TRKA","Trk-A","TRK","p140-TrkA","MTC"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4914,"hugoSymbol":"NTRK1","oncogene":true,"grch37Isoform":"ENST00000524377","grch37RefSeq":"NM_002529.3","grch38Isoform":"ENST00000524377","grch38RefSeq":"NM_002529.3","geneAliases":["TRK1","TRKA","Trk-A","TRK","p140-TrkA","MTC"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C114984","drugName":"Entrectinib","uuid":"2371f7f5-6407-4a4b-b951-a0f786355455","synonyms":["RXDX-101\"","N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide","Entrectinib","\"ENTRECTINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1579140139000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"28183697","title":"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).","journal":"Cancer discovery","pubDate":"2017 Apr","volume":"7","issue":"4","pages":"400-409","authors":"Drilon A et al","elocationId":"doi: 10.1158/2159-8290.CD-16-1237","link":null,"reference":"Drilon A et al. Cancer discovery. 2017 Apr;7(4)400-409.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583","reference":"null. null. .","abstract":"Demetri et al. Abstract# LBA17, ESMO 2018 Congress"},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407","reference":"null. null. .","abstract":"Rolfo et al. Abstract# 65P, ESMO 2019"},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://meetinglibrary.asco.org/record/155954/abstract","reference":"null. null. .","abstract":"Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018"},{"pmid":"31838007","title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.","journal":"The Lancet. Oncology","pubDate":"2020 Feb","volume":"21","issue":"2","pages":"271-282","authors":"Doebele RC et al","elocationId":"doi: 10.1016/S1470-2045(19)30691-6","link":null,"reference":"Doebele RC et al. The Lancet. Oncology. 2020 Feb;21(2)271-282.","abstract":null}]},{"id":12695,"uuid":"4762c5f1-9c3c-42b3-a0a7-50196f00c3b2","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V654A","name":"V654A","refResidues":"V","proteinStart":654,"proteinEnd":654,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":4,"drugs":[{"ncitCode":null,"drugName":"Ripretinib","uuid":"2841f955-5295-416c-a7a3-3dd39962bfae","synonyms":[],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1597940368000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32511981","title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2020 Jul","volume":"21","issue":"7","pages":"923-934","authors":"Blay JY et al","elocationId":"doi: 10.1016/S1470-2045(20)30168-6","link":null,"reference":"Blay JY et al. The Lancet. Oncology. 2020 Jul;21(7)923-934.","abstract":null}]},{"id":20634,"uuid":"292a0fc9-6465-4e6d-8968-b90f5548d68c","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5979,"hugoSymbol":"RET","oncogene":true,"grch37Isoform":"ENST00000355710","grch37RefSeq":"NM_020975.4","grch38Isoform":"ENST00000355710","grch38RefSeq":"NM_020975.4","geneAliases":["MTC1","CDHF12","CDHR16","MEN2A","HSCR1","MEN2B","RET-ELE1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5979,"hugoSymbol":"RET","oncogene":true,"grch37Isoform":"ENST00000355710","grch37RefSeq":"NM_020975.4","grch38Isoform":"ENST00000355710","grch38RefSeq":"NM_020975.4","geneAliases":["MTC1","CDHF12","CDHR16","MEN2A","HSCR1","MEN2B","RET-ELE1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C134987","drugName":"Selpercatinib","uuid":"f495e1be-c45d-4858-99bd-eac4a7eead23","synonyms":["RET Inhibitor LOXO-292","RET Kinase Inhibitor LOXO-292","LOXO-292"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1598628156000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://www.jto.org/article/S1556-0864(19","reference":"null. null. .","abstract":"Drilon et al. Abstract# PL02.08, IASCL 2019"},{"pmid":"32846060","title":"Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer.","journal":"The New England journal of medicine","pubDate":"2020 Aug 27","volume":"383","issue":"9","pages":"813-824","authors":"Drilon A et al","elocationId":"doi: 10.1056/NEJMoa2005653","link":null,"reference":"Drilon A et al. The New England journal of medicine. 2020 Aug 27;383(9)813-824.","abstract":null}]},{"id":20635,"uuid":"ab38d10b-ddc1-4cb0-b797-d87cf3bcd041","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5979,"hugoSymbol":"RET","oncogene":true,"grch37Isoform":"ENST00000355710","grch37RefSeq":"NM_020975.4","grch38Isoform":"ENST00000355710","grch38RefSeq":"NM_020975.4","geneAliases":["MTC1","CDHF12","CDHR16","MEN2A","HSCR1","MEN2B","RET-ELE1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5979,"hugoSymbol":"RET","oncogene":true,"grch37Isoform":"ENST00000355710","grch37RefSeq":"NM_020975.4","grch38Isoform":"ENST00000355710","grch38RefSeq":"NM_020975.4","geneAliases":["MTC1","CDHF12","CDHR16","MEN2A","HSCR1","MEN2B","RET-ELE1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":4,"drugs":[{"ncitCode":null,"drugName":"Pralsetinib","uuid":"9fea34f7-1977-4434-88e8-551b093a2e69","synonyms":[],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1600140044000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109","reference":"null. null. .","abstract":"Subbiah et al. Abstract# 109, ASCO 2020"}]},{"id":23708,"uuid":"f55d1f64-fe8c-4fcf-9745-a45edfe6f0da","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":889,"subtype":"","code":"","color":"Gray","mainType":"CNS Cancer","level":0,"tissue":"CNS/Brain","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7249,"hugoSymbol":"TSC2","oncogene":false,"grch37Isoform":"ENST00000219476","grch37RefSeq":"NM_000548.3","grch38Isoform":"ENST00000219476","grch38RefSeq":"NM_000548.3","geneAliases":["PPP1R160","TSC4"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":7249,"hugoSymbol":"TSC2","oncogene":false,"grch37Isoform":"ENST00000219476","grch37RefSeq":"NM_000548.3","grch38Isoform":"ENST00000219476","grch38RefSeq":"NM_000548.3","geneAliases":["PPP1R160","TSC4"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Everolimus is FDA-approved for the treatment of pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected."],"priority":1,"drugs":[{"ncitCode":"C48387","drugName":"Everolimus","uuid":"dacd7256-8305-466d-af04-bfd1c4e5dad5","synonyms":["RAD 001","everolimus\"","EVEROLIMUS","42-O-(2-Hydroxy)ethyl Rapamycin","Zortress","\"(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone","Certican","Votubia","Afinitor","RAD001","Everolimus"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1552341755000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"23158522","title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.","journal":"Lancet (London, England)","pubDate":"2013 Jan 12","volume":"381","issue":"9861","pages":"125-32","authors":"Franz DN et al","elocationId":"doi: 10.1016/S0140-6736(12)61134-9","link":null,"reference":"Franz DN et al. Lancet (London, England). 2013 Jan 12;381(9861)125-32.","abstract":null}]},{"id":20637,"uuid":"4a3d1c10-8bf5-46f7-bb3a-053e44b0f860","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":898,"subtype":"","code":"","color":"Teal","mainType":"Thyroid Cancer","level":0,"tissue":"Thyroid","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5979,"hugoSymbol":"RET","oncogene":true,"grch37Isoform":"ENST00000355710","grch37RefSeq":"NM_020975.4","grch38Isoform":"ENST00000355710","grch38RefSeq":"NM_020975.4","geneAliases":["MTC1","CDHF12","CDHR16","MEN2A","HSCR1","MEN2B","RET-ELE1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5979,"hugoSymbol":"RET","oncogene":true,"grch37Isoform":"ENST00000355710","grch37RefSeq":"NM_020975.4","grch38Isoform":"ENST00000355710","grch38RefSeq":"NM_020975.4","geneAliases":["MTC1","CDHF12","CDHR16","MEN2A","HSCR1","MEN2B","RET-ELE1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C134987","drugName":"Selpercatinib","uuid":"f495e1be-c45d-4858-99bd-eac4a7eead23","synonyms":["RET Inhibitor LOXO-292","RET Kinase Inhibitor LOXO-292","LOXO-292"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1589233045000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://www.sciencedirect.com/science/article/pii/S0923753419604539","reference":"null. null. .","abstract":"Wirth et al. Abstract# LBA93, ESMO 2019"}]},{"id":12701,"uuid":"f3f72677-7231-4bb1-a8f9-08248b69e8ba","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"K642E","name":"K642E","refResidues":"K","proteinStart":642,"proteinEnd":642,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580417971000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"28196207","title":"Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.","journal":"JAMA oncology","pubDate":"2017 Jul 1","volume":"3","issue":"7","pages":"944-952","authors":"Heinrich MC et al","elocationId":"doi: 10.1001/jamaoncol.2016.6728","link":null,"reference":"Heinrich MC et al. JAMA oncology. 2017 Jul 1;3(7)944-952.","abstract":null},{"pmid":"18235122","title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Feb 1","volume":"26","issue":"4","pages":"626-32","authors":"Blanke CD et al","elocationId":"doi: 10.1200/JCO.2007.13.4452","link":null,"reference":"Blanke CD et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Feb 1;26(4)626-32.","abstract":null},{"pmid":"12181401","title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.","journal":"The New England journal of medicine","pubDate":"2002 Aug 15","volume":"347","issue":"7","pages":"472-80","authors":"Demetri GD et al","elocationId":"","link":null,"reference":"Demetri GD et al. The New England journal of medicine. 2002 Aug 15;347(7)472-80.","abstract":null},{"pmid":"18955451","title":"Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5360-7","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2008.17.4284","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5360-7.","abstract":null}]},{"id":17565,"uuid":"901a2a6e-2fbd-4943-a785-4f89acee6ae3","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":285,"subtype":"Myelodysplastic/Myeloproliferative Neoplasms","code":"MDS/MPN","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5159,"hugoSymbol":"PDGFRB","oncogene":true,"grch37Isoform":"ENST00000261799","grch37RefSeq":"NM_002609.3","grch38Isoform":"ENST00000261799","grch38RefSeq":"NM_002609.3","geneAliases":["PDGFR1","KOGS","PDGFR-1","JTK12","PDGFR","IBGC4","IMF1","PENTT","CD140B"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5159,"hugoSymbol":"PDGFRB","oncogene":true,"grch37Isoform":"ENST00000261799","grch37RefSeq":"NM_002609.3","grch38Isoform":"ENST00000261799","grch38RefSeq":"NM_002609.3","geneAliases":["PDGFR1","KOGS","PDGFR-1","JTK12","PDGFR","IBGC4","IMF1","PENTT","CD140B"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements."],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1525892603000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"12676775","title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.","journal":"Blood","pubDate":"2003 Jun 15","volume":"101","issue":"12","pages":"4660-6","authors":"Klion AD et al","elocationId":"","link":null,"reference":"Klion AD et al. Blood. 2003 Jun 15;101(12)4660-6.","abstract":null},{"pmid":"14504092","title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.","journal":"Blood","pubDate":"2004 Jan 15","volume":"103","issue":"2","pages":"473-8","authors":"Klion AD et al","elocationId":"","link":null,"reference":"Klion AD et al. Blood. 2004 Jan 15;103(2)473-8.","abstract":null},{"pmid":"22897847","title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.","journal":"Cancer cell","pubDate":"2012 Aug 14","volume":"22","issue":"2","pages":"153-66","authors":"Roberts KG et al","elocationId":"doi: 10.1016/j.ccr.2012.06.005","link":null,"reference":"Roberts KG et al. Cancer cell. 2012 Aug 14;22(2)153-66.","abstract":null},{"pmid":"26355392","title":"Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.","journal":"Genes, chromosomes & cancer","pubDate":"2015 Dec","volume":"54","issue":"12","pages":"762-70","authors":"Naumann N et al","elocationId":"doi: 10.1002/gcc.22287","link":null,"reference":"Naumann N et al. Genes, chromosomes & cancer. 2015 Dec;54(12)762-70.","abstract":null},{"pmid":"18950453","title":"Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.","journal":"British journal of haematology","pubDate":"2008 Dec","volume":"143","issue":"5","pages":"707-15","authors":"Metzgeroth G et al","elocationId":"doi: 10.1111/j.1365-2141.2008.07294.x","link":null,"reference":"Metzgeroth G et al. British journal of haematology. 2008 Dec;143(5)707-15.","abstract":null},{"pmid":"12181402","title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.","journal":"The New England journal of medicine","pubDate":"2002 Aug 15","volume":"347","issue":"7","pages":"481-7","authors":"Apperley JF et al","elocationId":"","link":null,"reference":"Apperley JF et al. The New England journal of medicine. 2002 Aug 15;347(7)481-7.","abstract":null},{"pmid":"16960151","title":"Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.","journal":"Blood","pubDate":"2007 Jan 1","volume":"109","issue":"1","pages":"61-4","authors":"David M et al","elocationId":"","link":null,"reference":"David M et al. Blood. 2007 Jan 1;109(1)61-4.","abstract":null},{"pmid":"1516603","title":"Adverse events in phase one studies: a study in 430 healthy volunteers.","journal":"European journal of clinical pharmacology","pubDate":"1992","volume":"42","issue":"4","pages":"389-93","authors":"Sibille M et al","elocationId":"","link":null,"reference":"Sibille M et al. European journal of clinical pharmacology. 1992;42(4)389-93.","abstract":null},{"pmid":"24687085","title":"Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.","journal":"Blood","pubDate":"2014 Jun 5","volume":"123","issue":"23","pages":"3574-7","authors":"Cheah CY et al","elocationId":"doi: 10.1182/blood-2014-02-555607","link":null,"reference":"Cheah CY et al. Blood. 2014 Jun 5;123(23)3574-7.","abstract":null}]},{"id":20638,"uuid":"833697f9-b9cb-4080-8a71-7754a1a8d768","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":898,"subtype":"","code":"","color":"Teal","mainType":"Thyroid Cancer","level":0,"tissue":"Thyroid","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5979,"hugoSymbol":"RET","oncogene":true,"grch37Isoform":"ENST00000355710","grch37RefSeq":"NM_020975.4","grch38Isoform":"ENST00000355710","grch38RefSeq":"NM_020975.4","geneAliases":["MTC1","CDHF12","CDHR16","MEN2A","HSCR1","MEN2B","RET-ELE1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5979,"hugoSymbol":"RET","oncogene":true,"grch37Isoform":"ENST00000355710","grch37RefSeq":"NM_020975.4","grch38Isoform":"ENST00000355710","grch38RefSeq":"NM_020975.4","geneAliases":["MTC1","CDHF12","CDHR16","MEN2A","HSCR1","MEN2B","RET-ELE1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":null,"drugName":"Pralsetinib","uuid":"9fea34f7-1977-4434-88e8-551b093a2e69","synonyms":[],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1608170941000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109","reference":"null. null. .","abstract":"Subbiah et al. Abstract# 109, ASCO 2020"},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy","reference":"null. null. .","abstract":"Hu et al. Abstract# 19130, ESMO 2020"},{"pmid":"29657135","title":"Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers.","journal":"Cancer discovery","pubDate":"2018 Jul","volume":"8","issue":"7","pages":"836-849","authors":"Subbiah V et al","elocationId":"doi: 10.1158/2159-8290.CD-18-0338","link":null,"reference":"Subbiah V et al. Cancer discovery. 2018 Jul;8(7)836-849.","abstract":null}]},{"id":12702,"uuid":"0dc51207-23b5-47a0-9a99-5f7c729b351d","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"K642E","name":"K642E","refResidues":"K","proteinStart":642,"proteinEnd":642,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C71622","drugName":"Sunitinib","uuid":"5b548883-0142-4d15-a324-22d7b29800b2","synonyms":["\"1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-","Sunitinib","SUNITINIB","sunitinib\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580417990000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"17046465","title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.","journal":"Lancet (London, England)","pubDate":"2006 Oct 14","volume":"368","issue":"9544","pages":"1329-38","authors":"Demetri GD et al","elocationId":"","link":null,"reference":"Demetri GD et al. Lancet (London, England). 2006 Oct 14;368(9544)1329-38.","abstract":null}]},{"id":12703,"uuid":"3875f3d5-b7dd-4349-aad4-192df4fbbe54","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"K642E","name":"K642E","refResidues":"K","proteinStart":642,"proteinEnd":642,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C78204","drugName":"Regorafenib","uuid":"e0d0786c-307a-4a7a-bfff-036cfa7f9df5","synonyms":["Regorafenib","Stivarga","REGORAFENIB","BAY 73-4506","4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580418006000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"23177515","title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.","journal":"Lancet (London, England)","pubDate":"2013 Jan 26","volume":"381","issue":"9863","pages":"295-302","authors":"Demetri GD et al","elocationId":"doi: 10.1016/S0140-6736(12)61857-1","link":null,"reference":"Demetri GD et al. Lancet (London, England). 2013 Jan 26;381(9863)295-302.","abstract":null}]},{"id":12704,"uuid":"51574db0-2baa-4d93-891e-2d81c2faec19","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"K642E","name":"K642E","refResidues":"K","proteinStart":642,"proteinEnd":642,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":4,"drugs":[{"ncitCode":null,"drugName":"Ripretinib","uuid":"2841f955-5295-416c-a7a3-3dd39962bfae","synonyms":[],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1597940338000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32511981","title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2020 Jul","volume":"21","issue":"7","pages":"923-934","authors":"Blay JY et al","elocationId":"doi: 10.1016/S1470-2045(20)30168-6","link":null,"reference":"Blay JY et al. The Lancet. Oncology. 2020 Jul;21(7)923-934.","abstract":null}]},{"id":12709,"uuid":"4044a124-cc5a-42d8-b644-08c8f97864bb","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T670I","name":"T670I","refResidues":"T","proteinStart":670,"proteinEnd":670,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580404387000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"28196207","title":"Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.","journal":"JAMA oncology","pubDate":"2017 Jul 1","volume":"3","issue":"7","pages":"944-952","authors":"Heinrich MC et al","elocationId":"doi: 10.1001/jamaoncol.2016.6728","link":null,"reference":"Heinrich MC et al. JAMA oncology. 2017 Jul 1;3(7)944-952.","abstract":null},{"pmid":"18235122","title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Feb 1","volume":"26","issue":"4","pages":"626-32","authors":"Blanke CD et al","elocationId":"doi: 10.1200/JCO.2007.13.4452","link":null,"reference":"Blanke CD et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Feb 1;26(4)626-32.","abstract":null},{"pmid":"12181401","title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.","journal":"The New England journal of medicine","pubDate":"2002 Aug 15","volume":"347","issue":"7","pages":"472-80","authors":"Demetri GD et al","elocationId":"","link":null,"reference":"Demetri GD et al. The New England journal of medicine. 2002 Aug 15;347(7)472-80.","abstract":null},{"pmid":"18955451","title":"Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5360-7","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2008.17.4284","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5360-7.","abstract":null}]},{"id":12710,"uuid":"d3748724-9a44-4da3-b6a1-688f2b3cba6a","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T670I","name":"T670I","refResidues":"T","proteinStart":670,"proteinEnd":670,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C71622","drugName":"Sunitinib","uuid":"5b548883-0142-4d15-a324-22d7b29800b2","synonyms":["\"1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-","Sunitinib","SUNITINIB","sunitinib\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580404483000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"17046465","title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.","journal":"Lancet (London, England)","pubDate":"2006 Oct 14","volume":"368","issue":"9544","pages":"1329-38","authors":"Demetri GD et al","elocationId":"","link":null,"reference":"Demetri GD et al. Lancet (London, England). 2006 Oct 14;368(9544)1329-38.","abstract":null}]},{"id":12711,"uuid":"4194f11d-cb23-4ae6-9069-3cb92d9f6470","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T670I","name":"T670I","refResidues":"T","proteinStart":670,"proteinEnd":670,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C78204","drugName":"Regorafenib","uuid":"e0d0786c-307a-4a7a-bfff-036cfa7f9df5","synonyms":["Regorafenib","Stivarga","REGORAFENIB","BAY 73-4506","4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580404470000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"23177515","title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.","journal":"Lancet (London, England)","pubDate":"2013 Jan 26","volume":"381","issue":"9863","pages":"295-302","authors":"Demetri GD et al","elocationId":"doi: 10.1016/S0140-6736(12)61857-1","link":null,"reference":"Demetri GD et al. Lancet (London, England). 2013 Jan 26;381(9863)295-302.","abstract":null}]},{"id":12712,"uuid":"808d3a97-5a9e-48b8-852d-f73ce8135fcc","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T670I","name":"T670I","refResidues":"T","proteinStart":670,"proteinEnd":670,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":4,"drugs":[{"ncitCode":null,"drugName":"Ripretinib","uuid":"2841f955-5295-416c-a7a3-3dd39962bfae","synonyms":[],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1597940297000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32511981","title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2020 Jul","volume":"21","issue":"7","pages":"923-934","authors":"Blay JY et al","elocationId":"doi: 10.1016/S1470-2045(20)30168-6","link":null,"reference":"Blay JY et al. The Lancet. Oncology. 2020 Jul;21(7)923-934.","abstract":null}]},{"id":12715,"uuid":"e9bbfd7f-76ab-4c98-8698-cf90cd117ada","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D816","name":"D816","refResidues":"D","proteinStart":816,"proteinEnd":816,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y823D","name":"Y823D","refResidues":"Y","proteinStart":823,"proteinEnd":823,"variantResidues":"D","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D820","name":"D820","refResidues":"D","proteinStart":820,"proteinEnd":820,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"N822","name":"N822","refResidues":"N","proteinStart":822,"proteinEnd":822,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"A829P","name":"A829P","refResidues":"A","proteinStart":829,"proteinEnd":829,"variantResidues":"P","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"C809G","name":"C809G","refResidues":"C","proteinStart":809,"proteinEnd":809,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580405567000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"28196207","title":"Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.","journal":"JAMA oncology","pubDate":"2017 Jul 1","volume":"3","issue":"7","pages":"944-952","authors":"Heinrich MC et al","elocationId":"doi: 10.1001/jamaoncol.2016.6728","link":null,"reference":"Heinrich MC et al. JAMA oncology. 2017 Jul 1;3(7)944-952.","abstract":null},{"pmid":"18235122","title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Feb 1","volume":"26","issue":"4","pages":"626-32","authors":"Blanke CD et al","elocationId":"doi: 10.1200/JCO.2007.13.4452","link":null,"reference":"Blanke CD et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Feb 1;26(4)626-32.","abstract":null},{"pmid":"12181401","title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.","journal":"The New England journal of medicine","pubDate":"2002 Aug 15","volume":"347","issue":"7","pages":"472-80","authors":"Demetri GD et al","elocationId":"","link":null,"reference":"Demetri GD et al. The New England journal of medicine. 2002 Aug 15;347(7)472-80.","abstract":null},{"pmid":"18955451","title":"Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5360-7","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2008.17.4284","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5360-7.","abstract":null}]},{"id":6571,"uuid":"86ad6d3a-99da-4e2d-8eb8-709f8390742d","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"G719","name":"G719","refResidues":"G","proteinStart":719,"proteinEnd":719,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C66940","drugName":"Afatinib","uuid":"e1f45ae7-33ae-428c-9e77-da4a9b7270b6","synonyms":["BIBW 2992","Afatinib","BIBW2992","AFATINIB","(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1589522786000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"22452895","title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2012 May","volume":"13","issue":"5","pages":"539-48","authors":"Yang JC et al","elocationId":"doi: 10.1016/S1470-2045(12)70086-4","link":null,"reference":"Yang JC et al. The Lancet. Oncology. 2012 May;13(5)539-48.","abstract":null},{"pmid":"25589191","title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.","journal":"The Lancet. Oncology","pubDate":"2015 Feb","volume":"16","issue":"2","pages":"141-51","authors":"Yang JC et al","elocationId":"doi: 10.1016/S1470-2045(14)71173-8","link":null,"reference":"Yang JC et al. The Lancet. Oncology. 2015 Feb;16(2)141-51.","abstract":null},{"pmid":"23816960","title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2013 Sep 20","volume":"31","issue":"27","pages":"3327-34","authors":"Sequist LV et al","elocationId":"doi: 10.1200/JCO.2012.44.2806","link":null,"reference":"Sequist LV et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 20;31(27)3327-34.","abstract":null}]},{"id":12716,"uuid":"0419777c-5edb-4204-8ef6-5a0da107f023","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D816","name":"D816","refResidues":"D","proteinStart":816,"proteinEnd":816,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y823D","name":"Y823D","refResidues":"Y","proteinStart":823,"proteinEnd":823,"variantResidues":"D","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D820","name":"D820","refResidues":"D","proteinStart":820,"proteinEnd":820,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"N822","name":"N822","refResidues":"N","proteinStart":822,"proteinEnd":822,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"A829P","name":"A829P","refResidues":"A","proteinStart":829,"proteinEnd":829,"variantResidues":"P","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"C809G","name":"C809G","refResidues":"C","proteinStart":809,"proteinEnd":809,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C71622","drugName":"Sunitinib","uuid":"5b548883-0142-4d15-a324-22d7b29800b2","synonyms":["\"1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-","Sunitinib","SUNITINIB","sunitinib\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580405978000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"17046465","title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.","journal":"Lancet (London, England)","pubDate":"2006 Oct 14","volume":"368","issue":"9544","pages":"1329-38","authors":"Demetri GD et al","elocationId":"","link":null,"reference":"Demetri GD et al. Lancet (London, England). 2006 Oct 14;368(9544)1329-38.","abstract":null}]},{"id":12717,"uuid":"6a762328-6f22-441f-99e4-3caeb1c1ecbd","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D816","name":"D816","refResidues":"D","proteinStart":816,"proteinEnd":816,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y823D","name":"Y823D","refResidues":"Y","proteinStart":823,"proteinEnd":823,"variantResidues":"D","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D820","name":"D820","refResidues":"D","proteinStart":820,"proteinEnd":820,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"N822","name":"N822","refResidues":"N","proteinStart":822,"proteinEnd":822,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"A829P","name":"A829P","refResidues":"A","proteinStart":829,"proteinEnd":829,"variantResidues":"P","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"C809G","name":"C809G","refResidues":"C","proteinStart":809,"proteinEnd":809,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Regorafenib is FDA-approved for patients with advanced, unresectable gastrointestinal stromal tumors (GIST) that no longer respond to imatinib and sunitinib."],"priority":3,"drugs":[{"ncitCode":"C78204","drugName":"Regorafenib","uuid":"e0d0786c-307a-4a7a-bfff-036cfa7f9df5","synonyms":["Regorafenib","Stivarga","REGORAFENIB","BAY 73-4506","4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1544205622000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"23177515","title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.","journal":"Lancet (London, England)","pubDate":"2013 Jan 26","volume":"381","issue":"9863","pages":"295-302","authors":"Demetri GD et al","elocationId":"doi: 10.1016/S0140-6736(12)61857-1","link":null,"reference":"Demetri GD et al. Lancet (London, England). 2013 Jan 26;381(9863)295-302.","abstract":null}]},{"id":12719,"uuid":"138f7b30-fb5c-4092-add4-82756ef2856e","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D816","name":"D816","refResidues":"D","proteinStart":816,"proteinEnd":816,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y823D","name":"Y823D","refResidues":"Y","proteinStart":823,"proteinEnd":823,"variantResidues":"D","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D820","name":"D820","refResidues":"D","proteinStart":820,"proteinEnd":820,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"N822","name":"N822","refResidues":"N","proteinStart":822,"proteinEnd":822,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"A829P","name":"A829P","refResidues":"A","proteinStart":829,"proteinEnd":829,"variantResidues":"P","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"C809G","name":"C809G","refResidues":"C","proteinStart":809,"proteinEnd":809,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":5,"drugs":[{"ncitCode":null,"drugName":"Ripretinib","uuid":"2841f955-5295-416c-a7a3-3dd39962bfae","synonyms":[],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1597940273000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32511981","title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2020 Jul","volume":"21","issue":"7","pages":"923-934","authors":"Blay JY et al","elocationId":"doi: 10.1016/S1470-2045(20)30168-6","link":null,"reference":"Blay JY et al. The Lancet. Oncology. 2020 Jul;21(7)923-934.","abstract":null}]},{"id":6576,"uuid":"9abe73bf-099e-4a02-85c0-7a23cd107f5d","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T790M","name":"T790M","refResidues":"T","proteinStart":790,"proteinEnd":790,"variantResidues":"M","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["FDA granted accelerated approval to osimertinib once daily tablets for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy."],"priority":1,"drugs":[{"ncitCode":"C116377","drugName":"Osimertinib","uuid":"4c2c1261-bfc3-4180-8113-127194366320","synonyms":["OSIMERTINIB","AZD-9291","Osimertinib","\"2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-","Tagrisso\"","Mereletinib","AZD9291"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1550019272000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"25923549","title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.","journal":"The New England journal of medicine","pubDate":"2015 Apr 30","volume":"372","issue":"18","pages":"1689-99","authors":"Jänne PA et al","elocationId":"doi: 10.1056/NEJMoa1411817","link":null,"reference":"Jänne PA et al. The New England journal of medicine. 2015 Apr 30;372(18)1689-99.","abstract":null},{"pmid":"30059262","title":"CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2018 Sep 10","volume":"36","issue":"26","pages":"2702-2709","authors":"Wu YL et al","elocationId":"doi: 10.1200/JCO.2018.77.9363","link":null,"reference":"Wu YL et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Sep 10;36(26)2702-2709.","abstract":null},{"pmid":"29151359","title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.","journal":"The New England journal of medicine","pubDate":"2018 Jan 11","volume":"378","issue":"2","pages":"113-125","authors":"Soria JC et al","elocationId":"doi: 10.1056/NEJMoa1713137","link":null,"reference":"Soria JC et al. The New England journal of medicine. 2018 Jan 11;378(2)113-125.","abstract":null},{"pmid":"27751847","title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.","journal":"The Lancet. Oncology","pubDate":"2016 Dec","volume":"17","issue":"12","pages":"1643-1652","authors":"Goss G et al","elocationId":"doi: 10.1016/S1470-2045(16)30508-3","link":null,"reference":"Goss G et al. The Lancet. Oncology. 2016 Dec;17(12)1643-1652.","abstract":null}]},{"id":10930,"uuid":"51531472-c3c0-4d7b-a55b-29d0a95140b5","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"572_630ins","name":"Internal tandem duplication","refResidues":null,"proteinStart":572,"proteinEnd":630,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"I836","name":"I836","refResidues":"I","proteinStart":836,"proteinEnd":836,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D835","name":"D835","refResidues":"D","proteinStart":835,"proteinEnd":835,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C116722","drugName":"Gilteritinib","uuid":"562b1317-49f3-471d-82fe-211cf5e5e290","synonyms":["6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide","GILTERITINIB","ASP2215","ASP-2215","Gilteritinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1578359521000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"LEVEL_3B","articles":[{"pmid":"31665578","title":"Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AML.","journal":"The New England journal of medicine","pubDate":"2019 Oct 31","volume":"381","issue":"18","pages":"1728-1740","authors":"Perl AE et al","elocationId":"doi: 10.1056/NEJMoa1902688","link":null,"reference":"Perl AE et al. The New England journal of medicine. 2019 Oct 31;381(18)1728-1740.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://meetinglibrary.asco.org/record/173640/abstract","reference":"null. null. .","abstract":"Levis et al. Abstract# 7000, ASCO 2019"},{"pmid":"28645776","title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.","journal":"The Lancet. Oncology","pubDate":"2017 Aug","volume":"18","issue":"8","pages":"1061-1075","authors":"Perl AE et al","elocationId":"doi: 10.1016/S1470-2045(17)30416-3","link":null,"reference":"Perl AE et al. The Lancet. Oncology. 2017 Aug;18(8)1061-1075.","abstract":null},{"pmid":"28516360","title":"Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.","journal":"Investigational new drugs","pubDate":"2017 Oct","volume":"35","issue":"5","pages":"556-565","authors":"Mori M et al","elocationId":"doi: 10.1007/s10637-017-0470-z","link":null,"reference":"Mori M et al. Investigational new drugs. 2017 Oct;35(5)556-565.","abstract":null}]},{"id":10931,"uuid":"0a8d561c-018a-42ad-8dfa-26da50775844","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"572_630ins","name":"Internal tandem duplication","refResidues":null,"proteinStart":572,"proteinEnd":630,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"I836","name":"I836","refResidues":"I","proteinStart":836,"proteinEnd":836,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D835","name":"D835","refResidues":"D","proteinStart":835,"proteinEnd":835,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C1872","drugName":"Midostaurin","uuid":"b4012b4d-f7a5-49d9-9101-a4e1de203e9e","synonyms":["CGP 41251","N-Benzoyl-Staurosporine","N-benzoyl-staurosporine","N-Benzoylstaurosporine","midostaurin","PKC-412","CGP41251","MIDOSTAURIN","Midostaurin","Rydapt","PKC412"],"priority":1},{"ncitCode":"C15807","drugName":"High Dose Chemotherapy","uuid":"faef6994-b7f8-4845-9f10-8eab19d7cb86","synonyms":["High Dose Chemotherapy","high-dose chemotherapy"],"priority":2}]}],"knownEffect":"Sensitive","lastEdit":1606859031000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"28644114","title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.","journal":"The New England journal of medicine","pubDate":"2017 Aug 3","volume":"377","issue":"5","pages":"454-464","authors":"Stone RM et al","elocationId":"doi: 10.1056/NEJMoa1614359","link":null,"reference":"Stone RM et al. The New England journal of medicine. 2017 Aug 3;377(5)454-464.","abstract":null}]},{"id":6583,"uuid":"ab18e4fd-1081-4bb0-a997-d1560265cfe6","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L858R","name":"L858R","refResidues":"L","proteinStart":858,"proteinEnd":858,"variantResidues":"R","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"729_761del","name":"Exon 19 deletion","refResidues":null,"proteinStart":729,"proteinEnd":761,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Erlotinib is FDA-approved for (1) First-line treatment of metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test"," (3) locally advanced or metastatic NSCLC after failure of chemotherapy"," (2) maintenance treatment of non small cell lung cancer (NSCLC) that has stabilized after platinum-based chemotherapy"],"priority":1,"drugs":[{"ncitCode":"C65530","drugName":"Erlotinib","uuid":"83754311-3f3b-4782-bfbf-08e71c790b9a","synonyms":["Erlotinib","erlotinib","ERLOTINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1546043690000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"27987585","title":"Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).","journal":"Lung cancer (Amsterdam, Netherlands)","pubDate":"2016 Dec","volume":"102","issue":"","pages":"30-37","authors":"Cicènas S et al","elocationId":"doi: 10.1016/j.lungcan.2016.10.007","link":null,"reference":"Cicènas S et al. Lung cancer (Amsterdam, Netherlands). 2016 Dec;102()30-37.","abstract":null},{"pmid":"22285168","title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2012 Mar","volume":"13","issue":"3","pages":"239-46","authors":"Rosell R et al","elocationId":"doi: 10.1016/S1470-2045(11)70393-X","link":null,"reference":"Rosell R et al. The Lancet. Oncology. 2012 Mar;13(3)239-46.","abstract":null}]},{"id":6584,"uuid":"9725b4ed-1c53-414e-9b14-74310c331605","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L858R","name":"L858R","refResidues":"L","proteinStart":858,"proteinEnd":858,"variantResidues":"R","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"729_761del","name":"Exon 19 deletion","refResidues":null,"proteinStart":729,"proteinEnd":761,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[" (2) Treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy","Afatinib is FDA-approved for (1) First-line treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test"],"priority":2,"drugs":[{"ncitCode":"C66940","drugName":"Afatinib","uuid":"e1f45ae7-33ae-428c-9e77-da4a9b7270b6","synonyms":["BIBW 2992","Afatinib","BIBW2992","AFATINIB","(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1533320526000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"22452895","title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2012 May","volume":"13","issue":"5","pages":"539-48","authors":"Yang JC et al","elocationId":"doi: 10.1016/S1470-2045(12)70086-4","link":null,"reference":"Yang JC et al. The Lancet. Oncology. 2012 May;13(5)539-48.","abstract":null},{"pmid":"25589191","title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.","journal":"The Lancet. Oncology","pubDate":"2015 Feb","volume":"16","issue":"2","pages":"141-51","authors":"Yang JC et al","elocationId":"doi: 10.1016/S1470-2045(14)71173-8","link":null,"reference":"Yang JC et al. The Lancet. Oncology. 2015 Feb;16(2)141-51.","abstract":null},{"pmid":"23816960","title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2013 Sep 20","volume":"31","issue":"27","pages":"3327-34","authors":"Sequist LV et al","elocationId":"doi: 10.1200/JCO.2012.44.2806","link":null,"reference":"Sequist LV et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 20;31(27)3327-34.","abstract":null}]},{"id":6585,"uuid":"66c1e6d4-f9b7-4d74-a732-bf007b3a0912","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L858R","name":"L858R","refResidues":"L","proteinStart":858,"proteinEnd":858,"variantResidues":"R","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"729_761del","name":"Exon 19 deletion","refResidues":null,"proteinStart":729,"proteinEnd":761,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Gefitinib is FDA-approved for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test."],"priority":3,"drugs":[{"ncitCode":"C1855","drugName":"Gefitinib","uuid":"b76d7b2b-b5fb-4561-892f-6b00bfaf0dfa","synonyms":["GEFITINIB","Iressa","N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine","ZD 1839","gefitinib","Gefitinib","4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline","ZD1839"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1578377771000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"19692680","title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.","journal":"The New England journal of medicine","pubDate":"2009 Sep 3","volume":"361","issue":"10","pages":"947-57","authors":"Mok TS et al","elocationId":"doi: 10.1056/NEJMoa0810699","link":null,"reference":"Mok TS et al. The New England journal of medicine. 2009 Sep 3;361(10)947-57.","abstract":null},{"pmid":"20022809","title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2010 Feb","volume":"11","issue":"2","pages":"121-8","authors":"Mitsudomi T et al","elocationId":"doi: 10.1016/S1470-2045(09)70364-X","link":null,"reference":"Mitsudomi T et al. The Lancet. Oncology. 2010 Feb;11(2)121-8.","abstract":null},{"pmid":"21670455","title":"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2011 Jul 20","volume":"29","issue":"21","pages":"2866-74","authors":"Fukuoka M et al","elocationId":"doi: 10.1200/JCO.2010.33.4235","link":null,"reference":"Fukuoka M et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Jul 20;29(21)2866-74.","abstract":null},{"pmid":"22370314","title":"First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2012 Apr 1","volume":"30","issue":"10","pages":"1122-8","authors":"Han JY et al","elocationId":"doi: 10.1200/JCO.2011.36.8456","link":null,"reference":"Han JY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Apr 1;30(10)1122-8.","abstract":null},{"pmid":"31682542","title":"Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2020 Jan 10","volume":"38","issue":"2","pages":"115-123","authors":"Hosomi Y et al","elocationId":"doi: 10.1200/JCO.19.01488","link":null,"reference":"Hosomi Y et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Jan 10;38(2)115-123.","abstract":null},{"pmid":"20573926","title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.","journal":"The New England journal of medicine","pubDate":"2010 Jun 24","volume":"362","issue":"25","pages":"2380-8","authors":"Maemondo M et al","elocationId":"doi: 10.1056/NEJMoa0909530","link":null,"reference":"Maemondo M et al. The New England journal of medicine. 2010 Jun 24;362(25)2380-8.","abstract":null}]},{"id":6586,"uuid":"7cfaeb0f-4b7a-4bdd-9a49-e487581259bf","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L858R","name":"L858R","refResidues":"L","proteinStart":858,"proteinEnd":858,"variantResidues":"R","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"729_761del","name":"Exon 19 deletion","refResidues":null,"proteinStart":729,"proteinEnd":761,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations"],"priority":4,"drugs":[{"ncitCode":"C116377","drugName":"Osimertinib","uuid":"4c2c1261-bfc3-4180-8113-127194366320","synonyms":["OSIMERTINIB","AZD-9291","Osimertinib","\"2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-","Tagrisso\"","Mereletinib","AZD9291"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1573023466000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://academic.oup.com/annonc/article/30/Supplement_5/mdz394.076/55783630","reference":"null. null. .","abstract":"Ramalingam et al. Abstract# LBA5_PR, ESMO 2019"},{"pmid":"30659024","title":"Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 Apr 1","volume":"25","issue":"7","pages":"2058-2063","authors":"Planchard D et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-3325","link":null,"reference":"Planchard D et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Apr 1;25(7)2058-2063.","abstract":null},{"pmid":"29151359","title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.","journal":"The New England journal of medicine","pubDate":"2018 Jan 11","volume":"378","issue":"2","pages":"113-125","authors":"Soria JC et al","elocationId":"doi: 10.1056/NEJMoa1713137","link":null,"reference":"Soria JC et al. The New England journal of medicine. 2018 Jan 11;378(2)113-125.","abstract":null}]},{"id":6587,"uuid":"583f86c3-868f-4e7e-b10f-3bec17f20e14","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L858R","name":"L858R","refResidues":"L","proteinStart":858,"proteinEnd":858,"variantResidues":"R","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"729_761del","name":"Exon 19 deletion","refResidues":null,"proteinStart":729,"proteinEnd":761,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["FDA-approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test."],"priority":5,"drugs":[{"ncitCode":"C53398","drugName":"Dacomitinib","uuid":"ee16e91a-38a2-4433-97d2-9b9ae9d2a497","synonyms":["DACOMITINIB","EGFR Inhibitor PF-00299804","(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide","PF-00299804","Dacomitinib","PF-00299804-03","PF-299804","Vizimpro"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1538597687000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"29864379","title":"Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2018 Aug 1","volume":"36","issue":"22","pages":"2244-2250","authors":"Mok TS et al","elocationId":"doi: 10.1200/JCO.2018.78.7994","link":null,"reference":"Mok TS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Aug 1;36(22)2244-2250.","abstract":null},{"pmid":"28958502","title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2017 Nov","volume":"18","issue":"11","pages":"1454-1466","authors":"Wu YL et al","elocationId":"doi: 10.1016/S1470-2045(17)30608-3","link":null,"reference":"Wu YL et al. The Lancet. Oncology. 2017 Nov;18(11)1454-1466.","abstract":null}]},{"id":2749,"uuid":"86fcd13a-1d26-475f-8e8d-dcd6eacf4c7e","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":557,"subtype":"Ovary/Fallopian Tube","code":"OVARY","color":"LightBlue","mainType":"Ovarian/Fallopian Tube Cancer, NOS","level":1,"tissue":"Ovary/Fallopian Tube","tumorForm":"SOLID"},{"id":880,"subtype":"","code":"","color":"LightBlue","mainType":"Ovarian Cancer","level":0,"tissue":"Ovary/Fallopian Tube","tumorForm":"SOLID"},{"id":863,"subtype":"Peritoneal Serous Carcinoma","code":"PSEC","color":"Green","mainType":"Peritoneal Cancer, NOS","level":2,"tissue":"Peritoneum","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":672,"hugoSymbol":"BRCA1","oncogene":false,"grch37Isoform":"ENST00000357654","grch37RefSeq":"NM_007294.3","grch38Isoform":"ENST00000357654","grch38RefSeq":"NM_007294.3","geneAliases":["RNF53","IRIS","BRCAI","PNCA4","PSCP","BROVCA1","BRCC1","FANCS","PPP1R53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":672,"hugoSymbol":"BRCA1","oncogene":false,"grch37Isoform":"ENST00000357654","grch37RefSeq":"NM_007294.3","grch38Isoform":"ENST00000357654","grch38RefSeq":"NM_007294.3","geneAliases":["RNF53","IRIS","BRCAI","PNCA4","PSCP","BROVCA1","BRCC1","FANCS","PPP1R53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Olaparib is FDA-approved as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy"],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1598246449000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"24882434","title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2014 Jul","volume":"15","issue":"8","pages":"852-61","authors":"Ledermann J et al","elocationId":"doi: 10.1016/S1470-2045(14)70228-1","link":null,"reference":"Ledermann J et al. The Lancet. Oncology. 2014 Jul;15(8)852-61.","abstract":null},{"pmid":"30345884","title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.","journal":"The New England journal of medicine","pubDate":"2018 Dec 27","volume":"379","issue":"26","pages":"2495-2505","authors":"Moore K et al","elocationId":"doi: 10.1056/NEJMoa1810858","link":null,"reference":"Moore K et al. The New England journal of medicine. 2018 Dec 27;379(26)2495-2505.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://meetinglibrary.asco.org/record/173435/abstract","reference":"null. null. .","abstract":"Penson et al. Abstract# 5506, ASCO 2019"},{"pmid":"25366685","title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2015 Jan 20","volume":"33","issue":"3","pages":"244-50","authors":"Kaufman B et al","elocationId":"doi: 10.1200/JCO.2014.56.2728","link":null,"reference":"Kaufman B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 20;33(3)244-50.","abstract":null}]},{"id":2750,"uuid":"e6b287f8-9f2b-4d1b-a4bf-9dcee9a59af7","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":557,"subtype":"Ovary/Fallopian Tube","code":"OVARY","color":"LightBlue","mainType":"Ovarian/Fallopian Tube Cancer, NOS","level":1,"tissue":"Ovary/Fallopian Tube","tumorForm":"SOLID"},{"id":880,"subtype":"","code":"","color":"LightBlue","mainType":"Ovarian Cancer","level":0,"tissue":"Ovary/Fallopian Tube","tumorForm":"SOLID"},{"id":863,"subtype":"Peritoneal Serous Carcinoma","code":"PSEC","color":"Green","mainType":"Peritoneal Cancer, NOS","level":2,"tissue":"Peritoneum","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":672,"hugoSymbol":"BRCA1","oncogene":false,"grch37Isoform":"ENST00000357654","grch37RefSeq":"NM_007294.3","grch38Isoform":"ENST00000357654","grch38RefSeq":"NM_007294.3","geneAliases":["RNF53","IRIS","BRCAI","PNCA4","PSCP","BROVCA1","BRCC1","FANCS","PPP1R53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":672,"hugoSymbol":"BRCA1","oncogene":false,"grch37Isoform":"ENST00000357654","grch37RefSeq":"NM_007294.3","grch38Isoform":"ENST00000357654","grch38RefSeq":"NM_007294.3","geneAliases":["RNF53","IRIS","BRCAI","PNCA4","PSCP","BROVCA1","BRCC1","FANCS","PPP1R53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Rucaparib is FDA-approved for patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies."],"priority":2,"drugs":[{"ncitCode":"C137800","drugName":"Rucaparib","uuid":"75ceadf8-0171-4f62-97ff-b008b15effb3","synonyms":["Rucaparib\"","8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one","Rucaparib","RUCAPARIB","\"6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1595388683000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"30425037","title":"<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.","journal":"Cancer discovery","pubDate":"2019 Feb","volume":"9","issue":"2","pages":"210-219","authors":"Lin KK et al","elocationId":"doi: 10.1158/2159-8290.CD-18-0715","link":null,"reference":"Lin KK et al. Cancer discovery. 2019 Feb;9(2)210-219.","abstract":null},{"pmid":"28882436","title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.","journal":"Gynecologic oncology","pubDate":"2017 Nov","volume":"147","issue":"2","pages":"267-275","authors":"Oza AM et al","elocationId":"doi: 10.1016/j.ygyno.2017.08.022","link":null,"reference":"Oza AM et al. Gynecologic oncology. 2017 Nov;147(2)267-275.","abstract":null},{"pmid":"28916367","title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.","journal":"Lancet (London, England)","pubDate":"2017 Oct 28","volume":"390","issue":"10106","pages":"1949-1961","authors":"Coleman RL et al","elocationId":"doi: 10.1016/S0140-6736(17)32440-6","link":null,"reference":"Coleman RL et al. Lancet (London, England). 2017 Oct 28;390(10106)1949-1961.","abstract":null},{"pmid":"32359490","title":"Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2020 May","volume":"21","issue":"5","pages":"710-722","authors":"Ledermann JA et al","elocationId":"doi: 10.1016/S1470-2045(20)30061-9","link":null,"reference":"Ledermann JA et al. The Lancet. Oncology. 2020 May;21(5)710-722.","abstract":null}]},{"id":2751,"uuid":"2815c9c7-4825-45ee-8ee6-c34e220d350a","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":557,"subtype":"Ovary/Fallopian Tube","code":"OVARY","color":"LightBlue","mainType":"Ovarian/Fallopian Tube Cancer, NOS","level":1,"tissue":"Ovary/Fallopian Tube","tumorForm":"SOLID"},{"id":880,"subtype":"","code":"","color":"LightBlue","mainType":"Ovarian Cancer","level":0,"tissue":"Ovary/Fallopian Tube","tumorForm":"SOLID"},{"id":863,"subtype":"Peritoneal Serous Carcinoma","code":"PSEC","color":"Green","mainType":"Peritoneal Cancer, NOS","level":2,"tissue":"Peritoneum","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":672,"hugoSymbol":"BRCA1","oncogene":false,"grch37Isoform":"ENST00000357654","grch37RefSeq":"NM_007294.3","grch38Isoform":"ENST00000357654","grch38RefSeq":"NM_007294.3","geneAliases":["RNF53","IRIS","BRCAI","PNCA4","PSCP","BROVCA1","BRCC1","FANCS","PPP1R53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":672,"hugoSymbol":"BRCA1","oncogene":false,"grch37Isoform":"ENST00000357654","grch37RefSeq":"NM_007294.3","grch38Isoform":"ENST00000357654","grch38RefSeq":"NM_007294.3","geneAliases":["RNF53","IRIS","BRCAI","PNCA4","PSCP","BROVCA1","BRCC1","FANCS","PPP1R53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Niraparib is FDA-approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy irrespective of BRCA1/2 mutant status"],"priority":3,"drugs":[{"ncitCode":"C80059","drugName":"Niraparib","uuid":"d6cdce1b-5d80-4c71-8e5a-d1a9d3c81e17","synonyms":["MK-4827","MK4827","Niraparib","NIRAPARIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1581018936000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"30948273","title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2019 May","volume":"20","issue":"5","pages":"636-648","authors":"Moore KN et al","elocationId":"doi: 10.1016/S1470-2045(19)30029-4","link":null,"reference":"Moore KN et al. The Lancet. Oncology. 2019 May;20(5)636-648.","abstract":null},{"pmid":"27717299","title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.","journal":"The New England journal of medicine","pubDate":"2016 Dec 1","volume":"375","issue":"22","pages":"2154-2164","authors":"Mirza MR et al","elocationId":"","link":null,"reference":"Mirza MR et al. The New England journal of medicine. 2016 Dec 1;375(22)2154-2164.","abstract":null},{"pmid":"31562799","title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.","journal":"The New England journal of medicine","pubDate":"2019 Dec 19","volume":"381","issue":"25","pages":"2391-2402","authors":"González-Martín A et al","elocationId":"doi: 10.1056/NEJMoa1910962","link":null,"reference":"González-Martín A et al. The New England journal of medicine. 2019 Dec 19;381(25)2391-2402.","abstract":null}]},{"id":20931,"uuid":"c89514ef-b096-442a-828d-6ed357e12d57","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6098,"hugoSymbol":"ROS1","oncogene":true,"grch37Isoform":"ENST00000368508","grch37RefSeq":"NM_002944.2","grch38Isoform":"ENST00000368508","grch38RefSeq":"NM_002944.2","geneAliases":["MCF3","ROS","c-ros-1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6098,"hugoSymbol":"ROS1","oncogene":true,"grch37Isoform":"ENST00000368508","grch37RefSeq":"NM_002944.2","grch38Isoform":"ENST00000368508","grch38RefSeq":"NM_002944.2","geneAliases":["MCF3","ROS","c-ros-1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Crizotinib is FDA approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive."],"priority":1,"drugs":[{"ncitCode":"C74061","drugName":"Crizotinib","uuid":"f05d12ab-6204-4a1c-803f-f3a7f6e30af2","synonyms":["MET Tyrosine Kinase Inhibitor PF-02341066","Crizotinib","2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-","Xalkori\"","PF-02341066","CRIZOTINIB","PF-2341066","\"(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine","MET tyrosine kinase inhibitor PF-02341066"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1566283998000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"25264305","title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer.","journal":"The New England journal of medicine","pubDate":"2014 Nov 20","volume":"371","issue":"21","pages":"1963-71","authors":"Shaw AT et al","elocationId":"doi: 10.1056/NEJMoa1406766","link":null,"reference":"Shaw AT et al. The New England journal of medicine. 2014 Nov 20;371(21)1963-71.","abstract":null},{"pmid":"29596029","title":"Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2018 May 10","volume":"36","issue":"14","pages":"1405-1411","authors":"Wu YL et al","elocationId":"doi: 10.1200/JCO.2017.75.5587","link":null,"reference":"Wu YL et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 May 10;36(14)1405-1411.","abstract":null},{"pmid":"30980071","title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.","journal":"Annals of oncology : official journal of the European Society for Medical Oncology","pubDate":"2019 Jul 1","volume":"30","issue":"7","pages":"1121-1126","authors":"Shaw AT et al","elocationId":"doi: 10.1093/annonc/mdz131","link":null,"reference":"Shaw AT et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Jul 1;30(7)1121-1126.","abstract":null}]},{"id":2756,"uuid":"0fa1bfd9-4b60-4370-bf70-7fa72f89a99a","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":944,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer, NOS","level":0,"tissue":"Prostate","tumorForm":"SOLID"},{"id":936,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer","level":0,"tissue":"Prostate","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":672,"hugoSymbol":"BRCA1","oncogene":false,"grch37Isoform":"ENST00000357654","grch37RefSeq":"NM_007294.3","grch38Isoform":"ENST00000357654","grch38RefSeq":"NM_007294.3","geneAliases":["RNF53","IRIS","BRCAI","PNCA4","PSCP","BROVCA1","BRCC1","FANCS","PPP1R53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":672,"hugoSymbol":"BRCA1","oncogene":false,"grch37Isoform":"ENST00000357654","grch37RefSeq":"NM_007294.3","grch38Isoform":"ENST00000357654","grch38RefSeq":"NM_007294.3","geneAliases":["RNF53","IRIS","BRCAI","PNCA4","PSCP","BROVCA1","BRCC1","FANCS","PPP1R53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1598335457000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"26510020","title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.","journal":"The New England journal of medicine","pubDate":"2015 Oct 29","volume":"373","issue":"18","pages":"1697-708","authors":"Mateo J et al","elocationId":"doi: 10.1056/NEJMoa1506859","link":null,"reference":"Mateo J et al. The New England journal of medicine. 2015 Oct 29;373(18)1697-708.","abstract":null},{"pmid":"32343890","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer.","journal":"The New England journal of medicine","pubDate":"2020 May 28","volume":"382","issue":"22","pages":"2091-2102","authors":"de Bono J et al","elocationId":"doi: 10.1056/NEJMoa1911440","link":null,"reference":"de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.","abstract":null}]},{"id":20932,"uuid":"3dbaf733-ca83-47d3-b8d6-f15162c4055f","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6098,"hugoSymbol":"ROS1","oncogene":true,"grch37Isoform":"ENST00000368508","grch37RefSeq":"NM_002944.2","grch38Isoform":"ENST00000368508","grch38RefSeq":"NM_002944.2","geneAliases":["MCF3","ROS","c-ros-1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6098,"hugoSymbol":"ROS1","oncogene":true,"grch37Isoform":"ENST00000368508","grch37RefSeq":"NM_002944.2","grch38Isoform":"ENST00000368508","grch38RefSeq":"NM_002944.2","geneAliases":["MCF3","ROS","c-ros-1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C114984","drugName":"Entrectinib","uuid":"2371f7f5-6407-4a4b-b951-a0f786355455","synonyms":["RXDX-101\"","N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide","Entrectinib","\"ENTRECTINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1578470568000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"28183697","title":"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).","journal":"Cancer discovery","pubDate":"2017 Apr","volume":"7","issue":"4","pages":"400-409","authors":"Drilon A et al","elocationId":"doi: 10.1158/2159-8290.CD-16-1237","link":null,"reference":"Drilon A et al. Cancer discovery. 2017 Apr;7(4)400-409.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060","reference":"null. null. .","abstract":"Drilon et al. Abstract# CT060, AACR 2017"},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397","reference":"null. null. .","abstract":"Braud et al. Abstract# 64P, ESMO 2019"}]},{"id":2757,"uuid":"90918096-e0d7-4d7e-86ad-62ac39218b28","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":944,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer, NOS","level":0,"tissue":"Prostate","tumorForm":"SOLID"},{"id":936,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer","level":0,"tissue":"Prostate","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":672,"hugoSymbol":"BRCA1","oncogene":false,"grch37Isoform":"ENST00000357654","grch37RefSeq":"NM_007294.3","grch38Isoform":"ENST00000357654","grch38RefSeq":"NM_007294.3","geneAliases":["RNF53","IRIS","BRCAI","PNCA4","PSCP","BROVCA1","BRCC1","FANCS","PPP1R53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":672,"hugoSymbol":"BRCA1","oncogene":false,"grch37Isoform":"ENST00000357654","grch37RefSeq":"NM_007294.3","grch38Isoform":"ENST00000357654","grch38RefSeq":"NM_007294.3","geneAliases":["RNF53","IRIS","BRCAI","PNCA4","PSCP","BROVCA1","BRCC1","FANCS","PPP1R53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C137800","drugName":"Rucaparib","uuid":"75ceadf8-0171-4f62-97ff-b008b15effb3","synonyms":["Rucaparib\"","8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one","Rucaparib","RUCAPARIB","\"6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1598337840000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://www.sciencedirect.com/science/article/pii/S0923753419590627","reference":"null. null. .","abstract":"Abida et al. Abstract# 846PD, ESMO 2019"},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://ascopubs.org/doi/full/10.1200/JCO.20.01035","reference":"null. null. .","abstract":"Abida et al. JCO, Aug 2020"}]},{"id":16846,"uuid":"c9918d38-274b-44e5-b91d-a8c8855e1b76","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":935,"subtype":"","code":"","color":"SaddleBrown","mainType":"Colorectal Cancer","level":0,"tissue":"Bowel","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Wildtype","name":"Wildtype","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C1857","drugName":"Panitumumab","uuid":"d7b1d12a-e942-4801-bb64-916c9bdfaaf3","synonyms":["ABX-EGF, Clone E7.6.3","PANITUMUMAB","\"ABX-EGF","Panitumumab","Vectibix","MoAb ABX-EGF","ABX-EGF","panitumumab","panitumumab\"","ABX-EGF Monoclonal Antibody","Monoclonal Antibody ABX-EGF"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1608173457000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"27736842","title":"A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.","journal":"British journal of cancer","pubDate":"2016 Nov 8","volume":"115","issue":"10","pages":"1206-1214","authors":"Kim TW et al","elocationId":"doi: 10.1038/bjc.2016.309","link":null,"reference":"Kim TW et al. British journal of cancer. 2016 Nov 8;115(10)1206-1214.","abstract":null}]},{"id":720,"uuid":"8745a8af-c17b-4a61-b781-215cab39d421","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Crizotinib is FDA approved for the treatment of ALK fusion-positive metastatic non-small celll lung cancer"],"priority":1,"drugs":[{"ncitCode":"C74061","drugName":"Crizotinib","uuid":"f05d12ab-6204-4a1c-803f-f3a7f6e30af2","synonyms":["MET Tyrosine Kinase Inhibitor PF-02341066","Crizotinib","2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-","Xalkori\"","PF-02341066","CRIZOTINIB","PF-2341066","\"(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine","MET tyrosine kinase inhibitor PF-02341066"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1589434438000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"23724913","title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.","journal":"The New England journal of medicine","pubDate":"2013 Jun 20","volume":"368","issue":"25","pages":"2385-94","authors":"Shaw AT et al","elocationId":"doi: 10.1056/NEJMoa1214886","link":null,"reference":"Shaw AT et al. The New England journal of medicine. 2013 Jun 20;368(25)2385-94.","abstract":null},{"pmid":"29596029","title":"Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2018 May 10","volume":"36","issue":"14","pages":"1405-1411","authors":"Wu YL et al","elocationId":"doi: 10.1200/JCO.2017.75.5587","link":null,"reference":"Wu YL et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 May 10;36(14)1405-1411.","abstract":null}]},{"id":16337,"uuid":"a15ccb16-ec8c-4772-9f0c-b1cf6f188666","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":638,"subtype":"Neurofibroma","code":"NFIB","color":"Gray","mainType":"Nerve Sheath Tumor","level":3,"tissue":"Peripheral Nervous System","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4763,"hugoSymbol":"NF1","oncogene":false,"grch37Isoform":"ENST00000356175","grch37RefSeq":"NM_000267","grch38Isoform":"ENST00000356175","grch38RefSeq":"NM_000267","geneAliases":["WSS","NFNS","VRNF"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4763,"hugoSymbol":"NF1","oncogene":false,"grch37Isoform":"ENST00000356175","grch37RefSeq":"NM_000267","grch38Isoform":"ENST00000356175","grch38RefSeq":"NM_000267","geneAliases":["WSS","NFNS","VRNF"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C66939","drugName":"Selumetinib","uuid":"3f154145-525b-4865-8baf-12b374697b2a","synonyms":["Selumetinib","AZD6244","SELUMETINIB","ARRY-142886","MEK Inhibitor AZD6244","MEK inhibitor AZD6244"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1587013051000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"32187457","title":"Selumetinib in Children with Inoperable Plexiform Neurofibromas.","journal":"The New England journal of medicine","pubDate":"2020 Apr 9","volume":"382","issue":"15","pages":"1430-1442","authors":"Gross AM et al","elocationId":"doi: 10.1056/NEJMoa1912735","link":null,"reference":"Gross AM et al. The New England journal of medicine. 2020 Apr 9;382(15)1430-1442.","abstract":null},{"pmid":"28029918","title":"Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.","journal":"The New England journal of medicine","pubDate":"2016 Dec 29","volume":"375","issue":"26","pages":"2550-2560","authors":"Dombi E et al","elocationId":"doi: 10.1056/NEJMoa1605943","link":null,"reference":"Dombi E et al. The New England journal of medicine. 2016 Dec 29;375(26)2550-2560.","abstract":null}]},{"id":721,"uuid":"d13f9a4d-f095-4102-ac32-c3bb67f5ef93","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Creritinib is FDA approved for the treatment of ALK-fusion positive metastatic non-small cell lung cancer with disease progression on or intolerance to crizotinib."],"priority":2,"drugs":[{"ncitCode":"C115112","drugName":"Ceritinib","uuid":"5e9aa568-30cf-48ef-b9ce-18851af2f622","synonyms":["LDK378","Zykadia\"","LDK 378","CERITINIB","\"2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-","Ceritinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1589434331000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390","reference":"null. null. .","abstract":"Chow et al. Abstract# 1478O, ESMO 2019"},{"pmid":"28126333","title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.","journal":"Lancet (London, England)","pubDate":"2017 Mar 4","volume":"389","issue":"10072","pages":"917-929","authors":"Soria JC et al","elocationId":"doi: 10.1016/S0140-6736(17)30123-X","link":null,"reference":"Soria JC et al. Lancet (London, England). 2017 Mar 4;389(10072)917-929.","abstract":null}]},{"id":17362,"uuid":"922563c6-7fd0-46ff-bac5-a1b6916aeaca","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":408,"subtype":"Dermatofibrosarcoma Protuberans","code":"DFSP","color":"Black","mainType":"Skin Cancer, Non-Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5155,"hugoSymbol":"PDGFB","oncogene":true,"grch37Isoform":"ENST00000331163","grch37RefSeq":"NM_002608.2","grch38Isoform":"ENST00000331163","grch38RefSeq":"NM_002608.2","geneAliases":["IBGC5","SSV","PDGF2","c-sis","PDGF-2","SIS"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5155,"hugoSymbol":"PDGFB","oncogene":true,"grch37Isoform":"ENST00000331163","grch37RefSeq":"NM_002608.2","grch38Isoform":"ENST00000331163","grch38RefSeq":"NM_002608.2","geneAliases":["IBGC5","SSV","PDGF2","c-sis","PDGF-2","SIS"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"COL1A1-PDGFB Fusion","name":"COL1A1-PDGFB Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Imatinib is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans"],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1548970031000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"19620561","title":"Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.","journal":"Archives of dermatology","pubDate":"2009 Jul","volume":"145","issue":"7","pages":"792-6","authors":"Han A et al","elocationId":"doi: 10.1001/archdermatol.2009.140","link":null,"reference":"Han A et al. Archives of dermatology. 2009 Jul;145(7)792-6.","abstract":null},{"pmid":"20439456","title":"Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2010 Jun 15","volume":"16","issue":"12","pages":"3288-95","authors":"Kérob D et al","elocationId":"doi: 10.1158/1078-0432.CCR-09-3401","link":null,"reference":"Kérob D et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Jun 15;16(12)3288-95.","abstract":null},{"pmid":"15746584","title":"Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.","journal":"Anti-cancer drugs","pubDate":"2005 Apr","volume":"16","issue":"4","pages":"461-6","authors":"Labropoulos SV et al","elocationId":"","link":null,"reference":"Labropoulos SV et al. Anti-cancer drugs. 2005 Apr;16(4)461-6.","abstract":null},{"pmid":"18451237","title":"Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2008 May 1","volume":"14","issue":"9","pages":"2717-25","authors":"Heinrich MC et al","elocationId":"doi: 10.1158/1078-0432.CCR-07-4575","link":null,"reference":"Heinrich MC et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 May 1;14(9)2717-25.","abstract":null},{"pmid":"15503291","title":"Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans.","journal":"Pediatric blood & cancer","pubDate":"2005 May","volume":"44","issue":"5","pages":"511-5","authors":"Price VE et al","elocationId":"","link":null,"reference":"Price VE et al. Pediatric blood & cancer. 2005 May;44(5)511-5.","abstract":null},{"pmid":"15681532","title":"Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2005 Feb 1","volume":"23","issue":"4","pages":"866-73","authors":"McArthur GA et al","elocationId":"","link":null,"reference":"McArthur GA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Feb 1;23(4)866-73.","abstract":null},{"pmid":"21128251","title":"Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.","journal":"International journal of cancer","pubDate":"2011 Oct 1","volume":"129","issue":"7","pages":"1761-72","authors":"Stacchiotti S et al","elocationId":"doi: 10.1002/ijc.25826","link":null,"reference":"Stacchiotti S et al. International journal of cancer. 2011 Oct 1;129(7)1761-72.","abstract":null}]},{"id":722,"uuid":"917bd2b0-c605-4333-a269-61044070cf74","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Alectinib is FDA approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer who have failed crizotinib therapy. Patients who are intolerant of crizotinib and also eligible for treatment with Alectinib."],"priority":3,"drugs":[{"ncitCode":"C101790","drugName":"Alectinib","uuid":"ef2bee25-4fa3-40c4-a79f-4f885377afa7","synonyms":["AF802","Alectinib","RO5424802\"","ALECTINIB","\"5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-","AF-802","Alecensa","CH5424802","RG7853"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1589435421000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"29668860","title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.","journal":"Annals of oncology : official journal of the European Society for Medical Oncology","pubDate":"2018 Jun 1","volume":"29","issue":"6","pages":"1409-1416","authors":"Novello S et al","elocationId":"doi: 10.1093/annonc/mdy121","link":null,"reference":"Novello S et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Jun 1;29(6)1409-1416.","abstract":null},{"pmid":"30215676","title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.","journal":"Annals of oncology : official journal of the European Society for Medical Oncology","pubDate":"2018 Nov 1","volume":"29","issue":"11","pages":"2214-2222","authors":"Gadgeel S et al","elocationId":"doi: 10.1093/annonc/mdy405","link":null,"reference":"Gadgeel S et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Nov 1;29(11)2214-2222.","abstract":null},{"pmid":"28586279","title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.","journal":"The New England journal of medicine","pubDate":"2017 Aug 31","volume":"377","issue":"9","pages":"829-838","authors":"Peters S et al","elocationId":"doi: 10.1056/NEJMoa1704795","link":null,"reference":"Peters S et al. The New England journal of medicine. 2017 Aug 31;377(9)829-838.","abstract":null}]},{"id":732,"uuid":"09bde177-1da1-447a-a0ad-dfc0ba18411d","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C113655","drugName":"Lorlatinib","uuid":"ed76aa01-059c-4b22-b391-94ec86320122","synonyms":["\"2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-","PF-06463922\"","Lorlatinib","LORLATINIB","7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1602803112000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"30892989","title":"<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2019 Jun 1","volume":"37","issue":"16","pages":"1370-1379","authors":"Shaw AT et al","elocationId":"doi: 10.1200/JCO.18.02236","link":null,"reference":"Shaw AT et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Jun 1;37(16)1370-1379.","abstract":null},{"pmid":"29074098","title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.","journal":"The Lancet. Oncology","pubDate":"2017 Dec","volume":"18","issue":"12","pages":"1590-1599","authors":"Shaw AT et al","elocationId":"doi: 10.1016/S1470-2045(17)30680-0","link":null,"reference":"Shaw AT et al. The Lancet. Oncology. 2017 Dec;18(12)1590-1599.","abstract":null},{"pmid":"30413378","title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.","journal":"The Lancet. Oncology","pubDate":"2018 Dec","volume":"19","issue":"12","pages":"1654-1667","authors":"Solomon BJ et al","elocationId":"doi: 10.1016/S1470-2045(18)30649-1","link":null,"reference":"Solomon BJ et al. The Lancet. Oncology. 2018 Dec;19(12)1654-1667.","abstract":null},{"pmid":"27432227","title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.","journal":"Cancer discovery","pubDate":"2016 Oct","volume":"6","issue":"10","pages":"1118-1133","authors":"Gainor JF et al","elocationId":"","link":null,"reference":"Gainor JF et al. Cancer discovery. 2016 Oct;6(10)1118-1133.","abstract":null}]},{"id":733,"uuid":"3be22d24-4ef0-4cbf-97cc-33f2f6f74625","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C98831","drugName":"Brigatinib","uuid":"e3f55518-0ebb-4998-9e78-3124b5b987ec","synonyms":["Brigatinib","AP26113","Alunbrig","5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine","AP-26113","BRIGATINIB","\"(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone","AP 26113","Brigatinib\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1590367352000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"30280657","title":"Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.","journal":"The New England journal of medicine","pubDate":"2018 Nov 22","volume":"379","issue":"21","pages":"2027-2039","authors":"Camidge DR et al","elocationId":"doi: 10.1056/NEJMoa1810171","link":null,"reference":"Camidge DR et al. The New England journal of medicine. 2018 Nov 22;379(21)2027-2039.","abstract":null},{"pmid":"28475456","title":"Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Aug 1","volume":"35","issue":"22","pages":"2490-2498","authors":"Kim DW et al","elocationId":"doi: 10.1200/JCO.2016.71.5904","link":null,"reference":"Kim DW et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Aug 1;35(22)2490-2498.","abstract":null}]},{"id":2015,"uuid":"86887f5d-62df-429b-9968-7b73c31a9504","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600E","name":"V600E","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Dabrafenib is FDA-approved for BRAF V600E mutant unresectable or metastatic melanoma."],"priority":1,"drugs":[{"ncitCode":"C82386","drugName":"Dabrafenib","uuid":"939cd40b-b515-499d-b099-fd29027c0d17","synonyms":["DABRAFENIB","GSK2118436\"","\"BRAF Inhibitor GSK2118436","GSK-2118436","GSK-2118436A","Dabrafenib","Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1589437069000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"23051966","title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2012 Nov","volume":"13","issue":"11","pages":"1087-95","authors":"Long GV et al","elocationId":"doi: 10.1016/S1470-2045(12)70431-X","link":null,"reference":"Long GV et al. The Lancet. Oncology. 2012 Nov;13(11)1087-95.","abstract":null},{"pmid":"22608338","title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.","journal":"Lancet (London, England)","pubDate":"2012 May 19","volume":"379","issue":"9829","pages":"1893-901","authors":"Falchook GS et al","elocationId":"doi: 10.1016/S0140-6736(12)60398-5","link":null,"reference":"Falchook GS et al. Lancet (London, England). 2012 May 19;379(9829)1893-901.","abstract":null},{"pmid":"22735384","title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.","journal":"Lancet (London, England)","pubDate":"2012 Jul 28","volume":"380","issue":"9839","pages":"358-65","authors":"Hauschild A et al","elocationId":"doi: 10.1016/S0140-6736(12)60868-X","link":null,"reference":"Hauschild A et al. Lancet (London, England). 2012 Jul 28;380(9839)358-65.","abstract":null}]},{"id":2016,"uuid":"09c8f359-ae07-4746-a2b1-2cc3d948b09f","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600E","name":"V600E","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Vemurafenib is FDA-approved for BRAF V600E mutant unresectable or metastatic melanoma"],"priority":2,"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib","uuid":"4e91da20-6cf0-4e07-995f-7f7db4c7c077","synonyms":["Vemurafenib","BRAF(V600E) Kinase Inhibitor RO5185426","RO 5185426","PLX4032","PLX-4032","RG 7204","Zelboraf\"","BRAF (V600E) kinase inhibitor RO5185426","RG7204","\"1-propanesulfonamide, n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-","VEMURAFENIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1564665994000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"24508103","title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.","journal":"The Lancet. Oncology","pubDate":"2014 Mar","volume":"15","issue":"3","pages":"323-32","authors":"McArthur GA et al","elocationId":"doi: 10.1016/S1470-2045(14)70012-9","link":null,"reference":"McArthur GA et al. The Lancet. Oncology. 2014 Mar;15(3)323-32.","abstract":null},{"pmid":"25399551","title":"Improved overall survival in melanoma with combined dabrafenib and trametinib.","journal":"The New England journal of medicine","pubDate":"2015 Jan 1","volume":"372","issue":"1","pages":"30-9","authors":"Robert C et al","elocationId":"doi: 10.1056/NEJMoa1412690","link":null,"reference":"Robert C et al. The New England journal of medicine. 2015 Jan 1;372(1)30-9.","abstract":null},{"pmid":"28961848","title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.","journal":"Annals of oncology : official journal of the European Society for Medical Oncology","pubDate":"2017 Oct 1","volume":"28","issue":"10","pages":"2581-2587","authors":"Chapman PB et al","elocationId":"doi: 10.1093/annonc/mdx339","link":null,"reference":"Chapman PB et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Oct 1;28(10)2581-2587.","abstract":null}]},{"id":5346,"uuid":"b00f2ed8-c653-4a18-aa98-48cc5b77ccae","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":936,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer","level":0,"tissue":"Prostate","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":51755,"hugoSymbol":"CDK12","oncogene":false,"grch37Isoform":"ENST00000447079","grch37RefSeq":"NM_016507.2","grch38Isoform":"ENST00000447079","grch38RefSeq":"NM_016507.2","geneAliases":["CRK7","CRKR","CRKRS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":51755,"hugoSymbol":"CDK12","oncogene":false,"grch37Isoform":"ENST00000447079","grch37RefSeq":"NM_016507.2","grch38Isoform":"ENST00000447079","grch38RefSeq":"NM_016507.2","geneAliases":["CRK7","CRKR","CRKRS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1591166250000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32343890","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer.","journal":"The New England journal of medicine","pubDate":"2020 May 28","volume":"382","issue":"22","pages":"2091-2102","authors":"de Bono J et al","elocationId":"doi: 10.1056/NEJMoa1911440","link":null,"reference":"de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.","abstract":null}]},{"id":2018,"uuid":"c63b34cb-c1fa-4784-c031-98566ad048bb","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600E","name":"V600E","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Dabrafenib and trametinib are FDA-approved for use in combination in the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation"],"priority":1,"drugs":[{"ncitCode":"C77908","drugName":"Trametinib","uuid":"fb2bb01c-c0ec-4641-abf7-87f486075022","synonyms":["Mekinist","\"GSK1120212","Trametinib\"","TRAMETINIB","JTP-74057","MEK Inhibitor GSK1120212","N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","Trametinib"],"priority":2},{"ncitCode":"C82386","drugName":"Dabrafenib","uuid":"939cd40b-b515-499d-b099-fd29027c0d17","synonyms":["DABRAFENIB","GSK2118436\"","\"BRAF Inhibitor GSK2118436","GSK-2118436","GSK-2118436A","Dabrafenib","Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1526574955000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"28919011","title":"Dabrafenib plus trametinib in patients with previously untreated BRAF<sup>V600E</sup>-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2017 Oct","volume":"18","issue":"10","pages":"1307-1316","authors":"Planchard D et al","elocationId":"doi: 10.1016/S1470-2045(17)30679-4","link":null,"reference":"Planchard D et al. The Lancet. Oncology. 2017 Oct;18(10)1307-1316.","abstract":null},{"pmid":"27283860","title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2016 Jul","volume":"17","issue":"7","pages":"984-993","authors":"Planchard D et al","elocationId":"doi: 10.1016/S1470-2045(16)30146-2","link":null,"reference":"Planchard D et al. The Lancet. Oncology. 2016 Jul;17(7)984-993.","abstract":null}]},{"id":6627,"uuid":"0974c6a3-9067-4e88-8697-6a2e633cee9d","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"S768I","name":"S768I","refResidues":"S","proteinStart":768,"proteinEnd":768,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C66940","drugName":"Afatinib","uuid":"e1f45ae7-33ae-428c-9e77-da4a9b7270b6","synonyms":["BIBW 2992","Afatinib","BIBW2992","AFATINIB","(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1576178617000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"25521405","title":"Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2014 Oct","volume":"9","issue":"10","pages":"e73-4","authors":"Hellmann MD et al","elocationId":"doi: 10.1097/JTO.0000000000000221","link":null,"reference":"Hellmann MD et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Oct;9(10)e73-4.","abstract":null},{"pmid":"28336552","title":"Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.","journal":"Cancer discovery","pubDate":"2017 Jun","volume":"7","issue":"6","pages":"596-609","authors":"Jordan EJ et al","elocationId":"doi: 10.1158/2159-8290.CD-16-1337","link":null,"reference":"Jordan EJ et al. Cancer discovery. 2017 Jun;7(6)596-609.","abstract":null},{"pmid":"17285735","title":"Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.","journal":"The oncologist","pubDate":"2007 Jan","volume":"12","issue":"1","pages":"90-8","authors":"Sequist LV et al","elocationId":"","link":null,"reference":"Sequist LV et al. The oncologist. 2007 Jan;12(1)90-8.","abstract":null},{"pmid":"26051236","title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.","journal":"The Lancet. Oncology","pubDate":"2015 Jul","volume":"16","issue":"7","pages":"830-8","authors":"Yang JC et al","elocationId":"doi: 10.1016/S1470-2045(15)00026-1","link":null,"reference":"Yang JC et al. The Lancet. Oncology. 2015 Jul;16(7)830-8.","abstract":null}]},{"id":2020,"uuid":"87b2f23f-8d71-4664-b259-c2384202937b","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":409,"subtype":"Anaplastic Thyroid Cancer","code":"THAP","color":"Teal","mainType":"Thyroid Cancer","level":2,"tissue":"Thyroid","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600E","name":"V600E","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Dabrafenib in combination with trametinib is FDA-approved for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options."],"priority":1,"drugs":[{"ncitCode":"C82386","drugName":"Dabrafenib","uuid":"939cd40b-b515-499d-b099-fd29027c0d17","synonyms":["DABRAFENIB","GSK2118436\"","\"BRAF Inhibitor GSK2118436","GSK-2118436","GSK-2118436A","Dabrafenib","Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-"],"priority":1},{"ncitCode":"C77908","drugName":"Trametinib","uuid":"fb2bb01c-c0ec-4641-abf7-87f486075022","synonyms":["Mekinist","\"GSK1120212","Trametinib\"","TRAMETINIB","JTP-74057","MEK Inhibitor GSK1120212","N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","Trametinib"],"priority":2}]}],"knownEffect":"Sensitive","lastEdit":1526589118000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"29072975","title":"Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2018 Jan 1","volume":"36","issue":"1","pages":"7-13","authors":"Subbiah V et al","elocationId":"doi: 10.1200/JCO.2017.73.6785","link":null,"reference":"Subbiah V et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Jan 1;36(1)7-13.","abstract":null}]},{"id":17125,"uuid":"540b19c1-c8c0-40a1-a293-41ef3ade7af8","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4915,"hugoSymbol":"NTRK2","oncogene":true,"grch37Isoform":"ENST00000277120","grch37RefSeq":"NM_006180.3","grch38Isoform":"ENST00000277120","grch38RefSeq":"NM_006180.3","geneAliases":["TRKB","EIEE58","GP145-TrkB","trk-B","OBHD"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4915,"hugoSymbol":"NTRK2","oncogene":true,"grch37Isoform":"ENST00000277120","grch37RefSeq":"NM_006180.3","grch38Isoform":"ENST00000277120","grch38RefSeq":"NM_006180.3","geneAliases":["TRKB","EIEE58","GP145-TrkB","trk-B","OBHD"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C115977","drugName":"Larotrectinib","uuid":"b0b3d8ee-86a5-4421-b4a9-053d3c1ff544","synonyms":["LAROTRECTINIB","LOXO-101","Larotrectinib","LOXO 101","\"1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-","ARRY 470","3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide","Larotrectinib\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1544568084000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"26216294","title":"An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.","journal":"Cancer discovery","pubDate":"2015 Oct","volume":"5","issue":"10","pages":"1049-57","authors":"Doebele RC et al","elocationId":"doi: 10.1158/2159-8290.CD-15-0443","link":null,"reference":"Doebele RC et al. Cancer discovery. 2015 Oct;5(10)1049-57.","abstract":null},{"pmid":"29466156","title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.","journal":"The New England journal of medicine","pubDate":"2018 Feb 22","volume":"378","issue":"8","pages":"731-739","authors":"Drilon A et al","elocationId":"doi: 10.1056/NEJMoa1714448","link":null,"reference":"Drilon A et al. The New England journal of medicine. 2018 Feb 22;378(8)731-739.","abstract":null}]},{"id":17126,"uuid":"91dff87f-347e-4dfb-a2a8-56e4d7501439","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4915,"hugoSymbol":"NTRK2","oncogene":true,"grch37Isoform":"ENST00000277120","grch37RefSeq":"NM_006180.3","grch38Isoform":"ENST00000277120","grch38RefSeq":"NM_006180.3","geneAliases":["TRKB","EIEE58","GP145-TrkB","trk-B","OBHD"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4915,"hugoSymbol":"NTRK2","oncogene":true,"grch37Isoform":"ENST00000277120","grch37RefSeq":"NM_006180.3","grch38Isoform":"ENST00000277120","grch38RefSeq":"NM_006180.3","geneAliases":["TRKB","EIEE58","GP145-TrkB","trk-B","OBHD"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C114984","drugName":"Entrectinib","uuid":"2371f7f5-6407-4a4b-b951-a0f786355455","synonyms":["RXDX-101\"","N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide","Entrectinib","\"ENTRECTINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1579140171000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"28183697","title":"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).","journal":"Cancer discovery","pubDate":"2017 Apr","volume":"7","issue":"4","pages":"400-409","authors":"Drilon A et al","elocationId":"doi: 10.1158/2159-8290.CD-16-1237","link":null,"reference":"Drilon A et al. Cancer discovery. 2017 Apr;7(4)400-409.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583","reference":"null. null. .","abstract":"Demetri et al. Abstract# LBA17, ESMO 2018 Congress"},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407","reference":"null. null. .","abstract":"Rolfo et al. Abstract# 65P, ESMO 2019"},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://meetinglibrary.asco.org/record/155954/abstract","reference":"null. null. .","abstract":"Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018"},{"pmid":"31838007","title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.","journal":"The Lancet. Oncology","pubDate":"2020 Feb","volume":"21","issue":"2","pages":"271-282","authors":"Doebele RC et al","elocationId":"doi: 10.1016/S1470-2045(19)30691-6","link":null,"reference":"Doebele RC et al. The Lancet. Oncology. 2020 Feb;21(2)271-282.","abstract":null}]},{"id":2022,"uuid":"5d3556f9-89b7-4be9-9fa8-69fee10f032b","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":935,"subtype":"","code":"","color":"SaddleBrown","mainType":"Colorectal Cancer","level":0,"tissue":"Bowel","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600E","name":"V600E","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C1723","drugName":"Cetuximab","uuid":"5fce3074-e420-4c36-9603-2423daf20118","synonyms":["CETUXIMAB","Cetuximab Biosimilar CMAB009","IMC-C225","Chimeric Anti-EGFR Monoclonal Antibody","Cetuximab Biosimilar KL 140","cetuximab","Cetuximab Biosimilar CDP-1","Chimeric Monoclonal Antibody C225","Cetuximab","Chimeric MoAb C225","Erbitux"],"priority":2},{"ncitCode":"C98283","drugName":"Encorafenib","uuid":"001e534f-3e63-432f-90a6-d1af1759e4e2","synonyms":["LGX-818","Encorafenib","LGX818","LGX 818","ENCORAFENIB","Braftovi"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1587075030000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"31566309","title":"Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer.","journal":"The New England journal of medicine","pubDate":"2019 Oct 24","volume":"381","issue":"17","pages":"1632-1643","authors":"Kopetz S et al","elocationId":"doi: 10.1056/NEJMoa1908075","link":null,"reference":"Kopetz S et al. The New England journal of medicine. 2019 Oct 24;381(17)1632-1643.","abstract":null}]},{"id":11754,"uuid":"6c4b4619-8d90-443f-9835-f87399f812bb","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3417,"hugoSymbol":"IDH1","oncogene":true,"grch37Isoform":"ENST00000345146","grch37RefSeq":"NM_005896.2","grch38Isoform":"ENST00000345146","grch38RefSeq":"NM_005896.2","geneAliases":["HEL-216","IDPC","IDCD","HEL-S-26","PICD"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3417,"hugoSymbol":"IDH1","oncogene":true,"grch37Isoform":"ENST00000345146","grch37RefSeq":"NM_005896.2","grch38Isoform":"ENST00000345146","grch38RefSeq":"NM_005896.2","geneAliases":["HEL-216","IDPC","IDCD","HEL-S-26","PICD"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["For adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation"],"priority":1,"drugs":[{"ncitCode":"C114383","drugName":"Ivosidenib","uuid":"6e09176b-e044-4190-8bbd-767c907577eb","synonyms":["AG-120","Ivosidenib","IVOSIDENIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1536171837000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"LEVEL_3B","articles":[{"pmid":"29860938","title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.","journal":"The New England journal of medicine","pubDate":"2018 Jun 21","volume":"378","issue":"25","pages":"2386-2398","authors":"DiNardo CD et al","elocationId":"doi: 10.1056/NEJMoa1716984","link":null,"reference":"DiNardo CD et al. The New England journal of medicine. 2018 Jun 21;378(25)2386-2398.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/124/21/3734?sso-checked=true","reference":"null. null. .","abstract":"Hansen et al. Abstract# 3734, ASH 2014"},{"pmid":"23393090","title":"(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.","journal":"Science (New York, N.Y.)","pubDate":"2013 Mar 29","volume":"339","issue":"6127","pages":"1621-5","authors":"Losman JA et al","elocationId":"doi: 10.1126/science.1231677","link":null,"reference":"Losman JA et al. Science (New York, N.Y.). 2013 Mar 29;339(6127)1621-5.","abstract":null},{"pmid":"23558169","title":"An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.","journal":"Science (New York, N.Y.)","pubDate":"2013 May 3","volume":"340","issue":"6132","pages":"626-30","authors":"Rohle D et al","elocationId":"doi: 10.1126/science.1236062","link":null,"reference":"Rohle D et al. Science (New York, N.Y.). 2013 May 3;340(6132)626-30.","abstract":null}]},{"id":6635,"uuid":"8d831348-0a9b-48e3-9daa-b1cf522cfbca","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":83,"subtype":"Non-Small Cell Lung Cancer","code":"NSCLC","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":2,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L861Q","name":"L861Q","refResidues":"L","proteinStart":861,"proteinEnd":861,"variantResidues":"Q","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C66940","drugName":"Afatinib","uuid":"e1f45ae7-33ae-428c-9e77-da4a9b7270b6","synonyms":["BIBW 2992","Afatinib","BIBW2992","AFATINIB","(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1576712894000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"28336552","title":"Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.","journal":"Cancer discovery","pubDate":"2017 Jun","volume":"7","issue":"6","pages":"596-609","authors":"Jordan EJ et al","elocationId":"doi: 10.1158/2159-8290.CD-16-1337","link":null,"reference":"Jordan EJ et al. Cancer discovery. 2017 Jun;7(6)596-609.","abstract":null},{"pmid":"26051236","title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.","journal":"The Lancet. Oncology","pubDate":"2015 Jul","volume":"16","issue":"7","pages":"830-8","authors":"Yang JC et al","elocationId":"doi: 10.1016/S1470-2045(15)00026-1","link":null,"reference":"Yang JC et al. The Lancet. Oncology. 2015 Jul;16(7)830-8.","abstract":null},{"pmid":"22452895","title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2012 May","volume":"13","issue":"5","pages":"539-48","authors":"Yang JC et al","elocationId":"doi: 10.1016/S1470-2045(12)70086-4","link":null,"reference":"Yang JC et al. The Lancet. Oncology. 2012 May;13(5)539-48.","abstract":null},{"pmid":"21531810","title":"Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2011 Jun 1","volume":"17","issue":"11","pages":"3812-21","authors":"Wu JY et al","elocationId":"doi: 10.1158/1078-0432.CCR-10-3408","link":null,"reference":"Wu JY et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Jun 1;17(11)3812-21.","abstract":null},{"pmid":"25589191","title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.","journal":"The Lancet. Oncology","pubDate":"2015 Feb","volume":"16","issue":"2","pages":"141-51","authors":"Yang JC et al","elocationId":"doi: 10.1016/S1470-2045(14)71173-8","link":null,"reference":"Yang JC et al. The Lancet. Oncology. 2015 Feb;16(2)141-51.","abstract":null},{"pmid":"23816960","title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2013 Sep 20","volume":"31","issue":"27","pages":"3327-34","authors":"Sequist LV et al","elocationId":"doi: 10.1200/JCO.2012.44.2806","link":null,"reference":"Sequist LV et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 20;31(27)3327-34.","abstract":null}]},{"id":1259,"uuid":"e9dff6d0-5129-4895-b36d-41b8f54dd2b9","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":936,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer","level":0,"tissue":"Prostate","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":472,"hugoSymbol":"ATM","oncogene":false,"grch37Isoform":"ENST00000278616","grch37RefSeq":"NM_000051.3","grch38Isoform":"ENST00000278616","grch38RefSeq":"NM_000051.3","geneAliases":["ATC","ATD","TEL1","ATE","ATDC","TELO1","AT1","ATA"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":472,"hugoSymbol":"ATM","oncogene":false,"grch37Isoform":"ENST00000278616","grch37RefSeq":"NM_000051.3","grch38Isoform":"ENST00000278616","grch38RefSeq":"NM_000051.3","geneAliases":["ATC","ATD","TEL1","ATE","ATDC","TELO1","AT1","ATA"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1591308177000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32343890","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer.","journal":"The New England journal of medicine","pubDate":"2020 May 28","volume":"382","issue":"22","pages":"2091-2102","authors":"de Bono J et al","elocationId":"doi: 10.1056/NEJMoa1911440","link":null,"reference":"de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.","abstract":null}]},{"id":1776,"uuid":"48160115-6aaf-4fd6-9884-cf262c0e4436","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":936,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer","level":0,"tissue":"Prostate","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":580,"hugoSymbol":"BARD1","oncogene":false,"grch37Isoform":"ENST00000260947","grch37RefSeq":"NM_000465.2","grch38Isoform":"ENST00000260947","grch38RefSeq":"NM_000465.2","geneAliases":[],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":580,"hugoSymbol":"BARD1","oncogene":false,"grch37Isoform":"ENST00000260947","grch37RefSeq":"NM_000465.2","grch38Isoform":"ENST00000260947","grch38RefSeq":"NM_000465.2","geneAliases":[],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1591153521000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32343890","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer.","journal":"The New England journal of medicine","pubDate":"2020 May 28","volume":"382","issue":"22","pages":"2091-2102","authors":"de Bono J et al","elocationId":"doi: 10.1056/NEJMoa1911440","link":null,"reference":"de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.","abstract":null}]},{"id":7923,"uuid":"deb68dea-ab1b-4e61-9eb2-f48c6a7778ac","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":873,"subtype":"","code":"","color":"HotPink","mainType":"Breast Cancer","level":0,"tissue":"Breast","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Trastuzumab is FDA-approved for (1) Adjuvant treatment of ERBB2-overexpressing, node positive or node negative (ER/PR negative or with one high risk feature) breast cancer, either as: (a) monotherapy following anthracycline therapy (b) in combination with docetaxel and carboplatin or (c) as a part of the doxorubicin, cyclophosphamide regimen with either paclitaxel or docetaxel. (2) ERBB2-overexpressing metastatic breast cancer, administered in combination with paclitaxel as first-line metastatic treatment or as monotherapy in patients whose metastatic disease was previously treated with at least one chemotherapy regimen."],"priority":1,"drugs":[{"ncitCode":"C1647","drugName":"Trastuzumab","uuid":"b29b3641-d866-4b09-bff6-3063d8316935","synonyms":["Anti-erbB2 Monoclonal Antibody","Anti-p185-HER2","Trastuzumab Biosimilar ABP 980","\"ABP 980","Trastuzumab Biosimilar PF-05280014","Anti-ERB-2","Herceptin","Trastuzumab-QYYP","Trastuzumab-dkst","PF-05280014","MoAb HER2","c-erb-2 Monoclonal Antibody","Trazimera","Anti-c-erbB2 Monoclonal Antibody","Trastuzumab Biosimilar ALT02","Herzuma","Trastuzumab-DTTB","Anti-erbB-2","Trastuzumab-pkrb","Ontruzant","TRASTUZUMAB","Trastuzumab Biosimilar HLX02","Anti-HER2/c-erbB2 Monoclonal Antibody","RO0452317","Monoclonal Antibody HER2","Monoclonal Antibody c-erb-2","Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer","rhuMAb HER2","trastuzumab","HER2 Monoclonal Antibody","Anti-c-ERB-2","Ogivri","Herceptin Biosimilar PF-05280014","Herceptin Trastuzumab Biosimilar PF-05280014","trastuzumab biosimilar EG12014\"","ALT02","Trastuzumab"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1560988775000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"16236738","title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.","journal":"The New England journal of medicine","pubDate":"2005 Oct 20","volume":"353","issue":"16","pages":"1673-84","authors":"Romond EH et al","elocationId":"","link":null,"reference":"Romond EH et al. The New England journal of medicine. 2005 Oct 20;353(16)1673-84.","abstract":null}]},{"id":7924,"uuid":"04348d37-fbc7-4fbe-aa06-512bbab1abc6","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":873,"subtype":"","code":"","color":"HotPink","mainType":"Breast Cancer","level":0,"tissue":"Breast","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Ado-Trastuzumab Emtansine is FDA-approved as single agent treatment of ERBB2-positive, metastatic breast cancer in patients who previously received trastuzumab and a taxane, separately or in combination, and have either received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy."],"priority":2,"drugs":[{"ncitCode":"C82492","drugName":"Ado-Trastuzumab Emtansine","uuid":"598e7b9f-976d-46bc-aea7-42f1005db988","synonyms":["\"ADO-TRASTUZUMAB EMTANSINE","Trastuzumab Emtansine","Immunoglobulin G1, Anti-(Human p185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide with N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine","Trastuzumab-DM1","ADO-Trastuzumab Emtansine","Kadcyla","Ado Trastuzumab Emtansine","Trastuzumab-MCC-DM1 Antibody-Drug Conjugate","Trastuzumab-MCC-DM1 Immunoconjugate\"","RO5304020","T-DM1","PRO132365","Trastuzumab-MCC-DM1"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1560988774000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"30516102","title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.","journal":"The New England journal of medicine","pubDate":"2019 Feb 14","volume":"380","issue":"7","pages":"617-628","authors":"von Minckwitz G et al","elocationId":"doi: 10.1056/NEJMoa1814017","link":null,"reference":"von Minckwitz G et al. The New England journal of medicine. 2019 Feb 14;380(7)617-628.","abstract":null},{"pmid":"23020162","title":"Trastuzumab emtansine for HER2-positive advanced breast cancer.","journal":"The New England journal of medicine","pubDate":"2012 Nov 8","volume":"367","issue":"19","pages":"1783-91","authors":"Verma S et al","elocationId":"doi: 10.1056/NEJMoa1209124","link":null,"reference":"Verma S et al. The New England journal of medicine. 2012 Nov 8;367(19)1783-91.","abstract":null}]},{"id":7925,"uuid":"7efbeac2-1eb3-46e5-8fca-e614e6f9d0fe","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":873,"subtype":"","code":"","color":"HotPink","mainType":"Breast Cancer","level":0,"tissue":"Breast","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Lapatinib is FDA-approved (1) in combination with capecitabine for advanced or metastatic ERBB2-overexpressing breast cancer in patients who have received prior therapy including an anthracycline, a taxane and trastuzumab, (2) as a combination therapy with letrozole for postmenopausal women with hormone receptor positive, metastatic breast cancer that overexpressed the HER2 receptor and for whom hormonal therapy is approved."],"priority":3,"drugs":[{"ncitCode":"C26653","drugName":"Lapatinib","uuid":"6b1eee04-b74c-46d3-bdd3-1c68d1ec11b0","synonyms":["LAPATINIB","GW572016","lapatinib","GW 2016","GW2016","GSK572016","Lapatinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1560988774000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"17192538","title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer.","journal":"The New England journal of medicine","pubDate":"2006 Dec 28","volume":"355","issue":"26","pages":"2733-43","authors":"Geyer CE et al","elocationId":"","link":null,"reference":"Geyer CE et al. The New England journal of medicine. 2006 Dec 28;355(26)2733-43.","abstract":null},{"pmid":"19786658","title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2009 Nov 20","volume":"27","issue":"33","pages":"5538-46","authors":"Johnston S et al","elocationId":"doi: 10.1200/JCO.2009.23.3734","link":null,"reference":"Johnston S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Nov 20;27(33)5538-46.","abstract":null}]},{"id":7926,"uuid":"f619af1e-6f26-4c66-80c8-a6f99100ab8e","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":873,"subtype":"","code":"","color":"HotPink","mainType":"Breast Cancer","level":0,"tissue":"Breast","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Pertuzumab in combination with trastuzumab and docetaxel is FDA-approved for (1) ERBB2-positive metastatic breast cancer in patients not previously treated with anti-ERBB2 therapy or chemotherapy for metastatic disease, (2) neoadjuvant treatment of ERBB2-positive, locally advanced, inflammatory, or early stage breast cancer."],"priority":4,"drugs":[{"ncitCode":"C1647","drugName":"Trastuzumab","uuid":"b29b3641-d866-4b09-bff6-3063d8316935","synonyms":["Anti-erbB2 Monoclonal Antibody","Anti-p185-HER2","Trastuzumab Biosimilar ABP 980","\"ABP 980","Trastuzumab Biosimilar PF-05280014","Anti-ERB-2","Herceptin","Trastuzumab-QYYP","Trastuzumab-dkst","PF-05280014","MoAb HER2","c-erb-2 Monoclonal Antibody","Trazimera","Anti-c-erbB2 Monoclonal Antibody","Trastuzumab Biosimilar ALT02","Herzuma","Trastuzumab-DTTB","Anti-erbB-2","Trastuzumab-pkrb","Ontruzant","TRASTUZUMAB","Trastuzumab Biosimilar HLX02","Anti-HER2/c-erbB2 Monoclonal Antibody","RO0452317","Monoclonal Antibody HER2","Monoclonal Antibody c-erb-2","Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer","rhuMAb HER2","trastuzumab","HER2 Monoclonal Antibody","Anti-c-ERB-2","Ogivri","Herceptin Biosimilar PF-05280014","Herceptin Trastuzumab Biosimilar PF-05280014","trastuzumab biosimilar EG12014\"","ALT02","Trastuzumab"],"priority":2},{"ncitCode":"C38692","drugName":"Pertuzumab","uuid":"b89a5c78-1828-4adf-a9fa-937f99410c1d","synonyms":["Monoclonal Antibody 2C4","Perjeta","\"2C4","RO4368451","Pertuzumab","2C4 Antibody","Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide with Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer","pertuzumab","MoAb 2C4","Omnitarg","PERTUZUMAB","rhuMAb2C4\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1595385582000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22149875","title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.","journal":"The New England journal of medicine","pubDate":"2012 Jan 12","volume":"366","issue":"2","pages":"109-19","authors":"Baselga J et al","elocationId":"doi: 10.1056/NEJMoa1113216","link":null,"reference":"Baselga J et al. The New England journal of medicine. 2012 Jan 12;366(2)109-19.","abstract":null},{"pmid":"29320312","title":"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2018 Feb 20","volume":"36","issue":"6","pages":"536-542","authors":"Hainsworth JD et al","elocationId":"doi: 10.1200/JCO.2017.75.3780","link":null,"reference":"Hainsworth JD et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Feb 20;36(6)536-542.","abstract":null},{"pmid":"22153890","title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2012 Jan","volume":"13","issue":"1","pages":"25-32","authors":"Gianni L et al","elocationId":"doi: 10.1016/S1470-2045(11)70336-9","link":null,"reference":"Gianni L et al. The Lancet. Oncology. 2012 Jan;13(1)25-32.","abstract":null},{"pmid":"31647503","title":"Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.","journal":"JAMA oncology","pubDate":"2020 Mar 1","volume":"6","issue":"3","pages":"e193692","authors":"Shao Z et al","elocationId":"doi: 10.1001/jamaoncol.2019.3692","link":null,"reference":"Shao Z et al. JAMA oncology. 2020 Mar 1;6(3)e193692.","abstract":null},{"pmid":"32171426","title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.","journal":"The Lancet. Oncology","pubDate":"2020 Apr","volume":"21","issue":"4","pages":"519-530","authors":"Swain SM et al","elocationId":"doi: 10.1016/S1470-2045(19)30863-0","link":null,"reference":"Swain SM et al. The Lancet. Oncology. 2020 Apr;21(4)519-530.","abstract":null},{"pmid":"23602601","title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.","journal":"The Lancet. Oncology","pubDate":"2013 May","volume":"14","issue":"6","pages":"461-71","authors":"Swain SM et al","elocationId":"doi: 10.1016/S1470-2045(13)70130-X","link":null,"reference":"Swain SM et al. The Lancet. Oncology. 2013 May;14(6)461-71.","abstract":null}]},{"id":7927,"uuid":"8205c47e-d3ac-4a14-b258-8443e5702804","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":873,"subtype":"","code":"","color":"HotPink","mainType":"Breast Cancer","level":0,"tissue":"Breast","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["For the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy."],"priority":5,"drugs":[{"ncitCode":"C49094","drugName":"Neratinib","uuid":"d7f80cb7-3281-4a3a-a248-5158436af8e1","synonyms":["HKI-272","HKI 272","PB-272\"","\"(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide","NERATINIB","PB 272","Neratinib","2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1560988774000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"26874901","title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2016 Mar","volume":"17","issue":"3","pages":"367-377","authors":"Chan A et al","elocationId":"doi: 10.1016/S1470-2045(15)00551-3","link":null,"reference":"Chan A et al. The Lancet. Oncology. 2016 Mar;17(3)367-377.","abstract":null},{"pmid":"30860945","title":"TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2019 May 1","volume":"37","issue":"13","pages":"1081-1089","authors":"Freedman RA et al","elocationId":"doi: 10.1200/JCO.18.01511","link":null,"reference":"Freedman RA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 May 1;37(13)1081-1089.","abstract":null},{"pmid":"29146401","title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2017 Dec","volume":"18","issue":"12","pages":"1688-1700","authors":"Martin M et al","elocationId":"doi: 10.1016/S1470-2045(17)30717-9","link":null,"reference":"Martin M et al. The Lancet. Oncology. 2017 Dec;18(12)1688-1700.","abstract":null},{"pmid":"30274983","title":"Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER<sup>+</sup>/HER2<sup>+</sup> Breast Cancers: Implications to the ExteNET Trial.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 Jan 15","volume":"25","issue":"2","pages":"771-783","authors":"Sudhan DR et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-1131","link":null,"reference":"Sudhan DR et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Jan 15;25(2)771-783.","abstract":null}]},{"id":7928,"uuid":"fb5a6215-d86d-4a2b-a4ee-0a052a0e3865","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":873,"subtype":"","code":"","color":"HotPink","mainType":"Breast Cancer","level":0,"tissue":"Breast","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":6,"drugs":[{"ncitCode":"C1647","drugName":"Trastuzumab","uuid":"b29b3641-d866-4b09-bff6-3063d8316935","synonyms":["Anti-erbB2 Monoclonal Antibody","Anti-p185-HER2","Trastuzumab Biosimilar ABP 980","\"ABP 980","Trastuzumab Biosimilar PF-05280014","Anti-ERB-2","Herceptin","Trastuzumab-QYYP","Trastuzumab-dkst","PF-05280014","MoAb HER2","c-erb-2 Monoclonal Antibody","Trazimera","Anti-c-erbB2 Monoclonal Antibody","Trastuzumab Biosimilar ALT02","Herzuma","Trastuzumab-DTTB","Anti-erbB-2","Trastuzumab-pkrb","Ontruzant","TRASTUZUMAB","Trastuzumab Biosimilar HLX02","Anti-HER2/c-erbB2 Monoclonal Antibody","RO0452317","Monoclonal Antibody HER2","Monoclonal Antibody c-erb-2","Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer","rhuMAb HER2","trastuzumab","HER2 Monoclonal Antibody","Anti-c-ERB-2","Ogivri","Herceptin Biosimilar PF-05280014","Herceptin Trastuzumab Biosimilar PF-05280014","trastuzumab biosimilar EG12014\"","ALT02","Trastuzumab"],"priority":2},{"ncitCode":"C1794","drugName":"Capecitabine","uuid":"2dce108f-c9ab-4112-b956-e4b19a1dabef","synonyms":["CAPECITABINE","Xeloda","capecitabine","Capecitabine","5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine","Ro 09-1978/000"],"priority":1},{"ncitCode":"C77896","drugName":"Tucatinib","uuid":"b8df68a1-e34e-4772-8bcf-c03593aeeb55","synonyms":["Irbinitinib","Tucatinib\"","\"ARRY-380","Tucatinib","TUCATINIB","ONT-380","N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine"],"priority":3}]}],"knownEffect":"Sensitive","lastEdit":1588545932000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"31825569","title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.","journal":"The New England journal of medicine","pubDate":"2020 Feb 13","volume":"382","issue":"7","pages":"597-609","authors":"Murthy RK et al","elocationId":"doi: 10.1056/NEJMoa1914609","link":null,"reference":"Murthy RK et al. The New England journal of medicine. 2020 Feb 13;382(7)597-609.","abstract":null}]},{"id":7929,"uuid":"6014d8b8-c942-4005-b39c-2b434cbb45b2","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":873,"subtype":"","code":"","color":"HotPink","mainType":"Breast Cancer","level":0,"tissue":"Breast","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":7,"drugs":[{"ncitCode":"C128799","drugName":"Trastuzumab Deruxtecan","uuid":"37dd10c7-69c0-4d63-a171-8cb2570c1a54","synonyms":["DS-8201a","ADC DS-8201a","Anti-HER2 Antibody-Drug Conjugate DS-8201a","Anti-HER2-DX-8951 Derivative ADC DS-8201a","Anti-HER2 ADC DS-8201a","Trastuzumab Deruxtecan"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1588736214000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"31825192","title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.","journal":"The New England journal of medicine","pubDate":"2020 Feb 13","volume":"382","issue":"7","pages":"610-621","authors":"Modi S et al","elocationId":"doi: 10.1056/NEJMoa1914510","link":null,"reference":"Modi S et al. The New England journal of medicine. 2020 Feb 13;382(7)610-621.","abstract":null}]},{"id":2041,"uuid":"729d93d7-aa18-4bf0-9c84-13b9ecce25fb","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":611,"subtype":"Erdheim-Chester Disease","code":"ECD","color":"LightSalmon","mainType":"Histiocytosis","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"V600","name":"V600","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Vemurafenib is FDA-approved for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation as detected by an FDA-approved test."],"priority":1,"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib","uuid":"4e91da20-6cf0-4e07-995f-7f7db4c7c077","synonyms":["Vemurafenib","BRAF(V600E) Kinase Inhibitor RO5185426","RO 5185426","PLX4032","PLX-4032","RG 7204","Zelboraf\"","BRAF (V600E) kinase inhibitor RO5185426","RG7204","\"1-propanesulfonamide, n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-","VEMURAFENIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1525888622000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29188284","title":"Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.","journal":"JAMA oncology","pubDate":"2018 Mar 1","volume":"4","issue":"3","pages":"384-388","authors":"Diamond EL et al","elocationId":"doi: 10.1001/jamaoncol.2017.5029","link":null,"reference":"Diamond EL et al. JAMA oncology. 2018 Mar 1;4(3)384-388.","abstract":null},{"pmid":"26287849","title":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.","journal":"The New England journal of medicine","pubDate":"2015 Aug 20","volume":"373","issue":"8","pages":"726-36","authors":"Hyman DM et al","elocationId":"doi: 10.1056/NEJMoa1502309","link":null,"reference":"Hyman DM et al. The New England journal of medicine. 2015 Aug 20;373(8)726-36.","abstract":null}]},{"id":7931,"uuid":"a94ae919-56b0-4d6d-8b7d-6595c01692ce","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":933,"subtype":"","code":"","color":"LightSkyBlue","mainType":"Esophagogastric Cancer","level":0,"tissue":"Esophagus/Stomach","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Trastuzumab combined with cisplatin and capecitabine or 5-fluorouracil is FDA-approved for ERBB2-overexpressing metastatic gastric or gastroesophageal (GE) junction adenocarcinoma in patients not previously treated for metastatic disease."],"priority":1,"drugs":[{"ncitCode":"C1647","drugName":"Trastuzumab","uuid":"b29b3641-d866-4b09-bff6-3063d8316935","synonyms":["Anti-erbB2 Monoclonal Antibody","Anti-p185-HER2","Trastuzumab Biosimilar ABP 980","\"ABP 980","Trastuzumab Biosimilar PF-05280014","Anti-ERB-2","Herceptin","Trastuzumab-QYYP","Trastuzumab-dkst","PF-05280014","MoAb HER2","c-erb-2 Monoclonal Antibody","Trazimera","Anti-c-erbB2 Monoclonal Antibody","Trastuzumab Biosimilar ALT02","Herzuma","Trastuzumab-DTTB","Anti-erbB-2","Trastuzumab-pkrb","Ontruzant","TRASTUZUMAB","Trastuzumab Biosimilar HLX02","Anti-HER2/c-erbB2 Monoclonal Antibody","RO0452317","Monoclonal Antibody HER2","Monoclonal Antibody c-erb-2","Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer","rhuMAb HER2","trastuzumab","HER2 Monoclonal Antibody","Anti-c-ERB-2","Ogivri","Herceptin Biosimilar PF-05280014","Herceptin Trastuzumab Biosimilar PF-05280014","trastuzumab biosimilar EG12014\"","ALT02","Trastuzumab"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1525890834000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"20728210","title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.","journal":"Lancet (London, England)","pubDate":"2010 Aug 28","volume":"376","issue":"9742","pages":"687-97","authors":"Bang YJ et al","elocationId":"doi: 10.1016/S0140-6736(10)61121-X","link":null,"reference":"Bang YJ et al. Lancet (London, England). 2010 Aug 28;376(9742)687-97.","abstract":null}]},{"id":2047,"uuid":"2e0a9edd-9248-4da3-b5f8-acdfe19039d6","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"V600","name":"V600","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":4,"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib","uuid":"4e91da20-6cf0-4e07-995f-7f7db4c7c077","synonyms":["Vemurafenib","BRAF(V600E) Kinase Inhibitor RO5185426","RO 5185426","PLX4032","PLX-4032","RG 7204","Zelboraf\"","BRAF (V600E) kinase inhibitor RO5185426","RG7204","\"1-propanesulfonamide, n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-","VEMURAFENIB"],"priority":1},{"ncitCode":"C106250","drugName":"Atezolizumab","uuid":"9a54c73a-15d8-41a8-8ea0-730f874831da","synonyms":["MPDL 3280A","MPDL328OA","MPDL 328OA","Immunoglobulin G1, Anti-(human CD Antigen cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide with Human Monoclonal MPDL3280A Kappa-chain, Dimer","\"ATEZOLIZUMAB","MPDL-3280A","RG7446","MPDL3280A","RO5541267","Tecentriq\"","Atezolizumab"],"priority":2},{"ncitCode":"C68923","drugName":"Cobimetinib","uuid":"eb357145-3b18-4aca-b75a-5e18dd2bf4f9","synonyms":["Cotellic","Cobimetinib","XL518","COBIMETINIB","GDC-0973","MEK Inhibitor GDC-0973"],"priority":3}]}],"knownEffect":"Sensitive","lastEdit":1598305898000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32534646","title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF<sup>V600</sup> mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.","journal":"Lancet (London, England)","pubDate":"2020 Jun 13","volume":"395","issue":"10240","pages":"1835-1844","authors":"Gutzmer R et al","elocationId":"doi: 10.1016/S0140-6736(20)30934-X","link":null,"reference":"Gutzmer R et al. Lancet (London, England). 2020 Jun 13;395(10240)1835-1844.","abstract":null}]},{"id":17152,"uuid":"fe5674a6-cb6b-4f32-bcd7-fb39012e5b9e","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4916,"hugoSymbol":"NTRK3","oncogene":true,"grch37Isoform":"ENST00000360948","grch37RefSeq":"NM_001012338.2","grch38Isoform":"ENST00000360948","grch38RefSeq":"NM_001012338.2","geneAliases":["TRKC","GP145-TrkC","gp145(trkC)"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4916,"hugoSymbol":"NTRK3","oncogene":true,"grch37Isoform":"ENST00000360948","grch37RefSeq":"NM_001012338.2","grch38Isoform":"ENST00000360948","grch38RefSeq":"NM_001012338.2","geneAliases":["TRKC","GP145-TrkC","gp145(trkC)"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C115977","drugName":"Larotrectinib","uuid":"b0b3d8ee-86a5-4421-b4a9-053d3c1ff544","synonyms":["LAROTRECTINIB","LOXO-101","Larotrectinib","LOXO 101","\"1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-","ARRY 470","3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide","Larotrectinib\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1544568152000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"26216294","title":"An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.","journal":"Cancer discovery","pubDate":"2015 Oct","volume":"5","issue":"10","pages":"1049-57","authors":"Doebele RC et al","elocationId":"doi: 10.1158/2159-8290.CD-15-0443","link":null,"reference":"Doebele RC et al. Cancer discovery. 2015 Oct;5(10)1049-57.","abstract":null},{"pmid":"29466156","title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.","journal":"The New England journal of medicine","pubDate":"2018 Feb 22","volume":"378","issue":"8","pages":"731-739","authors":"Drilon A et al","elocationId":"doi: 10.1056/NEJMoa1714448","link":null,"reference":"Drilon A et al. The New England journal of medicine. 2018 Feb 22;378(8)731-739.","abstract":null}]},{"id":17153,"uuid":"2ae45d55-417c-4eb7-bf76-d0b0e6c44009","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4916,"hugoSymbol":"NTRK3","oncogene":true,"grch37Isoform":"ENST00000360948","grch37RefSeq":"NM_001012338.2","grch38Isoform":"ENST00000360948","grch38RefSeq":"NM_001012338.2","geneAliases":["TRKC","GP145-TrkC","gp145(trkC)"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4916,"hugoSymbol":"NTRK3","oncogene":true,"grch37Isoform":"ENST00000360948","grch37RefSeq":"NM_001012338.2","grch38Isoform":"ENST00000360948","grch38RefSeq":"NM_001012338.2","geneAliases":["TRKC","GP145-TrkC","gp145(trkC)"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C114984","drugName":"Entrectinib","uuid":"2371f7f5-6407-4a4b-b951-a0f786355455","synonyms":["RXDX-101\"","N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide","Entrectinib","\"ENTRECTINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1579140210000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"28183697","title":"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).","journal":"Cancer discovery","pubDate":"2017 Apr","volume":"7","issue":"4","pages":"400-409","authors":"Drilon A et al","elocationId":"doi: 10.1158/2159-8290.CD-16-1237","link":null,"reference":"Drilon A et al. Cancer discovery. 2017 Apr;7(4)400-409.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583","reference":"null. null. .","abstract":"Demetri et al. Abstract# LBA17, ESMO 2018 Congress"},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407","reference":"null. null. .","abstract":"Rolfo et al. Abstract# 65P, ESMO 2019"},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://meetinglibrary.asco.org/record/155954/abstract","reference":"null. null. .","abstract":"Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018"},{"pmid":"31838007","title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.","journal":"The Lancet. Oncology","pubDate":"2020 Feb","volume":"21","issue":"2","pages":"271-282","authors":"Doebele RC et al","elocationId":"doi: 10.1016/S1470-2045(19)30691-6","link":null,"reference":"Doebele RC et al. The Lancet. Oncology. 2020 Feb;21(2)271-282.","abstract":null}]},{"id":2057,"uuid":"bc28ec2e-60ae-4a5d-9401-524e357b5bed","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600K","name":"V600K","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600E","name":"V600E","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Dabrafenib + Trametinib is FDA-approved for BRAF V600E or V600K mutant unresectable or metastatic melanoma"],"priority":1,"drugs":[{"ncitCode":"C82386","drugName":"Dabrafenib","uuid":"939cd40b-b515-499d-b099-fd29027c0d17","synonyms":["DABRAFENIB","GSK2118436\"","\"BRAF Inhibitor GSK2118436","GSK-2118436","GSK-2118436A","Dabrafenib","Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-"],"priority":1},{"ncitCode":"C77908","drugName":"Trametinib","uuid":"fb2bb01c-c0ec-4641-abf7-87f486075022","synonyms":["Mekinist","\"GSK1120212","Trametinib\"","TRAMETINIB","JTP-74057","MEK Inhibitor GSK1120212","N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","Trametinib"],"priority":2}]}],"knownEffect":"Sensitive","lastEdit":1576623376000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"23020132","title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.","journal":"The New England journal of medicine","pubDate":"2012 Nov 1","volume":"367","issue":"18","pages":"1694-703","authors":"Flaherty KT et al","elocationId":"doi: 10.1056/NEJMoa1210093","link":null,"reference":"Flaherty KT et al. The New England journal of medicine. 2012 Nov 1;367(18)1694-703.","abstract":null},{"pmid":"29361468","title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2018 Feb","volume":"19","issue":"2","pages":"181-193","authors":"Amaria RN et al","elocationId":"doi: 10.1016/S1470-2045(18)30015-9","link":null,"reference":"Amaria RN et al. The Lancet. Oncology. 2018 Feb;19(2)181-193.","abstract":null},{"pmid":"25287827","title":"Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2014 Nov 20","volume":"32","issue":"33","pages":"3697-704","authors":"Johnson DB et al","elocationId":"doi: 10.1200/JCO.2014.57.3535","link":null,"reference":"Johnson DB et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Nov 20;32(33)3697-704.","abstract":null},{"pmid":"28891408","title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.","journal":"The New England journal of medicine","pubDate":"2017 Nov 9","volume":"377","issue":"19","pages":"1813-1823","authors":"Long GV et al","elocationId":"doi: 10.1056/NEJMoa1708539","link":null,"reference":"Long GV et al. The New England journal of medicine. 2017 Nov 9;377(19)1813-1823.","abstract":null},{"pmid":"31171876","title":"Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.","journal":"Nature medicine","pubDate":"2019 Jun","volume":"25","issue":"6","pages":"929-935","authors":"Sullivan RJ et al","elocationId":"doi: 10.1038/s41591-019-0474-7","link":null,"reference":"Sullivan RJ et al. Nature medicine. 2019 Jun;25(6)929-935.","abstract":null},{"pmid":"28991513","title":"Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2018 Mar 1","volume":"36","issue":"7","pages":"667-673","authors":"Long GV et al","elocationId":"doi: 10.1200/JCO.2017.74.1025","link":null,"reference":"Long GV et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Mar 1;36(7)667-673.","abstract":null},{"pmid":"31171878","title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.","journal":"Nature medicine","pubDate":"2019 Jun","volume":"25","issue":"6","pages":"941-946","authors":"Ascierto PA et al","elocationId":"doi: 10.1038/s41591-019-0448-9","link":null,"reference":"Ascierto PA et al. Nature medicine. 2019 Jun;25(6)941-946.","abstract":null},{"pmid":"31171879","title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.","journal":"Nature medicine","pubDate":"2019 Jun","volume":"25","issue":"6","pages":"936-940","authors":"Ribas A et al","elocationId":"doi: 10.1038/s41591-019-0476-5","link":null,"reference":"Ribas A et al. Nature medicine. 2019 Jun;25(6)936-940.","abstract":null},{"pmid":"25399551","title":"Improved overall survival in melanoma with combined dabrafenib and trametinib.","journal":"The New England journal of medicine","pubDate":"2015 Jan 1","volume":"372","issue":"1","pages":"30-9","authors":"Robert C et al","elocationId":"doi: 10.1056/NEJMoa1412690","link":null,"reference":"Robert C et al. The New England journal of medicine. 2015 Jan 1;372(1)30-9.","abstract":null},{"pmid":"25265492","title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.","journal":"The New England journal of medicine","pubDate":"2014 Nov 13","volume":"371","issue":"20","pages":"1877-88","authors":"Long GV et al","elocationId":"doi: 10.1056/NEJMoa1406037","link":null,"reference":"Long GV et al. The New England journal of medicine. 2014 Nov 13;371(20)1877-88.","abstract":null}]},{"id":2058,"uuid":"873eaae0-4bf1-4d6d-a312-f8ff9770f393","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600K","name":"V600K","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600E","name":"V600E","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Trametinib is FDA-approved for BRAF V600E or V600K mutant unresectable or metastatic melanoma"],"priority":2,"drugs":[{"ncitCode":"C77908","drugName":"Trametinib","uuid":"fb2bb01c-c0ec-4641-abf7-87f486075022","synonyms":["Mekinist","\"GSK1120212","Trametinib\"","TRAMETINIB","JTP-74057","MEK Inhibitor GSK1120212","N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","Trametinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1526574597000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"29361468","title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2018 Feb","volume":"19","issue":"2","pages":"181-193","authors":"Amaria RN et al","elocationId":"doi: 10.1016/S1470-2045(18)30015-9","link":null,"reference":"Amaria RN et al. The Lancet. Oncology. 2018 Feb;19(2)181-193.","abstract":null},{"pmid":"22663011","title":"Improved survival with MEK inhibition in BRAF-mutated melanoma.","journal":"The New England journal of medicine","pubDate":"2012 Jul 12","volume":"367","issue":"2","pages":"107-14","authors":"Flaherty KT et al","elocationId":"doi: 10.1056/NEJMoa1203421","link":null,"reference":"Flaherty KT et al. The New England journal of medicine. 2012 Jul 12;367(2)107-14.","abstract":null},{"pmid":"25399551","title":"Improved overall survival in melanoma with combined dabrafenib and trametinib.","journal":"The New England journal of medicine","pubDate":"2015 Jan 1","volume":"372","issue":"1","pages":"30-9","authors":"Robert C et al","elocationId":"doi: 10.1056/NEJMoa1412690","link":null,"reference":"Robert C et al. The New England journal of medicine. 2015 Jan 1;372(1)30-9.","abstract":null},{"pmid":"25265492","title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.","journal":"The New England journal of medicine","pubDate":"2014 Nov 13","volume":"371","issue":"20","pages":"1877-88","authors":"Long GV et al","elocationId":"doi: 10.1056/NEJMoa1406037","link":null,"reference":"Long GV et al. The New England journal of medicine. 2014 Nov 13;371(20)1877-88.","abstract":null}]},{"id":2059,"uuid":"19caa107-e92a-4246-9d01-6d707b9ecd4e","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600K","name":"V600K","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600E","name":"V600E","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Cobimetinib is FDA-approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma."],"priority":3,"drugs":[{"ncitCode":"C68923","drugName":"Cobimetinib","uuid":"eb357145-3b18-4aca-b75a-5e18dd2bf4f9","synonyms":["Cotellic","Cobimetinib","XL518","COBIMETINIB","GDC-0973","MEK Inhibitor GDC-0973"],"priority":2},{"ncitCode":"C64768","drugName":"Vemurafenib","uuid":"4e91da20-6cf0-4e07-995f-7f7db4c7c077","synonyms":["Vemurafenib","BRAF(V600E) Kinase Inhibitor RO5185426","RO 5185426","PLX4032","PLX-4032","RG 7204","Zelboraf\"","BRAF (V600E) kinase inhibitor RO5185426","RG7204","\"1-propanesulfonamide, n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-","VEMURAFENIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1578522783000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"27480103","title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2016 Sep","volume":"17","issue":"9","pages":"1248-60","authors":"Ascierto PA et al","elocationId":"doi: 10.1016/S1470-2045(16)30122-X","link":null,"reference":"Ascierto PA et al. The Lancet. Oncology. 2016 Sep;17(9)1248-60.","abstract":null},{"pmid":"31732523","title":"Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant Melanoma.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2020 Jan 1","volume":"26","issue":"1","pages":"46-53","authors":"Ribas A et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-4180","link":null,"reference":"Ribas A et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Jan 1;26(1)46-53.","abstract":null},{"pmid":"25265494","title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.","journal":"The New England journal of medicine","pubDate":"2014 Nov 13","volume":"371","issue":"20","pages":"1867-76","authors":"Larkin J et al","elocationId":"doi: 10.1056/NEJMoa1408868","link":null,"reference":"Larkin J et al. The New England journal of medicine. 2014 Nov 13;371(20)1867-76.","abstract":null}]},{"id":2060,"uuid":"b76c8407-558c-49e9-ab3c-90a181df0044","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600K","name":"V600K","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600E","name":"V600E","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["In combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation"],"priority":4,"drugs":[{"ncitCode":"C84865","drugName":"Binimetinib","uuid":"feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677","synonyms":["ARRY-438162","Mektovi","Binimetinib","ARRY-162","MEK162","BINIMETINIB"],"priority":2},{"ncitCode":"C98283","drugName":"Encorafenib","uuid":"001e534f-3e63-432f-90a6-d1af1759e4e2","synonyms":["LGX-818","Encorafenib","LGX818","LGX 818","ENCORAFENIB","Braftovi"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1530815994000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"29573941","title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2018 May","volume":"19","issue":"5","pages":"603-615","authors":"Dummer R et al","elocationId":"doi: 10.1016/S1470-2045(18)30142-6","link":null,"reference":"Dummer R et al. The Lancet. Oncology. 2018 May;19(5)603-615.","abstract":null}]},{"id":15,"uuid":"d073eec9-fd6a-4b39-981a-c306e0deb1f7","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BCR-ABL1 Fusion","name":"BCR-ABL1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia"],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1559162757000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"11287973","title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.","journal":"The New England journal of medicine","pubDate":"2001 Apr 5","volume":"344","issue":"14","pages":"1038-42","authors":"Druker BJ et al","elocationId":"","link":null,"reference":"Druker BJ et al. The New England journal of medicine. 2001 Apr 5;344(14)1038-42.","abstract":null},{"pmid":"24441288","title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.","journal":"Leukemia","pubDate":"2014 Jul","volume":"28","issue":"7","pages":"1467-71","authors":"Schultz KR et al","elocationId":"doi: 10.1038/leu.2014.30","link":null,"reference":"Schultz KR et al. Leukemia. 2014 Jul;28(7)1467-71.","abstract":null},{"pmid":"12200353","title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.","journal":"Blood","pubDate":"2002 Sep 15","volume":"100","issue":"6","pages":"1965-71","authors":"Ottmann OG et al","elocationId":"","link":null,"reference":"Ottmann OG et al. Blood. 2002 Sep 15;100(6)1965-71.","abstract":null}]},{"id":16,"uuid":"8b9dc0bb-e481-49e4-87b9-0e93d7ef531c","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BCR-ABL1 Fusion","name":"BCR-ABL1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Adults or children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy."],"priority":2,"drugs":[{"ncitCode":"C38713","drugName":"Dasatinib","uuid":"df40a264-628f-4070-9078-965c0471bd2c","synonyms":["Dasatinib","dasatinib","Sprycel","BMS-354825","DASATINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1559162756000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"20131302","title":"Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.","journal":"American journal of hematology","pubDate":"2010 Mar","volume":"85","issue":"3","pages":"164-70","authors":"Lilly MB et al","elocationId":"doi: 10.1002/ajh.21615","link":null,"reference":"Lilly MB et al. American journal of hematology. 2010 Mar;85(3)164-70.","abstract":null},{"pmid":"17496201","title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.","journal":"Blood","pubDate":"2007 Oct 1","volume":"110","issue":"7","pages":"2309-15","authors":"Ottmann O et al","elocationId":"","link":null,"reference":"Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/130/Suppl_1/98","reference":"null. null. .","abstract":"Hunger et al. ASH 2017"},{"pmid":"21931113","title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.","journal":"Blood","pubDate":"2011 Dec 15","volume":"118","issue":"25","pages":"6521-8","authors":"Foà R et al","elocationId":"doi: 10.1182/blood-2011-05-351403","link":null,"reference":"Foà R et al. Blood. 2011 Dec 15;118(25)6521-8.","abstract":null}]},{"id":19,"uuid":"494bd8ff-82eb-4d15-8b9a-cee4fde75557","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BCR-ABL1 Fusion","name":"BCR-ABL1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":5,"drugs":[{"ncitCode":"C95777","drugName":"Ponatinib","uuid":"122b8921-3cd6-4b57-bdc8-5d39cc5465a1","synonyms":["\"AP-24534","PONATINIB","AP24534","Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)","Ponatinib\"","Ponatinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1559162756000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"24180494","title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.","journal":"The New England journal of medicine","pubDate":"2013 Nov 7","volume":"369","issue":"19","pages":"1783-96","authors":"Cortes JE et al","elocationId":"doi: 10.1056/NEJMoa1306494","link":null,"reference":"Cortes JE et al. The New England journal of medicine. 2013 Nov 7;369(19)1783-96.","abstract":null}]},{"id":10515,"uuid":"0da0b6ef-b2e4-4764-aa06-ba143ed4aaaa","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":900,"subtype":"","code":"","color":"Yellow","mainType":"Bladder Cancer","level":0,"tissue":"Bladder/Urinary Tract","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2261,"hugoSymbol":"FGFR3","oncogene":true,"grch37Isoform":"ENST00000260795","grch37RefSeq":"NM_000142.4","grch38Isoform":"ENST00000440486","grch38RefSeq":"NM_000142.4","geneAliases":["JTK4","HSFGFR3EX","ACH","CEK2","CD333"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2261,"hugoSymbol":"FGFR3","oncogene":true,"grch37Isoform":"ENST00000260795","grch37RefSeq":"NM_000142.4","grch38Isoform":"ENST00000440486","grch38RefSeq":"NM_000142.4","geneAliases":["JTK4","HSFGFR3EX","ACH","CEK2","CD333"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C103273","drugName":"Erdafitinib","uuid":"f2e41d69-c383-4e33-ba25-0bf5f837db11","synonyms":["\"1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-","Balversa","Erdafitinib","JNJ-42756493\"","ERDAFITINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1564110272000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"31340094","title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.","journal":"The New England journal of medicine","pubDate":"2019 Jul 25","volume":"381","issue":"4","pages":"338-348","authors":"Loriot Y et al","elocationId":"doi: 10.1056/NEJMoa1817323","link":null,"reference":"Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.","abstract":null},{"pmid":"26324363","title":"Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2015 Oct 20","volume":"33","issue":"30","pages":"3401-8","authors":"Tabernero J et al","elocationId":"doi: 10.1200/JCO.2014.60.7341","link":null,"reference":"Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.","abstract":null}]},{"id":23,"uuid":"3dd5e15a-9f42-4242-a22e-ab9e8d0807cd","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":560,"subtype":"Chronic Myelogenous Leukemia","code":"CML","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BCR-ABL1 Fusion","name":"BCR-ABL1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["1) Newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase. 2) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. 3) Pediatric patients with Ph+ CML in chronic phase who are newly diagnosed or whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy."],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1547235943000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"12637609","title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","journal":"The New England journal of medicine","pubDate":"2003 Mar 13","volume":"348","issue":"11","pages":"994-1004","authors":"O'Brien SG et al","elocationId":"","link":null,"reference":"O'Brien SG et al. The New England journal of medicine. 2003 Mar 13;348(11)994-1004.","abstract":null},{"pmid":"11287972","title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","journal":"The New England journal of medicine","pubDate":"2001 Apr 5","volume":"344","issue":"14","pages":"1031-7","authors":"Druker BJ et al","elocationId":"","link":null,"reference":"Druker BJ et al. The New England journal of medicine. 2001 Apr 5;344(14)1031-7.","abstract":null},{"pmid":"11287973","title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.","journal":"The New England journal of medicine","pubDate":"2001 Apr 5","volume":"344","issue":"14","pages":"1038-42","authors":"Druker BJ et al","elocationId":"","link":null,"reference":"Druker BJ et al. The New England journal of medicine. 2001 Apr 5;344(14)1038-42.","abstract":null},{"pmid":"28095277","title":"Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Jan 20","volume":"35","issue":"3","pages":"298-305","authors":"Etienne G et al","elocationId":"doi: 10.1200/JCO.2016.68.2914","link":null,"reference":"Etienne G et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 20;35(3)298-305.","abstract":null}]},{"id":24,"uuid":"f5575019-f109-4aef-8802-23bcdf21346e","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":560,"subtype":"Chronic Myelogenous Leukemia","code":"CML","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BCR-ABL1 Fusion","name":"BCR-ABL1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["1) For the treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy, including imatinib"," 2) For the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP-CML) 3) for pediatric patients 1 year of age or older with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy."],"priority":2,"drugs":[{"ncitCode":"C48375","drugName":"Nilotinib","uuid":"0f991d49-4cf2-4975-b52f-d7d037aa7f11","synonyms":["Nilotinib","AMN 107 Base Form","nilotinib","4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide","NILOTINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1567007565000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"23502220","title":"Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.","journal":"Blood","pubDate":"2013 May 2","volume":"121","issue":"18","pages":"3703-8","authors":"Hochhaus A et al","elocationId":"doi: 10.1182/blood-2012-04-423418","link":null,"reference":"Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.","abstract":null},{"pmid":"28218239","title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.","journal":"Leukemia","pubDate":"2017 Jul","volume":"31","issue":"7","pages":"1525-1531","authors":"Hochhaus A et al","elocationId":"doi: 10.1038/leu.2017.63","link":null,"reference":"Hochhaus A et al. Leukemia. 2017 Jul;31(7)1525-1531.","abstract":null},{"pmid":"20525993","title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","journal":"The New England journal of medicine","pubDate":"2010 Jun 17","volume":"362","issue":"24","pages":"2251-9","authors":"Saglio G et al","elocationId":"doi: 10.1056/NEJMoa0912614","link":null,"reference":"Saglio G et al. The New England journal of medicine. 2010 Jun 17;362(24)2251-9.","abstract":null}]},{"id":25,"uuid":"a1bbebee-33b7-4acc-a83c-986565d6f52a","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":560,"subtype":"Chronic Myelogenous Leukemia","code":"CML","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BCR-ABL1 Fusion","name":"BCR-ABL1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["For the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in chronic phase (CP-CML)."],"priority":3,"drugs":[{"ncitCode":"C38713","drugName":"Dasatinib","uuid":"df40a264-628f-4070-9078-965c0471bd2c","synonyms":["Dasatinib","dasatinib","Sprycel","BMS-354825","DASATINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1539271003000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"20525995","title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","journal":"The New England journal of medicine","pubDate":"2010 Jun 17","volume":"362","issue":"24","pages":"2260-70","authors":"Kantarjian H et al","elocationId":"doi: 10.1056/NEJMoa1002315","link":null,"reference":"Kantarjian H et al. The New England journal of medicine. 2010 Jun 17;362(24)2260-70.","abstract":null},{"pmid":"27217448","title":"Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2016 Jul 10","volume":"34","issue":"20","pages":"2333-40","authors":"Cortes JE et al","elocationId":"doi: 10.1200/JCO.2015.64.8899","link":null,"reference":"Cortes JE et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Jul 10;34(20)2333-40.","abstract":null}]},{"id":10521,"uuid":"8b14150d-f23d-4389-c00d-e2147399791e","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":900,"subtype":"","code":"","color":"Yellow","mainType":"Bladder Cancer","level":0,"tissue":"Bladder/Urinary Tract","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2261,"hugoSymbol":"FGFR3","oncogene":true,"grch37Isoform":"ENST00000260795","grch37RefSeq":"NM_000142.4","grch38Isoform":"ENST00000440486","grch38RefSeq":"NM_000142.4","geneAliases":["JTK4","HSFGFR3EX","ACH","CEK2","CD333"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2261,"hugoSymbol":"FGFR3","oncogene":true,"grch37Isoform":"ENST00000260795","grch37RefSeq":"NM_000142.4","grch38Isoform":"ENST00000440486","grch38RefSeq":"NM_000142.4","geneAliases":["JTK4","HSFGFR3EX","ACH","CEK2","CD333"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"R248C","name":"R248C","refResidues":"R","proteinStart":248,"proteinEnd":248,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2261,"hugoSymbol":"FGFR3","oncogene":true,"grch37Isoform":"ENST00000260795","grch37RefSeq":"NM_000142.4","grch38Isoform":"ENST00000440486","grch38RefSeq":"NM_000142.4","geneAliases":["JTK4","HSFGFR3EX","ACH","CEK2","CD333"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"G370C","name":"G370C","refResidues":"G","proteinStart":370,"proteinEnd":370,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2261,"hugoSymbol":"FGFR3","oncogene":true,"grch37Isoform":"ENST00000260795","grch37RefSeq":"NM_000142.4","grch38Isoform":"ENST00000440486","grch38RefSeq":"NM_000142.4","geneAliases":["JTK4","HSFGFR3EX","ACH","CEK2","CD333"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"S249C","name":"S249C","refResidues":"S","proteinStart":249,"proteinEnd":249,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2261,"hugoSymbol":"FGFR3","oncogene":true,"grch37Isoform":"ENST00000260795","grch37RefSeq":"NM_000142.4","grch38Isoform":"ENST00000440486","grch38RefSeq":"NM_000142.4","geneAliases":["JTK4","HSFGFR3EX","ACH","CEK2","CD333"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y373C","name":"Y373C","refResidues":"Y","proteinStart":373,"proteinEnd":373,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C103273","drugName":"Erdafitinib","uuid":"f2e41d69-c383-4e33-ba25-0bf5f837db11","synonyms":["\"1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-","Balversa","Erdafitinib","JNJ-42756493\"","ERDAFITINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1570689819000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"31340094","title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.","journal":"The New England journal of medicine","pubDate":"2019 Jul 25","volume":"381","issue":"4","pages":"338-348","authors":"Loriot Y et al","elocationId":"doi: 10.1056/NEJMoa1817323","link":null,"reference":"Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.","abstract":null},{"pmid":"26324363","title":"Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2015 Oct 20","volume":"33","issue":"30","pages":"3401-8","authors":"Tabernero J et al","elocationId":"doi: 10.1200/JCO.2014.60.7341","link":null,"reference":"Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.","abstract":null}]},{"id":26,"uuid":"5cecd125-a4b1-4041-a067-cd0dc6d2868a","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":560,"subtype":"Chronic Myelogenous Leukemia","code":"CML","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BCR-ABL1 Fusion","name":"BCR-ABL1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":4,"drugs":[{"ncitCode":"C60809","drugName":"Bosutinib","uuid":"80a4278a-4622-45e5-9e3f-8ca98657692f","synonyms":["BOSUTINIB","\"4-Anilino-3-quinolinecarbonitrile","SKI-606\"","4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile","SKI 606","Bosulif","SKI-606","4-Anilinobenzo(g)quinoline-3-carbonitrile","Bosutinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1576603552000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"26040495","title":"Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.","journal":"American journal of hematology","pubDate":"2015 Sep","volume":"90","issue":"9","pages":"755-68","authors":"Gambacorti-Passerini C et al","elocationId":"doi: 10.1002/ajh.24034","link":null,"reference":"Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.","abstract":null},{"pmid":"24345751","title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.","journal":"Blood","pubDate":"2014 Feb 27","volume":"123","issue":"9","pages":"1309-18","authors":"Kantarjian HM et al","elocationId":"doi: 10.1182/blood-2013-07-513937","link":null,"reference":"Kantarjian HM et al. Blood. 2014 Feb 27;123(9)1309-18.","abstract":null},{"pmid":"29091516","title":"Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2018 Jan 20","volume":"36","issue":"3","pages":"231-237","authors":"Cortes JE et al","elocationId":"doi: 10.1200/JCO.2017.74.7162","link":null,"reference":"Cortes JE et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Jan 20;36(3)231-237.","abstract":null}]},{"id":5676,"uuid":"3422b1f0-33cd-4572-97a2-70326d9995a5","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":936,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer","level":0,"tissue":"Prostate","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1111,"hugoSymbol":"CHEK1","oncogene":false,"grch37Isoform":"ENST00000428830","grch37RefSeq":"NM_001274.5","grch38Isoform":"ENST00000428830","grch38RefSeq":"NM_001274.5","geneAliases":["CHK1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":1111,"hugoSymbol":"CHEK1","oncogene":false,"grch37Isoform":"ENST00000428830","grch37RefSeq":"NM_001274.5","grch38Isoform":"ENST00000428830","grch38RefSeq":"NM_001274.5","geneAliases":["CHK1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1591158982000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32343890","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer.","journal":"The New England journal of medicine","pubDate":"2020 May 28","volume":"382","issue":"22","pages":"2091-2102","authors":"de Bono J et al","elocationId":"doi: 10.1056/NEJMoa1911440","link":null,"reference":"de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.","abstract":null}]},{"id":10291,"uuid":"045d5153-748a-4d7c-86a1-bb4050119efb","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":900,"subtype":"","code":"","color":"Yellow","mainType":"Bladder Cancer","level":0,"tissue":"Bladder/Urinary Tract","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2263,"hugoSymbol":"FGFR2","oncogene":true,"grch37Isoform":"ENST00000358487","grch37RefSeq":"NM_000141.4","grch38Isoform":"ENST00000358487","grch38RefSeq":"NM_000141.4","geneAliases":["BBDS","BFR-1","CEK3","JWS","BEK","ECT1","K-SAM","KGFR","TK14","TK25","CD332","CFD1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2263,"hugoSymbol":"FGFR2","oncogene":true,"grch37Isoform":"ENST00000358487","grch37RefSeq":"NM_000141.4","grch38Isoform":"ENST00000358487","grch38RefSeq":"NM_000141.4","geneAliases":["BBDS","BFR-1","CEK3","JWS","BEK","ECT1","K-SAM","KGFR","TK14","TK25","CD332","CFD1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C103273","drugName":"Erdafitinib","uuid":"f2e41d69-c383-4e33-ba25-0bf5f837db11","synonyms":["\"1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-","Balversa","Erdafitinib","JNJ-42756493\"","ERDAFITINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1567621404000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"31340094","title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.","journal":"The New England journal of medicine","pubDate":"2019 Jul 25","volume":"381","issue":"4","pages":"338-348","authors":"Loriot Y et al","elocationId":"doi: 10.1056/NEJMoa1817323","link":null,"reference":"Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.","abstract":null},{"pmid":"26324363","title":"Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2015 Oct 20","volume":"33","issue":"30","pages":"3401-8","authors":"Tabernero J et al","elocationId":"doi: 10.1200/JCO.2014.60.7341","link":null,"reference":"Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.","abstract":null}]},{"id":10293,"uuid":"5dd71df4-3f40-4823-a5d6-7b5303c37aa7","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":283,"subtype":"Cholangiocarcinoma","code":"CHOL","color":"Green","mainType":"Hepatobiliary Cancer","level":2,"tissue":"Biliary Tract","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2263,"hugoSymbol":"FGFR2","oncogene":true,"grch37Isoform":"ENST00000358487","grch37RefSeq":"NM_000141.4","grch38Isoform":"ENST00000358487","grch38RefSeq":"NM_000141.4","geneAliases":["BBDS","BFR-1","CEK3","JWS","BEK","ECT1","K-SAM","KGFR","TK14","TK25","CD332","CFD1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2263,"hugoSymbol":"FGFR2","oncogene":true,"grch37Isoform":"ENST00000358487","grch37RefSeq":"NM_000141.4","grch38Isoform":"ENST00000358487","grch38RefSeq":"NM_000141.4","geneAliases":["BBDS","BFR-1","CEK3","JWS","BEK","ECT1","K-SAM","KGFR","TK14","TK25","CD332","CFD1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C121553","drugName":"Pemigatinib","uuid":"b205be87-a4cb-48d2-904b-3cac09f51d96","synonyms":["PEMIGATINIB","INCB054828","\"2H-Pyrrolo(3',2':5,6)pyrido(4,3-d)pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-","Pemigatinib","Pemigatinib\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1588042834000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32203698","title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.","journal":"The Lancet. Oncology","pubDate":"2020 May","volume":"21","issue":"5","pages":"671-684","authors":"Abou-Alfa GK et al","elocationId":"doi: 10.1016/S1470-2045(20)30109-1","link":null,"reference":"Abou-Alfa GK et al. The Lancet. Oncology. 2020 May;21(5)671-684.","abstract":null}]},{"id":20278,"uuid":"91abed1f-103e-4007-b93c-e4003609ae80","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":936,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer","level":0,"tissue":"Prostate","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5890,"hugoSymbol":"RAD51B","oncogene":false,"grch37Isoform":"ENST00000487270","grch37RefSeq":"NM_133509.3","grch38Isoform":"ENST00000487270","grch38RefSeq":"NM_133509.3","geneAliases":["R51H2","REC2","RAD51L1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":5890,"hugoSymbol":"RAD51B","oncogene":false,"grch37Isoform":"ENST00000487270","grch37RefSeq":"NM_133509.3","grch38Isoform":"ENST00000487270","grch38RefSeq":"NM_133509.3","geneAliases":["R51H2","REC2","RAD51L1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1591160463000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32343890","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer.","journal":"The New England journal of medicine","pubDate":"2020 May 28","volume":"382","issue":"22","pages":"2091-2102","authors":"de Bono J et al","elocationId":"doi: 10.1056/NEJMoa1911440","link":null,"reference":"de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.","abstract":null}]},{"id":3641,"uuid":"14f4f349-e2ba-4ed8-92af-068a20764889","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":557,"subtype":"Ovary/Fallopian Tube","code":"OVARY","color":"LightBlue","mainType":"Ovarian/Fallopian Tube Cancer, NOS","level":1,"tissue":"Ovary/Fallopian Tube","tumorForm":"SOLID"},{"id":880,"subtype":"","code":"","color":"LightBlue","mainType":"Ovarian Cancer","level":0,"tissue":"Ovary/Fallopian Tube","tumorForm":"SOLID"},{"id":863,"subtype":"Peritoneal Serous Carcinoma","code":"PSEC","color":"Green","mainType":"Peritoneal Cancer, NOS","level":2,"tissue":"Peritoneum","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Olaparib is FDA-approved as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy"],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1598337253000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"24882434","title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2014 Jul","volume":"15","issue":"8","pages":"852-61","authors":"Ledermann J et al","elocationId":"doi: 10.1016/S1470-2045(14)70228-1","link":null,"reference":"Ledermann J et al. The Lancet. Oncology. 2014 Jul;15(8)852-61.","abstract":null},{"pmid":"30345884","title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.","journal":"The New England journal of medicine","pubDate":"2018 Dec 27","volume":"379","issue":"26","pages":"2495-2505","authors":"Moore K et al","elocationId":"doi: 10.1056/NEJMoa1810858","link":null,"reference":"Moore K et al. The New England journal of medicine. 2018 Dec 27;379(26)2495-2505.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://meetinglibrary.asco.org/record/173435/abstract","reference":"null. null. .","abstract":"Penson et al. Abstract# 5506, ASCO 2019"},{"pmid":"25366685","title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2015 Jan 20","volume":"33","issue":"3","pages":"244-50","authors":"Kaufman B et al","elocationId":"doi: 10.1200/JCO.2014.56.2728","link":null,"reference":"Kaufman B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 20;33(3)244-50.","abstract":null},{"pmid":"30285518","title":"First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2018 Nov 20","volume":"36","issue":"33","pages":"3298-3306","authors":"Strickler JH et al","elocationId":"doi: 10.1200/JCO.2018.78.7697","link":null,"reference":"Strickler JH et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Nov 20;36(33)3298-3306.","abstract":null}]},{"id":11833,"uuid":"da254d80-dea7-48ed-bc9b-49b6ba604841","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3418,"hugoSymbol":"IDH2","oncogene":true,"grch37Isoform":"ENST00000330062","grch37RefSeq":"NM_002168.2","grch38Isoform":"ENST00000330062","grch38RefSeq":"NM_002168.2","geneAliases":["IDHM","D2HGA2","mNADP-IDH","IDPM","ICD-M"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3418,"hugoSymbol":"IDH2","oncogene":true,"grch37Isoform":"ENST00000330062","grch37RefSeq":"NM_002168.2","grch38Isoform":"ENST00000330062","grch38RefSeq":"NM_002168.2","geneAliases":["IDHM","D2HGA2","mNADP-IDH","IDPM","ICD-M"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C111573","drugName":"Enasidenib","uuid":"788cb524-1a76-4280-b6e8-02b07d65f765","synonyms":["AG-221","CC-90007","Enasidenib","ENASIDENIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1579070343000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"LEVEL_3B","articles":[{"pmid":"30967620","title":"Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.","journal":"Leukemia","pubDate":"2019 Nov","volume":"33","issue":"11","pages":"2575-2584","authors":"Pollyea DA et al","elocationId":"doi: 10.1038/s41375-019-0472-2","link":null,"reference":"Pollyea DA et al. Leukemia. 2019 Nov;33(11)2575-2584.","abstract":null},{"pmid":"28588020","title":"Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia.","journal":"Blood","pubDate":"2017 Aug 10","volume":"130","issue":"6","pages":"722-731","authors":"Stein EM et al","elocationId":"doi: 10.1182/blood-2017-04-779405","link":null,"reference":"Stein EM et al. Blood. 2017 Aug 10;130(6)722-731.","abstract":null}]},{"id":3642,"uuid":"2cbc291b-8059-4b2e-a91b-6efb38056c97","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":557,"subtype":"Ovary/Fallopian Tube","code":"OVARY","color":"LightBlue","mainType":"Ovarian/Fallopian Tube Cancer, NOS","level":1,"tissue":"Ovary/Fallopian Tube","tumorForm":"SOLID"},{"id":880,"subtype":"","code":"","color":"LightBlue","mainType":"Ovarian Cancer","level":0,"tissue":"Ovary/Fallopian Tube","tumorForm":"SOLID"},{"id":863,"subtype":"Peritoneal Serous Carcinoma","code":"PSEC","color":"Green","mainType":"Peritoneal Cancer, NOS","level":2,"tissue":"Peritoneum","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Rucaparib is FDA-approved for patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies."],"priority":2,"drugs":[{"ncitCode":"C137800","drugName":"Rucaparib","uuid":"75ceadf8-0171-4f62-97ff-b008b15effb3","synonyms":["Rucaparib\"","8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one","Rucaparib","RUCAPARIB","\"6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1595388746000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"30425037","title":"<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.","journal":"Cancer discovery","pubDate":"2019 Feb","volume":"9","issue":"2","pages":"210-219","authors":"Lin KK et al","elocationId":"doi: 10.1158/2159-8290.CD-18-0715","link":null,"reference":"Lin KK et al. Cancer discovery. 2019 Feb;9(2)210-219.","abstract":null},{"pmid":"28882436","title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.","journal":"Gynecologic oncology","pubDate":"2017 Nov","volume":"147","issue":"2","pages":"267-275","authors":"Oza AM et al","elocationId":"doi: 10.1016/j.ygyno.2017.08.022","link":null,"reference":"Oza AM et al. Gynecologic oncology. 2017 Nov;147(2)267-275.","abstract":null},{"pmid":"28916367","title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.","journal":"Lancet (London, England)","pubDate":"2017 Oct 28","volume":"390","issue":"10106","pages":"1949-1961","authors":"Coleman RL et al","elocationId":"doi: 10.1016/S0140-6736(17)32440-6","link":null,"reference":"Coleman RL et al. Lancet (London, England). 2017 Oct 28;390(10106)1949-1961.","abstract":null},{"pmid":"32359490","title":"Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2020 May","volume":"21","issue":"5","pages":"710-722","authors":"Ledermann JA et al","elocationId":"doi: 10.1016/S1470-2045(20)30061-9","link":null,"reference":"Ledermann JA et al. The Lancet. Oncology. 2020 May;21(5)710-722.","abstract":null}]},{"id":3643,"uuid":"81b05f6c-6832-405b-935e-b385dd993bea","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":557,"subtype":"Ovary/Fallopian Tube","code":"OVARY","color":"LightBlue","mainType":"Ovarian/Fallopian Tube Cancer, NOS","level":1,"tissue":"Ovary/Fallopian Tube","tumorForm":"SOLID"},{"id":880,"subtype":"","code":"","color":"LightBlue","mainType":"Ovarian Cancer","level":0,"tissue":"Ovary/Fallopian Tube","tumorForm":"SOLID"},{"id":863,"subtype":"Peritoneal Serous Carcinoma","code":"PSEC","color":"Green","mainType":"Peritoneal Cancer, NOS","level":2,"tissue":"Peritoneum","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Niraparib is FDA-approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy irrespective of BRCA1/2 mutant status"],"priority":3,"drugs":[{"ncitCode":"C80059","drugName":"Niraparib","uuid":"d6cdce1b-5d80-4c71-8e5a-d1a9d3c81e17","synonyms":["MK-4827","MK4827","Niraparib","NIRAPARIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1571892665000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"30948273","title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2019 May","volume":"20","issue":"5","pages":"636-648","authors":"Moore KN et al","elocationId":"doi: 10.1016/S1470-2045(19)30029-4","link":null,"reference":"Moore KN et al. The Lancet. Oncology. 2019 May;20(5)636-648.","abstract":null},{"pmid":"27717299","title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.","journal":"The New England journal of medicine","pubDate":"2016 Dec 1","volume":"375","issue":"22","pages":"2154-2164","authors":"Mirza MR et al","elocationId":"","link":null,"reference":"Mirza MR et al. The New England journal of medicine. 2016 Dec 1;375(22)2154-2164.","abstract":null},{"pmid":"31562799","title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.","journal":"The New England journal of medicine","pubDate":"2019 Dec 19","volume":"381","issue":"25","pages":"2391-2402","authors":"González-Martín A et al","elocationId":"doi: 10.1056/NEJMoa1910962","link":null,"reference":"González-Martín A et al. The New England journal of medicine. 2019 Dec 19;381(25)2391-2402.","abstract":null}]},{"id":3648,"uuid":"2d7653b1-376f-49e5-a911-24a155b299f2","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":944,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer, NOS","level":0,"tissue":"Prostate","tumorForm":"SOLID"},{"id":936,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer","level":0,"tissue":"Prostate","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1598337689000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"26510020","title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.","journal":"The New England journal of medicine","pubDate":"2015 Oct 29","volume":"373","issue":"18","pages":"1697-708","authors":"Mateo J et al","elocationId":"doi: 10.1056/NEJMoa1506859","link":null,"reference":"Mateo J et al. The New England journal of medicine. 2015 Oct 29;373(18)1697-708.","abstract":null},{"pmid":"32343890","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer.","journal":"The New England journal of medicine","pubDate":"2020 May 28","volume":"382","issue":"22","pages":"2091-2102","authors":"de Bono J et al","elocationId":"doi: 10.1056/NEJMoa1911440","link":null,"reference":"de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.","abstract":null}]},{"id":3649,"uuid":"9415bd9e-1a28-438e-97b4-93817bea0980","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":944,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer, NOS","level":0,"tissue":"Prostate","tumorForm":"SOLID"},{"id":936,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer","level":0,"tissue":"Prostate","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C137800","drugName":"Rucaparib","uuid":"75ceadf8-0171-4f62-97ff-b008b15effb3","synonyms":["Rucaparib\"","8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one","Rucaparib","RUCAPARIB","\"6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1598337803000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://www.sciencedirect.com/science/article/pii/S0923753419590627","reference":"null. null. .","abstract":"Abida et al. Abstract# 846PD, ESMO 2019"},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://ascopubs.org/doi/full/10.1200/JCO.20.01035","reference":"null. null. .","abstract":"Abida et al. JCO, Aug 2020"}]},{"id":9802,"uuid":"a51e4bb2-6636-4f11-8781-25e5c6b6aec0","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":286,"subtype":"Follicular Lymphoma","code":"FL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y646C","name":"Y646C","refResidues":"Y","proteinStart":646,"proteinEnd":646,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y646S","name":"Y646S","refResidues":"Y","proteinStart":646,"proteinEnd":646,"variantResidues":"S","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y646N","name":"Y646N","refResidues":"Y","proteinStart":646,"proteinEnd":646,"variantResidues":"N","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"A692V","name":"A692V","refResidues":"A","proteinStart":692,"proteinEnd":692,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y646F","name":"Y646F","refResidues":"Y","proteinStart":646,"proteinEnd":646,"variantResidues":"F","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y646H","name":"Y646H","refResidues":"Y","proteinStart":646,"proteinEnd":646,"variantResidues":"H","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"A682G","name":"A682G","refResidues":"A","proteinStart":682,"proteinEnd":682,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C107506","drugName":"Tazemetostat","uuid":"49e07d49-ee64-4049-c09d-37c6ce612cad","synonyms":["TAZEMETOSTAT","N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide","Tazemetostat","Tazemetostat\"","EPZ-6438","EPZ6438","N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide","\"E7438"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1604891101000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"33035457","title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2020 Nov","volume":"21","issue":"11","pages":"1433-1442","authors":"Morschhauser F et al","elocationId":"doi: 10.1016/S1470-2045(20)30441-1","link":null,"reference":"Morschhauser F et al. The Lancet. Oncology. 2020 Nov;21(11)1433-1442.","abstract":null}]},{"id":17743,"uuid":"46a0644c-173c-40b8-8df5-826f36801b0d","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":873,"subtype":"","code":"","color":"HotPink","mainType":"Breast Cancer","level":0,"tissue":"Breast","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5290,"hugoSymbol":"PIK3CA","oncogene":true,"grch37Isoform":"ENST00000263967","grch37RefSeq":"NM_006218.2","grch38Isoform":"ENST00000263967","grch38RefSeq":"NM_006218.2","geneAliases":["p110-alpha","CLAPO","CLOVE","MCM","PI3K-alpha","CWS5","MCMTC"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5290,"hugoSymbol":"PIK3CA","oncogene":true,"grch37Isoform":"ENST00000263967","grch37RefSeq":"NM_006218.2","grch38Isoform":"ENST00000263967","grch38RefSeq":"NM_006218.2","geneAliases":["p110-alpha","CLAPO","CLOVE","MCM","PI3K-alpha","CWS5","MCMTC"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C94214","drugName":"Alpelisib","uuid":"d76cc0eb-d098-4133-95a5-5f59fad65f80","synonyms":["BYL719","ALPELISIB","Alpelisib","Phosphoinositide 3-kinase Inhibitor BYL719"],"priority":2},{"ncitCode":"C1379","drugName":"Fulvestrant","uuid":"b25af9e9-2195-4f16-90ea-7c21fcf3882d","synonyms":["ICI 182,780","ICI 182780","FULVESTRANT","Faslodex(ICI 182,780)","ZD9238","\"7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol","Faslodex","fulvestrant\"","Fulvestrant"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1560317923000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"30543347","title":"Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.","journal":"JAMA oncology","pubDate":"2019 Feb 1","volume":"5","issue":"2","pages":"e184475","authors":"Juric D et al","elocationId":"doi: 10.1001/jamaoncol.2018.4475","link":null,"reference":"Juric D et al. JAMA oncology. 2019 Feb 1;5(2)e184475.","abstract":null},{"pmid":"31091374","title":"Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.","journal":"The New England journal of medicine","pubDate":"2019 May 16","volume":"380","issue":"20","pages":"1929-1940","authors":"André F et al","elocationId":"doi: 10.1056/NEJMoa1813904","link":null,"reference":"André F et al. The New England journal of medicine. 2019 May 16;380(20)1929-1940.","abstract":null},{"pmid":"25877889","title":"PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.","journal":"Science translational medicine","pubDate":"2015 Apr 15","volume":"7","issue":"283","pages":"283ra51","authors":"Bosch A et al","elocationId":"doi: 10.1126/scitranslmed.aaa4442","link":null,"reference":"Bosch A et al. Science translational medicine. 2015 Apr 15;7(283)283ra51.","abstract":null}]},{"id":5711,"uuid":"e9b5bcce-6a72-436d-8895-ed4557cb8c6a","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":936,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer","level":0,"tissue":"Prostate","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":11200,"hugoSymbol":"CHEK2","oncogene":false,"grch37Isoform":"ENST00000328354","grch37RefSeq":"NM_007194.3","grch38Isoform":"ENST00000404276","grch38RefSeq":"NM_007194.3","geneAliases":["CDS1","HuCds1","RAD53","CHK2","PP1425","LFS2","hCds1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":11200,"hugoSymbol":"CHEK2","oncogene":false,"grch37Isoform":"ENST00000328354","grch37RefSeq":"NM_007194.3","grch38Isoform":"ENST00000404276","grch38RefSeq":"NM_007194.3","geneAliases":["CDS1","HuCds1","RAD53","CHK2","PP1425","LFS2","hCds1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1591159717000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32343890","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer.","journal":"The New England journal of medicine","pubDate":"2020 May 28","volume":"382","issue":"22","pages":"2091-2102","authors":"de Bono J et al","elocationId":"doi: 10.1056/NEJMoa1911440","link":null,"reference":"de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.","abstract":null}]},{"id":17234,"uuid":"619fc3e1-fdb0-4bf1-aea3-39c1041f6a7b","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":935,"subtype":"","code":"","color":"SaddleBrown","mainType":"Colorectal Cancer","level":0,"tissue":"Bowel","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":-2,"hugoSymbol":"Other Biomarkers","oncogene":false,"grch37Isoform":null,"grch37RefSeq":null,"grch38Isoform":null,"grch38RefSeq":null,"geneAliases":[],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":-2,"hugoSymbol":"Other Biomarkers","oncogene":false,"grch37Isoform":null,"grch37RefSeq":null,"grch38Isoform":null,"grch38RefSeq":null,"geneAliases":[],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"MSI-H","name":"Microsatellite Instability-High","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"Nivolumab is a human anti-PD1 antibody that exerts its anti-tumorigenic effect by immune checkpoint blockade and that is FDA-approved for patients with treatment-refractory metastatic colorectal cancer that has high microsatellite instability (MSI-H) or DNA mismatch repair deficiency (dMMR). FDA-approval was based on results from the multicenter, open-label Phase II CheckMate-142 trial of nivolumab in 74 patients with dMMR/MSI-H metastatic colorectal cancer in which 51 patients had disease control at the median follow-up, 23 patients (31.1%; 95% CI 20.8-42.9) achieved an objective partial response and only three of 23 responders went on to have progressive disease (PMID: 28734759). Preliminary data from the combination arm of CheckMate-142 in which 119 patients with dMMR/MSI-H metastatic colorectal cancer were treated with nivolumab plus ipilimumab showed an overall response rate of 55% and a disease control rate of 80% at the median follow-up of 13.4 months (Abstract: Andre et al. Abstract# 553, GCS 2018. https://meetinglibrary.asco.org/record/155742/abstract). Nivolumab has also shown efficacy in other non-colorectal MSI-H/dMMR cancers (PMID: 31765263).","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C68814","drugName":"Nivolumab","uuid":"e5402b72-1dbf-4735-97a1-3c86f27e8799","synonyms":["NIVO","Nivolumab","ONO-4538","Opdivo","BMS-936558","NIVOLUMAB","MDX-1106"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1579067692000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"31765263","title":"Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2020 Jan 20","volume":"38","issue":"3","pages":"214-222","authors":"Azad NS et al","elocationId":"doi: 10.1200/JCO.19.00818","link":null,"reference":"Azad NS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Jan 20;38(3)214-222.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://meetinglibrary.asco.org/record/155742/abstract","reference":"null. null. .","abstract":"Andre et al. Abstract# 553, GCS 2018"},{"pmid":"28734759","title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.","journal":"The Lancet. Oncology","pubDate":"2017 Sep","volume":"18","issue":"9","pages":"1182-1191","authors":"Overman MJ et al","elocationId":"doi: 10.1016/S1470-2045(17)30422-9","link":null,"reference":"Overman MJ et al. The Lancet. Oncology. 2017 Sep;18(9)1182-1191.","abstract":null}]},{"id":82,"uuid":"11d43111-be32-4bd4-a40c-e3ce9fdf9a7b","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":560,"subtype":"Chronic Myelogenous Leukemia","code":"CML","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T315I","name":"T315I","refResidues":"T","proteinStart":315,"proteinEnd":315,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C95777","drugName":"Ponatinib","uuid":"122b8921-3cd6-4b57-bdc8-5d39cc5465a1","synonyms":["\"AP-24534","PONATINIB","AP24534","Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)","Ponatinib\"","Ponatinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1557359683000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"23190221","title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias.","journal":"The New England journal of medicine","pubDate":"2012 Nov 29","volume":"367","issue":"22","pages":"2075-88","authors":"Cortes JE et al","elocationId":"doi: 10.1056/NEJMoa1205127","link":null,"reference":"Cortes JE et al. The New England journal of medicine. 2012 Nov 29;367(22)2075-88.","abstract":null},{"pmid":"24180494","title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.","journal":"The New England journal of medicine","pubDate":"2013 Nov 7","volume":"369","issue":"19","pages":"1783-96","authors":"Cortes JE et al","elocationId":"doi: 10.1056/NEJMoa1306494","link":null,"reference":"Cortes JE et al. The New England journal of medicine. 2013 Nov 7;369(19)1783-96.","abstract":null},{"pmid":"19878872","title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.","journal":"Cancer cell","pubDate":"2009 Nov 6","volume":"16","issue":"5","pages":"401-12","authors":"O'Hare T et al","elocationId":"doi: 10.1016/j.ccr.2009.09.028","link":null,"reference":"O'Hare T et al. Cancer cell. 2009 Nov 6;16(5)401-12.","abstract":null}]},{"id":17235,"uuid":"5e9513f9-4228-489b-b8ec-a0530fda0d9a","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":935,"subtype":"","code":"","color":"SaddleBrown","mainType":"Colorectal Cancer","level":0,"tissue":"Bowel","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":-2,"hugoSymbol":"Other Biomarkers","oncogene":false,"grch37Isoform":null,"grch37RefSeq":null,"grch38Isoform":null,"grch38RefSeq":null,"geneAliases":[],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":-2,"hugoSymbol":"Other Biomarkers","oncogene":false,"grch37Isoform":null,"grch37RefSeq":null,"grch38Isoform":null,"grch38RefSeq":null,"geneAliases":[],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"MSI-H","name":"Microsatellite Instability-High","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"Nivolumab, a human anti-PD1 antibody, and ipilimumab, a human anti-CTLA-4 antibody, are immunotherapies that are FDA-approved in combination for the treatment of patients 12 years and older with microsatellite instability high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) who experienced disease progression after chemotherapy. The FDA-approval was based on results of the Phase II CheckMate-142 study of nivolumab plus ipilimumab in 119 patients with MSI-H or dMMR mCRC in which the overall response rate was 49% (Complete response = 4.2%, partial response = 45%), the progression-free survival rate at 12 months was 71%, and the median duration of response was not reached (PMID: 29355075).","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C2654","drugName":"Ipilimumab","uuid":"298c501f-d184-45d6-8d6d-f9e0b132534e","synonyms":["BMS-734016","MDX-010","Ipilimumab","ipilimumab","Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody","MDX-CTLA4","IPILIMUMAB","Yervoy"],"priority":1},{"ncitCode":"C68814","drugName":"Nivolumab","uuid":"e5402b72-1dbf-4735-97a1-3c86f27e8799","synonyms":["NIVO","Nivolumab","ONO-4538","Opdivo","BMS-936558","NIVOLUMAB","MDX-1106"],"priority":2}]}],"knownEffect":"Sensitive","lastEdit":1571968156000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29355075","title":"Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2018 Mar 10","volume":"36","issue":"8","pages":"773-779","authors":"Overman MJ et al","elocationId":"doi: 10.1200/JCO.2017.76.9901","link":null,"reference":"Overman MJ et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Mar 10;36(8)773-779.","abstract":null}]},{"id":20307,"uuid":"8b44b13d-a7f3-41b9-9041-003c1ef3173d","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":936,"subtype":"","code":"","color":"Cyan","mainType":"Prostate Cancer","level":0,"tissue":"Prostate","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5889,"hugoSymbol":"RAD51C","oncogene":false,"grch37Isoform":"ENST00000337432","grch37RefSeq":"NM_058216.2","grch38Isoform":"ENST00000337432","grch38RefSeq":"NM_058216.2","geneAliases":["BROVCA3","FANCO","RAD51L2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":5889,"hugoSymbol":"RAD51C","oncogene":false,"grch37Isoform":"ENST00000337432","grch37RefSeq":"NM_058216.2","grch38Isoform":"ENST00000337432","grch38RefSeq":"NM_058216.2","geneAliases":["BROVCA3","FANCO","RAD51L2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1591160607000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32343890","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer.","journal":"The New England journal of medicine","pubDate":"2020 May 28","volume":"382","issue":"22","pages":"2091-2102","authors":"de Bono J et al","elocationId":"doi: 10.1056/NEJMoa1911440","link":null,"reference":"de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.","abstract":null}]},{"id":17237,"uuid":"9726df05-697a-4dd1-a560-56b6da0e7a4d","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":-2,"hugoSymbol":"Other Biomarkers","oncogene":false,"grch37Isoform":null,"grch37RefSeq":null,"grch38Isoform":null,"grch38RefSeq":null,"geneAliases":[],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":-2,"hugoSymbol":"Other Biomarkers","oncogene":false,"grch37Isoform":null,"grch37RefSeq":null,"grch38Isoform":null,"grch38RefSeq":null,"geneAliases":[],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"MSI-H","name":"Microsatellite Instability-High","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"Pembrolizumab is a human anti-PD1 antibody that exerts its anti-tumorigenic effect by immune checkpoint blockade and that is FDA-approved for patients with treatment-refractory solid tumors that have high microsatellite instability (MSI-H) or DNA mismatch repair deficiency (dMMR). FDA-approval was based on results of pembrolizumab treatment in 149 patients with cancers prospectively assessed as MSI-H or dMMR that were enrolled across five uncontrolled, multi-cohort, multi-center, single-arm clinical trials. In one trial, 66 of 86 patients (77%; 95% CI 66-85) with MSI-H/dMMR solid tumors had disease control, while 46 of 86 patients (53%; 95% CI 42-64) had objective radiographic responses and 18 of 86 patients (21%) had complete radiographic responses upon treatment with pembrolizumab (PMID: 28596308). Neither median progression-free survival nor median overall survival had been reached at median follow-up of 12.5 months (PMID: 28596308). In another trial of 41 patients with progressive metastatic carcinoma with or without mismatch-repair deficiency, the overall response rate to pembrolizumab in patients with MSI-H/dMMR colorectal cancer or MSI-H/dMMR non-colorectal solid tumors was 40% and 71%, respectively, while the overall response rate to pembrolizumab in patients with MMR-proficient colorectal cancer was 0% (PMID: 26028255). While median overall survival was not reached in patients with dMMR tumors, median progression-free survival in patients with MMR-proficient tumors was 2.2 months (95% CI 1.4-2.8) and median overall survival was 5.0 months (95% CI 3.0-not estimable) (PMID: 26028255). In a study of 1033 patients with prostate cancer who were prospectively screened for MSI, of the 32 patients with MSI-H/dMMR, six of eleven patients who were given pembrolizumab had more than 50% decline in prostate-specific antigen and four of the six patients had a radiographic partial response (PMID: 30589920). Results from the KEYNOTE-164 study of pembrolizumab in MSI-H/dMMR colorectal cancer demonstrated an objective response rate of 33% and a median overall survival of 31.4 months (95% CI, 21.4 months to not reached)(PMID: 31725351).","additionalInfo":null,"treatments":[{"approvedIndications":["Adult and pediatric patients with unresectable or metastatic MSI-H or dMMR (MMR deficient) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options or with MSI-H or dMMR colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan."],"priority":1,"drugs":[{"ncitCode":"C106432","drugName":"Pembrolizumab","uuid":"0746dd92-8f4d-4bf7-9161-57a223cb67d5","synonyms":["Pembrolizumab","MK-3475","PEMBROLIZUMAB","Keytruda","Lambrolizumab","SCH 900475\"","\"Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1578882885000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"28596308","title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.","journal":"Science (New York, N.Y.)","pubDate":"2017 Jul 28","volume":"357","issue":"6349","pages":"409-413","authors":"Le DT et al","elocationId":"doi: 10.1126/science.aan6733","link":null,"reference":"Le DT et al. Science (New York, N.Y.). 2017 Jul 28;357(6349)409-413.","abstract":null},{"pmid":"30589920","title":"Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.","journal":"JAMA oncology","pubDate":"2019 Apr 1","volume":"5","issue":"4","pages":"471-478","authors":"Abida W et al","elocationId":"doi: 10.1001/jamaoncol.2018.5801","link":null,"reference":"Abida W et al. JAMA oncology. 2019 Apr 1;5(4)471-478.","abstract":null},{"pmid":"31725351","title":"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2020 Jan 1","volume":"38","issue":"1","pages":"11-19","authors":"Le DT et al","elocationId":"doi: 10.1200/JCO.19.02107","link":null,"reference":"Le DT et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Jan 1;38(1)11-19.","abstract":null},{"pmid":"26028255","title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.","journal":"The New England journal of medicine","pubDate":"2015 Jun 25","volume":"372","issue":"26","pages":"2509-20","authors":"Le DT et al","elocationId":"doi: 10.1056/NEJMoa1500596","link":null,"reference":"Le DT et al. The New England journal of medicine. 2015 Jun 25;372(26)2509-20.","abstract":null}]},{"id":85,"uuid":"97aa7901-059c-42c8-95cc-7f8f3a600fbd","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T315I","name":"T315I","refResidues":"T","proteinStart":315,"proteinEnd":315,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C95777","drugName":"Ponatinib","uuid":"122b8921-3cd6-4b57-bdc8-5d39cc5465a1","synonyms":["\"AP-24534","PONATINIB","AP24534","Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)","Ponatinib\"","Ponatinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1576693360000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"23190221","title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias.","journal":"The New England journal of medicine","pubDate":"2012 Nov 29","volume":"367","issue":"22","pages":"2075-88","authors":"Cortes JE et al","elocationId":"doi: 10.1056/NEJMoa1205127","link":null,"reference":"Cortes JE et al. The New England journal of medicine. 2012 Nov 29;367(22)2075-88.","abstract":null},{"pmid":"24180494","title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.","journal":"The New England journal of medicine","pubDate":"2013 Nov 7","volume":"369","issue":"19","pages":"1783-96","authors":"Cortes JE et al","elocationId":"doi: 10.1056/NEJMoa1306494","link":null,"reference":"Cortes JE et al. The New England journal of medicine. 2013 Nov 7;369(19)1783-96.","abstract":null},{"pmid":"29567798","title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.","journal":"Blood","pubDate":"2018 Jul 26","volume":"132","issue":"4","pages":"393-404","authors":"Cortes JE et al","elocationId":"doi: 10.1182/blood-2016-09-739086","link":null,"reference":"Cortes JE et al. Blood. 2018 Jul 26;132(4)393-404.","abstract":null}]},{"id":21845,"uuid":"bd57fc0c-d7f3-45b0-a457-8fd27efe3a91","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":598,"subtype":"Epithelioid Sarcoma","code":"EPIS","color":"LightYellow","mainType":"Soft Tissue Sarcoma","level":2,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6598,"hugoSymbol":"SMARCB1","oncogene":false,"grch37Isoform":"ENST00000263121","grch37RefSeq":"NM_003073.3","grch38Isoform":"ENST00000618915","grch38RefSeq":"NM_003073.3","geneAliases":["MRD15","SNF5L1","RDT","RTPS1","BAF47","PPP1R144","SNF5","CSS3","INI1","hSNFS","Sfh1p","SWNTS1","Snr1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":6598,"hugoSymbol":"SMARCB1","oncogene":false,"grch37Isoform":"ENST00000263121","grch37RefSeq":"NM_003073.3","grch38Isoform":"ENST00000618915","grch38RefSeq":"NM_003073.3","geneAliases":["MRD15","SNF5L1","RDT","RTPS1","BAF47","PPP1R144","SNF5","CSS3","INI1","hSNFS","Sfh1p","SWNTS1","Snr1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Deletion","name":"Deletion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C107506","drugName":"Tazemetostat","uuid":"49e07d49-ee64-4049-c09d-37c6ce612cad","synonyms":["TAZEMETOSTAT","N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide","Tazemetostat","Tazemetostat\"","EPZ-6438","EPZ6438","N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide","\"E7438"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1604891498000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"33035459","title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.","journal":"The Lancet. Oncology","pubDate":"2020 Nov","volume":"21","issue":"11","pages":"1423-1432","authors":"Gounder M et al","elocationId":"doi: 10.1016/S1470-2045(20)30451-4","link":null,"reference":"Gounder M et al. The Lancet. Oncology. 2020 Nov;21(11)1423-1432.","abstract":null}]},{"id":17241,"uuid":"eed2df81-1a36-482e-9e92-f872f2fca091","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":-2,"hugoSymbol":"Other Biomarkers","oncogene":false,"grch37Isoform":null,"grch37RefSeq":null,"grch38Isoform":null,"grch38RefSeq":null,"geneAliases":[],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":-2,"hugoSymbol":"Other Biomarkers","oncogene":false,"grch37Isoform":null,"grch37RefSeq":null,"grch38Isoform":null,"grch38RefSeq":null,"geneAliases":[],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"TMB-H","name":"Tumor Mutational Burden-High","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"Pembrolizumab is an anti-PD1 antibody that is FDA-approved for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors that have no other satisfactory treatment options. FDA-approval was based on the Phase II multicenter, non-randomized, open-label KEYNOTE-158 trial of pembrolizumab in 102 patients with unresectable or metastatic TMB-H solid tumors in which the overall response rate was 29% (95% CI= 21-39), 57% of responses lasted more than twelve months, and 50% of responses lasted more than 24 months (Abstract: Marabelle et al. Abstract# 1192O, ESMO 2019. https://www.sciencedirect.com/science/article/pii/S0923753419594042), https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s071s090lbl.pdf)","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C106432","drugName":"Pembrolizumab","uuid":"0746dd92-8f4d-4bf7-9161-57a223cb67d5","synonyms":["Pembrolizumab","MK-3475","PEMBROLIZUMAB","Keytruda","Lambrolizumab","SCH 900475\"","\"Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1595454073000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://www.sciencedirect.com/science/article/pii/S0923753419594042","reference":"null. null. .","abstract":"Marabelle et al. Abstract# 1192O, ESMO 2019"}]},{"id":17500,"uuid":"5e6e26b4-cbcd-4008-878c-f5394f624db6","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":545,"subtype":"Chronic Eosinophilic Leukemia, NOS","code":"CELNOS","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"FIP1L1-PDGFRA Fusion","name":"FIP1L1-PDGFRA Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Imatinib is FDA-approved for the treatment of patients with hypereosinophilic syndrome (HES) or chronic eosinophilic leukemia (CEL) harboring the FIP1L1- PDGFRA fusion."],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1525892430000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"18950453","title":"Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.","journal":"British journal of haematology","pubDate":"2008 Dec","volume":"143","issue":"5","pages":"707-15","authors":"Metzgeroth G et al","elocationId":"doi: 10.1111/j.1365-2141.2008.07294.x","link":null,"reference":"Metzgeroth G et al. British journal of haematology. 2008 Dec;143(5)707-15.","abstract":null}]},{"id":17505,"uuid":"20724595-3a6f-44aa-a452-076111479f45","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":285,"subtype":"Myelodysplastic/Myeloproliferative Neoplasms","code":"MDS/MPN","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Imatinib is FDA-approved for the treatment of adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements."],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1525892474000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"17555450","title":"Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.","journal":"British journal of haematology","pubDate":"2007 Jul","volume":"138","issue":"1","pages":"77-81","authors":"Curtis CE et al","elocationId":"","link":null,"reference":"Curtis CE et al. British journal of haematology. 2007 Jul;138(1)77-81.","abstract":null},{"pmid":"15034867","title":"Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia.","journal":"Genes, chromosomes & cancer","pubDate":"2004 May","volume":"40","issue":"1","pages":"44-50","authors":"Safley AM et al","elocationId":"","link":null,"reference":"Safley AM et al. Genes, chromosomes & cancer. 2004 May;40(1)44-50.","abstract":null},{"pmid":"12660384","title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.","journal":"The New England journal of medicine","pubDate":"2003 Mar 27","volume":"348","issue":"13","pages":"1201-14","authors":"Cools J et al","elocationId":"","link":null,"reference":"Cools J et al. The New England journal of medicine. 2003 Mar 27;348(13)1201-14.","abstract":null},{"pmid":"14504092","title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.","journal":"Blood","pubDate":"2004 Jan 15","volume":"103","issue":"2","pages":"473-8","authors":"Klion AD et al","elocationId":"","link":null,"reference":"Klion AD et al. Blood. 2004 Jan 15;103(2)473-8.","abstract":null},{"pmid":"12944919","title":"Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec.","journal":"Oncogene","pubDate":"2003 Aug 28","volume":"22","issue":"36","pages":"5702-6","authors":"Trempat P et al","elocationId":"","link":null,"reference":"Trempat P et al. Oncogene. 2003 Aug 28;22(36)5702-6.","abstract":null},{"pmid":"16845659","title":"Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.","journal":"Genes, chromosomes & cancer","pubDate":"2006 Oct","volume":"45","issue":"10","pages":"950-6","authors":"Walz C et al","elocationId":"","link":null,"reference":"Walz C et al. Genes, chromosomes & cancer. 2006 Oct;45(10)950-6.","abstract":null},{"pmid":"18950453","title":"Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.","journal":"British journal of haematology","pubDate":"2008 Dec","volume":"143","issue":"5","pages":"707-15","authors":"Metzgeroth G et al","elocationId":"doi: 10.1111/j.1365-2141.2008.07294.x","link":null,"reference":"Metzgeroth G et al. British journal of haematology. 2008 Dec;143(5)707-15.","abstract":null},{"pmid":"16498388","title":"Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.","journal":"Leukemia","pubDate":"2006 May","volume":"20","issue":"5","pages":"827-32","authors":"Score J et al","elocationId":"","link":null,"reference":"Score J et al. Leukemia. 2006 May;20(5)827-32.","abstract":null}]},{"id":14690,"uuid":"0ddc190b-19b9-454a-8bc2-2b1a47f05afa","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Y1003","name":"Y1003","refResidues":"Y","proteinStart":1003,"proteinEnd":1003,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"consequence":{"term":"splice_region_variant","isGenerallyTruncating":true,"description":"A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron"},"alteration":"963_1010splice","name":"Exon 14 splice mutation","refResidues":null,"proteinStart":963,"proteinEnd":1010,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"963_1010del","name":"Exon 14 deletion","refResidues":null,"proteinStart":963,"proteinEnd":1010,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D1010","name":"D1010","refResidues":"D","proteinStart":1010,"proteinEnd":1010,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C90564","drugName":"Capmatinib","uuid":"8ddbbd88-3730-4ea2-8cba-b5038d250fd1","synonyms":["INC280","INCB028060","INCB28060\"","INCB 28060","Capmatinib","INC-280","\"2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide","CAPMATINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1589148639000,"lastReview":null,"levelOfEvidence":"LEVEL_1","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9004","reference":"null. null. .","abstract":"Wolf et al. Abstract# 9004, ASCO 2019"}]}],"LEVEL_Dx2":[{"id":22243,"uuid":"448a058f-e021-4436-bdee-912c096eb1f8","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":224,"subtype":"Chronic Myelomonocytic Leukemia","code":"CMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22919025","title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).","journal":"Blood","pubDate":"2012 Oct 11","volume":"120","issue":"15","pages":"3080-8","authors":"Meggendorfer M et al","elocationId":"doi: 10.1182/blood-2012-01-404863","link":null,"reference":"Meggendorfer M et al. Blood. 2012 Oct 11;120(15)3080-8.","abstract":null},{"pmid":"25305095","title":"The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia.","journal":"Human pathology","pubDate":"2014 Dec","volume":"45","issue":"12","pages":"2471-9","authors":"Federmann B et al","elocationId":"doi: 10.1016/j.humpath.2014.08.014","link":null,"reference":"Federmann B et al. Human pathology. 2014 Dec;45(12)2471-9.","abstract":null},{"pmid":"24695057","title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.","journal":"Leukemia","pubDate":"2014 Nov","volume":"28","issue":"11","pages":"2206-12","authors":"Patnaik MM et al","elocationId":"doi: 10.1038/leu.2014.125","link":null,"reference":"Patnaik MM et al. Leukemia. 2014 Nov;28(11)2206-12.","abstract":null}]},{"id":21096,"uuid":"b52320b2-c32d-4e59-9763-a1b139022670","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":224,"subtype":"Chronic Myelomonocytic Leukemia","code":"CMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"26341525","title":"An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.","journal":"Haematologica","pubDate":"2015 Sep","volume":"100","issue":"9","pages":"1117-30","authors":"Mughal TI et al","elocationId":"doi: 10.3324/haematol.2014.114660","link":null,"reference":"Mughal TI et al. Haematologica. 2015 Sep;100(9)1117-30.","abstract":null},{"pmid":"23690417","title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2013 Jul 1","volume":"31","issue":"19","pages":"2428-36","authors":"Itzykson R et al","elocationId":"doi: 10.1200/JCO.2012.47.3314","link":null,"reference":"Itzykson R et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jul 1;31(19)2428-36.","abstract":null}]},{"id":11753,"uuid":"066056e0-8bdc-4bf3-a8cb-814e8239104a","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3417,"hugoSymbol":"IDH1","oncogene":true,"grch37Isoform":"ENST00000345146","grch37RefSeq":"NM_005896.2","grch38Isoform":"ENST00000345146","grch38RefSeq":"NM_005896.2","geneAliases":["HEL-216","IDPC","IDCD","HEL-S-26","PICD"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3417,"hugoSymbol":"IDH1","oncogene":true,"grch37Isoform":"ENST00000345146","grch37RefSeq":"NM_005896.2","grch38Isoform":"ENST00000345146","grch38RefSeq":"NM_005896.2","geneAliases":["HEL-216","IDPC","IDCD","HEL-S-26","PICD"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1606852748000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22397365","title":"Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.","journal":"Journal of hematology & oncology","pubDate":"2012 Mar 7","volume":"5","issue":"","pages":"5","authors":"Chotirat S et al","elocationId":"doi: 10.1186/1756-8722-5-5","link":null,"reference":"Chotirat S et al. Journal of hematology & oncology. 2012 Mar 7;5()5.","abstract":null},{"pmid":"19657110","title":"Recurring mutations found by sequencing an acute myeloid leukemia genome.","journal":"The New England journal of medicine","pubDate":"2009 Sep 10","volume":"361","issue":"11","pages":"1058-66","authors":"Mardis ER et al","elocationId":"doi: 10.1056/NEJMoa0903840","link":null,"reference":"Mardis ER et al. The New England journal of medicine. 2009 Sep 10;361(11)1058-66.","abstract":null},{"pmid":"20368543","title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2010 May 10","volume":"28","issue":"14","pages":"2348-55","authors":"Marcucci G et al","elocationId":"doi: 10.1200/JCO.2009.27.3730","link":null,"reference":"Marcucci G et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 May 10;28(14)2348-55.","abstract":null},{"pmid":"20567020","title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2010 Aug 1","volume":"28","issue":"22","pages":"3636-43","authors":"Paschka P et al","elocationId":"doi: 10.1200/JCO.2010.28.3762","link":null,"reference":"Paschka P et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Aug 1;28(22)3636-43.","abstract":null},{"pmid":"22417203","title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.","journal":"The New England journal of medicine","pubDate":"2012 Mar 22","volume":"366","issue":"12","pages":"1079-89","authors":"Patel JP et al","elocationId":"doi: 10.1056/NEJMoa1112304","link":null,"reference":"Patel JP et al. The New England journal of medicine. 2012 Mar 22;366(12)1079-89.","abstract":null},{"pmid":"20097881","title":"Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.","journal":"Blood","pubDate":"2010 Apr 8","volume":"115","issue":"14","pages":"2749-54","authors":"Chou WC et al","elocationId":"doi: 10.1182/blood-2009-11-253070","link":null,"reference":"Chou WC et al. Blood. 2010 Apr 8;115(14)2749-54.","abstract":null},{"pmid":"20538800","title":"Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.","journal":"Blood","pubDate":"2010 Sep 23","volume":"116","issue":"12","pages":"2122-6","authors":"Abbas S et al","elocationId":"doi: 10.1182/blood-2009-11-250878","link":null,"reference":"Abbas S et al. Blood. 2010 Sep 23;116(12)2122-6.","abstract":null}]},{"id":13034,"uuid":"6310f45f-aa2c-468a-a23e-b2d7ca497744","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4297,"hugoSymbol":"KMT2A","oncogene":false,"grch37Isoform":"ENST00000534358","grch37RefSeq":"NM_001197104.1","grch38Isoform":"ENST00000534358","grch38RefSeq":"NM_001197104.1","geneAliases":["MLL1","TRX1","HTRX1","ALL-1","MLL","MLL1A","CXXC7","HRX","WDSTS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4297,"hugoSymbol":"KMT2A","oncogene":false,"grch37Isoform":"ENST00000534358","grch37RefSeq":"NM_001197104.1","grch38Isoform":"ENST00000534358","grch38RefSeq":"NM_001197104.1","geneAliases":["MLL1","TRX1","HTRX1","ALL-1","MLL","MLL1A","CXXC7","HRX","WDSTS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"8630416","title":"Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5.","journal":"Blood","pubDate":"1996 Mar 15","volume":"87","issue":"6","pages":"2496-505","authors":"Poirel H et al","elocationId":"","link":null,"reference":"Poirel H et al. Blood. 1996 Mar 15;87(6)2496-505.","abstract":null},{"pmid":"12057554","title":"Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region.","journal":"Lancet (London, England)","pubDate":"2002 Jun 1","volume":"359","issue":"9321","pages":"1909-15","authors":"Pui CH et al","elocationId":"","link":null,"reference":"Pui CH et al. Lancet (London, England). 2002 Jun 1;359(9321)1909-15.","abstract":null},{"pmid":"28701730","title":"The MLL recombinome of acute leukemias in 2017.","journal":"Leukemia","pubDate":"2018 Feb","volume":"32","issue":"2","pages":"273-284","authors":"Meyer C et al","elocationId":"doi: 10.1038/leu.2017.213","link":null,"reference":"Meyer C et al. Leukemia. 2018 Feb;32(2)273-284.","abstract":null},{"pmid":"12805060","title":"AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases.","journal":"Blood","pubDate":"2003 Oct 1","volume":"102","issue":"7","pages":"2395-402","authors":"Schoch C et al","elocationId":"","link":null,"reference":"Schoch C et al. Blood. 2003 Oct 1;102(7)2395-402.","abstract":null},{"pmid":"26709255","title":"Systematic Classification of Mixed-Lineage Leukemia Fusion Partners Predicts Additional Cancer Pathways.","journal":"Annals of laboratory medicine","pubDate":"2016 Mar","volume":"36","issue":"2","pages":"85-100","authors":"Marschalek R","elocationId":"doi: 10.3343/alm.2016.36.2.85","link":null,"reference":"Marschalek R. Annals of laboratory medicine. 2016 Mar;36(2)85-100.","abstract":null}]},{"id":2028,"uuid":"565e1375-b008-47ab-9b14-5807616072fb","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":276,"subtype":"Hairy Cell Leukemia","code":"HCL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600E","name":"V600E","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25480661","title":"BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.","journal":"Blood","pubDate":"2015 Feb 19","volume":"125","issue":"8","pages":"1207-16","authors":"Pettirossi V et al","elocationId":"doi: 10.1182/blood-2014-10-603100","link":null,"reference":"Pettirossi V et al. Blood. 2015 Feb 19;125(8)1207-16.","abstract":null},{"pmid":"26071465","title":"Immunohistochemistry for BRAF V600E in the Differential Diagnosis of Hairy Cell Leukemia vs Other Splenic B-Cell Lymphomas.","journal":"American journal of clinical pathology","pubDate":"2015 Jul","volume":"144","issue":"1","pages":"87-93","authors":"Turakhia S et al","elocationId":"doi: 10.1309/AJCP5WVXJ2KTLODO","link":null,"reference":"Turakhia S et al. American journal of clinical pathology. 2015 Jul;144(1)87-93.","abstract":null},{"pmid":"22531170","title":"Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia.","journal":"The American journal of surgical pathology","pubDate":"2012 Dec","volume":"36","issue":"12","pages":"1796-800","authors":"Andrulis M et al","elocationId":"doi: 10.1097/PAS.0b013e3182549b50","link":null,"reference":"Andrulis M et al. The American journal of surgical pathology. 2012 Dec;36(12)1796-800.","abstract":null},{"pmid":"22028477","title":"Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation.","journal":"Blood","pubDate":"2012 Jan 5","volume":"119","issue":"1","pages":"192-5","authors":"Tiacci E et al","elocationId":"doi: 10.1182/blood-2011-08-371179","link":null,"reference":"Tiacci E et al. Blood. 2012 Jan 5;119(1)192-5.","abstract":null},{"pmid":"22210875","title":"Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.","journal":"Blood","pubDate":"2012 Apr 5","volume":"119","issue":"14","pages":"3330-2","authors":"Xi L et al","elocationId":"doi: 10.1182/blood-2011-09-379339","link":null,"reference":"Xi L et al. Blood. 2012 Apr 5;119(14)3330-2.","abstract":null},{"pmid":"22072557","title":"The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms.","journal":"Blood","pubDate":"2012 Jan 5","volume":"119","issue":"1","pages":"188-91","authors":"Arcaini L et al","elocationId":"doi: 10.1182/blood-2011-08-368209","link":null,"reference":"Arcaini L et al. Blood. 2012 Jan 5;119(1)188-91.","abstract":null},{"pmid":"21910720","title":"High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies.","journal":"British journal of haematology","pubDate":"2011 Dec","volume":"155","issue":"5","pages":"609-12","authors":"Boyd EM et al","elocationId":"doi: 10.1111/j.1365-2141.2011.08868.x","link":null,"reference":"Boyd EM et al. British journal of haematology. 2011 Dec;155(5)609-12.","abstract":null},{"pmid":"23347903","title":"Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.","journal":"Leukemia research","pubDate":"2013 Apr","volume":"37","issue":"4","pages":"401-409","authors":"Shao H et al","elocationId":"doi: 10.1016/j.leukres.2012.11.021","link":null,"reference":"Shao H et al. Leukemia research. 2013 Apr;37(4)401-409.","abstract":null},{"pmid":"21663470","title":"BRAF mutations in hairy-cell leukemia.","journal":"The New England journal of medicine","pubDate":"2011 Jun 16","volume":"364","issue":"24","pages":"2305-15","authors":"Tiacci E et al","elocationId":"doi: 10.1056/NEJMoa1014209","link":null,"reference":"Tiacci E et al. The New England journal of medicine. 2011 Jun 16;364(24)2305-15.","abstract":null},{"pmid":"25120816","title":"Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia.","journal":"International journal of clinical and experimental pathology","pubDate":"2014","volume":"7","issue":"7","pages":"4323-8","authors":"Wang XJ et al","elocationId":"","link":null,"reference":"Wang XJ et al. International journal of clinical and experimental pathology. 2014;7(7)4323-8.","abstract":null}]},{"id":11885,"uuid":"e2e19d47-1f4c-4af4-bf3d-59d80cf02505","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":184,"subtype":"AML with BCR-ABL1","code":"AMLBCRABL1","color":"LightSalmon","mainType":"Leukemia","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":10320,"hugoSymbol":"IKZF1","oncogene":false,"grch37Isoform":"ENST00000331340","grch37RefSeq":"ENST00000331340","grch38Isoform":"ENST00000331340","grch38RefSeq":"ENST00000331340","geneAliases":["CVID13","IKAROS","PRO0758","LyF-1","LYF1","Hs.54452","ZNFN1A1","IK1","PPP1R92"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":10320,"hugoSymbol":"IKZF1","oncogene":false,"grch37Isoform":"ENST00000331340","grch37RefSeq":"ENST00000331340","grch38Isoform":"ENST00000331340","grch38RefSeq":"ENST00000331340","geneAliases":["CVID13","IKAROS","PRO0758","LyF-1","LYF1","Hs.54452","ZNFN1A1","IK1","PPP1R92"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Deletion","name":"Deletion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"26069293","title":"Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia.","journal":"Haematologica","pubDate":"2015 Sep","volume":"100","issue":"9","pages":"1151-9","authors":"de Rooij JD et al","elocationId":"doi: 10.3324/haematol.2015.124321","link":null,"reference":"de Rooij JD et al. Haematologica. 2015 Sep;100(9)1151-9.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/124/21/2346","reference":"null. null. .","abstract":"de Rooij, J. et al., Blood 124:2346, 2014"}]},{"id":21102,"uuid":"50652756-6bfd-4780-81bc-b46375fd5c31","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"21714648","title":"Clinical effect of point mutations in myelodysplastic syndromes.","journal":"The New England journal of medicine","pubDate":"2011 Jun 30","volume":"364","issue":"26","pages":"2496-506","authors":"Bejar R et al","elocationId":"doi: 10.1056/NEJMoa1013343","link":null,"reference":"Bejar R et al. The New England journal of medicine. 2011 Jun 30;364(26)2496-506.","abstract":null},{"pmid":"22389253","title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.","journal":"Blood","pubDate":"2012 Apr 12","volume":"119","issue":"15","pages":"3578-84","authors":"Thol F et al","elocationId":"doi: 10.1182/blood-2011-12-399337","link":null,"reference":"Thol F et al. Blood. 2012 Apr 12;119(15)3578-84.","abstract":null},{"pmid":"24881041","title":"Clinical and genetic predictors of prognosis in myelodysplastic syndromes.","journal":"Haematologica","pubDate":"2014 Jun","volume":"99","issue":"6","pages":"956-64","authors":"Bejar R","elocationId":"doi: 10.3324/haematol.2013.085217","link":null,"reference":"Bejar R. Haematologica. 2014 Jun;99(6)956-64.","abstract":null},{"pmid":"24030381","title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes.","journal":"Blood","pubDate":"2013 Nov 21","volume":"122","issue":"22","pages":"3616-27; quiz 3699","authors":"Papaemmanuil E et al","elocationId":"doi: 10.1182/blood-2013-08-518886","link":null,"reference":"Papaemmanuil E et al. Blood. 2013 Nov 21;122(22)3616-27; quiz 3699.","abstract":null},{"pmid":"25465125","title":"The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.","journal":"Leukemia research","pubDate":"2015 Jan","volume":"39","issue":"1","pages":"6-17","authors":"Zhang L et al","elocationId":"doi: 10.1016/j.leukres.2014.10.006","link":null,"reference":"Zhang L et al. Leukemia research. 2015 Jan;39(1)6-17.","abstract":null},{"pmid":"11830488","title":"In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.","journal":"Blood","pubDate":"2002 Feb 15","volume":"99","issue":"4","pages":"1364-72","authors":"Michaud J et al","elocationId":"","link":null,"reference":"Michaud J et al. Blood. 2002 Feb 15;99(4)1364-72.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null}]},{"id":22254,"uuid":"9bbca0aa-cdf0-450e-98a9-63b8f42d3c3b","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"P95","name":"P95","refResidues":"P","proteinStart":95,"proteinEnd":95,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22389253","title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.","journal":"Blood","pubDate":"2012 Apr 12","volume":"119","issue":"15","pages":"3578-84","authors":"Thol F et al","elocationId":"doi: 10.1182/blood-2011-12-399337","link":null,"reference":"Thol F et al. Blood. 2012 Apr 12;119(15)3578-84.","abstract":null},{"pmid":"24030381","title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes.","journal":"Blood","pubDate":"2013 Nov 21","volume":"122","issue":"22","pages":"3616-27; quiz 3699","authors":"Papaemmanuil E et al","elocationId":"doi: 10.1182/blood-2013-08-518886","link":null,"reference":"Papaemmanuil E et al. Blood. 2013 Nov 21;122(22)3616-27; quiz 3699.","abstract":null},{"pmid":"25465125","title":"The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.","journal":"Leukemia research","pubDate":"2015 Jan","volume":"39","issue":"1","pages":"6-17","authors":"Zhang L et al","elocationId":"doi: 10.1016/j.leukres.2014.10.006","link":null,"reference":"Zhang L et al. Leukemia research. 2015 Jan;39(1)6-17.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null}]},{"id":2031,"uuid":"97cde25b-b793-4cf6-b4e2-b787c0a398e9","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":862,"subtype":"Langerhans Cell Histiocytosis","code":"LCH","color":"LightSalmon","mainType":"Histiocytosis","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600E","name":"V600E","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"20519626","title":"Recurrent BRAF mutations in Langerhans cell histiocytosis.","journal":"Blood","pubDate":"2010 Sep 16","volume":"116","issue":"11","pages":"1919-23","authors":"Badalian-Very G et al","elocationId":"doi: 10.1182/blood-2010-04-279083","link":null,"reference":"Badalian-Very G et al. Blood. 2010 Sep 16;116(11)1919-23.","abstract":null},{"pmid":"26637772","title":"Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.","journal":"Hematology. American Society of Hematology. Education Program","pubDate":"2015","volume":"2015","issue":"","pages":"559-64","authors":"Allen CE et al","elocationId":"doi: 10.1182/asheducation-2015.1.559","link":null,"reference":"Allen CE et al. Hematology. American Society of Hematology. Education Program. 2015;2015()559-64.","abstract":null},{"pmid":"30157397","title":"Langerhans-Cell Histiocytosis.","journal":"The New England journal of medicine","pubDate":"2018 Aug 30","volume":"379","issue":"9","pages":"856-868","authors":"Allen CE et al","elocationId":"doi: 10.1056/NEJMra1607548","link":null,"reference":"Allen CE et al. The New England journal of medicine. 2018 Aug 30;379(9)856-868.","abstract":null},{"pmid":"24938183","title":"Potential clinical implications of BRAF mutations in histiocytic proliferations.","journal":"Oncotarget","pubDate":"2014 Jun 30","volume":"5","issue":"12","pages":"4060-70","authors":"Bubolz AM et al","elocationId":"","link":null,"reference":"Bubolz AM et al. Oncotarget. 2014 Jun 30;5(12)4060-70.","abstract":null}]},{"id":11887,"uuid":"010b0b0a-f536-49d9-a2a3-efad522c78e9","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":688,"subtype":"B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like","code":"BLLBCRABL1L","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":10320,"hugoSymbol":"IKZF1","oncogene":false,"grch37Isoform":"ENST00000331340","grch37RefSeq":"ENST00000331340","grch38Isoform":"ENST00000331340","grch38RefSeq":"ENST00000331340","geneAliases":["CVID13","IKAROS","PRO0758","LyF-1","LYF1","Hs.54452","ZNFN1A1","IK1","PPP1R92"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":10320,"hugoSymbol":"IKZF1","oncogene":false,"grch37Isoform":"ENST00000331340","grch37RefSeq":"ENST00000331340","grch38Isoform":"ENST00000331340","grch38RefSeq":"ENST00000331340","geneAliases":["CVID13","IKAROS","PRO0758","LyF-1","LYF1","Hs.54452","ZNFN1A1","IK1","PPP1R92"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Deletion","name":"Deletion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"26045294","title":"BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures.","journal":"Haematologica","pubDate":"2015 Sep","volume":"100","issue":"9","pages":"e354-7","authors":"Boer JM et al","elocationId":"doi: 10.3324/haematol.2015.124941","link":null,"reference":"Boer JM et al. Haematologica. 2015 Sep;100(9)e354-7.","abstract":null}]},{"id":13040,"uuid":"02d2bf81-d1bb-4281-a59e-5655a56c6755","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":784,"subtype":"Myeloid Sarcoma","code":"MS","color":"LightSalmon","mainType":"Leukemia","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4297,"hugoSymbol":"KMT2A","oncogene":false,"grch37Isoform":"ENST00000534358","grch37RefSeq":"NM_001197104.1","grch38Isoform":"ENST00000534358","grch38RefSeq":"NM_001197104.1","geneAliases":["MLL1","TRX1","HTRX1","ALL-1","MLL","MLL1A","CXXC7","HRX","WDSTS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4297,"hugoSymbol":"KMT2A","oncogene":false,"grch37Isoform":"ENST00000534358","grch37RefSeq":"NM_001197104.1","grch38Isoform":"ENST00000534358","grch38RefSeq":"NM_001197104.1","geneAliases":["MLL1","TRX1","HTRX1","ALL-1","MLL","MLL1A","CXXC7","HRX","WDSTS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"17170724","title":"Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients.","journal":"Leukemia","pubDate":"2007 Feb","volume":"21","issue":"2","pages":"340-50","authors":"Pileri SA et al","elocationId":"","link":null,"reference":"Pileri SA et al. Leukemia. 2007 Feb;21(2)340-50.","abstract":null}]},{"id":22256,"uuid":"fcf012d4-6380-4a8e-889b-bb511f3b877b","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":267,"subtype":"MDS with Ring Sideroblasts","code":"MDSRS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"P95","name":"P95","refResidues":"P","proteinStart":95,"proteinEnd":95,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25957392","title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.","journal":"Blood","pubDate":"2015 Jul 9","volume":"126","issue":"2","pages":"233-41","authors":"Malcovati L et al","elocationId":"doi: 10.1182/blood-2015-03-633537","link":null,"reference":"Malcovati L et al. Blood. 2015 Jul 9;126(2)233-41.","abstract":null},{"pmid":"21909114","title":"Frequent pathway mutations of splicing machinery in myelodysplasia.","journal":"Nature","pubDate":"2011 Sep 11","volume":"478","issue":"7367","pages":"64-9","authors":"Yoshida K et al","elocationId":"doi: 10.1038/nature10496","link":null,"reference":"Yoshida K et al. Nature. 2011 Sep 11;478(7367)64-9.","abstract":null}]},{"id":13042,"uuid":"f843ca36-12e2-4ca1-a01f-9cae3debdcb3","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":293,"subtype":"T-Lymphoblastic Leukemia/Lymphoma","code":"TLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4297,"hugoSymbol":"KMT2A","oncogene":false,"grch37Isoform":"ENST00000534358","grch37RefSeq":"NM_001197104.1","grch38Isoform":"ENST00000534358","grch38RefSeq":"NM_001197104.1","geneAliases":["MLL1","TRX1","HTRX1","ALL-1","MLL","MLL1A","CXXC7","HRX","WDSTS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4297,"hugoSymbol":"KMT2A","oncogene":false,"grch37Isoform":"ENST00000534358","grch37RefSeq":"NM_001197104.1","grch38Isoform":"ENST00000534358","grch38RefSeq":"NM_001197104.1","geneAliases":["MLL1","TRX1","HTRX1","ALL-1","MLL","MLL1A","CXXC7","HRX","WDSTS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"16826225","title":"Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast.","journal":"Leukemia","pubDate":"2006 Sep","volume":"20","issue":"9","pages":"1496-510","authors":"Graux C et al","elocationId":"","link":null,"reference":"Graux C et al. Leukemia. 2006 Sep;20(9)1496-510.","abstract":null},{"pmid":"12066788","title":"Recurrent involvement of the MLL gene in adult T-lineage acute lymphoblastic leukemia.","journal":"Blood","pubDate":"2002 Jun 15","volume":"99","issue":"12","pages":"4647-9","authors":"Hayette S et al","elocationId":"","link":null,"reference":"Hayette S et al. Blood. 2002 Jun 15;99(12)4647-9.","abstract":null}]},{"id":15346,"uuid":"8ef2bf52-df10-4700-8558-3fdd85e8268d","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":695,"subtype":"Essential Thrombocythemia","code":"ET","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4352,"hugoSymbol":"MPL","oncogene":true,"grch37Isoform":"ENST00000372470","grch37RefSeq":"NM_005373.2","grch38Isoform":"ENST00000372470","grch38RefSeq":"NM_005373.2","geneAliases":["CD110","THCYT2","TPOR","MPLV","C-MPL","THPOR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4352,"hugoSymbol":"MPL","oncogene":true,"grch37Isoform":"ENST00000372470","grch37RefSeq":"NM_005373.2","grch38Isoform":"ENST00000372470","grch38RefSeq":"NM_005373.2","geneAliases":["CD110","THCYT2","TPOR","MPLV","C-MPL","THPOR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"29296692","title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia.","journal":"Blood advances","pubDate":"2016 Nov 29","volume":"1","issue":"1","pages":"21-30","authors":"Tefferi A et al","elocationId":"doi: 10.1182/bloodadvances.2016000216","link":null,"reference":"Tefferi A et al. Blood advances. 2016 Nov 29;1(1)21-30.","abstract":null},{"pmid":"16868251","title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.","journal":"Blood","pubDate":"2006 Nov 15","volume":"108","issue":"10","pages":"3472-6","authors":"Pardanani AD et al","elocationId":"","link":null,"reference":"Pardanani AD et al. Blood. 2006 Nov 15;108(10)3472-6.","abstract":null},{"pmid":"27069254","title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","journal":"Blood","pubDate":"2016 May 19","volume":"127","issue":"20","pages":"2391-405","authors":"Arber DA et al","elocationId":"doi: 10.1182/blood-2016-03-643544","link":null,"reference":"Arber DA et al. Blood. 2016 May 19;127(20)2391-405.","abstract":null},{"pmid":"25037629","title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.","journal":"Blood","pubDate":"2014 Oct 16","volume":"124","issue":"16","pages":"2507-13; quiz 2615","authors":"Tefferi A et al","elocationId":"doi: 10.1182/blood-2014-05-579136","link":null,"reference":"Tefferi A et al. Blood. 2014 Oct 16;124(16)2507-13; quiz 2615.","abstract":null},{"pmid":"20428194","title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.","journal":"Leukemia","pubDate":"2010 Jun","volume":"24","issue":"6","pages":"1128-38","authors":"Tefferi A","elocationId":"doi: 10.1038/leu.2010.69","link":null,"reference":"Tefferi A. Leukemia. 2010 Jun;24(6)1128-38.","abstract":null},{"pmid":"21220604","title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2011 Feb 10","volume":"29","issue":"5","pages":"573-82","authors":"Tefferi A et al","elocationId":"doi: 10.1200/JCO.2010.29.8711","link":null,"reference":"Tefferi A et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Feb 10;29(5)573-82.","abstract":null},{"pmid":"24791854","title":"Calreticulin mutations and long-term survival in essential thrombocythemia.","journal":"Leukemia","pubDate":"2014 Dec","volume":"28","issue":"12","pages":"2300-3","authors":"Tefferi A et al","elocationId":"doi: 10.1038/leu.2014.148","link":null,"reference":"Tefferi A et al. Leukemia. 2014 Dec;28(12)2300-3.","abstract":null}]},{"id":16243,"uuid":"0c89a9a2-15ac-401c-b295-c933d12c224d","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":534,"subtype":"Lymphoplasmacytic Lymphoma","code":"LPL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4615,"hugoSymbol":"MYD88","oncogene":true,"grch37Isoform":"ENST00000396334","grch37RefSeq":"NM_002468.4","grch38Isoform":"ENST00000396334","grch38RefSeq":"NM_002468.4","geneAliases":["MYD88D","IMD68"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4615,"hugoSymbol":"MYD88","oncogene":true,"grch37Isoform":"ENST00000396334","grch37RefSeq":"NM_002468.4","grch38Isoform":"ENST00000396334","grch38RefSeq":"NM_002468.4","geneAliases":["MYD88D","IMD68"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L265P","name":"L265P","refResidues":"L","proteinStart":265,"proteinEnd":265,"variantResidues":"P","referenceGenomes":["GRCh37"]},{"gene":{"entrezGeneId":4615,"hugoSymbol":"MYD88","oncogene":true,"grch37Isoform":"ENST00000396334","grch37RefSeq":"NM_002468.4","grch38Isoform":"ENST00000396334","grch38RefSeq":"NM_002468.4","geneAliases":["MYD88D","IMD68"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L252P","name":"L252P","refResidues":"L","proteinStart":252,"proteinEnd":252,"variantResidues":"P","referenceGenomes":["GRCh38"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25819228","title":"MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.","journal":"British journal of haematology","pubDate":"2015 Jun","volume":"169","issue":"6","pages":"795-803","authors":"Schmidt J et al","elocationId":"doi: 10.1111/bjh.13361","link":null,"reference":"Schmidt J et al. British journal of haematology. 2015 Jun;169(6)795-803.","abstract":null},{"pmid":"26454445","title":"The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing.","journal":"Virchows Archiv : an international journal of pathology","pubDate":"2016 Mar","volume":"468","issue":"3","pages":"259-75","authors":"Swerdlow SH et al","elocationId":"doi: 10.1007/s00428-015-1858-9","link":null,"reference":"Swerdlow SH et al. Virchows Archiv : an international journal of pathology. 2016 Mar;468(3)259-75.","abstract":null},{"pmid":"25216226","title":"MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.","journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","pubDate":"2015 Apr","volume":"28","issue":"4","pages":"564-74","authors":"Hamadeh F et al","elocationId":"doi: 10.1038/modpathol.2014.120","link":null,"reference":"Hamadeh F et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2015 Apr;28(4)564-74.","abstract":null},{"pmid":"23955458","title":"MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders.","journal":"American journal of clinical pathology","pubDate":"2013 Sep","volume":"140","issue":"3","pages":"387-94","authors":"Ondrejka SL et al","elocationId":"doi: 10.1309/AJCP10ZCLFZGYZIP","link":null,"reference":"Ondrejka SL et al. American journal of clinical pathology. 2013 Sep;140(3)387-94.","abstract":null},{"pmid":"24553177","title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.","journal":"Blood","pubDate":"2014 May 1","volume":"123","issue":"18","pages":"2791-6","authors":"Treon SP et al","elocationId":"doi: 10.1182/blood-2014-01-550905","link":null,"reference":"Treon SP et al. Blood. 2014 May 1;123(18)2791-6.","abstract":null},{"pmid":"24366360","title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.","journal":"Blood","pubDate":"2014 Mar 13","volume":"123","issue":"11","pages":"1637-46","authors":"Hunter ZR et al","elocationId":"doi: 10.1182/blood-2013-09-525808","link":null,"reference":"Hunter ZR et al. Blood. 2014 Mar 13;123(11)1637-46.","abstract":null},{"pmid":"23355535","title":"Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.","journal":"Blood","pubDate":"2013 Mar 28","volume":"121","issue":"13","pages":"2522-8","authors":"Varettoni M et al","elocationId":"doi: 10.1182/blood-2012-09-457101","link":null,"reference":"Varettoni M et al. Blood. 2013 Mar 28;121(13)2522-8.","abstract":null},{"pmid":"22931316","title":"MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.","journal":"The New England journal of medicine","pubDate":"2012 Aug 30","volume":"367","issue":"9","pages":"826-33","authors":"Treon SP et al","elocationId":"doi: 10.1056/NEJMoa1200710","link":null,"reference":"Treon SP et al. The New England journal of medicine. 2012 Aug 30;367(9)826-33.","abstract":null},{"pmid":"26244327","title":"MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia.","journal":"The New England journal of medicine","pubDate":"2015 Aug 6","volume":"373","issue":"6","pages":"584-6","authors":"Treon SP et al","elocationId":"doi: 10.1056/NEJMc1506192","link":null,"reference":"Treon SP et al. The New England journal of medicine. 2015 Aug 6;373(6)584-6.","abstract":null}]},{"id":11891,"uuid":"774dcf7b-323d-4f22-b7be-c8704e153ef3","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":10320,"hugoSymbol":"IKZF1","oncogene":false,"grch37Isoform":"ENST00000331340","grch37RefSeq":"ENST00000331340","grch38Isoform":"ENST00000331340","grch38RefSeq":"ENST00000331340","geneAliases":["CVID13","IKAROS","PRO0758","LyF-1","LYF1","Hs.54452","ZNFN1A1","IK1","PPP1R92"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":10320,"hugoSymbol":"IKZF1","oncogene":false,"grch37Isoform":"ENST00000331340","grch37RefSeq":"ENST00000331340","grch38Isoform":"ENST00000331340","grch38RefSeq":"ENST00000331340","geneAliases":["CVID13","IKAROS","PRO0758","LyF-1","LYF1","Hs.54452","ZNFN1A1","IK1","PPP1R92"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Deletion","name":"Deletion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23065506","title":"Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia.","journal":"Haematologica","pubDate":"2013 Apr","volume":"98","issue":"4","pages":"597-601","authors":"Caye A et al","elocationId":"doi: 10.3324/haematol.2012.073965","link":null,"reference":"Caye A et al. Haematologica. 2013 Apr;98(4)597-601.","abstract":null},{"pmid":"18408710","title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.","journal":"Nature","pubDate":"2008 May 1","volume":"453","issue":"7191","pages":"110-4","authors":"Mullighan CG et al","elocationId":"doi: 10.1038/nature06866","link":null,"reference":"Mullighan CG et al. Nature. 2008 May 1;453(7191)110-4.","abstract":null},{"pmid":"19589926","title":"Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP).","journal":"Blood","pubDate":"2009 Sep 3","volume":"114","issue":"10","pages":"2159-67","authors":"Iacobucci I et al","elocationId":"doi: 10.1182/blood-2008-08-173963","link":null,"reference":"Iacobucci I et al. Blood. 2009 Sep 3;114(10)2159-67.","abstract":null},{"pmid":"19129520","title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.","journal":"The New England journal of medicine","pubDate":"2009 Jan 29","volume":"360","issue":"5","pages":"470-80","authors":"Mullighan CG et al","elocationId":"doi: 10.1056/NEJMoa0808253","link":null,"reference":"Mullighan CG et al. The New England journal of medicine. 2009 Jan 29;360(5)470-80.","abstract":null}]},{"id":15348,"uuid":"7efea487-c7c4-4bff-8265-e60618d19c63","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":831,"subtype":"Myeloproliferative Neoplasms, Unclassifiable","code":"MPNU","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4352,"hugoSymbol":"MPL","oncogene":true,"grch37Isoform":"ENST00000372470","grch37RefSeq":"NM_005373.2","grch38Isoform":"ENST00000372470","grch38RefSeq":"NM_005373.2","geneAliases":["CD110","THCYT2","TPOR","MPLV","C-MPL","THPOR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4352,"hugoSymbol":"MPL","oncogene":true,"grch37Isoform":"ENST00000372470","grch37RefSeq":"NM_005373.2","grch38Isoform":"ENST00000372470","grch38RefSeq":"NM_005373.2","geneAliases":["CD110","THCYT2","TPOR","MPLV","C-MPL","THPOR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25873496","title":"CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.","journal":"American journal of clinical pathology","pubDate":"2015 May","volume":"143","issue":"5","pages":"635-44","authors":"Kim SY et al","elocationId":"doi: 10.1309/AJCPUAAC16LIWZMM","link":null,"reference":"Kim SY et al. American journal of clinical pathology. 2015 May;143(5)635-44.","abstract":null}]},{"id":21365,"uuid":"614a4870-3f2a-4e08-8e9e-52e6d663777c","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25957392","title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.","journal":"Blood","pubDate":"2015 Jul 9","volume":"126","issue":"2","pages":"233-41","authors":"Malcovati L et al","elocationId":"doi: 10.1182/blood-2015-03-633537","link":null,"reference":"Malcovati L et al. Blood. 2015 Jul 9;126(2)233-41.","abstract":null}]},{"id":11765,"uuid":"a5beabfc-8391-4d9b-87ee-a514d6ec4547","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3417,"hugoSymbol":"IDH1","oncogene":true,"grch37Isoform":"ENST00000345146","grch37RefSeq":"NM_005896.2","grch38Isoform":"ENST00000345146","grch38RefSeq":"NM_005896.2","geneAliases":["HEL-216","IDPC","IDCD","HEL-S-26","PICD"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3417,"hugoSymbol":"IDH1","oncogene":true,"grch37Isoform":"ENST00000345146","grch37RefSeq":"NM_005896.2","grch38Isoform":"ENST00000345146","grch38RefSeq":"NM_005896.2","geneAliases":["HEL-216","IDPC","IDCD","HEL-S-26","PICD"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"R132","name":"R132","refResidues":"R","proteinStart":132,"proteinEnd":132,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"26228814","title":"IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression.","journal":"Leukemia","pubDate":"2016 Apr","volume":"30","issue":"4","pages":"980-4","authors":"DiNardo CD et al","elocationId":"doi: 10.1038/leu.2015.211","link":null,"reference":"DiNardo CD et al. Leukemia. 2016 Apr;30(4)980-4.","abstract":null},{"pmid":"21714648","title":"Clinical effect of point mutations in myelodysplastic syndromes.","journal":"The New England journal of medicine","pubDate":"2011 Jun 30","volume":"364","issue":"26","pages":"2496-506","authors":"Bejar R et al","elocationId":"doi: 10.1056/NEJMoa1013343","link":null,"reference":"Bejar R et al. The New England journal of medicine. 2011 Jun 30;364(26)2496-506.","abstract":null},{"pmid":"22389253","title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.","journal":"Blood","pubDate":"2012 Apr 12","volume":"119","issue":"15","pages":"3578-84","authors":"Thol F et al","elocationId":"doi: 10.1182/blood-2011-12-399337","link":null,"reference":"Thol F et al. Blood. 2012 Apr 12;119(15)3578-84.","abstract":null},{"pmid":"24030381","title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes.","journal":"Blood","pubDate":"2013 Nov 21","volume":"122","issue":"22","pages":"3616-27; quiz 3699","authors":"Papaemmanuil E et al","elocationId":"doi: 10.1182/blood-2013-08-518886","link":null,"reference":"Papaemmanuil E et al. Blood. 2013 Nov 21;122(22)3616-27; quiz 3699.","abstract":null},{"pmid":"25465125","title":"The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.","journal":"Leukemia research","pubDate":"2015 Jan","volume":"39","issue":"1","pages":"6-17","authors":"Zhang L et al","elocationId":"doi: 10.1016/j.leukres.2014.10.006","link":null,"reference":"Zhang L et al. Leukemia research. 2015 Jan;39(1)6-17.","abstract":null},{"pmid":"20962861","title":"A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders.","journal":"Leukemia","pubDate":"2011 Jan","volume":"25","issue":"1","pages":"184-6","authors":"Yoshida K et al","elocationId":"doi: 10.1038/leu.2010.241","link":null,"reference":"Yoshida K et al. Leukemia. 2011 Jan;25(1)184-6.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null}]},{"id":15350,"uuid":"d3b145a4-f6bd-43d0-b3da-15b9bc66f6e9","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":632,"subtype":"Primary Myelofibrosis","code":"PMF","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4352,"hugoSymbol":"MPL","oncogene":true,"grch37Isoform":"ENST00000372470","grch37RefSeq":"NM_005373.2","grch38Isoform":"ENST00000372470","grch38RefSeq":"NM_005373.2","geneAliases":["CD110","THCYT2","TPOR","MPLV","C-MPL","THPOR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4352,"hugoSymbol":"MPL","oncogene":true,"grch37Isoform":"ENST00000372470","grch37RefSeq":"NM_005373.2","grch38Isoform":"ENST00000372470","grch38RefSeq":"NM_005373.2","geneAliases":["CD110","THCYT2","TPOR","MPLV","C-MPL","THPOR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"16868251","title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.","journal":"Blood","pubDate":"2006 Nov 15","volume":"108","issue":"10","pages":"3472-6","authors":"Pardanani AD et al","elocationId":"","link":null,"reference":"Pardanani AD et al. Blood. 2006 Nov 15;108(10)3472-6.","abstract":null},{"pmid":"15837627","title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","journal":"Cancer cell","pubDate":"2005 Apr","volume":"7","issue":"4","pages":"387-97","authors":"Levine RL et al","elocationId":"","link":null,"reference":"Levine RL et al. Cancer cell. 2005 Apr;7(4)387-97.","abstract":null},{"pmid":"27069254","title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","journal":"Blood","pubDate":"2016 May 19","volume":"127","issue":"20","pages":"2391-405","authors":"Arber DA et al","elocationId":"doi: 10.1182/blood-2016-03-643544","link":null,"reference":"Arber DA et al. Blood. 2016 May 19;127(20)2391-405.","abstract":null},{"pmid":"25037629","title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.","journal":"Blood","pubDate":"2014 Oct 16","volume":"124","issue":"16","pages":"2507-13; quiz 2615","authors":"Tefferi A et al","elocationId":"doi: 10.1182/blood-2014-05-579136","link":null,"reference":"Tefferi A et al. Blood. 2014 Oct 16;124(16)2507-13; quiz 2615.","abstract":null},{"pmid":"20428194","title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.","journal":"Leukemia","pubDate":"2010 Jun","volume":"24","issue":"6","pages":"1128-38","authors":"Tefferi A","elocationId":"doi: 10.1038/leu.2010.69","link":null,"reference":"Tefferi A. Leukemia. 2010 Jun;24(6)1128-38.","abstract":null},{"pmid":"16834459","title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.","journal":"PLoS medicine","pubDate":"2006 Jul","volume":"3","issue":"7","pages":"e270","authors":"Pikman Y et al","elocationId":"","link":null,"reference":"Pikman Y et al. PLoS medicine. 2006 Jul;3(7)e270.","abstract":null},{"pmid":"21220604","title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2011 Feb 10","volume":"29","issue":"5","pages":"573-82","authors":"Tefferi A et al","elocationId":"doi: 10.1200/JCO.2010.29.8711","link":null,"reference":"Tefferi A et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Feb 10;29(5)573-82.","abstract":null},{"pmid":"24986690","title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.","journal":"Blood","pubDate":"2014 Aug 14","volume":"124","issue":"7","pages":"1062-9","authors":"Rumi E et al","elocationId":"doi: 10.1182/blood-2014-05-578435","link":null,"reference":"Rumi E et al. Blood. 2014 Aug 14;124(7)1062-9.","abstract":null}]},{"id":15352,"uuid":"54ef472c-7e9b-4661-8866-1b43e192931f","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":801,"subtype":"MDS/MPN with Ring Sideroblasts and Thrombocytosis","code":"MDSMPNRST","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4352,"hugoSymbol":"MPL","oncogene":true,"grch37Isoform":"ENST00000372470","grch37RefSeq":"NM_005373.2","grch38Isoform":"ENST00000372470","grch38RefSeq":"NM_005373.2","geneAliases":["CD110","THCYT2","TPOR","MPLV","C-MPL","THPOR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4352,"hugoSymbol":"MPL","oncogene":true,"grch37Isoform":"ENST00000372470","grch37RefSeq":"NM_005373.2","grch38Isoform":"ENST00000372470","grch38RefSeq":"NM_005373.2","geneAliases":["CD110","THCYT2","TPOR","MPLV","C-MPL","THPOR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"W515","name":"W515","refResidues":"W","proteinStart":515,"proteinEnd":515,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"19692701","title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.","journal":"Blood","pubDate":"2009 Oct 22","volume":"114","issue":"17","pages":"3538-45","authors":"Malcovati L et al","elocationId":"doi: 10.1182/blood-2009-05-222331","link":null,"reference":"Malcovati L et al. Blood. 2009 Oct 22;114(17)3538-45.","abstract":null},{"pmid":"22532522","title":"Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.","journal":"Haematologica","pubDate":"2012 Jul","volume":"97","issue":"7","pages":"1036-41","authors":"Broseus J et al","elocationId":"doi: 10.3324/haematol.2011.053918","link":null,"reference":"Broseus J et al. Haematologica. 2012 Jul;97(7)1036-41.","abstract":null}]},{"id":21370,"uuid":"26f80ec1-23f2-4e0e-b22e-d4c8bc2e963a","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":267,"subtype":"MDS with Ring Sideroblasts","code":"MDSRS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22096241","title":"SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.","journal":"Blood","pubDate":"2012 Jan 12","volume":"119","issue":"2","pages":"569-72","authors":"Patnaik MM et al","elocationId":"doi: 10.1182/blood-2011-09-377994","link":null,"reference":"Patnaik MM et al. Blood. 2012 Jan 12;119(2)569-72.","abstract":null},{"pmid":"25957392","title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.","journal":"Blood","pubDate":"2015 Jul 9","volume":"126","issue":"2","pages":"233-41","authors":"Malcovati L et al","elocationId":"doi: 10.1182/blood-2015-03-633537","link":null,"reference":"Malcovati L et al. Blood. 2015 Jul 9;126(2)233-41.","abstract":null}]},{"id":21243,"uuid":"6879e875-d3b3-4764-bf73-94833b7fa7c0","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":835,"subtype":"Atypical Chronic Myeloid Leukemia, BCR-ABL1-","code":"ACML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":26040,"hugoSymbol":"SETBP1","oncogene":true,"grch37Isoform":"ENST00000282030","grch37RefSeq":"NM_015559.2","grch38Isoform":"ENST00000649279","grch38RefSeq":"NM_015559.2","geneAliases":["SEB","MRD29"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":26040,"hugoSymbol":"SETBP1","oncogene":true,"grch37Isoform":"ENST00000282030","grch37RefSeq":"NM_015559.2","grch38Isoform":"ENST00000649279","grch38RefSeq":"NM_015559.2","geneAliases":["SEB","MRD29"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23222956","title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.","journal":"Nature genetics","pubDate":"2013 Jan","volume":"45","issue":"1","pages":"18-24","authors":"Piazza R et al","elocationId":"doi: 10.1038/ng.2495","link":null,"reference":"Piazza R et al. Nature genetics. 2013 Jan;45(1)18-24.","abstract":null}]},{"id":21245,"uuid":"d3abef31-4bd3-451d-ad84-1a3cb48ee7f0","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":908,"subtype":"","code":"","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":0,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":26040,"hugoSymbol":"SETBP1","oncogene":true,"grch37Isoform":"ENST00000282030","grch37RefSeq":"NM_015559.2","grch38Isoform":"ENST00000649279","grch38RefSeq":"NM_015559.2","geneAliases":["SEB","MRD29"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":26040,"hugoSymbol":"SETBP1","oncogene":true,"grch37Isoform":"ENST00000282030","grch37RefSeq":"NM_015559.2","grch38Isoform":"ENST00000649279","grch38RefSeq":"NM_015559.2","geneAliases":["SEB","MRD29"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"I865","name":"I865","refResidues":"I","proteinStart":865,"proteinEnd":865,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":26040,"hugoSymbol":"SETBP1","oncogene":true,"grch37Isoform":"ENST00000282030","grch37RefSeq":"NM_015559.2","grch38Isoform":"ENST00000649279","grch38RefSeq":"NM_015559.2","geneAliases":["SEB","MRD29"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"S869","name":"S869","refResidues":"S","proteinStart":869,"proteinEnd":869,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":26040,"hugoSymbol":"SETBP1","oncogene":true,"grch37Isoform":"ENST00000282030","grch37RefSeq":"NM_015559.2","grch38Isoform":"ENST00000649279","grch38RefSeq":"NM_015559.2","geneAliases":["SEB","MRD29"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D868","name":"D868","refResidues":"D","proteinStart":868,"proteinEnd":868,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":26040,"hugoSymbol":"SETBP1","oncogene":true,"grch37Isoform":"ENST00000282030","grch37RefSeq":"NM_015559.2","grch38Isoform":"ENST00000649279","grch38RefSeq":"NM_015559.2","geneAliases":["SEB","MRD29"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"T864","name":"T864","refResidues":"T","proteinStart":864,"proteinEnd":864,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":26040,"hugoSymbol":"SETBP1","oncogene":true,"grch37Isoform":"ENST00000282030","grch37RefSeq":"NM_015559.2","grch38Isoform":"ENST00000649279","grch38RefSeq":"NM_015559.2","geneAliases":["SEB","MRD29"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"G870","name":"G870","refResidues":"G","proteinStart":870,"proteinEnd":870,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":26040,"hugoSymbol":"SETBP1","oncogene":true,"grch37Isoform":"ENST00000282030","grch37RefSeq":"NM_015559.2","grch38Isoform":"ENST00000649279","grch38RefSeq":"NM_015559.2","geneAliases":["SEB","MRD29"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"E858","name":"E858","refResidues":"E","proteinStart":858,"proteinEnd":858,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23648668","title":"SETBP1 mutation analysis in 944 patients with MDS and AML.","journal":"Leukemia","pubDate":"2013 Oct","volume":"27","issue":"10","pages":"2072-5","authors":"Thol F et al","elocationId":"doi: 10.1038/leu.2013.145","link":null,"reference":"Thol F et al. Leukemia. 2013 Oct;27(10)2072-5.","abstract":null},{"pmid":"24127063","title":"Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.","journal":"American journal of hematology","pubDate":"2014 Feb","volume":"89","issue":"2","pages":"181-6","authors":"Hou HA et al","elocationId":"doi: 10.1002/ajh.23611","link":null,"reference":"Hou HA et al. American journal of hematology. 2014 Feb;89(2)181-6.","abstract":null},{"pmid":"23832012","title":"Somatic SETBP1 mutations in myeloid malignancies.","journal":"Nature genetics","pubDate":"2013 Aug","volume":"45","issue":"8","pages":"942-6","authors":"Makishima H et al","elocationId":"doi: 10.1038/ng.2696","link":null,"reference":"Makishima H et al. Nature genetics. 2013 Aug;45(8)942-6.","abstract":null},{"pmid":"23889083","title":"Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.","journal":"British journal of haematology","pubDate":"2013 Oct","volume":"163","issue":"2","pages":"235-9","authors":"Fernandez-Mercado M et al","elocationId":"doi: 10.1111/bjh.12491","link":null,"reference":"Fernandez-Mercado M et al. British journal of haematology. 2013 Oct;163(2)235-9.","abstract":null}]},{"id":21374,"uuid":"44f11893-c7ab-443b-8ac4-66f5912d4e74","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":801,"subtype":"MDS/MPN with Ring Sideroblasts and Thrombocytosis","code":"MDSMPNRST","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25957392","title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.","journal":"Blood","pubDate":"2015 Jul 9","volume":"126","issue":"2","pages":"233-41","authors":"Malcovati L et al","elocationId":"doi: 10.1182/blood-2015-03-633537","link":null,"reference":"Malcovati L et al. Blood. 2015 Jul 9;126(2)233-41.","abstract":null},{"pmid":"19692701","title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.","journal":"Blood","pubDate":"2009 Oct 22","volume":"114","issue":"17","pages":"3538-45","authors":"Malcovati L et al","elocationId":"doi: 10.1182/blood-2009-05-222331","link":null,"reference":"Malcovati L et al. Blood. 2009 Oct 22;114(17)3538-45.","abstract":null}]},{"id":21247,"uuid":"a70ecd1f-0113-4c0d-9900-8c2434ce1a5b","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":224,"subtype":"Chronic Myelomonocytic Leukemia","code":"CMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":26040,"hugoSymbol":"SETBP1","oncogene":true,"grch37Isoform":"ENST00000282030","grch37RefSeq":"NM_015559.2","grch38Isoform":"ENST00000649279","grch38RefSeq":"NM_015559.2","geneAliases":["SEB","MRD29"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":26040,"hugoSymbol":"SETBP1","oncogene":true,"grch37Isoform":"ENST00000282030","grch37RefSeq":"NM_015559.2","grch38Isoform":"ENST00000649279","grch38RefSeq":"NM_015559.2","geneAliases":["SEB","MRD29"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"I865","name":"I865","refResidues":"I","proteinStart":865,"proteinEnd":865,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":26040,"hugoSymbol":"SETBP1","oncogene":true,"grch37Isoform":"ENST00000282030","grch37RefSeq":"NM_015559.2","grch38Isoform":"ENST00000649279","grch38RefSeq":"NM_015559.2","geneAliases":["SEB","MRD29"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"S869","name":"S869","refResidues":"S","proteinStart":869,"proteinEnd":869,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":26040,"hugoSymbol":"SETBP1","oncogene":true,"grch37Isoform":"ENST00000282030","grch37RefSeq":"NM_015559.2","grch38Isoform":"ENST00000649279","grch38RefSeq":"NM_015559.2","geneAliases":["SEB","MRD29"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D868","name":"D868","refResidues":"D","proteinStart":868,"proteinEnd":868,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":26040,"hugoSymbol":"SETBP1","oncogene":true,"grch37Isoform":"ENST00000282030","grch37RefSeq":"NM_015559.2","grch38Isoform":"ENST00000649279","grch38RefSeq":"NM_015559.2","geneAliases":["SEB","MRD29"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"T864","name":"T864","refResidues":"T","proteinStart":864,"proteinEnd":864,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":26040,"hugoSymbol":"SETBP1","oncogene":true,"grch37Isoform":"ENST00000282030","grch37RefSeq":"NM_015559.2","grch38Isoform":"ENST00000649279","grch38RefSeq":"NM_015559.2","geneAliases":["SEB","MRD29"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"G870","name":"G870","refResidues":"G","proteinStart":870,"proteinEnd":870,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":26040,"hugoSymbol":"SETBP1","oncogene":true,"grch37Isoform":"ENST00000282030","grch37RefSeq":"NM_015559.2","grch38Isoform":"ENST00000649279","grch38RefSeq":"NM_015559.2","geneAliases":["SEB","MRD29"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"E858","name":"E858","refResidues":"E","proteinStart":858,"proteinEnd":858,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24695057","title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.","journal":"Leukemia","pubDate":"2014 Nov","volume":"28","issue":"11","pages":"2206-12","authors":"Patnaik MM et al","elocationId":"doi: 10.1038/leu.2014.125","link":null,"reference":"Patnaik MM et al. Leukemia. 2014 Nov;28(11)2206-12.","abstract":null}]},{"id":24320,"uuid":"a8463d0f-6e9c-48b6-a5d6-b87296ff0805","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8233,"hugoSymbol":"ZRSR2","oncogene":false,"grch37Isoform":"ENST00000307771","grch37RefSeq":"NM_005089.3","grch38Isoform":"ENST00000307771","grch38RefSeq":"NM_005089.3","geneAliases":["URP","ZC3H22","U2AF1-RS2","U2AF1RS2","U2AF1L2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":8233,"hugoSymbol":"ZRSR2","oncogene":false,"grch37Isoform":"ENST00000307771","grch37RefSeq":"NM_005089.3","grch38Isoform":"ENST00000307771","grch38RefSeq":"NM_005089.3","geneAliases":["URP","ZC3H22","U2AF1-RS2","U2AF1RS2","U2AF1L2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22389253","title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.","journal":"Blood","pubDate":"2012 Apr 12","volume":"119","issue":"15","pages":"3578-84","authors":"Thol F et al","elocationId":"doi: 10.1182/blood-2011-12-399337","link":null,"reference":"Thol F et al. Blood. 2012 Apr 12;119(15)3578-84.","abstract":null},{"pmid":"21909114","title":"Frequent pathway mutations of splicing machinery in myelodysplasia.","journal":"Nature","pubDate":"2011 Sep 11","volume":"478","issue":"7367","pages":"64-9","authors":"Yoshida K et al","elocationId":"doi: 10.1038/nature10496","link":null,"reference":"Yoshida K et al. Nature. 2011 Sep 11;478(7367)64-9.","abstract":null},{"pmid":"24030381","title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes.","journal":"Blood","pubDate":"2013 Nov 21","volume":"122","issue":"22","pages":"3616-27; quiz 3699","authors":"Papaemmanuil E et al","elocationId":"doi: 10.1182/blood-2013-08-518886","link":null,"reference":"Papaemmanuil E et al. Blood. 2013 Nov 21;122(22)3616-27; quiz 3699.","abstract":null},{"pmid":"25465125","title":"The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.","journal":"Leukemia research","pubDate":"2015 Jan","volume":"39","issue":"1","pages":"6-17","authors":"Zhang L et al","elocationId":"doi: 10.1016/j.leukres.2014.10.006","link":null,"reference":"Zhang L et al. Leukemia research. 2015 Jan;39(1)6-17.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null}]},{"id":1921,"uuid":"805f0b84-999e-4d0c-b4fe-fe925e35abd9","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":531,"subtype":"High-Grade B-Cell Lymphoma, with MYC and BCL2 and/or BCL6 Rearrangements","code":"HGBCLMYCBCL2","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":604,"hugoSymbol":"BCL6","oncogene":true,"grch37Isoform":"ENST00000232014","grch37RefSeq":"NM_001706.4","grch38Isoform":"ENST00000232014","grch38RefSeq":"NM_001706.4","geneAliases":["BCL5","ZBTB27","ZNF51","BCL6A","LAZ3"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":604,"hugoSymbol":"BCL6","oncogene":true,"grch37Isoform":"ENST00000232014","grch37RefSeq":"NM_001706.4","grch38Isoform":"ENST00000232014","grch38RefSeq":"NM_001706.4","geneAliases":["BCL5","ZBTB27","ZNF51","BCL6A","LAZ3"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27821509","title":"Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.","journal":"Blood","pubDate":"2017 Jan 19","volume":"129","issue":"3","pages":"280-288","authors":"Sesques P et al","elocationId":"doi: 10.1182/blood-2016-02-636316","link":null,"reference":"Sesques P et al. Blood. 2017 Jan 19;129(3)280-288.","abstract":null},{"pmid":"26980727","title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","journal":"Blood","pubDate":"2016 May 19","volume":"127","issue":"20","pages":"2375-90","authors":"Swerdlow SH et al","elocationId":"doi: 10.1182/blood-2016-01-643569","link":null,"reference":"Swerdlow SH et al. Blood. 2016 May 19;127(20)2375-90.","abstract":null}]},{"id":5890,"uuid":"1260a1a4-6905-4ea4-96bc-e5d750f5100b","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1387,"hugoSymbol":"CREBBP","oncogene":false,"grch37Isoform":"ENST00000262367","grch37RefSeq":"NM_004380.2","grch38Isoform":"ENST00000262367","grch38RefSeq":"NM_004380.2","geneAliases":["MKHK1","KAT3A","RSTS","RSTS1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":1387,"hugoSymbol":"CREBBP","oncogene":false,"grch37Isoform":"ENST00000262367","grch37RefSeq":"NM_004380.2","grch38Isoform":"ENST00000262367","grch38RefSeq":"NM_004380.2","geneAliases":["MKHK1","KAT3A","RSTS","RSTS1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"KAT6A-CREBBP Fusion","name":"KAT6A-CREBBP Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"7596149","title":"A distinct subtype of M4/M5 acute myeloblastic leukemia (AML) associated with t(8:16)(p11:p13), in a patient with the variant t(8:19)(p11:q13)--case report and review of the literature.","journal":"Leukemia research","pubDate":"1995 Jun","volume":"19","issue":"6","pages":"367-79","authors":"Stark B et al","elocationId":"","link":null,"reference":"Stark B et al. Leukemia research. 1995 Jun;19(6)367-79.","abstract":null},{"pmid":"23102703","title":"Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis.","journal":"Leukemia research","pubDate":"2013 Jan","volume":"37","issue":"1","pages":"32-6","authors":"Diab A et al","elocationId":"doi: 10.1016/j.leukres.2012.08.025","link":null,"reference":"Diab A et al. Leukemia research. 2013 Jan;37(1)32-6.","abstract":null},{"pmid":"8782817","title":"The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein.","journal":"Nature genetics","pubDate":"1996 Sep","volume":"14","issue":"1","pages":"33-41","authors":"Borrow J et al","elocationId":"","link":null,"reference":"Borrow J et al. Nature genetics. 1996 Sep;14(1)33-41.","abstract":null}]},{"id":24323,"uuid":"484e4826-11b1-4321-b116-09b8b7a5e0ca","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":267,"subtype":"MDS with Ring Sideroblasts","code":"MDSRS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8233,"hugoSymbol":"ZRSR2","oncogene":false,"grch37Isoform":"ENST00000307771","grch37RefSeq":"NM_005089.3","grch38Isoform":"ENST00000307771","grch38RefSeq":"NM_005089.3","geneAliases":["URP","ZC3H22","U2AF1-RS2","U2AF1RS2","U2AF1L2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":8233,"hugoSymbol":"ZRSR2","oncogene":false,"grch37Isoform":"ENST00000307771","grch37RefSeq":"NM_005089.3","grch38Isoform":"ENST00000307771","grch38RefSeq":"NM_005089.3","geneAliases":["URP","ZC3H22","U2AF1-RS2","U2AF1RS2","U2AF1L2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25957392","title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.","journal":"Blood","pubDate":"2015 Jul 9","volume":"126","issue":"2","pages":"233-41","authors":"Malcovati L et al","elocationId":"doi: 10.1182/blood-2015-03-633537","link":null,"reference":"Malcovati L et al. Blood. 2015 Jul 9;126(2)233-41.","abstract":null},{"pmid":"21909114","title":"Frequent pathway mutations of splicing machinery in myelodysplasia.","journal":"Nature","pubDate":"2011 Sep 11","volume":"478","issue":"7367","pages":"64-9","authors":"Yoshida K et al","elocationId":"doi: 10.1038/nature10496","link":null,"reference":"Yoshida K et al. Nature. 2011 Sep 11;478(7367)64-9.","abstract":null}]},{"id":13188,"uuid":"4801619c-f78f-4084-bf44-18b77cf4e669","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":692,"subtype":"Juvenile Myelomonocytic Leukemia","code":"JMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23832011","title":"Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.","journal":"Nature genetics","pubDate":"2013 Aug","volume":"45","issue":"8","pages":"937-41","authors":"Sakaguchi H et al","elocationId":"doi: 10.1038/ng.2698","link":null,"reference":"Sakaguchi H et al. Nature genetics. 2013 Aug;45(8)937-41.","abstract":null},{"pmid":"10049057","title":"RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML).","journal":"Leukemia","pubDate":"1999 Jan","volume":"13","issue":"1","pages":"32-7","authors":"Flotho C et al","elocationId":"","link":null,"reference":"Flotho C et al. Leukemia. 1999 Jan;13(1)32-7.","abstract":null},{"pmid":"26457647","title":"The genomic landscape of juvenile myelomonocytic leukemia.","journal":"Nature genetics","pubDate":"2015 Nov","volume":"47","issue":"11","pages":"1326-1333","authors":"Stieglitz E et al","elocationId":"doi: 10.1038/ng.3400","link":null,"reference":"Stieglitz E et al. Nature genetics. 2015 Nov;47(11)1326-1333.","abstract":null},{"pmid":"12717436","title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.","journal":"Nature genetics","pubDate":"2003 Jun","volume":"34","issue":"2","pages":"148-50","authors":"Tartaglia M et al","elocationId":"","link":null,"reference":"Tartaglia M et al. Nature genetics. 2003 Jun;34(2)148-50.","abstract":null}]},{"id":9734,"uuid":"50d5c5b7-b9d7-4696-87fb-35283e0014d2","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2120,"hugoSymbol":"ETV6","oncogene":false,"grch37Isoform":"ENST00000396373","grch37RefSeq":"NM_001987.4","grch38Isoform":"ENST00000396373","grch38RefSeq":"NM_001987.4","geneAliases":["THC5","TEL/ABL","TEL"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":2120,"hugoSymbol":"ETV6","oncogene":false,"grch37Isoform":"ENST00000396373","grch37RefSeq":"NM_001987.4","grch38Isoform":"ENST00000396373","grch38RefSeq":"NM_001987.4","geneAliases":["THC5","TEL/ABL","TEL"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24997145","title":"ETV6 mutation in a cohort of 970 patients with hematologic malignancies.","journal":"Haematologica","pubDate":"2014 Oct","volume":"99","issue":"10","pages":"e176-8","authors":"Wang Q et al","elocationId":"doi: 10.3324/haematol.2014.104406","link":null,"reference":"Wang Q et al. Haematologica. 2014 Oct;99(10)e176-8.","abstract":null},{"pmid":"21714648","title":"Clinical effect of point mutations in myelodysplastic syndromes.","journal":"The New England journal of medicine","pubDate":"2011 Jun 30","volume":"364","issue":"26","pages":"2496-506","authors":"Bejar R et al","elocationId":"doi: 10.1056/NEJMoa1013343","link":null,"reference":"Bejar R et al. The New England journal of medicine. 2011 Jun 30;364(26)2496-506.","abstract":null}]},{"id":12167,"uuid":"82281e89-23ca-4c18-ba0c-da85192ef041","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":806,"subtype":"Polycythemia Vera","code":"PV","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"D505_F547del","name":"Exon 12 deletion","refResidues":null,"proteinStart":505,"proteinEnd":547,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"D505_F547ins","name":"Exon 12 insertion","refResidues":null,"proteinStart":505,"proteinEnd":547,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"D505_F547mis","name":"Exon 12 missense mutation","refResidues":null,"proteinStart":505,"proteinEnd":547,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"29296692","title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia.","journal":"Blood advances","pubDate":"2016 Nov 29","volume":"1","issue":"1","pages":"21-30","authors":"Tefferi A et al","elocationId":"doi: 10.1182/bloodadvances.2016000216","link":null,"reference":"Tefferi A et al. Blood advances. 2016 Nov 29;1(1)21-30.","abstract":null},{"pmid":"17597810","title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.","journal":"Leukemia","pubDate":"2007 Sep","volume":"21","issue":"9","pages":"1960-3","authors":"Pardanani A et al","elocationId":"","link":null,"reference":"Pardanani A et al. Leukemia. 2007 Sep;21(9)1960-3.","abstract":null},{"pmid":"17267906","title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.","journal":"The New England journal of medicine","pubDate":"2007 Feb 1","volume":"356","issue":"5","pages":"459-68","authors":"Scott LM et al","elocationId":"","link":null,"reference":"Scott LM et al. The New England journal of medicine. 2007 Feb 1;356(5)459-68.","abstract":null},{"pmid":"27069254","title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","journal":"Blood","pubDate":"2016 May 19","volume":"127","issue":"20","pages":"2391-405","authors":"Arber DA et al","elocationId":"doi: 10.1182/blood-2016-03-643544","link":null,"reference":"Arber DA et al. Blood. 2016 May 19;127(20)2391-405.","abstract":null},{"pmid":"17984312","title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.","journal":"Blood","pubDate":"2008 Feb 1","volume":"111","issue":"3","pages":"1686-9","authors":"Pietra D et al","elocationId":"","link":null,"reference":"Pietra D et al. Blood. 2008 Feb 1;111(3)1686-9.","abstract":null},{"pmid":"20428194","title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.","journal":"Leukemia","pubDate":"2010 Jun","volume":"24","issue":"6","pages":"1128-38","authors":"Tefferi A","elocationId":"doi: 10.1038/leu.2010.69","link":null,"reference":"Tefferi A. Leukemia. 2010 Jun;24(6)1128-38.","abstract":null},{"pmid":"20472853","title":"Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.","journal":"American journal of clinical pathology","pubDate":"2010 Jun","volume":"133","issue":"6","pages":"942-8","authors":"Lakey MA et al","elocationId":"doi: 10.1309/AJCP3Z2AKUWRGTNM","link":null,"reference":"Lakey MA et al. American journal of clinical pathology. 2010 Jun;133(6)942-8.","abstract":null}]},{"id":13192,"uuid":"4a6c7be9-9476-4e79-a804-9c3272c41558","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22934674","title":"Molecular pathophysiology of myelodysplastic syndromes.","journal":"Annual review of pathology","pubDate":"2013 Jan 24","volume":"8","issue":"","pages":"21-47","authors":"Lindsley RC et al","elocationId":"doi: 10.1146/annurev-pathol-011811-132436","link":null,"reference":"Lindsley RC et al. Annual review of pathology. 2013 Jan 24;8()21-47.","abstract":null},{"pmid":"23512829","title":"Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.","journal":"American journal of hematology","pubDate":"2013 May","volume":"88","issue":"5","pages":"365-9","authors":"Al-Kali A et al","elocationId":"doi: 10.1002/ajh.23410","link":null,"reference":"Al-Kali A et al. American journal of hematology. 2013 May;88(5)365-9.","abstract":null}]},{"id":23949,"uuid":"8356dc03-8190-4e69-98e5-246e780a90e0","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7307,"hugoSymbol":"U2AF1","oncogene":true,"grch37Isoform":"ENST00000291552","grch37RefSeq":"NM_006758.2","grch38Isoform":"ENST00000291552","grch38RefSeq":"NM_006758.2","geneAliases":["FP793","U2AFBP","RN","RNU2AF1","U2AF35"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":7307,"hugoSymbol":"U2AF1","oncogene":true,"grch37Isoform":"ENST00000291552","grch37RefSeq":"NM_006758.2","grch38Isoform":"ENST00000291552","grch38RefSeq":"NM_006758.2","geneAliases":["FP793","U2AFBP","RN","RNU2AF1","U2AF35"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22389253","title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.","journal":"Blood","pubDate":"2012 Apr 12","volume":"119","issue":"15","pages":"3578-84","authors":"Thol F et al","elocationId":"doi: 10.1182/blood-2011-12-399337","link":null,"reference":"Thol F et al. Blood. 2012 Apr 12;119(15)3578-84.","abstract":null},{"pmid":"24030381","title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes.","journal":"Blood","pubDate":"2013 Nov 21","volume":"122","issue":"22","pages":"3616-27; quiz 3699","authors":"Papaemmanuil E et al","elocationId":"doi: 10.1182/blood-2013-08-518886","link":null,"reference":"Papaemmanuil E et al. Blood. 2013 Nov 21;122(22)3616-27; quiz 3699.","abstract":null},{"pmid":"25465125","title":"The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.","journal":"Leukemia research","pubDate":"2015 Jan","volume":"39","issue":"1","pages":"6-17","authors":"Zhang L et al","elocationId":"doi: 10.1016/j.leukres.2014.10.006","link":null,"reference":"Zhang L et al. Leukemia research. 2015 Jan;39(1)6-17.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null},{"pmid":"22158538","title":"Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.","journal":"Nature genetics","pubDate":"2011 Dec 11","volume":"44","issue":"1","pages":"53-7","authors":"Graubert TA et al","elocationId":"doi: 10.1038/ng.1031","link":null,"reference":"Graubert TA et al. Nature genetics. 2011 Dec 11;44(1)53-7.","abstract":null}]},{"id":16782,"uuid":"4bd101b5-e25a-4ffa-a4b5-c389cf9efd79","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":784,"subtype":"Myeloid Sarcoma","code":"MS","color":"LightSalmon","mainType":"Leukemia","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4869,"hugoSymbol":"NPM1","oncogene":false,"grch37Isoform":"ENST00000296930","grch37RefSeq":"NM_002520.6","grch38Isoform":"ENST00000296930","grch38RefSeq":"NM_002520.6","geneAliases":["B23","NPM"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4869,"hugoSymbol":"NPM1","oncogene":false,"grch37Isoform":"ENST00000296930","grch37RefSeq":"NM_002520.6","grch38Isoform":"ENST00000296930","grch38RefSeq":"NM_002520.6","geneAliases":["B23","NPM"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25787914","title":"Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma.","journal":"Leukemia","pubDate":"2015 Oct","volume":"29","issue":"10","pages":"2113-6","authors":"Li Z et al","elocationId":"doi: 10.1038/leu.2015.81","link":null,"reference":"Li Z et al. Leukemia. 2015 Oct;29(10)2113-6.","abstract":null},{"pmid":"15659725","title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.","journal":"The New England journal of medicine","pubDate":"2005 Jan 20","volume":"352","issue":"3","pages":"254-66","authors":"Falini B et al","elocationId":"","link":null,"reference":"Falini B et al. The New England journal of medicine. 2005 Jan 20;352(3)254-66.","abstract":null},{"pmid":"28633614","title":"Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing.","journal":"Leukemia & lymphoma","pubDate":"2018 Feb","volume":"59","issue":"2","pages":"501-504","authors":"Kashofer K et al","elocationId":"doi: 10.1080/10428194.2017.1339879","link":null,"reference":"Kashofer K et al. Leukemia & lymphoma. 2018 Feb;59(2)501-504.","abstract":null},{"pmid":"17443224","title":"Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas.","journal":"Leukemia","pubDate":"2007 Jul","volume":"21","issue":"7","pages":"1566-70","authors":"Falini B et al","elocationId":"","link":null,"reference":"Falini B et al. Leukemia. 2007 Jul;21(7)1566-70.","abstract":null}]},{"id":23952,"uuid":"66c88d76-ff4f-4c33-9901-4b374bba12b4","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":267,"subtype":"MDS with Ring Sideroblasts","code":"MDSRS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7307,"hugoSymbol":"U2AF1","oncogene":true,"grch37Isoform":"ENST00000291552","grch37RefSeq":"NM_006758.2","grch38Isoform":"ENST00000291552","grch38RefSeq":"NM_006758.2","geneAliases":["FP793","U2AFBP","RN","RNU2AF1","U2AF35"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":7307,"hugoSymbol":"U2AF1","oncogene":true,"grch37Isoform":"ENST00000291552","grch37RefSeq":"NM_006758.2","grch38Isoform":"ENST00000291552","grch38RefSeq":"NM_006758.2","geneAliases":["FP793","U2AFBP","RN","RNU2AF1","U2AF35"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25957392","title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.","journal":"Blood","pubDate":"2015 Jul 9","volume":"126","issue":"2","pages":"233-41","authors":"Malcovati L et al","elocationId":"doi: 10.1182/blood-2015-03-633537","link":null,"reference":"Malcovati L et al. Blood. 2015 Jul 9;126(2)233-41.","abstract":null},{"pmid":"21909114","title":"Frequent pathway mutations of splicing machinery in myelodysplasia.","journal":"Nature","pubDate":"2011 Sep 11","volume":"478","issue":"7367","pages":"64-9","authors":"Yoshida K et al","elocationId":"doi: 10.1038/nature10496","link":null,"reference":"Yoshida K et al. Nature. 2011 Sep 11;478(7367)64-9.","abstract":null}]},{"id":13458,"uuid":"8c9ddbc7-f007-44d9-8473-b9fedeafe875","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":293,"subtype":"T-Lymphoblastic Leukemia/Lymphoma","code":"TLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4005,"hugoSymbol":"LMO2","oncogene":true,"grch37Isoform":"ENST00000395833","grch37RefSeq":"NM_001142315.1","grch38Isoform":"ENST00000395833","grch38RefSeq":"NM_001142315.1","geneAliases":["LMO-2","RBTNL1","RBTN2","RHOM2","TTG2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4005,"hugoSymbol":"LMO2","oncogene":true,"grch37Isoform":"ENST00000395833","grch37RefSeq":"NM_001142315.1","grch38Isoform":"ENST00000395833","grch38RefSeq":"NM_001142315.1","geneAliases":["LMO-2","RBTNL1","RBTN2","RHOM2","TTG2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"20861166","title":"The molecular basis of Lmo2-induced T-cell acute lymphoblastic leukemia.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2010 Dec 1","volume":"16","issue":"23","pages":"5618-23","authors":"Curtis DJ et al","elocationId":"doi: 10.1158/1078-0432.CCR-10-0440","link":null,"reference":"Curtis DJ et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Dec 1;16(23)5618-23.","abstract":null},{"pmid":"29279377","title":"Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia.","journal":"Proceedings of the National Academy of Sciences of the United States of America","pubDate":"2018 Jan 9","volume":"115","issue":"2","pages":"373-378","authors":"Chen B et al","elocationId":"doi: 10.1073/pnas.1717125115","link":null,"reference":"Chen B et al. Proceedings of the National Academy of Sciences of the United States of America. 2018 Jan 9;115(2)373-378.","abstract":null},{"pmid":"25682596","title":"High frequency of cryptic chromosomal rearrangements involving the LMO2 gene in T-cell acute lymphoblastic leukemia.","journal":"Haematologica","pubDate":"2015 Jun","volume":"100","issue":"6","pages":"e233-6","authors":"Wu L et al","elocationId":"doi: 10.3324/haematol.2014.120089","link":null,"reference":"Wu L et al. Haematologica. 2015 Jun;100(6)e233-6.","abstract":null},{"pmid":"17928886","title":"Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences.","journal":"Leukemia","pubDate":"2008 Jan","volume":"22","issue":"1","pages":"124-31","authors":"van Grotel M et al","elocationId":"","link":null,"reference":"van Grotel M et al. Leukemia. 2008 Jan;22(1)124-31.","abstract":null}]},{"id":6035,"uuid":"a19d0d3e-d3dd-437b-b80d-bec626e17647","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":43,"subtype":"Chronic Neutrophilic Leukemia","code":"CNL","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1441,"hugoSymbol":"CSF3R","oncogene":true,"grch37Isoform":"ENST00000361632","grch37RefSeq":"NM_000760.3","grch38Isoform":"ENST00000361632","grch38RefSeq":"NM_000760.3","geneAliases":["GCSFR","CD114","SCN7"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1441,"hugoSymbol":"CSF3R","oncogene":true,"grch37Isoform":"ENST00000361632","grch37RefSeq":"NM_000760.3","grch38Isoform":"ENST00000361632","grch38RefSeq":"NM_000760.3","geneAliases":["GCSFR","CD114","SCN7"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25239264","title":"Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia.","journal":"Haematologica","pubDate":"2014 Dec","volume":"99","issue":"12","pages":"e244-6","authors":"Meggendorfer M et al","elocationId":"doi: 10.3324/haematol.2014.113159","link":null,"reference":"Meggendorfer M et al. Haematologica. 2014 Dec;99(12)e244-6.","abstract":null},{"pmid":"28028025","title":"Genomics of chronic neutrophilic leukemia.","journal":"Blood","pubDate":"2017 Feb 9","volume":"129","issue":"6","pages":"715-722","authors":"Maxson JE et al","elocationId":"doi: 10.1182/blood-2016-10-695981","link":null,"reference":"Maxson JE et al. Blood. 2017 Feb 9;129(6)715-722.","abstract":null},{"pmid":"23656643","title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.","journal":"The New England journal of medicine","pubDate":"2013 May 9","volume":"368","issue":"19","pages":"1781-90","authors":"Maxson JE et al","elocationId":"doi: 10.1056/NEJMoa1214514","link":null,"reference":"Maxson JE et al. The New England journal of medicine. 2013 May 9;368(19)1781-90.","abstract":null},{"pmid":"24212483","title":"CSF3R T618I co-occurs with mutations of splicing and epigenetic genes and with a new PIM3 truncated fusion gene in chronic neutrophilic leukemia.","journal":"Blood cancer journal","pubDate":"2013 Nov 8","volume":"3","issue":"","pages":"e158","authors":"Menezes J et al","elocationId":"doi: 10.1038/bcj.2013.55","link":null,"reference":"Menezes J et al. Blood cancer journal. 2013 Nov 8;3()e158.","abstract":null},{"pmid":"24445868","title":"Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.","journal":"Leukemia","pubDate":"2014 Jun","volume":"28","issue":"6","pages":"1363-5","authors":"Lasho TL et al","elocationId":"doi: 10.1038/leu.2014.39","link":null,"reference":"Lasho TL et al. Leukemia. 2014 Jun;28(6)1363-5.","abstract":null},{"pmid":"23604229","title":"CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.","journal":"Leukemia","pubDate":"2013 Sep","volume":"27","issue":"9","pages":"1870-3","authors":"Pardanani A et al","elocationId":"doi: 10.1038/leu.2013.122","link":null,"reference":"Pardanani A et al. Leukemia. 2013 Sep;27(9)1870-3.","abstract":null}]},{"id":22293,"uuid":"05130463-122d-4c9b-a52b-77e666fbc58b","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":10735,"hugoSymbol":"STAG2","oncogene":false,"grch37Isoform":"ENST00000218089","grch37RefSeq":"NM_001042749.1","grch38Isoform":"ENST00000218089","grch38RefSeq":"NM_001042749.1","geneAliases":["MKMS","HPE13","SCC3B","bA517O1.1","SA-2","SA2","NEDXCF"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":10735,"hugoSymbol":"STAG2","oncogene":false,"grch37Isoform":"ENST00000218089","grch37RefSeq":"NM_001042749.1","grch38Isoform":"ENST00000218089","grch38RefSeq":"NM_001042749.1","geneAliases":["MKMS","HPE13","SCC3B","bA517O1.1","SA-2","SA2","NEDXCF"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24030381","title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes.","journal":"Blood","pubDate":"2013 Nov 21","volume":"122","issue":"22","pages":"3616-27; quiz 3699","authors":"Papaemmanuil E et al","elocationId":"doi: 10.1182/blood-2013-08-518886","link":null,"reference":"Papaemmanuil E et al. Blood. 2013 Nov 21;122(22)3616-27; quiz 3699.","abstract":null},{"pmid":"25465125","title":"The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.","journal":"Leukemia research","pubDate":"2015 Jan","volume":"39","issue":"1","pages":"6-17","authors":"Zhang L et al","elocationId":"doi: 10.1016/j.leukres.2014.10.006","link":null,"reference":"Zhang L et al. Leukemia research. 2015 Jan;39(1)6-17.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null}]},{"id":22549,"uuid":"923ae4db-a333-4f49-9987-f66998a0ef5e","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":293,"subtype":"T-Lymphoblastic Leukemia/Lymphoma","code":"TLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6886,"hugoSymbol":"TAL1","oncogene":true,"grch37Isoform":"ENST00000294339","grch37RefSeq":"NM_001287347.2","grch38Isoform":"ENST00000294339","grch38RefSeq":"NM_001287347.2","geneAliases":["tal-1","bHLHa17","SCL","TCL5"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6886,"hugoSymbol":"TAL1","oncogene":true,"grch37Isoform":"ENST00000294339","grch37RefSeq":"NM_001287347.2","grch38Isoform":"ENST00000294339","grch38RefSeq":"NM_001287347.2","geneAliases":["tal-1","bHLHa17","SCL","TCL5"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"16826225","title":"Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast.","journal":"Leukemia","pubDate":"2006 Sep","volume":"20","issue":"9","pages":"1496-510","authors":"Graux C et al","elocationId":"","link":null,"reference":"Graux C et al. Leukemia. 2006 Sep;20(9)1496-510.","abstract":null},{"pmid":"29279377","title":"Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia.","journal":"Proceedings of the National Academy of Sciences of the United States of America","pubDate":"2018 Jan 9","volume":"115","issue":"2","pages":"373-378","authors":"Chen B et al","elocationId":"doi: 10.1073/pnas.1717125115","link":null,"reference":"Chen B et al. Proceedings of the National Academy of Sciences of the United States of America. 2018 Jan 9;115(2)373-378.","abstract":null},{"pmid":"28652130","title":"TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia.","journal":"Experimental hematology","pubDate":"2017 Sep","volume":"53","issue":"","pages":"7-15","authors":"Sanda T et al","elocationId":"doi: 10.1016/j.exphem.2017.06.001","link":null,"reference":"Sanda T et al. Experimental hematology. 2017 Sep;53()7-15.","abstract":null}]},{"id":11029,"uuid":"4898d707-1e68-46d9-b48b-b2a7107db847","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"E604_Y958ins","name":"E604_Y958ins","refResidues":null,"proteinStart":604,"proteinEnd":958,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"E604_Y958del","name":"Tyrosine kinase domain mutation","refResidues":null,"proteinStart":604,"proteinEnd":958,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E604_Y958mis","name":"E604_Y958mis","refResidues":null,"proteinStart":604,"proteinEnd":958,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1604464741000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"18450602","title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.","journal":"The New England journal of medicine","pubDate":"2008 May 1","volume":"358","issue":"18","pages":"1909-18","authors":"Schlenk RF et al","elocationId":"doi: 10.1056/NEJMoa074306","link":null,"reference":"Schlenk RF et al. The New England journal of medicine. 2008 May 1;358(18)1909-18.","abstract":null},{"pmid":"17940205","title":"FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.","journal":"Blood","pubDate":"2008 Feb 1","volume":"111","issue":"3","pages":"1552-9","authors":"Whitman SP et al","elocationId":"","link":null,"reference":"Whitman SP et al. Blood. 2008 Feb 1;111(3)1552-9.","abstract":null},{"pmid":"11290608","title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.","journal":"Blood","pubDate":"2001 Apr 15","volume":"97","issue":"8","pages":"2434-9","authors":"Yamamoto Y et al","elocationId":"","link":null,"reference":"Yamamoto Y et al. Blood. 2001 Apr 15;97(8)2434-9.","abstract":null},{"pmid":"12393388","title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.","journal":"Blood","pubDate":"2002 Dec 15","volume":"100","issue":"13","pages":"4372-80","authors":"Fröhling S et al","elocationId":"","link":null,"reference":"Fröhling S et al. Blood. 2002 Dec 15;100(13)4372-80.","abstract":null}]},{"id":1946,"uuid":"43471170-b5d1-48d1-90d3-c496ce9720d4","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":224,"subtype":"Chronic Myelomonocytic Leukemia","code":"CMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":54880,"hugoSymbol":"BCOR","oncogene":false,"grch37Isoform":"ENST00000378444","grch37RefSeq":"NM_001123385.1","grch38Isoform":"ENST00000378444","grch38RefSeq":"NM_001123385.1","geneAliases":["MAA2","ANOP2","MCOPS2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":54880,"hugoSymbol":"BCOR","oncogene":false,"grch37Isoform":"ENST00000378444","grch37RefSeq":"NM_001123385.1","grch38Isoform":"ENST00000378444","grch38RefSeq":"NM_001123385.1","geneAliases":["MAA2","ANOP2","MCOPS2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24047651","title":"BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.","journal":"Blood","pubDate":"2013 Oct 31","volume":"122","issue":"18","pages":"3169-77","authors":"Damm F et al","elocationId":"doi: 10.1182/blood-2012-11-469619","link":null,"reference":"Damm F et al. Blood. 2013 Oct 31;122(18)3169-77.","abstract":null}]},{"id":1948,"uuid":"d5d3f340-e502-48be-a485-48bc624967e9","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":54880,"hugoSymbol":"BCOR","oncogene":false,"grch37Isoform":"ENST00000378444","grch37RefSeq":"NM_001123385.1","grch38Isoform":"ENST00000378444","grch38RefSeq":"NM_001123385.1","geneAliases":["MAA2","ANOP2","MCOPS2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":54880,"hugoSymbol":"BCOR","oncogene":false,"grch37Isoform":"ENST00000378444","grch37RefSeq":"NM_001123385.1","grch38Isoform":"ENST00000378444","grch38RefSeq":"NM_001123385.1","geneAliases":["MAA2","ANOP2","MCOPS2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24047651","title":"BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.","journal":"Blood","pubDate":"2013 Oct 31","volume":"122","issue":"18","pages":"3169-77","authors":"Damm F et al","elocationId":"doi: 10.1182/blood-2012-11-469619","link":null,"reference":"Damm F et al. Blood. 2013 Oct 31;122(18)3169-77.","abstract":null}]},{"id":1821,"uuid":"6e3b9249-74b5-4e13-8ec4-5bb4b605fe15","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":286,"subtype":"Follicular Lymphoma","code":"FL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":596,"hugoSymbol":"BCL2","oncogene":true,"grch37Isoform":"ENST00000333681","grch37RefSeq":"NM_000633.2","grch38Isoform":"ENST00000333681","grch38RefSeq":"NM_000633.2","geneAliases":["Bcl-2","PPP1R50"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":596,"hugoSymbol":"BCL2","oncogene":true,"grch37Isoform":"ENST00000333681","grch37RefSeq":"NM_000633.2","grch38Isoform":"ENST00000333681","grch38RefSeq":"NM_000633.2","geneAliases":["Bcl-2","PPP1R50"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"IGH-BCL2 Fusion","name":"IGH-BCL2 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"9166827","title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.","journal":"Blood","pubDate":"1997 Jun 1","volume":"89","issue":"11","pages":"3909-18","authors":"","elocationId":"","link":null,"reference":". Blood. 1997 Jun 1;89(11)3909-18.","abstract":null},{"pmid":"3284977","title":"Chromosome studies in the non-Hodgkin's lymphomas: the role of the 14;18 translocation.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"1988 May","volume":"6","issue":"5","pages":"919-25","authors":"Rowley JD","elocationId":"","link":null,"reference":"Rowley JD. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1988 May;6(5)919-25.","abstract":null},{"pmid":"7726146","title":"Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14; 18) in follicular lymphoma.","journal":"American journal of clinical pathology","pubDate":"1995 Apr","volume":"103","issue":"4","pages":"472-8","authors":"Horsman DE et al","elocationId":"","link":null,"reference":"Horsman DE et al. American journal of clinical pathology. 1995 Apr;103(4)472-8.","abstract":null}]},{"id":19232,"uuid":"7eb0269d-9349-4184-8421-5668706966a5","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8493,"hugoSymbol":"PPM1D","oncogene":true,"grch37Isoform":"ENST00000305921","grch37RefSeq":"NM_003620.3","grch38Isoform":"ENST00000305921","grch38RefSeq":"NM_003620.3","geneAliases":["IDDGIP","JDVS","PP2C-DELTA","WIP1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":8493,"hugoSymbol":"PPM1D","oncogene":true,"grch37Isoform":"ENST00000305921","grch37RefSeq":"NM_003620.3","grch38Isoform":"ENST00000305921","grch38RefSeq":"NM_003620.3","geneAliases":["IDDGIP","JDVS","PP2C-DELTA","WIP1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/130/Suppl_1/4275?sso-checked=true","reference":"null. null. .","abstract":"Panagiota, V. et al., Abstract# Blood130:4275, 2017"},{"pmid":"28177873","title":"Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.","journal":"The New England journal of medicine","pubDate":"2017 Feb 9","volume":"376","issue":"6","pages":"536-547","authors":"Lindsley RC et al","elocationId":"doi: 10.1056/NEJMoa1611604","link":null,"reference":"Lindsley RC et al. The New England journal of medicine. 2017 Feb 9;376(6)536-547.","abstract":null}]},{"id":5027,"uuid":"10f57935-a0d9-4b89-92bb-0fdfefa460a7","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":224,"subtype":"Chronic Myelomonocytic Leukemia","code":"CMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":867,"hugoSymbol":"CBL","oncogene":false,"grch37Isoform":"ENST00000264033","grch37RefSeq":"NM_005188.3","grch38Isoform":"ENST00000264033","grch38RefSeq":"NM_005188.3","geneAliases":["NSLL","RNF55","C-CBL","FRA11B","CBL2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":867,"hugoSymbol":"CBL","oncogene":false,"grch37Isoform":"ENST00000264033","grch37RefSeq":"NM_005188.3","grch38Isoform":"ENST00000264033","grch38RefSeq":"NM_005188.3","geneAliases":["NSLL","RNF55","C-CBL","FRA11B","CBL2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22919025","title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).","journal":"Blood","pubDate":"2012 Oct 11","volume":"120","issue":"15","pages":"3080-8","authors":"Meggendorfer M et al","elocationId":"doi: 10.1182/blood-2012-01-404863","link":null,"reference":"Meggendorfer M et al. Blood. 2012 Oct 11;120(15)3080-8.","abstract":null},{"pmid":"23690417","title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2013 Jul 1","volume":"31","issue":"19","pages":"2428-36","authors":"Itzykson R et al","elocationId":"doi: 10.1200/JCO.2012.47.3314","link":null,"reference":"Itzykson R et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jul 1;31(19)2428-36.","abstract":null}]},{"id":6436,"uuid":"909ffbb9-6bf0-43ee-a955-fcf238b6eb13","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1788,"hugoSymbol":"DNMT3A","oncogene":false,"grch37Isoform":"ENST00000264709","grch37RefSeq":"NM_022552.4","grch38Isoform":"ENST00000264709","grch38RefSeq":"NM_022552.4","geneAliases":["DNMT3A2","HESJAS","TBRS","M.HsaIIIA"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":1788,"hugoSymbol":"DNMT3A","oncogene":false,"grch37Isoform":"ENST00000264709","grch37RefSeq":"NM_022552.4","grch38Isoform":"ENST00000264709","grch38RefSeq":"NM_022552.4","geneAliases":["DNMT3A2","HESJAS","TBRS","M.HsaIIIA"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"21415852","title":"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2011 Jul","volume":"25","issue":"7","pages":"1153-8","authors":"Walter MJ et al","elocationId":"doi: 10.1038/leu.2011.44","link":null,"reference":"Walter MJ et al. Leukemia. 2011 Jul;25(7)1153-8.","abstract":null}]},{"id":5029,"uuid":"ef4346ea-9537-4dca-bab8-a9a5d70be239","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":692,"subtype":"Juvenile Myelomonocytic Leukemia","code":"JMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":867,"hugoSymbol":"CBL","oncogene":false,"grch37Isoform":"ENST00000264033","grch37RefSeq":"NM_005188.3","grch38Isoform":"ENST00000264033","grch38RefSeq":"NM_005188.3","geneAliases":["NSLL","RNF55","C-CBL","FRA11B","CBL2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":867,"hugoSymbol":"CBL","oncogene":false,"grch37Isoform":"ENST00000264033","grch37RefSeq":"NM_005188.3","grch38Isoform":"ENST00000264033","grch38RefSeq":"NM_005188.3","geneAliases":["NSLL","RNF55","C-CBL","FRA11B","CBL2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23832011","title":"Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.","journal":"Nature genetics","pubDate":"2013 Aug","volume":"45","issue":"8","pages":"937-41","authors":"Sakaguchi H et al","elocationId":"doi: 10.1038/ng.2698","link":null,"reference":"Sakaguchi H et al. Nature genetics. 2013 Aug;45(8)937-41.","abstract":null},{"pmid":"20543203","title":"Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia.","journal":"Journal of medical genetics","pubDate":"2010 Oct","volume":"47","issue":"10","pages":"686-91","authors":"Pérez B et al","elocationId":"doi: 10.1136/jmg.2010.076836","link":null,"reference":"Pérez B et al. Journal of medical genetics. 2010 Oct;47(10)686-91.","abstract":null}]},{"id":23589,"uuid":"fa690d3e-e1cf-4a5a-9ad1-af0d4be2abd9","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":293,"subtype":"T-Lymphoblastic Leukemia/Lymphoma","code":"TLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6955,"hugoSymbol":"TRA","oncogene":true,"grch37Isoform":"","grch37RefSeq":"","grch38Isoform":"","grch38RefSeq":"","geneAliases":["IMD7","TCRA","TRA@"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6955,"hugoSymbol":"TRA","oncogene":true,"grch37Isoform":"","grch37RefSeq":"","grch38Isoform":"","grch38RefSeq":"","geneAliases":["IMD7","TCRA","TRA@"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"16826225","title":"Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast.","journal":"Leukemia","pubDate":"2006 Sep","volume":"20","issue":"9","pages":"1496-510","authors":"Graux C et al","elocationId":"","link":null,"reference":"Graux C et al. Leukemia. 2006 Sep;20(9)1496-510.","abstract":null},{"pmid":"16673021","title":"Molecular cytogenetic study of 126 unselected T-ALL cases reveals high incidence of TCRbeta locus rearrangements and putative new T-cell oncogenes.","journal":"Leukemia","pubDate":"2006 Jul","volume":"20","issue":"7","pages":"1238-44","authors":"Cauwelier B et al","elocationId":"","link":null,"reference":"Cauwelier B et al. Leukemia. 2006 Jul;20(7)1238-44.","abstract":null},{"pmid":"2900030","title":"Chromosome translocations involving band 7q35 or 7p15 in childhood T-cell leukemia/lymphoma.","journal":"Blood","pubDate":"1988 Aug","volume":"72","issue":"2","pages":"534-8","authors":"Kaneko Y et al","elocationId":"","link":null,"reference":"Kaneko Y et al. Blood. 1988 Aug;72(2)534-8.","abstract":null},{"pmid":"16079112","title":"Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia.","journal":"Haematologica","pubDate":"2005 Aug","volume":"90","issue":"8","pages":"1116-27","authors":"De Keersmaecker K et al","elocationId":"","link":null,"reference":"De Keersmaecker K et al. Haematologica. 2005 Aug;90(8)1116-27.","abstract":null}]},{"id":5033,"uuid":"8bc24736-2b56-464f-a1da-83d6f350c92c","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":867,"hugoSymbol":"CBL","oncogene":false,"grch37Isoform":"ENST00000264033","grch37RefSeq":"NM_005188.3","grch38Isoform":"ENST00000264033","grch38RefSeq":"NM_005188.3","geneAliases":["NSLL","RNF55","C-CBL","FRA11B","CBL2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":867,"hugoSymbol":"CBL","oncogene":false,"grch37Isoform":"ENST00000264033","grch37RefSeq":"NM_005188.3","grch38Isoform":"ENST00000264033","grch38RefSeq":"NM_005188.3","geneAliases":["NSLL","RNF55","C-CBL","FRA11B","CBL2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"19387008","title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.","journal":"Blood","pubDate":"2009 Jun 11","volume":"113","issue":"24","pages":"6182-92","authors":"Grand FH et al","elocationId":"doi: 10.1182/blood-2008-12-194548","link":null,"reference":"Grand FH et al. Blood. 2009 Jun 11;113(24)6182-92.","abstract":null},{"pmid":"21714648","title":"Clinical effect of point mutations in myelodysplastic syndromes.","journal":"The New England journal of medicine","pubDate":"2011 Jun 30","volume":"364","issue":"26","pages":"2496-506","authors":"Bejar R et al","elocationId":"doi: 10.1056/NEJMoa1013343","link":null,"reference":"Bejar R et al. The New England journal of medicine. 2011 Jun 30;364(26)2496-506.","abstract":null},{"pmid":"24030381","title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes.","journal":"Blood","pubDate":"2013 Nov 21","volume":"122","issue":"22","pages":"3616-27; quiz 3699","authors":"Papaemmanuil E et al","elocationId":"doi: 10.1182/blood-2013-08-518886","link":null,"reference":"Papaemmanuil E et al. Blood. 2013 Nov 21;122(22)3616-27; quiz 3699.","abstract":null},{"pmid":"25465125","title":"The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.","journal":"Leukemia research","pubDate":"2015 Jan","volume":"39","issue":"1","pages":"6-17","authors":"Zhang L et al","elocationId":"doi: 10.1016/j.leukres.2014.10.006","link":null,"reference":"Zhang L et al. Leukemia research. 2015 Jan;39(1)6-17.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null}]},{"id":1833,"uuid":"0237ba98-92fa-499d-97f3-d9b4014231c8","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":531,"subtype":"High-Grade B-Cell Lymphoma, with MYC and BCL2 and/or BCL6 Rearrangements","code":"HGBCLMYCBCL2","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":596,"hugoSymbol":"BCL2","oncogene":true,"grch37Isoform":"ENST00000333681","grch37RefSeq":"NM_000633.2","grch38Isoform":"ENST00000333681","grch38RefSeq":"NM_000633.2","geneAliases":["Bcl-2","PPP1R50"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":596,"hugoSymbol":"BCL2","oncogene":true,"grch37Isoform":"ENST00000333681","grch37RefSeq":"NM_000633.2","grch38Isoform":"ENST00000333681","grch38RefSeq":"NM_000633.2","geneAliases":["Bcl-2","PPP1R50"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27821509","title":"Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.","journal":"Blood","pubDate":"2017 Jan 19","volume":"129","issue":"3","pages":"280-288","authors":"Sesques P et al","elocationId":"doi: 10.1182/blood-2016-02-636316","link":null,"reference":"Sesques P et al. Blood. 2017 Jan 19;129(3)280-288.","abstract":null},{"pmid":"26980727","title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","journal":"Blood","pubDate":"2016 May 19","volume":"127","issue":"20","pages":"2375-90","authors":"Swerdlow SH et al","elocationId":"doi: 10.1182/blood-2016-01-643569","link":null,"reference":"Swerdlow SH et al. Blood. 2016 May 19;127(20)2375-90.","abstract":null}]},{"id":17709,"uuid":"37e4fd32-c1fc-4369-a4a0-be4c506b4048","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":84295,"hugoSymbol":"PHF6","oncogene":false,"grch37Isoform":"ENST00000332070","grch37RefSeq":"NM_001015877.1","grch38Isoform":"ENST00000332070","grch38RefSeq":"NM_001015877.1","geneAliases":["BFLS","CENP-31","BORJ"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":84295,"hugoSymbol":"PHF6","oncogene":false,"grch37Isoform":"ENST00000332070","grch37RefSeq":"NM_001015877.1","grch38Isoform":"ENST00000332070","grch38RefSeq":"NM_001015877.1","geneAliases":["BFLS","CENP-31","BORJ"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27479181","title":"Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms.","journal":"Leukemia","pubDate":"2016 Nov","volume":"30","issue":"11","pages":"2270-2273","authors":"Mori T et al","elocationId":"doi: 10.1038/leu.2016.212","link":null,"reference":"Mori T et al. Leukemia. 2016 Nov;30(11)2270-2273.","abstract":null}]},{"id":12077,"uuid":"3c54d4c3-1134-437e-ab7e-a5c52b0aeb89","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":695,"subtype":"Essential Thrombocythemia","code":"ET","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"29296692","title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia.","journal":"Blood advances","pubDate":"2016 Nov 29","volume":"1","issue":"1","pages":"21-30","authors":"Tefferi A et al","elocationId":"doi: 10.1182/bloodadvances.2016000216","link":null,"reference":"Tefferi A et al. Blood advances. 2016 Nov 29;1(1)21-30.","abstract":null},{"pmid":"15837627","title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","journal":"Cancer cell","pubDate":"2005 Apr","volume":"7","issue":"4","pages":"387-97","authors":"Levine RL et al","elocationId":"","link":null,"reference":"Levine RL et al. Cancer cell. 2005 Apr;7(4)387-97.","abstract":null},{"pmid":"27069254","title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","journal":"Blood","pubDate":"2016 May 19","volume":"127","issue":"20","pages":"2391-405","authors":"Arber DA et al","elocationId":"doi: 10.1182/blood-2016-03-643544","link":null,"reference":"Arber DA et al. Blood. 2016 May 19;127(20)2391-405.","abstract":null},{"pmid":"25037629","title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.","journal":"Blood","pubDate":"2014 Oct 16","volume":"124","issue":"16","pages":"2507-13; quiz 2615","authors":"Tefferi A et al","elocationId":"doi: 10.1182/blood-2014-05-579136","link":null,"reference":"Tefferi A et al. Blood. 2014 Oct 16;124(16)2507-13; quiz 2615.","abstract":null},{"pmid":"20428194","title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.","journal":"Leukemia","pubDate":"2010 Jun","volume":"24","issue":"6","pages":"1128-38","authors":"Tefferi A","elocationId":"doi: 10.1038/leu.2010.69","link":null,"reference":"Tefferi A. Leukemia. 2010 Jun;24(6)1128-38.","abstract":null},{"pmid":"21220604","title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2011 Feb 10","volume":"29","issue":"5","pages":"573-82","authors":"Tefferi A et al","elocationId":"doi: 10.1200/JCO.2010.29.8711","link":null,"reference":"Tefferi A et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Feb 10;29(5)573-82.","abstract":null},{"pmid":"24791854","title":"Calreticulin mutations and long-term survival in essential thrombocythemia.","journal":"Leukemia","pubDate":"2014 Dec","volume":"28","issue":"12","pages":"2300-3","authors":"Tefferi A et al","elocationId":"doi: 10.1038/leu.2014.148","link":null,"reference":"Tefferi A et al. Leukemia. 2014 Dec;28(12)2300-3.","abstract":null}]},{"id":17711,"uuid":"aaedb2f7-a1e4-424e-9b86-aeee9c75e4de","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":293,"subtype":"T-Lymphoblastic Leukemia/Lymphoma","code":"TLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":84295,"hugoSymbol":"PHF6","oncogene":false,"grch37Isoform":"ENST00000332070","grch37RefSeq":"NM_001015877.1","grch38Isoform":"ENST00000332070","grch38RefSeq":"NM_001015877.1","geneAliases":["BFLS","CENP-31","BORJ"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":84295,"hugoSymbol":"PHF6","oncogene":false,"grch37Isoform":"ENST00000332070","grch37RefSeq":"NM_001015877.1","grch38Isoform":"ENST00000332070","grch38RefSeq":"NM_001015877.1","geneAliases":["BFLS","CENP-31","BORJ"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"20228800","title":"PHF6 mutations in T-cell acute lymphoblastic leukemia.","journal":"Nature genetics","pubDate":"2010 Apr","volume":"42","issue":"4","pages":"338-42","authors":"Van Vlierberghe P et al","elocationId":"doi: 10.1038/ng.542","link":null,"reference":"Van Vlierberghe P et al. Nature genetics. 2010 Apr;42(4)338-42.","abstract":null},{"pmid":"27347093","title":"Co-existence of <i>PHF6</i> and <i>NOTCH1</i> mutations in adult T-cell acute lymphoblastic leukemia.","journal":"Oncology letters","pubDate":"2016 Jul","volume":"12","issue":"1","pages":"16-22","authors":"Li M et al","elocationId":"","link":null,"reference":"Li M et al. Oncology letters. 2016 Jul;12(1)16-22.","abstract":null}]},{"id":12079,"uuid":"e3a1a16f-b276-4a4b-8290-b7b576dee764","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":831,"subtype":"Myeloproliferative Neoplasms, Unclassifiable","code":"MPNU","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25873496","title":"CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.","journal":"American journal of clinical pathology","pubDate":"2015 May","volume":"143","issue":"5","pages":"635-44","authors":"Kim SY et al","elocationId":"doi: 10.1309/AJCPUAAC16LIWZMM","link":null,"reference":"Kim SY et al. American journal of clinical pathology. 2015 May;143(5)635-44.","abstract":null},{"pmid":"23233635","title":"The spectrum of JAK2-positive myeloproliferative neoplasms.","journal":"Hematology. American Society of Hematology. Education Program","pubDate":"2012","volume":"2012","issue":"","pages":"561-6","authors":"Kiladjian JJ","elocationId":"doi: 10.1182/asheducation-2012.1.561","link":null,"reference":"Kiladjian JJ. Hematology. American Society of Hematology. Education Program. 2012;2012()561-6.","abstract":null}]},{"id":12081,"uuid":"9bcdce28-dc62-4599-a686-487f463c8d6b","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":632,"subtype":"Primary Myelofibrosis","code":"PMF","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"16868251","title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.","journal":"Blood","pubDate":"2006 Nov 15","volume":"108","issue":"10","pages":"3472-6","authors":"Pardanani AD et al","elocationId":"","link":null,"reference":"Pardanani AD et al. Blood. 2006 Nov 15;108(10)3472-6.","abstract":null},{"pmid":"15837627","title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","journal":"Cancer cell","pubDate":"2005 Apr","volume":"7","issue":"4","pages":"387-97","authors":"Levine RL et al","elocationId":"","link":null,"reference":"Levine RL et al. Cancer cell. 2005 Apr;7(4)387-97.","abstract":null},{"pmid":"27069254","title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","journal":"Blood","pubDate":"2016 May 19","volume":"127","issue":"20","pages":"2391-405","authors":"Arber DA et al","elocationId":"doi: 10.1182/blood-2016-03-643544","link":null,"reference":"Arber DA et al. Blood. 2016 May 19;127(20)2391-405.","abstract":null},{"pmid":"25037629","title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.","journal":"Blood","pubDate":"2014 Oct 16","volume":"124","issue":"16","pages":"2507-13; quiz 2615","authors":"Tefferi A et al","elocationId":"doi: 10.1182/blood-2014-05-579136","link":null,"reference":"Tefferi A et al. Blood. 2014 Oct 16;124(16)2507-13; quiz 2615.","abstract":null},{"pmid":"20428194","title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.","journal":"Leukemia","pubDate":"2010 Jun","volume":"24","issue":"6","pages":"1128-38","authors":"Tefferi A","elocationId":"doi: 10.1038/leu.2010.69","link":null,"reference":"Tefferi A. Leukemia. 2010 Jun;24(6)1128-38.","abstract":null},{"pmid":"21220604","title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2011 Feb 10","volume":"29","issue":"5","pages":"573-82","authors":"Tefferi A et al","elocationId":"doi: 10.1200/JCO.2010.29.8711","link":null,"reference":"Tefferi A et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Feb 10;29(5)573-82.","abstract":null},{"pmid":"24986690","title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.","journal":"Blood","pubDate":"2014 Aug 14","volume":"124","issue":"7","pages":"1062-9","authors":"Rumi E et al","elocationId":"doi: 10.1182/blood-2014-05-578435","link":null,"reference":"Rumi E et al. Blood. 2014 Aug 14;124(7)1062-9.","abstract":null}]},{"id":16691,"uuid":"9a2a8aef-0b8b-4240-ae49-a6fca8e47bae","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":941,"subtype":"","code":"","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":0,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4851,"hugoSymbol":"NOTCH1","oncogene":true,"grch37Isoform":"ENST00000277541","grch37RefSeq":"NM_017617.3","grch38Isoform":"ENST00000651671","grch38RefSeq":"NM_017617.5","geneAliases":["TAN1","hN1","AOVD1","AOS5"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4851,"hugoSymbol":"NOTCH1","oncogene":true,"grch37Isoform":"ENST00000277541","grch37RefSeq":"NM_017617.3","grch38Isoform":"ENST00000651671","grch38RefSeq":"NM_017617.5","geneAliases":["TAN1","hN1","AOVD1","AOS5"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"16826225","title":"Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast.","journal":"Leukemia","pubDate":"2006 Sep","volume":"20","issue":"9","pages":"1496-510","authors":"Graux C et al","elocationId":"","link":null,"reference":"Graux C et al. Leukemia. 2006 Sep;20(9)1496-510.","abstract":null},{"pmid":"16707600","title":"NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2006 May 15","volume":"12","issue":"10","pages":"3043-9","authors":"Zhu YM et al","elocationId":"","link":null,"reference":"Zhu YM et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 May 15;12(10)3043-9.","abstract":null},{"pmid":"15472075","title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.","journal":"Science (New York, N.Y.)","pubDate":"2004 Oct 8","volume":"306","issue":"5694","pages":"269-71","authors":"Weng AP et al","elocationId":"","link":null,"reference":"Weng AP et al. Science (New York, N.Y.). 2004 Oct 8;306(5694)269-71.","abstract":null},{"pmid":"19794079","title":"Mutations of NOTCH1, FBXW7, and prognosis in T-lineage acute lymphoblastic leukemia.","journal":"Haematologica","pubDate":"2009 Oct","volume":"94","issue":"10","pages":"1338-40","authors":"Mullighan CG","elocationId":"doi: 10.3324/haematol.2009.012047","link":null,"reference":"Mullighan CG. Haematologica. 2009 Oct;94(10)1338-40.","abstract":null}]},{"id":22708,"uuid":"237051ac-614c-4d14-b68b-d7755364192c","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":224,"subtype":"Chronic Myelomonocytic Leukemia","code":"CMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":54790,"hugoSymbol":"TET2","oncogene":false,"grch37Isoform":"ENST00000380013","grch37RefSeq":"NM_001127208.2","grch38Isoform":"ENST00000380013","grch38RefSeq":"NM_001127208.2","geneAliases":["KIAA1546"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":54790,"hugoSymbol":"TET2","oncogene":false,"grch37Isoform":"ENST00000380013","grch37RefSeq":"NM_001127208.2","grch38Isoform":"ENST00000380013","grch38RefSeq":"NM_001127208.2","geneAliases":["KIAA1546"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1603940466000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"20693430","title":"Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.","journal":"Blood","pubDate":"2010 Nov 11","volume":"116","issue":"19","pages":"3923-32","authors":"Smith AE et al","elocationId":"doi: 10.1182/blood-2010-03-274704","link":null,"reference":"Smith AE et al. Blood. 2010 Nov 11;116(19)3923-32.","abstract":null},{"pmid":"26771811","title":"Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.","journal":"Blood cancer journal","pubDate":"2016 Jan 15","volume":"6","issue":"","pages":"e385","authors":"Patnaik MM et al","elocationId":"doi: 10.1038/bcj.2015.113","link":null,"reference":"Patnaik MM et al. Blood cancer journal. 2016 Jan 15;6()e385.","abstract":null},{"pmid":"22919025","title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).","journal":"Blood","pubDate":"2012 Oct 11","volume":"120","issue":"15","pages":"3080-8","authors":"Meggendorfer M et al","elocationId":"doi: 10.1182/blood-2012-01-404863","link":null,"reference":"Meggendorfer M et al. Blood. 2012 Oct 11;120(15)3080-8.","abstract":null},{"pmid":"24695057","title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.","journal":"Leukemia","pubDate":"2014 Nov","volume":"28","issue":"11","pages":"2206-12","authors":"Patnaik MM et al","elocationId":"doi: 10.1038/leu.2014.125","link":null,"reference":"Patnaik MM et al. Leukemia. 2014 Nov;28(11)2206-12.","abstract":null},{"pmid":"27662201","title":"Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance.","journal":"Blood cancer journal","pubDate":"2016 Sep 23","volume":"6","issue":"9","pages":"e472","authors":"Patnaik MM et al","elocationId":"doi: 10.1038/bcj.2016.82","link":null,"reference":"Patnaik MM et al. Blood cancer journal. 2016 Sep 23;6(9)e472.","abstract":null},{"pmid":"21828135","title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.","journal":"Blood","pubDate":"2011 Oct 6","volume":"118","issue":"14","pages":"3932-41","authors":"Jankowska AM et al","elocationId":"doi: 10.1182/blood-2010-10-311019","link":null,"reference":"Jankowska AM et al. Blood. 2011 Oct 6;118(14)3932-41.","abstract":null}]},{"id":22710,"uuid":"c0f1526e-038f-4b12-9608-9bc06568a8b2","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":54790,"hugoSymbol":"TET2","oncogene":false,"grch37Isoform":"ENST00000380013","grch37RefSeq":"NM_001127208.2","grch38Isoform":"ENST00000380013","grch38RefSeq":"NM_001127208.2","geneAliases":["KIAA1546"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":54790,"hugoSymbol":"TET2","oncogene":false,"grch37Isoform":"ENST00000380013","grch37RefSeq":"NM_001127208.2","grch38Isoform":"ENST00000380013","grch38RefSeq":"NM_001127208.2","geneAliases":["KIAA1546"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"21714648","title":"Clinical effect of point mutations in myelodysplastic syndromes.","journal":"The New England journal of medicine","pubDate":"2011 Jun 30","volume":"364","issue":"26","pages":"2496-506","authors":"Bejar R et al","elocationId":"doi: 10.1056/NEJMoa1013343","link":null,"reference":"Bejar R et al. The New England journal of medicine. 2011 Jun 30;364(26)2496-506.","abstract":null},{"pmid":"24030381","title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes.","journal":"Blood","pubDate":"2013 Nov 21","volume":"122","issue":"22","pages":"3616-27; quiz 3699","authors":"Papaemmanuil E et al","elocationId":"doi: 10.1182/blood-2013-08-518886","link":null,"reference":"Papaemmanuil E et al. Blood. 2013 Nov 21;122(22)3616-27; quiz 3699.","abstract":null},{"pmid":"25465125","title":"The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.","journal":"Leukemia research","pubDate":"2015 Jan","volume":"39","issue":"1","pages":"6-17","authors":"Zhang L et al","elocationId":"doi: 10.1016/j.leukres.2014.10.006","link":null,"reference":"Zhang L et al. Leukemia research. 2015 Jan;39(1)6-17.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null}]},{"id":9784,"uuid":"981cfba1-e1b1-4573-84df-fb1d90836441","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":224,"subtype":"Chronic Myelomonocytic Leukemia","code":"CMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"29358618","title":"EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental.","journal":"Blood cancer journal","pubDate":"2018 Jan 22","volume":"8","issue":"1","pages":"12","authors":"Patnaik MM et al","elocationId":"doi: 10.1038/s41408-017-0045-4","link":null,"reference":"Patnaik MM et al. Blood cancer journal. 2018 Jan 22;8(1)12.","abstract":null}]},{"id":11832,"uuid":"58eb1cd3-bec6-4d50-9e25-d6e0da4e751d","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3418,"hugoSymbol":"IDH2","oncogene":true,"grch37Isoform":"ENST00000330062","grch37RefSeq":"NM_002168.2","grch38Isoform":"ENST00000330062","grch38RefSeq":"NM_002168.2","geneAliases":["IDHM","D2HGA2","mNADP-IDH","IDPM","ICD-M"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3418,"hugoSymbol":"IDH2","oncogene":true,"grch37Isoform":"ENST00000330062","grch37RefSeq":"NM_002168.2","grch38Isoform":"ENST00000330062","grch38RefSeq":"NM_002168.2","geneAliases":["IDHM","D2HGA2","mNADP-IDH","IDPM","ICD-M"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1606852438000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22397365","title":"Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.","journal":"Journal of hematology & oncology","pubDate":"2012 Mar 7","volume":"5","issue":"","pages":"5","authors":"Chotirat S et al","elocationId":"doi: 10.1186/1756-8722-5-5","link":null,"reference":"Chotirat S et al. Journal of hematology & oncology. 2012 Mar 7;5()5.","abstract":null},{"pmid":"20567020","title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2010 Aug 1","volume":"28","issue":"22","pages":"3636-43","authors":"Paschka P et al","elocationId":"doi: 10.1200/JCO.2010.28.3762","link":null,"reference":"Paschka P et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Aug 1;28(22)3636-43.","abstract":null},{"pmid":"22417203","title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.","journal":"The New England journal of medicine","pubDate":"2012 Mar 22","volume":"366","issue":"12","pages":"1079-89","authors":"Patel JP et al","elocationId":"doi: 10.1056/NEJMoa1112304","link":null,"reference":"Patel JP et al. The New England journal of medicine. 2012 Mar 22;366(12)1079-89.","abstract":null},{"pmid":"20538800","title":"Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.","journal":"Blood","pubDate":"2010 Sep 23","volume":"116","issue":"12","pages":"2122-6","authors":"Abbas S et al","elocationId":"doi: 10.1182/blood-2009-11-250878","link":null,"reference":"Abbas S et al. Blood. 2010 Sep 23;116(12)2122-6.","abstract":null},{"pmid":"21079611","title":"The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia.","journal":"Leukemia","pubDate":"2011 Feb","volume":"25","issue":"2","pages":"246-53","authors":"Chou WC et al","elocationId":"doi: 10.1038/leu.2010.267","link":null,"reference":"Chou WC et al. Leukemia. 2011 Feb;25(2)246-53.","abstract":null}]},{"id":10938,"uuid":"f4dfcf55-b30f-42f9-aca4-4ee65e098440","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"572_630ins","name":"Internal tandem duplication","refResidues":null,"proteinStart":572,"proteinEnd":630,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1604695974000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"18450602","title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.","journal":"The New England journal of medicine","pubDate":"2008 May 1","volume":"358","issue":"18","pages":"1909-18","authors":"Schlenk RF et al","elocationId":"doi: 10.1056/NEJMoa074306","link":null,"reference":"Schlenk RF et al. The New England journal of medicine. 2008 May 1;358(18)1909-18.","abstract":null},{"pmid":"11133746","title":"Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.","journal":"Blood","pubDate":"2001 Jan 1","volume":"97","issue":"1","pages":"89-94","authors":"Meshinchi S et al","elocationId":"","link":null,"reference":"Meshinchi S et al. Blood. 2001 Jan 1;97(1)89-94.","abstract":null},{"pmid":"11535508","title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.","journal":"Blood","pubDate":"2001 Sep 15","volume":"98","issue":"6","pages":"1752-9","authors":"Kottaridis PD et al","elocationId":"","link":null,"reference":"Kottaridis PD et al. Blood. 2001 Sep 15;98(6)1752-9.","abstract":null},{"pmid":"15746041","title":"Risk assessment in patients with acute myeloid leukemia and a normal karyotype.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2005 Feb 15","volume":"11","issue":"4","pages":"1416-24","authors":"Bienz M et al","elocationId":"","link":null,"reference":"Bienz M et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Feb 15;11(4)1416-24.","abstract":null},{"pmid":"12522450","title":"Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16).","journal":"The hematology journal : the official journal of the European Haematology Association","pubDate":"2002","volume":"3","issue":"6","pages":"283-9","authors":"Kainz B et al","elocationId":"","link":null,"reference":"Kainz B et al. The hematology journal : the official journal of the European Haematology Association. 2002;3(6)283-9.","abstract":null},{"pmid":"20656931","title":"FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.","journal":"Blood","pubDate":"2010 Nov 4","volume":"116","issue":"18","pages":"3622-6","authors":"Whitman SP et al","elocationId":"doi: 10.1182/blood-2010-05-283648","link":null,"reference":"Whitman SP et al. Blood. 2010 Nov 4;116(18)3622-6.","abstract":null},{"pmid":"11585760","title":"Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.","journal":"Cancer research","pubDate":"2001 Oct 1","volume":"61","issue":"19","pages":"7233-9","authors":"Whitman SP et al","elocationId":"","link":null,"reference":"Whitman SP et al. Cancer research. 2001 Oct 1;61(19)7233-9.","abstract":null},{"pmid":"11290608","title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.","journal":"Blood","pubDate":"2001 Apr 15","volume":"97","issue":"8","pages":"2434-9","authors":"Yamamoto Y et al","elocationId":"","link":null,"reference":"Yamamoto Y et al. Blood. 2001 Apr 15;97(8)2434-9.","abstract":null},{"pmid":"12393388","title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.","journal":"Blood","pubDate":"2002 Dec 15","volume":"100","issue":"13","pages":"4372-80","authors":"Fröhling S et al","elocationId":"","link":null,"reference":"Fröhling S et al. Blood. 2002 Dec 15;100(13)4372-80.","abstract":null}]},{"id":16831,"uuid":"fd31af3d-c34e-4d93-973c-5a7fccc18293","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":224,"subtype":"Chronic Myelomonocytic Leukemia","code":"CMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/124/21/1893?sso-checked=true","reference":"null. null. .","abstract":"Patel, B. et al., Abstract# Blood 124:1893, 2014"},{"pmid":"26341525","title":"An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.","journal":"Haematologica","pubDate":"2015 Sep","volume":"100","issue":"9","pages":"1117-30","authors":"Mughal TI et al","elocationId":"doi: 10.3324/haematol.2014.114660","link":null,"reference":"Mughal TI et al. Haematologica. 2015 Sep;100(9)1117-30.","abstract":null},{"pmid":"23690417","title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2013 Jul 1","volume":"31","issue":"19","pages":"2428-36","authors":"Itzykson R et al","elocationId":"doi: 10.1200/JCO.2012.47.3314","link":null,"reference":"Itzykson R et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jul 1;31(19)2428-36.","abstract":null}]},{"id":12097,"uuid":"977ad7d3-6133-4cb2-ac94-43fb47c6abac","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":801,"subtype":"MDS/MPN with Ring Sideroblasts and Thrombocytosis","code":"MDSMPNRST","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V617F","name":"V617F","refResidues":"V","proteinStart":617,"proteinEnd":617,"variantResidues":"F","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"18166783","title":"JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.","journal":"Haematologica","pubDate":"2008 Jan","volume":"93","issue":"1","pages":"34-40","authors":"Schmitt-Graeff AH et al","elocationId":"doi: 10.3324/haematol.11581","link":null,"reference":"Schmitt-Graeff AH et al. Haematologica. 2008 Jan;93(1)34-40.","abstract":null}]},{"id":9794,"uuid":"195ae51d-793f-4cdd-9c4c-3c1a3b21a513","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"21714648","title":"Clinical effect of point mutations in myelodysplastic syndromes.","journal":"The New England journal of medicine","pubDate":"2011 Jun 30","volume":"364","issue":"26","pages":"2496-506","authors":"Bejar R et al","elocationId":"doi: 10.1056/NEJMoa1013343","link":null,"reference":"Bejar R et al. The New England journal of medicine. 2011 Jun 30;364(26)2496-506.","abstract":null},{"pmid":"24030381","title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes.","journal":"Blood","pubDate":"2013 Nov 21","volume":"122","issue":"22","pages":"3616-27; quiz 3699","authors":"Papaemmanuil E et al","elocationId":"doi: 10.1182/blood-2013-08-518886","link":null,"reference":"Papaemmanuil E et al. Blood. 2013 Nov 21;122(22)3616-27; quiz 3699.","abstract":null},{"pmid":"25465125","title":"The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.","journal":"Leukemia research","pubDate":"2015 Jan","volume":"39","issue":"1","pages":"6-17","authors":"Zhang L et al","elocationId":"doi: 10.1016/j.leukres.2014.10.006","link":null,"reference":"Zhang L et al. Leukemia research. 2015 Jan;39(1)6-17.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null}]},{"id":16835,"uuid":"dff80ad5-df24-4e8c-9db6-ea9cd3da7466","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":692,"subtype":"Juvenile Myelomonocytic Leukemia","code":"JMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23832011","title":"Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.","journal":"Nature genetics","pubDate":"2013 Aug","volume":"45","issue":"8","pages":"937-41","authors":"Sakaguchi H et al","elocationId":"doi: 10.1038/ng.2698","link":null,"reference":"Sakaguchi H et al. Nature genetics. 2013 Aug;45(8)937-41.","abstract":null},{"pmid":"10049057","title":"RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML).","journal":"Leukemia","pubDate":"1999 Jan","volume":"13","issue":"1","pages":"32-7","authors":"Flotho C et al","elocationId":"","link":null,"reference":"Flotho C et al. Leukemia. 1999 Jan;13(1)32-7.","abstract":null},{"pmid":"26457647","title":"The genomic landscape of juvenile myelomonocytic leukemia.","journal":"Nature genetics","pubDate":"2015 Nov","volume":"47","issue":"11","pages":"1326-1333","authors":"Stieglitz E et al","elocationId":"doi: 10.1038/ng.3400","link":null,"reference":"Stieglitz E et al. Nature genetics. 2015 Nov;47(11)1326-1333.","abstract":null},{"pmid":"12717436","title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.","journal":"Nature genetics","pubDate":"2003 Jun","volume":"34","issue":"2","pages":"148-50","authors":"Tartaglia M et al","elocationId":"","link":null,"reference":"Tartaglia M et al. Nature genetics. 2003 Jun;34(2)148-50.","abstract":null}]},{"id":22851,"uuid":"83f14c15-f897-4e5b-b006-69db4d235898","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":293,"subtype":"T-Lymphoblastic Leukemia/Lymphoma","code":"TLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3195,"hugoSymbol":"TLX1","oncogene":true,"grch37Isoform":"ENST00000370196","grch37RefSeq":"NM_005521.3","grch38Isoform":"ENST00000370196","grch38RefSeq":"NM_005521.3","geneAliases":["TCL3","HOX11"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3195,"hugoSymbol":"TLX1","oncogene":true,"grch37Isoform":"ENST00000370196","grch37RefSeq":"NM_005521.3","grch38Isoform":"ENST00000370196","grch38RefSeq":"NM_005521.3","geneAliases":["TCL3","HOX11"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"1676542","title":"Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia.","journal":"Science (New York, N.Y.)","pubDate":"1991 Jul 5","volume":"253","issue":"5015","pages":"79-82","authors":"Hatano M et al","elocationId":"","link":null,"reference":"Hatano M et al. Science (New York, N.Y.). 1991 Jul 5;253(5015)79-82.","abstract":null},{"pmid":"29279377","title":"Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia.","journal":"Proceedings of the National Academy of Sciences of the United States of America","pubDate":"2018 Jan 9","volume":"115","issue":"2","pages":"373-378","authors":"Chen B et al","elocationId":"doi: 10.1073/pnas.1717125115","link":null,"reference":"Chen B et al. Proceedings of the National Academy of Sciences of the United States of America. 2018 Jan 9;115(2)373-378.","abstract":null},{"pmid":"21705452","title":"TLX1-induced T-cell acute lymphoblastic leukemia.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2011 Oct 15","volume":"17","issue":"20","pages":"6381-6","authors":"De Keersmaecker K et al","elocationId":"doi: 10.1158/1078-0432.CCR-10-3037","link":null,"reference":"De Keersmaecker K et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Oct 15;17(20)6381-6.","abstract":null},{"pmid":"14975618","title":"Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia.","journal":"Lancet (London, England)","pubDate":"2004 Feb 14","volume":"363","issue":"9408","pages":"535-6","authors":"Ferrando AA et al","elocationId":"","link":null,"reference":"Ferrando AA et al. Lancet (London, England). 2004 Feb 14;363(9408)535-6.","abstract":null}]},{"id":12099,"uuid":"be6d87a9-9723-4087-b7ef-b7f98b564091","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":806,"subtype":"Polycythemia Vera","code":"PV","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V617F","name":"V617F","refResidues":"V","proteinStart":617,"proteinEnd":617,"variantResidues":"F","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"29296692","title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia.","journal":"Blood advances","pubDate":"2016 Nov 29","volume":"1","issue":"1","pages":"21-30","authors":"Tefferi A et al","elocationId":"doi: 10.1182/bloodadvances.2016000216","link":null,"reference":"Tefferi A et al. Blood advances. 2016 Nov 29;1(1)21-30.","abstract":null},{"pmid":"23739289","title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.","journal":"Leukemia","pubDate":"2013 Sep","volume":"27","issue":"9","pages":"1874-81","authors":"Tefferi A et al","elocationId":"doi: 10.1038/leu.2013.163","link":null,"reference":"Tefferi A et al. Leukemia. 2013 Sep;27(9)1874-81.","abstract":null},{"pmid":"17267906","title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.","journal":"The New England journal of medicine","pubDate":"2007 Feb 1","volume":"356","issue":"5","pages":"459-68","authors":"Scott LM et al","elocationId":"","link":null,"reference":"Scott LM et al. The New England journal of medicine. 2007 Feb 1;356(5)459-68.","abstract":null},{"pmid":"15837627","title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","journal":"Cancer cell","pubDate":"2005 Apr","volume":"7","issue":"4","pages":"387-97","authors":"Levine RL et al","elocationId":"","link":null,"reference":"Levine RL et al. Cancer cell. 2005 Apr;7(4)387-97.","abstract":null},{"pmid":"27069254","title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","journal":"Blood","pubDate":"2016 May 19","volume":"127","issue":"20","pages":"2391-405","authors":"Arber DA et al","elocationId":"doi: 10.1182/blood-2016-03-643544","link":null,"reference":"Arber DA et al. Blood. 2016 May 19;127(20)2391-405.","abstract":null},{"pmid":"20428194","title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.","journal":"Leukemia","pubDate":"2010 Jun","volume":"24","issue":"6","pages":"1128-38","authors":"Tefferi A","elocationId":"doi: 10.1038/leu.2010.69","link":null,"reference":"Tefferi A. Leukemia. 2010 Jun;24(6)1128-38.","abstract":null}]},{"id":23619,"uuid":"c0f26d20-aa8b-4872-8be4-946cb8db6b8a","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":293,"subtype":"T-Lymphoblastic Leukemia/Lymphoma","code":"TLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6957,"hugoSymbol":"TRB","oncogene":true,"grch37Isoform":"","grch37RefSeq":"","grch38Isoform":"","grch38RefSeq":"","geneAliases":["TCRB","TRB@"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6957,"hugoSymbol":"TRB","oncogene":true,"grch37Isoform":"","grch37RefSeq":"","grch38Isoform":"","grch38RefSeq":"","geneAliases":["TCRB","TRB@"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"16826225","title":"Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast.","journal":"Leukemia","pubDate":"2006 Sep","volume":"20","issue":"9","pages":"1496-510","authors":"Graux C et al","elocationId":"","link":null,"reference":"Graux C et al. Leukemia. 2006 Sep;20(9)1496-510.","abstract":null},{"pmid":"16673021","title":"Molecular cytogenetic study of 126 unselected T-ALL cases reveals high incidence of TCRbeta locus rearrangements and putative new T-cell oncogenes.","journal":"Leukemia","pubDate":"2006 Jul","volume":"20","issue":"7","pages":"1238-44","authors":"Cauwelier B et al","elocationId":"","link":null,"reference":"Cauwelier B et al. Leukemia. 2006 Jul;20(7)1238-44.","abstract":null},{"pmid":"2900030","title":"Chromosome translocations involving band 7q35 or 7p15 in childhood T-cell leukemia/lymphoma.","journal":"Blood","pubDate":"1988 Aug","volume":"72","issue":"2","pages":"534-8","authors":"Kaneko Y et al","elocationId":"","link":null,"reference":"Kaneko Y et al. Blood. 1988 Aug;72(2)534-8.","abstract":null},{"pmid":"16079112","title":"Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia.","journal":"Haematologica","pubDate":"2005 Aug","volume":"90","issue":"8","pages":"1116-27","authors":"De Keersmaecker K et al","elocationId":"","link":null,"reference":"De Keersmaecker K et al. Haematologica. 2005 Aug;90(8)1116-27.","abstract":null}]},{"id":22596,"uuid":"71d38349-dfa2-4e4e-a43e-635258557d65","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":156,"subtype":"T-Cell Prolymphocytic Leukemia","code":"TPLL","color":"LimeGreen","mainType":"Mature T and NK Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8115,"hugoSymbol":"TCL1A","oncogene":true,"grch37Isoform":"ENST00000402399","grch37RefSeq":"NM_001098725.1","grch38Isoform":"ENST00000402399","grch38RefSeq":"NM_001098725.1","geneAliases":["TCL1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":8115,"hugoSymbol":"TCL1A","oncogene":true,"grch37Isoform":"ENST00000402399","grch37RefSeq":"NM_001098725.1","grch38Isoform":"ENST00000402399","grch38RefSeq":"NM_001098725.1","geneAliases":["TCL1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"TRA-TCL1A Fusion","name":"TRA-TCL1A Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"26917488","title":"Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.","journal":"British journal of haematology","pubDate":"2016 Apr","volume":"173","issue":"2","pages":"265-73","authors":"López C et al","elocationId":"doi: 10.1111/bjh.13952","link":null,"reference":"López C et al. British journal of haematology. 2016 Apr;173(2)265-73.","abstract":null},{"pmid":"10077617","title":"Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes.","journal":"Proceedings of the National Academy of Sciences of the United States of America","pubDate":"1999 Mar 16","volume":"96","issue":"6","pages":"2949-51","authors":"Pekarsky Y et al","elocationId":"","link":null,"reference":"Pekarsky Y et al. Proceedings of the National Academy of Sciences of the United States of America. 1999 Mar 16;96(6)2949-51.","abstract":null}]},{"id":12743,"uuid":"08ecfabc-8ab9-436f-862b-06af5c61169c","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":791,"subtype":"AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1","code":"AMLRUNX1RUNX1T1","color":"LightSalmon","mainType":"Leukemia","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"16921041","title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2006 Aug 20","volume":"24","issue":"24","pages":"3904-11","authors":"Paschka P et al","elocationId":"","link":null,"reference":"Paschka P et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Aug 20;24(24)3904-11.","abstract":null}]},{"id":16839,"uuid":"704621a2-992f-49a6-9027-40b11da2abc7","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"29146900","title":"The genomic landscape of pediatric myelodysplastic syndromes.","journal":"Nature communications","pubDate":"2017 Nov 16","volume":"8","issue":"1","pages":"1557","authors":"Schwartz JR et al","elocationId":"doi: 10.1038/s41467-017-01590-5","link":null,"reference":"Schwartz JR et al. Nature communications. 2017 Nov 16;8(1)1557.","abstract":null},{"pmid":"21714648","title":"Clinical effect of point mutations in myelodysplastic syndromes.","journal":"The New England journal of medicine","pubDate":"2011 Jun 30","volume":"364","issue":"26","pages":"2496-506","authors":"Bejar R et al","elocationId":"doi: 10.1056/NEJMoa1013343","link":null,"reference":"Bejar R et al. The New England journal of medicine. 2011 Jun 30;364(26)2496-506.","abstract":null},{"pmid":"24881041","title":"Clinical and genetic predictors of prognosis in myelodysplastic syndromes.","journal":"Haematologica","pubDate":"2014 Jun","volume":"99","issue":"6","pages":"956-64","authors":"Bejar R","elocationId":"doi: 10.3324/haematol.2013.085217","link":null,"reference":"Bejar R. Haematologica. 2014 Jun;99(6)956-64.","abstract":null},{"pmid":"24030381","title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes.","journal":"Blood","pubDate":"2013 Nov 21","volume":"122","issue":"22","pages":"3616-27; quiz 3699","authors":"Papaemmanuil E et al","elocationId":"doi: 10.1182/blood-2013-08-518886","link":null,"reference":"Papaemmanuil E et al. Blood. 2013 Nov 21;122(22)3616-27; quiz 3699.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null}]},{"id":19911,"uuid":"e092ed5e-7ac9-4572-b836-06e96c256ace","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":692,"subtype":"Juvenile Myelomonocytic Leukemia","code":"JMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5781,"hugoSymbol":"PTPN11","oncogene":true,"grch37Isoform":"ENST00000351677","grch37RefSeq":"NM_002834.3","grch38Isoform":"ENST00000351677","grch38RefSeq":"NM_002834.3","geneAliases":["JMML","CFC","SHP2","PTP2C","PTP-1D","NS1","BPTP3","METCDS","SH-PTP3","SH-PTP2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5781,"hugoSymbol":"PTPN11","oncogene":true,"grch37Isoform":"ENST00000351677","grch37RefSeq":"NM_002834.3","grch38Isoform":"ENST00000351677","grch38RefSeq":"NM_002834.3","geneAliases":["JMML","CFC","SHP2","PTP2C","PTP-1D","NS1","BPTP3","METCDS","SH-PTP3","SH-PTP2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"14644997","title":"Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.","journal":"Blood","pubDate":"2004 Mar 15","volume":"103","issue":"6","pages":"2325-31","authors":"Loh ML et al","elocationId":"","link":null,"reference":"Loh ML et al. Blood. 2004 Mar 15;103(6)2325-31.","abstract":null},{"pmid":"12717436","title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.","journal":"Nature genetics","pubDate":"2003 Jun","volume":"34","issue":"2","pages":"148-50","authors":"Tartaglia M et al","elocationId":"","link":null,"reference":"Tartaglia M et al. Nature genetics. 2003 Jun;34(2)148-50.","abstract":null}]},{"id":5576,"uuid":"d326ddee-1bbf-4386-9ca0-fafb7fa59466","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":184,"subtype":"AML with BCR-ABL1","code":"AMLBCRABL1","color":"LightSalmon","mainType":"Leukemia","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1029,"hugoSymbol":"CDKN2A","oncogene":false,"grch37Isoform":"ENST00000304494","grch37RefSeq":"NM_000077.4","grch38Isoform":"ENST00000304494","grch38RefSeq":"NM_000077.4","geneAliases":["P16INK4A","CDKN2Ap14ARF","MTS1","TP16","P16INK4","CDKN2Ap14IRF","INK4","P14ARF","P19ARF","MLM","CMM2","P14","MTS-1","P16","ARF","P19","INK4A","P16-INK4A","CDKN2","CDKN2Ap16INK4A"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":1029,"hugoSymbol":"CDKN2A","oncogene":false,"grch37Isoform":"ENST00000304494","grch37RefSeq":"NM_000077.4","grch38Isoform":"ENST00000304494","grch38RefSeq":"NM_000077.4","geneAliases":["P16INK4A","CDKN2Ap14ARF","MTS1","TP16","P16INK4","CDKN2Ap14IRF","INK4","P14ARF","P19ARF","MLM","CMM2","P14","MTS-1","P16","ARF","P19","INK4A","P16-INK4A","CDKN2","CDKN2Ap16INK4A"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Deletion","name":"Deletion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23521501","title":"Does BCR/ABL1 positive acute myeloid leukaemia exist?","journal":"British journal of haematology","pubDate":"2013 May","volume":"161","issue":"4","pages":"541-50","authors":"Nacheva EP et al","elocationId":"doi: 10.1111/bjh.12301","link":null,"reference":"Nacheva EP et al. British journal of haematology. 2013 May;161(4)541-50.","abstract":null}]},{"id":23625,"uuid":"be9d826e-2092-4034-89bb-179c54a001db","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":293,"subtype":"T-Lymphoblastic Leukemia/Lymphoma","code":"TLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6964,"hugoSymbol":"TRD","oncogene":true,"grch37Isoform":"","grch37RefSeq":"","grch38Isoform":"","grch38RefSeq":"","geneAliases":["TCRDV1","TCRD","TRD@"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6964,"hugoSymbol":"TRD","oncogene":true,"grch37Isoform":"","grch37RefSeq":"","grch38Isoform":"","grch38RefSeq":"","geneAliases":["TCRDV1","TCRD","TRD@"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"16826225","title":"Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast.","journal":"Leukemia","pubDate":"2006 Sep","volume":"20","issue":"9","pages":"1496-510","authors":"Graux C et al","elocationId":"","link":null,"reference":"Graux C et al. Leukemia. 2006 Sep;20(9)1496-510.","abstract":null},{"pmid":"16673021","title":"Molecular cytogenetic study of 126 unselected T-ALL cases reveals high incidence of TCRbeta locus rearrangements and putative new T-cell oncogenes.","journal":"Leukemia","pubDate":"2006 Jul","volume":"20","issue":"7","pages":"1238-44","authors":"Cauwelier B et al","elocationId":"","link":null,"reference":"Cauwelier B et al. Leukemia. 2006 Jul;20(7)1238-44.","abstract":null},{"pmid":"2900030","title":"Chromosome translocations involving band 7q35 or 7p15 in childhood T-cell leukemia/lymphoma.","journal":"Blood","pubDate":"1988 Aug","volume":"72","issue":"2","pages":"534-8","authors":"Kaneko Y et al","elocationId":"","link":null,"reference":"Kaneko Y et al. Blood. 1988 Aug;72(2)534-8.","abstract":null},{"pmid":"16079112","title":"Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia.","journal":"Haematologica","pubDate":"2005 Aug","volume":"90","issue":"8","pages":"1116-27","authors":"De Keersmaecker K et al","elocationId":"","link":null,"reference":"De Keersmaecker K et al. Haematologica. 2005 Aug;90(8)1116-27.","abstract":null}]},{"id":22857,"uuid":"db44e7d6-441f-4b7c-9948-db3587bf89a1","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":293,"subtype":"T-Lymphoblastic Leukemia/Lymphoma","code":"TLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":30012,"hugoSymbol":"TLX3","oncogene":true,"grch37Isoform":"ENST00000296921","grch37RefSeq":"NM_021025.2","grch38Isoform":"ENST00000296921","grch38RefSeq":"NM_021025.2","geneAliases":["HOX11L2","RNX"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":30012,"hugoSymbol":"TLX3","oncogene":true,"grch37Isoform":"ENST00000296921","grch37RefSeq":"NM_021025.2","grch38Isoform":"ENST00000296921","grch38RefSeq":"NM_021025.2","geneAliases":["HOX11L2","RNX"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"11587205","title":"A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia.","journal":"Leukemia","pubDate":"2001 Oct","volume":"15","issue":"10","pages":"1495-504","authors":"Bernard OA et al","elocationId":"","link":null,"reference":"Bernard OA et al. Leukemia. 2001 Oct;15(10)1495-504.","abstract":null},{"pmid":"18185524","title":"Cooperative genetic defects in TLX3 rearranged pediatric T-ALL.","journal":"Leukemia","pubDate":"2008 Apr","volume":"22","issue":"4","pages":"762-70","authors":"Van Vlierberghe P et al","elocationId":"doi: 10.1038/sj.leu.2405082","link":null,"reference":"Van Vlierberghe P et al. Leukemia. 2008 Apr;22(4)762-70.","abstract":null},{"pmid":"29279377","title":"Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia.","journal":"Proceedings of the National Academy of Sciences of the United States of America","pubDate":"2018 Jan 9","volume":"115","issue":"2","pages":"373-378","authors":"Chen B et al","elocationId":"doi: 10.1073/pnas.1717125115","link":null,"reference":"Chen B et al. Proceedings of the National Academy of Sciences of the United States of America. 2018 Jan 9;115(2)373-378.","abstract":null}]},{"id":5578,"uuid":"444e4fde-517c-4f63-a211-266bf3272661","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1029,"hugoSymbol":"CDKN2A","oncogene":false,"grch37Isoform":"ENST00000304494","grch37RefSeq":"NM_000077.4","grch38Isoform":"ENST00000304494","grch38RefSeq":"NM_000077.4","geneAliases":["P16INK4A","CDKN2Ap14ARF","MTS1","TP16","P16INK4","CDKN2Ap14IRF","INK4","P14ARF","P19ARF","MLM","CMM2","P14","MTS-1","P16","ARF","P19","INK4A","P16-INK4A","CDKN2","CDKN2Ap16INK4A"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":1029,"hugoSymbol":"CDKN2A","oncogene":false,"grch37Isoform":"ENST00000304494","grch37RefSeq":"NM_000077.4","grch38Isoform":"ENST00000304494","grch38RefSeq":"NM_000077.4","geneAliases":["P16INK4A","CDKN2Ap14ARF","MTS1","TP16","P16INK4","CDKN2Ap14IRF","INK4","P14ARF","P19ARF","MLM","CMM2","P14","MTS-1","P16","ARF","P19","INK4A","P16-INK4A","CDKN2","CDKN2Ap16INK4A"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Deletion","name":"Deletion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"18838613","title":"A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups.","journal":"Blood","pubDate":"2009 Jan 1","volume":"113","issue":"1","pages":"100-7","authors":"Sulong S et al","elocationId":"doi: 10.1182/blood-2008-07-166801","link":null,"reference":"Sulong S et al. Blood. 2009 Jan 1;113(1)100-7.","abstract":null}]},{"id":22602,"uuid":"ea2398f9-1700-495c-a51c-4ab2c68c7f54","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":156,"subtype":"T-Cell Prolymphocytic Leukemia","code":"TPLL","color":"LimeGreen","mainType":"Mature T and NK Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":9623,"hugoSymbol":"TCL1B","oncogene":true,"grch37Isoform":"ENST00000340722","grch37RefSeq":"NM_004918.3","grch38Isoform":"ENST00000340722","grch38RefSeq":"NM_004918.3","geneAliases":["SYN-1","TML1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":9623,"hugoSymbol":"TCL1B","oncogene":true,"grch37Isoform":"ENST00000340722","grch37RefSeq":"NM_004918.3","grch38Isoform":"ENST00000340722","grch38RefSeq":"NM_004918.3","geneAliases":["SYN-1","TML1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"TRA-TCL1B Fusion","name":"TRA-TCL1B Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"10077617","title":"Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes.","journal":"Proceedings of the National Academy of Sciences of the United States of America","pubDate":"1999 Mar 16","volume":"96","issue":"6","pages":"2949-51","authors":"Pekarsky Y et al","elocationId":"","link":null,"reference":"Pekarsky Y et al. Proceedings of the National Academy of Sciences of the United States of America. 1999 Mar 16;96(6)2949-51.","abstract":null}]},{"id":1227,"uuid":"7319e0bf-749e-4c9d-a7c8-0bb806c32b87","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":224,"subtype":"Chronic Myelomonocytic Leukemia","code":"CMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":171023,"hugoSymbol":"ASXL1","oncogene":false,"grch37Isoform":"ENST00000375687","grch37RefSeq":"NM_015338.5","grch38Isoform":"ENST00000375687","grch38RefSeq":"NM_015338.5","geneAliases":["BOPS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":171023,"hugoSymbol":"ASXL1","oncogene":false,"grch37Isoform":"ENST00000375687","grch37RefSeq":"NM_015338.5","grch38Isoform":"ENST00000375687","grch38RefSeq":"NM_015338.5","geneAliases":["BOPS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22919025","title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).","journal":"Blood","pubDate":"2012 Oct 11","volume":"120","issue":"15","pages":"3080-8","authors":"Meggendorfer M et al","elocationId":"doi: 10.1182/blood-2012-01-404863","link":null,"reference":"Meggendorfer M et al. Blood. 2012 Oct 11;120(15)3080-8.","abstract":null},{"pmid":"24695057","title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.","journal":"Leukemia","pubDate":"2014 Nov","volume":"28","issue":"11","pages":"2206-12","authors":"Patnaik MM et al","elocationId":"doi: 10.1038/leu.2014.125","link":null,"reference":"Patnaik MM et al. Leukemia. 2014 Nov;28(11)2206-12.","abstract":null}]},{"id":4812,"uuid":"267bfede-31f0-4536-801c-8c17f088e2d1","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":695,"subtype":"Essential Thrombocythemia","code":"ET","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":811,"hugoSymbol":"CALR","oncogene":true,"grch37Isoform":"ENST00000316448","grch37RefSeq":"NM_004343.3","grch38Isoform":"ENST00000316448","grch38RefSeq":"NM_004343.3","geneAliases":["SSA","cC1qR","CRT","HEL-S-99n","RO"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":811,"hugoSymbol":"CALR","oncogene":true,"grch37Isoform":"ENST00000316448","grch37RefSeq":"NM_004343.3","grch38Isoform":"ENST00000316448","grch38RefSeq":"NM_004343.3","geneAliases":["SSA","cC1qR","CRT","HEL-S-99n","RO"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"29296692","title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia.","journal":"Blood advances","pubDate":"2016 Nov 29","volume":"1","issue":"1","pages":"21-30","authors":"Tefferi A et al","elocationId":"doi: 10.1182/bloodadvances.2016000216","link":null,"reference":"Tefferi A et al. Blood advances. 2016 Nov 29;1(1)21-30.","abstract":null},{"pmid":"27069254","title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","journal":"Blood","pubDate":"2016 May 19","volume":"127","issue":"20","pages":"2391-405","authors":"Arber DA et al","elocationId":"doi: 10.1182/blood-2016-03-643544","link":null,"reference":"Arber DA et al. Blood. 2016 May 19;127(20)2391-405.","abstract":null},{"pmid":"25037629","title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.","journal":"Blood","pubDate":"2014 Oct 16","volume":"124","issue":"16","pages":"2507-13; quiz 2615","authors":"Tefferi A et al","elocationId":"doi: 10.1182/blood-2014-05-579136","link":null,"reference":"Tefferi A et al. Blood. 2014 Oct 16;124(16)2507-13; quiz 2615.","abstract":null},{"pmid":"26449662","title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.","journal":"Leukemia","pubDate":"2016 Feb","volume":"30","issue":"2","pages":"431-8","authors":"Pietra D et al","elocationId":"doi: 10.1038/leu.2015.277","link":null,"reference":"Pietra D et al. Leukemia. 2016 Feb;30(2)431-8.","abstract":null},{"pmid":"24791854","title":"Calreticulin mutations and long-term survival in essential thrombocythemia.","journal":"Leukemia","pubDate":"2014 Dec","volume":"28","issue":"12","pages":"2300-3","authors":"Tefferi A et al","elocationId":"doi: 10.1038/leu.2014.148","link":null,"reference":"Tefferi A et al. Leukemia. 2014 Dec;28(12)2300-3.","abstract":null}]},{"id":5580,"uuid":"b16d45e6-f3f1-4729-90db-da1942dd0fc8","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":293,"subtype":"T-Lymphoblastic Leukemia/Lymphoma","code":"TLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1029,"hugoSymbol":"CDKN2A","oncogene":false,"grch37Isoform":"ENST00000304494","grch37RefSeq":"NM_000077.4","grch38Isoform":"ENST00000304494","grch38RefSeq":"NM_000077.4","geneAliases":["P16INK4A","CDKN2Ap14ARF","MTS1","TP16","P16INK4","CDKN2Ap14IRF","INK4","P14ARF","P19ARF","MLM","CMM2","P14","MTS-1","P16","ARF","P19","INK4A","P16-INK4A","CDKN2","CDKN2Ap16INK4A"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":1029,"hugoSymbol":"CDKN2A","oncogene":false,"grch37Isoform":"ENST00000304494","grch37RefSeq":"NM_000077.4","grch38Isoform":"ENST00000304494","grch38RefSeq":"NM_000077.4","geneAliases":["P16INK4A","CDKN2Ap14ARF","MTS1","TP16","P16INK4","CDKN2Ap14IRF","INK4","P14ARF","P19ARF","MLM","CMM2","P14","MTS-1","P16","ARF","P19","INK4A","P16-INK4A","CDKN2","CDKN2Ap16INK4A"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Deletion","name":"Deletion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"18838613","title":"A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups.","journal":"Blood","pubDate":"2009 Jan 1","volume":"113","issue":"1","pages":"100-7","authors":"Sulong S et al","elocationId":"doi: 10.1182/blood-2008-07-166801","link":null,"reference":"Sulong S et al. Blood. 2009 Jan 1;113(1)100-7.","abstract":null},{"pmid":"16079112","title":"Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia.","journal":"Haematologica","pubDate":"2005 Aug","volume":"90","issue":"8","pages":"1116-27","authors":"De Keersmaecker K et al","elocationId":"","link":null,"reference":"De Keersmaecker K et al. Haematologica. 2005 Aug;90(8)1116-27.","abstract":null}]},{"id":16204,"uuid":"b5c3beb4-9a5c-459a-b9bc-25e273e42901","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":23,"subtype":"Burkitt Lymphoma","code":"BL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4609,"hugoSymbol":"MYC","oncogene":true,"grch37Isoform":"ENST00000377970","grch37RefSeq":"NM_002467.4","grch38Isoform":"ENST00000621592","grch38RefSeq":"NM_002467.4","geneAliases":["c-Myc","MYCC","MRTL","bHLHe39"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4609,"hugoSymbol":"MYC","oncogene":true,"grch37Isoform":"ENST00000377970","grch37RefSeq":"NM_002467.4","grch38Isoform":"ENST00000621592","grch38RefSeq":"NM_002467.4","geneAliases":["c-Myc","MYCC","MRTL","bHLHe39"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"16614233","title":"Burkitt's lymphoma: clinicopathologic features and differential diagnosis.","journal":"The oncologist","pubDate":"2006 Apr","volume":"11","issue":"4","pages":"375-83","authors":"Ferry JA","elocationId":"","link":null,"reference":"Ferry JA. The oncologist. 2006 Apr;11(4)375-83.","abstract":null}]},{"id":16333,"uuid":"d0247e3b-0a00-4a1c-9dc1-6b69b4f3fbb5","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":224,"subtype":"Chronic Myelomonocytic Leukemia","code":"CMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4763,"hugoSymbol":"NF1","oncogene":false,"grch37Isoform":"ENST00000356175","grch37RefSeq":"NM_000267","grch38Isoform":"ENST00000356175","grch38RefSeq":"NM_000267","geneAliases":["WSS","NFNS","VRNF"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4763,"hugoSymbol":"NF1","oncogene":false,"grch37Isoform":"ENST00000356175","grch37RefSeq":"NM_000267","grch38Isoform":"ENST00000356175","grch38RefSeq":"NM_000267","geneAliases":["WSS","NFNS","VRNF"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"18925961","title":"Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.","journal":"BMC cancer","pubDate":"2008 Oct 16","volume":"8","issue":"","pages":"299","authors":"Gelsi-Boyer V et al","elocationId":"doi: 10.1186/1471-2407-8-299","link":null,"reference":"Gelsi-Boyer V et al. BMC cancer. 2008 Oct 16;8()299.","abstract":null}]},{"id":4814,"uuid":"ef93fee5-764b-4094-807a-9e75f6393af0","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":801,"subtype":"MDS/MPN with Ring Sideroblasts and Thrombocytosis","code":"MDSMPNRST","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":811,"hugoSymbol":"CALR","oncogene":true,"grch37Isoform":"ENST00000316448","grch37RefSeq":"NM_004343.3","grch38Isoform":"ENST00000316448","grch38RefSeq":"NM_004343.3","geneAliases":["SSA","cC1qR","CRT","HEL-S-99n","RO"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":811,"hugoSymbol":"CALR","oncogene":true,"grch37Isoform":"ENST00000316448","grch37RefSeq":"NM_004343.3","grch38Isoform":"ENST00000316448","grch38RefSeq":"NM_004343.3","geneAliases":["SSA","cC1qR","CRT","HEL-S-99n","RO"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25926061","title":"Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis.","journal":"Leukemia & lymphoma","pubDate":"2016","volume":"57","issue":"1","pages":"212-5","authors":"Visconte V et al","elocationId":"doi: 10.3109/10428194.2015.1045895","link":null,"reference":"Visconte V et al. Leukemia & lymphoma. 2016;57(1)212-5.","abstract":null},{"pmid":"24325356","title":"Somatic mutations of calreticulin in myeloproliferative neoplasms.","journal":"The New England journal of medicine","pubDate":"2013 Dec 19","volume":"369","issue":"25","pages":"2379-90","authors":"Klampfl T et al","elocationId":"doi: 10.1056/NEJMoa1311347","link":null,"reference":"Klampfl T et al. The New England journal of medicine. 2013 Dec 19;369(25)2379-90.","abstract":null}]},{"id":1231,"uuid":"bd491225-2dce-425e-a6dc-99aa56340c75","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":171023,"hugoSymbol":"ASXL1","oncogene":false,"grch37Isoform":"ENST00000375687","grch37RefSeq":"NM_015338.5","grch38Isoform":"ENST00000375687","grch38RefSeq":"NM_015338.5","geneAliases":["BOPS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":171023,"hugoSymbol":"ASXL1","oncogene":false,"grch37Isoform":"ENST00000375687","grch37RefSeq":"NM_015338.5","grch38Isoform":"ENST00000375687","grch38RefSeq":"NM_015338.5","geneAliases":["BOPS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22919025","title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).","journal":"Blood","pubDate":"2012 Oct 11","volume":"120","issue":"15","pages":"3080-8","authors":"Meggendorfer M et al","elocationId":"doi: 10.1182/blood-2012-01-404863","link":null,"reference":"Meggendorfer M et al. Blood. 2012 Oct 11;120(15)3080-8.","abstract":null},{"pmid":"24695057","title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.","journal":"Leukemia","pubDate":"2014 Nov","volume":"28","issue":"11","pages":"2206-12","authors":"Patnaik MM et al","elocationId":"doi: 10.1038/leu.2014.125","link":null,"reference":"Patnaik MM et al. Leukemia. 2014 Nov;28(11)2206-12.","abstract":null}]},{"id":23631,"uuid":"d50bb5a0-5afe-47dc-8492-0d372d5faddb","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":293,"subtype":"T-Lymphoblastic Leukemia/Lymphoma","code":"TLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6965,"hugoSymbol":"TRG","oncogene":true,"grch37Isoform":"","grch37RefSeq":"","grch38Isoform":"","grch38RefSeq":"","geneAliases":["TRG@","TCRG"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6965,"hugoSymbol":"TRG","oncogene":true,"grch37Isoform":"","grch37RefSeq":"","grch38Isoform":"","grch38RefSeq":"","geneAliases":["TRG@","TCRG"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"16826225","title":"Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast.","journal":"Leukemia","pubDate":"2006 Sep","volume":"20","issue":"9","pages":"1496-510","authors":"Graux C et al","elocationId":"","link":null,"reference":"Graux C et al. Leukemia. 2006 Sep;20(9)1496-510.","abstract":null},{"pmid":"16673021","title":"Molecular cytogenetic study of 126 unselected T-ALL cases reveals high incidence of TCRbeta locus rearrangements and putative new T-cell oncogenes.","journal":"Leukemia","pubDate":"2006 Jul","volume":"20","issue":"7","pages":"1238-44","authors":"Cauwelier B et al","elocationId":"","link":null,"reference":"Cauwelier B et al. Leukemia. 2006 Jul;20(7)1238-44.","abstract":null},{"pmid":"2900030","title":"Chromosome translocations involving band 7q35 or 7p15 in childhood T-cell leukemia/lymphoma.","journal":"Blood","pubDate":"1988 Aug","volume":"72","issue":"2","pages":"534-8","authors":"Kaneko Y et al","elocationId":"","link":null,"reference":"Kaneko Y et al. Blood. 1988 Aug;72(2)534-8.","abstract":null},{"pmid":"16079112","title":"Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia.","journal":"Haematologica","pubDate":"2005 Aug","volume":"90","issue":"8","pages":"1116-27","authors":"De Keersmaecker K et al","elocationId":"","link":null,"reference":"De Keersmaecker K et al. Haematologica. 2005 Aug;90(8)1116-27.","abstract":null}]},{"id":16335,"uuid":"13ed18cf-ecf7-4f8c-b8bd-9614e2c3e5ea","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":692,"subtype":"Juvenile Myelomonocytic Leukemia","code":"JMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4763,"hugoSymbol":"NF1","oncogene":false,"grch37Isoform":"ENST00000356175","grch37RefSeq":"NM_000267","grch38Isoform":"ENST00000356175","grch38RefSeq":"NM_000267","geneAliases":["WSS","NFNS","VRNF"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4763,"hugoSymbol":"NF1","oncogene":false,"grch37Isoform":"ENST00000356175","grch37RefSeq":"NM_000267","grch38Isoform":"ENST00000356175","grch38RefSeq":"NM_000267","geneAliases":["WSS","NFNS","VRNF"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23832011","title":"Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.","journal":"Nature genetics","pubDate":"2013 Aug","volume":"45","issue":"8","pages":"937-41","authors":"Sakaguchi H et al","elocationId":"doi: 10.1038/ng.2698","link":null,"reference":"Sakaguchi H et al. Nature genetics. 2013 Aug;45(8)937-41.","abstract":null},{"pmid":"14644997","title":"Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.","journal":"Blood","pubDate":"2004 Mar 15","volume":"103","issue":"6","pages":"2325-31","authors":"Loh ML et al","elocationId":"","link":null,"reference":"Loh ML et al. Blood. 2004 Mar 15;103(6)2325-31.","abstract":null},{"pmid":"26457647","title":"The genomic landscape of juvenile myelomonocytic leukemia.","journal":"Nature genetics","pubDate":"2015 Nov","volume":"47","issue":"11","pages":"1326-1333","authors":"Stieglitz E et al","elocationId":"doi: 10.1038/ng.3400","link":null,"reference":"Stieglitz E et al. Nature genetics. 2015 Nov;47(11)1326-1333.","abstract":null},{"pmid":"9639526","title":"Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1.","journal":"Blood","pubDate":"1998 Jul 1","volume":"92","issue":"1","pages":"267-72","authors":"Side LE et al","elocationId":"","link":null,"reference":"Side LE et al. Blood. 1998 Jul 1;92(1)267-72.","abstract":null}]},{"id":4816,"uuid":"53bc893b-eefc-4b9a-80ed-382348a0b512","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":831,"subtype":"Myeloproliferative Neoplasms, Unclassifiable","code":"MPNU","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":811,"hugoSymbol":"CALR","oncogene":true,"grch37Isoform":"ENST00000316448","grch37RefSeq":"NM_004343.3","grch38Isoform":"ENST00000316448","grch38RefSeq":"NM_004343.3","geneAliases":["SSA","cC1qR","CRT","HEL-S-99n","RO"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":811,"hugoSymbol":"CALR","oncogene":true,"grch37Isoform":"ENST00000316448","grch37RefSeq":"NM_004343.3","grch38Isoform":"ENST00000316448","grch38RefSeq":"NM_004343.3","geneAliases":["SSA","cC1qR","CRT","HEL-S-99n","RO"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25873496","title":"CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.","journal":"American journal of clinical pathology","pubDate":"2015 May","volume":"143","issue":"5","pages":"635-44","authors":"Kim SY et al","elocationId":"doi: 10.1309/AJCPUAAC16LIWZMM","link":null,"reference":"Kim SY et al. American journal of clinical pathology. 2015 May;143(5)635-44.","abstract":null}]},{"id":4820,"uuid":"d258a298-e47c-4418-8dd0-6544774f519e","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":632,"subtype":"Primary Myelofibrosis","code":"PMF","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":811,"hugoSymbol":"CALR","oncogene":true,"grch37Isoform":"ENST00000316448","grch37RefSeq":"NM_004343.3","grch38Isoform":"ENST00000316448","grch38RefSeq":"NM_004343.3","geneAliases":["SSA","cC1qR","CRT","HEL-S-99n","RO"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":811,"hugoSymbol":"CALR","oncogene":true,"grch37Isoform":"ENST00000316448","grch37RefSeq":"NM_004343.3","grch38Isoform":"ENST00000316448","grch38RefSeq":"NM_004343.3","geneAliases":["SSA","cC1qR","CRT","HEL-S-99n","RO"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24569778","title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact.","journal":"Leukemia","pubDate":"2014 Jul","volume":"28","issue":"7","pages":"1568-70","authors":"Tefferi A et al","elocationId":"doi: 10.1038/leu.2014.83","link":null,"reference":"Tefferi A et al. Leukemia. 2014 Jul;28(7)1568-70.","abstract":null},{"pmid":"27069254","title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","journal":"Blood","pubDate":"2016 May 19","volume":"127","issue":"20","pages":"2391-405","authors":"Arber DA et al","elocationId":"doi: 10.1182/blood-2016-03-643544","link":null,"reference":"Arber DA et al. Blood. 2016 May 19;127(20)2391-405.","abstract":null},{"pmid":"26449662","title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.","journal":"Leukemia","pubDate":"2016 Feb","volume":"30","issue":"2","pages":"431-8","authors":"Pietra D et al","elocationId":"doi: 10.1038/leu.2015.277","link":null,"reference":"Pietra D et al. Leukemia. 2016 Feb;30(2)431-8.","abstract":null},{"pmid":"24986690","title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.","journal":"Blood","pubDate":"2014 Aug 14","volume":"124","issue":"7","pages":"1062-9","authors":"Rumi E et al","elocationId":"doi: 10.1182/blood-2014-05-578435","link":null,"reference":"Rumi E et al. Blood. 2014 Aug 14;124(7)1062-9.","abstract":null}]},{"id":11223,"uuid":"b4493eea-3b37-4f86-b80a-372d91e0bd8e","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2623,"hugoSymbol":"GATA1","oncogene":false,"grch37Isoform":"ENST00000376670","grch37RefSeq":"NM_002049.3","grch38Isoform":"ENST00000376670","grch38RefSeq":"NM_002049.3","geneAliases":["NFE1","GF-1","XLANP","ERYF1","XLTDA","GATA-1","XLTT"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2623,"hugoSymbol":"GATA1","oncogene":false,"grch37Isoform":"ENST00000376670","grch37RefSeq":"NM_002049.3","grch38Isoform":"ENST00000376670","grch38RefSeq":"NM_002049.3","geneAliases":["NFE1","GF-1","XLANP","ERYF1","XLTDA","GATA-1","XLTT"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"MYB-GATA1 Fusion","name":"MYB-GATA1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"21474671","title":"Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants.","journal":"Blood","pubDate":"2011 May 26","volume":"117","issue":"21","pages":"5719-22","authors":"Quelen C et al","elocationId":"doi: 10.1182/blood-2011-01-333013","link":null,"reference":"Quelen C et al. Blood. 2011 May 26;117(21)5719-22.","abstract":null},{"pmid":"9233581","title":"Acute basophilic leukaemia and translocation t(X;6)(p11;q23).","journal":"British journal of haematology","pubDate":"1997 Jul","volume":"98","issue":"1","pages":"170-6","authors":"Dastugue N et al","elocationId":"","link":null,"reference":"Dastugue N et al. British journal of haematology. 1997 Jul;98(1)170-6.","abstract":null}]},{"id":11225,"uuid":"4378a113-4ed0-4119-917f-dd7c0025261c","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":844,"subtype":"Myeloid Proliferations Related to Down Syndrome","code":"MPRDS","color":"LightSalmon","mainType":"Leukemia","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2623,"hugoSymbol":"GATA1","oncogene":false,"grch37Isoform":"ENST00000376670","grch37RefSeq":"NM_002049.3","grch38Isoform":"ENST00000376670","grch38RefSeq":"NM_002049.3","geneAliases":["NFE1","GF-1","XLANP","ERYF1","XLTDA","GATA-1","XLTT"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2623,"hugoSymbol":"GATA1","oncogene":false,"grch37Isoform":"ENST00000376670","grch37RefSeq":"NM_002049.3","grch38Isoform":"ENST00000376670","grch38RefSeq":"NM_002049.3","geneAliases":["NFE1","GF-1","XLANP","ERYF1","XLTDA","GATA-1","XLTT"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"20729467","title":"Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia.","journal":"Blood","pubDate":"2010 Nov 25","volume":"116","issue":"22","pages":"4631-8","authors":"Kanezaki R et al","elocationId":"doi: 10.1182/blood-2010-05-282426","link":null,"reference":"Kanezaki R et al. Blood. 2010 Nov 25;116(22)4631-8.","abstract":null},{"pmid":"17224656","title":"Molecular insights into Down syndrome-associated leukemia.","journal":"Current opinion in pediatrics","pubDate":"2007 Feb","volume":"19","issue":"1","pages":"9-14","authors":"Vyas P et al","elocationId":"","link":null,"reference":"Vyas P et al. Current opinion in pediatrics. 2007 Feb;19(1)9-14.","abstract":null},{"pmid":"12586620","title":"GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.","journal":"Blood","pubDate":"2003 Jun 1","volume":"101","issue":"11","pages":"4301-4","authors":"Hitzler JK et al","elocationId":"","link":null,"reference":"Hitzler JK et al. Blood. 2003 Jun 1;101(11)4301-4.","abstract":null},{"pmid":"14636651","title":"Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.","journal":"Blood cells, molecules & diseases","pubDate":"2003 Nov-Dec","volume":"31","issue":"3","pages":"351-6","authors":"Greene ME et al","elocationId":"","link":null,"reference":"Greene ME et al. Blood cells, molecules & diseases. 2003 Nov-Dec;31(3)351-6.","abstract":null},{"pmid":"16631466","title":"GATA1 mutations in acute leukemia in children with Down syndrome.","journal":"Cancer genetics and cytogenetics","pubDate":"2006 Apr 15","volume":"166","issue":"2","pages":"112-6","authors":"Magalhães IQ et al","elocationId":"","link":null,"reference":"Magalhães IQ et al. Cancer genetics and cytogenetics. 2006 Apr 15;166(2)112-6.","abstract":null}]},{"id":5081,"uuid":"b57fe6a3-73ca-4bd7-ae8c-52cc415ccd58","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":586,"subtype":"Mantle Cell Lymphoma","code":"MCL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":595,"hugoSymbol":"CCND1","oncogene":true,"grch37Isoform":"ENST00000227507","grch37RefSeq":"NM_053056.2","grch38Isoform":"ENST00000227507","grch38RefSeq":"NM_053056.2","geneAliases":["PRAD1","D11S287E","BCL1","U21B31"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":595,"hugoSymbol":"CCND1","oncogene":true,"grch37Isoform":"ENST00000227507","grch37RefSeq":"NM_053056.2","grch38Isoform":"ENST00000227507","grch38RefSeq":"NM_053056.2","geneAliases":["PRAD1","D11S287E","BCL1","U21B31"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"IGH-CCND1 Fusion","name":"IGH-CCND1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"1682919","title":"PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.","journal":"Proceedings of the National Academy of Sciences of the United States of America","pubDate":"1991 Nov 1","volume":"88","issue":"21","pages":"9638-42","authors":"Rosenberg CL et al","elocationId":"","link":null,"reference":"Rosenberg CL et al. Proceedings of the National Academy of Sciences of the United States of America. 1991 Nov 1;88(21)9638-42.","abstract":null},{"pmid":"31015206","title":"Characterization of a cryptic <i>IGH/CCND1</i> rearrangement in a case of mantle cell lymphoma with negative <i>CCND1</i> FISH studies.","journal":"Blood advances","pubDate":"2019 Apr 23","volume":"3","issue":"8","pages":"1298-1302","authors":"Peterson JF et al","elocationId":"doi: 10.1182/bloodadvances.2019031450","link":null,"reference":"Peterson JF et al. Blood advances. 2019 Apr 23;3(8)1298-1302.","abstract":null},{"pmid":"10329598","title":"Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization.","journal":"The American journal of pathology","pubDate":"1999 May","volume":"154","issue":"5","pages":"1449-52","authors":"Li JY et al","elocationId":"","link":null,"reference":"Li JY et al. The American journal of pathology. 1999 May;154(5)1449-52.","abstract":null},{"pmid":"8695834","title":"Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization.","journal":"Blood","pubDate":"1996 Aug 15","volume":"88","issue":"4","pages":"1177-82","authors":"Vaandrager JW et al","elocationId":"","link":null,"reference":"Vaandrager JW et al. Blood. 1996 Aug 15;88(4)1177-82.","abstract":null},{"pmid":"8426477","title":"Chromosome 11 translocation breakpoints at the PRAD1/cyclin D1 gene locus in centrocytic lymphoma.","journal":"Leukemia","pubDate":"1993 Feb","volume":"7","issue":"2","pages":"241-5","authors":"Williams ME et al","elocationId":"","link":null,"reference":"Williams ME et al. Leukemia. 1993 Feb;7(2)241-5.","abstract":null},{"pmid":"2002419","title":"Translocation (11;14): a cytogenetic anomaly associated with B-cell lymphomas of non-follicle centre cell lineage.","journal":"The Journal of pathology","pubDate":"1991 Jan","volume":"163","issue":"1","pages":"13-8","authors":"Vandenberghe E et al","elocationId":"","link":null,"reference":"Vandenberghe E et al. The Journal of pathology. 1991 Jan;163(1)13-8.","abstract":null},{"pmid":"10733493","title":"Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma.","journal":"Blood","pubDate":"2000 Apr 1","volume":"95","issue":"7","pages":"2253-61","authors":"Yatabe Y et al","elocationId":"","link":null,"reference":"Yatabe Y et al. Blood. 2000 Apr 1;95(7)2253-61.","abstract":null}]},{"id":9947,"uuid":"8e152a08-8c69-42c4-897c-aeaf7b47c5b6","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":293,"subtype":"T-Lymphoblastic Leukemia/Lymphoma","code":"TLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":55294,"hugoSymbol":"FBXW7","oncogene":false,"grch37Isoform":"ENST00000281708","grch37RefSeq":"NM_033632.3","grch38Isoform":"ENST00000281708","grch38RefSeq":"NM_033632.3","geneAliases":["FBX30","hAgo","FBXW6","SEL-10","hCdc4","AGO","FBW6","SEL10","FBW7","CDC4","FBXO30"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":55294,"hugoSymbol":"FBXW7","oncogene":false,"grch37Isoform":"ENST00000281708","grch37RefSeq":"NM_033632.3","grch38Isoform":"ENST00000281708","grch38RefSeq":"NM_033632.3","geneAliases":["FBX30","hAgo","FBXW6","SEL-10","hCdc4","AGO","FBW6","SEL10","FBW7","CDC4","FBXO30"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"17575125","title":"The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.","journal":"Cancer research","pubDate":"2007 Jun 15","volume":"67","issue":"12","pages":"5611-6","authors":"Malyukova A et al","elocationId":"","link":null,"reference":"Malyukova A et al. Cancer research. 2007 Jun 15;67(12)5611-6.","abstract":null},{"pmid":"19794079","title":"Mutations of NOTCH1, FBXW7, and prognosis in T-lineage acute lymphoblastic leukemia.","journal":"Haematologica","pubDate":"2009 Oct","volume":"94","issue":"10","pages":"1338-40","authors":"Mullighan CG","elocationId":"doi: 10.3324/haematol.2009.012047","link":null,"reference":"Mullighan CG. Haematologica. 2009 Oct;94(10)1338-40.","abstract":null}]},{"id":12642,"uuid":"7d505dc4-d328-49d5-9da2-b25e95738808","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":204,"subtype":"Systemic Mastocytosis","code":"SM","color":"LightSalmon","mainType":"Mastocytosis","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"D816V","name":"D816V","refResidues":"D","proteinStart":816,"proteinEnd":816,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"19363219","title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.","journal":"Blood","pubDate":"2009 Jun 4","volume":"113","issue":"23","pages":"5727-36","authors":"Lim KH et al","elocationId":"doi: 10.1182/blood-2009-02-205237","link":null,"reference":"Lim KH et al. Blood. 2009 Jun 4;113(23)5727-36.","abstract":null},{"pmid":"19806146","title":"Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.","journal":"Nature reviews. Clinical oncology","pubDate":"2009 Nov","volume":"6","issue":"11","pages":"627-37","authors":"Tefferi A et al","elocationId":"doi: 10.1038/nrclinonc.2009.149","link":null,"reference":"Tefferi A et al. Nature reviews. Clinical oncology. 2009 Nov;6(11)627-37.","abstract":null}]},{"id":9698,"uuid":"e7ce0c46-94d4-4fa0-a302-c6ca895da397","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":835,"subtype":"Atypical Chronic Myeloid Leukemia, BCR-ABL1-","code":"ACML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":55500,"hugoSymbol":"ETNK1","oncogene":false,"grch37Isoform":"ENST00000266517","grch37RefSeq":"NM_018638.4","grch38Isoform":"ENST00000671733","grch38RefSeq":"NM_018638.4","geneAliases":["EKI","Nbla10396","EKI 1","EKI1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":55500,"hugoSymbol":"ETNK1","oncogene":false,"grch37Isoform":"ENST00000266517","grch37RefSeq":"NM_018638.4","grch38Isoform":"ENST00000671733","grch38RefSeq":"NM_018638.4","geneAliases":["EKI","Nbla10396","EKI 1","EKI1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25343957","title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.","journal":"Blood","pubDate":"2015 Jan 15","volume":"125","issue":"3","pages":"499-503","authors":"Gambacorti-Passerini CB et al","elocationId":"doi: 10.1182/blood-2014-06-579466","link":null,"reference":"Gambacorti-Passerini CB et al. Blood. 2015 Jan 15;125(3)499-503.","abstract":null}]}],"LEVEL_Px1":[{"id":35,"uuid":"a7a781b4-0484-47b8-a009-90e6dcc35172","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":734,"subtype":"Acute Leukemias of Ambiguous Lineage","code":"ALAL","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BCR-ABL1 Fusion","name":"BCR-ABL1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"10457405","title":"Outcome of biphenotypic acute leukemia.","journal":"Haematologica","pubDate":"1999 Aug","volume":"84","issue":"8","pages":"699-706","authors":"Killick S et al","elocationId":"","link":null,"reference":"Killick S et al. Haematologica. 1999 Aug;84(8)699-706.","abstract":null},{"pmid":"21228332","title":"Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification.","journal":"Blood","pubDate":"2011 Mar 17","volume":"117","issue":"11","pages":"3163-71","authors":"Matutes E et al","elocationId":"doi: 10.1182/blood-2010-10-314682","link":null,"reference":"Matutes E et al. Blood. 2011 Mar 17;117(11)3163-71.","abstract":null}]},{"id":21092,"uuid":"3fa3a3d0-212f-4cfb-940b-81db8f7d7ab3","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":892,"subtype":"","code":"","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":0,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"ETV6-RUNX1 Fusion","name":"ETV6-RUNX1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"9060558","title":"TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"1997 Mar","volume":"15","issue":"3","pages":"1150-7","authors":"Rubnitz JE et al","elocationId":"","link":null,"reference":"Rubnitz JE et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Mar;15(3)1150-7.","abstract":null},{"pmid":"8943861","title":"TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia.","journal":"Blood","pubDate":"1996 Dec 1","volume":"88","issue":"11","pages":"4252-8","authors":"McLean TW et al","elocationId":"","link":null,"reference":"McLean TW et al. Blood. 1996 Dec 1;88(11)4252-8.","abstract":null}]},{"id":4965,"uuid":"a6b7150e-5049-4ad7-8f79-7f345c63071a","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":865,"hugoSymbol":"CBFB","oncogene":false,"grch37Isoform":"ENST00000412916","grch37RefSeq":"NM_022845.2","grch38Isoform":"ENST00000412916","grch38RefSeq":"NM_022845.2","geneAliases":["PEBP2B"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":865,"hugoSymbol":"CBFB","oncogene":false,"grch37Isoform":"ENST00000412916","grch37RefSeq":"NM_022845.2","grch38Isoform":"ENST00000412916","grch38RefSeq":"NM_022845.2","geneAliases":["PEBP2B"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"CBFB-MYH11 Fusion","name":"CBFB-MYH11 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"20625124","title":"Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2010 Aug 10","volume":"28","issue":"23","pages":"3724-9","authors":"Corbacioglu A et al","elocationId":"doi: 10.1200/JCO.2010.28.6468","link":null,"reference":"Corbacioglu A et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Aug 10;28(23)3724-9.","abstract":null}]},{"id":7910,"uuid":"0c976044-c115-4028-8049-302c9b5a8492","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":688,"subtype":"B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like","code":"BLLBCRABL1L","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2057,"hugoSymbol":"EPOR","oncogene":true,"grch37Isoform":"ENST00000222139","grch37RefSeq":"NM_000121.3","grch38Isoform":"ENST00000222139","grch38RefSeq":"NM_000121.3","geneAliases":["EPO-R"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2057,"hugoSymbol":"EPOR","oncogene":true,"grch37Isoform":"ENST00000222139","grch37RefSeq":"NM_000121.3","grch38Isoform":"ENST00000222139","grch38RefSeq":"NM_000121.3","geneAliases":["EPO-R"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27870571","title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Feb","volume":"35","issue":"4","pages":"394-401","authors":"Roberts KG et al","elocationId":"doi: 10.1200/JCO.2016.69.0073","link":null,"reference":"Roberts KG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb;35(4)394-401.","abstract":null}]},{"id":6310,"uuid":"6d6b73fc-e84e-4076-89a6-281768949292","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7913,"hugoSymbol":"DEK","oncogene":true,"grch37Isoform":"ENST00000397239","grch37RefSeq":"NM_003472.3","grch38Isoform":"ENST00000652689","grch38RefSeq":"NM_003472.4","geneAliases":["D6S231E"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":7913,"hugoSymbol":"DEK","oncogene":true,"grch37Isoform":"ENST00000397239","grch37RefSeq":"NM_003472.3","grch38Isoform":"ENST00000652689","grch38RefSeq":"NM_003472.4","geneAliases":["D6S231E"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"DEK-NUP214 Fusion","name":"DEK-NUP214 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"16628187","title":"A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies.","journal":"Leukemia","pubDate":"2006 Jul","volume":"20","issue":"7","pages":"1295-7","authors":"Slovak ML et al","elocationId":"","link":null,"reference":"Slovak ML et al. Leukemia. 2006 Jul;20(7)1295-7.","abstract":null}]},{"id":22247,"uuid":"176ce4d7-64d2-42fb-b759-83f1fcf26040","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22343920","title":"Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.","journal":"Blood","pubDate":"2012 Apr 5","volume":"119","issue":"14","pages":"3211-8","authors":"Damm F et al","elocationId":"doi: 10.1182/blood-2011-12-400994","link":null,"reference":"Damm F et al. Blood. 2012 Apr 5;119(14)3211-8.","abstract":null},{"pmid":"22389253","title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.","journal":"Blood","pubDate":"2012 Apr 12","volume":"119","issue":"15","pages":"3578-84","authors":"Thol F et al","elocationId":"doi: 10.1182/blood-2011-12-399337","link":null,"reference":"Thol F et al. Blood. 2012 Apr 12;119(15)3578-84.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null},{"pmid":"22932795","title":"The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution.","journal":"Blood","pubDate":"2012 Oct 11","volume":"120","issue":"15","pages":"3106-11","authors":"Wu SJ et al","elocationId":"doi: 10.1182/blood-2012-02-412296","link":null,"reference":"Wu SJ et al. Blood. 2012 Oct 11;120(15)3106-11.","abstract":null},{"pmid":"28953917","title":"Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis.","journal":"PloS one","pubDate":"2017","volume":"12","issue":"9","pages":"e0185053","authors":"Zheng X et al","elocationId":"doi: 10.1371/journal.pone.0185053","link":null,"reference":"Zheng X et al. PloS one. 2017;12(9)e0185053.","abstract":null}]},{"id":5032,"uuid":"32ba7a03-39a3-4bc1-9179-5969c5d50b85","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":867,"hugoSymbol":"CBL","oncogene":false,"grch37Isoform":"ENST00000264033","grch37RefSeq":"NM_005188.3","grch38Isoform":"ENST00000264033","grch38RefSeq":"NM_005188.3","geneAliases":["NSLL","RNF55","C-CBL","FRA11B","CBL2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":867,"hugoSymbol":"CBL","oncogene":false,"grch37Isoform":"ENST00000264033","grch37RefSeq":"NM_005188.3","grch38Isoform":"ENST00000264033","grch38RefSeq":"NM_005188.3","geneAliases":["NSLL","RNF55","C-CBL","FRA11B","CBL2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"21714648","title":"Clinical effect of point mutations in myelodysplastic syndromes.","journal":"The New England journal of medicine","pubDate":"2011 Jun 30","volume":"364","issue":"26","pages":"2496-506","authors":"Bejar R et al","elocationId":"doi: 10.1056/NEJMoa1013343","link":null,"reference":"Bejar R et al. The New England journal of medicine. 2011 Jun 30;364(26)2496-506.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null}]},{"id":20456,"uuid":"378b7e3f-ac3e-46a7-9d47-e7ad26f0be21","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":260,"subtype":"APL with PML-RARA","code":"APLPMLRARA","color":"LightSalmon","mainType":"Leukemia","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5914,"hugoSymbol":"RARA","oncogene":false,"grch37Isoform":"ENST00000254066","grch37RefSeq":"NM_000964.3","grch38Isoform":"ENST00000254066","grch38RefSeq":"NM_000964.3","geneAliases":["RAR","NR1B1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5914,"hugoSymbol":"RARA","oncogene":false,"grch37Isoform":"ENST00000254066","grch37RefSeq":"NM_000964.3","grch38Isoform":"ENST00000254066","grch38RefSeq":"NM_000964.3","geneAliases":["RAR","NR1B1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"20018913","title":"Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.","journal":"Blood","pubDate":"2010 Mar 4","volume":"115","issue":"9","pages":"1690-6","authors":"Adès L et al","elocationId":"doi: 10.1182/blood-2009-07-233387","link":null,"reference":"Adès L et al. Blood. 2010 Mar 4;115(9)1690-6.","abstract":null}]},{"id":12073,"uuid":"5974ef49-eac8-4313-8492-046566a78913","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":688,"subtype":"B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like","code":"BLLBCRABL1L","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27870571","title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Feb","volume":"35","issue":"4","pages":"394-401","authors":"Roberts KG et al","elocationId":"doi: 10.1200/JCO.2016.69.0073","link":null,"reference":"Roberts KG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb;35(4)394-401.","abstract":null}]},{"id":22250,"uuid":"049b101a-a41c-40f9-9343-2c03ca7bcb23","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":632,"subtype":"Primary Myelofibrosis","code":"PMF","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23619563","title":"Mutations and prognosis in primary myelofibrosis.","journal":"Leukemia","pubDate":"2013 Sep","volume":"27","issue":"9","pages":"1861-9","authors":"Vannucchi AM et al","elocationId":"doi: 10.1038/leu.2013.119","link":null,"reference":"Vannucchi AM et al. Leukemia. 2013 Sep;27(9)1861-9.","abstract":null},{"pmid":"22968464","title":"SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival.","journal":"Blood","pubDate":"2012 Nov 15","volume":"120","issue":"20","pages":"4168-71","authors":"Lasho TL et al","elocationId":"doi: 10.1182/blood-2012-05-429696","link":null,"reference":"Lasho TL et al. Blood. 2012 Nov 15;120(20)4168-71.","abstract":null}]},{"id":21101,"uuid":"238e8ba4-2517-4bb8-ac8c-769f4329d3fa","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"21714648","title":"Clinical effect of point mutations in myelodysplastic syndromes.","journal":"The New England journal of medicine","pubDate":"2011 Jun 30","volume":"364","issue":"26","pages":"2496-506","authors":"Bejar R et al","elocationId":"doi: 10.1056/NEJMoa1013343","link":null,"reference":"Bejar R et al. The New England journal of medicine. 2011 Jun 30;364(26)2496-506.","abstract":null},{"pmid":"17910630","title":"RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome.","journal":"British journal of haematology","pubDate":"2007 Nov","volume":"139","issue":"3","pages":"405-14","authors":"Chen CY et al","elocationId":"","link":null,"reference":"Chen CY et al. British journal of haematology. 2007 Nov;139(3)405-14.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null}]},{"id":23280,"uuid":"ee6b8c2d-0e7a-42bb-ab8f-ef29344cd081","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":17,"subtype":"AML with Myelodysplasia-Related Changes","code":"AMLMRC","color":"LightSalmon","mainType":"Leukemia","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25860933","title":"Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.","journal":"Oncotarget","pubDate":"2015 Apr 10","volume":"6","issue":"10","pages":"8388-96","authors":"Devillier R et al","elocationId":"","link":null,"reference":"Devillier R et al. Oncotarget. 2015 Apr 10;6(10)8388-96.","abstract":null},{"pmid":"25412851","title":"Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.","journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","pubDate":"2015 May","volume":"28","issue":"5","pages":"706-14","authors":"Ohgami RS et al","elocationId":"doi: 10.1038/modpathol.2014.160","link":null,"reference":"Ohgami RS et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2015 May;28(5)706-14.","abstract":null}]},{"id":21104,"uuid":"a1254264-db18-4c52-b1d6-52193097f5ec","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22753902","title":"RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2012 Sep 1","volume":"30","issue":"25","pages":"3109-18","authors":"Mendler JH et al","elocationId":"doi: 10.1200/JCO.2011.40.6652","link":null,"reference":"Mendler JH et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Sep 1;30(25)3109-18.","abstract":null},{"pmid":"19808697","title":"AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.","journal":"Blood","pubDate":"2009 Dec 17","volume":"114","issue":"26","pages":"5352-61","authors":"Tang JL et al","elocationId":"doi: 10.1182/blood-2009-05-223784","link":null,"reference":"Tang JL et al. Blood. 2009 Dec 17;114(26)5352-61.","abstract":null}]},{"id":6001,"uuid":"1a58cfeb-6583-4967-bc99-11b6a72fd678","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":688,"subtype":"B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like","code":"BLLBCRABL1L","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":64109,"hugoSymbol":"CRLF2","oncogene":true,"grch37Isoform":"ENST00000381566","grch37RefSeq":"NM_022148.2","grch38Isoform":"ENST00000381566","grch38RefSeq":"NM_022148.4","geneAliases":["TSLPR","CRL2","CRLF2Y"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":64109,"hugoSymbol":"CRLF2","oncogene":true,"grch37Isoform":"ENST00000381566","grch37RefSeq":"NM_022148.2","grch38Isoform":"ENST00000381566","grch38RefSeq":"NM_022148.4","geneAliases":["TSLPR","CRL2","CRLF2Y"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27870571","title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Feb","volume":"35","issue":"4","pages":"394-401","authors":"Roberts KG et al","elocationId":"doi: 10.1200/JCO.2016.69.0073","link":null,"reference":"Roberts KG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb;35(4)394-401.","abstract":null}]},{"id":23282,"uuid":"e43a1d21-8fe5-454e-8200-34d72533a72e","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22186996","title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.","journal":"Blood","pubDate":"2012 Mar 1","volume":"119","issue":"9","pages":"2114-21","authors":"Rücker FG et al","elocationId":"doi: 10.1182/blood-2011-08-375758","link":null,"reference":"Rücker FG et al. Blood. 2012 Mar 1;119(9)2114-21.","abstract":null},{"pmid":"18596741","title":"TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis.","journal":"Leukemia","pubDate":"2009 Jan","volume":"23","issue":"1","pages":"203-6","authors":"Bowen D et al","elocationId":"doi: 10.1038/leu.2008.173","link":null,"reference":"Bowen D et al. Leukemia. 2009 Jan;23(1)203-6.","abstract":null}]},{"id":21042,"uuid":"4df8865f-6c26-4586-9dcf-3faafc8c2b3d","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"RUNX1-RUNX1T1 Fusion","name":"RUNX1-RUNX1T1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"9746770","title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.","journal":"Blood","pubDate":"1998 Oct 1","volume":"92","issue":"7","pages":"2322-33","authors":"Grimwade D et al","elocationId":"","link":null,"reference":"Grimwade D et al. Blood. 1998 Oct 1;92(7)2322-33.","abstract":null},{"pmid":"24402164","title":"High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.","journal":"Leukemia","pubDate":"2014 Jul","volume":"28","issue":"7","pages":"1449-58","authors":"Krauth MT et al","elocationId":"doi: 10.1038/leu.2014.4","link":null,"reference":"Krauth MT et al. Leukemia. 2014 Jul;28(7)1449-58.","abstract":null}]},{"id":21364,"uuid":"e50e12f7-3011-4667-a34f-22bb734f210b","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"21998214","title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.","journal":"Blood","pubDate":"2011 Dec 8","volume":"118","issue":"24","pages":"6239-46","authors":"Malcovati L et al","elocationId":"doi: 10.1182/blood-2011-09-377275","link":null,"reference":"Malcovati L et al. Blood. 2011 Dec 8;118(24)6239-46.","abstract":null}]},{"id":23284,"uuid":"17eadd11-3a15-408a-853b-121286199008","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":418,"subtype":"Therapy-Related Myeloid Neoplasms","code":"TMN","color":"LightSalmon","mainType":"Leukemia","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25412846","title":"High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.","journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","pubDate":"2015 Apr","volume":"28","issue":"4","pages":"552-63","authors":"Cleven AH et al","elocationId":"doi: 10.1038/modpathol.2014.153","link":null,"reference":"Cleven AH et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2015 Apr;28(4)552-63.","abstract":null},{"pmid":"25952993","title":"TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.","journal":"Journal of hematology & oncology","pubDate":"2015 May 8","volume":"8","issue":"","pages":"45","authors":"Ok CY et al","elocationId":"doi: 10.1186/s13045-015-0139-z","link":null,"reference":"Ok CY et al. Journal of hematology & oncology. 2015 May 8;8()45.","abstract":null}]},{"id":13044,"uuid":"eda0a1c1-0ff7-4de4-b6d1-d93c7badec73","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":734,"subtype":"Acute Leukemias of Ambiguous Lineage","code":"ALAL","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4297,"hugoSymbol":"KMT2A","oncogene":false,"grch37Isoform":"ENST00000534358","grch37RefSeq":"NM_001197104.1","grch38Isoform":"ENST00000534358","grch38RefSeq":"NM_001197104.1","geneAliases":["MLL1","TRX1","HTRX1","ALL-1","MLL","MLL1A","CXXC7","HRX","WDSTS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4297,"hugoSymbol":"KMT2A","oncogene":false,"grch37Isoform":"ENST00000534358","grch37RefSeq":"NM_001197104.1","grch38Isoform":"ENST00000534358","grch38RefSeq":"NM_001197104.1","geneAliases":["MLL1","TRX1","HTRX1","ALL-1","MLL","MLL1A","CXXC7","HRX","WDSTS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"10457405","title":"Outcome of biphenotypic acute leukemia.","journal":"Haematologica","pubDate":"1999 Aug","volume":"84","issue":"8","pages":"699-706","authors":"Killick S et al","elocationId":"","link":null,"reference":"Killick S et al. Haematologica. 1999 Aug;84(8)699-706.","abstract":null},{"pmid":"17611554","title":"Acute bilineal leukemia: a rare disease with poor outcome.","journal":"Leukemia","pubDate":"2007 Nov","volume":"21","issue":"11","pages":"2264-70","authors":"Weir EG et al","elocationId":"","link":null,"reference":"Weir EG et al. Leukemia. 2007 Nov;21(11)2264-70.","abstract":null}]},{"id":23286,"uuid":"8d78d7c1-2bf2-4199-9d9b-8fdb688bb9be","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":533,"subtype":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","code":"CLLSLL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24652989","title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.","journal":"Blood","pubDate":"2014 May 22","volume":"123","issue":"21","pages":"3247-54","authors":"Stilgenbauer S et al","elocationId":"doi: 10.1182/blood-2014-01-546150","link":null,"reference":"Stilgenbauer S et al. Blood. 2014 May 22;123(21)3247-54.","abstract":null},{"pmid":"23243274","title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.","journal":"Blood","pubDate":"2013 Feb 21","volume":"121","issue":"8","pages":"1403-12","authors":"Rossi D et al","elocationId":"doi: 10.1182/blood-2012-09-458265","link":null,"reference":"Rossi D et al. Blood. 2013 Feb 21;121(8)1403-12.","abstract":null},{"pmid":"24004666","title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.","journal":"Blood","pubDate":"2013 Oct 10","volume":"122","issue":"15","pages":"2673-82","authors":"Chigrinova E et al","elocationId":"doi: 10.1182/blood-2013-03-489518","link":null,"reference":"Chigrinova E et al. Blood. 2013 Oct 10;122(15)2673-82.","abstract":null},{"pmid":"20697090","title":"TP53 mutation and survival in chronic lymphocytic leukemia.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2010 Oct 10","volume":"28","issue":"29","pages":"4473-9","authors":"Zenz T et al","elocationId":"doi: 10.1200/JCO.2009.27.8762","link":null,"reference":"Zenz T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Oct 10;28(29)4473-9.","abstract":null},{"pmid":"19188171","title":"The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2009 Feb 1","volume":"15","issue":"3","pages":"995-1004","authors":"Rossi D et al","elocationId":"doi: 10.1158/1078-0432.CCR-08-1630","link":null,"reference":"Rossi D et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Feb 1;15(3)995-1004.","abstract":null}]},{"id":13046,"uuid":"b9b0b857-b41c-4f9a-840c-33a5abd859bd","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4297,"hugoSymbol":"KMT2A","oncogene":false,"grch37Isoform":"ENST00000534358","grch37RefSeq":"NM_001197104.1","grch38Isoform":"ENST00000534358","grch38RefSeq":"NM_001197104.1","geneAliases":["MLL1","TRX1","HTRX1","ALL-1","MLL","MLL1A","CXXC7","HRX","WDSTS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4297,"hugoSymbol":"KMT2A","oncogene":false,"grch37Isoform":"ENST00000534358","grch37RefSeq":"NM_001197104.1","grch38Isoform":"ENST00000534358","grch38RefSeq":"NM_001197104.1","geneAliases":["MLL1","TRX1","HTRX1","ALL-1","MLL","MLL1A","CXXC7","HRX","WDSTS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"17658395","title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.","journal":"Lancet (London, England)","pubDate":"2007 Jul 21","volume":"370","issue":"9583","pages":"240-250","authors":"Pieters R et al","elocationId":"doi: 10.1016/S0140-6736(07)61126-X","link":null,"reference":"Pieters R et al. Lancet (London, England). 2007 Jul 21;370(9583)240-250.","abstract":null}]},{"id":183,"uuid":"5f723d7b-a04e-42b4-8637-15a199adcb95","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":688,"subtype":"B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like","code":"BLLBCRABL1L","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":27,"hugoSymbol":"ABL2","oncogene":true,"grch37Isoform":"ENST00000502732","grch37RefSeq":"NM_007314.3","grch38Isoform":"ENST00000502732","grch38RefSeq":"NM_007314.3","geneAliases":["ARG","ABLL"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":27,"hugoSymbol":"ABL2","oncogene":true,"grch37Isoform":"ENST00000502732","grch37RefSeq":"NM_007314.3","grch38Isoform":"ENST00000502732","grch38RefSeq":"NM_007314.3","geneAliases":["ARG","ABLL"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27870571","title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Feb","volume":"35","issue":"4","pages":"394-401","authors":"Roberts KG et al","elocationId":"doi: 10.1200/JCO.2016.69.0073","link":null,"reference":"Roberts KG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb;35(4)394-401.","abstract":null}]},{"id":23288,"uuid":"4e8b3dca-b8a1-43bf-986a-54d18b445ceb","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"21714648","title":"Clinical effect of point mutations in myelodysplastic syndromes.","journal":"The New England journal of medicine","pubDate":"2011 Jun 30","volume":"364","issue":"26","pages":"2496-506","authors":"Bejar R et al","elocationId":"doi: 10.1056/NEJMoa1013343","link":null,"reference":"Bejar R et al. The New England journal of medicine. 2011 Jun 30;364(26)2496-506.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null},{"pmid":"25092778","title":"Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2014 Sep 1","volume":"32","issue":"25","pages":"2691-8","authors":"Bejar R et al","elocationId":"doi: 10.1200/JCO.2013.52.3381","link":null,"reference":"Bejar R et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Sep 1;32(25)2691-8.","abstract":null}]},{"id":10937,"uuid":"0861730c-d6e5-42cb-a028-e22b5d1f9899","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"572_630ins","name":"Internal tandem duplication","refResidues":null,"proteinStart":572,"proteinEnd":630,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1604695993000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"15746041","title":"Risk assessment in patients with acute myeloid leukemia and a normal karyotype.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2005 Feb 15","volume":"11","issue":"4","pages":"1416-24","authors":"Bienz M et al","elocationId":"","link":null,"reference":"Bienz M et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Feb 15;11(4)1416-24.","abstract":null},{"pmid":"22417203","title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.","journal":"The New England journal of medicine","pubDate":"2012 Mar 22","volume":"366","issue":"12","pages":"1079-89","authors":"Patel JP et al","elocationId":"doi: 10.1056/NEJMoa1112304","link":null,"reference":"Patel JP et al. The New England journal of medicine. 2012 Mar 22;366(12)1079-89.","abstract":null},{"pmid":"11585760","title":"Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.","journal":"Cancer research","pubDate":"2001 Oct 1","volume":"61","issue":"19","pages":"7233-9","authors":"Whitman SP et al","elocationId":"","link":null,"reference":"Whitman SP et al. Cancer research. 2001 Oct 1;61(19)7233-9.","abstract":null}]},{"id":23290,"uuid":"b6f54e8b-aa53-4c55-9cd8-5edc0c81fb77","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":695,"subtype":"Essential Thrombocythemia","code":"ET","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"29296692","title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia.","journal":"Blood advances","pubDate":"2016 Nov 29","volume":"1","issue":"1","pages":"21-30","authors":"Tefferi A et al","elocationId":"doi: 10.1182/bloodadvances.2016000216","link":null,"reference":"Tefferi A et al. Blood advances. 2016 Nov 29;1(1)21-30.","abstract":null},{"pmid":"22887079","title":"Clinical significance of genetic aberrations in secondary acute myeloid leukemia.","journal":"American journal of hematology","pubDate":"2012 Nov","volume":"87","issue":"11","pages":"1010-6","authors":"Milosevic JD et al","elocationId":"doi: 10.1002/ajh.23309","link":null,"reference":"Milosevic JD et al. American journal of hematology. 2012 Nov;87(11)1010-6.","abstract":null},{"pmid":"24478400","title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.","journal":"Blood","pubDate":"2014 Apr 3","volume":"123","issue":"14","pages":"2220-8","authors":"Lundberg P et al","elocationId":"doi: 10.1182/blood-2013-11-537167","link":null,"reference":"Lundberg P et al. Blood. 2014 Apr 3;123(14)2220-8.","abstract":null}]},{"id":23292,"uuid":"b487b052-7db8-4a2c-8441-ee6b295823c6","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":185,"subtype":"Myeloproliferative Neoplasms","code":"MPN","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22887079","title":"Clinical significance of genetic aberrations in secondary acute myeloid leukemia.","journal":"American journal of hematology","pubDate":"2012 Nov","volume":"87","issue":"11","pages":"1010-6","authors":"Milosevic JD et al","elocationId":"doi: 10.1002/ajh.23309","link":null,"reference":"Milosevic JD et al. American journal of hematology. 2012 Nov;87(11)1010-6.","abstract":null},{"pmid":"25516983","title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.","journal":"Proceedings of the National Academy of Sciences of the United States of America","pubDate":"2014 Dec 16","volume":"111","issue":"50","pages":"E5401-10","authors":"Rampal R et al","elocationId":"doi: 10.1073/pnas.1407792111","link":null,"reference":"Rampal R et al. Proceedings of the National Academy of Sciences of the United States of America. 2014 Dec 16;111(50)E5401-10.","abstract":null},{"pmid":"22052707","title":"TP53 mutations and polymorphisms in primary myelofibrosis.","journal":"American journal of hematology","pubDate":"2012 Feb","volume":"87","issue":"2","pages":"204-6","authors":"Raza S et al","elocationId":"doi: 10.1002/ajh.22216","link":null,"reference":"Raza S et al. American journal of hematology. 2012 Feb;87(2)204-6.","abstract":null}]},{"id":21373,"uuid":"7ca2438e-2bfc-42c8-97b1-29405306d387","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":801,"subtype":"MDS/MPN with Ring Sideroblasts and Thrombocytosis","code":"MDSMPNRST","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23594705","title":"Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.","journal":"Leukemia","pubDate":"2013 Sep","volume":"27","issue":"9","pages":"1826-31","authors":"Broséus J et al","elocationId":"doi: 10.1038/leu.2013.120","link":null,"reference":"Broséus J et al. Leukemia. 2013 Sep;27(9)1826-31.","abstract":null},{"pmid":"21998214","title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.","journal":"Blood","pubDate":"2011 Dec 8","volume":"118","issue":"24","pages":"6239-46","authors":"Malcovati L et al","elocationId":"doi: 10.1182/blood-2011-09-377275","link":null,"reference":"Malcovati L et al. Blood. 2011 Dec 8;118(24)6239-46.","abstract":null}]},{"id":23294,"uuid":"7940b806-79c6-4cda-a468-befdd8806bb7","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":632,"subtype":"Primary Myelofibrosis","code":"PMF","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22887079","title":"Clinical significance of genetic aberrations in secondary acute myeloid leukemia.","journal":"American journal of hematology","pubDate":"2012 Nov","volume":"87","issue":"11","pages":"1010-6","authors":"Milosevic JD et al","elocationId":"doi: 10.1002/ajh.23309","link":null,"reference":"Milosevic JD et al. American journal of hematology. 2012 Nov;87(11)1010-6.","abstract":null},{"pmid":"25516983","title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.","journal":"Proceedings of the National Academy of Sciences of the United States of America","pubDate":"2014 Dec 16","volume":"111","issue":"50","pages":"E5401-10","authors":"Rampal R et al","elocationId":"doi: 10.1073/pnas.1407792111","link":null,"reference":"Rampal R et al. Proceedings of the National Academy of Sciences of the United States of America. 2014 Dec 16;111(50)E5401-10.","abstract":null},{"pmid":"22052707","title":"TP53 mutations and polymorphisms in primary myelofibrosis.","journal":"American journal of hematology","pubDate":"2012 Feb","volume":"87","issue":"2","pages":"204-6","authors":"Raza S et al","elocationId":"doi: 10.1002/ajh.22216","link":null,"reference":"Raza S et al. American journal of hematology. 2012 Feb;87(2)204-6.","abstract":null}]},{"id":9793,"uuid":"47be4b3a-04e2-4793-afa4-ff2705d6992a","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"21714648","title":"Clinical effect of point mutations in myelodysplastic syndromes.","journal":"The New England journal of medicine","pubDate":"2011 Jun 30","volume":"364","issue":"26","pages":"2496-506","authors":"Bejar R et al","elocationId":"doi: 10.1056/NEJMoa1013343","link":null,"reference":"Bejar R et al. The New England journal of medicine. 2011 Jun 30;364(26)2496-506.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null}]},{"id":9796,"uuid":"928de82e-9cac-4d88-918f-502e8f6112f9","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":632,"subtype":"Primary Myelofibrosis","code":"PMF","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23619563","title":"Mutations and prognosis in primary myelofibrosis.","journal":"Leukemia","pubDate":"2013 Sep","volume":"27","issue":"9","pages":"1861-9","authors":"Vannucchi AM et al","elocationId":"doi: 10.1038/leu.2013.119","link":null,"reference":"Vannucchi AM et al. Leukemia. 2013 Sep;27(9)1861-9.","abstract":null},{"pmid":"21921040","title":"EZH2 mutational status predicts poor survival in myelofibrosis.","journal":"Blood","pubDate":"2011 Nov 10","volume":"118","issue":"19","pages":"5227-34","authors":"Guglielmelli P et al","elocationId":"doi: 10.1182/blood-2011-06-363424","link":null,"reference":"Guglielmelli P et al. Blood. 2011 Nov 10;118(19)5227-34.","abstract":null}]},{"id":12101,"uuid":"34546dc5-23f3-493a-8381-5c3133bc8b22","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":632,"subtype":"Primary Myelofibrosis","code":"PMF","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V617F","name":"V617F","refResidues":"V","proteinStart":617,"proteinEnd":617,"variantResidues":"F","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"17712047","title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.","journal":"Blood","pubDate":"2007 Dec 1","volume":"110","issue":"12","pages":"4030-6","authors":"Barosi G et al","elocationId":"","link":null,"reference":"Barosi G et al. Blood. 2007 Dec 1;110(12)4030-6.","abstract":null},{"pmid":"16293597","title":"V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.","journal":"Blood","pubDate":"2006 Mar 1","volume":"107","issue":"5","pages":"2098-100","authors":"Campbell PJ et al","elocationId":"","link":null,"reference":"Campbell PJ et al. Blood. 2006 Mar 1;107(5)2098-100.","abstract":null},{"pmid":"16563504","title":"JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.","journal":"Leukemia research","pubDate":"2006 Nov","volume":"30","issue":"11","pages":"1457-60","authors":"Mesa RA et al","elocationId":"","link":null,"reference":"Mesa RA et al. Leukemia research. 2006 Nov;30(11)1457-60.","abstract":null},{"pmid":"21691276","title":"Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.","journal":"Leukemia","pubDate":"2011 Dec","volume":"25","issue":"12","pages":"1834-9","authors":"Pardanani A et al","elocationId":"doi: 10.1038/leu.2011.161","link":null,"reference":"Pardanani A et al. Leukemia. 2011 Dec;25(12)1834-9.","abstract":null}]},{"id":12742,"uuid":"2a2a9384-6cd7-449f-923b-80f5c4eeb411","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":791,"subtype":"AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1","code":"AMLRUNX1RUNX1T1","color":"LightSalmon","mainType":"Leukemia","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"16598313","title":"Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).","journal":"Leukemia","pubDate":"2006 Jun","volume":"20","issue":"6","pages":"965-70","authors":"Boissel N et al","elocationId":"","link":null,"reference":"Boissel N et al. Leukemia. 2006 Jun;20(6)965-70.","abstract":null},{"pmid":"16254134","title":"KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.","journal":"Blood","pubDate":"2006 Mar 1","volume":"107","issue":"5","pages":"1791-9","authors":"Schnittger S et al","elocationId":"","link":null,"reference":"Schnittger S et al. Blood. 2006 Mar 1;107(5)1791-9.","abstract":null},{"pmid":"16384925","title":"Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.","journal":"Blood","pubDate":"2006 May 1","volume":"107","issue":"9","pages":"3463-8","authors":"Cairoli R et al","elocationId":"","link":null,"reference":"Cairoli R et al. Blood. 2006 May 1;107(9)3463-8.","abstract":null},{"pmid":"16921041","title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2006 Aug 20","volume":"24","issue":"24","pages":"3904-11","authors":"Paschka P et al","elocationId":"","link":null,"reference":"Paschka P et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Aug 20;24(24)3904-11.","abstract":null}]},{"id":16838,"uuid":"d3da5c34-8781-40ea-b643-9a1b5dfadbf5","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"8329714","title":"N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome.","journal":"Blood","pubDate":"1993 Jul 15","volume":"82","issue":"2","pages":"590-9","authors":"Paquette RL et al","elocationId":"","link":null,"reference":"Paquette RL et al. Blood. 1993 Jul 15;82(2)590-9.","abstract":null},{"pmid":"21714648","title":"Clinical effect of point mutations in myelodysplastic syndromes.","journal":"The New England journal of medicine","pubDate":"2011 Jun 30","volume":"364","issue":"26","pages":"2496-506","authors":"Bejar R et al","elocationId":"doi: 10.1056/NEJMoa1013343","link":null,"reference":"Bejar R et al. The New England journal of medicine. 2011 Jun 30;364(26)2496-506.","abstract":null},{"pmid":"24881041","title":"Clinical and genetic predictors of prognosis in myelodysplastic syndromes.","journal":"Haematologica","pubDate":"2014 Jun","volume":"99","issue":"6","pages":"956-64","authors":"Bejar R","elocationId":"doi: 10.3324/haematol.2013.085217","link":null,"reference":"Bejar R. Haematologica. 2014 Jun;99(6)956-64.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null}]},{"id":8,"uuid":"aa11f5f1-5da0-4700-99ad-861b1e790aa7","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":688,"subtype":"B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like","code":"BLLBCRABL1L","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27870571","title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Feb","volume":"35","issue":"4","pages":"394-401","authors":"Roberts KG et al","elocationId":"doi: 10.1200/JCO.2016.69.0073","link":null,"reference":"Roberts KG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb;35(4)394-401.","abstract":null}]},{"id":23304,"uuid":"143077a9-08b8-4800-8c52-db80dad34385","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":645,"subtype":"Plasma Cell Myeloma","code":"PCM","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Deletion","name":"Deletion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"9680348","title":"Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.","journal":"Blood","pubDate":"1998 Aug 1","volume":"92","issue":"3","pages":"802-9","authors":"Drach J et al","elocationId":"","link":null,"reference":"Drach J et al. Blood. 1998 Aug 1;92(3)802-9.","abstract":null},{"pmid":"17209057","title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.","journal":"Blood","pubDate":"2007 Apr 15","volume":"109","issue":"8","pages":"3489-95","authors":"Avet-Loiseau H et al","elocationId":"","link":null,"reference":"Avet-Loiseau H et al. Blood. 2007 Apr 15;109(8)3489-95.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/128/22/3271?sso-checked=true","reference":"null. null. .","abstract":"Hofste op Bruinink, D. et al. Abstract# Blood 128:3271, 2017"},{"pmid":"18337559","title":"An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.","journal":"Blood","pubDate":"2008 Nov 15","volume":"112","issue":"10","pages":"4235-46","authors":"Xiong W et al","elocationId":"doi: 10.1182/blood-2007-10-119123","link":null,"reference":"Xiong W et al. Blood. 2008 Nov 15;112(10)4235-46.","abstract":null}]},{"id":1226,"uuid":"462490cf-d424-420f-bf51-94c41b9b888f","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":224,"subtype":"Chronic Myelomonocytic Leukemia","code":"CMML","color":"LightSalmon","mainType":"Myelodysplastic/Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":171023,"hugoSymbol":"ASXL1","oncogene":false,"grch37Isoform":"ENST00000375687","grch37RefSeq":"NM_015338.5","grch38Isoform":"ENST00000375687","grch38RefSeq":"NM_015338.5","geneAliases":["BOPS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":171023,"hugoSymbol":"ASXL1","oncogene":false,"grch37Isoform":"ENST00000375687","grch37RefSeq":"NM_015338.5","grch38Isoform":"ENST00000375687","grch38RefSeq":"NM_015338.5","geneAliases":["BOPS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/126/23/1673?sso-checked=true","reference":"null. null. .","abstract":"Sallman, D. et al. Abstract# Blood 126: 1673, 2015"},{"pmid":"24695057","title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.","journal":"Leukemia","pubDate":"2014 Nov","volume":"28","issue":"11","pages":"2206-12","authors":"Patnaik MM et al","elocationId":"doi: 10.1038/leu.2014.125","link":null,"reference":"Patnaik MM et al. Leukemia. 2014 Nov;28(11)2206-12.","abstract":null},{"pmid":"23690417","title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2013 Jul 1","volume":"31","issue":"19","pages":"2428-36","authors":"Itzykson R et al","elocationId":"doi: 10.1200/JCO.2012.47.3314","link":null,"reference":"Itzykson R et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jul 1;31(19)2428-36.","abstract":null},{"pmid":"29176559","title":"ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS.","journal":"Blood cancer journal","pubDate":"2017 Nov 27","volume":"7","issue":"12","pages":"633","authors":"Sallman DA et al","elocationId":"doi: 10.1038/s41408-017-0004-0","link":null,"reference":"Sallman DA et al. Blood cancer journal. 2017 Nov 27;7(12)633.","abstract":null}]},{"id":6026,"uuid":"4bf9b29a-1a25-45eb-aace-ca0c5fdba78d","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":688,"subtype":"B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like","code":"BLLBCRABL1L","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1436,"hugoSymbol":"CSF1R","oncogene":false,"grch37Isoform":"ENST00000286301","grch37RefSeq":"NM_005211.3","grch38Isoform":"ENST00000286301","grch38RefSeq":"NM_005211.3","geneAliases":["BANDDOS","HDLS","CSFR","C-FMS","FIM2","CD115","M-CSF-R","FMS","CSF-1R"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1436,"hugoSymbol":"CSF1R","oncogene":false,"grch37Isoform":"ENST00000286301","grch37RefSeq":"NM_005211.3","grch38Isoform":"ENST00000286301","grch38RefSeq":"NM_005211.3","geneAliases":["BANDDOS","HDLS","CSFR","C-FMS","FIM2","CD115","M-CSF-R","FMS","CSF-1R"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27870571","title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Feb","volume":"35","issue":"4","pages":"394-401","authors":"Roberts KG et al","elocationId":"doi: 10.1200/JCO.2016.69.0073","link":null,"reference":"Roberts KG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb;35(4)394-401.","abstract":null}]},{"id":4811,"uuid":"cb457d83-4258-4375-b441-f4f8512175d4","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":695,"subtype":"Essential Thrombocythemia","code":"ET","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":811,"hugoSymbol":"CALR","oncogene":true,"grch37Isoform":"ENST00000316448","grch37RefSeq":"NM_004343.3","grch38Isoform":"ENST00000316448","grch38RefSeq":"NM_004343.3","geneAliases":["SSA","cC1qR","CRT","HEL-S-99n","RO"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":811,"hugoSymbol":"CALR","oncogene":true,"grch37Isoform":"ENST00000316448","grch37RefSeq":"NM_004343.3","grch38Isoform":"ENST00000316448","grch38RefSeq":"NM_004343.3","geneAliases":["SSA","cC1qR","CRT","HEL-S-99n","RO"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24402162","title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.","journal":"Leukemia","pubDate":"2014 Jul","volume":"28","issue":"7","pages":"1472-7","authors":"Tefferi A et al","elocationId":"doi: 10.1038/leu.2014.3","link":null,"reference":"Tefferi A et al. Leukemia. 2014 Jul;28(7)1472-7.","abstract":null},{"pmid":"24325356","title":"Somatic mutations of calreticulin in myeloproliferative neoplasms.","journal":"The New England journal of medicine","pubDate":"2013 Dec 19","volume":"369","issue":"25","pages":"2379-90","authors":"Klampfl T et al","elocationId":"doi: 10.1056/NEJMoa1311347","link":null,"reference":"Klampfl T et al. The New England journal of medicine. 2013 Dec 19;369(25)2379-90.","abstract":null},{"pmid":"24753125","title":"Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.","journal":"American journal of hematology","pubDate":"2014 Aug","volume":"89","issue":"8","pages":"E121-4","authors":"Tefferi A et al","elocationId":"doi: 10.1002/ajh.23743","link":null,"reference":"Tefferi A et al. American journal of hematology. 2014 Aug;89(8)E121-4.","abstract":null}]},{"id":16780,"uuid":"6eb6f2e2-1b1c-404a-aa40-e492cb6aecda","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4869,"hugoSymbol":"NPM1","oncogene":false,"grch37Isoform":"ENST00000296930","grch37RefSeq":"NM_002520.6","grch38Isoform":"ENST00000296930","grch38RefSeq":"NM_002520.6","geneAliases":["B23","NPM"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4869,"hugoSymbol":"NPM1","oncogene":false,"grch37Isoform":"ENST00000296930","grch37RefSeq":"NM_002520.6","grch38Isoform":"ENST00000296930","grch38RefSeq":"NM_002520.6","geneAliases":["B23","NPM"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"18450602","title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.","journal":"The New England journal of medicine","pubDate":"2008 May 1","volume":"358","issue":"18","pages":"1909-18","authors":"Schlenk RF et al","elocationId":"doi: 10.1056/NEJMoa074306","link":null,"reference":"Schlenk RF et al. The New England journal of medicine. 2008 May 1;358(18)1909-18.","abstract":null},{"pmid":"16051734","title":"Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.","journal":"Blood","pubDate":"2005 Dec 1","volume":"106","issue":"12","pages":"3740-6","authors":"Döhner K et al","elocationId":"","link":null,"reference":"Döhner K et al. Blood. 2005 Dec 1;106(12)3740-6.","abstract":null},{"pmid":"16791266","title":"Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype.","journal":"Leukemia","pubDate":"2006 Sep","volume":"20","issue":"9","pages":"1644-6","authors":"Bardet V et al","elocationId":"","link":null,"reference":"Bardet V et al. Leukemia. 2006 Sep;20(9)1644-6.","abstract":null},{"pmid":"16076867","title":"Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.","journal":"Blood","pubDate":"2005 Dec 1","volume":"106","issue":"12","pages":"3733-9","authors":"Schnittger S et al","elocationId":"","link":null,"reference":"Schnittger S et al. Blood. 2005 Dec 1;106(12)3733-9.","abstract":null},{"pmid":"16455956","title":"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).","journal":"Blood","pubDate":"2006 May 15","volume":"107","issue":"10","pages":"4011-20","authors":"Thiede C et al","elocationId":"","link":null,"reference":"Thiede C et al. Blood. 2006 May 15;107(10)4011-20.","abstract":null},{"pmid":"20026798","title":"Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2010 Feb 1","volume":"28","issue":"4","pages":"596-604","authors":"Becker H et al","elocationId":"doi: 10.1200/JCO.2009.25.1496","link":null,"reference":"Becker H et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Feb 1;28(4)596-604.","abstract":null}]},{"id":1230,"uuid":"ed4b0423-a8b4-4ec6-a41e-534e01bf13c1","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":355,"subtype":"Myelodysplastic Syndromes","code":"MDS","color":"LightSalmon","mainType":"Myelodysplastic Syndromes","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":171023,"hugoSymbol":"ASXL1","oncogene":false,"grch37Isoform":"ENST00000375687","grch37RefSeq":"NM_015338.5","grch38Isoform":"ENST00000375687","grch38RefSeq":"NM_015338.5","geneAliases":["BOPS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":171023,"hugoSymbol":"ASXL1","oncogene":false,"grch37Isoform":"ENST00000375687","grch37RefSeq":"NM_015338.5","grch38Isoform":"ENST00000375687","grch38RefSeq":"NM_015338.5","geneAliases":["BOPS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/126/23/1673?sso-checked=true","reference":"null. null. .","abstract":"Sallman, D. et al. Abstract# Blood 126: 1673, 2015"},{"pmid":"21714648","title":"Clinical effect of point mutations in myelodysplastic syndromes.","journal":"The New England journal of medicine","pubDate":"2011 Jun 30","volume":"364","issue":"26","pages":"2496-506","authors":"Bejar R et al","elocationId":"doi: 10.1056/NEJMoa1013343","link":null,"reference":"Bejar R et al. The New England journal of medicine. 2011 Jun 30;364(26)2496-506.","abstract":null},{"pmid":"21576631","title":"Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2011 Jun 20","volume":"29","issue":"18","pages":"2499-506","authors":"Thol F et al","elocationId":"doi: 10.1200/JCO.2010.33.4938","link":null,"reference":"Thol F et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Jun 20;29(18)2499-506.","abstract":null},{"pmid":"24220272","title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","journal":"Leukemia","pubDate":"2014 Feb","volume":"28","issue":"2","pages":"241-7","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2013.336","link":null,"reference":"Haferlach T et al. Leukemia. 2014 Feb;28(2)241-7.","abstract":null}]},{"id":14,"uuid":"4f1a9d38-f694-44ff-a76d-76d5fbf3d790","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BCR-ABL1 Fusion","name":"BCR-ABL1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"10749961","title":"Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.","journal":"The New England journal of medicine","pubDate":"2000 Apr 6","volume":"342","issue":"14","pages":"998-1006","authors":"Aricò M et al","elocationId":"","link":null,"reference":"Aricò M et al. The New England journal of medicine. 2000 Apr 6;342(14)998-1006.","abstract":null}]},{"id":1233,"uuid":"ab2c18ef-44d0-4682-bce3-a984402e9f78","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":171023,"hugoSymbol":"ASXL1","oncogene":false,"grch37Isoform":"ENST00000375687","grch37RefSeq":"NM_015338.5","grch38Isoform":"ENST00000375687","grch38RefSeq":"NM_015338.5","geneAliases":["BOPS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":171023,"hugoSymbol":"ASXL1","oncogene":false,"grch37Isoform":"ENST00000375687","grch37RefSeq":"NM_015338.5","grch38Isoform":"ENST00000375687","grch38RefSeq":"NM_015338.5","geneAliases":["BOPS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"20693432","title":"Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations.","journal":"Blood","pubDate":"2010 Nov 18","volume":"116","issue":"20","pages":"4086-94","authors":"Chou WC et al","elocationId":"doi: 10.1182/blood-2010-05-283291","link":null,"reference":"Chou WC et al. Blood. 2010 Nov 18;116(20)4086-94.","abstract":null},{"pmid":"25596267","title":"ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.","journal":"Haematologica","pubDate":"2015 Mar","volume":"100","issue":"3","pages":"324-30","authors":"Paschka P et al","elocationId":"doi: 10.3324/haematol.2014.114157","link":null,"reference":"Paschka P et al. Haematologica. 2015 Mar;100(3)324-30.","abstract":null},{"pmid":"22058207","title":"Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.","journal":"Haematologica","pubDate":"2012 Mar","volume":"97","issue":"3","pages":"388-92","authors":"Pratcorona M et al","elocationId":"doi: 10.3324/haematol.2011.051532","link":null,"reference":"Pratcorona M et al. Haematologica. 2012 Mar;97(3)388-92.","abstract":null}]},{"id":1235,"uuid":"19c3f923-4004-4467-81d8-78a787fe06b6","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":632,"subtype":"Primary Myelofibrosis","code":"PMF","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":171023,"hugoSymbol":"ASXL1","oncogene":false,"grch37Isoform":"ENST00000375687","grch37RefSeq":"NM_015338.5","grch38Isoform":"ENST00000375687","grch38RefSeq":"NM_015338.5","geneAliases":["BOPS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":171023,"hugoSymbol":"ASXL1","oncogene":false,"grch37Isoform":"ENST00000375687","grch37RefSeq":"NM_015338.5","grch38Isoform":"ENST00000375687","grch38RefSeq":"NM_015338.5","geneAliases":["BOPS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23619563","title":"Mutations and prognosis in primary myelofibrosis.","journal":"Leukemia","pubDate":"2013 Sep","volume":"27","issue":"9","pages":"1861-9","authors":"Vannucchi AM et al","elocationId":"doi: 10.1038/leu.2013.119","link":null,"reference":"Vannucchi AM et al. Leukemia. 2013 Sep;27(9)1861-9.","abstract":null},{"pmid":"24402162","title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.","journal":"Leukemia","pubDate":"2014 Jul","volume":"28","issue":"7","pages":"1472-7","authors":"Tefferi A et al","elocationId":"doi: 10.1038/leu.2014.3","link":null,"reference":"Tefferi A et al. Leukemia. 2014 Jul;28(7)1472-7.","abstract":null},{"pmid":"24496303","title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.","journal":"Leukemia","pubDate":"2014 Jul","volume":"28","issue":"7","pages":"1494-500","authors":"Tefferi A et al","elocationId":"doi: 10.1038/leu.2014.57","link":null,"reference":"Tefferi A et al. Leukemia. 2014 Jul;28(7)1494-500.","abstract":null}]},{"id":4819,"uuid":"66e36f5a-f996-463b-8c11-a613f9803989","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":632,"subtype":"Primary Myelofibrosis","code":"PMF","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":811,"hugoSymbol":"CALR","oncogene":true,"grch37Isoform":"ENST00000316448","grch37RefSeq":"NM_004343.3","grch38Isoform":"ENST00000316448","grch38RefSeq":"NM_004343.3","geneAliases":["SSA","cC1qR","CRT","HEL-S-99n","RO"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":811,"hugoSymbol":"CALR","oncogene":true,"grch37Isoform":"ENST00000316448","grch37RefSeq":"NM_004343.3","grch38Isoform":"ENST00000316448","grch38RefSeq":"NM_004343.3","geneAliases":["SSA","cC1qR","CRT","HEL-S-99n","RO"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24402162","title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.","journal":"Leukemia","pubDate":"2014 Jul","volume":"28","issue":"7","pages":"1472-7","authors":"Tefferi A et al","elocationId":"doi: 10.1038/leu.2014.3","link":null,"reference":"Tefferi A et al. Leukemia. 2014 Jul;28(7)1472-7.","abstract":null},{"pmid":"24325356","title":"Somatic mutations of calreticulin in myeloproliferative neoplasms.","journal":"The New England journal of medicine","pubDate":"2013 Dec 19","volume":"369","issue":"25","pages":"2379-90","authors":"Klampfl T et al","elocationId":"doi: 10.1056/NEJMoa1311347","link":null,"reference":"Klampfl T et al. The New England journal of medicine. 2013 Dec 19;369(25)2379-90.","abstract":null},{"pmid":"24986690","title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.","journal":"Blood","pubDate":"2014 Aug 14","volume":"124","issue":"7","pages":"1062-9","authors":"Rumi E et al","elocationId":"doi: 10.1182/blood-2014-05-578435","link":null,"reference":"Rumi E et al. Blood. 2014 Aug 14;124(7)1062-9.","abstract":null}]},{"id":23576,"uuid":"b463eb8a-283b-408d-a1d1-eafc17264686","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":160,"subtype":"Anaplastic Large-Cell Lymphoma ALK Negative","code":"ALCLALKN","color":"LimeGreen","mainType":"Mature T and NK Neoplasms","level":6,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8626,"hugoSymbol":"TP63","oncogene":true,"grch37Isoform":"ENST00000264731","grch37RefSeq":"NM_003722.4","grch38Isoform":"ENST00000264731","grch38RefSeq":"NM_003722.4","geneAliases":["OFC8","SHFM4","p63","B(p51B)","p51","B(p51A)","p73H","EEC3","TP53CP","TP73L","LMS","p73L","TP53L","p53CP","KET","RHS","NBP"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":8626,"hugoSymbol":"TP63","oncogene":true,"grch37Isoform":"ENST00000264731","grch37RefSeq":"NM_003722.4","grch38Isoform":"ENST00000264731","grch38RefSeq":"NM_003722.4","geneAliases":["OFC8","SHFM4","p63","B(p51B)","p51","B(p51A)","p73H","EEC3","TP53CP","TP73L","LMS","p73L","TP53L","p53CP","KET","RHS","NBP"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"28522440","title":"<i>DUSP22</i> and <i>TP63</i> rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study.","journal":"Blood","pubDate":"2017 Jul 27","volume":"130","issue":"4","pages":"554-557","authors":"Pedersen MB et al","elocationId":"doi: 10.1182/blood-2016-12-755496","link":null,"reference":"Pedersen MB et al. Blood. 2017 Jul 27;130(4)554-557.","abstract":null},{"pmid":"24894770","title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.","journal":"Blood","pubDate":"2014 Aug 28","volume":"124","issue":"9","pages":"1473-80","authors":"Parrilla Castellar ER et al","elocationId":"doi: 10.1182/blood-2014-04-571091","link":null,"reference":"Parrilla Castellar ER et al. Blood. 2014 Aug 28;124(9)1473-80.","abstract":null}]},{"id":5663,"uuid":"d724c0d0-b2b8-4846-b159-506089c1b55e","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1050,"hugoSymbol":"CEBPA","oncogene":false,"grch37Isoform":"ENST00000498907","grch37RefSeq":"NM_004364.3","grch38Isoform":"ENST00000498907","grch38RefSeq":"NM_004364.3","geneAliases":["C/EBP-alpha","CEBP"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":1050,"hugoSymbol":"CEBPA","oncogene":false,"grch37Isoform":"ENST00000498907","grch37RefSeq":"NM_004364.3","grch38Isoform":"ENST00000498907","grch38RefSeq":"NM_004364.3","geneAliases":["C/EBP-alpha","CEBP"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"20038735","title":"Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2010 Feb 1","volume":"28","issue":"4","pages":"570-7","authors":"Dufour A et al","elocationId":"doi: 10.1200/JCO.2008.21.6010","link":null,"reference":"Dufour A et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Feb 1;28(4)570-7.","abstract":null},{"pmid":"19277035","title":"Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.","journal":"British journal of cancer","pubDate":"2009 Apr 21","volume":"100","issue":"8","pages":"1343-6","authors":"Pabst T et al","elocationId":"doi: 10.1038/sj.bjc.6604977","link":null,"reference":"Pabst T et al. British journal of cancer. 2009 Apr 21;100(8)1343-6.","abstract":null},{"pmid":"20439648","title":"Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2010 Jun 1","volume":"28","issue":"16","pages":"2739-47","authors":"Green CL et al","elocationId":"doi: 10.1200/JCO.2009.26.2501","link":null,"reference":"Green CL et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Jun 1;28(16)2739-47.","abstract":null},{"pmid":"19171880","title":"Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.","journal":"Blood","pubDate":"2009 Mar 26","volume":"113","issue":"13","pages":"3088-91","authors":"Wouters BJ et al","elocationId":"doi: 10.1182/blood-2008-09-179895","link":null,"reference":"Wouters BJ et al. Blood. 2009 Mar 26;113(13)3088-91.","abstract":null},{"pmid":"19623175","title":"Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'.","journal":"British journal of cancer","pubDate":"2009 Aug 18","volume":"101","issue":"4","pages":"738-40","authors":"Hou HA et al","elocationId":"doi: 10.1038/sj.bjc.6605207","link":null,"reference":"Hou HA et al. British journal of cancer. 2009 Aug 18;101(4)738-40.","abstract":null}]},{"id":17568,"uuid":"6b9c54e6-b600-4a7d-b773-2b5c34c630e2","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":688,"subtype":"B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like","code":"BLLBCRABL1L","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5159,"hugoSymbol":"PDGFRB","oncogene":true,"grch37Isoform":"ENST00000261799","grch37RefSeq":"NM_002609.3","grch38Isoform":"ENST00000261799","grch38RefSeq":"NM_002609.3","geneAliases":["PDGFR1","KOGS","PDGFR-1","JTK12","PDGFR","IBGC4","IMF1","PENTT","CD140B"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5159,"hugoSymbol":"PDGFRB","oncogene":true,"grch37Isoform":"ENST00000261799","grch37RefSeq":"NM_002609.3","grch38Isoform":"ENST00000261799","grch38RefSeq":"NM_002609.3","geneAliases":["PDGFR1","KOGS","PDGFR-1","JTK12","PDGFR","IBGC4","IMF1","PENTT","CD140B"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27870571","title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Feb","volume":"35","issue":"4","pages":"394-401","authors":"Roberts KG et al","elocationId":"doi: 10.1200/JCO.2016.69.0073","link":null,"reference":"Roberts KG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb;35(4)394-401.","abstract":null}]}],"LEVEL_Dx1":[{"id":4963,"uuid":"150e1b5a-be8a-40f5-969d-26a4594f6b89","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":12,"subtype":"AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11","code":"AMLCBFBMYH11","color":"LightSalmon","mainType":"Leukemia","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":865,"hugoSymbol":"CBFB","oncogene":false,"grch37Isoform":"ENST00000412916","grch37RefSeq":"NM_022845.2","grch38Isoform":"ENST00000412916","grch38RefSeq":"NM_022845.2","geneAliases":["PEBP2B"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":865,"hugoSymbol":"CBFB","oncogene":false,"grch37Isoform":"ENST00000412916","grch37RefSeq":"NM_022845.2","grch38Isoform":"ENST00000412916","grch38RefSeq":"NM_022845.2","geneAliases":["PEBP2B"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"CBFB-MYH11 Fusion","name":"CBFB-MYH11 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"17287858","title":"Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients.","journal":"Leukemia","pubDate":"2007 Apr","volume":"21","issue":"4","pages":"725-31","authors":"Schnittger S et al","elocationId":"","link":null,"reference":"Schnittger S et al. Leukemia. 2007 Apr;21(4)725-31.","abstract":null},{"pmid":"17052753","title":"Detection of the CBFB/MYH11 fusion gene in de novo acute myeloid leukemia (AML): a single-institution study of 224 Japanese AML patients.","journal":"Leukemia research","pubDate":"2007 Apr","volume":"31","issue":"4","pages":"471-6","authors":"Monma F et al","elocationId":"","link":null,"reference":"Monma F et al. Leukemia research. 2007 Apr;31(4)471-6.","abstract":null}]},{"id":12067,"uuid":"7f7466c4-276a-45bd-b02d-572be2735295","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":691,"subtype":"Myeloid/Lymphoid Neoplasms with PCM1-JAK2","code":"MLNPCM1JAK2","color":"LightSalmon","mainType":"Leukemia","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"PCM1-JAK2 Fusion","name":"PCM1-JAK2 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24913195","title":"Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?","journal":"British journal of haematology","pubDate":"2014 Sep","volume":"166","issue":"6","pages":"809-17","authors":"Bain BJ et al","elocationId":"doi: 10.1111/bjh.12963","link":null,"reference":"Bain BJ et al. British journal of haematology. 2014 Sep;166(6)809-17.","abstract":null}]},{"id":17571,"uuid":"15706396-9b5e-4872-8246-d57570c5ddc3","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":650,"subtype":"Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement","code":"MLNPDGFRB","color":"LightSalmon","mainType":"Leukemia","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5159,"hugoSymbol":"PDGFRB","oncogene":true,"grch37Isoform":"ENST00000261799","grch37RefSeq":"NM_002609.3","grch38Isoform":"ENST00000261799","grch38RefSeq":"NM_002609.3","geneAliases":["PDGFR1","KOGS","PDGFR-1","JTK12","PDGFR","IBGC4","IMF1","PENTT","CD140B"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5159,"hugoSymbol":"PDGFRB","oncogene":true,"grch37Isoform":"ENST00000261799","grch37RefSeq":"NM_002609.3","grch38Isoform":"ENST00000261799","grch38RefSeq":"NM_002609.3","geneAliases":["PDGFR1","KOGS","PDGFR-1","JTK12","PDGFR","IBGC4","IMF1","PENTT","CD140B"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"8168137","title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.","journal":"Cell","pubDate":"1994 Apr 22","volume":"77","issue":"2","pages":"307-16","authors":"Golub TR et al","elocationId":"","link":null,"reference":"Golub TR et al. Cell. 1994 Apr 22;77(2)307-16.","abstract":null},{"pmid":"20442440","title":"Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1.","journal":"Haematologica","pubDate":"2010 May","volume":"95","issue":"5","pages":"696-8","authors":"Bain BJ","elocationId":"doi: 10.3324/haematol.2009.021675","link":null,"reference":"Bain BJ. Haematologica. 2010 May;95(5)696-8.","abstract":null},{"pmid":"3478077","title":"Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association.","journal":"British journal of haematology","pubDate":"1987 Sep","volume":"67","issue":"1","pages":"25-31","authors":"Keene P et al","elocationId":"","link":null,"reference":"Keene P et al. British journal of haematology. 1987 Sep;67(1)25-31.","abstract":null},{"pmid":"29567772","title":"Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of <i>PDGFRA, PDGFRB, FGFR1</i> or <i>PCM1-JAK2</i>.","journal":"Haematologica","pubDate":"2018 Aug","volume":"103","issue":"8","pages":"e348-e350","authors":"Baer C et al","elocationId":"doi: 10.3324/haematol.2017.187302","link":null,"reference":"Baer C et al. Haematologica. 2018 Aug;103(8)e348-e350.","abstract":null},{"pmid":"11919393","title":"Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta.","journal":"Acta haematologica","pubDate":"2002","volume":"107","issue":"2","pages":"113-22","authors":"Steer EJ et al","elocationId":"","link":null,"reference":"Steer EJ et al. Acta haematologica. 2002;107(2)113-22.","abstract":null}]},{"id":17507,"uuid":"2de6a847-7978-4efb-8300-e54f14c9b2ae","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":306,"subtype":"Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement","code":"MLNPDGFRA","color":"LightSalmon","mainType":"Leukemia","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"17377585","title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.","journal":"Leukemia","pubDate":"2007 Jun","volume":"21","issue":"6","pages":"1183-8","authors":"Metzgeroth G et al","elocationId":"","link":null,"reference":"Metzgeroth G et al. Leukemia. 2007 Jun;21(6)1183-8.","abstract":null},{"pmid":"12660384","title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.","journal":"The New England journal of medicine","pubDate":"2003 Mar 27","volume":"348","issue":"13","pages":"1201-14","authors":"Cools J et al","elocationId":"","link":null,"reference":"Cools J et al. The New England journal of medicine. 2003 Mar 27;348(13)1201-14.","abstract":null},{"pmid":"20442440","title":"Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1.","journal":"Haematologica","pubDate":"2010 May","volume":"95","issue":"5","pages":"696-8","authors":"Bain BJ","elocationId":"doi: 10.3324/haematol.2009.021675","link":null,"reference":"Bain BJ. Haematologica. 2010 May;95(5)696-8.","abstract":null},{"pmid":"29567772","title":"Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of <i>PDGFRA, PDGFRB, FGFR1</i> or <i>PCM1-JAK2</i>.","journal":"Haematologica","pubDate":"2018 Aug","volume":"103","issue":"8","pages":"e348-e350","authors":"Baer C et al","elocationId":"doi: 10.3324/haematol.2017.187302","link":null,"reference":"Baer C et al. Haematologica. 2018 Aug;103(8)e348-e350.","abstract":null}]},{"id":6308,"uuid":"c1607104-dc12-4a54-8215-41db0d6979db","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":429,"subtype":"AML with t(6;9)(p23;q34.1);DEK-NUP214","code":"AMLDEKNUP214","color":"LightSalmon","mainType":"Leukemia","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7913,"hugoSymbol":"DEK","oncogene":true,"grch37Isoform":"ENST00000397239","grch37RefSeq":"NM_003472.3","grch38Isoform":"ENST00000652689","grch38RefSeq":"NM_003472.4","geneAliases":["D6S231E"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":7913,"hugoSymbol":"DEK","oncogene":true,"grch37Isoform":"ENST00000397239","grch37RefSeq":"NM_003472.3","grch38Isoform":"ENST00000652689","grch38RefSeq":"NM_003472.4","geneAliases":["D6S231E"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"DEK-NUP214 Fusion","name":"DEK-NUP214 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/116/21/2386","reference":"null. null. .","abstract":"Ishiyama, K. et al. Abstract# Blood 116:2386, 2010"}]},{"id":21094,"uuid":"c869504e-94a1-4e76-93ef-27d6bb11f346","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":805,"subtype":"AML with Mutated RUNX1","code":"AMLRUNX1","color":"LightSalmon","mainType":"Leukemia","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27211269","title":"The new provisional WHO entity 'RUNX1 mutated AML' shows specific genetics but no prognostic influence of dysplasia.","journal":"Leukemia","pubDate":"2016 Oct","volume":"30","issue":"10","pages":"2109-2112","authors":"Haferlach T et al","elocationId":"doi: 10.1038/leu.2016.150","link":null,"reference":"Haferlach T et al. Leukemia. 2016 Oct;30(10)2109-2112.","abstract":null}]},{"id":7911,"uuid":"ff1a2350-717e-4e1a-996f-a9306c02f299","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":688,"subtype":"B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like","code":"BLLBCRABL1L","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2057,"hugoSymbol":"EPOR","oncogene":true,"grch37Isoform":"ENST00000222139","grch37RefSeq":"NM_000121.3","grch38Isoform":"ENST00000222139","grch38RefSeq":"NM_000121.3","geneAliases":["EPO-R"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2057,"hugoSymbol":"EPOR","oncogene":true,"grch37Isoform":"ENST00000222139","grch37RefSeq":"NM_000121.3","grch38Isoform":"ENST00000222139","grch38RefSeq":"NM_000121.3","geneAliases":["EPO-R"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27870571","title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Feb","volume":"35","issue":"4","pages":"394-401","authors":"Roberts KG et al","elocationId":"doi: 10.1200/JCO.2016.69.0073","link":null,"reference":"Roberts KG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb;35(4)394-401.","abstract":null}]},{"id":20457,"uuid":"c5fc5767-83ff-4f80-a28c-094e132d96a4","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":260,"subtype":"APL with PML-RARA","code":"APLPMLRARA","color":"LightSalmon","mainType":"Leukemia","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5914,"hugoSymbol":"RARA","oncogene":false,"grch37Isoform":"ENST00000254066","grch37RefSeq":"NM_000964.3","grch38Isoform":"ENST00000254066","grch38RefSeq":"NM_000964.3","geneAliases":["RAR","NR1B1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5914,"hugoSymbol":"RARA","oncogene":false,"grch37Isoform":"ENST00000254066","grch37RefSeq":"NM_000964.3","grch38Isoform":"ENST00000254066","grch38RefSeq":"NM_000964.3","geneAliases":["RAR","NR1B1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"1652369","title":"The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR.","journal":"Cell","pubDate":"1991 Aug 23","volume":"66","issue":"4","pages":"675-84","authors":"de Thé H et al","elocationId":"","link":null,"reference":"de Thé H et al. Cell. 1991 Aug 23;66(4)675-84.","abstract":null}]},{"id":12074,"uuid":"ae368531-d008-4a44-ab31-5c91952952a4","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":688,"subtype":"B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like","code":"BLLBCRABL1L","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27870571","title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Feb","volume":"35","issue":"4","pages":"394-401","authors":"Roberts KG et al","elocationId":"doi: 10.1200/JCO.2016.69.0073","link":null,"reference":"Roberts KG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb;35(4)394-401.","abstract":null}]},{"id":13036,"uuid":"dc314150-8c39-459b-ae9b-1880808123ac","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":775,"subtype":"B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3);KMT2A Rearranged","code":"BLLKMT2A","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4297,"hugoSymbol":"KMT2A","oncogene":false,"grch37Isoform":"ENST00000534358","grch37RefSeq":"NM_001197104.1","grch38Isoform":"ENST00000534358","grch38RefSeq":"NM_001197104.1","geneAliases":["MLL1","TRX1","HTRX1","ALL-1","MLL","MLL1A","CXXC7","HRX","WDSTS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4297,"hugoSymbol":"KMT2A","oncogene":false,"grch37Isoform":"ENST00000534358","grch37RefSeq":"NM_001197104.1","grch38Isoform":"ENST00000534358","grch38RefSeq":"NM_001197104.1","geneAliases":["MLL1","TRX1","HTRX1","ALL-1","MLL","MLL1A","CXXC7","HRX","WDSTS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27282883","title":"Molecular characterization of KMT2A fusion partner genes in 13 cases of pediatric leukemia with complex or cryptic karyotypes.","journal":"Hematological oncology","pubDate":"2017 Dec","volume":"35","issue":"4","pages":"760-768","authors":"Ney Garcia DR et al","elocationId":"doi: 10.1002/hon.2299","link":null,"reference":"Ney Garcia DR et al. Hematological oncology. 2017 Dec;35(4)760-768.","abstract":null},{"pmid":"17268512","title":"Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement.","journal":"Leukemia","pubDate":"2007 Apr","volume":"21","issue":"4","pages":"633-41","authors":"Jansen MW et al","elocationId":"","link":null,"reference":"Jansen MW et al. Leukemia. 2007 Apr;21(4)633-41.","abstract":null}]},{"id":13038,"uuid":"baf27521-6d86-4b66-ade8-f39bcfe73697","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":273,"subtype":"Mixed Phenotype Acute Leukemia with t(v;11q23.3); KMT2A Rearranged","code":"MPALKMT2A","color":"LightSalmon","mainType":"Leukemia","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4297,"hugoSymbol":"KMT2A","oncogene":false,"grch37Isoform":"ENST00000534358","grch37RefSeq":"NM_001197104.1","grch38Isoform":"ENST00000534358","grch38RefSeq":"NM_001197104.1","geneAliases":["MLL1","TRX1","HTRX1","ALL-1","MLL","MLL1A","CXXC7","HRX","WDSTS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4297,"hugoSymbol":"KMT2A","oncogene":false,"grch37Isoform":"ENST00000534358","grch37RefSeq":"NM_001197104.1","grch38Isoform":"ENST00000534358","grch38RefSeq":"NM_001197104.1","geneAliases":["MLL1","TRX1","HTRX1","ALL-1","MLL","MLL1A","CXXC7","HRX","WDSTS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"10457405","title":"Outcome of biphenotypic acute leukemia.","journal":"Haematologica","pubDate":"1999 Aug","volume":"84","issue":"8","pages":"699-706","authors":"Killick S et al","elocationId":"","link":null,"reference":"Killick S et al. Haematologica. 1999 Aug;84(8)699-706.","abstract":null},{"pmid":"8709632","title":"Cytogenetic findings in acute biphenotypic leukaemia.","journal":"Leukemia","pubDate":"1996 Aug","volume":"10","issue":"8","pages":"1283-7","authors":"Carbonell F et al","elocationId":"","link":null,"reference":"Carbonell F et al. Leukemia. 1996 Aug;10(8)1283-7.","abstract":null},{"pmid":"17611554","title":"Acute bilineal leukemia: a rare disease with poor outcome.","journal":"Leukemia","pubDate":"2007 Nov","volume":"21","issue":"11","pages":"2264-70","authors":"Weir EG et al","elocationId":"","link":null,"reference":"Weir EG et al. Leukemia. 2007 Nov;21(11)2264-70.","abstract":null}]},{"id":23918,"uuid":"5c519328-feb8-498e-9d97-ef49f75aeb9e","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":688,"subtype":"B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like","code":"BLLBCRABL1L","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7297,"hugoSymbol":"TYK2","oncogene":true,"grch37Isoform":"ENST00000264818","grch37RefSeq":"NM_003331.4","grch38Isoform":"ENST00000264818","grch38RefSeq":"NM_003331.4","geneAliases":["JTK1","IMD35"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":7297,"hugoSymbol":"TYK2","oncogene":true,"grch37Isoform":"ENST00000264818","grch37RefSeq":"NM_003331.4","grch38Isoform":"ENST00000264818","grch38RefSeq":"NM_003331.4","geneAliases":["JTK1","IMD35"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27870571","title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Feb","volume":"35","issue":"4","pages":"394-401","authors":"Roberts KG et al","elocationId":"doi: 10.1200/JCO.2016.69.0073","link":null,"reference":"Roberts KG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb;35(4)394-401.","abstract":null}]},{"id":22575,"uuid":"c120ecf3-fcb9-4d6f-aa36-607c3c88806d","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":743,"subtype":"B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1","code":"BLLTCF3PBX1","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6929,"hugoSymbol":"TCF3","oncogene":false,"grch37Isoform":"ENST00000344749","grch37RefSeq":"NM_001136139.2","grch38Isoform":"ENST00000588136","grch38RefSeq":"NM_001136139.2","geneAliases":["TCF-3","ITF1","E2A","E47","AGM8","VDIR","bHLHb21"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":6929,"hugoSymbol":"TCF3","oncogene":false,"grch37Isoform":"ENST00000344749","grch37RefSeq":"NM_001136139.2","grch38Isoform":"ENST00000588136","grch38RefSeq":"NM_001136139.2","geneAliases":["TCF-3","ITF1","E2A","E47","AGM8","VDIR","bHLHb21"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"TCF3-PBX1 Fusion","name":"TCF3-PBX1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"8608207","title":"Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis.","journal":"Blood","pubDate":"1996 Feb 15","volume":"87","issue":"4","pages":"1211-24","authors":"Hunger SP","elocationId":"","link":null,"reference":"Hunger SP. Blood. 1996 Feb 15;87(4)1211-24.","abstract":null}]},{"id":21040,"uuid":"44f663f7-8e13-4984-b8c0-488df347840d","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":791,"subtype":"AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1","code":"AMLRUNX1RUNX1T1","color":"LightSalmon","mainType":"Leukemia","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"RUNX1-RUNX1T1 Fusion","name":"RUNX1-RUNX1T1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"8499624","title":"An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation.","journal":"Blood","pubDate":"1993 Jun 1","volume":"81","issue":"11","pages":"2860-5","authors":"Downing JR et al","elocationId":"","link":null,"reference":"Downing JR et al. Blood. 1993 Jun 1;81(11)2860-5.","abstract":null}]},{"id":6002,"uuid":"546e8451-0d79-4431-a35a-17670d3acd2e","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":688,"subtype":"B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like","code":"BLLBCRABL1L","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":64109,"hugoSymbol":"CRLF2","oncogene":true,"grch37Isoform":"ENST00000381566","grch37RefSeq":"NM_022148.2","grch38Isoform":"ENST00000381566","grch38RefSeq":"NM_022148.4","geneAliases":["TSLPR","CRL2","CRLF2Y"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":64109,"hugoSymbol":"CRLF2","oncogene":true,"grch37Isoform":"ENST00000381566","grch37RefSeq":"NM_022148.2","grch38Isoform":"ENST00000381566","grch38RefSeq":"NM_022148.4","geneAliases":["TSLPR","CRL2","CRLF2Y"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27870571","title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Feb","volume":"35","issue":"4","pages":"394-401","authors":"Roberts KG et al","elocationId":"doi: 10.1200/JCO.2016.69.0073","link":null,"reference":"Roberts KG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb;35(4)394-401.","abstract":null}]},{"id":184,"uuid":"166d4a1b-3282-4477-ad9b-51f029996d5f","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":688,"subtype":"B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like","code":"BLLBCRABL1L","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":27,"hugoSymbol":"ABL2","oncogene":true,"grch37Isoform":"ENST00000502732","grch37RefSeq":"NM_007314.3","grch38Isoform":"ENST00000502732","grch38RefSeq":"NM_007314.3","geneAliases":["ARG","ABLL"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":27,"hugoSymbol":"ABL2","oncogene":true,"grch37Isoform":"ENST00000502732","grch37RefSeq":"NM_007314.3","grch38Isoform":"ENST00000502732","grch38RefSeq":"NM_007314.3","geneAliases":["ARG","ABLL"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27870571","title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Feb","volume":"35","issue":"4","pages":"394-401","authors":"Roberts KG et al","elocationId":"doi: 10.1200/JCO.2016.69.0073","link":null,"reference":"Roberts KG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb;35(4)394-401.","abstract":null}]},{"id":13052,"uuid":"a20171b5-7343-46c2-9880-1d532cfe3bb3","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":246,"subtype":"AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A","code":"AMLMLLT3KMT2A","color":"LightSalmon","mainType":"Leukemia","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4297,"hugoSymbol":"KMT2A","oncogene":false,"grch37Isoform":"ENST00000534358","grch37RefSeq":"NM_001197104.1","grch38Isoform":"ENST00000534358","grch38RefSeq":"NM_001197104.1","geneAliases":["MLL1","TRX1","HTRX1","ALL-1","MLL","MLL1A","CXXC7","HRX","WDSTS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4297,"hugoSymbol":"KMT2A","oncogene":false,"grch37Isoform":"ENST00000534358","grch37RefSeq":"NM_001197104.1","grch38Isoform":"ENST00000534358","grch38RefSeq":"NM_001197104.1","geneAliases":["MLL1","TRX1","HTRX1","ALL-1","MLL","MLL1A","CXXC7","HRX","WDSTS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"KMT2A-MLLT3 Fusion","name":"KMT2A-MLLT3 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"20395514","title":"Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases.","journal":"American journal of clinical pathology","pubDate":"2010 May","volume":"133","issue":"5","pages":"686-93","authors":"Chandra P et al","elocationId":"doi: 10.1309/AJCPGII1TT4NYOGI","link":null,"reference":"Chandra P et al. American journal of clinical pathology. 2010 May;133(5)686-93.","abstract":null}]},{"id":11905,"uuid":"87480663-ee2d-4ba4-82aa-15323ac03178","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":513,"subtype":"B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH","code":"BLLIL3IGH","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3562,"hugoSymbol":"IL3","oncogene":true,"grch37Isoform":"ENST00000296870","grch37RefSeq":"NM_000588.3","grch38Isoform":"ENST00000296870","grch38RefSeq":"NM_000588.3","geneAliases":["MCGF","MULTI-CSF","IL-3"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3562,"hugoSymbol":"IL3","oncogene":true,"grch37Isoform":"ENST00000296870","grch37RefSeq":"NM_000588.3","grch38Isoform":"ENST00000296870","grch38RefSeq":"NM_000588.3","geneAliases":["MCGF","MULTI-CSF","IL-3"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"IGH-IL3 Fusion","name":"IGH-IL3 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25382309","title":"Cutaneous B-lymphoblastic lymphoma with IL3/IgH translocation presenting with hypereosinophilia and acute endocarditis.","journal":"Pediatric blood & cancer","pubDate":"2015 Jun","volume":"62","issue":"6","pages":"1055-7","authors":"Bomken S et al","elocationId":"doi: 10.1002/pbc.25318","link":null,"reference":"Bomken S et al. Pediatric blood & cancer. 2015 Jun;62(6)1055-7.","abstract":null}]},{"id":9,"uuid":"be7cf3ad-86c3-41d6-ae66-54b39788fc03","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":688,"subtype":"B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like","code":"BLLBCRABL1L","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27870571","title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Feb","volume":"35","issue":"4","pages":"394-401","authors":"Roberts KG et al","elocationId":"doi: 10.1200/JCO.2016.69.0073","link":null,"reference":"Roberts KG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb;35(4)394-401.","abstract":null}]},{"id":16778,"uuid":"0bc47a24-095b-439b-9288-b7a52707edaf","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":789,"subtype":"AML with Mutated NPM1","code":"AMLNPM1","color":"LightSalmon","mainType":"Leukemia","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4869,"hugoSymbol":"NPM1","oncogene":false,"grch37Isoform":"ENST00000296930","grch37RefSeq":"NM_002520.6","grch38Isoform":"ENST00000296930","grch38RefSeq":"NM_002520.6","geneAliases":["B23","NPM"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4869,"hugoSymbol":"NPM1","oncogene":false,"grch37Isoform":"ENST00000296930","grch37RefSeq":"NM_002520.6","grch38Isoform":"ENST00000296930","grch38RefSeq":"NM_002520.6","geneAliases":["B23","NPM"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"21030560","title":"Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?","journal":"Blood","pubDate":"2011 Jan 27","volume":"117","issue":"4","pages":"1109-20","authors":"Falini B et al","elocationId":"doi: 10.1182/blood-2010-08-299990","link":null,"reference":"Falini B et al. Blood. 2011 Jan 27;117(4)1109-20.","abstract":null}]},{"id":10058,"uuid":"855edba0-6bec-4be8-91d3-536411ede420","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":97,"subtype":"Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement","code":"MLNFGFR1","color":"LightSalmon","mainType":"Leukemia","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2260,"hugoSymbol":"FGFR1","oncogene":true,"grch37Isoform":"ENST00000425967","grch37RefSeq":"NM_001174067.1","grch38Isoform":"ENST00000425967","grch38RefSeq":"NM_001174067.1","geneAliases":["FLG","N-SAM","FLT2","ECCL","CEK","HBGFR","HRTFDS","BFGFR","FGFR-1","FLT-2","OGD","FGFBR","HH2","bFGF-R-1","CD331","KAL2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2260,"hugoSymbol":"FGFR1","oncogene":true,"grch37Isoform":"ENST00000425967","grch37RefSeq":"NM_001174067.1","grch38Isoform":"ENST00000425967","grch38RefSeq":"NM_001174067.1","geneAliases":["FLG","N-SAM","FLT2","ECCL","CEK","HBGFR","HRTFDS","BFGFR","FGFR-1","FLT-2","OGD","FGFBR","HH2","bFGF-R-1","CD331","KAL2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"11919391","title":"The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1.","journal":"Acta haematologica","pubDate":"2002","volume":"107","issue":"2","pages":"101-7","authors":"Macdonald D et al","elocationId":"","link":null,"reference":"Macdonald D et al. Acta haematologica. 2002;107(2)101-7.","abstract":null}]},{"id":11980,"uuid":"fe8b5c3b-75ae-4148-8e2c-d7ddeb89c954","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":314,"subtype":"Large B-Cell Lymphoma with IRF4 Rearrangement","code":"LBLIRF4","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[{"id":314,"subtype":"Large B-Cell Lymphoma with IRF4 Rearrangement","code":"LBLIRF4","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"gene":{"entrezGeneId":3662,"hugoSymbol":"IRF4","oncogene":true,"grch37Isoform":"ENST00000380956","grch37RefSeq":"NM_002460.3","grch38Isoform":"ENST00000380956","grch38RefSeq":"NM_002460.3","geneAliases":["NF-EM5","LSIRF","MUM1","SHEP8"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3662,"hugoSymbol":"IRF4","oncogene":true,"grch37Isoform":"ENST00000380956","grch37RefSeq":"NM_002460.3","grch38Isoform":"ENST00000380956","grch38RefSeq":"NM_002460.3","geneAliases":["NF-EM5","LSIRF","MUM1","SHEP8"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"21487109","title":"Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults.","journal":"Blood","pubDate":"2011 Jul 7","volume":"118","issue":"1","pages":"139-47","authors":"Salaverria I et al","elocationId":"doi: 10.1182/blood-2011-01-330795","link":null,"reference":"Salaverria I et al. Blood. 2011 Jul 7;118(1)139-47.","abstract":null},{"pmid":"26980727","title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","journal":"Blood","pubDate":"2016 May 19","volume":"127","issue":"20","pages":"2375-90","authors":"Swerdlow SH et al","elocationId":"doi: 10.1182/blood-2016-01-643569","link":null,"reference":"Swerdlow SH et al. Blood. 2016 May 19;127(20)2375-90.","abstract":null}]},{"id":16208,"uuid":"b6865540-d3f2-4860-976d-8bc231db87d4","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":531,"subtype":"High-Grade B-Cell Lymphoma, with MYC and BCL2 and/or BCL6 Rearrangements","code":"HGBCLMYCBCL2","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[{"id":531,"subtype":"High-Grade B-Cell Lymphoma, with MYC and BCL2 and/or BCL6 Rearrangements","code":"HGBCLMYCBCL2","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"gene":{"entrezGeneId":4609,"hugoSymbol":"MYC","oncogene":true,"grch37Isoform":"ENST00000377970","grch37RefSeq":"NM_002467.4","grch38Isoform":"ENST00000621592","grch38RefSeq":"NM_002467.4","geneAliases":["c-Myc","MYCC","MRTL","bHLHe39"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4609,"hugoSymbol":"MYC","oncogene":true,"grch37Isoform":"ENST00000377970","grch37RefSeq":"NM_002467.4","grch38Isoform":"ENST00000621592","grch38RefSeq":"NM_002467.4","geneAliases":["c-Myc","MYCC","MRTL","bHLHe39"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27821509","title":"Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.","journal":"Blood","pubDate":"2017 Jan 19","volume":"129","issue":"3","pages":"280-288","authors":"Sesques P et al","elocationId":"doi: 10.1182/blood-2016-02-636316","link":null,"reference":"Sesques P et al. Blood. 2017 Jan 19;129(3)280-288.","abstract":null},{"pmid":"26980727","title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","journal":"Blood","pubDate":"2016 May 19","volume":"127","issue":"20","pages":"2375-90","authors":"Swerdlow SH et al","elocationId":"doi: 10.1182/blood-2016-01-643569","link":null,"reference":"Swerdlow SH et al. Blood. 2016 May 19;127(20)2375-90.","abstract":null}]},{"id":21,"uuid":"80d81875-f299-4f94-b23d-c42a33bda1d2","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":351,"subtype":"B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1","code":"BLLBCRABL1","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BCR-ABL1 Fusion","name":"BCR-ABL1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"28665419","title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update.","journal":"Blood cancer journal","pubDate":"2017 Jun 30","volume":"7","issue":"6","pages":"e577","authors":"Terwilliger T et al","elocationId":"doi: 10.1038/bcj.2017.53","link":null,"reference":"Terwilliger T et al. Blood cancer journal. 2017 Jun 30;7(6)e577.","abstract":null}]},{"id":727,"uuid":"fc9aad48-c4a1-4e2f-8a56-0440e5a1c796","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":106,"subtype":"ALK Positive Large B-Cell Lymphoma","code":"ALKLBCL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[{"id":106,"subtype":"ALK Positive Large B-Cell Lymphoma","code":"ALKLBCL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"8122112","title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.","journal":"Science (New York, N.Y.)","pubDate":"1994 Mar 4","volume":"263","issue":"5151","pages":"1281-4","authors":"Morris SW et al","elocationId":"","link":null,"reference":"Morris SW et al. Science (New York, N.Y.). 1994 Mar 4;263(5151)1281-4.","abstract":null}]},{"id":729,"uuid":"d7d0c31c-13ae-470c-a7a4-96331a32f8ad","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":336,"subtype":"Anaplastic Large-Cell Lymphoma ALK Positive","code":"ALCLALKP","color":"LimeGreen","mainType":"Mature T and NK Neoplasms","level":6,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"26104084","title":"Genetics of anaplastic large cell lymphoma.","journal":"Leukemia & lymphoma","pubDate":"2016","volume":"57","issue":"1","pages":"21-7","authors":"Zeng Y et al","elocationId":"doi: 10.3109/10428194.2015.1064530","link":null,"reference":"Zeng Y et al. Leukemia & lymphoma. 2016;57(1)21-7.","abstract":null}]},{"id":20570,"uuid":"08ce3de2-1f0b-4e25-837b-22cbd1dc3875","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":390,"subtype":"AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1","code":"AMLRBM15MKL1","color":"LightSalmon","mainType":"Leukemia","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":64783,"hugoSymbol":"RBM15","oncogene":true,"grch37Isoform":"ENST00000369784","grch37RefSeq":"NM_022768.4","grch38Isoform":"ENST00000369784","grch38RefSeq":"NM_022768.4","geneAliases":["OTT1","OTT"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":64783,"hugoSymbol":"RBM15","oncogene":true,"grch37Isoform":"ENST00000369784","grch37RefSeq":"NM_022768.4","grch38Isoform":"ENST00000369784","grch38RefSeq":"NM_022768.4","geneAliases":["OTT1","OTT"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"RBM15-MRTFA Fusion","name":"RBM15-MRTFA Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"11431691","title":"Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia.","journal":"Nature genetics","pubDate":"2001 Jul","volume":"28","issue":"3","pages":"220-1","authors":"Ma Z et al","elocationId":"","link":null,"reference":"Ma Z et al. Nature genetics. 2001 Jul;28(3)220-1.","abstract":null}]},{"id":29,"uuid":"0955a57c-3f60-4cc8-bd8e-e40aae3a3e70","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":184,"subtype":"AML with BCR-ABL1","code":"AMLBCRABL1","color":"LightSalmon","mainType":"Leukemia","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BCR-ABL1 Fusion","name":"BCR-ABL1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27297971","title":"BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features.","journal":"Annals of hematology","pubDate":"2016 Aug","volume":"95","issue":"8","pages":"1211-21","authors":"Neuendorff NR et al","elocationId":"doi: 10.1007/s00277-016-2721-z","link":null,"reference":"Neuendorff NR et al. Annals of hematology. 2016 Aug;95(8)1211-21.","abstract":null}]},{"id":5661,"uuid":"06c99bf7-7317-4844-9dd7-deaf78270b39","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":29,"subtype":"AML with Biallelic Mutations of CEBPA","code":"AMLCEBPA","color":"LightSalmon","mainType":"Leukemia","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1050,"hugoSymbol":"CEBPA","oncogene":false,"grch37Isoform":"ENST00000498907","grch37RefSeq":"NM_004364.3","grch38Isoform":"ENST00000498907","grch38RefSeq":"NM_004364.3","geneAliases":["C/EBP-alpha","CEBP"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":1050,"hugoSymbol":"CEBPA","oncogene":false,"grch37Isoform":"ENST00000498907","grch37RefSeq":"NM_004364.3","grch38Isoform":"ENST00000498907","grch38RefSeq":"NM_004364.3","geneAliases":["C/EBP-alpha","CEBP"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"15575056","title":"Mutation of CEBPA in familial acute myeloid leukemia.","journal":"The New England journal of medicine","pubDate":"2004 Dec 2","volume":"351","issue":"23","pages":"2403-7","authors":"Smith ML et al","elocationId":"","link":null,"reference":"Smith ML et al. The New England journal of medicine. 2004 Dec 2;351(23)2403-7.","abstract":null},{"pmid":"19171880","title":"Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.","journal":"Blood","pubDate":"2009 Mar 26","volume":"113","issue":"13","pages":"3088-91","authors":"Wouters BJ et al","elocationId":"doi: 10.1182/blood-2008-09-179895","link":null,"reference":"Wouters BJ et al. Blood. 2009 Mar 26;113(13)3088-91.","abstract":null}]},{"id":31,"uuid":"78d05b7c-767a-4ae4-a686-b4b3be006ef8","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":597,"subtype":"Chronic Myeloid Leukemia, BCR-ABL1+","code":"CMLBCRABL1","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[{"id":560,"subtype":"Chronic Myelogenous Leukemia","code":"CML","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"},{"id":597,"subtype":"Chronic Myeloid Leukemia, BCR-ABL1+","code":"CMLBCRABL1","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":5,"tissue":"Myeloid","tumorForm":"LIQUID"}],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BCR-ABL1 Fusion","name":"BCR-ABL1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"2989692","title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.","journal":"Nature","pubDate":"1985 Jun 13-19","volume":"315","issue":"6020","pages":"550-4","authors":"Shtivelman E et al","elocationId":"","link":null,"reference":"Shtivelman E et al. Nature. 1985 Jun 13-19;315(6020)550-4.","abstract":null}]},{"id":33,"uuid":"71002a27-9c84-4d90-b6af-b4736b209c31","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":104,"subtype":"Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1","code":"MPALBCRABL1","color":"LightSalmon","mainType":"Leukemia","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BCR-ABL1 Fusion","name":"BCR-ABL1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22015493","title":"Clinical characteristics and outcomes of mixed phenotype acute leukemia with Philadelphia chromosome positive and/or bcr-abl positive in adult.","journal":"International journal of hematology","pubDate":"2011 Dec","volume":"94","issue":"6","pages":"552-5","authors":"Wang Y et al","elocationId":"doi: 10.1007/s12185-011-0953-1","link":null,"reference":"Wang Y et al. International journal of hematology. 2011 Dec;94(6)552-5.","abstract":null},{"pmid":"7564526","title":"Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).","journal":"Leukemia","pubDate":"1995 Oct","volume":"9","issue":"10","pages":"1783-6","authors":"Bene MC et al","elocationId":"","link":null,"reference":"Bene MC et al. Leukemia. 1995 Oct;9(10)1783-6.","abstract":null}]},{"id":17569,"uuid":"ecc67577-541b-44c0-999d-a931e38f0853","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":688,"subtype":"B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like","code":"BLLBCRABL1L","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5159,"hugoSymbol":"PDGFRB","oncogene":true,"grch37Isoform":"ENST00000261799","grch37RefSeq":"NM_002609.3","grch38Isoform":"ENST00000261799","grch38RefSeq":"NM_002609.3","geneAliases":["PDGFR1","KOGS","PDGFR-1","JTK12","PDGFR","IBGC4","IMF1","PENTT","CD140B"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5159,"hugoSymbol":"PDGFRB","oncogene":true,"grch37Isoform":"ENST00000261799","grch37RefSeq":"NM_002609.3","grch38Isoform":"ENST00000261799","grch38RefSeq":"NM_002609.3","geneAliases":["PDGFR1","KOGS","PDGFR-1","JTK12","PDGFR","IBGC4","IMF1","PENTT","CD140B"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27870571","title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Feb","volume":"35","issue":"4","pages":"394-401","authors":"Roberts KG et al","elocationId":"doi: 10.1200/JCO.2016.69.0073","link":null,"reference":"Roberts KG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb;35(4)394-401.","abstract":null}]},{"id":21090,"uuid":"9a928b0e-cd18-4cc7-9892-cbd347e94479","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":193,"subtype":"B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1","code":"BLLETV6RUNX1","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"ETV6-RUNX1 Fusion","name":"ETV6-RUNX1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx1","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"7780150","title":"The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion.","journal":"Blood","pubDate":"1995 Jun 15","volume":"85","issue":"12","pages":"3662-70","authors":"Romana SP et al","elocationId":"","link":null,"reference":"Romana SP et al. Blood. 1995 Jun 15;85(12)3662-70.","abstract":null},{"pmid":"8609706","title":"TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.","journal":"Leukemia","pubDate":"1995 Dec","volume":"9","issue":"12","pages":"1985-9","authors":"Shurtleff SA et al","elocationId":"","link":null,"reference":"Shurtleff SA et al. Leukemia. 1995 Dec;9(12)1985-9.","abstract":null}]}],"LEVEL_Px2":[{"id":9798,"uuid":"dde9ea0a-f14b-4def-bce0-9ba6b858de04","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":695,"subtype":"Essential Thrombocythemia","code":"ET","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"29296692","title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia.","journal":"Blood advances","pubDate":"2016 Nov 29","volume":"1","issue":"1","pages":"21-30","authors":"Tefferi A et al","elocationId":"doi: 10.1182/bloodadvances.2016000216","link":null,"reference":"Tefferi A et al. Blood advances. 2016 Nov 29;1(1)21-30.","abstract":null},{"pmid":"27991718","title":"Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.","journal":"American journal of hematology","pubDate":"2017 Jan","volume":"92","issue":"1","pages":"94-108","authors":"Tefferi A et al","elocationId":"doi: 10.1002/ajh.24607","link":null,"reference":"Tefferi A et al. American journal of hematology. 2017 Jan;92(1)94-108.","abstract":null}]},{"id":15368,"uuid":"2068f76f-da03-4a1d-842c-1c41274634d1","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":632,"subtype":"Primary Myelofibrosis","code":"PMF","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4352,"hugoSymbol":"MPL","oncogene":true,"grch37Isoform":"ENST00000372470","grch37RefSeq":"NM_005373.2","grch38Isoform":"ENST00000372470","grch38RefSeq":"NM_005373.2","geneAliases":["CD110","THCYT2","TPOR","MPLV","C-MPL","THPOR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4352,"hugoSymbol":"MPL","oncogene":true,"grch37Isoform":"ENST00000372470","grch37RefSeq":"NM_005373.2","grch38Isoform":"ENST00000372470","grch38RefSeq":"NM_005373.2","geneAliases":["CD110","THCYT2","TPOR","MPLV","C-MPL","THPOR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"W515L","name":"W515L","refResidues":"W","proteinStart":515,"proteinEnd":515,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":4352,"hugoSymbol":"MPL","oncogene":true,"grch37Isoform":"ENST00000372470","grch37RefSeq":"NM_005373.2","grch38Isoform":"ENST00000372470","grch38RefSeq":"NM_005373.2","geneAliases":["CD110","THCYT2","TPOR","MPLV","C-MPL","THPOR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"W515K","name":"W515K","refResidues":"W","proteinStart":515,"proteinEnd":515,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25037629","title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.","journal":"Blood","pubDate":"2014 Oct 16","volume":"124","issue":"16","pages":"2507-13; quiz 2615","authors":"Tefferi A et al","elocationId":"doi: 10.1182/blood-2014-05-579136","link":null,"reference":"Tefferi A et al. Blood. 2014 Oct 16;124(16)2507-13; quiz 2615.","abstract":null},{"pmid":"24986690","title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.","journal":"Blood","pubDate":"2014 Aug 14","volume":"124","issue":"7","pages":"1062-9","authors":"Rumi E et al","elocationId":"doi: 10.1182/blood-2014-05-578435","link":null,"reference":"Rumi E et al. Blood. 2014 Aug 14;124(7)1062-9.","abstract":null}]},{"id":24235,"uuid":"f2d02bbb-3955-47e7-8eab-ebd62d73b12b","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7490,"hugoSymbol":"WT1","oncogene":true,"grch37Isoform":"ENST00000332351","grch37RefSeq":"NM_024426.4","grch38Isoform":"ENST00000452863","grch38RefSeq":"NM_024426.4","geneAliases":["WT33","GUD","NPHS4","WIT-2","AWT1","WAGR"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":7490,"hugoSymbol":"WT1","oncogene":true,"grch37Isoform":"ENST00000332351","grch37RefSeq":"NM_024426.4","grch38Isoform":"ENST00000452863","grch38RefSeq":"NM_024426.4","geneAliases":["WT33","GUD","NPHS4","WIT-2","AWT1","WAGR"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"18559874","title":"Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Oct 1","volume":"26","issue":"28","pages":"4595-602","authors":"Paschka P et al","elocationId":"doi: 10.1200/JCO.2007.15.2058","link":null,"reference":"Paschka P et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Oct 1;26(28)4595-602.","abstract":null},{"pmid":"20368469","title":"WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.","journal":"Blood","pubDate":"2010 Jun 24","volume":"115","issue":"25","pages":"5222-31","authors":"Hou HA et al","elocationId":"doi: 10.1182/blood-2009-12-259390","link":null,"reference":"Hou HA et al. Blood. 2010 Jun 24;115(25)5222-31.","abstract":null},{"pmid":"18591546","title":"Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5429-35","authors":"Virappane P et al","elocationId":"doi: 10.1200/JCO.2008.16.0333","link":null,"reference":"Virappane P et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5429-35.","abstract":null},{"pmid":"25110071","title":"WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.","journal":"Leukemia","pubDate":"2015 Mar","volume":"29","issue":"3","pages":"660-7","authors":"Krauth MT et al","elocationId":"doi: 10.1038/leu.2014.243","link":null,"reference":"Krauth MT et al. Leukemia. 2015 Mar;29(3)660-7.","abstract":null}]},{"id":22252,"uuid":"71209f28-efd1-41b6-bae9-5f67d74842bb","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":806,"subtype":"Polycythemia Vera","code":"PV","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6427,"hugoSymbol":"SRSF2","oncogene":false,"grch37Isoform":"ENST00000359995","grch37RefSeq":"NM_003016.4","grch38Isoform":"ENST00000359995","grch38RefSeq":"NM_003016.4","geneAliases":["SFRS2A","PR264","SC35","SFRS2","SRp30b","SC-35"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"29296692","title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia.","journal":"Blood advances","pubDate":"2016 Nov 29","volume":"1","issue":"1","pages":"21-30","authors":"Tefferi A et al","elocationId":"doi: 10.1182/bloodadvances.2016000216","link":null,"reference":"Tefferi A et al. Blood advances. 2016 Nov 29;1(1)21-30.","abstract":null}]},{"id":11758,"uuid":"4633fc19-e9ce-47b4-952b-6966202ed32f","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":632,"subtype":"Primary Myelofibrosis","code":"PMF","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3417,"hugoSymbol":"IDH1","oncogene":true,"grch37Isoform":"ENST00000345146","grch37RefSeq":"NM_005896.2","grch38Isoform":"ENST00000345146","grch38RefSeq":"NM_005896.2","geneAliases":["HEL-216","IDPC","IDCD","HEL-S-26","PICD"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3417,"hugoSymbol":"IDH1","oncogene":true,"grch37Isoform":"ENST00000345146","grch37RefSeq":"NM_005896.2","grch38Isoform":"ENST00000345146","grch38RefSeq":"NM_005896.2","geneAliases":["HEL-216","IDPC","IDCD","HEL-S-26","PICD"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23619563","title":"Mutations and prognosis in primary myelofibrosis.","journal":"Leukemia","pubDate":"2013 Sep","volume":"27","issue":"9","pages":"1861-9","authors":"Vannucchi AM et al","elocationId":"doi: 10.1038/leu.2013.119","link":null,"reference":"Vannucchi AM et al. Leukemia. 2013 Sep;27(9)1861-9.","abstract":null},{"pmid":"26668680","title":"The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis.","journal":"Journal of clinical medicine research","pubDate":"2016 Jan","volume":"8","issue":"1","pages":"29-39","authors":"Yonal-Hindilerden I et al","elocationId":"doi: 10.14740/jocmr2405w","link":null,"reference":"Yonal-Hindilerden I et al. Journal of clinical medicine research. 2016 Jan;8(1)29-39.","abstract":null}]},{"id":10511,"uuid":"a533e88e-301b-4ab9-9d8c-e8d62f93dc5a","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":645,"subtype":"Plasma Cell Myeloma","code":"PCM","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2261,"hugoSymbol":"FGFR3","oncogene":true,"grch37Isoform":"ENST00000260795","grch37RefSeq":"NM_000142.4","grch38Isoform":"ENST00000440486","grch38RefSeq":"NM_000142.4","geneAliases":["JTK4","HSFGFR3EX","ACH","CEK2","CD333"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2261,"hugoSymbol":"FGFR3","oncogene":true,"grch37Isoform":"ENST00000260795","grch37RefSeq":"NM_000142.4","grch38Isoform":"ENST00000440486","grch38RefSeq":"NM_000142.4","geneAliases":["JTK4","HSFGFR3EX","ACH","CEK2","CD333"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"IGH-FGFR3 Fusion","name":"IGH-FGFR3 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"9865713","title":"High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.","journal":"Cancer research","pubDate":"1998 Dec 15","volume":"58","issue":"24","pages":"5640-5","authors":"Avet-Loiseau H et al","elocationId":"","link":null,"reference":"Avet-Loiseau H et al. Cancer research. 1998 Dec 15;58(24)5640-5.","abstract":null},{"pmid":"23456262","title":"Molecular pathogenesis of multiple myeloma: basic and clinical updates.","journal":"International journal of hematology","pubDate":"2013 Mar","volume":"97","issue":"3","pages":"313-23","authors":"Chesi M et al","elocationId":"doi: 10.1007/s12185-013-1291-2","link":null,"reference":"Chesi M et al. International journal of hematology. 2013 Mar;97(3)313-23.","abstract":null},{"pmid":"9354676","title":"A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.","journal":"Blood","pubDate":"1997 Nov 15","volume":"90","issue":"10","pages":"4062-70","authors":"Richelda R et al","elocationId":"","link":null,"reference":"Richelda R et al. Blood. 1997 Nov 15;90(10)4062-70.","abstract":null},{"pmid":"28584253","title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.","journal":"Leukemia","pubDate":"2018 Jan","volume":"32","issue":"1","pages":"102-110","authors":"Shah V et al","elocationId":"doi: 10.1038/leu.2017.179","link":null,"reference":"Shah V et al. Leukemia. 2018 Jan;32(1)102-110.","abstract":null}]},{"id":23954,"uuid":"04761ef2-e78c-47a3-9e9e-089d938a3a4d","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":695,"subtype":"Essential Thrombocythemia","code":"ET","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7307,"hugoSymbol":"U2AF1","oncogene":true,"grch37Isoform":"ENST00000291552","grch37RefSeq":"NM_006758.2","grch38Isoform":"ENST00000291552","grch38RefSeq":"NM_006758.2","geneAliases":["FP793","U2AFBP","RN","RNU2AF1","U2AF35"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":7307,"hugoSymbol":"U2AF1","oncogene":true,"grch37Isoform":"ENST00000291552","grch37RefSeq":"NM_006758.2","grch38Isoform":"ENST00000291552","grch38RefSeq":"NM_006758.2","geneAliases":["FP793","U2AFBP","RN","RNU2AF1","U2AF35"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"29296692","title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia.","journal":"Blood advances","pubDate":"2016 Nov 29","volume":"1","issue":"1","pages":"21-30","authors":"Tefferi A et al","elocationId":"doi: 10.1182/bloodadvances.2016000216","link":null,"reference":"Tefferi A et al. Blood advances. 2016 Nov 29;1(1)21-30.","abstract":null}]},{"id":1237,"uuid":"619f9e77-7608-465b-9a4d-b26a380db876","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":806,"subtype":"Polycythemia Vera","code":"PV","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":171023,"hugoSymbol":"ASXL1","oncogene":false,"grch37Isoform":"ENST00000375687","grch37RefSeq":"NM_015338.5","grch38Isoform":"ENST00000375687","grch38RefSeq":"NM_015338.5","geneAliases":["BOPS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":171023,"hugoSymbol":"ASXL1","oncogene":false,"grch37Isoform":"ENST00000375687","grch37RefSeq":"NM_015338.5","grch38Isoform":"ENST00000375687","grch38RefSeq":"NM_015338.5","geneAliases":["BOPS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"29296692","title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia.","journal":"Blood advances","pubDate":"2016 Nov 29","volume":"1","issue":"1","pages":"21-30","authors":"Tefferi A et al","elocationId":"doi: 10.1182/bloodadvances.2016000216","link":null,"reference":"Tefferi A et al. Blood advances. 2016 Nov 29;1(1)21-30.","abstract":null}]},{"id":13560,"uuid":"0989cc59-d0d5-4331-a77b-5c099f5464b3","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":645,"subtype":"Plasma Cell Myeloma","code":"PCM","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4094,"hugoSymbol":"MAF","oncogene":false,"grch37Isoform":"ENST00000393350","grch37RefSeq":"NM_001031804.2","grch38Isoform":"ENST00000393350","grch38RefSeq":"NM_001031804.2","geneAliases":["AYGRP","c-MAF","CTRCT21","CCA4"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4094,"hugoSymbol":"MAF","oncogene":false,"grch37Isoform":"ENST00000393350","grch37RefSeq":"NM_001031804.2","grch38Isoform":"ENST00000393350","grch38RefSeq":"NM_001031804.2","geneAliases":["AYGRP","c-MAF","CTRCT21","CCA4"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"IGH-MAF Fusion","name":"IGH-MAF Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23456262","title":"Molecular pathogenesis of multiple myeloma: basic and clinical updates.","journal":"International journal of hematology","pubDate":"2013 Mar","volume":"97","issue":"3","pages":"313-23","authors":"Chesi M et al","elocationId":"doi: 10.1007/s12185-013-1291-2","link":null,"reference":"Chesi M et al. International journal of hematology. 2013 Mar;97(3)313-23.","abstract":null},{"pmid":"12576322","title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma.","journal":"Blood","pubDate":"2003 Jun 1","volume":"101","issue":"11","pages":"4569-75","authors":"Fonseca R et al","elocationId":"","link":null,"reference":"Fonseca R et al. Blood. 2003 Jun 1;101(11)4569-75.","abstract":null},{"pmid":"28584253","title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.","journal":"Leukemia","pubDate":"2018 Jan","volume":"32","issue":"1","pages":"102-110","authors":"Shah V et al","elocationId":"doi: 10.1038/leu.2017.179","link":null,"reference":"Shah V et al. Leukemia. 2018 Jan;32(1)102-110.","abstract":null}]},{"id":5147,"uuid":"7db6f5fa-1e0e-4672-8456-e2a3e111cce0","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":645,"subtype":"Plasma Cell Myeloma","code":"PCM","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":896,"hugoSymbol":"CCND3","oncogene":true,"grch37Isoform":"ENST00000372991","grch37RefSeq":"NM_001760.3","grch38Isoform":"ENST00000372991","grch38RefSeq":"NM_001760.3","geneAliases":[],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":896,"hugoSymbol":"CCND3","oncogene":true,"grch37Isoform":"ENST00000372991","grch37RefSeq":"NM_001760.3","grch38Isoform":"ENST00000372991","grch38RefSeq":"NM_001760.3","geneAliases":[],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"IGH-CCND3 Fusion","name":"IGH-CCND3 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23456262","title":"Molecular pathogenesis of multiple myeloma: basic and clinical updates.","journal":"International journal of hematology","pubDate":"2013 Mar","volume":"97","issue":"3","pages":"313-23","authors":"Chesi M et al","elocationId":"doi: 10.1007/s12185-013-1291-2","link":null,"reference":"Chesi M et al. International journal of hematology. 2013 Mar;97(3)313-23.","abstract":null},{"pmid":"11418483","title":"Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.","journal":"Blood","pubDate":"2001 Jul 1","volume":"98","issue":"1","pages":"217-23","authors":"Shaughnessy J Jr et al","elocationId":"","link":null,"reference":"Shaughnessy J Jr et al. Blood. 2001 Jul 1;98(1)217-23.","abstract":null},{"pmid":"2923814","title":"Chromosome rearrangement, t(6;14) (p21.1;q32.3), in multiple myeloma.","journal":"British journal of haematology","pubDate":"1989 Feb","volume":"71","issue":"2","pages":"295-6","authors":"Nishida K et al","elocationId":"","link":null,"reference":"Nishida K et al. British journal of haematology. 1989 Feb;71(2)295-6.","abstract":null}]},{"id":5083,"uuid":"bad8b45c-3c2e-4866-a2f2-754a7ff5b4bc","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":645,"subtype":"Plasma Cell Myeloma","code":"PCM","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":595,"hugoSymbol":"CCND1","oncogene":true,"grch37Isoform":"ENST00000227507","grch37RefSeq":"NM_053056.2","grch38Isoform":"ENST00000227507","grch38RefSeq":"NM_053056.2","geneAliases":["PRAD1","D11S287E","BCL1","U21B31"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":595,"hugoSymbol":"CCND1","oncogene":true,"grch37Isoform":"ENST00000227507","grch37RefSeq":"NM_053056.2","grch38Isoform":"ENST00000227507","grch38RefSeq":"NM_053056.2","geneAliases":["PRAD1","D11S287E","BCL1","U21B31"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"IGH-CCND1 Fusion","name":"IGH-CCND1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"28655925","title":"Natural history of t(11;14) multiple myeloma.","journal":"Leukemia","pubDate":"2018 Jan","volume":"32","issue":"1","pages":"131-138","authors":"Lakshman A et al","elocationId":"doi: 10.1038/leu.2017.204","link":null,"reference":"Lakshman A et al. Leukemia. 2018 Jan;32(1)131-138.","abstract":null},{"pmid":"9865713","title":"High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.","journal":"Cancer research","pubDate":"1998 Dec 15","volume":"58","issue":"24","pages":"5640-5","authors":"Avet-Loiseau H et al","elocationId":"","link":null,"reference":"Avet-Loiseau H et al. Cancer research. 1998 Dec 15;58(24)5640-5.","abstract":null},{"pmid":"14514791","title":"Insertion of the CCND1 gene into the IgH locus in a case of leukaemic small cell mantle lymphoma with normal chromosomes 11 and 14.","journal":"Journal of clinical pathology","pubDate":"2003 Oct","volume":"56","issue":"10","pages":"798-800","authors":"Aventín A et al","elocationId":"","link":null,"reference":"Aventín A et al. Journal of clinical pathology. 2003 Oct;56(10)798-800.","abstract":null},{"pmid":"23456262","title":"Molecular pathogenesis of multiple myeloma: basic and clinical updates.","journal":"International journal of hematology","pubDate":"2013 Mar","volume":"97","issue":"3","pages":"313-23","authors":"Chesi M et al","elocationId":"doi: 10.1007/s12185-013-1291-2","link":null,"reference":"Chesi M et al. International journal of hematology. 2013 Mar;97(3)313-23.","abstract":null}]},{"id":21436,"uuid":"e21b70c2-4aa4-4c33-acac-dec76b63b454","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":695,"subtype":"Essential Thrombocythemia","code":"ET","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":10019,"hugoSymbol":"SH2B3","oncogene":false,"grch37Isoform":"ENST00000341259","grch37RefSeq":"NM_005475.2","grch38Isoform":"ENST00000341259","grch38RefSeq":"NM_005475.2","geneAliases":["LNK"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":10019,"hugoSymbol":"SH2B3","oncogene":false,"grch37Isoform":"ENST00000341259","grch37RefSeq":"NM_005475.2","grch38Isoform":"ENST00000341259","grch38RefSeq":"NM_005475.2","geneAliases":["LNK"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"29296692","title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia.","journal":"Blood advances","pubDate":"2016 Nov 29","volume":"1","issue":"1","pages":"21-30","authors":"Tefferi A et al","elocationId":"doi: 10.1182/bloodadvances.2016000216","link":null,"reference":"Tefferi A et al. Blood advances. 2016 Nov 29;1(1)21-30.","abstract":null}]},{"id":13566,"uuid":"8ac54b91-f71b-460b-86f4-46bf5401633d","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":645,"subtype":"Plasma Cell Myeloma","code":"PCM","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":9935,"hugoSymbol":"MAFB","oncogene":true,"grch37Isoform":"ENST00000373313","grch37RefSeq":"NM_005461.4","grch38Isoform":"ENST00000373313","grch38RefSeq":"NM_005461.4","geneAliases":["KRML","MCTO","DURS3"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":9935,"hugoSymbol":"MAFB","oncogene":true,"grch37Isoform":"ENST00000373313","grch37RefSeq":"NM_005461.4","grch38Isoform":"ENST00000373313","grch38RefSeq":"NM_005461.4","geneAliases":["KRML","MCTO","DURS3"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"IGH-MAFB Fusion","name":"IGH-MAFB Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"20410185","title":"The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance.","journal":"Haematologica","pubDate":"2010 Jul","volume":"95","issue":"7","pages":"1221-5","authors":"Ross FM et al","elocationId":"doi: 10.3324/haematol.2009.016329","link":null,"reference":"Ross FM et al. Haematologica. 2010 Jul;95(7)1221-5.","abstract":null},{"pmid":"23456262","title":"Molecular pathogenesis of multiple myeloma: basic and clinical updates.","journal":"International journal of hematology","pubDate":"2013 Mar","volume":"97","issue":"3","pages":"313-23","authors":"Chesi M et al","elocationId":"doi: 10.1007/s12185-013-1291-2","link":null,"reference":"Chesi M et al. International journal of hematology. 2013 Mar;97(3)313-23.","abstract":null},{"pmid":"15257707","title":"The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint.","journal":"British journal of haematology","pubDate":"2004 Aug","volume":"126","issue":"3","pages":"355-63","authors":"Boersma-Vreugdenhil GR et al","elocationId":"","link":null,"reference":"Boersma-Vreugdenhil GR et al. British journal of haematology. 2004 Aug;126(3)355-63.","abstract":null},{"pmid":"28584253","title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.","journal":"Leukemia","pubDate":"2018 Jan","volume":"32","issue":"1","pages":"102-110","authors":"Shah V et al","elocationId":"doi: 10.1038/leu.2017.179","link":null,"reference":"Shah V et al. Leukemia. 2018 Jan;32(1)102-110.","abstract":null}]},{"id":11838,"uuid":"512670c3-c953-45ea-9354-8d486a78fcf0","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":695,"subtype":"Essential Thrombocythemia","code":"ET","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3418,"hugoSymbol":"IDH2","oncogene":true,"grch37Isoform":"ENST00000330062","grch37RefSeq":"NM_002168.2","grch38Isoform":"ENST00000330062","grch38RefSeq":"NM_002168.2","geneAliases":["IDHM","D2HGA2","mNADP-IDH","IDPM","ICD-M"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3418,"hugoSymbol":"IDH2","oncogene":true,"grch37Isoform":"ENST00000330062","grch37RefSeq":"NM_002168.2","grch38Isoform":"ENST00000330062","grch38RefSeq":"NM_002168.2","geneAliases":["IDHM","D2HGA2","mNADP-IDH","IDPM","ICD-M"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"29296692","title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia.","journal":"Blood advances","pubDate":"2016 Nov 29","volume":"1","issue":"1","pages":"21-30","authors":"Tefferi A et al","elocationId":"doi: 10.1182/bloodadvances.2016000216","link":null,"reference":"Tefferi A et al. Blood advances. 2016 Nov 29;1(1)21-30.","abstract":null}]},{"id":21376,"uuid":"12c837b0-a437-4b56-91dd-facf7fd9e533","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":695,"subtype":"Essential Thrombocythemia","code":"ET","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"29296692","title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia.","journal":"Blood advances","pubDate":"2016 Nov 29","volume":"1","issue":"1","pages":"21-30","authors":"Tefferi A et al","elocationId":"doi: 10.1182/bloodadvances.2016000216","link":null,"reference":"Tefferi A et al. Blood advances. 2016 Nov 29;1(1)21-30.","abstract":null},{"pmid":"30594750","title":"Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms.","journal":"Human pathology","pubDate":"2019 Apr","volume":"86","issue":"","pages":"1-11","authors":"Boiocchi L et al","elocationId":"doi: 10.1016/j.humpath.2018.11.022","link":null,"reference":"Boiocchi L et al. Human pathology. 2019 Apr;86()1-11.","abstract":null}]},{"id":11840,"uuid":"a8e43c8e-07cc-42db-88af-ca9629f2428d","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":806,"subtype":"Polycythemia Vera","code":"PV","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3418,"hugoSymbol":"IDH2","oncogene":true,"grch37Isoform":"ENST00000330062","grch37RefSeq":"NM_002168.2","grch38Isoform":"ENST00000330062","grch38RefSeq":"NM_002168.2","geneAliases":["IDHM","D2HGA2","mNADP-IDH","IDPM","ICD-M"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3418,"hugoSymbol":"IDH2","oncogene":true,"grch37Isoform":"ENST00000330062","grch37RefSeq":"NM_002168.2","grch38Isoform":"ENST00000330062","grch38RefSeq":"NM_002168.2","geneAliases":["IDHM","D2HGA2","mNADP-IDH","IDPM","ICD-M"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"29296692","title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia.","journal":"Blood advances","pubDate":"2016 Nov 29","volume":"1","issue":"1","pages":"21-30","authors":"Tefferi A et al","elocationId":"doi: 10.1182/bloodadvances.2016000216","link":null,"reference":"Tefferi A et al. Blood advances. 2016 Nov 29;1(1)21-30.","abstract":null}]},{"id":11842,"uuid":"957b72a6-e140-47e2-9bd6-db31524ffaf1","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":632,"subtype":"Primary Myelofibrosis","code":"PMF","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3418,"hugoSymbol":"IDH2","oncogene":true,"grch37Isoform":"ENST00000330062","grch37RefSeq":"NM_002168.2","grch38Isoform":"ENST00000330062","grch38RefSeq":"NM_002168.2","geneAliases":["IDHM","D2HGA2","mNADP-IDH","IDPM","ICD-M"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3418,"hugoSymbol":"IDH2","oncogene":true,"grch37Isoform":"ENST00000330062","grch37RefSeq":"NM_002168.2","grch38Isoform":"ENST00000330062","grch38RefSeq":"NM_002168.2","geneAliases":["IDHM","D2HGA2","mNADP-IDH","IDPM","ICD-M"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px2","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23619563","title":"Mutations and prognosis in primary myelofibrosis.","journal":"Leukemia","pubDate":"2013 Sep","volume":"27","issue":"9","pages":"1861-9","authors":"Vannucchi AM et al","elocationId":"doi: 10.1038/leu.2013.119","link":null,"reference":"Vannucchi AM et al. Leukemia. 2013 Sep;27(9)1861-9.","abstract":null},{"pmid":"26668680","title":"The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis.","journal":"Journal of clinical medicine research","pubDate":"2016 Jan","volume":"8","issue":"1","pages":"29-39","authors":"Yonal-Hindilerden I et al","elocationId":"doi: 10.14740/jocmr2405w","link":null,"reference":"Yonal-Hindilerden I et al. Journal of clinical medicine research. 2016 Jan;8(1)29-39.","abstract":null}]}],"LEVEL_R2":[{"id":14756,"uuid":"330b2ef9-8d41-47fb-a266-1abf8e0cecca","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C1855","drugName":"Gefitinib","uuid":"b76d7b2b-b5fb-4561-892f-6b00bfaf0dfa","synonyms":["GEFITINIB","Iressa","N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine","ZD 1839","gefitinib","Gefitinib","4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline","ZD1839"],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C65530","drugName":"Erlotinib","uuid":"83754311-3f3b-4782-bfbf-08e71c790b9a","synonyms":["Erlotinib","erlotinib","ERLOTINIB"],"priority":1}]},{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C116377","drugName":"Osimertinib","uuid":"4c2c1261-bfc3-4180-8113-127194366320","synonyms":["OSIMERTINIB","AZD-9291","Osimertinib","\"2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-","Tagrisso\"","Mereletinib","AZD9291"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1558504606000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"18093943","title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.","journal":"Proceedings of the National Academy of Sciences of the United States of America","pubDate":"2007 Dec 26","volume":"104","issue":"52","pages":"20932-7","authors":"Bean J et al","elocationId":"","link":null,"reference":"Bean J et al. Proceedings of the National Academy of Sciences of the United States of America. 2007 Dec 26;104(52)20932-7.","abstract":null},{"pmid":"30676858","title":"Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2019 Apr 10","volume":"37","issue":"11","pages":"876-884","authors":"Lai GGY et al","elocationId":"doi: 10.1200/JCO.18.00177","link":null,"reference":"Lai GGY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Apr 10;37(11)876-884.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://ascopubs.org/doi/full/10.1200/PO.18.00210","reference":"null. null. .","abstract":"Michels et al. JCO PO, 2018"},{"pmid":"17463250","title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.","journal":"Science (New York, N.Y.)","pubDate":"2007 May 18","volume":"316","issue":"5827","pages":"1039-43","authors":"Engelman JA et al","elocationId":"","link":null,"reference":"Engelman JA et al. Science (New York, N.Y.). 2007 May 18;316(5827)1039-43.","abstract":null},{"pmid":"30073261","title":"Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.","journal":"JAMA oncology","pubDate":"2018 Nov 1","volume":"4","issue":"11","pages":"1527-1534","authors":"Oxnard GR et al","elocationId":"doi: 10.1001/jamaoncol.2018.2969","link":null,"reference":"Oxnard GR et al. JAMA oncology. 2018 Nov 1;4(11)1527-1534.","abstract":null}]},{"id":12713,"uuid":"c3e815d0-6b56-416d-a4f7-ec28dc09288b","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T670I","name":"T670I","refResidues":"T","proteinStart":670,"proteinEnd":670,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1580418357000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"1675110","title":"The use of analgesia in medical patients in neonatal intensive care units in Australia: results of a questionnaire.","journal":"Journal of paediatrics and child health","pubDate":"1991 Feb","volume":"27","issue":"1","pages":"64","authors":"Colditz PB","elocationId":"","link":null,"reference":"Colditz PB. Journal of paediatrics and child health. 1991 Feb;27(1)64.","abstract":null},{"pmid":"16551858","title":"Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2006 Mar 15","volume":"12","issue":"6","pages":"1743-9","authors":"Wardelmann E et al","elocationId":"","link":null,"reference":"Wardelmann E et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Mar 15;12(6)1743-9.","abstract":null},{"pmid":"23840364","title":"Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.","journal":"PloS one","pubDate":"2013","volume":"8","issue":"6","pages":"e65762","authors":"Hsueh YS et al","elocationId":"doi: 10.1371/journal.pone.0065762","link":null,"reference":"Hsueh YS et al. PloS one. 2013;8(6)e65762.","abstract":null},{"pmid":"17699867","title":"Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2007 Aug 15","volume":"13","issue":"16","pages":"4874-81","authors":"Guo T et al","elocationId":"","link":null,"reference":"Guo T et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Aug 15;13(16)4874-81.","abstract":null},{"pmid":"17545544","title":"Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2007 Jun 1","volume":"13","issue":"11","pages":"3363-9","authors":"Guida T et al","elocationId":"","link":null,"reference":"Guida T et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Jun 1;13(11)3363-9.","abstract":null},{"pmid":"16954519","title":"Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2006 Oct 10","volume":"24","issue":"29","pages":"4764-74","authors":"Heinrich MC et al","elocationId":"","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Oct 10;24(29)4764-74.","abstract":null}]},{"id":17071,"uuid":"6e354175-1f93-4306-b13a-054a3d53f0bf","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4914,"hugoSymbol":"NTRK1","oncogene":true,"grch37Isoform":"ENST00000524377","grch37RefSeq":"NM_002529.3","grch38Isoform":"ENST00000524377","grch38RefSeq":"NM_002529.3","geneAliases":["TRK1","TRKA","Trk-A","TRK","p140-TrkA","MTC"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4914,"hugoSymbol":"NTRK1","oncogene":true,"grch37Isoform":"ENST00000524377","grch37RefSeq":"NM_002529.3","grch38Isoform":"ENST00000524377","grch38RefSeq":"NM_002529.3","geneAliases":["TRK1","TRKA","Trk-A","TRK","p140-TrkA","MTC"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"G595R","name":"G595R","refResidues":"G","proteinStart":595,"proteinEnd":595,"variantResidues":"R","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C115977","drugName":"Larotrectinib","uuid":"b0b3d8ee-86a5-4421-b4a9-053d3c1ff544","synonyms":["LAROTRECTINIB","LOXO-101","Larotrectinib","LOXO 101","\"1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-","ARRY 470","3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide","Larotrectinib\""],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1544809616000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29466156","title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.","journal":"The New England journal of medicine","pubDate":"2018 Feb 22","volume":"378","issue":"8","pages":"731-739","authors":"Drilon A et al","elocationId":"doi: 10.1056/NEJMoa1714448","link":null,"reference":"Drilon A et al. The New England journal of medicine. 2018 Feb 22;378(8)731-739.","abstract":null}]},{"id":12723,"uuid":"74000183-6589-48e9-8a8c-54fd6772149b","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D816","name":"D816","refResidues":"D","proteinStart":816,"proteinEnd":816,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1580406488000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22301675","title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.","journal":"Leukemia","pubDate":"2012 Jul","volume":"26","issue":"7","pages":"1693-5","authors":"Lierman E et al","elocationId":"doi: 10.1038/leu.2012.8","link":null,"reference":"Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.","abstract":null},{"pmid":"18955458","title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5352-9","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2007.15.7461","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.","abstract":null},{"pmid":"23840364","title":"Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.","journal":"PloS one","pubDate":"2013","volume":"8","issue":"6","pages":"e65762","authors":"Hsueh YS et al","elocationId":"doi: 10.1371/journal.pone.0065762","link":null,"reference":"Hsueh YS et al. PloS one. 2013;8(6)e65762.","abstract":null},{"pmid":"25239608","title":"Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2014 Nov 15","volume":"20","issue":"22","pages":"5745-5755","authors":"Garner AP et al","elocationId":"doi: 10.1158/1078-0432.CCR-14-1397","link":null,"reference":"Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.","abstract":null}]},{"id":12724,"uuid":"aa889548-49c5-484d-80f0-944bc2c49672","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D816","name":"D816","refResidues":"D","proteinStart":816,"proteinEnd":816,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C71622","drugName":"Sunitinib","uuid":"5b548883-0142-4d15-a324-22d7b29800b2","synonyms":["\"1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-","Sunitinib","SUNITINIB","sunitinib\""],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1580406579000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22301675","title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.","journal":"Leukemia","pubDate":"2012 Jul","volume":"26","issue":"7","pages":"1693-5","authors":"Lierman E et al","elocationId":"doi: 10.1038/leu.2012.8","link":null,"reference":"Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.","abstract":null},{"pmid":"18955458","title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5352-9","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2007.15.7461","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.","abstract":null},{"pmid":"23840364","title":"Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.","journal":"PloS one","pubDate":"2013","volume":"8","issue":"6","pages":"e65762","authors":"Hsueh YS et al","elocationId":"doi: 10.1371/journal.pone.0065762","link":null,"reference":"Hsueh YS et al. PloS one. 2013;8(6)e65762.","abstract":null},{"pmid":"25239608","title":"Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2014 Nov 15","volume":"20","issue":"22","pages":"5745-5755","authors":"Garner AP et al","elocationId":"doi: 10.1158/1078-0432.CCR-14-1397","link":null,"reference":"Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.","abstract":null}]},{"id":757,"uuid":"b0413c2c-b817-467c-9737-210692ad4fc8","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"C1156Y","name":"C1156Y","refResidues":"C","proteinStart":1156,"proteinEnd":1156,"variantResidues":"Y","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C74061","drugName":"Crizotinib","uuid":"f05d12ab-6204-4a1c-803f-f3a7f6e30af2","synonyms":["MET Tyrosine Kinase Inhibitor PF-02341066","Crizotinib","2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-","Xalkori\"","PF-02341066","CRIZOTINIB","PF-2341066","\"(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine","MET tyrosine kinase inhibitor PF-02341066"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1539618859000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"26144315","title":"PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.","journal":"Cancer cell","pubDate":"2015 Jul 13","volume":"28","issue":"1","pages":"70-81","authors":"Zou HY et al","elocationId":"doi: 10.1016/j.ccell.2015.05.010","link":null,"reference":"Zou HY et al. Cancer cell. 2015 Jul 13;28(1)70-81.","abstract":null},{"pmid":"26698910","title":"Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.","journal":"The New England journal of medicine","pubDate":"2016 Jan 7","volume":"374","issue":"1","pages":"54-61","authors":"Shaw AT et al","elocationId":"doi: 10.1056/NEJMoa1508887","link":null,"reference":"Shaw AT et al. The New England journal of medicine. 2016 Jan 7;374(1)54-61.","abstract":null},{"pmid":"20979473","title":"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.","journal":"The New England journal of medicine","pubDate":"2010 Oct 28","volume":"363","issue":"18","pages":"1734-9","authors":"Choi YL et al","elocationId":"doi: 10.1056/NEJMoa1007478","link":null,"reference":"Choi YL et al. The New England journal of medicine. 2010 Oct 28;363(18)1734-9.","abstract":null},{"pmid":"24675041","title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.","journal":"Cancer discovery","pubDate":"2014 Jun","volume":"4","issue":"6","pages":"662-673","authors":"Friboulet L et al","elocationId":"doi: 10.1158/2159-8290.CD-13-0846","link":null,"reference":"Friboulet L et al. Cancer discovery. 2014 Jun;4(6)662-673.","abstract":null},{"pmid":"23434628","title":"Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.","journal":"Genomics","pubDate":"2013 Sep","volume":"102","issue":"3","pages":"157-62","authors":"Huang D et al","elocationId":"doi: 10.1016/j.ygeno.2013.02.006","link":null,"reference":"Huang D et al. Genomics. 2013 Sep;102(3)157-62.","abstract":null},{"pmid":"22235099","title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2012 Mar 1","volume":"18","issue":"5","pages":"1472-82","authors":"Doebele RC et al","elocationId":"doi: 10.1158/1078-0432.CCR-11-2906","link":null,"reference":"Doebele RC et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Mar 1;18(5)1472-82.","abstract":null},{"pmid":"27045755","title":"Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.","journal":"PloS one","pubDate":"2016","volume":"11","issue":"4","pages":"e0153065","authors":"Saber A et al","elocationId":"doi: 10.1371/journal.pone.0153065","link":null,"reference":"Saber A et al. PloS one. 2016;11(4)e0153065.","abstract":null}]},{"id":12728,"uuid":"81f72777-12a2-422a-81ea-93c15e115dc8","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D820","name":"D820","refResidues":"D","proteinStart":820,"proteinEnd":820,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1580407667000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22301675","title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.","journal":"Leukemia","pubDate":"2012 Jul","volume":"26","issue":"7","pages":"1693-5","authors":"Lierman E et al","elocationId":"doi: 10.1038/leu.2012.8","link":null,"reference":"Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.","abstract":null},{"pmid":"18955458","title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5352-9","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2007.15.7461","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.","abstract":null},{"pmid":"23840364","title":"Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.","journal":"PloS one","pubDate":"2013","volume":"8","issue":"6","pages":"e65762","authors":"Hsueh YS et al","elocationId":"doi: 10.1371/journal.pone.0065762","link":null,"reference":"Hsueh YS et al. PloS one. 2013;8(6)e65762.","abstract":null},{"pmid":"25239608","title":"Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2014 Nov 15","volume":"20","issue":"22","pages":"5745-5755","authors":"Garner AP et al","elocationId":"doi: 10.1158/1078-0432.CCR-14-1397","link":null,"reference":"Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.","abstract":null}]},{"id":12729,"uuid":"1081b914-747a-4752-9afc-311843353ec8","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D820","name":"D820","refResidues":"D","proteinStart":820,"proteinEnd":820,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C71622","drugName":"Sunitinib","uuid":"5b548883-0142-4d15-a324-22d7b29800b2","synonyms":["\"1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-","Sunitinib","SUNITINIB","sunitinib\""],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1580407669000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22301675","title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.","journal":"Leukemia","pubDate":"2012 Jul","volume":"26","issue":"7","pages":"1693-5","authors":"Lierman E et al","elocationId":"doi: 10.1038/leu.2012.8","link":null,"reference":"Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.","abstract":null},{"pmid":"18955458","title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5352-9","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2007.15.7461","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.","abstract":null},{"pmid":"23840364","title":"Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.","journal":"PloS one","pubDate":"2013","volume":"8","issue":"6","pages":"e65762","authors":"Hsueh YS et al","elocationId":"doi: 10.1371/journal.pone.0065762","link":null,"reference":"Hsueh YS et al. PloS one. 2013;8(6)e65762.","abstract":null},{"pmid":"25239608","title":"Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2014 Nov 15","volume":"20","issue":"22","pages":"5745-5755","authors":"Garner AP et al","elocationId":"doi: 10.1158/1078-0432.CCR-14-1397","link":null,"reference":"Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.","abstract":null}]},{"id":761,"uuid":"535b059c-d1bc-47cb-900d-e486eb98c16e","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"G1202R","name":"G1202R","refResidues":"G","proteinStart":1202,"proteinEnd":1202,"variantResidues":"R","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C101790","drugName":"Alectinib","uuid":"ef2bee25-4fa3-40c4-a79f-4f885377afa7","synonyms":["AF802","Alectinib","RO5424802\"","ALECTINIB","\"5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-","AF-802","Alecensa","CH5424802","RG7853"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1546019999000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29650534","title":"Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer.","journal":"Cancer discovery","pubDate":"2018 Jun","volume":"8","issue":"6","pages":"714-729","authors":"Yoda S et al","elocationId":"doi: 10.1158/2159-8290.CD-17-1256","link":null,"reference":"Yoda S et al. Cancer discovery. 2018 Jun;8(6)714-729.","abstract":null},{"pmid":"27130468","title":"Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.","journal":"Clinical lung cancer","pubDate":"2016 Sep","volume":"17","issue":"5","pages":"e77-e94","authors":"Lin YT et al","elocationId":"doi: 10.1016/j.cllc.2016.03.005","link":null,"reference":"Lin YT et al. Clinical lung cancer. 2016 Sep;17(5)e77-e94.","abstract":null},{"pmid":"29373100","title":"Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2018 Apr 20","volume":"36","issue":"12","pages":"1199-1206","authors":"Lin JJ et al","elocationId":"doi: 10.1200/JCO.2017.76.2294","link":null,"reference":"Lin JJ et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Apr 20;36(12)1199-1206.","abstract":null},{"pmid":"27432227","title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.","journal":"Cancer discovery","pubDate":"2016 Oct","volume":"6","issue":"10","pages":"1118-1133","authors":"Gainor JF et al","elocationId":"","link":null,"reference":"Gainor JF et al. Cancer discovery. 2016 Oct;6(10)1118-1133.","abstract":null},{"pmid":"29376144","title":"Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.","journal":"JCO precision oncology","pubDate":"2018","volume":"2018","issue":"","pages":"","authors":"Dagogo-Jack I et al","elocationId":"doi: 10.1200/PO.17.00160","link":null,"reference":"Dagogo-Jack I et al. JCO precision oncology. 2018;2018().","abstract":null},{"pmid":"24736079","title":"Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2014 Apr","volume":"9","issue":"4","pages":"549-53","authors":"Ignatius Ou SH et al","elocationId":"doi: 10.1097/JTO.0000000000000094","link":null,"reference":"Ignatius Ou SH et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Apr;9(4)549-53.","abstract":null}]},{"id":12666,"uuid":"8e0829de-2496-4fc8-95bc-2e6b8dd668ef","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":642,"subtype":"Gastrointestinal Stromal Tumor","code":"GIST","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":2,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"A829P","name":"A829P","refResidues":"A","proteinStart":829,"proteinEnd":829,"variantResidues":"P","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1577221743000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"18955458","title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5352-9","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2007.15.7461","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.","abstract":null},{"pmid":"31085175","title":"Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.","journal":"Cancer cell","pubDate":"2019 May 13","volume":"35","issue":"5","pages":"738-751.e9","authors":"Smith BD et al","elocationId":"doi: 10.1016/j.ccell.2019.04.006","link":null,"reference":"Smith BD et al. Cancer cell. 2019 May 13;35(5)738-751.e9.","abstract":null},{"pmid":"25239608","title":"Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2014 Nov 15","volume":"20","issue":"22","pages":"5745-5755","authors":"Garner AP et al","elocationId":"doi: 10.1158/1078-0432.CCR-14-1397","link":null,"reference":"Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.","abstract":null}]},{"id":12667,"uuid":"38b3ab5c-99bf-46a4-8039-f08c3a95dce9","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":642,"subtype":"Gastrointestinal Stromal Tumor","code":"GIST","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":2,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"A829P","name":"A829P","refResidues":"A","proteinStart":829,"proteinEnd":829,"variantResidues":"P","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C71622","drugName":"Sunitinib","uuid":"5b548883-0142-4d15-a324-22d7b29800b2","synonyms":["\"1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-","Sunitinib","SUNITINIB","sunitinib\""],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1577221762000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"31085175","title":"Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.","journal":"Cancer cell","pubDate":"2019 May 13","volume":"35","issue":"5","pages":"738-751.e9","authors":"Smith BD et al","elocationId":"doi: 10.1016/j.ccell.2019.04.006","link":null,"reference":"Smith BD et al. Cancer cell. 2019 May 13;35(5)738-751.e9.","abstract":null}]},{"id":12732,"uuid":"abfc1876-db48-4d59-a411-4564739b6727","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"N822","name":"N822","refResidues":"N","proteinStart":822,"proteinEnd":822,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1580406959000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22301675","title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.","journal":"Leukemia","pubDate":"2012 Jul","volume":"26","issue":"7","pages":"1693-5","authors":"Lierman E et al","elocationId":"doi: 10.1038/leu.2012.8","link":null,"reference":"Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.","abstract":null},{"pmid":"18955458","title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5352-9","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2007.15.7461","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.","abstract":null},{"pmid":"23840364","title":"Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.","journal":"PloS one","pubDate":"2013","volume":"8","issue":"6","pages":"e65762","authors":"Hsueh YS et al","elocationId":"doi: 10.1371/journal.pone.0065762","link":null,"reference":"Hsueh YS et al. PloS one. 2013;8(6)e65762.","abstract":null},{"pmid":"25239608","title":"Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2014 Nov 15","volume":"20","issue":"22","pages":"5745-5755","authors":"Garner AP et al","elocationId":"doi: 10.1158/1078-0432.CCR-14-1397","link":null,"reference":"Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.","abstract":null}]},{"id":12733,"uuid":"9a3e7926-f6ab-45cc-98ff-fab44dc53dd4","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"N822","name":"N822","refResidues":"N","proteinStart":822,"proteinEnd":822,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C71622","drugName":"Sunitinib","uuid":"5b548883-0142-4d15-a324-22d7b29800b2","synonyms":["\"1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-","Sunitinib","SUNITINIB","sunitinib\""],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1580406973000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22301675","title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.","journal":"Leukemia","pubDate":"2012 Jul","volume":"26","issue":"7","pages":"1693-5","authors":"Lierman E et al","elocationId":"doi: 10.1038/leu.2012.8","link":null,"reference":"Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.","abstract":null},{"pmid":"18955458","title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5352-9","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2007.15.7461","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.","abstract":null},{"pmid":"23840364","title":"Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.","journal":"PloS one","pubDate":"2013","volume":"8","issue":"6","pages":"e65762","authors":"Hsueh YS et al","elocationId":"doi: 10.1371/journal.pone.0065762","link":null,"reference":"Hsueh YS et al. PloS one. 2013;8(6)e65762.","abstract":null},{"pmid":"25239608","title":"Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2014 Nov 15","volume":"20","issue":"22","pages":"5745-5755","authors":"Garner AP et al","elocationId":"doi: 10.1158/1078-0432.CCR-14-1397","link":null,"reference":"Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.","abstract":null}]},{"id":766,"uuid":"8614b49e-3d7b-4360-ac06-53a1bf7c8d23","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"G1269A","name":"G1269A","refResidues":"G","proteinStart":1269,"proteinEnd":1269,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C74061","drugName":"Crizotinib","uuid":"f05d12ab-6204-4a1c-803f-f3a7f6e30af2","synonyms":["MET Tyrosine Kinase Inhibitor PF-02341066","Crizotinib","2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-","Xalkori\"","PF-02341066","CRIZOTINIB","PF-2341066","\"(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine","MET tyrosine kinase inhibitor PF-02341066"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1539632957000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"24675041","title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.","journal":"Cancer discovery","pubDate":"2014 Jun","volume":"4","issue":"6","pages":"662-673","authors":"Friboulet L et al","elocationId":"doi: 10.1158/2159-8290.CD-13-0846","link":null,"reference":"Friboulet L et al. Cancer discovery. 2014 Jun;4(6)662-673.","abstract":null},{"pmid":"28434515","title":"Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2017 May","volume":"12","issue":"5","pages":"e49-e51","authors":"Wang HY et al","elocationId":"doi: 10.1016/j.jtho.2017.01.009","link":null,"reference":"Wang HY et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017 May;12(5)e49-e51.","abstract":null},{"pmid":"23434628","title":"Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.","journal":"Genomics","pubDate":"2013 Sep","volume":"102","issue":"3","pages":"157-62","authors":"Huang D et al","elocationId":"doi: 10.1016/j.ygeno.2013.02.006","link":null,"reference":"Huang D et al. Genomics. 2013 Sep;102(3)157-62.","abstract":null},{"pmid":"23344087","title":"Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2013 Apr","volume":"8","issue":"4","pages":"415-22","authors":"Kim S et al","elocationId":"doi: 10.1097/JTO.0b013e318283dcc0","link":null,"reference":"Kim S et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Apr;8(4)415-22.","abstract":null},{"pmid":"22235099","title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2012 Mar 1","volume":"18","issue":"5","pages":"1472-82","authors":"Doebele RC et al","elocationId":"doi: 10.1158/1078-0432.CCR-11-2906","link":null,"reference":"Doebele RC et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Mar 1;18(5)1472-82.","abstract":null},{"pmid":"27045755","title":"Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.","journal":"PloS one","pubDate":"2016","volume":"11","issue":"4","pages":"e0153065","authors":"Saber A et al","elocationId":"doi: 10.1371/journal.pone.0153065","link":null,"reference":"Saber A et al. PloS one. 2016;11(4)e0153065.","abstract":null}]},{"id":770,"uuid":"d48508c3-b08a-4b2f-b678-04f651831023","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"I1171N","name":"I1171N","refResidues":"I","proteinStart":1171,"proteinEnd":1171,"variantResidues":"N","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C101790","drugName":"Alectinib","uuid":"ef2bee25-4fa3-40c4-a79f-4f885377afa7","synonyms":["AF802","Alectinib","RO5424802\"","ALECTINIB","\"5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-","AF-802","Alecensa","CH5424802","RG7853"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1539636551000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"23239810","title":"Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.","journal":"Molecular cancer research : MCR","pubDate":"2013 Feb","volume":"11","issue":"2","pages":"122-32","authors":"Ceccon M et al","elocationId":"doi: 10.1158/1541-7786.MCR-12-0569","link":null,"reference":"Ceccon M et al. Molecular cancer research : MCR. 2013 Feb;11(2)122-32.","abstract":null},{"pmid":"29650534","title":"Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer.","journal":"Cancer discovery","pubDate":"2018 Jun","volume":"8","issue":"6","pages":"714-729","authors":"Yoda S et al","elocationId":"doi: 10.1158/2159-8290.CD-17-1256","link":null,"reference":"Yoda S et al. Cancer discovery. 2018 Jun;8(6)714-729.","abstract":null},{"pmid":"25393798","title":"Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2014 Dec","volume":"9","issue":"12","pages":"e86-7","authors":"Toyokawa G et al","elocationId":"doi: 10.1097/JTO.0000000000000358","link":null,"reference":"Toyokawa G et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Dec;9(12)e86-7.","abstract":null},{"pmid":"25393796","title":"Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2014 Dec","volume":"9","issue":"12","pages":"1821-5","authors":"Ou SH et al","elocationId":"doi: 10.1097/JTO.0000000000000368","link":null,"reference":"Ou SH et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Dec;9(12)1821-5.","abstract":null},{"pmid":"25736571","title":"I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.","journal":"Lung cancer (Amsterdam, Netherlands)","pubDate":"2015 May","volume":"88","issue":"2","pages":"231-4","authors":"Ou SH et al","elocationId":"doi: 10.1016/j.lungcan.2015.02.005","link":null,"reference":"Ou SH et al. Lung cancer (Amsterdam, Netherlands). 2015 May;88(2)231-4.","abstract":null},{"pmid":"27565911","title":"Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.","journal":"Lung cancer (Amsterdam, Netherlands)","pubDate":"2016 Sep","volume":"99","issue":"","pages":"38-40","authors":"Johnson AC et al","elocationId":"doi: 10.1016/j.lungcan.2016.06.010","link":null,"reference":"Johnson AC et al. Lung cancer (Amsterdam, Netherlands). 2016 Sep;99()38-40.","abstract":null},{"pmid":"29376144","title":"Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.","journal":"JCO precision oncology","pubDate":"2018","volume":"2018","issue":"","pages":"","authors":"Dagogo-Jack I et al","elocationId":"doi: 10.1200/PO.17.00160","link":null,"reference":"Dagogo-Jack I et al. JCO precision oncology. 2018;2018().","abstract":null}]},{"id":7046,"uuid":"91807c6a-c8d0-43a4-8910-39e9525ebb31","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":83,"subtype":"Non-Small Cell Lung Cancer","code":"NSCLC","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":2,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L718V","name":"L718V","refResidues":"L","proteinStart":718,"proteinEnd":718,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C116377","drugName":"Osimertinib","uuid":"4c2c1261-bfc3-4180-8113-127194366320","synonyms":["OSIMERTINIB","AZD-9291","Osimertinib","\"2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-","Tagrisso\"","Mereletinib","AZD9291"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1580180888000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"31757379","title":"Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2019 Dec","volume":"14","issue":"12","pages":"e274-e275","authors":"Fang W et al","elocationId":"doi: 10.1016/j.jtho.2019.07.018","link":null,"reference":"Fang W et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Dec;14(12)e274-e275.","abstract":null},{"pmid":"29568384","title":"Structural insights into drug development strategy targeting EGFR T790M/C797S.","journal":"Oncotarget","pubDate":"2018 Mar 2","volume":"9","issue":"17","pages":"13652-13665","authors":"Zhu SJ et al","elocationId":"doi: 10.18632/oncotarget.24113","link":null,"reference":"Zhu SJ et al. Oncotarget. 2018 Mar 2;9(17)13652-13665.","abstract":null},{"pmid":"29571986","title":"Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.","journal":"Lung cancer (Amsterdam, Netherlands)","pubDate":"2018 Apr","volume":"118","issue":"","pages":"1-5","authors":"Liu Y et al","elocationId":"doi: 10.1016/j.lungcan.2018.01.015","link":null,"reference":"Liu Y et al. Lung cancer (Amsterdam, Netherlands). 2018 Apr;118()1-5.","abstract":null},{"pmid":"31301016","title":"Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.","journal":"Targeted oncology","pubDate":"2019 Aug","volume":"14","issue":"4","pages":"369-374","authors":"Yang Z et al","elocationId":"doi: 10.1007/s11523-019-00652-6","link":null,"reference":"Yang Z et al. Targeted oncology. 2019 Aug;14(4)369-374.","abstract":null}]},{"id":774,"uuid":"8bd2082f-6098-4e2f-bd54-871a6f46dbd4","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L1196M","name":"L1196M","refResidues":"L","proteinStart":1196,"proteinEnd":1196,"variantResidues":"M","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C74061","drugName":"Crizotinib","uuid":"f05d12ab-6204-4a1c-803f-f3a7f6e30af2","synonyms":["MET Tyrosine Kinase Inhibitor PF-02341066","Crizotinib","2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-","Xalkori\"","PF-02341066","CRIZOTINIB","PF-2341066","\"(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine","MET tyrosine kinase inhibitor PF-02341066"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1539637577000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22277784","title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.","journal":"Science translational medicine","pubDate":"2012 Feb 8","volume":"4","issue":"120","pages":"120ra17","authors":"Katayama R et al","elocationId":"doi: 10.1126/scitranslmed.3003316","link":null,"reference":"Katayama R et al. Science translational medicine. 2012 Feb 8;4(120)120ra17.","abstract":null},{"pmid":"24675041","title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.","journal":"Cancer discovery","pubDate":"2014 Jun","volume":"4","issue":"6","pages":"662-673","authors":"Friboulet L et al","elocationId":"doi: 10.1158/2159-8290.CD-13-0846","link":null,"reference":"Friboulet L et al. Cancer discovery. 2014 Jun;4(6)662-673.","abstract":null},{"pmid":"28434515","title":"Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2017 May","volume":"12","issue":"5","pages":"e49-e51","authors":"Wang HY et al","elocationId":"doi: 10.1016/j.jtho.2017.01.009","link":null,"reference":"Wang HY et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017 May;12(5)e49-e51.","abstract":null},{"pmid":"23434628","title":"Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.","journal":"Genomics","pubDate":"2013 Sep","volume":"102","issue":"3","pages":"157-62","authors":"Huang D et al","elocationId":"doi: 10.1016/j.ygeno.2013.02.006","link":null,"reference":"Huang D et al. Genomics. 2013 Sep;102(3)157-62.","abstract":null},{"pmid":"23344087","title":"Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2013 Apr","volume":"8","issue":"4","pages":"415-22","authors":"Kim S et al","elocationId":"doi: 10.1097/JTO.0b013e318283dcc0","link":null,"reference":"Kim S et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Apr;8(4)415-22.","abstract":null},{"pmid":"22235099","title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2012 Mar 1","volume":"18","issue":"5","pages":"1472-82","authors":"Doebele RC et al","elocationId":"doi: 10.1158/1078-0432.CCR-11-2906","link":null,"reference":"Doebele RC et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Mar 1;18(5)1472-82.","abstract":null},{"pmid":"27432227","title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.","journal":"Cancer discovery","pubDate":"2016 Oct","volume":"6","issue":"10","pages":"1118-1133","authors":"Gainor JF et al","elocationId":"","link":null,"reference":"Gainor JF et al. Cancer discovery. 2016 Oct;6(10)1118-1133.","abstract":null}]},{"id":6664,"uuid":"edbc9176-a418-4a99-8b44-d03219a68098","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"C797S","name":"C797S","refResidues":"C","proteinStart":797,"proteinEnd":797,"variantResidues":"S","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C116377","drugName":"Osimertinib","uuid":"4c2c1261-bfc3-4180-8113-127194366320","synonyms":["OSIMERTINIB","AZD-9291","Osimertinib","\"2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-","Tagrisso\"","Mereletinib","AZD9291"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1535659220000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"28625641","title":"Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.","journal":"Lung cancer (Amsterdam, Netherlands)","pubDate":"2017 Jun","volume":"108","issue":"","pages":"228-231","authors":"Ou SI et al","elocationId":"doi: 10.1016/j.lungcan.2017.04.003","link":null,"reference":"Ou SI et al. Lung cancer (Amsterdam, Netherlands). 2017 Jun;108()228-231.","abstract":null},{"pmid":"26181354","title":"Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.","journal":"JAMA oncology","pubDate":"2015 Oct","volume":"1","issue":"7","pages":"982-4","authors":"Yu HA et al","elocationId":"doi: 10.1001/jamaoncol.2015.1066","link":null,"reference":"Yu HA et al. JAMA oncology. 2015 Oct;1(7)982-4.","abstract":null},{"pmid":"25939061","title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.","journal":"Nature medicine","pubDate":"2015 Jun","volume":"21","issue":"6","pages":"560-2","authors":"Thress KS et al","elocationId":"doi: 10.1038/nm.3854","link":null,"reference":"Thress KS et al. Nature medicine. 2015 Jun;21(6)560-2.","abstract":null},{"pmid":"26749488","title":"Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2016 Apr","volume":"11","issue":"4","pages":"e45-7","authors":"Song HN et al","elocationId":"doi: 10.1016/j.jtho.2015.12.093","link":null,"reference":"Song HN et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Apr;11(4)e45-7.","abstract":null}]},{"id":17162,"uuid":"713e9bbc-dd66-472f-8769-cded1b89b38e","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":984,"subtype":"","code":"","color":"","mainType":"All Solid Tumors","level":-1,"tissue":"","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4916,"hugoSymbol":"NTRK3","oncogene":true,"grch37Isoform":"ENST00000360948","grch37RefSeq":"NM_001012338.2","grch38Isoform":"ENST00000360948","grch38RefSeq":"NM_001012338.2","geneAliases":["TRKC","GP145-TrkC","gp145(trkC)"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4916,"hugoSymbol":"NTRK3","oncogene":true,"grch37Isoform":"ENST00000360948","grch37RefSeq":"NM_001012338.2","grch38Isoform":"ENST00000360948","grch38RefSeq":"NM_001012338.2","geneAliases":["TRKC","GP145-TrkC","gp145(trkC)"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"G623R","name":"G623R","refResidues":"G","proteinStart":623,"proteinEnd":623,"variantResidues":"R","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C115977","drugName":"Larotrectinib","uuid":"b0b3d8ee-86a5-4421-b4a9-053d3c1ff544","synonyms":["LAROTRECTINIB","LOXO-101","Larotrectinib","LOXO 101","\"1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-","ARRY 470","3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide","Larotrectinib\""],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1544809974000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"28578312","title":"A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.","journal":"Cancer discovery","pubDate":"2017 Sep","volume":"7","issue":"9","pages":"963-972","authors":"Drilon A et al","elocationId":"doi: 10.1158/2159-8290.CD-17-0507","link":null,"reference":"Drilon A et al. Cancer discovery. 2017 Sep;7(9)963-972.","abstract":null},{"pmid":"29466156","title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.","journal":"The New England journal of medicine","pubDate":"2018 Feb 22","volume":"378","issue":"8","pages":"731-739","authors":"Drilon A et al","elocationId":"doi: 10.1056/NEJMoa1714448","link":null,"reference":"Drilon A et al. The New England journal of medicine. 2018 Feb 22;378(8)731-739.","abstract":null}]},{"id":12618,"uuid":"dbd05696-b065-4c6f-aeaa-2af19790ab27","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y823D","name":"Y823D","refResidues":"Y","proteinStart":823,"proteinEnd":823,"variantResidues":"D","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1580408243000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22301675","title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.","journal":"Leukemia","pubDate":"2012 Jul","volume":"26","issue":"7","pages":"1693-5","authors":"Lierman E et al","elocationId":"doi: 10.1038/leu.2012.8","link":null,"reference":"Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.","abstract":null},{"pmid":"18955458","title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5352-9","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2007.15.7461","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.","abstract":null},{"pmid":"23840364","title":"Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.","journal":"PloS one","pubDate":"2013","volume":"8","issue":"6","pages":"e65762","authors":"Hsueh YS et al","elocationId":"doi: 10.1371/journal.pone.0065762","link":null,"reference":"Hsueh YS et al. PloS one. 2013;8(6)e65762.","abstract":null},{"pmid":"25239608","title":"Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2014 Nov 15","volume":"20","issue":"22","pages":"5745-5755","authors":"Garner AP et al","elocationId":"doi: 10.1158/1078-0432.CCR-14-1397","link":null,"reference":"Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.","abstract":null}]},{"id":12619,"uuid":"4dfa1530-a55a-42ba-89cb-8cd7f451759f","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y823D","name":"Y823D","refResidues":"Y","proteinStart":823,"proteinEnd":823,"variantResidues":"D","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C71622","drugName":"Sunitinib","uuid":"5b548883-0142-4d15-a324-22d7b29800b2","synonyms":["\"1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-","Sunitinib","SUNITINIB","sunitinib\""],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1580408266000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22301675","title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.","journal":"Leukemia","pubDate":"2012 Jul","volume":"26","issue":"7","pages":"1693-5","authors":"Lierman E et al","elocationId":"doi: 10.1038/leu.2012.8","link":null,"reference":"Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.","abstract":null},{"pmid":"18955458","title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5352-9","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2007.15.7461","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.","abstract":null},{"pmid":"23840364","title":"Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.","journal":"PloS one","pubDate":"2013","volume":"8","issue":"6","pages":"e65762","authors":"Hsueh YS et al","elocationId":"doi: 10.1371/journal.pone.0065762","link":null,"reference":"Hsueh YS et al. PloS one. 2013;8(6)e65762.","abstract":null},{"pmid":"25239608","title":"Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2014 Nov 15","volume":"20","issue":"22","pages":"5745-5755","authors":"Garner AP et al","elocationId":"doi: 10.1158/1078-0432.CCR-14-1397","link":null,"reference":"Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.","abstract":null}]},{"id":6668,"uuid":"c606e809-7a9a-4334-b2e1-a34daf02a552","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"C797G","name":"C797G","refResidues":"C","proteinStart":797,"proteinEnd":797,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C116377","drugName":"Osimertinib","uuid":"4c2c1261-bfc3-4180-8113-127194366320","synonyms":["OSIMERTINIB","AZD-9291","Osimertinib","\"2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-","Tagrisso\"","Mereletinib","AZD9291"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1539205170000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"27086175","title":"A Novel EGFR(C797) Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2016 Sep","volume":"11","issue":"9","pages":"e105-7","authors":"Menon R et al","elocationId":"doi: 10.1016/j.jtho.2016.04.005","link":null,"reference":"Menon R et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Sep;11(9)e105-7.","abstract":null},{"pmid":"29713646","title":"Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients.","journal":"BioMed research international","pubDate":"2018","volume":"2018","issue":"","pages":"9010353","authors":"Nie K et al","elocationId":"doi: 10.1155/2018/9010353","link":null,"reference":"Nie K et al. BioMed research international. 2018;2018()9010353.","abstract":null}]},{"id":14733,"uuid":"828d3692-26fe-46d8-99e9-05a6a36cd4fe","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"D1228N","name":"D1228N","refResidues":"D","proteinStart":1228,"proteinEnd":1228,"variantResidues":"N","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C52200","drugName":"Cabozantinib","uuid":"6acebe88-de89-4ec1-bc38-74cb63861d23","synonyms":["\"1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-","CABOZANTINIB","Cabozantinib","N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide\""],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C74061","drugName":"Crizotinib","uuid":"f05d12ab-6204-4a1c-803f-f3a7f6e30af2","synonyms":["MET Tyrosine Kinase Inhibitor PF-02341066","Crizotinib","2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-","Xalkori\"","PF-02341066","CRIZOTINIB","PF-2341066","\"(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine","MET tyrosine kinase inhibitor PF-02341066"],"priority":1}]},{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C90564","drugName":"Capmatinib","uuid":"8ddbbd88-3730-4ea2-8cba-b5038d250fd1","synonyms":["INC280","INCB028060","INCB28060\"","INCB 28060","Capmatinib","INC-280","\"2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide","CAPMATINIB"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1540489817000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"27343442","title":"Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2016 Aug","volume":"11","issue":"8","pages":"1242-1245","authors":"Heist RS et al","elocationId":"doi: 10.1016/j.jtho.2016.06.013","link":null,"reference":"Heist RS et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Aug;11(8)1242-1245.","abstract":null},{"pmid":"29128427","title":"Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2018 Apr","volume":"13","issue":"4","pages":"e49-e53","authors":"Kang J et al","elocationId":"doi: 10.1016/j.jtho.2017.10.028","link":null,"reference":"Kang J et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Apr;13(4)e49-e53.","abstract":null},{"pmid":"28396313","title":"Acquired <i>MET</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2017 Aug 15","volume":"23","issue":"16","pages":"4929-4937","authors":"Li A et al","elocationId":"doi: 10.1158/1078-0432.CCR-16-3273","link":null,"reference":"Li A et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Aug 15;23(16)4929-4937.","abstract":null},{"pmid":"28522754","title":"<i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.","journal":"Cancer research","pubDate":"2017 Aug 15","volume":"77","issue":"16","pages":"4498-4505","authors":"Lu X et al","elocationId":"doi: 10.1158/0008-5472.CAN-16-1944","link":null,"reference":"Lu X et al. Cancer research. 2017 Aug 15;77(16)4498-4505.","abstract":null},{"pmid":"27987579","title":"Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.","journal":"Lung cancer (Amsterdam, Netherlands)","pubDate":"2016 Dec","volume":"102","issue":"","pages":"118-121","authors":"Dong HJ et al","elocationId":"doi: 10.1016/j.lungcan.2016.11.006","link":null,"reference":"Dong HJ et al. Lung cancer (Amsterdam, Netherlands). 2016 Dec;102()118-121.","abstract":null}]},{"id":12624,"uuid":"ae0ebd6f-f7fb-48f4-a48f-6dd8ec6c1fd8","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"C809G","name":"C809G","refResidues":"C","proteinStart":809,"proteinEnd":809,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1580407552000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22301675","title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.","journal":"Leukemia","pubDate":"2012 Jul","volume":"26","issue":"7","pages":"1693-5","authors":"Lierman E et al","elocationId":"doi: 10.1038/leu.2012.8","link":null,"reference":"Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.","abstract":null},{"pmid":"18955458","title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5352-9","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2007.15.7461","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.","abstract":null},{"pmid":"23840364","title":"Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.","journal":"PloS one","pubDate":"2013","volume":"8","issue":"6","pages":"e65762","authors":"Hsueh YS et al","elocationId":"doi: 10.1371/journal.pone.0065762","link":null,"reference":"Hsueh YS et al. PloS one. 2013;8(6)e65762.","abstract":null},{"pmid":"25239608","title":"Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2014 Nov 15","volume":"20","issue":"22","pages":"5745-5755","authors":"Garner AP et al","elocationId":"doi: 10.1158/1078-0432.CCR-14-1397","link":null,"reference":"Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.","abstract":null}]},{"id":12625,"uuid":"1883c1c7-a0eb-466b-b1c8-179ad6661cad","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"C809G","name":"C809G","refResidues":"C","proteinStart":809,"proteinEnd":809,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C71622","drugName":"Sunitinib","uuid":"5b548883-0142-4d15-a324-22d7b29800b2","synonyms":["\"1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-","Sunitinib","SUNITINIB","sunitinib\""],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1580407575000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22301675","title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.","journal":"Leukemia","pubDate":"2012 Jul","volume":"26","issue":"7","pages":"1693-5","authors":"Lierman E et al","elocationId":"doi: 10.1038/leu.2012.8","link":null,"reference":"Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.","abstract":null},{"pmid":"18955458","title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5352-9","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2007.15.7461","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.","abstract":null},{"pmid":"23840364","title":"Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.","journal":"PloS one","pubDate":"2013","volume":"8","issue":"6","pages":"e65762","authors":"Hsueh YS et al","elocationId":"doi: 10.1371/journal.pone.0065762","link":null,"reference":"Hsueh YS et al. PloS one. 2013;8(6)e65762.","abstract":null},{"pmid":"25239608","title":"Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2014 Nov 15","volume":"20","issue":"22","pages":"5745-5755","authors":"Garner AP et al","elocationId":"doi: 10.1158/1078-0432.CCR-14-1397","link":null,"reference":"Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.","abstract":null}]},{"id":6673,"uuid":"6d03974e-fa0b-4427-c0e2-4437f6958e05","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"D761Y","name":"D761Y","refResidues":"D","proteinStart":761,"proteinEnd":761,"variantResidues":"Y","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C1855","drugName":"Gefitinib","uuid":"b76d7b2b-b5fb-4561-892f-6b00bfaf0dfa","synonyms":["GEFITINIB","Iressa","N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine","ZD 1839","gefitinib","Gefitinib","4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline","ZD1839"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1539205199000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"17192902","title":"The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.","journal":"International journal of cancer","pubDate":"2007 Mar 15","volume":"120","issue":"6","pages":"1239-47","authors":"Ichihara S et al","elocationId":"","link":null,"reference":"Ichihara S et al. International journal of cancer. 2007 Mar 15;120(6)1239-47.","abstract":null},{"pmid":"17085664","title":"Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2006 Nov 1","volume":"12","issue":"21","pages":"6494-501","authors":"Balak MN et al","elocationId":"","link":null,"reference":"Balak MN et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Nov 1;12(21)6494-501.","abstract":null},{"pmid":"28424065","title":"Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.","journal":"BMC cancer","pubDate":"2017 Apr 19","volume":"17","issue":"1","pages":"281","authors":"Chiba M et al","elocationId":"doi: 10.1186/s12885-017-3263-z","link":null,"reference":"Chiba M et al. BMC cancer. 2017 Apr 19;17(1)281.","abstract":null},{"pmid":"22052230","title":"Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2011 Dec","volume":"6","issue":"12","pages":"2011-7","authors":"Yano S et al","elocationId":"doi: 10.1097/JTO.0b013e31823ab0dd","link":null,"reference":"Yano S et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Dec;6(12)2011-7.","abstract":null}]},{"id":14739,"uuid":"13d4ee32-8901-4057-8c76-d6a5c6cfd487","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y1230H","name":"Y1230H","refResidues":"Y","proteinStart":1230,"proteinEnd":1230,"variantResidues":"H","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C74061","drugName":"Crizotinib","uuid":"f05d12ab-6204-4a1c-803f-f3a7f6e30af2","synonyms":["MET Tyrosine Kinase Inhibitor PF-02341066","Crizotinib","2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-","Xalkori\"","PF-02341066","CRIZOTINIB","PF-2341066","\"(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine","MET tyrosine kinase inhibitor PF-02341066"],"priority":1}]},{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C90564","drugName":"Capmatinib","uuid":"8ddbbd88-3730-4ea2-8cba-b5038d250fd1","synonyms":["INC280","INCB028060","INCB28060\"","INCB 28060","Capmatinib","INC-280","\"2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide","CAPMATINIB"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1540489817000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"27666659","title":"Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2017 Jan","volume":"12","issue":"1","pages":"137-140","authors":"Ou SI et al","elocationId":"doi: 10.1016/j.jtho.2016.09.119","link":null,"reference":"Ou SI et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017 Jan;12(1)137-140.","abstract":null},{"pmid":"29128427","title":"Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2018 Apr","volume":"13","issue":"4","pages":"e49-e53","authors":"Kang J et al","elocationId":"doi: 10.1016/j.jtho.2017.10.028","link":null,"reference":"Kang J et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Apr;13(4)e49-e53.","abstract":null},{"pmid":"28396313","title":"Acquired <i>MET</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2017 Aug 15","volume":"23","issue":"16","pages":"4929-4937","authors":"Li A et al","elocationId":"doi: 10.1158/1078-0432.CCR-16-3273","link":null,"reference":"Li A et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Aug 15;23(16)4929-4937.","abstract":null},{"pmid":"28522754","title":"<i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.","journal":"Cancer research","pubDate":"2017 Aug 15","volume":"77","issue":"16","pages":"4498-4505","authors":"Lu X et al","elocationId":"doi: 10.1158/0008-5472.CAN-16-1944","link":null,"reference":"Lu X et al. Cancer research. 2017 Aug 15;77(16)4498-4505.","abstract":null},{"pmid":"27987579","title":"Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.","journal":"Lung cancer (Amsterdam, Netherlands)","pubDate":"2016 Dec","volume":"102","issue":"","pages":"118-121","authors":"Dong HJ et al","elocationId":"doi: 10.1016/j.lungcan.2016.11.006","link":null,"reference":"Dong HJ et al. Lung cancer (Amsterdam, Netherlands). 2016 Dec;102()118-121.","abstract":null}]},{"id":12696,"uuid":"9de2677a-47f2-4a3e-85eb-ce82cd07d6e6","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V654A","name":"V654A","refResidues":"V","proteinStart":654,"proteinEnd":654,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1580422661000,"lastReview":null,"levelOfEvidence":"LEVEL_R2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"18955458","title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5352-9","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2007.15.7461","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.","abstract":null},{"pmid":"16551858","title":"Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2006 Mar 15","volume":"12","issue":"6","pages":"1743-9","authors":"Wardelmann E et al","elocationId":"","link":null,"reference":"Wardelmann E et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Mar 15;12(6)1743-9.","abstract":null},{"pmid":"23840364","title":"Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.","journal":"PloS one","pubDate":"2013","volume":"8","issue":"6","pages":"e65762","authors":"Hsueh YS et al","elocationId":"doi: 10.1371/journal.pone.0065762","link":null,"reference":"Hsueh YS et al. PloS one. 2013;8(6)e65762.","abstract":null},{"pmid":"16954519","title":"Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2006 Oct 10","volume":"24","issue":"29","pages":"4764-74","authors":"Heinrich MC et al","elocationId":"","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Oct 10;24(29)4764-74.","abstract":null}]}],"LEVEL_Px3":[{"id":6216,"uuid":"f34bb102-86f6-4fe9-b468-ccbaa606f380","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":534,"subtype":"Lymphoplasmacytic Lymphoma","code":"LPL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7852,"hugoSymbol":"CXCR4","oncogene":true,"grch37Isoform":"ENST00000241393","grch37RefSeq":"NM_003467.2","grch38Isoform":"ENST00000241393","grch38RefSeq":"NM_003467.2","geneAliases":["NPYRL","CD184","NPY3R","HM89","NPYY3R","LAP-3","HSY3RR","D2S201E","LCR1","WHIMS","LESTR","LAP3","FB22","WHIM","NPYR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":7852,"hugoSymbol":"CXCR4","oncogene":true,"grch37Isoform":"ENST00000241393","grch37RefSeq":"NM_003467.2","grch38Isoform":"ENST00000241393","grch38RefSeq":"NM_003467.2","geneAliases":["NPYRL","CD184","NPY3R","HM89","NPYY3R","LAP-3","HSY3RR","D2S201E","LCR1","WHIMS","LESTR","LAP3","FB22","WHIM","NPYR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25819228","title":"MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.","journal":"British journal of haematology","pubDate":"2015 Jun","volume":"169","issue":"6","pages":"795-803","authors":"Schmidt J et al","elocationId":"doi: 10.1111/bjh.13361","link":null,"reference":"Schmidt J et al. British journal of haematology. 2015 Jun;169(6)795-803.","abstract":null},{"pmid":"24553177","title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.","journal":"Blood","pubDate":"2014 May 1","volume":"123","issue":"18","pages":"2791-6","authors":"Treon SP et al","elocationId":"doi: 10.1182/blood-2014-01-550905","link":null,"reference":"Treon SP et al. Blood. 2014 May 1;123(18)2791-6.","abstract":null},{"pmid":"25853747","title":"Ibrutinib in previously treated Waldenström's macroglobulinemia.","journal":"The New England journal of medicine","pubDate":"2015 Apr 9","volume":"372","issue":"15","pages":"1430-40","authors":"Treon SP et al","elocationId":"doi: 10.1056/NEJMoa1501548","link":null,"reference":"Treon SP et al. The New England journal of medicine. 2015 Apr 9;372(15)1430-40.","abstract":null}]},{"id":9946,"uuid":"e46ea769-143a-43cc-b2c7-ac0a5b09b059","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":293,"subtype":"T-Lymphoblastic Leukemia/Lymphoma","code":"TLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":55294,"hugoSymbol":"FBXW7","oncogene":false,"grch37Isoform":"ENST00000281708","grch37RefSeq":"NM_033632.3","grch38Isoform":"ENST00000281708","grch38RefSeq":"NM_033632.3","geneAliases":["FBX30","hAgo","FBXW6","SEL-10","hCdc4","AGO","FBW6","SEL10","FBW7","CDC4","FBXO30"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":55294,"hugoSymbol":"FBXW7","oncogene":false,"grch37Isoform":"ENST00000281708","grch37RefSeq":"NM_033632.3","grch38Isoform":"ENST00000281708","grch38RefSeq":"NM_033632.3","geneAliases":["FBX30","hAgo","FBXW6","SEL-10","hCdc4","AGO","FBW6","SEL10","FBW7","CDC4","FBXO30"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"20861920","title":"NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.","journal":"Leukemia","pubDate":"2010 Dec","volume":"24","issue":"12","pages":"2023-31","authors":"Clappier E et al","elocationId":"doi: 10.1038/leu.2010.205","link":null,"reference":"Clappier E et al. Leukemia. 2010 Dec;24(12)2023-31.","abstract":null},{"pmid":"20861909","title":"NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols.","journal":"Leukemia","pubDate":"2010 Dec","volume":"24","issue":"12","pages":"2014-22","authors":"Zuurbier L et al","elocationId":"doi: 10.1038/leu.2010.204","link":null,"reference":"Zuurbier L et al. Leukemia. 2010 Dec;24(12)2014-22.","abstract":null}]},{"id":6528,"uuid":"3a5d86a0-771c-4147-b86b-0d55645fc9f0","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":160,"subtype":"Anaplastic Large-Cell Lymphoma ALK Negative","code":"ALCLALKN","color":"LimeGreen","mainType":"Mature T and NK Neoplasms","level":6,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":56940,"hugoSymbol":"DUSP22","oncogene":false,"grch37Isoform":"ENST00000344450","grch37RefSeq":"NM_020185.4","grch38Isoform":"ENST00000344450","grch38RefSeq":"NM_020185.4","geneAliases":["LMW-DSP2","JKAP","JSP-1","MKPX","VHX","JSP1","MKP-x","LMWDSP2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":56940,"hugoSymbol":"DUSP22","oncogene":false,"grch37Isoform":"ENST00000344450","grch37RefSeq":"NM_020185.4","grch38Isoform":"ENST00000344450","grch38RefSeq":"NM_020185.4","geneAliases":["LMW-DSP2","JKAP","JSP-1","MKPX","VHX","JSP1","MKP-x","LMWDSP2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"28522440","title":"<i>DUSP22</i> and <i>TP63</i> rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study.","journal":"Blood","pubDate":"2017 Jul 27","volume":"130","issue":"4","pages":"554-557","authors":"Pedersen MB et al","elocationId":"doi: 10.1182/blood-2016-12-755496","link":null,"reference":"Pedersen MB et al. Blood. 2017 Jul 27;130(4)554-557.","abstract":null},{"pmid":"24894770","title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.","journal":"Blood","pubDate":"2014 Aug 28","volume":"124","issue":"9","pages":"1473-80","authors":"Parrilla Castellar ER et al","elocationId":"doi: 10.1182/blood-2014-04-571091","link":null,"reference":"Parrilla Castellar ER et al. Blood. 2014 Aug 28;124(9)1473-80.","abstract":null}]},{"id":23296,"uuid":"e05be7f2-30ba-4b12-84ab-aeba2c0e29ab","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":586,"subtype":"Mantle Cell Lymphoma","code":"MCL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":7157,"hugoSymbol":"TP53","oncogene":false,"grch37Isoform":"ENST00000269305","grch37RefSeq":"NM_000546.5","grch38Isoform":"ENST00000269305","grch38RefSeq":"NM_000546.5","geneAliases":["TRP53","BCC7","BMFS5","LFS1","P53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24684350","title":"SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.","journal":"British journal of haematology","pubDate":"2014 Jul","volume":"166","issue":"1","pages":"98-108","authors":"Nordström L et al","elocationId":"doi: 10.1111/bjh.12854","link":null,"reference":"Nordström L et al. British journal of haematology. 2014 Jul;166(1)98-108.","abstract":null},{"pmid":"8639789","title":"p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis.","journal":"Blood","pubDate":"1996 May 15","volume":"87","issue":"10","pages":"4302-10","authors":"Greiner TC et al","elocationId":"","link":null,"reference":"Greiner TC et al. Blood. 1996 May 15;87(10)4302-10.","abstract":null},{"pmid":"7579380","title":"p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32).","journal":"Blood","pubDate":"1995 Oct 15","volume":"86","issue":"8","pages":"2892-9","authors":"Louie DC et al","elocationId":"","link":null,"reference":"Louie DC et al. Blood. 1995 Oct 15;86(8)2892-9.","abstract":null},{"pmid":"26022239","title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.","journal":"Blood","pubDate":"2015 Jul 30","volume":"126","issue":"5","pages":"604-11","authors":"Delfau-Larue MH et al","elocationId":"doi: 10.1182/blood-2015-02-628792","link":null,"reference":"Delfau-Larue MH et al. Blood. 2015 Jul 30;126(5)604-11.","abstract":null},{"pmid":"28819011","title":"<i>TP53</i> mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.","journal":"Blood","pubDate":"2017 Oct 26","volume":"130","issue":"17","pages":"1903-1910","authors":"Eskelund CW et al","elocationId":"doi: 10.1182/blood-2017-04-779736","link":null,"reference":"Eskelund CW et al. Blood. 2017 Oct 26;130(17)1903-1910.","abstract":null}]},{"id":16690,"uuid":"a370d143-0815-49c1-a671-a992b72f639d","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":941,"subtype":"","code":"","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":0,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4851,"hugoSymbol":"NOTCH1","oncogene":true,"grch37Isoform":"ENST00000277541","grch37RefSeq":"NM_017617.3","grch38Isoform":"ENST00000651671","grch38RefSeq":"NM_017617.5","geneAliases":["TAN1","hN1","AOVD1","AOS5"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4851,"hugoSymbol":"NOTCH1","oncogene":true,"grch37Isoform":"ENST00000277541","grch37RefSeq":"NM_017617.3","grch38Isoform":"ENST00000651671","grch38RefSeq":"NM_017617.5","geneAliases":["TAN1","hN1","AOVD1","AOS5"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"16707600","title":"NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2006 May 15","volume":"12","issue":"10","pages":"3043-9","authors":"Zhu YM et al","elocationId":"","link":null,"reference":"Zhu YM et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 May 15;12(10)3043-9.","abstract":null},{"pmid":"20861920","title":"NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.","journal":"Leukemia","pubDate":"2010 Dec","volume":"24","issue":"12","pages":"2023-31","authors":"Clappier E et al","elocationId":"doi: 10.1038/leu.2010.205","link":null,"reference":"Clappier E et al. Leukemia. 2010 Dec;24(12)2023-31.","abstract":null},{"pmid":"20861909","title":"NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols.","journal":"Leukemia","pubDate":"2010 Dec","volume":"24","issue":"12","pages":"2014-22","authors":"Zuurbier L et al","elocationId":"doi: 10.1038/leu.2010.204","link":null,"reference":"Zuurbier L et al. Leukemia. 2010 Dec;24(12)2014-22.","abstract":null}]},{"id":16242,"uuid":"b9d3ff91-b1d9-4a09-add2-6ddc06a5b181","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":534,"subtype":"Lymphoplasmacytic Lymphoma","code":"LPL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4615,"hugoSymbol":"MYD88","oncogene":true,"grch37Isoform":"ENST00000396334","grch37RefSeq":"NM_002468.4","grch38Isoform":"ENST00000396334","grch38RefSeq":"NM_002468.4","geneAliases":["MYD88D","IMD68"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4615,"hugoSymbol":"MYD88","oncogene":true,"grch37Isoform":"ENST00000396334","grch37RefSeq":"NM_002468.4","grch38Isoform":"ENST00000396334","grch38RefSeq":"NM_002468.4","geneAliases":["MYD88D","IMD68"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L265P","name":"L265P","refResidues":"L","proteinStart":265,"proteinEnd":265,"variantResidues":"P","referenceGenomes":["GRCh37"]},{"gene":{"entrezGeneId":4615,"hugoSymbol":"MYD88","oncogene":true,"grch37Isoform":"ENST00000396334","grch37RefSeq":"NM_002468.4","grch38Isoform":"ENST00000396334","grch38RefSeq":"NM_002468.4","geneAliases":["MYD88D","IMD68"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L252P","name":"L252P","refResidues":"L","proteinStart":252,"proteinEnd":252,"variantResidues":"P","referenceGenomes":["GRCh38"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24553177","title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.","journal":"Blood","pubDate":"2014 May 1","volume":"123","issue":"18","pages":"2791-6","authors":"Treon SP et al","elocationId":"doi: 10.1182/blood-2014-01-550905","link":null,"reference":"Treon SP et al. Blood. 2014 May 1;123(18)2791-6.","abstract":null},{"pmid":"23355535","title":"Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.","journal":"Blood","pubDate":"2013 Mar 28","volume":"121","issue":"13","pages":"2522-8","authors":"Varettoni M et al","elocationId":"doi: 10.1182/blood-2012-09-457101","link":null,"reference":"Varettoni M et al. Blood. 2013 Mar 28;121(13)2522-8.","abstract":null},{"pmid":"25853747","title":"Ibrutinib in previously treated Waldenström's macroglobulinemia.","journal":"The New England journal of medicine","pubDate":"2015 Apr 9","volume":"372","issue":"15","pages":"1430-40","authors":"Treon SP et al","elocationId":"doi: 10.1056/NEJMoa1501548","link":null,"reference":"Treon SP et al. The New England journal of medicine. 2015 Apr 9;372(15)1430-40.","abstract":null}]},{"id":11890,"uuid":"a34a0999-f846-411d-bd69-d1949291cdbc","evidenceType":"PROGNOSTIC_IMPLICATION","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":10320,"hugoSymbol":"IKZF1","oncogene":false,"grch37Isoform":"ENST00000331340","grch37RefSeq":"ENST00000331340","grch38Isoform":"ENST00000331340","grch38RefSeq":"ENST00000331340","geneAliases":["CVID13","IKAROS","PRO0758","LyF-1","LYF1","Hs.54452","ZNFN1A1","IK1","PPP1R92"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":10320,"hugoSymbol":"IKZF1","oncogene":false,"grch37Isoform":"ENST00000331340","grch37RefSeq":"ENST00000331340","grch38Isoform":"ENST00000331340","grch38RefSeq":"ENST00000331340","geneAliases":["CVID13","IKAROS","PRO0758","LyF-1","LYF1","Hs.54452","ZNFN1A1","IK1","PPP1R92"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Deletion","name":"Deletion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Px3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"26202931","title":"Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.","journal":"Leukemia","pubDate":"2016 Jan","volume":"30","issue":"1","pages":"32-8","authors":"Boer JM et al","elocationId":"doi: 10.1038/leu.2015.199","link":null,"reference":"Boer JM et al. Leukemia. 2016 Jan;30(1)32-8.","abstract":null},{"pmid":"19129520","title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.","journal":"The New England journal of medicine","pubDate":"2009 Jan 29","volume":"360","issue":"5","pages":"470-80","authors":"Mullighan CG et al","elocationId":"doi: 10.1056/NEJMoa0808253","link":null,"reference":"Mullighan CG et al. The New England journal of medicine. 2009 Jan 29;360(5)470-80.","abstract":null},{"pmid":"27067989","title":"Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.","journal":"BMC cancer","pubDate":"2016 Apr 11","volume":"16","issue":"","pages":"269","authors":"Yao QM et al","elocationId":"doi: 10.1186/s12885-016-2300-7","link":null,"reference":"Yao QM et al. BMC cancer. 2016 Apr 11;16()269.","abstract":null}]}],"LEVEL_Dx3":[{"id":11747,"uuid":"5eb3b9b0-f0cc-4688-bf48-004ad6a3a289","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":23,"subtype":"Burkitt Lymphoma","code":"BL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3399,"hugoSymbol":"ID3","oncogene":false,"grch37Isoform":"ENST00000374561","grch37RefSeq":"NM_002167.4","grch38Isoform":"ENST00000374561","grch38RefSeq":"NM_002167.4","geneAliases":["HEIR-1","bHLHb25"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":3399,"hugoSymbol":"ID3","oncogene":false,"grch37Isoform":"ENST00000374561","grch37RefSeq":"NM_002167.4","grch38Isoform":"ENST00000374561","grch38RefSeq":"NM_002167.4","geneAliases":["HEIR-1","bHLHb25"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"28209658","title":"Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols.","journal":"Haematologica","pubDate":"2017 Jun","volume":"102","issue":"6","pages":"1091-1098","authors":"Rohde M et al","elocationId":"doi: 10.3324/haematol.2016.156885","link":null,"reference":"Rohde M et al. Haematologica. 2017 Jun;102(6)1091-1098.","abstract":null},{"pmid":"22885699","title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.","journal":"Nature","pubDate":"2012 Oct 4","volume":"490","issue":"7418","pages":"116-20","authors":"Schmitz R et al","elocationId":"doi: 10.1038/nature11378","link":null,"reference":"Schmitz R et al. Nature. 2012 Oct 4;490(7418)116-20.","abstract":null},{"pmid":"23143595","title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.","journal":"Nature genetics","pubDate":"2012 Dec","volume":"44","issue":"12","pages":"1316-20","authors":"Richter J et al","elocationId":"doi: 10.1038/ng.2469","link":null,"reference":"Richter J et al. Nature genetics. 2012 Dec;44(12)1316-20.","abstract":null}]},{"id":11237,"uuid":"0ccc70b0-93c9-4403-a16b-cb226e2b0929","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2624,"hugoSymbol":"GATA2","oncogene":true,"grch37Isoform":"ENST00000341105","grch37RefSeq":"NM_032638.4","grch38Isoform":"ENST00000341105","grch38RefSeq":"NM_032638.4","geneAliases":["DCML","MONOMAC","NFE1B","IMD21"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2624,"hugoSymbol":"GATA2","oncogene":true,"grch37Isoform":"ENST00000341105","grch37RefSeq":"NM_032638.4","grch38Isoform":"ENST00000341105","grch38RefSeq":"NM_032638.4","geneAliases":["DCML","MONOMAC","NFE1B","IMD21"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":20838,"uuid":"bb8f23ea-ae69-40c8-99de-eabc1b465b64","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":264,"subtype":"Angioimmunoblastic T-Cell Lymphoma","code":"AITL","color":"LimeGreen","mainType":"Mature T and NK Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":387,"hugoSymbol":"RHOA","oncogene":true,"grch37Isoform":"ENST00000418115","grch37RefSeq":"NM_001664.2","grch38Isoform":"ENST00000418115","grch38RefSeq":"NM_001664.2","geneAliases":["EDFAOB","ARH12","ARHA","RHOH12","RHO12"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":387,"hugoSymbol":"RHOA","oncogene":true,"grch37Isoform":"ENST00000418115","grch37RefSeq":"NM_001664.2","grch38Isoform":"ENST00000418115","grch38RefSeq":"NM_001664.2","geneAliases":["EDFAOB","ARH12","ARHA","RHOH12","RHO12"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24584070","title":"A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma.","journal":"Nature genetics","pubDate":"2014 Apr","volume":"46","issue":"4","pages":"371-5","authors":"Yoo HY et al","elocationId":"doi: 10.1038/ng.2916","link":null,"reference":"Yoo HY et al. Nature genetics. 2014 Apr;46(4)371-5.","abstract":null},{"pmid":"24413737","title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.","journal":"Nature genetics","pubDate":"2014 Feb","volume":"46","issue":"2","pages":"171-5","authors":"Sakata-Yanagimoto M et al","elocationId":"doi: 10.1038/ng.2872","link":null,"reference":"Sakata-Yanagimoto M et al. Nature genetics. 2014 Feb;46(2)171-5.","abstract":null},{"pmid":"24413734","title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.","journal":"Nature genetics","pubDate":"2014 Feb","volume":"46","issue":"2","pages":"166-70","authors":"Palomero T et al","elocationId":"doi: 10.1038/ng.2873","link":null,"reference":"Palomero T et al. Nature genetics. 2014 Feb;46(2)166-70.","abstract":null}]},{"id":2025,"uuid":"9bf86162-5aab-4df2-bd5d-de3313c2e96f","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":611,"subtype":"Erdheim-Chester Disease","code":"ECD","color":"LightSalmon","mainType":"Histiocytosis","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600E","name":"V600E","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"26637772","title":"Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.","journal":"Hematology. American Society of Hematology. Education Program","pubDate":"2015","volume":"2015","issue":"","pages":"559-64","authors":"Allen CE et al","elocationId":"doi: 10.1182/asheducation-2015.1.559","link":null,"reference":"Allen CE et al. Hematology. American Society of Hematology. Education Program. 2015;2015()559-64.","abstract":null},{"pmid":"25422482","title":"Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2015 Feb 10","volume":"33","issue":"5","pages":"411-8","authors":"Haroche J et al","elocationId":"doi: 10.1200/JCO.2014.57.1950","link":null,"reference":"Haroche J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Feb 10;33(5)411-8.","abstract":null}]},{"id":21098,"uuid":"3cbb0652-1896-4963-bd5f-8c27db9e48ff","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":861,"hugoSymbol":"RUNX1","oncogene":false,"grch37Isoform":"ENST00000300305","grch37RefSeq":"NM_001754.4","grch38Isoform":"ENST00000300305","grch38RefSeq":"NM_001754.4","geneAliases":["CBF2alpha","CBFA2","EVI-1","PEBP2aB","AMLCR1","PEBP2alpha","AML1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":22891,"uuid":"1aed16b0-bbcb-4575-88ae-d220a74a1d83","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":286,"subtype":"Follicular Lymphoma","code":"FL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":7128,"hugoSymbol":"TNFAIP3","oncogene":false,"grch37Isoform":"ENST00000237289","grch37RefSeq":"NM_006290.3","grch38Isoform":"ENST00000237289","grch38RefSeq":"NM_006290.3","geneAliases":["TNFA1P2","AISBL","OTUD7C","A20"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":7128,"hugoSymbol":"TNFAIP3","oncogene":false,"grch37Isoform":"ENST00000237289","grch37RefSeq":"NM_006290.3","grch38Isoform":"ENST00000237289","grch38RefSeq":"NM_006290.3","geneAliases":["TNFA1P2","AISBL","OTUD7C","A20"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"19380639","title":"TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.","journal":"The Journal of experimental medicine","pubDate":"2009 May 11","volume":"206","issue":"5","pages":"981-9","authors":"Schmitz R et al","elocationId":"doi: 10.1084/jem.20090528","link":null,"reference":"Schmitz R et al. The Journal of experimental medicine. 2009 May 11;206(5)981-9.","abstract":null},{"pmid":"19608751","title":"TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.","journal":"Blood","pubDate":"2009 Sep 17","volume":"114","issue":"12","pages":"2467-75","authors":"Honma K et al","elocationId":"doi: 10.1182/blood-2008-12-194852","link":null,"reference":"Honma K et al. Blood. 2009 Sep 17;114(12)2467-75.","abstract":null},{"pmid":"9087572","title":"Frequent deletions of 6q23-24 in B-cell non-Hodgkin's lymphomas detected by fluorescence in situ hybridization.","journal":"Genes, chromosomes & cancer","pubDate":"1997 Apr","volume":"18","issue":"4","pages":"310-3","authors":"Zhang Y et al","elocationId":"","link":null,"reference":"Zhang Y et al. Genes, chromosomes & cancer. 1997 Apr;18(4)310-3.","abstract":null},{"pmid":"24388756","title":"Genetics of follicular lymphoma transformation.","journal":"Cell reports","pubDate":"2014 Jan 16","volume":"6","issue":"1","pages":"130-40","authors":"Pasqualucci L et al","elocationId":"doi: 10.1016/j.celrep.2013.12.027","link":null,"reference":"Pasqualucci L et al. Cell reports. 2014 Jan 16;6(1)130-40.","abstract":null}]},{"id":11756,"uuid":"b6d08eac-b500-42db-b0c9-80cd12a9c219","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":418,"subtype":"Therapy-Related Myeloid Neoplasms","code":"TMN","color":"LightSalmon","mainType":"Leukemia","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3417,"hugoSymbol":"IDH1","oncogene":true,"grch37Isoform":"ENST00000345146","grch37RefSeq":"NM_005896.2","grch38Isoform":"ENST00000345146","grch38RefSeq":"NM_005896.2","geneAliases":["HEL-216","IDPC","IDCD","HEL-S-26","PICD"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3417,"hugoSymbol":"IDH1","oncogene":true,"grch37Isoform":"ENST00000345146","grch37RefSeq":"NM_005896.2","grch38Isoform":"ENST00000345146","grch38RefSeq":"NM_005896.2","geneAliases":["HEL-216","IDPC","IDCD","HEL-S-26","PICD"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23349305","title":"Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.","journal":"Haematologica","pubDate":"2013 Jun","volume":"98","issue":"6","pages":"908-12","authors":"Shih AH et al","elocationId":"doi: 10.3324/haematol.2012.076729","link":null,"reference":"Shih AH et al. Haematologica. 2013 Jun;98(6)908-12.","abstract":null},{"pmid":"25573287","title":"Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.","journal":"Leukemia research","pubDate":"2015 Mar","volume":"39","issue":"3","pages":"348-54","authors":"Ok CY et al","elocationId":"doi: 10.1016/j.leukres.2014.12.006","link":null,"reference":"Ok CY et al. Leukemia research. 2015 Mar;39(3)348-54.","abstract":null}]},{"id":22380,"uuid":"8e0ddecd-057d-422d-b614-ff1bfa9d24b7","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":488,"subtype":"T-Cell Large Granular Lymphocytic Leukemia","code":"TLGL","color":"LimeGreen","mainType":"Mature T and NK Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6777,"hugoSymbol":"STAT5B","oncogene":true,"grch37Isoform":"ENST00000293328","grch37RefSeq":"NM_012448.3","grch38Isoform":"ENST00000293328","grch38RefSeq":"NM_012448.3","geneAliases":["GHISID2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6777,"hugoSymbol":"STAT5B","oncogene":true,"grch37Isoform":"ENST00000293328","grch37RefSeq":"NM_012448.3","grch38Isoform":"ENST00000293328","grch38RefSeq":"NM_012448.3","geneAliases":["GHISID2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23596048","title":"Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia.","journal":"Blood","pubDate":"2013 May 30","volume":"121","issue":"22","pages":"4541-50","authors":"Rajala HL et al","elocationId":"doi: 10.1182/blood-2012-12-474577","link":null,"reference":"Rajala HL et al. Blood. 2013 May 30;121(22)4541-50.","abstract":null},{"pmid":"27697773","title":"High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia.","journal":"Blood","pubDate":"2016 Nov 17","volume":"128","issue":"20","pages":"2465-2468","authors":"Andersson EI et al","elocationId":"","link":null,"reference":"Andersson EI et al. Blood. 2016 Nov 17;128(20)2465-2468.","abstract":null}]},{"id":16750,"uuid":"a6ff2378-b9c1-4f17-a908-6b174c90aa9a","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":578,"subtype":"Splenic Marginal Zone Lymphoma","code":"SMZL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":6,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4853,"hugoSymbol":"NOTCH2","oncogene":true,"grch37Isoform":"ENST00000256646","grch37RefSeq":"NM_024408.3","grch38Isoform":"ENST00000256646","grch38RefSeq":"NM_024408.3","geneAliases":["HJCYS","AGS2","hN2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4853,"hugoSymbol":"NOTCH2","oncogene":true,"grch37Isoform":"ENST00000256646","grch37RefSeq":"NM_024408.3","grch38Isoform":"ENST00000256646","grch38RefSeq":"NM_024408.3","geneAliases":["HJCYS","AGS2","hN2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25779943","title":"Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2015 Sep 15","volume":"21","issue":"18","pages":"4174-4183","authors":"Parry M et al","elocationId":"doi: 10.1158/1078-0432.CCR-14-2759","link":null,"reference":"Parry M et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Sep 15;21(18)4174-4183.","abstract":null},{"pmid":"22891273","title":"The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.","journal":"The Journal of experimental medicine","pubDate":"2012 Aug 27","volume":"209","issue":"9","pages":"1537-51","authors":"Rossi D et al","elocationId":"doi: 10.1084/jem.20120904","link":null,"reference":"Rossi D et al. The Journal of experimental medicine. 2012 Aug 27;209(9)1537-51.","abstract":null},{"pmid":"22891276","title":"Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma.","journal":"The Journal of experimental medicine","pubDate":"2012 Aug 27","volume":"209","issue":"9","pages":"1553-65","authors":"Kiel MJ et al","elocationId":"doi: 10.1084/jem.20120910","link":null,"reference":"Kiel MJ et al. The Journal of experimental medicine. 2012 Aug 27;209(9)1553-65.","abstract":null},{"pmid":"24296945","title":"Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation.","journal":"Leukemia","pubDate":"2014 Jun","volume":"28","issue":"6","pages":"1334-40","authors":"Martínez N et al","elocationId":"doi: 10.1038/leu.2013.365","link":null,"reference":"Martínez N et al. Leukemia. 2014 Jun;28(6)1334-40.","abstract":null}]},{"id":16239,"uuid":"6f86dd18-6707-4c60-90b6-3671b0831722","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":490,"subtype":"Diffuse Large B-Cell Lymphoma, NOS","code":"DLBCLNOS","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4615,"hugoSymbol":"MYD88","oncogene":true,"grch37Isoform":"ENST00000396334","grch37RefSeq":"NM_002468.4","grch38Isoform":"ENST00000396334","grch38RefSeq":"NM_002468.4","geneAliases":["MYD88D","IMD68"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4615,"hugoSymbol":"MYD88","oncogene":true,"grch37Isoform":"ENST00000396334","grch37RefSeq":"NM_002468.4","grch38Isoform":"ENST00000396334","grch38RefSeq":"NM_002468.4","geneAliases":["MYD88D","IMD68"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L265P","name":"L265P","refResidues":"L","proteinStart":265,"proteinEnd":265,"variantResidues":"P","referenceGenomes":["GRCh37"]},{"gene":{"entrezGeneId":4615,"hugoSymbol":"MYD88","oncogene":true,"grch37Isoform":"ENST00000396334","grch37RefSeq":"NM_002468.4","grch38Isoform":"ENST00000396334","grch38RefSeq":"NM_002468.4","geneAliases":["MYD88D","IMD68"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L252P","name":"L252P","refResidues":"L","proteinStart":252,"proteinEnd":252,"variantResidues":"P","referenceGenomes":["GRCh38"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"28496180","title":"Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.","journal":"Scientific reports","pubDate":"2017 May 11","volume":"7","issue":"1","pages":"1785","authors":"Lee JH et al","elocationId":"doi: 10.1038/s41598-017-01998-5","link":null,"reference":"Lee JH et al. Scientific reports. 2017 May 11;7(1)1785.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/126/23/3881","reference":"null. null. .","abstract":"Seik, et al., Abstract# Blood 126:3881, 2015"},{"pmid":"21179087","title":"Oncogenically active MYD88 mutations in human lymphoma.","journal":"Nature","pubDate":"2011 Feb 3","volume":"470","issue":"7332","pages":"115-9","authors":"Ngo VN et al","elocationId":"doi: 10.1038/nature09671","link":null,"reference":"Ngo VN et al. Nature. 2011 Feb 3;470(7332)115-9.","abstract":null}]},{"id":22898,"uuid":"f1679dd3-f6be-4102-8605-a1b93d915cfb","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":286,"subtype":"Follicular Lymphoma","code":"FL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8764,"hugoSymbol":"TNFRSF14","oncogene":false,"grch37Isoform":"ENST00000355716","grch37RefSeq":"NM_003820.2","grch38Isoform":"ENST00000355716","grch38RefSeq":"NM_003820.2","geneAliases":["HVEM","CD270","TR2","HVEA","ATAR","LIGHTR"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":8764,"hugoSymbol":"TNFRSF14","oncogene":false,"grch37Isoform":"ENST00000355716","grch37RefSeq":"NM_003820.2","grch38Isoform":"ENST00000355716","grch38RefSeq":"NM_003820.2","geneAliases":["HVEM","CD270","TR2","HVEA","ATAR","LIGHTR"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"20884631","title":"Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis.","journal":"Cancer research","pubDate":"2010 Nov 15","volume":"70","issue":"22","pages":"9166-74","authors":"Cheung KJ et al","elocationId":"doi: 10.1158/0008-5472.CAN-10-2460","link":null,"reference":"Cheung KJ et al. Cancer research. 2010 Nov 15;70(22)9166-74.","abstract":null},{"pmid":"21941365","title":"High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis.","journal":"Leukemia","pubDate":"2012 Mar","volume":"26","issue":"3","pages":"559-62","authors":"Launay E et al","elocationId":"doi: 10.1038/leu.2011.266","link":null,"reference":"Launay E et al. Leukemia. 2012 Mar;26(3)559-62.","abstract":null},{"pmid":"23297126","title":"Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.","journal":"Blood","pubDate":"2013 Feb 28","volume":"121","issue":"9","pages":"1604-11","authors":"Green MR et al","elocationId":"doi: 10.1182/blood-2012-09-457283","link":null,"reference":"Green MR et al. Blood. 2013 Feb 28;121(9)1604-11.","abstract":null}]},{"id":20597,"uuid":"2fa8f10f-aff4-4cac-98fa-3ba8a92bd6fb","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5649,"hugoSymbol":"RELN","oncogene":false,"grch37Isoform":"ENST00000428762","grch37RefSeq":"NM_005045.3","grch38Isoform":"ENST00000428762","grch38RefSeq":"NM_005045.3","geneAliases":["PRO1598","ETL7","RL","LIS2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5649,"hugoSymbol":"RELN","oncogene":false,"grch37Isoform":"ENST00000428762","grch37RefSeq":"NM_005045.3","grch38Isoform":"ENST00000428762","grch38RefSeq":"NM_005045.3","geneAliases":["PRO1598","ETL7","RL","LIS2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":16245,"uuid":"01e88247-c97b-4374-9748-28c839288dff","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":588,"subtype":"Primary Cutaneous DLBCL, Leg Type","code":"PCLBCLLT","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4615,"hugoSymbol":"MYD88","oncogene":true,"grch37Isoform":"ENST00000396334","grch37RefSeq":"NM_002468.4","grch38Isoform":"ENST00000396334","grch38RefSeq":"NM_002468.4","geneAliases":["MYD88D","IMD68"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4615,"hugoSymbol":"MYD88","oncogene":true,"grch37Isoform":"ENST00000396334","grch37RefSeq":"NM_002468.4","grch38Isoform":"ENST00000396334","grch38RefSeq":"NM_002468.4","geneAliases":["MYD88D","IMD68"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L265P","name":"L265P","refResidues":"L","proteinStart":265,"proteinEnd":265,"variantResidues":"P","referenceGenomes":["GRCh37"]},{"gene":{"entrezGeneId":4615,"hugoSymbol":"MYD88","oncogene":true,"grch37Isoform":"ENST00000396334","grch37RefSeq":"NM_002468.4","grch38Isoform":"ENST00000396334","grch38RefSeq":"NM_002468.4","geneAliases":["MYD88D","IMD68"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L252P","name":"L252P","refResidues":"L","proteinStart":252,"proteinEnd":252,"variantResidues":"P","referenceGenomes":["GRCh38"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27189828","title":"MYD88 Somatic Mutation Is a Diagnostic Criterion in Primary Cutaneous Large B-Cell Lymphoma.","journal":"The Journal of investigative dermatology","pubDate":"2016 Aug","volume":"136","issue":"8","pages":"1741-1744","authors":"Menguy S et al","elocationId":"doi: 10.1016/j.jid.2016.04.018","link":null,"reference":"Menguy S et al. The Journal of investigative dermatology. 2016 Aug;136(8)1741-1744.","abstract":null},{"pmid":"25055137","title":"High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.","journal":"JAMA dermatology","pubDate":"2014 Nov","volume":"150","issue":"11","pages":"1173-9","authors":"Pham-Ledard A et al","elocationId":"doi: 10.1001/jamadermatol.2014.821","link":null,"reference":"Pham-Ledard A et al. JAMA dermatology. 2014 Nov;150(11)1173-9.","abstract":null}]},{"id":16247,"uuid":"16963640-782d-4dfa-979a-8c587cf94b21","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":726,"subtype":"Primary DLBCL of the central nervous system","code":"PCNSL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4615,"hugoSymbol":"MYD88","oncogene":true,"grch37Isoform":"ENST00000396334","grch37RefSeq":"NM_002468.4","grch38Isoform":"ENST00000396334","grch38RefSeq":"NM_002468.4","geneAliases":["MYD88D","IMD68"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4615,"hugoSymbol":"MYD88","oncogene":true,"grch37Isoform":"ENST00000396334","grch37RefSeq":"NM_002468.4","grch38Isoform":"ENST00000396334","grch38RefSeq":"NM_002468.4","geneAliases":["MYD88D","IMD68"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L265P","name":"L265P","refResidues":"L","proteinStart":265,"proteinEnd":265,"variantResidues":"P","referenceGenomes":["GRCh37"]},{"gene":{"entrezGeneId":4615,"hugoSymbol":"MYD88","oncogene":true,"grch37Isoform":"ENST00000396334","grch37RefSeq":"NM_002468.4","grch38Isoform":"ENST00000396334","grch38RefSeq":"NM_002468.4","geneAliases":["MYD88D","IMD68"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L252P","name":"L252P","refResidues":"L","proteinStart":252,"proteinEnd":252,"variantResidues":"P","referenceGenomes":["GRCh38"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22020631","title":"Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.","journal":"Acta neuropathologica","pubDate":"2011 Dec","volume":"122","issue":"6","pages":"791-2","authors":"Montesinos-Rongen M et al","elocationId":"doi: 10.1007/s00401-011-0891-2","link":null,"reference":"Montesinos-Rongen M et al. Acta neuropathologica. 2011 Dec;122(6)791-2.","abstract":null}]},{"id":21368,"uuid":"efc3901f-2ff7-468d-879d-e5670d73071d","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":533,"subtype":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","code":"CLLSLL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":23451,"hugoSymbol":"SF3B1","oncogene":true,"grch37Isoform":"ENST00000335508","grch37RefSeq":"NM_012433.2","grch38Isoform":"ENST00000335508","grch38RefSeq":"NM_012433.2","geneAliases":["PRP10","SAP155","Hsh155","PRPF10","SF3b155"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"26200345","title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia.","journal":"Nature","pubDate":"2015 Oct 22","volume":"526","issue":"7574","pages":"519-24","authors":"Puente XS et al","elocationId":"doi: 10.1038/nature14666","link":null,"reference":"Puente XS et al. Nature. 2015 Oct 22;526(7574)519-24.","abstract":null},{"pmid":"22039264","title":"Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.","journal":"Blood","pubDate":"2011 Dec 22","volume":"118","issue":"26","pages":"6904-8","authors":"Rossi D et al","elocationId":"doi: 10.1182/blood-2011-08-373159","link":null,"reference":"Rossi D et al. Blood. 2011 Dec 22;118(26)6904-8.","abstract":null},{"pmid":"26466571","title":"Mutations driving CLL and their evolution in progression and relapse.","journal":"Nature","pubDate":"2015 Oct 22","volume":"526","issue":"7574","pages":"525-30","authors":"Landau DA et al","elocationId":"doi: 10.1038/nature15395","link":null,"reference":"Landau DA et al. Nature. 2015 Oct 22;526(7574)525-30.","abstract":null},{"pmid":"22150006","title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.","journal":"The New England journal of medicine","pubDate":"2011 Dec 29","volume":"365","issue":"26","pages":"2497-506","authors":"Wang L et al","elocationId":"doi: 10.1056/NEJMoa1109016","link":null,"reference":"Wang L et al. The New England journal of medicine. 2011 Dec 29;365(26)2497-506.","abstract":null},{"pmid":"23415222","title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.","journal":"Cell","pubDate":"2013 Feb 14","volume":"152","issue":"4","pages":"714-26","authors":"Landau DA et al","elocationId":"doi: 10.1016/j.cell.2013.01.019","link":null,"reference":"Landau DA et al. Cell. 2013 Feb 14;152(4)714-26.","abstract":null},{"pmid":"24550227","title":"Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.","journal":"Blood","pubDate":"2014 Apr 10","volume":"123","issue":"15","pages":"2378-88","authors":"Messina M et al","elocationId":"doi: 10.1182/blood-2013-10-534271","link":null,"reference":"Messina M et al. Blood. 2014 Apr 10;123(15)2378-88.","abstract":null}]},{"id":11259,"uuid":"a961c23d-c59f-42e2-a9ed-3396abf568cb","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2625,"hugoSymbol":"GATA3","oncogene":true,"grch37Isoform":"ENST00000346208","grch37RefSeq":"NM_002051.2","grch38Isoform":"ENST00000346208","grch38RefSeq":"NM_002051.2","geneAliases":["HDR","HDRS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":2625,"hugoSymbol":"GATA3","oncogene":true,"grch37Isoform":"ENST00000346208","grch37RefSeq":"NM_002051.2","grch38Isoform":"ENST00000346208","grch38RefSeq":"NM_002051.2","geneAliases":["HDR","HDRS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":1919,"uuid":"082e2764-0625-47a6-aa8e-f3f65cef2ac5","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":490,"subtype":"Diffuse Large B-Cell Lymphoma, NOS","code":"DLBCLNOS","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":604,"hugoSymbol":"BCL6","oncogene":true,"grch37Isoform":"ENST00000232014","grch37RefSeq":"NM_001706.4","grch38Isoform":"ENST00000232014","grch38RefSeq":"NM_001706.4","geneAliases":["BCL5","ZBTB27","ZNF51","BCL6A","LAZ3"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":604,"hugoSymbol":"BCL6","oncogene":true,"grch37Isoform":"ENST00000232014","grch37RefSeq":"NM_001706.4","grch38Isoform":"ENST00000232014","grch38RefSeq":"NM_001706.4","geneAliases":["BCL5","ZBTB27","ZNF51","BCL6A","LAZ3"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"8167331","title":"LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients.","journal":"Blood","pubDate":"1994 May 1","volume":"83","issue":"9","pages":"2423-7","authors":"Bastard C et al","elocationId":"","link":null,"reference":"Bastard C et al. Blood. 1994 May 1;83(9)2423-7.","abstract":null},{"pmid":"17625604","title":"Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.","journal":"Leukemia","pubDate":"2007 Nov","volume":"21","issue":"11","pages":"2332-43","authors":"Iqbal J et al","elocationId":"","link":null,"reference":"Iqbal J et al. Leukemia. 2007 Nov;21(11)2332-43.","abstract":null},{"pmid":"11972514","title":"Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma.","journal":"British journal of haematology","pubDate":"2002 May","volume":"117","issue":"2","pages":"322-32","authors":"Barrans SL et al","elocationId":"","link":null,"reference":"Barrans SL et al. British journal of haematology. 2002 May;117(2)322-32.","abstract":null},{"pmid":"12389616","title":"Non-immunoglobulin/BCL6 gene fusion in diffuse large B-cell lymphoma: prognostic implications.","journal":"Leukemia & lymphoma","pubDate":"2002 Jul","volume":"43","issue":"7","pages":"1375-81","authors":"Ueda C et al","elocationId":"","link":null,"reference":"Ueda C et al. Leukemia & lymphoma. 2002 Jul;43(7)1375-81.","abstract":null},{"pmid":"19797725","title":"Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.","journal":"Haematologica","pubDate":"2010 Jan","volume":"95","issue":"1","pages":"96-101","authors":"Shustik J et al","elocationId":"doi: 10.3324/haematol.2009.007203","link":null,"reference":"Shustik J et al. Haematologica. 2010 Jan;95(1)96-101.","abstract":null},{"pmid":"11023530","title":"Nonimmunoglobulin (non-Ig)/BCL6 gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/BCL6.","journal":"Blood","pubDate":"2000 Oct 15","volume":"96","issue":"8","pages":"2907-9","authors":"Akasaka T et al","elocationId":"","link":null,"reference":"Akasaka T et al. Blood. 2000 Oct 15;96(8)2907-9.","abstract":null},{"pmid":"8208268","title":"Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma.","journal":"The New England journal of medicine","pubDate":"1994 Jul 14","volume":"331","issue":"2","pages":"74-80","authors":"Offit K et al","elocationId":"","link":null,"reference":"Offit K et al. The New England journal of medicine. 1994 Jul 14;331(2)74-80.","abstract":null},{"pmid":"14504078","title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.","journal":"Blood","pubDate":"2004 Jan 1","volume":"103","issue":"1","pages":"275-82","authors":"Hans CP et al","elocationId":"","link":null,"reference":"Hans CP et al. Blood. 2004 Jan 1;103(1)275-82.","abstract":null},{"pmid":"11493437","title":"Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.","journal":"Blood","pubDate":"2001 Aug 15","volume":"98","issue":"4","pages":"945-51","authors":"Lossos IS et al","elocationId":"","link":null,"reference":"Lossos IS et al. Blood. 2001 Aug 15;98(4)945-51.","abstract":null}]},{"id":13186,"uuid":"da98783a-6dcb-4937-b629-b83a74dbb440","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":22531,"uuid":"2d530175-b645-4ffd-bfbe-6abf2a4b6c8b","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":23512,"hugoSymbol":"SUZ12","oncogene":false,"grch37Isoform":"ENST00000322652","grch37RefSeq":"NM_015355.2","grch38Isoform":"ENST00000322652","grch38RefSeq":"NM_015355.2","geneAliases":["IMMAS","CHET9","JJAZ1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":23512,"hugoSymbol":"SUZ12","oncogene":false,"grch37Isoform":"ENST00000322652","grch37RefSeq":"NM_015355.2","grch38Isoform":"ENST00000322652","grch38RefSeq":"NM_015355.2","geneAliases":["IMMAS","CHET9","JJAZ1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":9732,"uuid":"3cb9eaf1-c2e9-4829-bb75-35904217f4bd","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2120,"hugoSymbol":"ETV6","oncogene":false,"grch37Isoform":"ENST00000396373","grch37RefSeq":"NM_001987.4","grch38Isoform":"ENST00000396373","grch38RefSeq":"NM_001987.4","geneAliases":["THC5","TEL/ABL","TEL"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":2120,"hugoSymbol":"ETV6","oncogene":false,"grch37Isoform":"ENST00000396373","grch37RefSeq":"NM_001987.4","grch38Isoform":"ENST00000396373","grch38RefSeq":"NM_001987.4","geneAliases":["THC5","TEL/ABL","TEL"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":5892,"uuid":"0b8fdbfc-c7e4-44b5-879a-c1efbb88f8ec","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":490,"subtype":"Diffuse Large B-Cell Lymphoma, NOS","code":"DLBCLNOS","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1387,"hugoSymbol":"CREBBP","oncogene":false,"grch37Isoform":"ENST00000262367","grch37RefSeq":"NM_004380.2","grch38Isoform":"ENST00000262367","grch38RefSeq":"NM_004380.2","geneAliases":["MKHK1","KAT3A","RSTS","RSTS1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":1387,"hugoSymbol":"CREBBP","oncogene":false,"grch37Isoform":"ENST00000262367","grch37RefSeq":"NM_004380.2","grch38Isoform":"ENST00000262367","grch38RefSeq":"NM_004380.2","geneAliases":["MKHK1","KAT3A","RSTS","RSTS1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"28302137","title":"Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.","journal":"Journal of hematology & oncology","pubDate":"2017 Mar 17","volume":"10","issue":"1","pages":"70","authors":"Juskevicius D et al","elocationId":"doi: 10.1186/s13045-017-0438-7","link":null,"reference":"Juskevicius D et al. Journal of hematology & oncology. 2017 Mar 17;10(1)70.","abstract":null},{"pmid":"21390126","title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma.","journal":"Nature","pubDate":"2011 Mar 10","volume":"471","issue":"7337","pages":"189-95","authors":"Pasqualucci L et al","elocationId":"doi: 10.1038/nature09730","link":null,"reference":"Pasqualucci L et al. Nature. 2011 Mar 10;471(7337)189-95.","abstract":null}]},{"id":13572,"uuid":"f0879c12-df4a-41f1-9e75-ec8da227ca27","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":388,"subtype":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT lymphoma)","code":"EMALT","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":6,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":10892,"hugoSymbol":"MALT1","oncogene":false,"grch37Isoform":"ENST00000348428","grch37RefSeq":"NM_006785.3","grch38Isoform":"ENST00000649217","grch38RefSeq":"NM_006785.3","geneAliases":["MLT","PCASP1","MLT1","IMD12"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":10892,"hugoSymbol":"MALT1","oncogene":false,"grch37Isoform":"ENST00000348428","grch37RefSeq":"NM_006785.3","grch38Isoform":"ENST00000649217","grch38RefSeq":"NM_006785.3","geneAliases":["MLT","PCASP1","MLT1","IMD12"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BIRC3-MALT1 Fusion","name":"BIRC3-MALT1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"9989495","title":"Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types.","journal":"Cell","pubDate":"1999 Jan 8","volume":"96","issue":"1","pages":"35-45","authors":"Willis TG et al","elocationId":"","link":null,"reference":"Willis TG et al. Cell. 1999 Jan 8;96(1)35-45.","abstract":null},{"pmid":"17122510","title":"The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America.","journal":"The American journal of surgical pathology","pubDate":"2006 Dec","volume":"30","issue":"12","pages":"1546-53","authors":"Remstein ED et al","elocationId":"","link":null,"reference":"Remstein ED et al. The American journal of surgical pathology. 2006 Dec;30(12)1546-53.","abstract":null},{"pmid":"18927281","title":"Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2008 Oct 15","volume":"14","issue":"20","pages":"6426-31","authors":"Vinatzer U et al","elocationId":"doi: 10.1158/1078-0432.CCR-08-0702","link":null,"reference":"Vinatzer U et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Oct 15;14(20)6426-31.","abstract":null},{"pmid":"14760068","title":"Frequency of chromosomal aberrations involving MALT1 in mucosa-associated lymphoid tissue lymphoma in patients with Sjögren's syndrome.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2004 Jan 15","volume":"10","issue":"2","pages":"476-80","authors":"Streubel B et al","elocationId":"","link":null,"reference":"Streubel B et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Jan 15;10(2)476-80.","abstract":null},{"pmid":"12499431","title":"Chromosomal translocation t(11;18)(q21;q21) in gastrointestinal mucosa associated lymphoid tissue lymphoma.","journal":"Journal of clinical pathology","pubDate":"2003 Jan","volume":"56","issue":"1","pages":"36-42","authors":"Nakamura S et al","elocationId":"","link":null,"reference":"Nakamura S et al. Journal of clinical pathology. 2003 Jan;56(1)36-42.","abstract":null}]},{"id":19716,"uuid":"f90abca7-49a6-4bac-b6c3-e999c5ffd025","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":293,"subtype":"T-Lymphoblastic Leukemia/Lymphoma","code":"TLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5728,"hugoSymbol":"PTEN","oncogene":false,"grch37Isoform":"ENST00000371953","grch37RefSeq":"NM_000314.4","grch38Isoform":"ENST00000371953","grch38RefSeq":"NM_000314.4","geneAliases":["DEC","MHAM","TEP1","BZS","PTEN1","GLM2","PTENbeta","CWS1","MMAC1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":5728,"hugoSymbol":"PTEN","oncogene":false,"grch37Isoform":"ENST00000371953","grch37RefSeq":"NM_000314.4","grch38Isoform":"ENST00000371953","grch38RefSeq":"NM_000314.4","geneAliases":["DEC","MHAM","TEP1","BZS","PTEN1","GLM2","PTENbeta","CWS1","MMAC1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"19458356","title":"High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.","journal":"Blood","pubDate":"2009 Jul 16","volume":"114","issue":"3","pages":"647-50","authors":"Gutierrez A et al","elocationId":"doi: 10.1182/blood-2009-02-206722","link":null,"reference":"Gutierrez A et al. Blood. 2009 Jul 16;114(3)647-50.","abstract":null},{"pmid":"19340001","title":"The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.","journal":"Leukemia","pubDate":"2009 Aug","volume":"23","issue":"8","pages":"1417-25","authors":"Larson Gedman A et al","elocationId":"doi: 10.1038/leu.2009.64","link":null,"reference":"Larson Gedman A et al. Leukemia. 2009 Aug;23(8)1417-25.","abstract":null},{"pmid":"22491738","title":"The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.","journal":"Haematologica","pubDate":"2012 Sep","volume":"97","issue":"9","pages":"1405-13","authors":"Zuurbier L et al","elocationId":"doi: 10.3324/haematol.2011.059030","link":null,"reference":"Zuurbier L et al. Haematologica. 2012 Sep;97(9)1405-13.","abstract":null}]},{"id":5894,"uuid":"9352751a-bd71-4e18-9836-17d44e425d10","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":286,"subtype":"Follicular Lymphoma","code":"FL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1387,"hugoSymbol":"CREBBP","oncogene":false,"grch37Isoform":"ENST00000262367","grch37RefSeq":"NM_004380.2","grch38Isoform":"ENST00000262367","grch38RefSeq":"NM_004380.2","geneAliases":["MKHK1","KAT3A","RSTS","RSTS1"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":1387,"hugoSymbol":"CREBBP","oncogene":false,"grch37Isoform":"ENST00000262367","grch37RefSeq":"NM_004380.2","grch38Isoform":"ENST00000262367","grch38RefSeq":"NM_004380.2","geneAliases":["MKHK1","KAT3A","RSTS","RSTS1"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24362818","title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.","journal":"Nature genetics","pubDate":"2014 Feb","volume":"46","issue":"2","pages":"176-181","authors":"Okosun J et al","elocationId":"doi: 10.1038/ng.2856","link":null,"reference":"Okosun J et al. Nature genetics. 2014 Feb;46(2)176-181.","abstract":null},{"pmid":"25713363","title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.","journal":"Proceedings of the National Academy of Sciences of the United States of America","pubDate":"2015 Mar 10","volume":"112","issue":"10","pages":"E1116-25","authors":"Green MR et al","elocationId":"doi: 10.1073/pnas.1501199112","link":null,"reference":"Green MR et al. Proceedings of the National Academy of Sciences of the United States of America. 2015 Mar 10;112(10)E1116-25.","abstract":null}]},{"id":13576,"uuid":"d8876a78-7423-42cc-ae2c-602b7809383b","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":388,"subtype":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT lymphoma)","code":"EMALT","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":6,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":10892,"hugoSymbol":"MALT1","oncogene":false,"grch37Isoform":"ENST00000348428","grch37RefSeq":"NM_006785.3","grch38Isoform":"ENST00000649217","grch38RefSeq":"NM_006785.3","geneAliases":["MLT","PCASP1","MLT1","IMD12"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":10892,"hugoSymbol":"MALT1","oncogene":false,"grch37Isoform":"ENST00000348428","grch37RefSeq":"NM_006785.3","grch38Isoform":"ENST00000649217","grch38RefSeq":"NM_006785.3","geneAliases":["MLT","PCASP1","MLT1","IMD12"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"IGH-MALT1 Fusion","name":"IGH-MALT1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"17906071","title":"Gastric MALT lymphoma with t(14;18)(q32;q21) involving IGH and BCL2 genes that responded to Helicobacter pylori eradication.","journal":"Journal of clinical pathology","pubDate":"2007 Oct","volume":"60","issue":"10","pages":"1171-3","authors":"Nakamura S et al","elocationId":"","link":null,"reference":"Nakamura S et al. Journal of clinical pathology. 2007 Oct;60(10)1171-3.","abstract":null},{"pmid":"15682443","title":"MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression.","journal":"The Journal of pathology","pubDate":"2005 Feb","volume":"205","issue":"3","pages":"293-301","authors":"Ye H et al","elocationId":"","link":null,"reference":"Ye H et al. The Journal of pathology. 2005 Feb;205(3)293-301.","abstract":null},{"pmid":"1535664","title":"Palmoplantar hyperkeratosis and deafness.","journal":"Journal of medical genetics","pubDate":"1992 Jun","volume":"29","issue":"6","pages":"440","authors":"Verbov J","elocationId":"","link":null,"reference":"Verbov J. Journal of medical genetics. 1992 Jun;29(6)440.","abstract":null},{"pmid":"17122510","title":"The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America.","journal":"The American journal of surgical pathology","pubDate":"2006 Dec","volume":"30","issue":"12","pages":"1546-53","authors":"Remstein ED et al","elocationId":"","link":null,"reference":"Remstein ED et al. The American journal of surgical pathology. 2006 Dec;30(12)1546-53.","abstract":null},{"pmid":"18927281","title":"Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2008 Oct 15","volume":"14","issue":"20","pages":"6426-31","authors":"Vinatzer U et al","elocationId":"doi: 10.1158/1078-0432.CCR-08-0702","link":null,"reference":"Vinatzer U et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Oct 15;14(20)6426-31.","abstract":null},{"pmid":"14760068","title":"Frequency of chromosomal aberrations involving MALT1 in mucosa-associated lymphoid tissue lymphoma in patients with Sjögren's syndrome.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2004 Jan 15","volume":"10","issue":"2","pages":"476-80","authors":"Streubel B et al","elocationId":"","link":null,"reference":"Streubel B et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Jan 15;10(2)476-80.","abstract":null}]},{"id":11913,"uuid":"11161716-e32a-41ab-83e2-a2fab6495e01","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3575,"hugoSymbol":"IL7R","oncogene":true,"grch37Isoform":"ENST00000303115","grch37RefSeq":"NM_002185.3","grch38Isoform":"ENST00000303115","grch38RefSeq":"NM_002185.3","geneAliases":["ILRA","IL-7R-alpha","CD127","CDW127","IL7RA"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3575,"hugoSymbol":"IL7R","oncogene":true,"grch37Isoform":"ENST00000303115","grch37RefSeq":"NM_002185.3","grch38Isoform":"ENST00000303115","grch38RefSeq":"NM_002185.3","geneAliases":["ILRA","IL-7R-alpha","CD127","CDW127","IL7RA"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":1802,"uuid":"e84c0bf2-1b98-44bd-b03e-66a8644ea873","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":388,"subtype":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT lymphoma)","code":"EMALT","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":6,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8915,"hugoSymbol":"BCL10","oncogene":false,"grch37Isoform":"ENST00000370580","grch37RefSeq":"NM_003921.4","grch38Isoform":"ENST00000648566","grch38RefSeq":"NM_003921.4","geneAliases":["c-E10","CIPER","mE10","CLAP","IMD37","CARMEN"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":8915,"hugoSymbol":"BCL10","oncogene":false,"grch37Isoform":"ENST00000370580","grch37RefSeq":"NM_003921.4","grch38Isoform":"ENST00000648566","grch38RefSeq":"NM_003921.4","geneAliases":["c-E10","CIPER","mE10","CLAP","IMD37","CARMEN"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"IGH-BCL10 Fusion","name":"IGH-BCL10 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"9989495","title":"Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types.","journal":"Cell","pubDate":"1999 Jan 8","volume":"96","issue":"1","pages":"35-45","authors":"Willis TG et al","elocationId":"","link":null,"reference":"Willis TG et al. Cell. 1999 Jan 8;96(1)35-45.","abstract":null},{"pmid":"15356642","title":"Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites.","journal":"Leukemia","pubDate":"2004 Oct","volume":"18","issue":"10","pages":"1722-6","authors":"Streubel B et al","elocationId":"","link":null,"reference":"Streubel B et al. Leukemia. 2004 Oct;18(10)1722-6.","abstract":null},{"pmid":"17122510","title":"The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America.","journal":"The American journal of surgical pathology","pubDate":"2006 Dec","volume":"30","issue":"12","pages":"1546-53","authors":"Remstein ED et al","elocationId":"","link":null,"reference":"Remstein ED et al. The American journal of surgical pathology. 2006 Dec;30(12)1546-53.","abstract":null},{"pmid":"18927281","title":"Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2008 Oct 15","volume":"14","issue":"20","pages":"6426-31","authors":"Vinatzer U et al","elocationId":"doi: 10.1158/1078-0432.CCR-08-0702","link":null,"reference":"Vinatzer U et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Oct 15;14(20)6426-31.","abstract":null}]},{"id":11021,"uuid":"01495f28-a10c-426e-8403-51b14b5e7ffb","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":6542,"uuid":"3fc67660-6aa4-424d-85ee-8fbe19c25cc8","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":345930,"hugoSymbol":"ECT2L","oncogene":false,"grch37Isoform":"ENST00000367682","grch37RefSeq":"NM_001077706.2","grch38Isoform":"ENST00000367682","grch38RefSeq":"NM_001077706.2","geneAliases":["C6orf91","ARHGEF32","dJ509I19.5","FBXO49","dJ509I19.2","LFDH","dJ509I19.3"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":345930,"hugoSymbol":"ECT2L","oncogene":false,"grch37Isoform":"ENST00000367682","grch37RefSeq":"NM_001077706.2","grch38Isoform":"ENST00000367682","grch38RefSeq":"NM_001077706.2","geneAliases":["C6orf91","ARHGEF32","dJ509I19.5","FBXO49","dJ509I19.2","LFDH","dJ509I19.3"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":12050,"uuid":"6015d658-d10c-40af-aedd-f37f4ef14879","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3716,"hugoSymbol":"JAK1","oncogene":true,"grch37Isoform":"ENST00000342505","grch37RefSeq":"NM_002227.2","grch38Isoform":"ENST00000342505","grch38RefSeq":"NM_002227.2","geneAliases":["JTK3","AIIDE","JAK1B","JAK1A"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":3716,"hugoSymbol":"JAK1","oncogene":true,"grch37Isoform":"ENST00000342505","grch37RefSeq":"NM_002227.2","grch38Isoform":"ENST00000342505","grch38RefSeq":"NM_002227.2","geneAliases":["JTK3","AIIDE","JAK1B","JAK1A"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":13586,"uuid":"567c727c-4dfe-46f3-9695-c56faeb23fbb","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":862,"subtype":"Langerhans Cell Histiocytosis","code":"LCH","color":"LightSalmon","mainType":"Histiocytosis","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5604,"hugoSymbol":"MAP2K1","oncogene":true,"grch37Isoform":"ENST00000307102","grch37RefSeq":"NM_002755.3","grch38Isoform":"ENST00000307102","grch38RefSeq":"NM_002755.3","geneAliases":["MKK1","PRKMK1","MEL","MEK1","MAPKK1","CFC3"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5604,"hugoSymbol":"MAP2K1","oncogene":true,"grch37Isoform":"ENST00000307102","grch37RefSeq":"NM_002755.3","grch38Isoform":"ENST00000307102","grch38RefSeq":"NM_002755.3","geneAliases":["MKK1","PRKMK1","MEL","MEK1","MAPKK1","CFC3"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25202140","title":"Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.","journal":"Blood","pubDate":"2014 Nov 6","volume":"124","issue":"19","pages":"3007-15","authors":"Chakraborty R et al","elocationId":"doi: 10.1182/blood-2014-05-577825","link":null,"reference":"Chakraborty R et al. Blood. 2014 Nov 6;124(19)3007-15.","abstract":null},{"pmid":"26637772","title":"Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.","journal":"Hematology. American Society of Hematology. Education Program","pubDate":"2015","volume":"2015","issue":"","pages":"559-64","authors":"Allen CE et al","elocationId":"doi: 10.1182/asheducation-2015.1.559","link":null,"reference":"Allen CE et al. Hematology. American Society of Hematology. Education Program. 2015;2015()559-64.","abstract":null}]},{"id":4885,"uuid":"7968264f-69fa-4239-b96a-6abbabba41a9","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":490,"subtype":"Diffuse Large B-Cell Lymphoma, NOS","code":"DLBCLNOS","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":84433,"hugoSymbol":"CARD11","oncogene":true,"grch37Isoform":"ENST00000396946","grch37RefSeq":"NM_032415.4","grch38Isoform":"ENST00000396946","grch38RefSeq":"NM_032415.4","geneAliases":["CARMA1","IMD11","BENTA","BIMP3","IMD11A","PPBL"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":84433,"hugoSymbol":"CARD11","oncogene":true,"grch37Isoform":"ENST00000396946","grch37RefSeq":"NM_032415.4","grch38Isoform":"ENST00000396946","grch38RefSeq":"NM_032415.4","geneAliases":["CARMA1","IMD11","BENTA","BIMP3","IMD11A","PPBL"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"20054396","title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.","journal":"Nature","pubDate":"2010 Jan 7","volume":"463","issue":"7277","pages":"88-92","authors":"Davis RE et al","elocationId":"doi: 10.1038/nature08638","link":null,"reference":"Davis RE et al. Nature. 2010 Jan 7;463(7277)88-92.","abstract":null},{"pmid":"21796119","title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.","journal":"Nature","pubDate":"2011 Jul 27","volume":"476","issue":"7360","pages":"298-303","authors":"Morin RD et al","elocationId":"doi: 10.1038/nature10351","link":null,"reference":"Morin RD et al. Nature. 2011 Jul 27;476(7360)298-303.","abstract":null}]},{"id":2071,"uuid":"46b031e3-4ae9-418b-8b17-3a6acfd197d8","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":23577,"uuid":"da3afbaf-1822-4f21-b1fa-38bf1038fcf9","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":160,"subtype":"Anaplastic Large-Cell Lymphoma ALK Negative","code":"ALCLALKN","color":"LimeGreen","mainType":"Mature T and NK Neoplasms","level":6,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8626,"hugoSymbol":"TP63","oncogene":true,"grch37Isoform":"ENST00000264731","grch37RefSeq":"NM_003722.4","grch38Isoform":"ENST00000264731","grch38RefSeq":"NM_003722.4","geneAliases":["OFC8","SHFM4","p63","B(p51B)","p51","B(p51A)","p73H","EEC3","TP53CP","TP73L","LMS","p73L","TP53L","p53CP","KET","RHS","NBP"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":8626,"hugoSymbol":"TP63","oncogene":true,"grch37Isoform":"ENST00000264731","grch37RefSeq":"NM_003722.4","grch38Isoform":"ENST00000264731","grch38RefSeq":"NM_003722.4","geneAliases":["OFC8","SHFM4","p63","B(p51B)","p51","B(p51A)","p73H","EEC3","TP53CP","TP73L","LMS","p73L","TP53L","p53CP","KET","RHS","NBP"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22855598","title":"Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.","journal":"Blood","pubDate":"2012 Sep 13","volume":"120","issue":"11","pages":"2280-9","authors":"Vasmatzis G et al","elocationId":"doi: 10.1182/blood-2012-03-419937","link":null,"reference":"Vasmatzis G et al. Blood. 2012 Sep 13;120(11)2280-9.","abstract":null},{"pmid":"26104084","title":"Genetics of anaplastic large cell lymphoma.","journal":"Leukemia & lymphoma","pubDate":"2016","volume":"57","issue":"1","pages":"21-7","authors":"Zeng Y et al","elocationId":"doi: 10.3109/10428194.2015.1064530","link":null,"reference":"Zeng Y et al. Leukemia & lymphoma. 2016;57(1)21-7.","abstract":null},{"pmid":"24894770","title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.","journal":"Blood","pubDate":"2014 Aug 28","volume":"124","issue":"9","pages":"1473-80","authors":"Parrilla Castellar ER et al","elocationId":"doi: 10.1182/blood-2014-04-571091","link":null,"reference":"Parrilla Castellar ER et al. Blood. 2014 Aug 28;124(9)1473-80.","abstract":null}]},{"id":6559,"uuid":"003ebce0-7ed2-4bfa-9237-ebf87c4cf87d","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8726,"hugoSymbol":"EED","oncogene":false,"grch37Isoform":"ENST00000263360","grch37RefSeq":"NM_003797.3","grch38Isoform":"ENST00000263360","grch38RefSeq":"NM_003797.3","geneAliases":["COGIS","WAIT1","HEED"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":8726,"hugoSymbol":"EED","oncogene":false,"grch37Isoform":"ENST00000263360","grch37RefSeq":"NM_003797.3","grch38Isoform":"ENST00000263360","grch38RefSeq":"NM_003797.3","geneAliases":["COGIS","WAIT1","HEED"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":1823,"uuid":"8269d2a8-20e2-4c1a-b2b9-2c7bfad879cc","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":490,"subtype":"Diffuse Large B-Cell Lymphoma, NOS","code":"DLBCLNOS","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":596,"hugoSymbol":"BCL2","oncogene":true,"grch37Isoform":"ENST00000333681","grch37RefSeq":"NM_000633.2","grch38Isoform":"ENST00000333681","grch38RefSeq":"NM_000633.2","geneAliases":["Bcl-2","PPP1R50"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":596,"hugoSymbol":"BCL2","oncogene":true,"grch37Isoform":"ENST00000333681","grch37RefSeq":"NM_000633.2","grch38Isoform":"ENST00000333681","grch38RefSeq":"NM_000633.2","geneAliases":["Bcl-2","PPP1R50"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"IGH-BCL2 Fusion","name":"IGH-BCL2 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22929980","title":"Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.","journal":"Haematologica","pubDate":"2013 Feb","volume":"98","issue":"2","pages":"255-63","authors":"Visco C et al","elocationId":"doi: 10.3324/haematol.2012.066209","link":null,"reference":"Visco C et al. Haematologica. 2013 Feb;98(2)255-63.","abstract":null},{"pmid":"14504078","title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.","journal":"Blood","pubDate":"2004 Jan 1","volume":"103","issue":"1","pages":"275-82","authors":"Hans CP et al","elocationId":"","link":null,"reference":"Hans CP et al. Blood. 2004 Jan 1;103(1)275-82.","abstract":null},{"pmid":"26240231","title":"Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2015 Sep 10","volume":"33","issue":"26","pages":"2848-56","authors":"Scott DW et al","elocationId":"doi: 10.1200/JCO.2014.60.2383","link":null,"reference":"Scott DW et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Sep 10;33(26)2848-56.","abstract":null},{"pmid":"19706817","title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2009 Sep 1","volume":"15","issue":"17","pages":"5494-502","authors":"Choi WW et al","elocationId":"doi: 10.1158/1078-0432.CCR-09-0113","link":null,"reference":"Choi WW et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Sep 1;15(17)5494-502.","abstract":null},{"pmid":"11895757","title":"The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile.","journal":"Blood","pubDate":"2002 Apr 1","volume":"99","issue":"7","pages":"2285-90","authors":"Huang JZ et al","elocationId":"","link":null,"reference":"Huang JZ et al. Blood. 2002 Apr 1;99(7)2285-90.","abstract":null},{"pmid":"16418494","title":"BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2006 Feb 20","volume":"24","issue":"6","pages":"961-8","authors":"Iqbal J et al","elocationId":"","link":null,"reference":"Iqbal J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Feb 20;24(6)961-8.","abstract":null},{"pmid":"12796378","title":"The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2003 Jun","volume":"9","issue":"6","pages":"2133-9","authors":"Barrans SL et al","elocationId":"","link":null,"reference":"Barrans SL et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Jun;9(6)2133-9.","abstract":null},{"pmid":"21135273","title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2011 Jan 10","volume":"29","issue":"2","pages":"200-7","authors":"Meyer PN et al","elocationId":"doi: 10.1200/JCO.2010.30.0368","link":null,"reference":"Meyer PN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Jan 10;29(2)200-7.","abstract":null},{"pmid":"15215171","title":"BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma.","journal":"The American journal of pathology","pubDate":"2004 Jul","volume":"165","issue":"1","pages":"159-66","authors":"Iqbal J et al","elocationId":"","link":null,"reference":"Iqbal J et al. The American journal of pathology. 2004 Jul;165(1)159-66.","abstract":null}]},{"id":6432,"uuid":"e38251ba-fa15-49b7-a9b7-52213ac78d34","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":264,"subtype":"Angioimmunoblastic T-Cell Lymphoma","code":"AITL","color":"LimeGreen","mainType":"Mature T and NK Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1788,"hugoSymbol":"DNMT3A","oncogene":false,"grch37Isoform":"ENST00000264709","grch37RefSeq":"NM_022552.4","grch38Isoform":"ENST00000264709","grch38RefSeq":"NM_022552.4","geneAliases":["DNMT3A2","HESJAS","TBRS","M.HsaIIIA"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":1788,"hugoSymbol":"DNMT3A","oncogene":false,"grch37Isoform":"ENST00000264709","grch37RefSeq":"NM_022552.4","grch38Isoform":"ENST00000264709","grch38RefSeq":"NM_022552.4","geneAliases":["DNMT3A2","HESJAS","TBRS","M.HsaIIIA"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24345752","title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.","journal":"Blood","pubDate":"2014 Feb 27","volume":"123","issue":"9","pages":"1293-6","authors":"Odejide O et al","elocationId":"doi: 10.1182/blood-2013-10-531509","link":null,"reference":"Odejide O et al. Blood. 2014 Feb 27;123(9)1293-6.","abstract":null}]},{"id":6434,"uuid":"524f7e69-ceca-4a2e-ace6-6a853396aa4c","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1788,"hugoSymbol":"DNMT3A","oncogene":false,"grch37Isoform":"ENST00000264709","grch37RefSeq":"NM_022552.4","grch38Isoform":"ENST00000264709","grch38RefSeq":"NM_022552.4","geneAliases":["DNMT3A2","HESJAS","TBRS","M.HsaIIIA"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":1788,"hugoSymbol":"DNMT3A","oncogene":false,"grch37Isoform":"ENST00000264709","grch37RefSeq":"NM_022552.4","grch38Isoform":"ENST00000264709","grch38RefSeq":"NM_022552.4","geneAliases":["DNMT3A2","HESJAS","TBRS","M.HsaIIIA"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":13096,"uuid":"86de8c2f-37c4-492e-ac30-671dfa2cb77a","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":490,"subtype":"Diffuse Large B-Cell Lymphoma, NOS","code":"DLBCLNOS","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8085,"hugoSymbol":"KMT2D","oncogene":false,"grch37Isoform":"ENST00000301067","grch37RefSeq":"NM_003482.3","grch38Isoform":"ENST00000301067","grch38RefSeq":"NM_003482.3","geneAliases":["KMS","AAD10","KABUK1","MLL2","TNRC21","ALR","CAGL114"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":8085,"hugoSymbol":"KMT2D","oncogene":false,"grch37Isoform":"ENST00000301067","grch37RefSeq":"NM_003482.3","grch38Isoform":"ENST00000301067","grch38RefSeq":"NM_003482.3","geneAliases":["KMS","AAD10","KABUK1","MLL2","TNRC21","ALR","CAGL114"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/128/22/1756?sso-checked=true","reference":"null. null. .","abstract":"Huang, Y. et al. Abstract# 128:1756, 2016"}]},{"id":5801,"uuid":"65b0851b-6f1c-49fb-b17e-f4aff756a1ed","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":500,"subtype":"Classical Hodgkin Lymphoma","code":"CHL","color":"LimeGreen","mainType":"Hodgkin Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4261,"hugoSymbol":"CIITA","oncogene":false,"grch37Isoform":"ENST00000324288","grch37RefSeq":"","grch38Isoform":"ENST00000324288","grch38RefSeq":"NM_000246.3","geneAliases":["CIITAIV","C2TA","NLRA","MHC2TA"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4261,"hugoSymbol":"CIITA","oncogene":false,"grch37Isoform":"ENST00000324288","grch37RefSeq":"","grch38Isoform":"ENST00000324288","grch38RefSeq":"NM_000246.3","geneAliases":["CIITAIV","C2TA","NLRA","MHC2TA"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"21368758","title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.","journal":"Nature","pubDate":"2011 Mar 17","volume":"471","issue":"7338","pages":"377-81","authors":"Steidl C et al","elocationId":"doi: 10.1038/nature09754","link":null,"reference":"Steidl C et al. Nature. 2011 Mar 17;471(7338)377-81.","abstract":null}]},{"id":13098,"uuid":"4cf71bf3-12f1-44c8-a999-18506830df18","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":286,"subtype":"Follicular Lymphoma","code":"FL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8085,"hugoSymbol":"KMT2D","oncogene":false,"grch37Isoform":"ENST00000301067","grch37RefSeq":"NM_003482.3","grch38Isoform":"ENST00000301067","grch38RefSeq":"NM_003482.3","geneAliases":["KMS","AAD10","KABUK1","MLL2","TNRC21","ALR","CAGL114"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":8085,"hugoSymbol":"KMT2D","oncogene":false,"grch37Isoform":"ENST00000301067","grch37RefSeq":"NM_003482.3","grch38Isoform":"ENST00000301067","grch38RefSeq":"NM_003482.3","geneAliases":["KMS","AAD10","KABUK1","MLL2","TNRC21","ALR","CAGL114"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24362818","title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.","journal":"Nature genetics","pubDate":"2014 Feb","volume":"46","issue":"2","pages":"176-181","authors":"Okosun J et al","elocationId":"doi: 10.1038/ng.2856","link":null,"reference":"Okosun J et al. Nature genetics. 2014 Feb;46(2)176-181.","abstract":null},{"pmid":"25713363","title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.","journal":"Proceedings of the National Academy of Sciences of the United States of America","pubDate":"2015 Mar 10","volume":"112","issue":"10","pages":"E1116-25","authors":"Green MR et al","elocationId":"doi: 10.1073/pnas.1501199112","link":null,"reference":"Green MR et al. Proceedings of the National Academy of Sciences of the United States of America. 2015 Mar 10;112(10)E1116-25.","abstract":null},{"pmid":"26366712","title":"Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.","journal":"Nature medicine","pubDate":"2015 Oct","volume":"21","issue":"10","pages":"1190-8","authors":"Zhang J et al","elocationId":"doi: 10.1038/nm.3940","link":null,"reference":"Zhang J et al. Nature medicine. 2015 Oct;21(10)1190-8.","abstract":null}]},{"id":17707,"uuid":"823afd62-152c-4e4f-a84e-88a2a85f5f72","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":84295,"hugoSymbol":"PHF6","oncogene":false,"grch37Isoform":"ENST00000332070","grch37RefSeq":"NM_001015877.1","grch38Isoform":"ENST00000332070","grch38RefSeq":"NM_001015877.1","geneAliases":["BFLS","CENP-31","BORJ"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":84295,"hugoSymbol":"PHF6","oncogene":false,"grch37Isoform":"ENST00000332070","grch37RefSeq":"NM_001015877.1","grch38Isoform":"ENST00000332070","grch38RefSeq":"NM_001015877.1","geneAliases":["BFLS","CENP-31","BORJ"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":5803,"uuid":"9cf863ad-af57-40a4-9fa0-7385385d4c5d","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":33,"subtype":"Primary Mediastinal (Thymic) Large B-Cell Lymphoma","code":"PMBL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4261,"hugoSymbol":"CIITA","oncogene":false,"grch37Isoform":"ENST00000324288","grch37RefSeq":"","grch38Isoform":"ENST00000324288","grch38RefSeq":"NM_000246.3","geneAliases":["CIITAIV","C2TA","NLRA","MHC2TA"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4261,"hugoSymbol":"CIITA","oncogene":false,"grch37Isoform":"ENST00000324288","grch37RefSeq":"","grch38Isoform":"ENST00000324288","grch38RefSeq":"NM_000246.3","geneAliases":["CIITAIV","C2TA","NLRA","MHC2TA"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"26549456","title":"Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression.","journal":"Cell reports","pubDate":"2015 Nov 17","volume":"13","issue":"7","pages":"1418-1431","authors":"Mottok A et al","elocationId":"doi: 10.1016/j.celrep.2015.10.008","link":null,"reference":"Mottok A et al. Cell reports. 2015 Nov 17;13(7)1418-1431.","abstract":null},{"pmid":"21368758","title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.","journal":"Nature","pubDate":"2011 Mar 17","volume":"471","issue":"7338","pages":"377-81","authors":"Steidl C et al","elocationId":"doi: 10.1038/nature09754","link":null,"reference":"Steidl C et al. Nature. 2011 Mar 17;471(7338)377-81.","abstract":null}]},{"id":5166,"uuid":"fa8da16e-c2c6-4a93-afc6-3b51181ed34c","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":500,"subtype":"Classical Hodgkin Lymphoma","code":"CHL","color":"LimeGreen","mainType":"Hodgkin Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":29126,"hugoSymbol":"CD274","oncogene":true,"grch37Isoform":"ENST00000381577","grch37RefSeq":"NM_014143.3","grch38Isoform":"ENST00000381577","grch38RefSeq":"NM_014143.3","geneAliases":["B7H1","PD-L1","hPD-L1","PDCD1L1","PDCD1LG1","PDL1","B7-H"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":29126,"hugoSymbol":"CD274","oncogene":true,"grch37Isoform":"ENST00000381577","grch37RefSeq":"NM_014143.3","grch38Isoform":"ENST00000381577","grch38RefSeq":"NM_014143.3","geneAliases":["B7H1","PD-L1","hPD-L1","PDCD1L1","PDCD1LG1","PDL1","B7-H"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.5_suppl.47","reference":"null. null. .","abstract":"Goodman, H. et al., Abstract# 47, JCO, 2018"},{"pmid":"21368758","title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.","journal":"Nature","pubDate":"2011 Mar 17","volume":"471","issue":"7338","pages":"377-81","authors":"Steidl C et al","elocationId":"doi: 10.1038/nature09754","link":null,"reference":"Steidl C et al. Nature. 2011 Mar 17;471(7338)377-81.","abstract":null}]},{"id":16687,"uuid":"57e45f1b-80ba-4521-b87b-f45c5e7ea590","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":533,"subtype":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","code":"CLLSLL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4851,"hugoSymbol":"NOTCH1","oncogene":true,"grch37Isoform":"ENST00000277541","grch37RefSeq":"NM_017617.3","grch38Isoform":"ENST00000651671","grch38RefSeq":"NM_017617.5","geneAliases":["TAN1","hN1","AOVD1","AOS5"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":4851,"hugoSymbol":"NOTCH1","oncogene":true,"grch37Isoform":"ENST00000277541","grch37RefSeq":"NM_017617.3","grch38Isoform":"ENST00000651671","grch38RefSeq":"NM_017617.5","geneAliases":["TAN1","hN1","AOVD1","AOS5"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"26200345","title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia.","journal":"Nature","pubDate":"2015 Oct 22","volume":"526","issue":"7574","pages":"519-24","authors":"Puente XS et al","elocationId":"doi: 10.1038/nature14666","link":null,"reference":"Puente XS et al. Nature. 2015 Oct 22;526(7574)519-24.","abstract":null},{"pmid":"21670202","title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.","journal":"The Journal of experimental medicine","pubDate":"2011 Jul 4","volume":"208","issue":"7","pages":"1389-401","authors":"Fabbri G et al","elocationId":"doi: 10.1084/jem.20110921","link":null,"reference":"Fabbri G et al. The Journal of experimental medicine. 2011 Jul 4;208(7)1389-401.","abstract":null},{"pmid":"22077063","title":"Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.","journal":"Blood","pubDate":"2012 Jan 12","volume":"119","issue":"2","pages":"521-9","authors":"Rossi D et al","elocationId":"doi: 10.1182/blood-2011-09-379966","link":null,"reference":"Rossi D et al. Blood. 2012 Jan 12;119(2)521-9.","abstract":null},{"pmid":"22150006","title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.","journal":"The New England journal of medicine","pubDate":"2011 Dec 29","volume":"365","issue":"26","pages":"2497-506","authors":"Wang L et al","elocationId":"doi: 10.1056/NEJMoa1109016","link":null,"reference":"Wang L et al. The New England journal of medicine. 2011 Dec 29;365(26)2497-506.","abstract":null},{"pmid":"24550227","title":"Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.","journal":"Blood","pubDate":"2014 Apr 10","volume":"123","issue":"15","pages":"2378-88","authors":"Messina M et al","elocationId":"doi: 10.1182/blood-2013-10-534271","link":null,"reference":"Messina M et al. Blood. 2014 Apr 10;123(15)2378-88.","abstract":null}]},{"id":5168,"uuid":"ee427e2d-5b67-4edd-b47f-b1cb28bc9e08","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":33,"subtype":"Primary Mediastinal (Thymic) Large B-Cell Lymphoma","code":"PMBL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":29126,"hugoSymbol":"CD274","oncogene":true,"grch37Isoform":"ENST00000381577","grch37RefSeq":"NM_014143.3","grch38Isoform":"ENST00000381577","grch38RefSeq":"NM_014143.3","geneAliases":["B7H1","PD-L1","hPD-L1","PDCD1L1","PDCD1LG1","PDL1","B7-H"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":29126,"hugoSymbol":"CD274","oncogene":true,"grch37Isoform":"ENST00000381577","grch37RefSeq":"NM_014143.3","grch38Isoform":"ENST00000381577","grch38RefSeq":"NM_014143.3","geneAliases":["B7H1","PD-L1","hPD-L1","PDCD1L1","PDCD1LG1","PDL1","B7-H"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"12975453","title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.","journal":"The Journal of experimental medicine","pubDate":"2003 Sep 15","volume":"198","issue":"6","pages":"851-62","authors":"Rosenwald A et al","elocationId":"","link":null,"reference":"Rosenwald A et al. The Journal of experimental medicine. 2003 Sep 15;198(6)851-62.","abstract":null},{"pmid":"24497532","title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.","journal":"Blood","pubDate":"2014 Mar 27","volume":"123","issue":"13","pages":"2062-5","authors":"Twa DD et al","elocationId":"doi: 10.1182/blood-2013-10-535443","link":null,"reference":"Twa DD et al. Blood. 2014 Mar 27;123(13)2062-5.","abstract":null},{"pmid":"20628145","title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.","journal":"Blood","pubDate":"2010 Oct 28","volume":"116","issue":"17","pages":"3268-77","authors":"Green MR et al","elocationId":"doi: 10.1182/blood-2010-05-282780","link":null,"reference":"Green MR et al. Blood. 2010 Oct 28;116(17)3268-77.","abstract":null}]},{"id":22706,"uuid":"efead874-c849-4943-aa77-1b763c66ccf5","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":264,"subtype":"Angioimmunoblastic T-Cell Lymphoma","code":"AITL","color":"LimeGreen","mainType":"Mature T and NK Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":54790,"hugoSymbol":"TET2","oncogene":false,"grch37Isoform":"ENST00000380013","grch37RefSeq":"NM_001127208.2","grch38Isoform":"ENST00000380013","grch38RefSeq":"NM_001127208.2","geneAliases":["KIAA1546"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":54790,"hugoSymbol":"TET2","oncogene":false,"grch37Isoform":"ENST00000380013","grch37RefSeq":"NM_001127208.2","grch38Isoform":"ENST00000380013","grch38RefSeq":"NM_001127208.2","geneAliases":["KIAA1546"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22760778","title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.","journal":"Blood","pubDate":"2012 Aug 16","volume":"120","issue":"7","pages":"1466-9","authors":"Lemonnier F et al","elocationId":"doi: 10.1182/blood-2012-02-408542","link":null,"reference":"Lemonnier F et al. Blood. 2012 Aug 16;120(7)1466-9.","abstract":null},{"pmid":"24345752","title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.","journal":"Blood","pubDate":"2014 Feb 27","volume":"123","issue":"9","pages":"1293-6","authors":"Odejide O et al","elocationId":"doi: 10.1182/blood-2013-10-531509","link":null,"reference":"Odejide O et al. Blood. 2014 Feb 27;123(9)1293-6.","abstract":null}]},{"id":14645,"uuid":"38edff62-799b-42b5-b3da-f3b0b7c37157","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":490,"subtype":"Diffuse Large B-Cell Lymphoma, NOS","code":"DLBCLNOS","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":100271849,"hugoSymbol":"MEF2B","oncogene":true,"grch37Isoform":"ENST00000162023","grch37RefSeq":"NM_001145785.1","grch38Isoform":"ENST00000424583","grch38RefSeq":"NM_001145785.1","geneAliases":["RSRFR2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":100271849,"hugoSymbol":"MEF2B","oncogene":true,"grch37Isoform":"ENST00000162023","grch37RefSeq":"NM_001145785.1","grch38Isoform":"ENST00000424583","grch38RefSeq":"NM_001145785.1","geneAliases":["RSRFR2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"23974956","title":"MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma.","journal":"Nature immunology","pubDate":"2013 Oct","volume":"14","issue":"10","pages":"1084-92","authors":"Ying CY et al","elocationId":"doi: 10.1038/ni.2688","link":null,"reference":"Ying CY et al. Nature immunology. 2013 Oct;14(10)1084-92.","abstract":null}]},{"id":12214,"uuid":"58a3fb71-e1cc-48ed-8f99-570bff122a2f","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3718,"hugoSymbol":"JAK3","oncogene":true,"grch37Isoform":"ENST00000458235","grch37RefSeq":"NM_000215.3","grch38Isoform":"ENST00000458235","grch38RefSeq":"NM_000215.3","geneAliases":["JAK3_HUMAN","L-JAK","JAKL","JAK-3","LJAK"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3718,"hugoSymbol":"JAK3","oncogene":true,"grch37Isoform":"ENST00000458235","grch37RefSeq":"NM_000215.3","grch38Isoform":"ENST00000458235","grch38RefSeq":"NM_000215.3","geneAliases":["JAK3_HUMAN","L-JAK","JAKL","JAK-3","LJAK"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":22583,"uuid":"4b3de2d9-4a14-4d08-8c16-b3215a61de40","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":23,"subtype":"Burkitt Lymphoma","code":"BL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6929,"hugoSymbol":"TCF3","oncogene":false,"grch37Isoform":"ENST00000344749","grch37RefSeq":"NM_001136139.2","grch38Isoform":"ENST00000588136","grch38RefSeq":"NM_001136139.2","geneAliases":["TCF-3","ITF1","E2A","E47","AGM8","VDIR","bHLHb21"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":6929,"hugoSymbol":"TCF3","oncogene":false,"grch37Isoform":"ENST00000344749","grch37RefSeq":"NM_001136139.2","grch38Isoform":"ENST00000588136","grch38RefSeq":"NM_001136139.2","geneAliases":["TCF-3","ITF1","E2A","E47","AGM8","VDIR","bHLHb21"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"28209658","title":"Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols.","journal":"Haematologica","pubDate":"2017 Jun","volume":"102","issue":"6","pages":"1091-1098","authors":"Rohde M et al","elocationId":"doi: 10.3324/haematol.2016.156885","link":null,"reference":"Rohde M et al. Haematologica. 2017 Jun;102(6)1091-1098.","abstract":null},{"pmid":"22885699","title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.","journal":"Nature","pubDate":"2012 Oct 4","volume":"490","issue":"7418","pages":"116-20","authors":"Schmitz R et al","elocationId":"doi: 10.1038/nature11378","link":null,"reference":"Schmitz R et al. Nature. 2012 Oct 4;490(7418)116-20.","abstract":null},{"pmid":"23143595","title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.","journal":"Nature genetics","pubDate":"2012 Dec","volume":"44","issue":"12","pages":"1316-20","authors":"Richter J et al","elocationId":"doi: 10.1038/ng.2469","link":null,"reference":"Richter J et al. Nature genetics. 2012 Dec;44(12)1316-20.","abstract":null}]},{"id":14647,"uuid":"afb824ed-7b3e-401a-9303-55c57ee32962","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":286,"subtype":"Follicular Lymphoma","code":"FL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":100271849,"hugoSymbol":"MEF2B","oncogene":true,"grch37Isoform":"ENST00000162023","grch37RefSeq":"NM_001145785.1","grch38Isoform":"ENST00000424583","grch38RefSeq":"NM_001145785.1","geneAliases":["RSRFR2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":100271849,"hugoSymbol":"MEF2B","oncogene":true,"grch37Isoform":"ENST00000162023","grch37RefSeq":"NM_001145785.1","grch38Isoform":"ENST00000424583","grch38RefSeq":"NM_001145785.1","geneAliases":["RSRFR2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"21796119","title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.","journal":"Nature","pubDate":"2011 Jul 27","volume":"476","issue":"7360","pages":"298-303","authors":"Morin RD et al","elocationId":"doi: 10.1038/nature10351","link":null,"reference":"Morin RD et al. Nature. 2011 Jul 27;476(7360)298-303.","abstract":null}]},{"id":9786,"uuid":"d3e76506-fd9e-4a85-aeb7-8ded65a9a110","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":490,"subtype":"Diffuse Large B-Cell Lymphoma, NOS","code":"DLBCLNOS","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"20054396","title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.","journal":"Nature","pubDate":"2010 Jan 7","volume":"463","issue":"7277","pages":"88-92","authors":"Davis RE et al","elocationId":"doi: 10.1038/nature08638","link":null,"reference":"Davis RE et al. Nature. 2010 Jan 7;463(7277)88-92.","abstract":null},{"pmid":"20081860","title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.","journal":"Nature genetics","pubDate":"2010 Feb","volume":"42","issue":"2","pages":"181-5","authors":"Morin RD et al","elocationId":"doi: 10.1038/ng.518","link":null,"reference":"Morin RD et al. Nature genetics. 2010 Feb;42(2)181-5.","abstract":null},{"pmid":"21796119","title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.","journal":"Nature","pubDate":"2011 Jul 27","volume":"476","issue":"7360","pages":"298-303","authors":"Morin RD et al","elocationId":"doi: 10.1038/nature10351","link":null,"reference":"Morin RD et al. Nature. 2011 Jul 27;476(7360)298-303.","abstract":null},{"pmid":"23680150","title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.","journal":"Cancer cell","pubDate":"2013 May 13","volume":"23","issue":"5","pages":"677-92","authors":"Béguelin W et al","elocationId":"doi: 10.1016/j.ccr.2013.04.011","link":null,"reference":"Béguelin W et al. Cancer cell. 2013 May 13;23(5)677-92.","abstract":null}]},{"id":21434,"uuid":"187a409f-9abb-427a-a6cf-aaae9694198c","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":10019,"hugoSymbol":"SH2B3","oncogene":false,"grch37Isoform":"ENST00000341259","grch37RefSeq":"NM_005475.2","grch38Isoform":"ENST00000341259","grch38RefSeq":"NM_005475.2","geneAliases":["LNK"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":10019,"hugoSymbol":"SH2B3","oncogene":false,"grch37Isoform":"ENST00000341259","grch37RefSeq":"NM_005475.2","grch38Isoform":"ENST00000341259","grch38RefSeq":"NM_005475.2","geneAliases":["LNK"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":11194,"uuid":"3d42b2e3-e883-4247-9a5f-901c24e161d2","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":388,"subtype":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT lymphoma)","code":"EMALT","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":6,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":27086,"hugoSymbol":"FOXP1","oncogene":true,"grch37Isoform":"ENST00000318789","grch37RefSeq":"NM_001244814.1","grch38Isoform":"ENST00000318789","grch38RefSeq":"NM_001244814.1","geneAliases":["HSPC215","12CC4","hFKH1B","QRF1","MFH"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":27086,"hugoSymbol":"FOXP1","oncogene":true,"grch37Isoform":"ENST00000318789","grch37RefSeq":"NM_001244814.1","grch38Isoform":"ENST00000318789","grch38RefSeq":"NM_001244814.1","geneAliases":["HSPC215","12CC4","hFKH1B","QRF1","MFH"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"IGH-FOXP1 Fusion","name":"IGH-FOXP1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"15703784","title":"T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma.","journal":"Leukemia","pubDate":"2005 Apr","volume":"19","issue":"4","pages":"652-8","authors":"Streubel B et al","elocationId":"","link":null,"reference":"Streubel B et al. Leukemia. 2005 Apr;19(4)652-8.","abstract":null},{"pmid":"17122510","title":"The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America.","journal":"The American journal of surgical pathology","pubDate":"2006 Dec","volume":"30","issue":"12","pages":"1546-53","authors":"Remstein ED et al","elocationId":"","link":null,"reference":"Remstein ED et al. The American journal of surgical pathology. 2006 Dec;30(12)1546-53.","abstract":null}]},{"id":9788,"uuid":"c6ae8613-c279-42c7-affe-e1d2c4fb6614","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":11836,"uuid":"699a5902-33c5-4959-a6ea-0d6eba2b084f","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":264,"subtype":"Angioimmunoblastic T-Cell Lymphoma","code":"AITL","color":"LimeGreen","mainType":"Mature T and NK Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3418,"hugoSymbol":"IDH2","oncogene":true,"grch37Isoform":"ENST00000330062","grch37RefSeq":"NM_002168.2","grch38Isoform":"ENST00000330062","grch38RefSeq":"NM_002168.2","geneAliases":["IDHM","D2HGA2","mNADP-IDH","IDPM","ICD-M"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3418,"hugoSymbol":"IDH2","oncogene":true,"grch37Isoform":"ENST00000330062","grch37RefSeq":"NM_002168.2","grch38Isoform":"ENST00000330062","grch38RefSeq":"NM_002168.2","geneAliases":["IDHM","D2HGA2","mNADP-IDH","IDPM","ICD-M"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22215888","title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.","journal":"Blood","pubDate":"2012 Feb 23","volume":"119","issue":"8","pages":"1901-3","authors":"Cairns RA et al","elocationId":"doi: 10.1182/blood-2011-11-391748","link":null,"reference":"Cairns RA et al. Blood. 2012 Feb 23;119(8)1901-3.","abstract":null},{"pmid":"24345752","title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.","journal":"Blood","pubDate":"2014 Feb 27","volume":"123","issue":"9","pages":"1293-6","authors":"Odejide O et al","elocationId":"doi: 10.1182/blood-2013-10-531509","link":null,"reference":"Odejide O et al. Blood. 2014 Feb 27;123(9)1293-6.","abstract":null}]},{"id":21949,"uuid":"40623ac8-6bed-408d-a9ff-02ce7fa4442e","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":490,"subtype":"Diffuse Large B-Cell Lymphoma, NOS","code":"DLBCLNOS","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8651,"hugoSymbol":"SOCS1","oncogene":false,"grch37Isoform":"ENST00000332029","grch37RefSeq":"NM_003745.1","grch38Isoform":"ENST00000332029","grch38RefSeq":"NM_003745.1","geneAliases":["TIP-3","CISH1","SSI-1","JAB","CIS1","SOCS-1","SSI1","TIP3"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":8651,"hugoSymbol":"SOCS1","oncogene":false,"grch37Isoform":"ENST00000332029","grch37RefSeq":"NM_003745.1","grch38Isoform":"ENST00000332029","grch38RefSeq":"NM_003745.1","geneAliases":["TIP-3","CISH1","SSI-1","JAB","CIS1","SOCS-1","SSI1","TIP3"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"28302137","title":"Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.","journal":"Journal of hematology & oncology","pubDate":"2017 Mar 17","volume":"10","issue":"1","pages":"70","authors":"Juskevicius D et al","elocationId":"doi: 10.1186/s13045-017-0438-7","link":null,"reference":"Juskevicius D et al. Journal of hematology & oncology. 2017 Mar 17;10(1)70.","abstract":null}]},{"id":9790,"uuid":"2531004f-4085-4d39-98a6-d988ac47e8c9","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":286,"subtype":"Follicular Lymphoma","code":"FL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":2146,"hugoSymbol":"EZH2","oncogene":true,"grch37Isoform":"ENST00000320356","grch37RefSeq":"NM_004456.4","grch38Isoform":"ENST00000320356","grch38RefSeq":"NM_004456.4","geneAliases":["ENX-1","ENX1","EZH2b","WVS","WVS2","KMT6","KMT6A"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"24362818","title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.","journal":"Nature genetics","pubDate":"2014 Feb","volume":"46","issue":"2","pages":"176-181","authors":"Okosun J et al","elocationId":"doi: 10.1038/ng.2856","link":null,"reference":"Okosun J et al. Nature genetics. 2014 Feb;46(2)176-181.","abstract":null},{"pmid":"24052547","title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma.","journal":"Blood","pubDate":"2013 Oct 31","volume":"122","issue":"18","pages":"3165-8","authors":"Bödör C et al","elocationId":"doi: 10.1182/blood-2013-04-496893","link":null,"reference":"Bödör C et al. Blood. 2013 Oct 31;122(18)3165-8.","abstract":null}]},{"id":16833,"uuid":"c637d244-0db8-4f70-9fc3-a406f46b673a","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":12996,"uuid":"5056c4de-af87-46d2-899b-b0896ab49de7","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":578,"subtype":"Splenic Marginal Zone Lymphoma","code":"SMZL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":6,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":10365,"hugoSymbol":"KLF2","oncogene":false,"grch37Isoform":"ENST00000248071","grch37RefSeq":"NM_016270.2","grch38Isoform":"ENST00000248071","grch38RefSeq":"NM_016270.2","geneAliases":["LKLF"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":10365,"hugoSymbol":"KLF2","oncogene":false,"grch37Isoform":"ENST00000248071","grch37RefSeq":"NM_016270.2","grch38Isoform":"ENST00000248071","grch38RefSeq":"NM_016270.2","geneAliases":["LKLF"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25428260","title":"KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.","journal":"Leukemia","pubDate":"2015 May","volume":"29","issue":"5","pages":"1177-85","authors":"Clipson A et al","elocationId":"doi: 10.1038/leu.2014.330","link":null,"reference":"Clipson A et al. Leukemia. 2015 May;29(5)1177-85.","abstract":null},{"pmid":"25283840","title":"The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma.","journal":"Leukemia","pubDate":"2015 Feb","volume":"29","issue":"2","pages":"503-7","authors":"Piva R et al","elocationId":"doi: 10.1038/leu.2014.294","link":null,"reference":"Piva R et al. Leukemia. 2015 Feb;29(2)503-7.","abstract":null}]},{"id":1223,"uuid":"cc833dde-cc75-4314-826d-5ea48fcc6b99","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":17,"subtype":"AML with Myelodysplasia-Related Changes","code":"AMLMRC","color":"LightSalmon","mainType":"Leukemia","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":171023,"hugoSymbol":"ASXL1","oncogene":false,"grch37Isoform":"ENST00000375687","grch37RefSeq":"NM_015338.5","grch38Isoform":"ENST00000375687","grch38RefSeq":"NM_015338.5","geneAliases":["BOPS"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":171023,"hugoSymbol":"ASXL1","oncogene":false,"grch37Isoform":"ENST00000375687","grch37RefSeq":"NM_015338.5","grch38Isoform":"ENST00000375687","grch38RefSeq":"NM_015338.5","geneAliases":["BOPS"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22535592","title":"Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.","journal":"American journal of hematology","pubDate":"2012 Jul","volume":"87","issue":"7","pages":"659-62","authors":"Devillier R et al","elocationId":"doi: 10.1002/ajh.23211","link":null,"reference":"Devillier R et al. American journal of hematology. 2012 Jul;87(7)659-62.","abstract":null},{"pmid":"25860933","title":"Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.","journal":"Oncotarget","pubDate":"2015 Apr 10","volume":"6","issue":"10","pages":"8388-96","authors":"Devillier R et al","elocationId":"","link":null,"reference":"Devillier R et al. Oncotarget. 2015 Apr 10;6(10)8388-96.","abstract":null}]},{"id":1993,"uuid":"d5a3174a-c777-465f-a7df-f3522673ba35","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":533,"subtype":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","code":"CLLSLL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":330,"hugoSymbol":"BIRC3","oncogene":false,"grch37Isoform":"ENST00000263464","grch37RefSeq":"NM_182962.2","grch38Isoform":"ENST00000263464","grch38RefSeq":"NM_182962.2","geneAliases":["MIHC","HAIP1","API2","AIP1","RNF49","c-IAP2","HIAP1","MALT2","CIAP2","IAP-1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":330,"hugoSymbol":"BIRC3","oncogene":false,"grch37Isoform":"ENST00000263464","grch37RefSeq":"NM_182962.2","grch38Isoform":"ENST00000263464","grch38RefSeq":"NM_182962.2","geneAliases":["MIHC","HAIP1","API2","AIP1","RNF49","c-IAP2","HIAP1","MALT2","CIAP2","IAP-1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27123097","title":"BIRC3 alterations in chronic and B-cell acute lymphocytic leukemia patients.","journal":"Oncology letters","pubDate":"2016 May","volume":"11","issue":"5","pages":"3240-3246","authors":"Alhourani E et al","elocationId":"","link":null,"reference":"Alhourani E et al. Oncology letters. 2016 May;11(5)3240-3246.","abstract":null},{"pmid":"26200345","title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia.","journal":"Nature","pubDate":"2015 Oct 22","volume":"526","issue":"7574","pages":"519-24","authors":"Puente XS et al","elocationId":"doi: 10.1038/nature14666","link":null,"reference":"Puente XS et al. Nature. 2015 Oct 22;526(7574)519-24.","abstract":null},{"pmid":"21670202","title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.","journal":"The Journal of experimental medicine","pubDate":"2011 Jul 4","volume":"208","issue":"7","pages":"1389-401","authors":"Fabbri G et al","elocationId":"doi: 10.1084/jem.20110921","link":null,"reference":"Fabbri G et al. The Journal of experimental medicine. 2011 Jul 4;208(7)1389-401.","abstract":null},{"pmid":"26466571","title":"Mutations driving CLL and their evolution in progression and relapse.","journal":"Nature","pubDate":"2015 Oct 22","volume":"526","issue":"7574","pages":"525-30","authors":"Landau DA et al","elocationId":"doi: 10.1038/nature15395","link":null,"reference":"Landau DA et al. Nature. 2015 Oct 22;526(7574)525-30.","abstract":null},{"pmid":"22308293","title":"Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.","journal":"Blood","pubDate":"2012 Mar 22","volume":"119","issue":"12","pages":"2854-62","authors":"Rossi D et al","elocationId":"doi: 10.1182/blood-2011-12-395673","link":null,"reference":"Rossi D et al. Blood. 2012 Mar 22;119(12)2854-62.","abstract":null},{"pmid":"22150006","title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.","journal":"The New England journal of medicine","pubDate":"2011 Dec 29","volume":"365","issue":"26","pages":"2497-506","authors":"Wang L et al","elocationId":"doi: 10.1056/NEJMoa1109016","link":null,"reference":"Wang L et al. The New England journal of medicine. 2011 Dec 29;365(26)2497-506.","abstract":null},{"pmid":"23415222","title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.","journal":"Cell","pubDate":"2013 Feb 14","volume":"152","issue":"4","pages":"714-26","authors":"Landau DA et al","elocationId":"doi: 10.1016/j.cell.2013.01.019","link":null,"reference":"Landau DA et al. Cell. 2013 Feb 14;152(4)714-26.","abstract":null},{"pmid":"24550227","title":"Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.","journal":"Blood","pubDate":"2014 Apr 10","volume":"123","issue":"15","pages":"2378-88","authors":"Messina M et al","elocationId":"doi: 10.1182/blood-2013-10-534271","link":null,"reference":"Messina M et al. Blood. 2014 Apr 10;123(15)2378-88.","abstract":null}]},{"id":17354,"uuid":"ec04b070-0206-4f0c-9e17-64fa0d6a83c8","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":500,"subtype":"Classical Hodgkin Lymphoma","code":"CHL","color":"LimeGreen","mainType":"Hodgkin Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":80380,"hugoSymbol":"PDCD1LG2","oncogene":true,"grch37Isoform":"ENST00000397747","grch37RefSeq":"NM_025239.3","grch38Isoform":"ENST00000397747","grch38RefSeq":"NM_025239.3","geneAliases":["CD273","bA574F11.2","PD-L2","PDCD1L2","B7DC","Btdc","PDL2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":80380,"hugoSymbol":"PDCD1LG2","oncogene":true,"grch37Isoform":"ENST00000397747","grch37RefSeq":"NM_025239.3","grch38Isoform":"ENST00000397747","grch38RefSeq":"NM_025239.3","geneAliases":["CD273","bA574F11.2","PD-L2","PDCD1L2","B7DC","Btdc","PDL2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"27069084","title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2016 Aug 10","volume":"34","issue":"23","pages":"2690-7","authors":"Roemer MG et al","elocationId":"doi: 10.1200/JCO.2016.66.4482","link":null,"reference":"Roemer MG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Aug 10;34(23)2690-7.","abstract":null}]},{"id":17356,"uuid":"4a105ba4-dc33-416e-bb8c-a2c465131913","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":33,"subtype":"Primary Mediastinal (Thymic) Large B-Cell Lymphoma","code":"PMBL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":80380,"hugoSymbol":"PDCD1LG2","oncogene":true,"grch37Isoform":"ENST00000397747","grch37RefSeq":"NM_025239.3","grch38Isoform":"ENST00000397747","grch38RefSeq":"NM_025239.3","geneAliases":["CD273","bA574F11.2","PD-L2","PDCD1L2","B7DC","Btdc","PDL2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":80380,"hugoSymbol":"PDCD1LG2","oncogene":true,"grch37Isoform":"ENST00000397747","grch37RefSeq":"NM_025239.3","grch38Isoform":"ENST00000397747","grch38RefSeq":"NM_025239.3","geneAliases":["CD273","bA574F11.2","PD-L2","PDCD1L2","B7DC","Btdc","PDL2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"25025450","title":"Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.","journal":"The American journal of surgical pathology","pubDate":"2014 Dec","volume":"38","issue":"12","pages":"1715-23","authors":"Shi M et al","elocationId":"doi: 10.1097/PAS.0000000000000297","link":null,"reference":"Shi M et al. The American journal of surgical pathology. 2014 Dec;38(12)1715-23.","abstract":null},{"pmid":"12975453","title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.","journal":"The Journal of experimental medicine","pubDate":"2003 Sep 15","volume":"198","issue":"6","pages":"851-62","authors":"Rosenwald A et al","elocationId":"","link":null,"reference":"Rosenwald A et al. The Journal of experimental medicine. 2003 Sep 15;198(6)851-62.","abstract":null},{"pmid":"24497532","title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.","journal":"Blood","pubDate":"2014 Mar 27","volume":"123","issue":"13","pages":"2062-5","authors":"Twa DD et al","elocationId":"doi: 10.1182/blood-2013-10-535443","link":null,"reference":"Twa DD et al. Blood. 2014 Mar 27;123(13)2062-5.","abstract":null}]},{"id":5198,"uuid":"71a37c79-9672-4325-b135-5f40a2b0ab83","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":490,"subtype":"Diffuse Large B-Cell Lymphoma, NOS","code":"DLBCLNOS","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":974,"hugoSymbol":"CD79B","oncogene":true,"grch37Isoform":"ENST00000392795","grch37RefSeq":"NM_001039933.1","grch38Isoform":"ENST00000392795","grch38RefSeq":"NM_001039933.1","geneAliases":["AGM6","IGB","B29"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":974,"hugoSymbol":"CD79B","oncogene":true,"grch37Isoform":"ENST00000392795","grch37RefSeq":"NM_001039933.1","grch38Isoform":"ENST00000392795","grch38RefSeq":"NM_001039933.1","geneAliases":["AGM6","IGB","B29"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"20054396","title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.","journal":"Nature","pubDate":"2010 Jan 7","volume":"463","issue":"7277","pages":"88-92","authors":"Davis RE et al","elocationId":"doi: 10.1038/nature08638","link":null,"reference":"Davis RE et al. Nature. 2010 Jan 7;463(7277)88-92.","abstract":null},{"pmid":"21796119","title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.","journal":"Nature","pubDate":"2011 Jul 27","volume":"476","issue":"7360","pages":"298-303","authors":"Morin RD et al","elocationId":"doi: 10.1038/nature10351","link":null,"reference":"Morin RD et al. Nature. 2011 Jul 27;476(7360)298-303.","abstract":null}]},{"id":16206,"uuid":"dd3ff694-845e-4908-a9a1-a3bedb0779a8","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":490,"subtype":"Diffuse Large B-Cell Lymphoma, NOS","code":"DLBCLNOS","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4609,"hugoSymbol":"MYC","oncogene":true,"grch37Isoform":"ENST00000377970","grch37RefSeq":"NM_002467.4","grch38Isoform":"ENST00000621592","grch38RefSeq":"NM_002467.4","geneAliases":["c-Myc","MYCC","MRTL","bHLHe39"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4609,"hugoSymbol":"MYC","oncogene":true,"grch37Isoform":"ENST00000377970","grch37RefSeq":"NM_002467.4","grch38Isoform":"ENST00000621592","grch38RefSeq":"NM_002467.4","geneAliases":["c-Myc","MYCC","MRTL","bHLHe39"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"18752503","title":"MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.","journal":"Histopathology","pubDate":"2008 Aug","volume":"53","issue":"2","pages":"205-17","authors":"Yoon SO et al","elocationId":"doi: 10.1111/j.1365-2559.2008.03076.x","link":null,"reference":"Yoon SO et al. Histopathology. 2008 Aug;53(2)205-17.","abstract":null},{"pmid":"20498406","title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2010 Jul 10","volume":"28","issue":"20","pages":"3360-5","authors":"Barrans S et al","elocationId":"doi: 10.1200/JCO.2009.26.3947","link":null,"reference":"Barrans S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Jul 10;28(20)3360-5.","abstract":null},{"pmid":"26158410","title":"MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma.","journal":"Oncotarget","pubDate":"2015 Jul 30","volume":"6","issue":"21","pages":"18374-88","authors":"Lu TX et al","elocationId":"","link":null,"reference":"Lu TX et al. Oncotarget. 2015 Jul 30;6(21)18374-88.","abstract":null},{"pmid":"26240231","title":"Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2015 Sep 10","volume":"33","issue":"26","pages":"2848-56","authors":"Scott DW et al","elocationId":"doi: 10.1200/JCO.2014.60.2383","link":null,"reference":"Scott DW et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Sep 10;33(26)2848-56.","abstract":null},{"pmid":"19704118","title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.","journal":"Blood","pubDate":"2009 Oct 22","volume":"114","issue":"17","pages":"3533-7","authors":"Savage KJ et al","elocationId":"doi: 10.1182/blood-2009-05-220095","link":null,"reference":"Savage KJ et al. Blood. 2009 Oct 22;114(17)3533-7.","abstract":null},{"pmid":"24336156","title":"Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.","journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","pubDate":"2014 Jul","volume":"27","issue":"7","pages":"958-71","authors":"Tzankov A et al","elocationId":"doi: 10.1038/modpathol.2013.214","link":null,"reference":"Tzankov A et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2014 Jul;27(7)958-71.","abstract":null}]},{"id":11982,"uuid":"b5bb5461-0ddb-462a-9e19-abadea0a86d5","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":588,"subtype":"Primary Cutaneous DLBCL, Leg Type","code":"PCLBCLLT","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3662,"hugoSymbol":"IRF4","oncogene":true,"grch37Isoform":"ENST00000380956","grch37RefSeq":"NM_002460.3","grch38Isoform":"ENST00000380956","grch38RefSeq":"NM_002460.3","geneAliases":["NF-EM5","LSIRF","MUM1","SHEP8"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3662,"hugoSymbol":"IRF4","oncogene":true,"grch37Isoform":"ENST00000380956","grch37RefSeq":"NM_002460.3","grch38Isoform":"ENST00000380956","grch38RefSeq":"NM_002460.3","geneAliases":["NF-EM5","LSIRF","MUM1","SHEP8"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"15308563","title":"Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling.","journal":"Blood","pubDate":"2005 May 1","volume":"105","issue":"9","pages":"3671-8","authors":"Hoefnagel JJ et al","elocationId":"","link":null,"reference":"Hoefnagel JJ et al. Blood. 2005 May 1;105(9)3671-8.","abstract":null},{"pmid":"12378521","title":"Primary cutaneous large B-cell lymphoma of the leg: histogenetic analysis of a controversial clinicopathologic entity.","journal":"Human pathology","pubDate":"2002 Sep","volume":"33","issue":"9","pages":"937-43","authors":"Paulli M et al","elocationId":"","link":null,"reference":"Paulli M et al. Human pathology. 2002 Sep;33(9)937-43.","abstract":null}]},{"id":11986,"uuid":"894c832d-5658-4649-b29b-141feac3c1d1","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":160,"subtype":"Anaplastic Large-Cell Lymphoma ALK Negative","code":"ALCLALKN","color":"LimeGreen","mainType":"Mature T and NK Neoplasms","level":6,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3662,"hugoSymbol":"IRF4","oncogene":true,"grch37Isoform":"ENST00000380956","grch37RefSeq":"NM_002460.3","grch38Isoform":"ENST00000380956","grch38RefSeq":"NM_002460.3","geneAliases":["NF-EM5","LSIRF","MUM1","SHEP8"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3662,"hugoSymbol":"IRF4","oncogene":true,"grch37Isoform":"ENST00000380956","grch37RefSeq":"NM_002460.3","grch38Isoform":"ENST00000380956","grch38RefSeq":"NM_002460.3","geneAliases":["NF-EM5","LSIRF","MUM1","SHEP8"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"DUSP22-IRF4 Fusion","name":"DUSP22-IRF4 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"21030553","title":"Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.","journal":"Blood","pubDate":"2011 Jan 20","volume":"117","issue":"3","pages":"915-9","authors":"Feldman AL et al","elocationId":"doi: 10.1182/blood-2010-08-303305","link":null,"reference":"Feldman AL et al. Blood. 2011 Jan 20;117(3)915-9.","abstract":null},{"pmid":"26104084","title":"Genetics of anaplastic large cell lymphoma.","journal":"Leukemia & lymphoma","pubDate":"2016","volume":"57","issue":"1","pages":"21-7","authors":"Zeng Y et al","elocationId":"doi: 10.3109/10428194.2015.1064530","link":null,"reference":"Zeng Y et al. Leukemia & lymphoma. 2016;57(1)21-7.","abstract":null}]},{"id":7767,"uuid":"4879c66c-694b-47a2-8f2a-f4f34c504695","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":857,"subtype":"Early T-Cell Precursor Lymphoblastic Leukemia","code":"ETPLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":4,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2033,"hugoSymbol":"EP300","oncogene":false,"grch37Isoform":"ENST00000263253","grch37RefSeq":"NM_001429.3","grch38Isoform":"ENST00000263253","grch38RefSeq":"NM_001429.3","geneAliases":["p300","MKHK2","KAT3B","RSTS2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":2033,"hugoSymbol":"EP300","oncogene":false,"grch37Isoform":"ENST00000263253","grch37RefSeq":"NM_001429.3","grch38Isoform":"ENST00000263253","grch38RefSeq":"NM_001429.3","geneAliases":["p300","MKHK2","KAT3B","RSTS2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22237106","title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","journal":"Nature","pubDate":"2012 Jan 11","volume":"481","issue":"7380","pages":"157-63","authors":"Zhang J et al","elocationId":"doi: 10.1038/nature10725","link":null,"reference":"Zhang J et al. Nature. 2012 Jan 11;481(7380)157-63.","abstract":null}]},{"id":7769,"uuid":"e21b4229-11f9-413d-9be8-4f94b5d21932","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":286,"subtype":"Follicular Lymphoma","code":"FL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2033,"hugoSymbol":"EP300","oncogene":false,"grch37Isoform":"ENST00000263253","grch37RefSeq":"NM_001429.3","grch38Isoform":"ENST00000263253","grch38RefSeq":"NM_001429.3","geneAliases":["p300","MKHK2","KAT3B","RSTS2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":2033,"hugoSymbol":"EP300","oncogene":false,"grch37Isoform":"ENST00000263253","grch37RefSeq":"NM_001429.3","grch38Isoform":"ENST00000263253","grch38RefSeq":"NM_001429.3","geneAliases":["p300","MKHK2","KAT3B","RSTS2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"21390126","title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma.","journal":"Nature","pubDate":"2011 Mar 10","volume":"471","issue":"7337","pages":"189-95","authors":"Pasqualucci L et al","elocationId":"doi: 10.1038/nature09730","link":null,"reference":"Pasqualucci L et al. Nature. 2011 Mar 10;471(7337)189-95.","abstract":null}]},{"id":22364,"uuid":"57b4be70-f93d-4cad-9889-875b067c6006","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":488,"subtype":"T-Cell Large Granular Lymphocytic Leukemia","code":"TLGL","color":"LimeGreen","mainType":"Mature T and NK Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":6774,"hugoSymbol":"STAT3","oncogene":true,"grch37Isoform":"ENST00000264657","grch37RefSeq":"NM_139276.2","grch38Isoform":"ENST00000264657","grch38RefSeq":"NM_139276.2","geneAliases":["ADMIO","ADMIO1","APRF","HIES"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":6774,"hugoSymbol":"STAT3","oncogene":true,"grch37Isoform":"ENST00000264657","grch37RefSeq":"NM_139276.2","grch38Isoform":"ENST00000264657","grch38RefSeq":"NM_139276.2","geneAliases":["ADMIO","ADMIO1","APRF","HIES"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"22859607","title":"STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia.","journal":"Blood","pubDate":"2012 Oct 11","volume":"120","issue":"15","pages":"3048-57","authors":"Jerez A et al","elocationId":"doi: 10.1182/blood-2012-06-435297","link":null,"reference":"Jerez A et al. Blood. 2012 Oct 11;120(15)3048-57.","abstract":null},{"pmid":"24317090","title":"Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation.","journal":"Blood cancer journal","pubDate":"2013 Dec 6","volume":"3","issue":"","pages":"e168","authors":"Andersson EI et al","elocationId":"doi: 10.1038/bcj.2013.65","link":null,"reference":"Andersson EI et al. Blood cancer journal. 2013 Dec 6;3()e168.","abstract":null},{"pmid":"29288042","title":"STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia.","journal":"Human pathology","pubDate":"2018 Mar","volume":"73","issue":"","pages":"74-81","authors":"Shi M et al","elocationId":"doi: 10.1016/j.humpath.2017.12.014","link":null,"reference":"Shi M et al. Human pathology. 2018 Mar;73()74-81.","abstract":null},{"pmid":"22591296","title":"Somatic STAT3 mutations in large granular lymphocytic leukemia.","journal":"The New England journal of medicine","pubDate":"2012 May 17","volume":"366","issue":"20","pages":"1905-13","authors":"Koskela HL et al","elocationId":"doi: 10.1056/NEJMoa1114885","link":null,"reference":"Koskela HL et al. The New England journal of medicine. 2012 May 17;366(20)1905-13.","abstract":null},{"pmid":"25281507","title":"The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia.","journal":"Haematologica","pubDate":"2015 Jan","volume":"100","issue":"1","pages":"91-9","authors":"Rajala HL et al","elocationId":"doi: 10.3324/haematol.2014.113142","link":null,"reference":"Rajala HL et al. Haematologica. 2015 Jan;100(1)91-9.","abstract":null}]},{"id":15324,"uuid":"53800a88-626e-4c0b-9059-f9e37d0f22ee","evidenceType":"DIAGNOSTIC_IMPLICATION","cancerTypes":[{"id":293,"subtype":"T-Lymphoblastic Leukemia/Lymphoma","code":"TLL","color":"LimeGreen","mainType":"T-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":8028,"hugoSymbol":"MLLT10","oncogene":true,"grch37Isoform":"ENST00000307729","grch37RefSeq":"NM_001195626.1","grch38Isoform":"ENST00000307729","grch38RefSeq":"NM_001195626.1","geneAliases":["AF10"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":8028,"hugoSymbol":"MLLT10","oncogene":true,"grch37Isoform":"ENST00000307729","grch37RefSeq":"NM_001195626.1","grch38Isoform":"ENST00000307729","grch38RefSeq":"NM_001195626.1","geneAliases":["AF10"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"PICALM-MLLT10 Fusion","name":"PICALM-MLLT10 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[],"knownEffect":null,"lastEdit":1600296735000,"lastReview":null,"levelOfEvidence":"LEVEL_Dx3","solidPropagationLevel":null,"liquidPropagationLevel":null,"articles":[{"pmid":"16826225","title":"Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast.","journal":"Leukemia","pubDate":"2006 Sep","volume":"20","issue":"9","pages":"1496-510","authors":"Graux C et al","elocationId":"","link":null,"reference":"Graux C et al. Leukemia. 2006 Sep;20(9)1496-510.","abstract":null},{"pmid":"23673860","title":"New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia.","journal":"Blood","pubDate":"2013 Jun 20","volume":"121","issue":"25","pages":"5064-7","authors":"Brandimarte L et al","elocationId":"doi: 10.1182/blood-2013-02-487256","link":null,"reference":"Brandimarte L et al. Blood. 2013 Jun 20;121(25)5064-7.","abstract":null}]}],"LEVEL_2":[{"id":14755,"uuid":"998db817-b4ef-4067-a50b-588788cbadc0","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Crizotinib is FDA-approved for (1) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive as detected by an FDA-approved test (2) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive."],"priority":1,"drugs":[{"ncitCode":"C74061","drugName":"Crizotinib","uuid":"f05d12ab-6204-4a1c-803f-f3a7f6e30af2","synonyms":["MET Tyrosine Kinase Inhibitor PF-02341066","Crizotinib","2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-","Xalkori\"","PF-02341066","CRIZOTINIB","PF-2341066","\"(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine","MET tyrosine kinase inhibitor PF-02341066"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1539208264000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"25971939","title":"Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.","journal":"Cancer discovery","pubDate":"2015 Aug","volume":"5","issue":"8","pages":"842-9","authors":"Paik PK et al","elocationId":"doi: 10.1158/2159-8290.CD-14-1467","link":null,"reference":"Paik PK et al. Cancer discovery. 2015 Aug;5(8)842-9.","abstract":null},{"pmid":"21623265","title":"Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2011 May","volume":"6","issue":"5","pages":"942-6","authors":"Ou SH et al","elocationId":"doi: 10.1097/JTO.0b013e31821528d3","link":null,"reference":"Ou SH et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 May;6(5)942-6.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://meetinglibrary.asco.org/content/132030-144","reference":"null. null. .","abstract":"Camidge et al. Abstract# 8001, ASCO 2014"},{"pmid":"26729443","title":"MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2016 Mar 1","volume":"34","issue":"7","pages":"721-30","authors":"Awad MM et al","elocationId":"doi: 10.1200/JCO.2015.63.4600","link":null,"reference":"Awad MM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Mar 1;34(7)721-30.","abstract":null}]},{"id":14758,"uuid":"54683a8e-5709-4324-91d0-16869a1dd7ef","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":875,"subtype":"","code":"","color":"Orange","mainType":"Renal Cell Carcinoma","level":0,"tissue":"Kidney","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C52200","drugName":"Cabozantinib","uuid":"6acebe88-de89-4ec1-bc38-74cb63861d23","synonyms":["\"1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-","CABOZANTINIB","Cabozantinib","N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1527702943000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"27462141","title":"Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy.","journal":"Drug design, development and therapy","pubDate":"2016","volume":"10","issue":"","pages":"2167-72","authors":"Grassi P et al","elocationId":"doi: 10.2147/DDDT.S104225","link":null,"reference":"Grassi P et al. Drug design, development and therapy. 2016;10()2167-72.","abstract":null},{"pmid":"27279544","title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2016 Jul","volume":"17","issue":"7","pages":"917-927","authors":"Choueiri TK et al","elocationId":"doi: 10.1016/S1470-2045(16)30107-3","link":null,"reference":"Choueiri TK et al. The Lancet. Oncology. 2016 Jul;17(7)917-927.","abstract":null}]},{"id":2023,"uuid":"d9b444f3-76b2-4f91-a919-8b8b4d853846","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":935,"subtype":"","code":"","color":"SaddleBrown","mainType":"Colorectal Cancer","level":0,"tissue":"Bowel","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600E","name":"V600E","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C98283","drugName":"Encorafenib","uuid":"001e534f-3e63-432f-90a6-d1af1759e4e2","synonyms":["LGX-818","Encorafenib","LGX818","LGX 818","ENCORAFENIB","Braftovi"],"priority":1},{"ncitCode":"C1857","drugName":"Panitumumab","uuid":"d7b1d12a-e942-4801-bb64-916c9bdfaaf3","synonyms":["ABX-EGF, Clone E7.6.3","PANITUMUMAB","\"ABX-EGF","Panitumumab","Vectibix","MoAb ABX-EGF","ABX-EGF","panitumumab","panitumumab\"","ABX-EGF Monoclonal Antibody","Monoclonal Antibody ABX-EGF"],"priority":2}]}],"knownEffect":"Sensitive","lastEdit":1587075050000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"31566309","title":"Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer.","journal":"The New England journal of medicine","pubDate":"2019 Oct 24","volume":"381","issue":"17","pages":"1632-1643","authors":"Kopetz S et al","elocationId":"doi: 10.1056/NEJMoa1908075","link":null,"reference":"Kopetz S et al. The New England journal of medicine. 2019 Oct 24;381(17)1632-1643.","abstract":null},{"pmid":"29431699","title":"Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer.","journal":"Cancer discovery","pubDate":"2018 Apr","volume":"8","issue":"4","pages":"428-443","authors":"Corcoran RB et al","elocationId":"doi: 10.1158/2159-8290.CD-17-1226","link":null,"reference":"Corcoran RB et al. Cancer discovery. 2018 Apr;8(4)428-443.","abstract":null}]},{"id":17511,"uuid":"fa7b3352-9544-4de6-bd76-ee2e7e18da80","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[" (2) adjuvant treatment of adult patients following complete gross resection of KIT-positive GIST.","Imatinib is FDA approved for the treatment of: (1) patients with KIT-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs)"],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1527703411000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"22718859","title":"Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2012 Aug 15","volume":"18","issue":"16","pages":"4458-64","authors":"Cassier PA et al","elocationId":"","link":null,"reference":"Cassier PA et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Aug 15;18(16)4458-64.","abstract":null}]},{"id":17512,"uuid":"8dcb83c0-3131-4252-8ed3-4b4fe3c436b5","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C71622","drugName":"Sunitinib","uuid":"5b548883-0142-4d15-a324-22d7b29800b2","synonyms":["\"1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-","Sunitinib","SUNITINIB","sunitinib\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1597978043000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"17046465","title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.","journal":"Lancet (London, England)","pubDate":"2006 Oct 14","volume":"368","issue":"9544","pages":"1329-38","authors":"Demetri GD et al","elocationId":"","link":null,"reference":"Demetri GD et al. Lancet (London, England). 2006 Oct 14;368(9544)1329-38.","abstract":null},{"pmid":"25641662","title":"Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.","journal":"Cancer","pubDate":"2015 May 1","volume":"121","issue":"9","pages":"1405-13","authors":"Reichardt P et al","elocationId":"doi: 10.1002/cncr.29220","link":null,"reference":"Reichardt P et al. Cancer. 2015 May 1;121(9)1405-13.","abstract":null},{"pmid":"19282169","title":"Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.","journal":"European journal of cancer (Oxford, England : 1990)","pubDate":"2009 Jul","volume":"45","issue":"11","pages":"1959-68","authors":"George S et al","elocationId":"doi: 10.1016/j.ejca.2009.02.011","link":null,"reference":"George S et al. European journal of cancer (Oxford, England : 1990). 2009 Jul;45(11)1959-68.","abstract":null}]},{"id":17513,"uuid":"b4d6305c-4f4f-437b-a144-17f323d47c27","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C78204","drugName":"Regorafenib","uuid":"e0d0786c-307a-4a7a-bfff-036cfa7f9df5","synonyms":["Regorafenib","Stivarga","REGORAFENIB","BAY 73-4506","4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1597981358000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"27371698","title":"Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.","journal":"Annals of oncology : official journal of the European Society for Medical Oncology","pubDate":"2016 Sep","volume":"27","issue":"9","pages":"1794-9","authors":"Ben-Ami E et al","elocationId":"doi: 10.1093/annonc/mdw228","link":null,"reference":"Ben-Ami E et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Sep;27(9)1794-9.","abstract":null},{"pmid":"23177515","title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.","journal":"Lancet (London, England)","pubDate":"2013 Jan 26","volume":"381","issue":"9863","pages":"295-302","authors":"Demetri GD et al","elocationId":"doi: 10.1016/S0140-6736(12)61857-1","link":null,"reference":"Demetri GD et al. Lancet (London, England). 2013 Jan 26;381(9863)295-302.","abstract":null}]},{"id":17514,"uuid":"e66a3fb2-b041-4b6f-a0fe-7e2831b40023","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":4,"drugs":[{"ncitCode":null,"drugName":"Ripretinib","uuid":"2841f955-5295-416c-a7a3-3dd39962bfae","synonyms":[],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1597942912000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"32511981","title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2020 Jul","volume":"21","issue":"7","pages":"923-934","authors":"Blay JY et al","elocationId":"doi: 10.1016/S1470-2045(20)30168-6","link":null,"reference":"Blay JY et al. The Lancet. Oncology. 2020 Jul;21(7)923-934.","abstract":null}]},{"id":7915,"uuid":"1eb47397-c2e5-47ce-ab29-94852fd9999d","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C82492","drugName":"Ado-Trastuzumab Emtansine","uuid":"598e7b9f-976d-46bc-aea7-42f1005db988","synonyms":["\"ADO-TRASTUZUMAB EMTANSINE","Trastuzumab Emtansine","Immunoglobulin G1, Anti-(Human p185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide with N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine","Trastuzumab-DM1","ADO-Trastuzumab Emtansine","Kadcyla","Ado Trastuzumab Emtansine","Trastuzumab-MCC-DM1 Antibody-Drug Conjugate","Trastuzumab-MCC-DM1 Immunoconjugate\"","RO5304020","T-DM1","PRO132365","Trastuzumab-MCC-DM1"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580713303000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"31588020","title":"Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.","journal":"Cancer cell","pubDate":"2019 Oct 14","volume":"36","issue":"4","pages":"444-457.e7","authors":"Robichaux JP et al","elocationId":"doi: 10.1016/j.ccell.2019.09.001","link":null,"reference":"Robichaux JP et al. Cancer cell. 2019 Oct 14;36(4)444-457.e7.","abstract":null},{"pmid":"29989854","title":"Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2018 Aug 20","volume":"36","issue":"24","pages":"2532-2537","authors":"Li BT et al","elocationId":"doi: 10.1200/JCO.2018.77.9777","link":null,"reference":"Li BT et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Aug 20;36(24)2532-2537.","abstract":null},{"pmid":"30206164","title":"Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 Jan 1","volume":"25","issue":"1","pages":"64-72","authors":"Peters S et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-1590","link":null,"reference":"Peters S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Jan 1;25(1)64-72.","abstract":null}]},{"id":109,"uuid":"d0500259-886b-4ea9-a312-c6b3976a33e2","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359V","name":"F359V","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y253H","name":"Y253H","refResidues":"Y","proteinStart":253,"proteinEnd":253,"variantResidues":"H","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317C","name":"F317C","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E255K","name":"E255K","refResidues":"E","proteinStart":255,"proteinEnd":255,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E255V","name":"E255V","refResidues":"E","proteinStart":255,"proteinEnd":255,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317V","name":"F317V","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359C","name":"F359C","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T315A","name":"T315A","refResidues":"T","proteinStart":315,"proteinEnd":315,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359I","name":"F359I","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317I","name":"F317I","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C60809","drugName":"Bosutinib","uuid":"80a4278a-4622-45e5-9e3f-8ca98657692f","synonyms":["BOSUTINIB","\"4-Anilino-3-quinolinecarbonitrile","SKI-606\"","4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile","SKI 606","Bosulif","SKI-606","4-Anilinobenzo(g)quinoline-3-carbonitrile","Bosutinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1576694883000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"19075254","title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2009 Jan 20","volume":"27","issue":"3","pages":"469-71","authors":"Redaelli S et al","elocationId":"doi: 10.1200/JCO.2008.19.8853","link":null,"reference":"Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.","abstract":null},{"pmid":"26040495","title":"Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.","journal":"American journal of hematology","pubDate":"2015 Sep","volume":"90","issue":"9","pages":"755-68","authors":"Gambacorti-Passerini C et al","elocationId":"doi: 10.1002/ajh.24034","link":null,"reference":"Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.","abstract":null}]},{"id":2029,"uuid":"4e56b02d-394e-4397-9465-a3cc2c5026cd","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":276,"subtype":"Hairy Cell Leukemia","code":"HCL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600E","name":"V600E","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib","uuid":"4e91da20-6cf0-4e07-995f-7f7db4c7c077","synonyms":["Vemurafenib","BRAF(V600E) Kinase Inhibitor RO5185426","RO 5185426","PLX4032","PLX-4032","RG 7204","Zelboraf\"","BRAF (V600E) kinase inhibitor RO5185426","RG7204","\"1-propanesulfonamide, n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-","VEMURAFENIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1564684586000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"26352686","title":"Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.","journal":"The New England journal of medicine","pubDate":"2015 Oct 29","volume":"373","issue":"18","pages":"1733-47","authors":"Tiacci E et al","elocationId":"doi: 10.1056/NEJMoa1506583","link":null,"reference":"Tiacci E et al. The New England journal of medicine. 2015 Oct 29;373(18)1733-47.","abstract":null}]},{"id":110,"uuid":"a0166ed8-f54d-4907-81db-39fe1b44f859","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":560,"subtype":"Chronic Myelogenous Leukemia","code":"CML","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359V","name":"F359V","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y253H","name":"Y253H","refResidues":"Y","proteinStart":253,"proteinEnd":253,"variantResidues":"H","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317C","name":"F317C","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E255K","name":"E255K","refResidues":"E","proteinStart":255,"proteinEnd":255,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E255V","name":"E255V","refResidues":"E","proteinStart":255,"proteinEnd":255,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317V","name":"F317V","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359C","name":"F359C","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T315A","name":"T315A","refResidues":"T","proteinStart":315,"proteinEnd":315,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359I","name":"F359I","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317I","name":"F317I","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C60809","drugName":"Bosutinib","uuid":"80a4278a-4622-45e5-9e3f-8ca98657692f","synonyms":["BOSUTINIB","\"4-Anilino-3-quinolinecarbonitrile","SKI-606\"","4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile","SKI 606","Bosulif","SKI-606","4-Anilinobenzo(g)quinoline-3-carbonitrile","Bosutinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1576706770000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"19075254","title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2009 Jan 20","volume":"27","issue":"3","pages":"469-71","authors":"Redaelli S et al","elocationId":"doi: 10.1200/JCO.2008.19.8853","link":null,"reference":"Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.","abstract":null},{"pmid":"15930265","title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","journal":"Cancer research","pubDate":"2005 Jun 1","volume":"65","issue":"11","pages":"4500-5","authors":"O'Hare T et al","elocationId":"","link":null,"reference":"O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.","abstract":null}]},{"id":12718,"uuid":"8c5a7a5e-74bc-442e-8228-4ca8fc3d81e6","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D816","name":"D816","refResidues":"D","proteinStart":816,"proteinEnd":816,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y823D","name":"Y823D","refResidues":"Y","proteinStart":823,"proteinEnd":823,"variantResidues":"D","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D820","name":"D820","refResidues":"D","proteinStart":820,"proteinEnd":820,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"N822","name":"N822","refResidues":"N","proteinStart":822,"proteinEnd":822,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"A829P","name":"A829P","refResidues":"A","proteinStart":829,"proteinEnd":829,"variantResidues":"P","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"C809G","name":"C809G","refResidues":"C","proteinStart":809,"proteinEnd":809,"variantResidues":"G","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[" 3) Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment"," 2) Advanced renal cell carcinoma","Sorafenib is FDA-approved for 1) Unresectable hepatocellular carcinoma"],"priority":4,"drugs":[{"ncitCode":"C61948","drugName":"Sorafenib","uuid":"b20f2bb4-5a53-40ff-8e26-acbd42df4e8b","synonyms":["BA4 43 9006","sorafenib","Bay-439006","Sorafenib","SORAFENIB","BAY 43-9006"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1548779134000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://meetinglibrary.asco.org/content/80567-102","reference":"null. null. .","abstract":"Kindler et al. Abstract# 10009, ASCO 2011"},{"pmid":"23140824","title":"Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.","journal":"European journal of cancer (Oxford, England : 1990)","pubDate":"2013 Mar","volume":"49","issue":"5","pages":"1027-31","authors":"Montemurro M et al","elocationId":"doi: 10.1016/j.ejca.2012.10.009","link":null,"reference":"Montemurro M et al. European journal of cancer (Oxford, England : 1990). 2013 Mar;49(5)1027-31.","abstract":null},{"pmid":"22270258","title":"Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.","journal":"Investigational new drugs","pubDate":"2012 Dec","volume":"30","issue":"6","pages":"2377-83","authors":"Park SH et al","elocationId":"doi: 10.1007/s10637-012-9795-9","link":null,"reference":"Park SH et al. Investigational new drugs. 2012 Dec;30(6)2377-83.","abstract":null}]},{"id":111,"uuid":"86b1a935-961b-407e-9f84-e566bd4dcf08","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359V","name":"F359V","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y253H","name":"Y253H","refResidues":"Y","proteinStart":253,"proteinEnd":253,"variantResidues":"H","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E255K","name":"E255K","refResidues":"E","proteinStart":255,"proteinEnd":255,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E255V","name":"E255V","refResidues":"E","proteinStart":255,"proteinEnd":255,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359C","name":"F359C","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359I","name":"F359I","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C38713","drugName":"Dasatinib","uuid":"df40a264-628f-4070-9078-965c0471bd2c","synonyms":["Dasatinib","dasatinib","Sprycel","BMS-354825","DASATINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1576605193000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"17496201","title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.","journal":"Blood","pubDate":"2007 Oct 1","volume":"110","issue":"7","pages":"2309-15","authors":"Ottmann O et al","elocationId":"","link":null,"reference":"Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.","abstract":null}]},{"id":112,"uuid":"9da0c49f-18fe-4c5a-8e28-bc7f12d01dcf","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":560,"subtype":"Chronic Myelogenous Leukemia","code":"CML","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359V","name":"F359V","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y253H","name":"Y253H","refResidues":"Y","proteinStart":253,"proteinEnd":253,"variantResidues":"H","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E255K","name":"E255K","refResidues":"E","proteinStart":255,"proteinEnd":255,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E255V","name":"E255V","refResidues":"E","proteinStart":255,"proteinEnd":255,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359C","name":"F359C","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359I","name":"F359I","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C38713","drugName":"Dasatinib","uuid":"df40a264-628f-4070-9078-965c0471bd2c","synonyms":["Dasatinib","dasatinib","Sprycel","BMS-354825","DASATINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1557359683000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"19075254","title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2009 Jan 20","volume":"27","issue":"3","pages":"469-71","authors":"Redaelli S et al","elocationId":"doi: 10.1200/JCO.2008.19.8853","link":null,"reference":"Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.","abstract":null},{"pmid":"15930265","title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","journal":"Cancer research","pubDate":"2005 Jun 1","volume":"65","issue":"11","pages":"4500-5","authors":"O'Hare T et al","elocationId":"","link":null,"reference":"O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.","abstract":null},{"pmid":"19779040","title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.","journal":"Blood","pubDate":"2009 Dec 3","volume":"114","issue":"24","pages":"4944-53","authors":"Müller MC et al","elocationId":"doi: 10.1182/blood-2009-04-214221","link":null,"reference":"Müller MC et al. Blood. 2009 Dec 3;114(24)4944-53.","abstract":null}]},{"id":113,"uuid":"9dbf114a-6529-4d2b-9a0b-e3969ddde19c","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317C","name":"F317C","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317L","name":"F317L","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V299L","name":"V299L","refResidues":"V","proteinStart":299,"proteinEnd":299,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317V","name":"F317V","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T315A","name":"T315A","refResidues":"T","proteinStart":315,"proteinEnd":315,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317I","name":"F317I","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C48375","drugName":"Nilotinib","uuid":"0f991d49-4cf2-4975-b52f-d7d037aa7f11","synonyms":["Nilotinib","AMN 107 Base Form","nilotinib","4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide","NILOTINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1576703351000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"19075254","title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2009 Jan 20","volume":"27","issue":"3","pages":"469-71","authors":"Redaelli S et al","elocationId":"doi: 10.1200/JCO.2008.19.8853","link":null,"reference":"Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.","abstract":null},{"pmid":"15930265","title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","journal":"Cancer research","pubDate":"2005 Jun 1","volume":"65","issue":"11","pages":"4500-5","authors":"O'Hare T et al","elocationId":"","link":null,"reference":"O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.","abstract":null},{"pmid":"23086624","title":"Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.","journal":"Blood","pubDate":"2012 Oct 18","volume":"120","issue":"16","pages":"3382-3","authors":"Jabbour E et al","elocationId":"doi: 10.1182/blood-2012-04-424192","link":null,"reference":"Jabbour E et al. Blood. 2012 Oct 18;120(16)3382-3.","abstract":null}]},{"id":2033,"uuid":"7f76d72e-ec85-4f42-91fe-b247dbe0e0e9","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":669,"subtype":"Ganglioglioma","code":"GNG","color":"Gray","mainType":"Glioma","level":3,"tissue":"CNS/Brain","tumorForm":"SOLID"},{"id":32,"subtype":"Pleomorphic Xanthoastrocytoma","code":"PXA","color":"Gray","mainType":"Glioma","level":3,"tissue":"CNS/Brain","tumorForm":"SOLID"},{"id":407,"subtype":"Pilocytic Astrocytoma","code":"PAST","color":"Gray","mainType":"Glioma","level":3,"tissue":"CNS/Brain","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V600E","name":"V600E","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib","uuid":"4e91da20-6cf0-4e07-995f-7f7db4c7c077","synonyms":["Vemurafenib","BRAF(V600E) Kinase Inhibitor RO5185426","RO 5185426","PLX4032","PLX-4032","RG 7204","Zelboraf\"","BRAF (V600E) kinase inhibitor RO5185426","RG7204","\"1-propanesulfonamide, n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-","VEMURAFENIB"],"priority":1},{"ncitCode":"C68923","drugName":"Cobimetinib","uuid":"eb357145-3b18-4aca-b75a-5e18dd2bf4f9","synonyms":["Cotellic","Cobimetinib","XL518","COBIMETINIB","GDC-0973","MEK Inhibitor GDC-0973"],"priority":2}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C77908","drugName":"Trametinib","uuid":"fb2bb01c-c0ec-4641-abf7-87f486075022","synonyms":["Mekinist","\"GSK1120212","Trametinib\"","TRAMETINIB","JTP-74057","MEK Inhibitor GSK1120212","N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","Trametinib"],"priority":2},{"ncitCode":"C82386","drugName":"Dabrafenib","uuid":"939cd40b-b515-499d-b099-fd29027c0d17","synonyms":["DABRAFENIB","GSK2118436\"","\"BRAF Inhibitor GSK2118436","GSK-2118436","GSK-2118436A","Dabrafenib","Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1588891530000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"30120137","title":"Vemurafenib and cobimetinib overcome resistance to vemurafenib in <i>BRAF</i>-mutant ganglioglioma.","journal":"Neurology","pubDate":"2018 Sep 11","volume":"91","issue":"11","pages":"523-525","authors":"Touat M et al","elocationId":"doi: 10.1212/WNL.0000000000006171","link":null,"reference":"Touat M et al. Neurology. 2018 Sep 11;91(11)523-525.","abstract":null},{"pmid":"26287849","title":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.","journal":"The New England journal of medicine","pubDate":"2015 Aug 20","volume":"373","issue":"8","pages":"726-36","authors":"Hyman DM et al","elocationId":"doi: 10.1056/NEJMoa1502309","link":null,"reference":"Hyman DM et al. The New England journal of medicine. 2015 Aug 20;373(8)726-36.","abstract":null},{"pmid":"29380516","title":"Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.","journal":"Pediatric blood & cancer","pubDate":"2018 May","volume":"65","issue":"5","pages":"e26969","authors":"Marks AM et al","elocationId":"doi: 10.1002/pbc.26969","link":null,"reference":"Marks AM et al. Pediatric blood & cancer. 2018 May;65(5)e26969.","abstract":null},{"pmid":"30351999","title":"BRAF Inhibition in <i>BRAF</i><sup>V600</sup>-Mutant Gliomas: Results From the VE-BASKET Study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2018 Dec 10","volume":"36","issue":"35","pages":"3477-3484","authors":"Kaley T et al","elocationId":"doi: 10.1200/JCO.2018.78.9990","link":null,"reference":"Kaley T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Dec 10;36(35)3477-3484.","abstract":null},{"pmid":"28984141","title":"Dabrafenib and trametinib in BRAFV600E mutated glioma.","journal":"CNS oncology","pubDate":"2017 Oct","volume":"6","issue":"4","pages":"291-296","authors":"Brown NF et al","elocationId":"doi: 10.2217/cns-2017-0006","link":null,"reference":"Brown NF et al. CNS oncology. 2017 Oct;6(4)291-296.","abstract":null}]},{"id":114,"uuid":"f7e9eeea-7550-42d6-bc57-c7884b9de622","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":560,"subtype":"Chronic Myelogenous Leukemia","code":"CML","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317C","name":"F317C","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317L","name":"F317L","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V299L","name":"V299L","refResidues":"V","proteinStart":299,"proteinEnd":299,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317V","name":"F317V","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T315A","name":"T315A","refResidues":"T","proteinStart":315,"proteinEnd":315,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317I","name":"F317I","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C48375","drugName":"Nilotinib","uuid":"0f991d49-4cf2-4975-b52f-d7d037aa7f11","synonyms":["Nilotinib","AMN 107 Base Form","nilotinib","4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide","NILOTINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1576276702000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"19075254","title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2009 Jan 20","volume":"27","issue":"3","pages":"469-71","authors":"Redaelli S et al","elocationId":"doi: 10.1200/JCO.2008.19.8853","link":null,"reference":"Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.","abstract":null},{"pmid":"15930265","title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","journal":"Cancer research","pubDate":"2005 Jun 1","volume":"65","issue":"11","pages":"4500-5","authors":"O'Hare T et al","elocationId":"","link":null,"reference":"O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.","abstract":null},{"pmid":"23086624","title":"Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.","journal":"Blood","pubDate":"2012 Oct 18","volume":"120","issue":"16","pages":"3382-3","authors":"Jabbour E et al","elocationId":"doi: 10.1182/blood-2012-04-424192","link":null,"reference":"Jabbour E et al. Blood. 2012 Oct 18;120(16)3382-3.","abstract":null}]},{"id":6643,"uuid":"31231158-559b-4a91-ae75-be10f1123684","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"A763_Y764insFQEA","name":"A763_Y764insFQEA","refResidues":null,"proteinStart":763,"proteinEnd":764,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C65530","drugName":"Erlotinib","uuid":"83754311-3f3b-4782-bfbf-08e71c790b9a","synonyms":["Erlotinib","erlotinib","ERLOTINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1582154371000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"23969006","title":"EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib--Letter.","journal":"Molecular cancer therapeutics","pubDate":"2013 Nov","volume":"12","issue":"11","pages":"2614-5","authors":"Voon PJ et al","elocationId":"doi: 10.1158/1535-7163.MCT-13-0192","link":null,"reference":"Voon PJ et al. Molecular cancer therapeutics. 2013 Nov;12(11)2614-5.","abstract":null},{"pmid":"26515464","title":"In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.","journal":"Oncotarget","pubDate":"2015 Nov 17","volume":"6","issue":"36","pages":"38789-803","authors":"Hirano T et al","elocationId":"doi: 10.18632/oncotarget.5887","link":null,"reference":"Hirano T et al. Oncotarget. 2015 Nov 17;6(36)38789-803.","abstract":null},{"pmid":"24285021","title":"Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.","journal":"Annals of oncology : official journal of the European Society for Medical Oncology","pubDate":"2014 Jan","volume":"25","issue":"1","pages":"126-31","authors":"Beau-Faller M et al","elocationId":"doi: 10.1093/annonc/mdt418","link":null,"reference":"Beau-Faller M et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Jan;25(1)126-31.","abstract":null},{"pmid":"24353160","title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.","journal":"Science translational medicine","pubDate":"2013 Dec 18","volume":"5","issue":"216","pages":"216ra177","authors":"Yasuda H et al","elocationId":"doi: 10.1126/scitranslmed.3007205","link":null,"reference":"Yasuda H et al. Science translational medicine. 2013 Dec 18;5(216)216ra177.","abstract":null},{"pmid":"23371856","title":"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.","journal":"Molecular cancer therapeutics","pubDate":"2013 Feb","volume":"12","issue":"2","pages":"220-9","authors":"Arcila ME et al","elocationId":"doi: 10.1158/1535-7163.MCT-12-0620","link":null,"reference":"Arcila ME et al. Molecular cancer therapeutics. 2013 Feb;12(2)220-9.","abstract":null},{"pmid":"23328547","title":"Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2013 Feb","volume":"8","issue":"2","pages":"179-84","authors":"Oxnard GR et al","elocationId":"doi: 10.1097/JTO.0b013e3182779d18","link":null,"reference":"Oxnard GR et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Feb;8(2)179-84.","abstract":null}]},{"id":2044,"uuid":"dc196791-41af-46c9-a295-299d1de62bb2","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"V600","name":"V600","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C98283","drugName":"Encorafenib","uuid":"001e534f-3e63-432f-90a6-d1af1759e4e2","synonyms":["LGX-818","Encorafenib","LGX818","LGX 818","ENCORAFENIB","Braftovi"],"priority":1},{"ncitCode":"C84865","drugName":"Binimetinib","uuid":"feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677","synonyms":["ARRY-438162","Mektovi","Binimetinib","ARRY-162","MEK162","BINIMETINIB"],"priority":2}]}],"knownEffect":"Sensitive","lastEdit":1576623414000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"29573941","title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2018 May","volume":"19","issue":"5","pages":"603-615","authors":"Dummer R et al","elocationId":"doi: 10.1016/S1470-2045(18)30142-6","link":null,"reference":"Dummer R et al. The Lancet. Oncology. 2018 May;19(5)603-615.","abstract":null}]},{"id":3645,"uuid":"ba33353e-abed-447e-8056-c44eb0396df2","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":873,"subtype":"","code":"","color":"HotPink","mainType":"Breast Cancer","level":0,"tissue":"Breast","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C95733","drugName":"Talazoparib","uuid":"2047c71e-58e0-4a54-9cfd-9267048e694f","synonyms":["TALAZOPARIB","BMN-673","Talazoparib","BMN 673"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1560900474000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"30110579","title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.","journal":"The New England journal of medicine","pubDate":"2018 Aug 23","volume":"379","issue":"8","pages":"753-763","authors":"Litton JK et al","elocationId":"doi: 10.1056/NEJMoa1802905","link":null,"reference":"Litton JK et al. The New England journal of medicine. 2018 Aug 23;379(8)753-763.","abstract":null},{"pmid":"30563931","title":"A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO).","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 May 1","volume":"25","issue":"9","pages":"2717-2724","authors":"Turner NC et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-1891","link":null,"reference":"Turner NC et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2717-2724.","abstract":null}]},{"id":2045,"uuid":"cfbf8fb3-ff8b-4786-90e2-a185f3e24009","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"V600","name":"V600","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C77908","drugName":"Trametinib","uuid":"fb2bb01c-c0ec-4641-abf7-87f486075022","synonyms":["Mekinist","\"GSK1120212","Trametinib\"","TRAMETINIB","JTP-74057","MEK Inhibitor GSK1120212","N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","Trametinib"],"priority":2},{"ncitCode":"C82386","drugName":"Dabrafenib","uuid":"939cd40b-b515-499d-b099-fd29027c0d17","synonyms":["DABRAFENIB","GSK2118436\"","\"BRAF Inhibitor GSK2118436","GSK-2118436","GSK-2118436A","Dabrafenib","Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1576623370000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"23020132","title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.","journal":"The New England journal of medicine","pubDate":"2012 Nov 1","volume":"367","issue":"18","pages":"1694-703","authors":"Flaherty KT et al","elocationId":"doi: 10.1056/NEJMoa1210093","link":null,"reference":"Flaherty KT et al. The New England journal of medicine. 2012 Nov 1;367(18)1694-703.","abstract":null},{"pmid":"29361468","title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2018 Feb","volume":"19","issue":"2","pages":"181-193","authors":"Amaria RN et al","elocationId":"doi: 10.1016/S1470-2045(18)30015-9","link":null,"reference":"Amaria RN et al. The Lancet. Oncology. 2018 Feb;19(2)181-193.","abstract":null},{"pmid":"25287827","title":"Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2014 Nov 20","volume":"32","issue":"33","pages":"3697-704","authors":"Johnson DB et al","elocationId":"doi: 10.1200/JCO.2014.57.3535","link":null,"reference":"Johnson DB et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Nov 20;32(33)3697-704.","abstract":null},{"pmid":"28891408","title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.","journal":"The New England journal of medicine","pubDate":"2017 Nov 9","volume":"377","issue":"19","pages":"1813-1823","authors":"Long GV et al","elocationId":"doi: 10.1056/NEJMoa1708539","link":null,"reference":"Long GV et al. The New England journal of medicine. 2017 Nov 9;377(19)1813-1823.","abstract":null},{"pmid":"31171876","title":"Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.","journal":"Nature medicine","pubDate":"2019 Jun","volume":"25","issue":"6","pages":"929-935","authors":"Sullivan RJ et al","elocationId":"doi: 10.1038/s41591-019-0474-7","link":null,"reference":"Sullivan RJ et al. Nature medicine. 2019 Jun;25(6)929-935.","abstract":null},{"pmid":"28991513","title":"Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2018 Mar 1","volume":"36","issue":"7","pages":"667-673","authors":"Long GV et al","elocationId":"doi: 10.1200/JCO.2017.74.1025","link":null,"reference":"Long GV et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Mar 1;36(7)667-673.","abstract":null},{"pmid":"31171878","title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.","journal":"Nature medicine","pubDate":"2019 Jun","volume":"25","issue":"6","pages":"941-946","authors":"Ascierto PA et al","elocationId":"doi: 10.1038/s41591-019-0448-9","link":null,"reference":"Ascierto PA et al. Nature medicine. 2019 Jun;25(6)941-946.","abstract":null},{"pmid":"31171879","title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.","journal":"Nature medicine","pubDate":"2019 Jun","volume":"25","issue":"6","pages":"936-940","authors":"Ribas A et al","elocationId":"doi: 10.1038/s41591-019-0476-5","link":null,"reference":"Ribas A et al. Nature medicine. 2019 Jun;25(6)936-940.","abstract":null},{"pmid":"25399551","title":"Improved overall survival in melanoma with combined dabrafenib and trametinib.","journal":"The New England journal of medicine","pubDate":"2015 Jan 1","volume":"372","issue":"1","pages":"30-9","authors":"Robert C et al","elocationId":"doi: 10.1056/NEJMoa1412690","link":null,"reference":"Robert C et al. The New England journal of medicine. 2015 Jan 1;372(1)30-9.","abstract":null},{"pmid":"25265492","title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.","journal":"The New England journal of medicine","pubDate":"2014 Nov 13","volume":"371","issue":"20","pages":"1877-88","authors":"Long GV et al","elocationId":"doi: 10.1056/NEJMoa1406037","link":null,"reference":"Long GV et al. The New England journal of medicine. 2014 Nov 13;371(20)1877-88.","abstract":null}]},{"id":3646,"uuid":"f05772d2-17a6-49fd-856d-5a4679ab8cbb","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":873,"subtype":"","code":"","color":"HotPink","mainType":"Breast Cancer","level":0,"tissue":"Breast","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1585195172000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2527","reference":"null. null. .","abstract":"Dhawan, MS et al. JCO. Abstract# 2527"},{"pmid":"28578601","title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.","journal":"The New England journal of medicine","pubDate":"2017 Aug 10","volume":"377","issue":"6","pages":"523-533","authors":"Robson M et al","elocationId":"doi: 10.1056/NEJMoa1706450","link":null,"reference":"Robson M et al. The New England journal of medicine. 2017 Aug 10;377(6)523-533.","abstract":null}]},{"id":7934,"uuid":"d2a6478d-6c0f-42a9-a144-b079ddfc7058","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":128,"subtype":"Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma","code":"USC","color":"PeachPuff","mainType":"Endometrial Cancer","level":3,"tissue":"Uterus","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C63402","drugName":"Carboplatin-Taxol Regimen","uuid":"4126682b-ac33-4d42-b856-b44eb064fd25","synonyms":["carboplatin-Taxol regimen","CaT regimen","PC Regimen","Carbo-Tax regimen","Carboplatin/Paclitaxel Regimen","CaT Regimen","PC regimen","Carboplatin/Paclitaxel","Carbo-Tax Regimen","Carboplatin-Paclitaxel Regimen","Carboplatin-Taxol Regimen"],"priority":1},{"ncitCode":"C1647","drugName":"Trastuzumab","uuid":"b29b3641-d866-4b09-bff6-3063d8316935","synonyms":["Anti-erbB2 Monoclonal Antibody","Anti-p185-HER2","Trastuzumab Biosimilar ABP 980","\"ABP 980","Trastuzumab Biosimilar PF-05280014","Anti-ERB-2","Herceptin","Trastuzumab-QYYP","Trastuzumab-dkst","PF-05280014","MoAb HER2","c-erb-2 Monoclonal Antibody","Trazimera","Anti-c-erbB2 Monoclonal Antibody","Trastuzumab Biosimilar ALT02","Herzuma","Trastuzumab-DTTB","Anti-erbB-2","Trastuzumab-pkrb","Ontruzant","TRASTUZUMAB","Trastuzumab Biosimilar HLX02","Anti-HER2/c-erbB2 Monoclonal Antibody","RO0452317","Monoclonal Antibody HER2","Monoclonal Antibody c-erb-2","Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer","rhuMAb HER2","trastuzumab","HER2 Monoclonal Antibody","Anti-c-ERB-2","Ogivri","Herceptin Biosimilar PF-05280014","Herceptin Trastuzumab Biosimilar PF-05280014","trastuzumab biosimilar EG12014\"","ALT02","Trastuzumab"],"priority":2}]}],"knownEffect":"Sensitive","lastEdit":1560989405000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"29584549","title":"Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2018 Jul 10","volume":"36","issue":"20","pages":"2044-2051","authors":"Fader AN et al","elocationId":"doi: 10.1200/JCO.2017.76.5966","link":null,"reference":"Fader AN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Jul 10;36(20)2044-2051.","abstract":null}]},{"id":2046,"uuid":"04ec8bf4-289b-4dad-a110-cc3f00045e4a","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"V600","name":"V600","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib","uuid":"4e91da20-6cf0-4e07-995f-7f7db4c7c077","synonyms":["Vemurafenib","BRAF(V600E) Kinase Inhibitor RO5185426","RO 5185426","PLX4032","PLX-4032","RG 7204","Zelboraf\"","BRAF (V600E) kinase inhibitor RO5185426","RG7204","\"1-propanesulfonamide, n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-","VEMURAFENIB"],"priority":1},{"ncitCode":"C68923","drugName":"Cobimetinib","uuid":"eb357145-3b18-4aca-b75a-5e18dd2bf4f9","synonyms":["Cotellic","Cobimetinib","XL518","COBIMETINIB","GDC-0973","MEK Inhibitor GDC-0973"],"priority":2}]}],"knownEffect":"Sensitive","lastEdit":1576623451000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"27480103","title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2016 Sep","volume":"17","issue":"9","pages":"1248-60","authors":"Ascierto PA et al","elocationId":"doi: 10.1016/S1470-2045(16)30122-X","link":null,"reference":"Ascierto PA et al. The Lancet. Oncology. 2016 Sep;17(9)1248-60.","abstract":null},{"pmid":"25265494","title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.","journal":"The New England journal of medicine","pubDate":"2014 Nov 13","volume":"371","issue":"20","pages":"1867-76","authors":"Larkin J et al","elocationId":"doi: 10.1056/NEJMoa1408868","link":null,"reference":"Larkin J et al. The New England journal of medicine. 2014 Nov 13;371(20)1867-76.","abstract":null}]},{"id":12736,"uuid":"1beae33a-b209-444f-8119-954ac559647e","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[" (2) adjuvant treatment of adult patients following complete gross resection of KIT-positive GIST.","Imatinib is FDA approved for the treatment of: (1) patients with KIT-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs)"],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1548779940000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"21642685","title":"KIT as a therapeutic target in metastatic melanoma.","journal":"JAMA","pubDate":"2011 Jun 8","volume":"305","issue":"22","pages":"2327-34","authors":"Carvajal RD et al","elocationId":"doi: 10.1001/jama.2011.746","link":null,"reference":"Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.","abstract":null},{"pmid":"23775962","title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2013 Sep 10","volume":"31","issue":"26","pages":"3182-90","authors":"Hodi FS et al","elocationId":"doi: 10.1200/JCO.2012.47.7836","link":null,"reference":"Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.","abstract":null}]},{"id":7936,"uuid":"e46d9bf0-c3eb-4e66-86ad-090066aed610","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":935,"subtype":"","code":"","color":"SaddleBrown","mainType":"Colorectal Cancer","level":0,"tissue":"Bowel","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C1647","drugName":"Trastuzumab","uuid":"b29b3641-d866-4b09-bff6-3063d8316935","synonyms":["Anti-erbB2 Monoclonal Antibody","Anti-p185-HER2","Trastuzumab Biosimilar ABP 980","\"ABP 980","Trastuzumab Biosimilar PF-05280014","Anti-ERB-2","Herceptin","Trastuzumab-QYYP","Trastuzumab-dkst","PF-05280014","MoAb HER2","c-erb-2 Monoclonal Antibody","Trazimera","Anti-c-erbB2 Monoclonal Antibody","Trastuzumab Biosimilar ALT02","Herzuma","Trastuzumab-DTTB","Anti-erbB-2","Trastuzumab-pkrb","Ontruzant","TRASTUZUMAB","Trastuzumab Biosimilar HLX02","Anti-HER2/c-erbB2 Monoclonal Antibody","RO0452317","Monoclonal Antibody HER2","Monoclonal Antibody c-erb-2","Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer","rhuMAb HER2","trastuzumab","HER2 Monoclonal Antibody","Anti-c-ERB-2","Ogivri","Herceptin Biosimilar PF-05280014","Herceptin Trastuzumab Biosimilar PF-05280014","trastuzumab biosimilar EG12014\"","ALT02","Trastuzumab"],"priority":1},{"ncitCode":"C38692","drugName":"Pertuzumab","uuid":"b89a5c78-1828-4adf-a9fa-937f99410c1d","synonyms":["Monoclonal Antibody 2C4","Perjeta","\"2C4","RO4368451","Pertuzumab","2C4 Antibody","Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide with Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer","pertuzumab","MoAb 2C4","Omnitarg","PERTUZUMAB","rhuMAb2C4\""],"priority":2}]}],"knownEffect":"Sensitive","lastEdit":1587077359000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"30857956","title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.","journal":"The Lancet. Oncology","pubDate":"2019 Apr","volume":"20","issue":"4","pages":"518-530","authors":"Meric-Bernstam F et al","elocationId":"doi: 10.1016/S1470-2045(18)30904-5","link":null,"reference":"Meric-Bernstam F et al. The Lancet. Oncology. 2019 Apr;20(4)518-530.","abstract":null}]},{"id":2753,"uuid":"ebedcec5-7241-4a17-b234-e645db8e7ffc","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":873,"subtype":"","code":"","color":"HotPink","mainType":"Breast Cancer","level":0,"tissue":"Breast","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":672,"hugoSymbol":"BRCA1","oncogene":false,"grch37Isoform":"ENST00000357654","grch37RefSeq":"NM_007294.3","grch38Isoform":"ENST00000357654","grch38RefSeq":"NM_007294.3","geneAliases":["RNF53","IRIS","BRCAI","PNCA4","PSCP","BROVCA1","BRCC1","FANCS","PPP1R53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":672,"hugoSymbol":"BRCA1","oncogene":false,"grch37Isoform":"ENST00000357654","grch37RefSeq":"NM_007294.3","grch38Isoform":"ENST00000357654","grch38RefSeq":"NM_007294.3","geneAliases":["RNF53","IRIS","BRCAI","PNCA4","PSCP","BROVCA1","BRCC1","FANCS","PPP1R53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["HER2-negative, metastatic breast cancer with pathogenic germline BRCA1 mutations"],"priority":1,"drugs":[{"ncitCode":"C95733","drugName":"Talazoparib","uuid":"2047c71e-58e0-4a54-9cfd-9267048e694f","synonyms":["TALAZOPARIB","BMN-673","Talazoparib","BMN 673"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1585194988000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"30110579","title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.","journal":"The New England journal of medicine","pubDate":"2018 Aug 23","volume":"379","issue":"8","pages":"753-763","authors":"Litton JK et al","elocationId":"doi: 10.1056/NEJMoa1802905","link":null,"reference":"Litton JK et al. The New England journal of medicine. 2018 Aug 23;379(8)753-763.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2527","reference":"null. null. .","abstract":"Dhawan, MS et al. JCO. Abstract# 2527"},{"pmid":"30563931","title":"A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO).","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 May 1","volume":"25","issue":"9","pages":"2717-2724","authors":"Turner NC et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-1891","link":null,"reference":"Turner NC et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2717-2724.","abstract":null}]},{"id":7937,"uuid":"7a88d4bf-ab60-4772-9ad6-e1a36c80df01","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":935,"subtype":"","code":"","color":"SaddleBrown","mainType":"Colorectal Cancer","level":0,"tissue":"Bowel","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C26653","drugName":"Lapatinib","uuid":"6b1eee04-b74c-46d3-bdd3-1c68d1ec11b0","synonyms":["LAPATINIB","GW572016","lapatinib","GW 2016","GW2016","GSK572016","Lapatinib"],"priority":1},{"ncitCode":"C1647","drugName":"Trastuzumab","uuid":"b29b3641-d866-4b09-bff6-3063d8316935","synonyms":["Anti-erbB2 Monoclonal Antibody","Anti-p185-HER2","Trastuzumab Biosimilar ABP 980","\"ABP 980","Trastuzumab Biosimilar PF-05280014","Anti-ERB-2","Herceptin","Trastuzumab-QYYP","Trastuzumab-dkst","PF-05280014","MoAb HER2","c-erb-2 Monoclonal Antibody","Trazimera","Anti-c-erbB2 Monoclonal Antibody","Trastuzumab Biosimilar ALT02","Herzuma","Trastuzumab-DTTB","Anti-erbB-2","Trastuzumab-pkrb","Ontruzant","TRASTUZUMAB","Trastuzumab Biosimilar HLX02","Anti-HER2/c-erbB2 Monoclonal Antibody","RO0452317","Monoclonal Antibody HER2","Monoclonal Antibody c-erb-2","Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer","rhuMAb HER2","trastuzumab","HER2 Monoclonal Antibody","Anti-c-ERB-2","Ogivri","Herceptin Biosimilar PF-05280014","Herceptin Trastuzumab Biosimilar PF-05280014","trastuzumab biosimilar EG12014\"","ALT02","Trastuzumab"],"priority":2}]}],"knownEffect":"Sensitive","lastEdit":1587161004000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"27108243","title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2016 Jun","volume":"17","issue":"6","pages":"738-746","authors":"Sartore-Bianchi A et al","elocationId":"doi: 10.1016/S1470-2045(16)00150-9","link":null,"reference":"Sartore-Bianchi A et al. The Lancet. Oncology. 2016 Jun;17(6)738-746.","abstract":null}]},{"id":2049,"uuid":"efa979c1-84eb-4c65-b291-9d395c322114","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":409,"subtype":"Anaplastic Thyroid Cancer","code":"THAP","color":"Teal","mainType":"Thyroid Cancer","level":2,"tissue":"Thyroid","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"V600","name":"V600","refResidues":"V","proteinStart":600,"proteinEnd":600,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C77908","drugName":"Trametinib","uuid":"fb2bb01c-c0ec-4641-abf7-87f486075022","synonyms":["Mekinist","\"GSK1120212","Trametinib\"","TRAMETINIB","JTP-74057","MEK Inhibitor GSK1120212","N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","Trametinib"],"priority":2},{"ncitCode":"C82386","drugName":"Dabrafenib","uuid":"939cd40b-b515-499d-b099-fd29027c0d17","synonyms":["DABRAFENIB","GSK2118436\"","\"BRAF Inhibitor GSK2118436","GSK-2118436","GSK-2118436A","Dabrafenib","Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1576623186000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"29072975","title":"Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2018 Jan 1","volume":"36","issue":"1","pages":"7-13","authors":"Subbiah V et al","elocationId":"doi: 10.1200/JCO.2017.73.6785","link":null,"reference":"Subbiah V et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Jan 1;36(1)7-13.","abstract":null}]},{"id":12738,"uuid":"45f36900-5398-417c-b04f-abe45f62304d","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":928,"subtype":"","code":"","color":"Purple","mainType":"Thymic Tumor","level":0,"tissue":"Thymus","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C71622","drugName":"Sunitinib","uuid":"5b548883-0142-4d15-a324-22d7b29800b2","synonyms":["\"1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-","Sunitinib","SUNITINIB","sunitinib\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1548779950000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"20571495","title":"Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.","journal":"British journal of cancer","pubDate":"2010 Jul 13","volume":"103","issue":"2","pages":"196-200","authors":"Ströbel P et al","elocationId":"doi: 10.1038/sj.bjc.6605740","link":null,"reference":"Ströbel P et al. British journal of cancer. 2010 Jul 13;103(2)196-200.","abstract":null},{"pmid":"14991904","title":"KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas.","journal":"The Journal of pathology","pubDate":"2004 Mar","volume":"202","issue":"3","pages":"375-81","authors":"Pan CC et al","elocationId":"","link":null,"reference":"Pan CC et al. The Journal of pathology. 2004 Mar;202(3)375-81.","abstract":null},{"pmid":"25592632","title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2015 Feb","volume":"16","issue":"2","pages":"177-86","authors":"Thomas A et al","elocationId":"doi: 10.1016/S1470-2045(14)71181-7","link":null,"reference":"Thomas A et al. The Lancet. Oncology. 2015 Feb;16(2)177-86.","abstract":null}]},{"id":2754,"uuid":"0f8b94b0-b92e-415b-b3ef-de93631f0ec9","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":873,"subtype":"","code":"","color":"HotPink","mainType":"Breast Cancer","level":0,"tissue":"Breast","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":672,"hugoSymbol":"BRCA1","oncogene":false,"grch37Isoform":"ENST00000357654","grch37RefSeq":"NM_007294.3","grch38Isoform":"ENST00000357654","grch38RefSeq":"NM_007294.3","geneAliases":["RNF53","IRIS","BRCAI","PNCA4","PSCP","BROVCA1","BRCC1","FANCS","PPP1R53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":672,"hugoSymbol":"BRCA1","oncogene":false,"grch37Isoform":"ENST00000357654","grch37RefSeq":"NM_007294.3","grch38Isoform":"ENST00000357654","grch38RefSeq":"NM_007294.3","geneAliases":["RNF53","IRIS","BRCAI","PNCA4","PSCP","BROVCA1","BRCC1","FANCS","PPP1R53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1576711138000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"28578601","title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.","journal":"The New England journal of medicine","pubDate":"2017 Aug 10","volume":"377","issue":"6","pages":"523-533","authors":"Robson M et al","elocationId":"doi: 10.1056/NEJMoa1706450","link":null,"reference":"Robson M et al. The New England journal of medicine. 2017 Aug 10;377(6)523-533.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://ascopubs.org/doi/full/10.1200/PO.19.00012","reference":"null. null. .","abstract":"Pascual et al. JCOPO, 2019"}]},{"id":17,"uuid":"e3436ce0-bd08-4929-9f38-c8ff5bf1eddb","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BCR-ABL1 Fusion","name":"BCR-ABL1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C60809","drugName":"Bosutinib","uuid":"80a4278a-4622-45e5-9e3f-8ca98657692f","synonyms":["BOSUTINIB","\"4-Anilino-3-quinolinecarbonitrile","SKI-606\"","4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile","SKI 606","Bosulif","SKI-606","4-Anilinobenzo(g)quinoline-3-carbonitrile","Bosutinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1576617864000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"25132497","title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.","journal":"Cancer cell","pubDate":"2014 Sep 8","volume":"26","issue":"3","pages":"428-442","authors":"Zabriskie MS et al","elocationId":"doi: 10.1016/j.ccr.2014.07.006","link":null,"reference":"Zabriskie MS et al. Cancer cell. 2014 Sep 8;26(3)428-442.","abstract":null},{"pmid":"19075254","title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2009 Jan 20","volume":"27","issue":"3","pages":"469-71","authors":"Redaelli S et al","elocationId":"doi: 10.1200/JCO.2008.19.8853","link":null,"reference":"Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.","abstract":null},{"pmid":"22371878","title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.","journal":"Blood","pubDate":"2012 Apr 12","volume":"119","issue":"15","pages":"3403-12","authors":"Khoury HJ et al","elocationId":"doi: 10.1182/blood-2011-11-390120","link":null,"reference":"Khoury HJ et al. Blood. 2012 Apr 12;119(15)3403-12.","abstract":null},{"pmid":"26040495","title":"Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.","journal":"American journal of hematology","pubDate":"2015 Sep","volume":"90","issue":"9","pages":"755-68","authors":"Gambacorti-Passerini C et al","elocationId":"doi: 10.1002/ajh.24034","link":null,"reference":"Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.","abstract":null},{"pmid":"24345751","title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.","journal":"Blood","pubDate":"2014 Feb 27","volume":"123","issue":"9","pages":"1309-18","authors":"Kantarjian HM et al","elocationId":"doi: 10.1182/blood-2013-07-513937","link":null,"reference":"Kantarjian HM et al. Blood. 2014 Feb 27;123(9)1309-18.","abstract":null},{"pmid":"21865346","title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.","journal":"Blood","pubDate":"2011 Oct 27","volume":"118","issue":"17","pages":"4567-76","authors":"Cortes JE et al","elocationId":"doi: 10.1182/blood-2011-05-355594","link":null,"reference":"Cortes JE et al. Blood. 2011 Oct 27;118(17)4567-76.","abstract":null}]},{"id":18,"uuid":"d393477d-6d91-4a21-9c10-7ea768b7c4ea","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BCR-ABL1 Fusion","name":"BCR-ABL1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":4,"drugs":[{"ncitCode":"C48375","drugName":"Nilotinib","uuid":"0f991d49-4cf2-4975-b52f-d7d037aa7f11","synonyms":["Nilotinib","AMN 107 Base Form","nilotinib","4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide","NILOTINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1576603282000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"26065651","title":"Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.","journal":"Blood","pubDate":"2015 Aug 6","volume":"126","issue":"6","pages":"746-56","authors":"Kim DY et al","elocationId":"doi: 10.1182/blood-2015-03-636548","link":null,"reference":"Kim DY et al. Blood. 2015 Aug 6;126(6)746-56.","abstract":null},{"pmid":"16775235","title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.","journal":"The New England journal of medicine","pubDate":"2006 Jun 15","volume":"354","issue":"24","pages":"2542-51","authors":"Kantarjian H et al","elocationId":"","link":null,"reference":"Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.","abstract":null}]},{"id":724,"uuid":"e9fc38ab-fa03-43a4-a1fb-b07a35510673","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":803,"subtype":"Inflammatory Myofibroblastic Tumor","code":"IMT","color":"LightYellow","mainType":"Soft Tissue Sarcoma","level":2,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Crizotinib is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive as detected by an FDA-approved test."],"priority":1,"drugs":[{"ncitCode":"C74061","drugName":"Crizotinib","uuid":"f05d12ab-6204-4a1c-803f-f3a7f6e30af2","synonyms":["MET Tyrosine Kinase Inhibitor PF-02341066","Crizotinib","2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-","Xalkori\"","PF-02341066","CRIZOTINIB","PF-2341066","\"(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine","MET tyrosine kinase inhibitor PF-02341066"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1558505445000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://ascopubs.org/doi/full/10.1200/PO.18.00297","reference":"null. null. .","abstract":"Trahair et al. JCO PO, 2018"},{"pmid":"23598171","title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.","journal":"The Lancet. Oncology","pubDate":"2013 May","volume":"14","issue":"6","pages":"472-80","authors":"Mossé YP et al","elocationId":"doi: 10.1016/S1470-2045(13)70095-0","link":null,"reference":"Mossé YP et al. The Lancet. Oncology. 2013 May;14(6)472-80.","abstract":null},{"pmid":"20979472","title":"Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.","journal":"The New England journal of medicine","pubDate":"2010 Oct 28","volume":"363","issue":"18","pages":"1727-33","authors":"Butrynski JE et al","elocationId":"doi: 10.1056/NEJMoa1007056","link":null,"reference":"Butrynski JE et al. The New England journal of medicine. 2010 Oct 28;363(18)1727-33.","abstract":null}]},{"id":725,"uuid":"ef268e17-cfe4-47de-9c54-6091b3b80165","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":803,"subtype":"Inflammatory Myofibroblastic Tumor","code":"IMT","color":"LightYellow","mainType":"Soft Tissue Sarcoma","level":2,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":238,"hugoSymbol":"ALK","oncogene":true,"grch37Isoform":"ENST00000389048","grch37RefSeq":"NM_004304.4","grch38Isoform":"ENST00000389048","grch38RefSeq":"NM_004304.4","geneAliases":["NBLST3","CD246"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Ceritinib is FDA-approved for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) with disease progression on or who are intolerant to crizotinib."],"priority":2,"drugs":[{"ncitCode":"C115112","drugName":"Ceritinib","uuid":"5e9aa568-30cf-48ef-b9ce-18851af2f622","synonyms":["LDK378","Zykadia\"","LDK 378","CERITINIB","\"2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-","Ceritinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1551764453000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"26020125","title":"Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2015 Jul","volume":"10","issue":"7","pages":"1058-66","authors":"Nishio M et al","elocationId":"doi: 10.1097/JTO.0000000000000566","link":null,"reference":"Nishio M et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Jul;10(7)1058-66.","abstract":null},{"pmid":"24670165","title":"Ceritinib in ALK-rearranged non-small-cell lung cancer.","journal":"The New England journal of medicine","pubDate":"2014 Mar 27","volume":"370","issue":"13","pages":"1189-97","authors":"Shaw AT et al","elocationId":"doi: 10.1056/NEJMoa1311107","link":null,"reference":"Shaw AT et al. The New England journal of medicine. 2014 Mar 27;370(13)1189-97.","abstract":null}]},{"id":20632,"uuid":"354c5b25-def4-4e66-8055-1d298c703dea","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5979,"hugoSymbol":"RET","oncogene":true,"grch37Isoform":"ENST00000355710","grch37RefSeq":"NM_020975.4","grch38Isoform":"ENST00000355710","grch38RefSeq":"NM_020975.4","geneAliases":["MTC1","CDHF12","CDHR16","MEN2A","HSCR1","MEN2B","RET-ELE1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5979,"hugoSymbol":"RET","oncogene":true,"grch37Isoform":"ENST00000355710","grch37RefSeq":"NM_020975.4","grch38Isoform":"ENST00000355710","grch38RefSeq":"NM_020975.4","geneAliases":["MTC1","CDHF12","CDHR16","MEN2A","HSCR1","MEN2B","RET-ELE1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Cabozantinib is FDA-approved for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy."],"priority":1,"drugs":[{"ncitCode":"C52200","drugName":"Cabozantinib","uuid":"6acebe88-de89-4ec1-bc38-74cb63861d23","synonyms":["\"1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-","CABOZANTINIB","Cabozantinib","N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1563344102000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"23533264","title":"Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.","journal":"Cancer discovery","pubDate":"2013 Jun","volume":"3","issue":"6","pages":"630-5","authors":"Drilon A et al","elocationId":"doi: 10.1158/2159-8290.CD-13-0035","link":null,"reference":"Drilon A et al. Cancer discovery. 2013 Jun;3(6)630-5.","abstract":null},{"pmid":"27825636","title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.","journal":"The Lancet. Oncology","pubDate":"2016 Dec","volume":"17","issue":"12","pages":"1653-1660","authors":"Drilon A et al","elocationId":"doi: 10.1016/S1470-2045(16)30562-9","link":null,"reference":"Drilon A et al. The Lancet. Oncology. 2016 Dec;17(12)1653-1660.","abstract":null},{"pmid":"28447912","title":"Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 May 1","volume":"35","issue":"13","pages":"1403-1410","authors":"Gautschi O et al","elocationId":"doi: 10.1200/JCO.2016.70.9352","link":null,"reference":"Gautschi O et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 May 1;35(13)1403-1410.","abstract":null}]},{"id":5400,"uuid":"f8abdc52-ed50-41b3-b8bf-88ba7197dbd2","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":164,"subtype":"Dedifferentiated Liposarcoma","code":"DDLS","color":"LightYellow","mainType":"Soft Tissue Sarcoma","level":3,"tissue":"Soft Tissue","tumorForm":"SOLID"},{"id":41,"subtype":"Well-Differentiated Liposarcoma","code":"WDLS","color":"LightYellow","mainType":"Soft Tissue Sarcoma","level":3,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1019,"hugoSymbol":"CDK4","oncogene":true,"grch37Isoform":"ENST00000257904","grch37RefSeq":"NM_000075.3","grch38Isoform":"ENST00000257904","grch38RefSeq":"NM_000075.3","geneAliases":["PSK-J3","CMM3"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1019,"hugoSymbol":"CDK4","oncogene":true,"grch37Isoform":"ENST00000257904","grch37RefSeq":"NM_000075.3","grch38Isoform":"ENST00000257904","grch38RefSeq":"NM_000075.3","geneAliases":["PSK-J3","CMM3"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Palbociclib is FDA-approved (1) in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy, (2) in combination with letrozole for the treatment of HR-positive, HER2-negative advanced breast cancer as initial endocrine based therapy in postmenopausal women."],"priority":1,"drugs":[{"ncitCode":"C49176","drugName":"Palbociclib","uuid":"9b59ba48-b340-4e20-8d01-c50dd438e731","synonyms":["PALBOCICLIB","\"6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one","PD 991","Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-\"","Palbociclib","PD-0332991","PD 332991","PD 0332991","Ibrance"],"priority":1}]},{"approvedIndications":["Palbociclib is FDA-approved (1) in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy, (2) in combination with letrozole for the treatment of HR-positive, HER2-negative advanced breast cancer as initial endocrine based therapy in postmenopausal women."],"priority":2,"drugs":[{"ncitCode":"C97660","drugName":"Abemaciclib","uuid":"d65def80-26cb-4af0-b87b-f9a6b498b2a4","synonyms":["Verzenio\"","Abemaciclib","\"2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)","LY-2835219","ABEMACICLIB","LY2835219"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1527699425000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"27124835","title":"Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.","journal":"JAMA oncology","pubDate":"2016 Jul 1","volume":"2","issue":"7","pages":"937-40","authors":"Dickson MA et al","elocationId":"doi: 10.1001/jamaoncol.2016.0264","link":null,"reference":"Dickson MA et al. JAMA oncology. 2016 Jul 1;2(7)937-40.","abstract":null},{"pmid":"23569312","title":"Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2013 Jun 1","volume":"31","issue":"16","pages":"2024-8","authors":"Dickson MA et al","elocationId":"doi: 10.1200/JCO.2012.46.5476","link":null,"reference":"Dickson MA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jun 1;31(16)2024-8.","abstract":null}]},{"id":20633,"uuid":"dcdb5ca8-eeba-4c19-972a-e907d3014c3a","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5979,"hugoSymbol":"RET","oncogene":true,"grch37Isoform":"ENST00000355710","grch37RefSeq":"NM_020975.4","grch38Isoform":"ENST00000355710","grch38RefSeq":"NM_020975.4","geneAliases":["MTC1","CDHF12","CDHR16","MEN2A","HSCR1","MEN2B","RET-ELE1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5979,"hugoSymbol":"RET","oncogene":true,"grch37Isoform":"ENST00000355710","grch37RefSeq":"NM_020975.4","grch38Isoform":"ENST00000355710","grch38RefSeq":"NM_020975.4","geneAliases":["MTC1","CDHF12","CDHR16","MEN2A","HSCR1","MEN2B","RET-ELE1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C2737","drugName":"Vandetanib","uuid":"ff6d46d6-dc87-484b-85ea-3aba89bbe86d","synonyms":["Vandetanib","ZD-6474","vandetanib","Zactima","AZD6474","Caprelsa","VANDETANIB","ZD6474"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1563986441000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"27803005","title":"Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.","journal":"Annals of oncology : official journal of the European Society for Medical Oncology","pubDate":"2017 Feb 1","volume":"28","issue":"2","pages":"292-297","authors":"Lee SH et al","elocationId":"doi: 10.1093/annonc/mdw559","link":null,"reference":"Lee SH et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Feb 1;28(2)292-297.","abstract":null}]},{"id":17436,"uuid":"84f79242-842e-4e41-b557-b227de74127d","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"D842V","name":"D842V","refResidues":"D","proteinStart":842,"proteinEnd":842,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Dasatinib is FDA-approved for 1) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase"," 2) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib"," 3) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy"],"priority":1,"drugs":[{"ncitCode":"C38713","drugName":"Dasatinib","uuid":"df40a264-628f-4070-9078-965c0471bd2c","synonyms":["Dasatinib","dasatinib","Sprycel","BMS-354825","DASATINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1546888063000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://meetinglibrary.asco.org/content/79120-102","reference":"null. null. .","abstract":"Trent et al. Abstract# 10006, ASCO 2011"}]},{"id":14689,"uuid":"fe0fb124-51b2-4c0c-af68-454243900613","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Y1003","name":"Y1003","refResidues":"Y","proteinStart":1003,"proteinEnd":1003,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"consequence":{"term":"splice_region_variant","isGenerallyTruncating":true,"description":"A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron"},"alteration":"963_1010splice","name":"Exon 14 splice mutation","refResidues":null,"proteinStart":963,"proteinEnd":1010,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"963_1010del","name":"Exon 14 deletion","refResidues":null,"proteinStart":963,"proteinEnd":1010,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":4233,"hugoSymbol":"MET","oncogene":true,"grch37Isoform":"ENST00000397752","grch37RefSeq":"NM_000245.2","grch38Isoform":"ENST00000397752","grch38RefSeq":"NM_000245.2","geneAliases":["HGFR","c-Met","DFNB97","AUTS9"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D1010","name":"D1010","refResidues":"D","proteinStart":1010,"proteinEnd":1010,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Crizotinib is FDA-approved for (1) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive as detected by an FDA-approved test (2) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive."],"priority":1,"drugs":[{"ncitCode":"C74061","drugName":"Crizotinib","uuid":"f05d12ab-6204-4a1c-803f-f3a7f6e30af2","synonyms":["MET Tyrosine Kinase Inhibitor PF-02341066","Crizotinib","2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-","Xalkori\"","PF-02341066","CRIZOTINIB","PF-2341066","\"(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine","MET tyrosine kinase inhibitor PF-02341066"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1579139076000,"lastReview":null,"levelOfEvidence":"LEVEL_2","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"31932802","title":"Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.","journal":"Nature medicine","pubDate":"2020 Jan","volume":"26","issue":"1","pages":"47-51","authors":"Drilon A et al","elocationId":"doi: 10.1038/s41591-019-0716-8","link":null,"reference":"Drilon A et al. Nature medicine. 2020 Jan;26(1)47-51.","abstract":null},{"pmid":"25971939","title":"Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.","journal":"Cancer discovery","pubDate":"2015 Aug","volume":"5","issue":"8","pages":"842-9","authors":"Paik PK et al","elocationId":"doi: 10.1158/2159-8290.CD-14-1467","link":null,"reference":"Paik PK et al. Cancer discovery. 2015 Aug;5(8)842-9.","abstract":null},{"pmid":"21623265","title":"Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2011 May","volume":"6","issue":"5","pages":"942-6","authors":"Ou SH et al","elocationId":"doi: 10.1097/JTO.0b013e31821528d3","link":null,"reference":"Ou SH et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 May;6(5)942-6.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://meetinglibrary.asco.org/content/132030-144","reference":"null. null. .","abstract":"Camidge et al. Abstract# 8001, ASCO 2014"},{"pmid":"26729443","title":"MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2016 Mar 1","volume":"34","issue":"7","pages":"721-30","authors":"Awad MM et al","elocationId":"doi: 10.1200/JCO.2015.63.4600","link":null,"reference":"Awad MM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Mar 1;34(7)721-30.","abstract":null},{"pmid":"31416808","title":"Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 Dec 15","volume":"25","issue":"24","pages":"7312-7319","authors":"Landi L et al","elocationId":"doi: 10.1158/1078-0432.CCR-19-0994","link":null,"reference":"Landi L et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Dec 15;25(24)7312-7319.","abstract":null}]}],"LEVEL_R1":[{"id":6577,"uuid":"1a34e0c0-211d-4249-8719-f598b85d6530","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_RESISTANCE","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T790M","name":"T790M","refResidues":"T","proteinStart":790,"proteinEnd":790,"variantResidues":"M","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C66940","drugName":"Afatinib","uuid":"e1f45ae7-33ae-428c-9e77-da4a9b7270b6","synonyms":["BIBW 2992","Afatinib","BIBW2992","AFATINIB","(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C65530","drugName":"Erlotinib","uuid":"83754311-3f3b-4782-bfbf-08e71c790b9a","synonyms":["Erlotinib","erlotinib","ERLOTINIB"],"priority":1}]},{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C1855","drugName":"Gefitinib","uuid":"b76d7b2b-b5fb-4561-892f-6b00bfaf0dfa","synonyms":["GEFITINIB","Iressa","N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine","ZD 1839","gefitinib","Gefitinib","4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline","ZD1839"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1548175002000,"lastReview":null,"levelOfEvidence":"LEVEL_R1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"24478319","title":"Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.","journal":"Annals of oncology : official journal of the European Society for Medical Oncology","pubDate":"2014 Feb","volume":"25","issue":"2","pages":"423-8","authors":"Yu HA et al","elocationId":"doi: 10.1093/annonc/mdt573","link":null,"reference":"Yu HA et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Feb;25(2)423-8.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://library.iaslc.org/search-speaker?search_speaker=17991","reference":"null. null. .","abstract":"Yang et al. Abstract# O03.05, IASLC 2013"},{"pmid":"26051236","title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.","journal":"The Lancet. Oncology","pubDate":"2015 Jul","volume":"16","issue":"7","pages":"830-8","authors":"Yang JC et al","elocationId":"doi: 10.1016/S1470-2045(15)00026-1","link":null,"reference":"Yang JC et al. The Lancet. Oncology. 2015 Jul;16(7)830-8.","abstract":null},{"pmid":"23816963","title":"LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2013 Sep 20","volume":"31","issue":"27","pages":"3335-41","authors":"Katakami N et al","elocationId":"doi: 10.1200/JCO.2012.45.0981","link":null,"reference":"Katakami N et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 20;31(27)3335-41.","abstract":null}]},{"id":4785,"uuid":"5b8f9776-69c9-48b1-afbf-8cce00c1b803","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_RESISTANCE","cancerTypes":[{"id":533,"subtype":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","code":"CLLSLL","color":"LimeGreen","mainType":"Mature B-Cell Neoplasms","level":5,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":695,"hugoSymbol":"BTK","oncogene":true,"grch37Isoform":"ENST00000308731","grch37RefSeq":"NM_000061.2","grch38Isoform":"ENST00000308731","grch38RefSeq":"NM_000061.2","geneAliases":["AT","IMD1","AGMX1","ATK","BPK","XLA","IGHD3","PSCTK1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":695,"hugoSymbol":"BTK","oncogene":true,"grch37Isoform":"ENST00000308731","grch37RefSeq":"NM_000061.2","grch38Isoform":"ENST00000308731","grch38RefSeq":"NM_000061.2","geneAliases":["AT","IMD1","AGMX1","ATK","BPK","XLA","IGHD3","PSCTK1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"C481S","name":"C481S","refResidues":"C","proteinStart":481,"proteinEnd":481,"variantResidues":"S","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C81934","drugName":"Ibrutinib","uuid":"343b7a45-c0c9-440e-97f9-fef7947ff97a","synonyms":["Imbruvica","CRA-032765","\"2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-","BTK Inhibitor PCI-32765","IBRUTINIB","PCI-32765\"","Ibrutinib"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1608269785000,"lastReview":null,"levelOfEvidence":"LEVEL_R1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"24869598","title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.","journal":"The New England journal of medicine","pubDate":"2014 Jun 12","volume":"370","issue":"24","pages":"2286-94","authors":"Woyach JA et al","elocationId":"doi: 10.1056/NEJMoa1400029","link":null,"reference":"Woyach JA et al. The New England journal of medicine. 2014 Jun 12;370(24)2286-94.","abstract":null},{"pmid":"28418267","title":"BTK<sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 May 1","volume":"35","issue":"13","pages":"1437-1443","authors":"Woyach JA et al","elocationId":"doi: 10.1200/JCO.2016.70.2282","link":null,"reference":"Woyach JA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 May 1;35(13)1437-1443.","abstract":null}]},{"id":83,"uuid":"8dda7c39-ef3b-431c-8263-0164af661cec","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_RESISTANCE","cancerTypes":[{"id":560,"subtype":"Chronic Myelogenous Leukemia","code":"CML","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T315I","name":"T315I","refResidues":"T","proteinStart":315,"proteinEnd":315,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]},{"approvedIndications":[],"priority":4,"drugs":[{"ncitCode":"C60809","drugName":"Bosutinib","uuid":"80a4278a-4622-45e5-9e3f-8ca98657692f","synonyms":["BOSUTINIB","\"4-Anilino-3-quinolinecarbonitrile","SKI-606\"","4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile","SKI 606","Bosulif","SKI-606","4-Anilinobenzo(g)quinoline-3-carbonitrile","Bosutinib"],"priority":1}]},{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C48375","drugName":"Nilotinib","uuid":"0f991d49-4cf2-4975-b52f-d7d037aa7f11","synonyms":["Nilotinib","AMN 107 Base Form","nilotinib","4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide","NILOTINIB"],"priority":1}]},{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C38713","drugName":"Dasatinib","uuid":"df40a264-628f-4070-9078-965c0471bd2c","synonyms":["Dasatinib","dasatinib","Sprycel","BMS-354825","DASATINIB"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1576706290000,"lastReview":null,"levelOfEvidence":"LEVEL_R1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"21562040","title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.","journal":"Blood","pubDate":"2011 Aug 4","volume":"118","issue":"5","pages":"1208-15","authors":"Soverini S et al","elocationId":"doi: 10.1182/blood-2010-12-326405","link":null,"reference":"Soverini S et al. Blood. 2011 Aug 4;118(5)1208-15.","abstract":null},{"pmid":"19075254","title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2009 Jan 20","volume":"27","issue":"3","pages":"469-71","authors":"Redaelli S et al","elocationId":"doi: 10.1200/JCO.2008.19.8853","link":null,"reference":"Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.","abstract":null},{"pmid":"17768119","title":"Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.","journal":"Haematologica","pubDate":"2007 Sep","volume":"92","issue":"9","pages":"1238-41","authors":"Nicolini FE et al","elocationId":"","link":null,"reference":"Nicolini FE et al. Haematologica. 2007 Sep;92(9)1238-41.","abstract":null},{"pmid":"18403620","title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.","journal":"Blood","pubDate":"2008 Jul 1","volume":"112","issue":"1","pages":"53-5","authors":"Jabbour E et al","elocationId":"doi: 10.1182/blood-2007-11-123950","link":null,"reference":"Jabbour E et al. Blood. 2008 Jul 1;112(1)53-5.","abstract":null},{"pmid":"17339191","title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.","journal":"Haematologica","pubDate":"2007 Mar","volume":"92","issue":"3","pages":"401-4","authors":"Soverini S et al","elocationId":"","link":null,"reference":"Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.","abstract":null}]},{"id":86,"uuid":"a2257c07-6acb-46e3-bdb6-d1d70a58a1b4","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_RESISTANCE","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T315I","name":"T315I","refResidues":"T","proteinStart":315,"proteinEnd":315,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C48375","drugName":"Nilotinib","uuid":"0f991d49-4cf2-4975-b52f-d7d037aa7f11","synonyms":["Nilotinib","AMN 107 Base Form","nilotinib","4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide","NILOTINIB"],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]},{"approvedIndications":[],"priority":4,"drugs":[{"ncitCode":"C60809","drugName":"Bosutinib","uuid":"80a4278a-4622-45e5-9e3f-8ca98657692f","synonyms":["BOSUTINIB","\"4-Anilino-3-quinolinecarbonitrile","SKI-606\"","4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile","SKI 606","Bosulif","SKI-606","4-Anilinobenzo(g)quinoline-3-carbonitrile","Bosutinib"],"priority":1}]},{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C38713","drugName":"Dasatinib","uuid":"df40a264-628f-4070-9078-965c0471bd2c","synonyms":["Dasatinib","dasatinib","Sprycel","BMS-354825","DASATINIB"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1576693405000,"lastReview":null,"levelOfEvidence":"LEVEL_R1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"21562040","title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.","journal":"Blood","pubDate":"2011 Aug 4","volume":"118","issue":"5","pages":"1208-15","authors":"Soverini S et al","elocationId":"doi: 10.1182/blood-2010-12-326405","link":null,"reference":"Soverini S et al. Blood. 2011 Aug 4;118(5)1208-15.","abstract":null},{"pmid":"19075254","title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2009 Jan 20","volume":"27","issue":"3","pages":"469-71","authors":"Redaelli S et al","elocationId":"doi: 10.1200/JCO.2008.19.8853","link":null,"reference":"Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.","abstract":null},{"pmid":"17768119","title":"Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.","journal":"Haematologica","pubDate":"2007 Sep","volume":"92","issue":"9","pages":"1238-41","authors":"Nicolini FE et al","elocationId":"","link":null,"reference":"Nicolini FE et al. Haematologica. 2007 Sep;92(9)1238-41.","abstract":null},{"pmid":"18403620","title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.","journal":"Blood","pubDate":"2008 Jul 1","volume":"112","issue":"1","pages":"53-5","authors":"Jabbour E et al","elocationId":"doi: 10.1182/blood-2007-11-123950","link":null,"reference":"Jabbour E et al. Blood. 2008 Jul 1;112(1)53-5.","abstract":null},{"pmid":"17339191","title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.","journal":"Haematologica","pubDate":"2007 Mar","volume":"92","issue":"3","pages":"401-4","authors":"Soverini S et al","elocationId":"","link":null,"reference":"Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.","abstract":null}]},{"id":121,"uuid":"d31b72b1-a668-4841-93e9-7796e0d02190","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_RESISTANCE","cancerTypes":[{"id":560,"subtype":"Chronic Myelogenous Leukemia","code":"CML","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317L","name":"F317L","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V299L","name":"V299L","refResidues":"V","proteinStart":299,"proteinEnd":299,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"G250E","name":"G250E","refResidues":"G","proteinStart":250,"proteinEnd":250,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C60809","drugName":"Bosutinib","uuid":"80a4278a-4622-45e5-9e3f-8ca98657692f","synonyms":["BOSUTINIB","\"4-Anilino-3-quinolinecarbonitrile","SKI-606\"","4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile","SKI 606","Bosulif","SKI-606","4-Anilinobenzo(g)quinoline-3-carbonitrile","Bosutinib"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1602654821000,"lastReview":null,"levelOfEvidence":"LEVEL_R1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22371878","title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.","journal":"Blood","pubDate":"2012 Apr 12","volume":"119","issue":"15","pages":"3403-12","authors":"Khoury HJ et al","elocationId":"doi: 10.1182/blood-2011-11-390120","link":null,"reference":"Khoury HJ et al. Blood. 2012 Apr 12;119(15)3403-12.","abstract":null},{"pmid":"21865346","title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.","journal":"Blood","pubDate":"2011 Oct 27","volume":"118","issue":"17","pages":"4567-76","authors":"Cortes JE et al","elocationId":"doi: 10.1182/blood-2011-05-355594","link":null,"reference":"Cortes JE et al. Blood. 2011 Oct 27;118(17)4567-76.","abstract":null}]},{"id":122,"uuid":"1626e6c9-8cac-47f2-9dc1-74d3c72745d7","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_RESISTANCE","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317L","name":"F317L","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V299L","name":"V299L","refResidues":"V","proteinStart":299,"proteinEnd":299,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"G250E","name":"G250E","refResidues":"G","proteinStart":250,"proteinEnd":250,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C60809","drugName":"Bosutinib","uuid":"80a4278a-4622-45e5-9e3f-8ca98657692f","synonyms":["BOSUTINIB","\"4-Anilino-3-quinolinecarbonitrile","SKI-606\"","4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile","SKI 606","Bosulif","SKI-606","4-Anilinobenzo(g)quinoline-3-carbonitrile","Bosutinib"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1602654851000,"lastReview":null,"levelOfEvidence":"LEVEL_R1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"26040495","title":"Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.","journal":"American journal of hematology","pubDate":"2015 Sep","volume":"90","issue":"9","pages":"755-68","authors":"Gambacorti-Passerini C et al","elocationId":"doi: 10.1002/ajh.24034","link":null,"reference":"Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.","abstract":null}]},{"id":123,"uuid":"c8a49f31-5abd-4e77-9b37-221f9805b89e","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_RESISTANCE","cancerTypes":[{"id":560,"subtype":"Chronic Myelogenous Leukemia","code":"CML","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317C","name":"F317C","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317L","name":"F317L","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V299L","name":"V299L","refResidues":"V","proteinStart":299,"proteinEnd":299,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317V","name":"F317V","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T315A","name":"T315A","refResidues":"T","proteinStart":315,"proteinEnd":315,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317I","name":"F317I","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C38713","drugName":"Dasatinib","uuid":"df40a264-628f-4070-9078-965c0471bd2c","synonyms":["Dasatinib","dasatinib","Sprycel","BMS-354825","DASATINIB"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1602654954000,"lastReview":null,"levelOfEvidence":"LEVEL_R1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"17785585","title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.","journal":"Blood","pubDate":"2007 Dec 1","volume":"110","issue":"12","pages":"4005-11","authors":"Cortes J et al","elocationId":"","link":null,"reference":"Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.","abstract":null},{"pmid":"17114651","title":"Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2006 Nov 20","volume":"24","issue":"33","pages":"e51-2","authors":"Soverini S et al","elocationId":"","link":null,"reference":"Soverini S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Nov 20;24(33)e51-2.","abstract":null},{"pmid":"19779040","title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.","journal":"Blood","pubDate":"2009 Dec 3","volume":"114","issue":"24","pages":"4944-53","authors":"Müller MC et al","elocationId":"doi: 10.1182/blood-2009-04-214221","link":null,"reference":"Müller MC et al. Blood. 2009 Dec 3;114(24)4944-53.","abstract":null},{"pmid":"17339191","title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.","journal":"Haematologica","pubDate":"2007 Mar","volume":"92","issue":"3","pages":"401-4","authors":"Soverini S et al","elocationId":"","link":null,"reference":"Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.","abstract":null},{"pmid":"19589924","title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.","journal":"Blood","pubDate":"2009 Sep 3","volume":"114","issue":"10","pages":"2168-71","authors":"Soverini S et al","elocationId":"doi: 10.1182/blood-2009-01-197186","link":null,"reference":"Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.","abstract":null},{"pmid":"17710227","title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.","journal":"The Journal of clinical investigation","pubDate":"2007 Sep","volume":"117","issue":"9","pages":"2562-9","authors":"Shah NP et al","elocationId":"","link":null,"reference":"Shah NP et al. The Journal of clinical investigation. 2007 Sep;117(9)2562-9.","abstract":null}]},{"id":124,"uuid":"8cf7d85d-cea2-4543-b87c-06ecbc1563a9","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_RESISTANCE","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317C","name":"F317C","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317L","name":"F317L","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V299L","name":"V299L","refResidues":"V","proteinStart":299,"proteinEnd":299,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317V","name":"F317V","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T315A","name":"T315A","refResidues":"T","proteinStart":315,"proteinEnd":315,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317I","name":"F317I","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C38713","drugName":"Dasatinib","uuid":"df40a264-628f-4070-9078-965c0471bd2c","synonyms":["Dasatinib","dasatinib","Sprycel","BMS-354825","DASATINIB"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1602654994000,"lastReview":null,"levelOfEvidence":"LEVEL_R1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"20131302","title":"Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.","journal":"American journal of hematology","pubDate":"2010 Mar","volume":"85","issue":"3","pages":"164-70","authors":"Lilly MB et al","elocationId":"doi: 10.1002/ajh.21615","link":null,"reference":"Lilly MB et al. American journal of hematology. 2010 Mar;85(3)164-70.","abstract":null},{"pmid":"17496201","title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.","journal":"Blood","pubDate":"2007 Oct 1","volume":"110","issue":"7","pages":"2309-15","authors":"Ottmann O et al","elocationId":"","link":null,"reference":"Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.","abstract":null},{"pmid":"17339191","title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.","journal":"Haematologica","pubDate":"2007 Mar","volume":"92","issue":"3","pages":"401-4","authors":"Soverini S et al","elocationId":"","link":null,"reference":"Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.","abstract":null}]},{"id":16828,"uuid":"fa321304-7448-4b77-98af-b7b2fed034e5","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_RESISTANCE","cancerTypes":[{"id":935,"subtype":"","code":"","color":"SaddleBrown","mainType":"Colorectal Cancer","level":0,"tissue":"Bowel","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C1723","drugName":"Cetuximab","uuid":"5fce3074-e420-4c36-9603-2423daf20118","synonyms":["CETUXIMAB","Cetuximab Biosimilar CMAB009","IMC-C225","Chimeric Anti-EGFR Monoclonal Antibody","Cetuximab Biosimilar KL 140","cetuximab","Cetuximab Biosimilar CDP-1","Chimeric Monoclonal Antibody C225","Cetuximab","Chimeric MoAb C225","Erbitux"],"priority":1}]},{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C1857","drugName":"Panitumumab","uuid":"d7b1d12a-e942-4801-bb64-916c9bdfaaf3","synonyms":["ABX-EGF, Clone E7.6.3","PANITUMUMAB","\"ABX-EGF","Panitumumab","Vectibix","MoAb ABX-EGF","ABX-EGF","panitumumab","panitumumab\"","ABX-EGF Monoclonal Antibody","Monoclonal Antibody ABX-EGF"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1492642509000,"lastReview":null,"levelOfEvidence":"LEVEL_R1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"24024839","title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.","journal":"The New England journal of medicine","pubDate":"2013 Sep 12","volume":"369","issue":"11","pages":"1023-34","authors":"Douillard JY et al","elocationId":"doi: 10.1056/NEJMoa1305275","link":null,"reference":"Douillard JY et al. The New England journal of medicine. 2013 Sep 12;369(11)1023-34.","abstract":null},{"pmid":"25110411","title":"Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.","journal":"World journal of gastroenterology","pubDate":"2014 Aug 7","volume":"20","issue":"29","pages":"9732-43","authors":"De Stefano A et al","elocationId":"doi: 10.3748/wjg.v20.i29.9732","link":null,"reference":"De Stefano A et al. World journal of gastroenterology. 2014 Aug 7;20(29)9732-43.","abstract":null},{"pmid":"20619739","title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.","journal":"The Lancet. Oncology","pubDate":"2010 Aug","volume":"11","issue":"8","pages":"753-62","authors":"De Roock W et al","elocationId":"doi: 10.1016/S1470-2045(10)70130-3","link":null,"reference":"De Roock W et al. The Lancet. Oncology. 2010 Aug;11(8)753-62.","abstract":null},{"pmid":"24024844","title":"Beyond exon 2--the developing story of RAS mutations in colorectal cancer.","journal":"The New England journal of medicine","pubDate":"2013 Sep 12","volume":"369","issue":"11","pages":"1059-60","authors":"Berlin J","elocationId":"doi: 10.1056/NEJMe1307992","link":null,"reference":"Berlin J. The New England journal of medicine. 2013 Sep 12;369(11)1059-60.","abstract":null}]},{"id":125,"uuid":"466fa714-6389-4a6a-99a2-12763628fc8f","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_RESISTANCE","cancerTypes":[{"id":560,"subtype":"Chronic Myelogenous Leukemia","code":"CML","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359V","name":"F359V","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y253H","name":"Y253H","refResidues":"Y","proteinStart":253,"proteinEnd":253,"variantResidues":"H","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E255K","name":"E255K","refResidues":"E","proteinStart":255,"proteinEnd":255,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"G250E","name":"G250E","refResidues":"G","proteinStart":250,"proteinEnd":250,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E255V","name":"E255V","refResidues":"E","proteinStart":255,"proteinEnd":255,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359C","name":"F359C","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359I","name":"F359I","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C48375","drugName":"Nilotinib","uuid":"0f991d49-4cf2-4975-b52f-d7d037aa7f11","synonyms":["Nilotinib","AMN 107 Base Form","nilotinib","4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide","NILOTINIB"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1602655063000,"lastReview":null,"levelOfEvidence":"LEVEL_R1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"17785585","title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.","journal":"Blood","pubDate":"2007 Dec 1","volume":"110","issue":"12","pages":"4005-11","authors":"Cortes J et al","elocationId":"","link":null,"reference":"Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.","abstract":null},{"pmid":"23502220","title":"Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.","journal":"Blood","pubDate":"2013 May 2","volume":"121","issue":"18","pages":"3703-8","authors":"Hochhaus A et al","elocationId":"doi: 10.1182/blood-2012-04-423418","link":null,"reference":"Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.","abstract":null},{"pmid":"16775235","title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.","journal":"The New England journal of medicine","pubDate":"2006 Jun 15","volume":"354","issue":"24","pages":"2542-51","authors":"Kantarjian H et al","elocationId":"","link":null,"reference":"Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.","abstract":null},{"pmid":"19589924","title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.","journal":"Blood","pubDate":"2009 Sep 3","volume":"114","issue":"10","pages":"2168-71","authors":"Soverini S et al","elocationId":"doi: 10.1182/blood-2009-01-197186","link":null,"reference":"Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.","abstract":null},{"pmid":"19652056","title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2009 Sep 1","volume":"27","issue":"25","pages":"4204-10","authors":"Hughes T et al","elocationId":"doi: 10.1200/JCO.2009.21.8230","link":null,"reference":"Hughes T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 1;27(25)4204-10.","abstract":null}]},{"id":17437,"uuid":"82915f1a-189e-41c2-9bbe-3bd55b87662f","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_RESISTANCE","cancerTypes":[{"id":968,"subtype":"","code":"","color":"LightYellow","mainType":"Gastrointestinal Stromal Tumor","level":0,"tissue":"Soft Tissue","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5156,"hugoSymbol":"PDGFRA","oncogene":true,"grch37Isoform":"ENST00000257290","grch37RefSeq":"NM_006206.4","grch38Isoform":"ENST00000257290","grch38RefSeq":"NM_006206.4","geneAliases":["PDGFR2","PDGFR-2","CD140A"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"D842V","name":"D842V","refResidues":"D","proteinStart":842,"proteinEnd":842,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1546888060000,"lastReview":null,"levelOfEvidence":"LEVEL_R1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22745105","title":"Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2012 Aug 15","volume":"18","issue":"16","pages":"4375-84","authors":"Heinrich MC et al","elocationId":"doi: 10.1158/1078-0432.CCR-12-0625","link":null,"reference":"Heinrich MC et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Aug 15;18(16)4375-84.","abstract":null},{"pmid":"12949711","title":"Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.","journal":"Gastroenterology","pubDate":"2003 Sep","volume":"125","issue":"3","pages":"660-7","authors":"Hirota S et al","elocationId":"","link":null,"reference":"Hirota S et al. Gastroenterology. 2003 Sep;125(3)660-7.","abstract":null},{"pmid":"18955458","title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Nov 20","volume":"26","issue":"33","pages":"5352-9","authors":"Heinrich MC et al","elocationId":"doi: 10.1200/JCO.2007.15.7461","link":null,"reference":"Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.","abstract":null},{"pmid":"23752188","title":"PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.","journal":"Oncogene","pubDate":"2014 May 15","volume":"33","issue":"20","pages":"2568-76","authors":"Velghe AI et al","elocationId":"doi: 10.1038/onc.2013.218","link":null,"reference":"Velghe AI et al. Oncogene. 2014 May 15;33(20)2568-76.","abstract":null},{"pmid":"15685537","title":"Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.","journal":"Gastroenterology","pubDate":"2005 Feb","volume":"128","issue":"2","pages":"270-9","authors":"Debiec-Rychter M et al","elocationId":"","link":null,"reference":"Debiec-Rychter M et al. Gastroenterology. 2005 Feb;128(2)270-9.","abstract":null},{"pmid":"18794084","title":"Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2008 Sep 15","volume":"14","issue":"18","pages":"5749-58","authors":"Dewaele B et al","elocationId":"doi: 10.1158/1078-0432.CCR-08-0533","link":null,"reference":"Dewaele B et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Sep 15;14(18)5749-58.","abstract":null},{"pmid":"24963404","title":"Imatinib: a breakthrough of targeted therapy in cancer.","journal":"Chemotherapy research and practice","pubDate":"2014","volume":"2014","issue":"","pages":"357027","authors":"Iqbal N et al","elocationId":"doi: 10.1155/2014/357027","link":null,"reference":"Iqbal N et al. Chemotherapy research and practice. 2014;2014()357027.","abstract":null},{"pmid":"22718859","title":"Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2012 Aug 15","volume":"18","issue":"16","pages":"4458-64","authors":"Cassier PA et al","elocationId":"","link":null,"reference":"Cassier PA et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Aug 15;18(16)4458-64.","abstract":null},{"pmid":"15928335","title":"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2005 Aug 10","volume":"23","issue":"23","pages":"5357-64","authors":"Corless CL et al","elocationId":"","link":null,"reference":"Corless CL et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Aug 10;23(23)5357-64.","abstract":null},{"pmid":"25905001","title":"Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.","journal":"Clinical sarcoma research","pubDate":"2014","volume":"4","issue":"","pages":"17","authors":"Kollàr A et al","elocationId":"doi: 10.1186/2045-3329-4-17","link":null,"reference":"Kollàr A et al. Clinical sarcoma research. 2014;4()17.","abstract":null},{"pmid":"17087936","title":"Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.","journal":"Gastroenterology","pubDate":"2006 Dec","volume":"131","issue":"6","pages":"1734-42","authors":"Weisberg E et al","elocationId":"","link":null,"reference":"Weisberg E et al. Gastroenterology. 2006 Dec;131(6)1734-42.","abstract":null}]},{"id":126,"uuid":"8aa1e884-1922-4530-b67e-1c759d93e1c6","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_RESISTANCE","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359V","name":"F359V","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y253H","name":"Y253H","refResidues":"Y","proteinStart":253,"proteinEnd":253,"variantResidues":"H","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E255K","name":"E255K","refResidues":"E","proteinStart":255,"proteinEnd":255,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"G250E","name":"G250E","refResidues":"G","proteinStart":250,"proteinEnd":250,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E255V","name":"E255V","refResidues":"E","proteinStart":255,"proteinEnd":255,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359C","name":"F359C","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359I","name":"F359I","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C48375","drugName":"Nilotinib","uuid":"0f991d49-4cf2-4975-b52f-d7d037aa7f11","synonyms":["Nilotinib","AMN 107 Base Form","nilotinib","4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide","NILOTINIB"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1602712353000,"lastReview":null,"levelOfEvidence":"LEVEL_R1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"17785585","title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.","journal":"Blood","pubDate":"2007 Dec 1","volume":"110","issue":"12","pages":"4005-11","authors":"Cortes J et al","elocationId":"","link":null,"reference":"Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.","abstract":null},{"pmid":"23502220","title":"Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.","journal":"Blood","pubDate":"2013 May 2","volume":"121","issue":"18","pages":"3703-8","authors":"Hochhaus A et al","elocationId":"doi: 10.1182/blood-2012-04-423418","link":null,"reference":"Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.","abstract":null},{"pmid":"16775235","title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.","journal":"The New England journal of medicine","pubDate":"2006 Jun 15","volume":"354","issue":"24","pages":"2542-51","authors":"Kantarjian H et al","elocationId":"","link":null,"reference":"Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.","abstract":null},{"pmid":"19589924","title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.","journal":"Blood","pubDate":"2009 Sep 3","volume":"114","issue":"10","pages":"2168-71","authors":"Soverini S et al","elocationId":"doi: 10.1182/blood-2009-01-197186","link":null,"reference":"Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.","abstract":null},{"pmid":"19652056","title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2009 Sep 1","volume":"27","issue":"25","pages":"4204-10","authors":"Hughes T et al","elocationId":"doi: 10.1200/JCO.2009.21.8230","link":null,"reference":"Hughes T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 1;27(25)4204-10.","abstract":null}]},{"id":13182,"uuid":"c3bf2b1b-e768-4d59-81a4-26344ec33a9f","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_RESISTANCE","cancerTypes":[{"id":935,"subtype":"","code":"","color":"SaddleBrown","mainType":"Colorectal Cancer","level":0,"tissue":"Bowel","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C1857","drugName":"Panitumumab","uuid":"d7b1d12a-e942-4801-bb64-916c9bdfaaf3","synonyms":["ABX-EGF, Clone E7.6.3","PANITUMUMAB","\"ABX-EGF","Panitumumab","Vectibix","MoAb ABX-EGF","ABX-EGF","panitumumab","panitumumab\"","ABX-EGF Monoclonal Antibody","Monoclonal Antibody ABX-EGF"],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C1723","drugName":"Cetuximab","uuid":"5fce3074-e420-4c36-9603-2423daf20118","synonyms":["CETUXIMAB","Cetuximab Biosimilar CMAB009","IMC-C225","Chimeric Anti-EGFR Monoclonal Antibody","Cetuximab Biosimilar KL 140","cetuximab","Cetuximab Biosimilar CDP-1","Chimeric Monoclonal Antibody C225","Cetuximab","Chimeric MoAb C225","Erbitux"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1493059748000,"lastReview":null,"levelOfEvidence":"LEVEL_R1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"24024839","title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.","journal":"The New England journal of medicine","pubDate":"2013 Sep 12","volume":"369","issue":"11","pages":"1023-34","authors":"Douillard JY et al","elocationId":"doi: 10.1056/NEJMoa1305275","link":null,"reference":"Douillard JY et al. The New England journal of medicine. 2013 Sep 12;369(11)1023-34.","abstract":null},{"pmid":"21228335","title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.","journal":"Annals of oncology : official journal of the European Society for Medical Oncology","pubDate":"2011 Jul","volume":"22","issue":"7","pages":"1535-1546","authors":"Bokemeyer C et al","elocationId":"doi: 10.1093/annonc/mdq632","link":null,"reference":"Bokemeyer C et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Jul;22(7)1535-1546.","abstract":null},{"pmid":"20619739","title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.","journal":"The Lancet. Oncology","pubDate":"2010 Aug","volume":"11","issue":"8","pages":"753-62","authors":"De Roock W et al","elocationId":"doi: 10.1016/S1470-2045(10)70130-3","link":null,"reference":"De Roock W et al. The Lancet. Oncology. 2010 Aug;11(8)753-62.","abstract":null},{"pmid":"18316791","title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2008 Apr 1","volume":"26","issue":"10","pages":"1626-34","authors":"Amado RG et al","elocationId":"doi: 10.1200/JCO.2007.14.7116","link":null,"reference":"Amado RG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Apr 1;26(10)1626-34.","abstract":null},{"pmid":"20921465","title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2010 Nov 1","volume":"28","issue":"31","pages":"4697-705","authors":"Douillard JY et al","elocationId":"doi: 10.1200/JCO.2009.27.4860","link":null,"reference":"Douillard JY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Nov 1;28(31)4697-705.","abstract":null}]},{"id":6654,"uuid":"3f178513-01a6-4159-8aeb-f1640ac2d0c4","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_RESISTANCE","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"762_823ins","name":"Exon 20 insertion","refResidues":null,"proteinStart":762,"proteinEnd":823,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C65530","drugName":"Erlotinib","uuid":"83754311-3f3b-4782-bfbf-08e71c790b9a","synonyms":["Erlotinib","erlotinib","ERLOTINIB"],"priority":1}]},{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C66940","drugName":"Afatinib","uuid":"e1f45ae7-33ae-428c-9e77-da4a9b7270b6","synonyms":["BIBW 2992","Afatinib","BIBW2992","AFATINIB","(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"],"priority":1}]},{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C1855","drugName":"Gefitinib","uuid":"b76d7b2b-b5fb-4561-892f-6b00bfaf0dfa","synonyms":["GEFITINIB","Iressa","N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine","ZD 1839","gefitinib","Gefitinib","4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline","ZD1839"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1576714495000,"lastReview":null,"levelOfEvidence":"LEVEL_R1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"15897572","title":"Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2005 May 15","volume":"11","issue":"10","pages":"3750-7","authors":"Chou TY et al","elocationId":"","link":null,"reference":"Chou TY et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 May 15;11(10)3750-7.","abstract":null},{"pmid":"24065731","title":"Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.","journal":"Cancer discovery","pubDate":"2013 Dec","volume":"3","issue":"12","pages":"1404-15","authors":"Walter AO et al","elocationId":"doi: 10.1158/2159-8290.CD-13-0314","link":null,"reference":"Walter AO et al. Cancer discovery. 2013 Dec;3(12)1404-15.","abstract":null},{"pmid":"18676761","title":"Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2008 Aug 1","volume":"14","issue":"15","pages":"4877-82","authors":"Wu JY et al","elocationId":"doi: 10.1158/1078-0432.CCR-07-5123","link":null,"reference":"Wu JY et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Aug 1;14(15)4877-82.","abstract":null},{"pmid":"19536777","title":"Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.","journal":"International journal of cancer","pubDate":"2010 Jan 1","volume":"126","issue":"1","pages":"247-55","authors":"Wu JY et al","elocationId":"doi: 10.1002/ijc.24657","link":null,"reference":"Wu JY et al. International journal of cancer. 2010 Jan 1;126(1)247-55.","abstract":null},{"pmid":"24353160","title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.","journal":"Science translational medicine","pubDate":"2013 Dec 18","volume":"5","issue":"216","pages":"216ra177","authors":"Yasuda H et al","elocationId":"doi: 10.1126/scitranslmed.3007205","link":null,"reference":"Yasuda H et al. Science translational medicine. 2013 Dec 18;5(216)216ra177.","abstract":null},{"pmid":"21764376","title":"EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.","journal":"The Lancet. Oncology","pubDate":"2012 Jan","volume":"13","issue":"1","pages":"e23-31","authors":"Yasuda H et al","elocationId":"doi: 10.1016/S1470-2045(11)70129-2","link":null,"reference":"Yasuda H et al. The Lancet. Oncology. 2012 Jan;13(1)e23-31.","abstract":null},{"pmid":"17686547","title":"EGFR exon 20 insertion mutation in Japanese lung cancer.","journal":"Lung cancer (Amsterdam, Netherlands)","pubDate":"2007 Dec","volume":"58","issue":"3","pages":"324-8","authors":"Sasaki H et al","elocationId":"","link":null,"reference":"Sasaki H et al. Lung cancer (Amsterdam, Netherlands). 2007 Dec;58(3)324-8.","abstract":null},{"pmid":"24893891","title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.","journal":"Cancer discovery","pubDate":"2014 Sep","volume":"4","issue":"9","pages":"1046-61","authors":"Cross DA et al","elocationId":"doi: 10.1158/2159-8290.CD-14-0337","link":null,"reference":"Cross DA et al. Cancer discovery. 2014 Sep;4(9)1046-61.","abstract":null},{"pmid":"23371856","title":"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.","journal":"Molecular cancer therapeutics","pubDate":"2013 Feb","volume":"12","issue":"2","pages":"220-9","authors":"Arcila ME et al","elocationId":"doi: 10.1158/1535-7163.MCT-12-0620","link":null,"reference":"Arcila ME et al. Molecular cancer therapeutics. 2013 Feb;12(2)220-9.","abstract":null},{"pmid":"23328547","title":"Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2013 Feb","volume":"8","issue":"2","pages":"179-84","authors":"Oxnard GR et al","elocationId":"doi: 10.1097/JTO.0b013e3182779d18","link":null,"reference":"Oxnard GR et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Feb;8(2)179-84.","abstract":null}]},{"id":127,"uuid":"c62773be-4e87-43f8-b256-8f1e91a006ea","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_RESISTANCE","cancerTypes":[{"id":560,"subtype":"Chronic Myelogenous Leukemia","code":"CML","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359V","name":"F359V","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317C","name":"F317C","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E255K","name":"E255K","refResidues":"E","proteinStart":255,"proteinEnd":255,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V299L","name":"V299L","refResidues":"V","proteinStart":299,"proteinEnd":299,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E255V","name":"E255V","refResidues":"E","proteinStart":255,"proteinEnd":255,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T315A","name":"T315A","refResidues":"T","proteinStart":315,"proteinEnd":315,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317I","name":"F317I","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y253H","name":"Y253H","refResidues":"Y","proteinStart":253,"proteinEnd":253,"variantResidues":"H","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317L","name":"F317L","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"G250E","name":"G250E","refResidues":"G","proteinStart":250,"proteinEnd":250,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317V","name":"F317V","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359C","name":"F359C","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359I","name":"F359I","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1604551344000,"lastReview":null,"levelOfEvidence":"LEVEL_R1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"17785585","title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.","journal":"Blood","pubDate":"2007 Dec 1","volume":"110","issue":"12","pages":"4005-11","authors":"Cortes J et al","elocationId":"","link":null,"reference":"Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.","abstract":null},{"pmid":"20010464","title":"Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.","journal":"Polskie Archiwum Medycyny Wewnetrznej","pubDate":"2009 Dec","volume":"119","issue":"12","pages":"789-94","authors":"Lewandowski K et al","elocationId":"","link":null,"reference":"Lewandowski K et al. Polskie Archiwum Medycyny Wewnetrznej. 2009 Dec;119(12)789-94.","abstract":null},{"pmid":"17189410","title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2006 Dec 15","volume":"12","issue":"24","pages":"7374-9","authors":"Soverini S et al","elocationId":"","link":null,"reference":"Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.","abstract":null},{"pmid":"12623848","title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.","journal":"Blood","pubDate":"2003 Jul 1","volume":"102","issue":"1","pages":"276-83","authors":"Branford S et al","elocationId":"","link":null,"reference":"Branford S et al. Blood. 2003 Jul 1;102(1)276-83.","abstract":null},{"pmid":"19925053","title":"Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.","journal":"Leukemia & lymphoma","pubDate":"2009 Dec","volume":"50","issue":"12","pages":"2092-5","authors":"Markose P et al","elocationId":"doi: 10.3109/10428190903332486","link":null,"reference":"Markose P et al. Leukemia & lymphoma. 2009 Dec;50(12)2092-5.","abstract":null}]},{"id":128,"uuid":"f3831a34-3b5b-4145-89ed-d574e9352f36","evidenceType":"STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_RESISTANCE","cancerTypes":[{"id":95,"subtype":"B-Lymphoblastic Leukemia/Lymphoma","code":"BLL","color":"LimeGreen","mainType":"B-Lymphoblastic Leukemia/Lymphoma","level":3,"tissue":"Lymphoid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359V","name":"F359V","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317C","name":"F317C","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E255K","name":"E255K","refResidues":"E","proteinStart":255,"proteinEnd":255,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"V299L","name":"V299L","refResidues":"V","proteinStart":299,"proteinEnd":299,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E255V","name":"E255V","refResidues":"E","proteinStart":255,"proteinEnd":255,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"T315A","name":"T315A","refResidues":"T","proteinStart":315,"proteinEnd":315,"variantResidues":"A","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317I","name":"F317I","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Y253H","name":"Y253H","refResidues":"Y","proteinStart":253,"proteinEnd":253,"variantResidues":"H","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317L","name":"F317L","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"L","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"G250E","name":"G250E","refResidues":"G","proteinStart":250,"proteinEnd":250,"variantResidues":"E","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F317V","name":"F317V","refResidues":"F","proteinStart":317,"proteinEnd":317,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359C","name":"F359C","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"F359I","name":"F359I","refResidues":"F","proteinStart":359,"proteinEnd":359,"variantResidues":"I","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C62035","drugName":"Imatinib","uuid":"f42768c5-4918-4244-98dd-6ea97a4d3c2a","synonyms":["Imatinib","IMATINIB","4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"],"priority":1}]}],"knownEffect":"Resistant","lastEdit":1602658129000,"lastReview":null,"levelOfEvidence":"LEVEL_R1","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"17189410","title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2006 Dec 15","volume":"12","issue":"24","pages":"7374-9","authors":"Soverini S et al","elocationId":"","link":null,"reference":"Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.","abstract":null},{"pmid":"11861307","title":"Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.","journal":"Blood","pubDate":"2002 Mar 1","volume":"99","issue":"5","pages":"1860-2","authors":"Hofmann WK et al","elocationId":"","link":null,"reference":"Hofmann WK et al. Blood. 2002 Mar 1;99(5)1860-2.","abstract":null},{"pmid":"17405907","title":"Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).","journal":"Blood","pubDate":"2007 Jul 15","volume":"110","issue":"2","pages":"727-34","authors":"Pfeifer H et al","elocationId":"","link":null,"reference":"Pfeifer H et al. Blood. 2007 Jul 15;110(2)727-34.","abstract":null}]}],"LEVEL_3A":[{"id":15972,"uuid":"396f2f75-def1-4de4-8d49-eb7c9fb02294","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":875,"subtype":"","code":"","color":"Orange","mainType":"Renal Cell Carcinoma","level":0,"tissue":"Kidney","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2475,"hugoSymbol":"MTOR","oncogene":true,"grch37Isoform":"ENST00000361445","grch37RefSeq":"NM_004958.3","grch38Isoform":"ENST00000361445","grch38RefSeq":"NM_004958.3","geneAliases":["FRAP1","RAFT1","FRAP2","FRAP","SKS","RAPT1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2475,"hugoSymbol":"MTOR","oncogene":true,"grch37Isoform":"ENST00000361445","grch37RefSeq":"NM_004958.3","grch38Isoform":"ENST00000361445","grch38RefSeq":"NM_004958.3","geneAliases":["FRAP1","RAFT1","FRAP2","FRAP","SKS","RAPT1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"Q2223K","name":"Q2223K","refResidues":"Q","proteinStart":2223,"proteinEnd":2223,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C48387","drugName":"Everolimus","uuid":"dacd7256-8305-466d-af04-bfd1c4e5dad5","synonyms":["RAD 001","everolimus\"","EVEROLIMUS","42-O-(2-Hydroxy)ethyl Rapamycin","Zortress","\"(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone","Certican","Votubia","Afinitor","RAD001","Everolimus"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1530202570000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"24622468","title":"Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2014 Apr 1","volume":"20","issue":"7","pages":"1955-64","authors":"Voss MH et al","elocationId":"doi: 10.1158/1078-0432.CCR-13-2345","link":null,"reference":"Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Apr 1;20(7)1955-64.","abstract":null}]},{"id":2085,"uuid":"b17106e4-9dd3-4157-90d2-0e791c15278b","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"K601","name":"K601","refResidues":"K","proteinStart":601,"proteinEnd":601,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C77908","drugName":"Trametinib","uuid":"fb2bb01c-c0ec-4641-abf7-87f486075022","synonyms":["Mekinist","\"GSK1120212","Trametinib\"","TRAMETINIB","JTP-74057","MEK Inhibitor GSK1120212","N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","Trametinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1596229907000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"24933606","title":"Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.","journal":"Melanoma research","pubDate":"2014 Oct","volume":"24","issue":"5","pages":"504-8","authors":"Bowyer SE et al","elocationId":"doi: 10.1097/CMR.0000000000000099","link":null,"reference":"Bowyer SE et al. Melanoma research. 2014 Oct;24(5)504-8.","abstract":null},{"pmid":"23248257","title":"Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2013 Feb 1","volume":"31","issue":"4","pages":"482-9","authors":"Kim KB et al","elocationId":"doi: 10.1200/JCO.2012.43.5966","link":null,"reference":"Kim KB et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Feb 1;31(4)482-9.","abstract":null},{"pmid":"28344857","title":"Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months.","journal":"Experimental hematology & oncology","pubDate":"2017","volume":"6","issue":"","pages":"6","authors":"Marconcini R et al","elocationId":"doi: 10.1186/s40164-017-0067-4","link":null,"reference":"Marconcini R et al. Experimental hematology & oncology. 2017;6()6.","abstract":null},{"pmid":"22798288","title":"BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.","journal":"Cancer discovery","pubDate":"2012 Sep","volume":"2","issue":"9","pages":"791-7","authors":"Dahlman KB et al","elocationId":"","link":null,"reference":"Dahlman KB et al. Cancer discovery. 2012 Sep;2(9)791-7.","abstract":null},{"pmid":"29903896","title":"Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2018 Dec 15","volume":"24","issue":"24","pages":"6483-6494","authors":"Dankner M et al","elocationId":"doi: 10.1158/1078-0432.CCR-17-3384","link":null,"reference":"Dankner M et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Dec 15;24(24)6483-6494.","abstract":null}]},{"id":11687,"uuid":"4f5e24a7-e544-451b-bbcd-b53c3a8df48a","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":44,"subtype":"Head and Neck Squamous Cell Carcinoma","code":"HNSC","color":"DarkRed","mainType":"Head and Neck Cancer","level":2,"tissue":"Head and Neck","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3265,"hugoSymbol":"HRAS","oncogene":true,"grch37Isoform":"ENST00000311189","grch37RefSeq":"NM_001130442.1","grch38Isoform":"ENST00000311189","grch38RefSeq":"NM_001130442.1","geneAliases":["C-H-RAS","HAMSV","p21ras","C-BAS/HAS","HRAS1","CTLO","H-RASIDX","C-HA-RAS1","RASH1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3265,"hugoSymbol":"HRAS","oncogene":true,"grch37Isoform":"ENST00000311189","grch37RefSeq":"NM_001130442.1","grch38Isoform":"ENST00000311189","grch38RefSeq":"NM_001130442.1","geneAliases":["C-H-RAS","HAMSV","p21ras","C-BAS/HAS","HRAS1","CTLO","H-RASIDX","C-HA-RAS1","RASH1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C1703","drugName":"Tipifarnib","uuid":"deede312-d06d-4691-8127-25517e77e5ee","synonyms":["TIPIFARNIB","R115777","Zarnestra","(+)-6-[Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone","Tipifarnib","tipifarnib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1598642862000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"24240680","title":"Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.","journal":"Oncogene","pubDate":"2014 Nov 20","volume":"33","issue":"47","pages":"5442-9","authors":"Chen X et al","elocationId":"doi: 10.1038/onc.2013.489","link":null,"reference":"Chen X et al. Oncogene. 2014 Nov 20;33(47)5442-9.","abstract":null},{"pmid":"12497061","title":"Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer.","journal":"Prostate cancer and prostatic diseases","pubDate":"2001","volume":"4","issue":"1","pages":"33-43","authors":"Sepp-Lorenzino L et al","elocationId":"","link":null,"reference":"Sepp-Lorenzino L et al. Prostate cancer and prostatic diseases. 2001;4(1)33-43.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS2618","reference":"null. null. .","abstract":"Ho et al. Abstract# TPS2618, JCO 2017"}]},{"id":7916,"uuid":"bd40a96c-074e-42ec-9d19-c6dc23296074","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C49094","drugName":"Neratinib","uuid":"d7f80cb7-3281-4a3a-a248-5158436af8e1","synonyms":["HKI-272","HKI 272","PB-272\"","\"(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide","NERATINIB","PB 272","Neratinib","2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1546537534000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"23220880","title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer.","journal":"Cancer discovery","pubDate":"2013 Feb","volume":"3","issue":"2","pages":"224-37","authors":"Bose R et al","elocationId":"doi: 10.1158/2159-8290.CD-12-0349","link":null,"reference":"Bose R et al. Cancer discovery. 2013 Feb;3(2)224-37.","abstract":null},{"pmid":"29420467","title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers.","journal":"Nature","pubDate":"2018 Feb 8","volume":"554","issue":"7691","pages":"189-194","authors":"Hyman DM et al","elocationId":"doi: 10.1038/nature25475","link":null,"reference":"Hyman DM et al. Nature. 2018 Feb 8;554(7691)189-194.","abstract":null}]},{"id":7918,"uuid":"0e4aba89-ca55-4a00-a783-10129b65d946","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":873,"subtype":"","code":"","color":"HotPink","mainType":"Breast Cancer","level":0,"tissue":"Breast","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2064,"hugoSymbol":"ERBB2","oncogene":true,"grch37Isoform":"ENST00000269571","grch37RefSeq":"NM_004448.2","grch38Isoform":"ENST00000269571","grch38RefSeq":"NM_004448.2","geneAliases":["CD340","MLN 19","TKR1","NGL","HER-2/neu","HER2","HER-2","NEU"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C49094","drugName":"Neratinib","uuid":"d7f80cb7-3281-4a3a-a248-5158436af8e1","synonyms":["HKI-272","HKI 272","PB-272\"","\"(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide","NERATINIB","PB 272","Neratinib","2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1597442787000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"23220880","title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer.","journal":"Cancer discovery","pubDate":"2013 Feb","volume":"3","issue":"2","pages":"224-37","authors":"Bose R et al","elocationId":"doi: 10.1158/2159-8290.CD-12-0349","link":null,"reference":"Bose R et al. Cancer discovery. 2013 Feb;3(2)224-37.","abstract":null},{"pmid":"17311002","title":"The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.","journal":"Oncogene","pubDate":"2007 Jul 26","volume":"26","issue":"34","pages":"5023-7","authors":"Minami Y et al","elocationId":"","link":null,"reference":"Minami Y et al. Oncogene. 2007 Jul 26;26(34)5023-7.","abstract":null},{"pmid":"29420467","title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers.","journal":"Nature","pubDate":"2018 Feb 8","volume":"554","issue":"7691","pages":"189-194","authors":"Hyman DM et al","elocationId":"doi: 10.1038/nature25475","link":null,"reference":"Hyman DM et al. Nature. 2018 Feb 8;554(7691)189-194.","abstract":null}]},{"id":11760,"uuid":"bb297406-d0a0-4500-8a0d-6d3a80eb2113","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":283,"subtype":"Cholangiocarcinoma","code":"CHOL","color":"Green","mainType":"Hepatobiliary Cancer","level":2,"tissue":"Biliary Tract","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3417,"hugoSymbol":"IDH1","oncogene":true,"grch37Isoform":"ENST00000345146","grch37RefSeq":"NM_005896.2","grch38Isoform":"ENST00000345146","grch38RefSeq":"NM_005896.2","geneAliases":["HEL-216","IDPC","IDCD","HEL-S-26","PICD"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3417,"hugoSymbol":"IDH1","oncogene":true,"grch37Isoform":"ENST00000345146","grch37RefSeq":"NM_005896.2","grch38Isoform":"ENST00000345146","grch38RefSeq":"NM_005896.2","geneAliases":["HEL-216","IDPC","IDCD","HEL-S-26","PICD"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C114383","drugName":"Ivosidenib","uuid":"6e09176b-e044-4190-8bbd-767c907577eb","synonyms":["AG-120","Ivosidenib","IVOSIDENIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1595392679000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://www.esmo.org/Oncology-News/Ivosidenib-Provides-Prolonged-Progression-Free-Survival-in-Patients-with-Cholangiocarcinoma-and-IDH1-Mutation","reference":"null. null. .","abstract":"Abou-Alfa et al. Abstract# LBA10_PR, ESMO 2019"},{"pmid":"32416072","title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.","journal":"The Lancet. Oncology","pubDate":"2020 Jun","volume":"21","issue":"6","pages":"796-807","authors":"Abou-Alfa GK et al","elocationId":"doi: 10.1016/S1470-2045(20)30157-1","link":null,"reference":"Abou-Alfa GK et al. The Lancet. Oncology. 2020 Jun;21(6)796-807.","abstract":null}]},{"id":14064,"uuid":"18e8edcc-633c-4b58-a59e-b599543a9c2c","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":934,"subtype":"","code":"","color":"LightSalmon","mainType":"Histiocytosis","level":0,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5605,"hugoSymbol":"MAP2K2","oncogene":true,"grch37Isoform":"ENST00000262948","grch37RefSeq":"NM_030662.3","grch38Isoform":"ENST00000262948","grch38RefSeq":"NM_030662.3","geneAliases":["MKK2","PRKMK2","MAPKK2","CFC4","MEK2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5605,"hugoSymbol":"MAP2K2","oncogene":true,"grch37Isoform":"ENST00000262948","grch37RefSeq":"NM_030662.3","grch38Isoform":"ENST00000262948","grch38RefSeq":"NM_030662.3","geneAliases":["MKK2","PRKMK2","MAPKK2","CFC4","MEK2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C68923","drugName":"Cobimetinib","uuid":"eb357145-3b18-4aca-b75a-5e18dd2bf4f9","synonyms":["Cotellic","Cobimetinib","XL518","COBIMETINIB","GDC-0973","MEK Inhibitor GDC-0973"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1564635965000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29236635","title":"Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.","journal":"The New England journal of medicine","pubDate":"2017 Dec 14","volume":"377","issue":"24","pages":"2398-2399","authors":"Jacobsen E et al","elocationId":"doi: 10.1056/NEJMc1713676","link":null,"reference":"Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.","abstract":null},{"pmid":"30867592","title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms.","journal":"Nature","pubDate":"2019 Mar","volume":"567","issue":"7749","pages":"521-524","authors":"Diamond EL et al","elocationId":"doi: 10.1038/s41586-019-1012-y","link":null,"reference":"Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.","abstract":null}]},{"id":12721,"uuid":"20f21fdb-a4ba-4d97-af50-935c2368e158","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":916,"subtype":"","code":"","color":"LightSalmon","mainType":"Mastocytosis","level":0,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3815,"hugoSymbol":"KIT","oncogene":true,"grch37Isoform":"ENST00000288135","grch37RefSeq":"NM_000222.2","grch38Isoform":"ENST00000288135","grch38RefSeq":"NM_000222.2","geneAliases":["PBT","MASTC","C-Kit","CD117","SCFR"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"D816","name":"D816","refResidues":"D","proteinStart":816,"proteinEnd":816,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C123827","drugName":"Avapritinib","uuid":"3d49e386-0cc4-401e-9acd-d2d33b2923a3","synonyms":["PDGFR alpha/KIT Mutant-specific Inhibitor BLU-285","BLU-285","Avapritinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1549576148000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"30274985","title":"Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 Jan 15","volume":"25","issue":"2","pages":"609-618","authors":"Gebreyohannes YK et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-1858","link":null,"reference":"Gebreyohannes YK et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Jan 15;25(2)609-618.","abstract":null},{"pmid":"29233825","title":"Rapid Responses to Avapritinib (BLU-285) in Mastocytosis.","journal":"Cancer discovery","pubDate":"2018 Feb","volume":"8","issue":"2","pages":"133","authors":"","elocationId":"doi: 10.1158/2159-8290.CD-NB2017-177","link":null,"reference":". Cancer discovery. 2018 Feb;8(2)133.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/130/Suppl_1/2","reference":"null. null. .","abstract":"DeAngelo et al. Blood 2017 130:2, ASH 2017"},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.bloodjournal.org/content/128/22/477","reference":"null. null. .","abstract":"Drummond et al. Blood 128:477, ASH 2016"}]},{"id":243,"uuid":"9d49b289-fb22-4736-aab2-74b201ce68f5","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":873,"subtype":"","code":"","color":"HotPink","mainType":"Breast Cancer","level":0,"tissue":"Breast","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":207,"hugoSymbol":"AKT1","oncogene":true,"grch37Isoform":"ENST00000349310","grch37RefSeq":"NM_001014431.1","grch38Isoform":"ENST00000349310","grch38RefSeq":"NM_001014431.1","geneAliases":["PRKBA","RAC","PKB","AKT","RAC-ALPHA","PKB-ALPHA"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":207,"hugoSymbol":"AKT1","oncogene":true,"grch37Isoform":"ENST00000349310","grch37RefSeq":"NM_001014431.1","grch38Isoform":"ENST00000349310","grch38RefSeq":"NM_001014431.1","geneAliases":["PRKBA","RAC","PKB","AKT","RAC-ALPHA","PKB-ALPHA"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E17K","name":"E17K","refResidues":"E","proteinStart":17,"proteinEnd":17,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C102564","drugName":"AZD5363","uuid":"beb74d50-0622-4df5-af40-a7acaa60beaa","synonyms":["CAPIVASERTIB","Capivasertib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1595966865000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"22294718","title":"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.","journal":"Molecular cancer therapeutics","pubDate":"2012 Apr","volume":"11","issue":"4","pages":"873-87","authors":"Davies BR et al","elocationId":"doi: 10.1158/1535-7163.MCT-11-0824-T","link":null,"reference":"Davies BR et al. Molecular cancer therapeutics. 2012 Apr;11(4)873-87.","abstract":null},{"pmid":"28489509","title":"AKT Inhibition in Solid Tumors With AKT1 Mutations.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Jul 10","volume":"35","issue":"20","pages":"2251-2259","authors":"Hyman DM et al","elocationId":"doi: 10.1200/JCO.2017.73.0143","link":null,"reference":"Hyman DM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jul 10;35(20)2251-2259.","abstract":null},{"pmid":"23394218","title":"Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.","journal":"Journal of medicinal chemistry","pubDate":"2013 Mar 14","volume":"56","issue":"5","pages":"2059-73","authors":"Addie M et al","elocationId":"doi: 10.1021/jm301762v","link":null,"reference":"Addie M et al. Journal of medicinal chemistry. 2013 Mar 14;56(5)2059-73.","abstract":null},{"pmid":"26351323","title":"Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.","journal":"Molecular cancer therapeutics","pubDate":"2015 Nov","volume":"14","issue":"11","pages":"2441-51","authors":"Davies BR et al","elocationId":"doi: 10.1158/1535-7163.MCT-15-0230","link":null,"reference":"Davies BR et al. Molecular cancer therapeutics. 2015 Nov;14(11)2441-51.","abstract":null}]},{"id":245,"uuid":"4a98d8b8-29bd-4d6f-8ec1-e1eedf125c80","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":880,"subtype":"","code":"","color":"LightBlue","mainType":"Ovarian Cancer","level":0,"tissue":"Ovary/Fallopian Tube","tumorForm":"SOLID"},{"id":884,"subtype":"","code":"","color":"PeachPuff","mainType":"Endometrial Cancer","level":0,"tissue":"Uterus","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":207,"hugoSymbol":"AKT1","oncogene":true,"grch37Isoform":"ENST00000349310","grch37RefSeq":"NM_001014431.1","grch38Isoform":"ENST00000349310","grch38RefSeq":"NM_001014431.1","geneAliases":["PRKBA","RAC","PKB","AKT","RAC-ALPHA","PKB-ALPHA"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":207,"hugoSymbol":"AKT1","oncogene":true,"grch37Isoform":"ENST00000349310","grch37RefSeq":"NM_001014431.1","grch38Isoform":"ENST00000349310","grch38RefSeq":"NM_001014431.1","geneAliases":["PRKBA","RAC","PKB","AKT","RAC-ALPHA","PKB-ALPHA"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E17K","name":"E17K","refResidues":"E","proteinStart":17,"proteinEnd":17,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C102564","drugName":"AZD5363","uuid":"beb74d50-0622-4df5-af40-a7acaa60beaa","synonyms":["CAPIVASERTIB","Capivasertib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1533152524000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"22294718","title":"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.","journal":"Molecular cancer therapeutics","pubDate":"2012 Apr","volume":"11","issue":"4","pages":"873-87","authors":"Davies BR et al","elocationId":"doi: 10.1158/1535-7163.MCT-11-0824-T","link":null,"reference":"Davies BR et al. Molecular cancer therapeutics. 2012 Apr;11(4)873-87.","abstract":null},{"pmid":"28489509","title":"AKT Inhibition in Solid Tumors With AKT1 Mutations.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Jul 10","volume":"35","issue":"20","pages":"2251-2259","authors":"Hyman DM et al","elocationId":"doi: 10.1200/JCO.2017.73.0143","link":null,"reference":"Hyman DM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jul 10;35(20)2251-2259.","abstract":null},{"pmid":"23394218","title":"Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.","journal":"Journal of medicinal chemistry","pubDate":"2013 Mar 14","volume":"56","issue":"5","pages":"2059-73","authors":"Addie M et al","elocationId":"doi: 10.1021/jm301762v","link":null,"reference":"Addie M et al. Journal of medicinal chemistry. 2013 Mar 14;56(5)2059-73.","abstract":null},{"pmid":"26351323","title":"Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.","journal":"Molecular cancer therapeutics","pubDate":"2015 Nov","volume":"14","issue":"11","pages":"2441-51","authors":"Davies BR et al","elocationId":"doi: 10.1158/1535-7163.MCT-15-0230","link":null,"reference":"Davies BR et al. Molecular cancer therapeutics. 2015 Nov;14(11)2441-51.","abstract":null}]},{"id":16823,"uuid":"39c83c4e-f386-4f93-8b7a-19e7b7c6a1d6","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C84865","drugName":"Binimetinib","uuid":"feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677","synonyms":["ARRY-438162","Mektovi","Binimetinib","ARRY-162","MEK162","BINIMETINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1517507122000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"28284557","title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2017 Apr","volume":"18","issue":"4","pages":"435-445","authors":"Dummer R et al","elocationId":"doi: 10.1016/S1470-2045(17)30180-8","link":null,"reference":"Dummer R et al. The Lancet. Oncology. 2017 Apr;18(4)435-445.","abstract":null},{"pmid":"16273091","title":"BRAF mutation predicts sensitivity to MEK inhibition.","journal":"Nature","pubDate":"2006 Jan 19","volume":"439","issue":"7074","pages":"358-62","authors":"Solit DB et al","elocationId":"","link":null,"reference":"Solit DB et al. Nature. 2006 Jan 19;439(7074)358-62.","abstract":null}]},{"id":16824,"uuid":"46962e7b-ddd0-4323-be68-85a641c5526c","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C95701","drugName":"Ribociclib","uuid":"b7734d8a-b096-4b64-9558-2fcfd63dd6ad","synonyms":["RIBOCICLIB","LEE-011","Ribociclib\"","LEE011","Ribociclib","Kisqali","\"7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide"],"priority":2},{"ncitCode":"C84865","drugName":"Binimetinib","uuid":"feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677","synonyms":["ARRY-438162","Mektovi","Binimetinib","ARRY-162","MEK162","BINIMETINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1567578610000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"22983396","title":"Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.","journal":"Nature medicine","pubDate":"2012 Oct","volume":"18","issue":"10","pages":"1503-10","authors":"Kwong LN et al","elocationId":"doi: 10.1038/nm.2941","link":null,"reference":"Kwong LN et al. Nature medicine. 2012 Oct;18(10)1503-10.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9519","reference":"null. null. .","abstract":"Schuler et al. Abstract #9519, ASCO 2017"},{"pmid":"30819666","title":"A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.","journal":"Cancer research","pubDate":"2019 May 1","volume":"79","issue":"9","pages":"2352-2366","authors":"Hayes TK et al","elocationId":"doi: 10.1158/0008-5472.CAN-18-2711","link":null,"reference":"Hayes TK et al. Cancer research. 2019 May 1;79(9)2352-2366.","abstract":null}]},{"id":6648,"uuid":"af35c8db-7153-4e0b-bbd3-b4bfaf1c3a41","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Kinase Domain Duplication","name":"Kinase Domain Duplication","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C66940","drugName":"Afatinib","uuid":"e1f45ae7-33ae-428c-9e77-da4a9b7270b6","synonyms":["BIBW 2992","Afatinib","BIBW2992","AFATINIB","(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1582154781000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"28336552","title":"Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.","journal":"Cancer discovery","pubDate":"2017 Jun","volume":"7","issue":"6","pages":"596-609","authors":"Jordan EJ et al","elocationId":"doi: 10.1158/2159-8290.CD-16-1337","link":null,"reference":"Jordan EJ et al. Cancer discovery. 2017 Jun;7(6)596-609.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://www.newoncology.com/fileadmin/content/Download_pdfs/Wiest_et_al_DGHO-2016-Abstract_final.pdf","reference":"null. null. .","abstract":"Wiest et al. Abstract #291, DGHO 2016"},{"pmid":"26286086","title":"EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.","journal":"Cancer discovery","pubDate":"2015 Nov","volume":"5","issue":"11","pages":"1155-63","authors":"Gallant JN et al","elocationId":"doi: 10.1158/2159-8290.CD-15-0654","link":null,"reference":"Gallant JN et al. Cancer discovery. 2015 Nov;5(11)1155-63.","abstract":null}]},{"id":20410,"uuid":"0aab0fc3-0e68-470e-ab5d-ea54eea826a6","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":934,"subtype":"","code":"","color":"LightSalmon","mainType":"Histiocytosis","level":0,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5894,"hugoSymbol":"RAF1","oncogene":true,"grch37Isoform":"ENST00000251849","grch37RefSeq":"NM_002880.3","grch38Isoform":"ENST00000251849","grch38RefSeq":"NM_002880.3","geneAliases":["NS5","c-Raf","CMD1NN","Raf-1","CRAF"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5894,"hugoSymbol":"RAF1","oncogene":true,"grch37Isoform":"ENST00000251849","grch37RefSeq":"NM_002880.3","grch38Isoform":"ENST00000251849","grch38RefSeq":"NM_002880.3","geneAliases":["NS5","c-Raf","CMD1NN","Raf-1","CRAF"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C68923","drugName":"Cobimetinib","uuid":"eb357145-3b18-4aca-b75a-5e18dd2bf4f9","synonyms":["Cotellic","Cobimetinib","XL518","COBIMETINIB","GDC-0973","MEK Inhibitor GDC-0973"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1589837678000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29236635","title":"Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.","journal":"The New England journal of medicine","pubDate":"2017 Dec 14","volume":"377","issue":"24","pages":"2398-2399","authors":"Jacobsen E et al","elocationId":"doi: 10.1056/NEJMc1713676","link":null,"reference":"Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.","abstract":null},{"pmid":"30867592","title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms.","journal":"Nature","pubDate":"2019 Mar","volume":"567","issue":"7749","pages":"521-524","authors":"Diamond EL et al","elocationId":"doi: 10.1038/s41586-019-1012-y","link":null,"reference":"Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.","abstract":null}]},{"id":16826,"uuid":"87479afd-2b29-40c1-a837-09b667d0eaf0","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":898,"subtype":"","code":"","color":"Teal","mainType":"Thyroid Cancer","level":0,"tissue":"Thyroid","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C74052","drugName":"Iodine I 131-6-Beta-Iodomethyl-19-Norcholesterol","uuid":"3a5810e6-6be4-49db-9629-ee02cbceb52f","synonyms":["Radioiodine-Labeled Norcholesterol","Iodine I 131-6-Beta-Iodomethyl-19-Norcholesterol","I-131 NP-59"],"priority":2},{"ncitCode":"C66939","drugName":"Selumetinib","uuid":"3f154145-525b-4865-8baf-12b374697b2a","synonyms":["Selumetinib","AZD6244","SELUMETINIB","ARRY-142886","MEK Inhibitor AZD6244","MEK inhibitor AZD6244"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1507566635000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"22105174","title":"Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.","journal":"The Journal of clinical investigation","pubDate":"2011 Dec","volume":"121","issue":"12","pages":"4700-11","authors":"Chakravarty D et al","elocationId":"doi: 10.1172/JCI46382","link":null,"reference":"Chakravarty D et al. The Journal of clinical investigation. 2011 Dec;121(12)4700-11.","abstract":null},{"pmid":"23406027","title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.","journal":"The New England journal of medicine","pubDate":"2013 Feb 14","volume":"368","issue":"7","pages":"623-32","authors":"Ho AL et al","elocationId":"doi: 10.1056/NEJMoa1209288","link":null,"reference":"Ho AL et al. The New England journal of medicine. 2013 Feb 14;368(7)623-32.","abstract":null}]},{"id":10939,"uuid":"94807c15-cc3c-48c0-8856-d08daca7c45b","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"572_630ins","name":"Internal tandem duplication","refResidues":null,"proteinStart":572,"proteinEnd":630,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C61948","drugName":"Sorafenib","uuid":"b20f2bb4-5a53-40ff-8e26-acbd42df4e8b","synonyms":["BA4 43 9006","sorafenib","Bay-439006","Sorafenib","SORAFENIB","BAY 43-9006"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1517439433000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"18230792","title":"Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.","journal":"Journal of the National Cancer Institute","pubDate":"2008 Feb 6","volume":"100","issue":"3","pages":"184-98","authors":"Zhang W et al","elocationId":"doi: 10.1093/jnci/djm328","link":null,"reference":"Zhang W et al. Journal of the National Cancer Institute. 2008 Feb 6;100(3)184-98.","abstract":null},{"pmid":"22368270","title":"Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.","journal":"Blood","pubDate":"2012 May 31","volume":"119","issue":"22","pages":"5133-43","authors":"Man CH et al","elocationId":"doi: 10.1182/blood-2011-06-363960","link":null,"reference":"Man CH et al. Blood. 2012 May 31;119(22)5133-43.","abstract":null}]},{"id":10940,"uuid":"9efce6b8-afb0-4ccf-a00c-d244d03aed5c","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"572_630ins","name":"Internal tandem duplication","refResidues":null,"proteinStart":572,"proteinEnd":630,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C64639","drugName":"Crenolanib","uuid":"c35733df-8320-4ddb-9b0f-3a6c4c114da9","synonyms":["Crenolanib","CP-868596","\"4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-","CP-868,596","CRENOLANIB","PDGFR Inhibitor CP-868596","[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine\""],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1557359683000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://learningcenter.ehaweb.org/eha/2017/22nd/181839/eunice.wang.variant.flt3.mutations.can.be.eradicated.by.cytarabine.html","reference":"null. null. .","abstract":"Wang E. et al. Abstract# P552, EHA Congress 2017"},{"pmid":"24227820","title":"Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.","journal":"Blood","pubDate":"2014 Jan 2","volume":"123","issue":"1","pages":"94-100","authors":"Galanis A et al","elocationId":"doi: 10.1182/blood-2013-10-529313","link":null,"reference":"Galanis A et al. Blood. 2014 Jan 2;123(1)94-100.","abstract":null}]},{"id":10941,"uuid":"1b98108d-fdb5-476a-b27a-85bce22bba10","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":527,"subtype":"Acute Myeloid Leukemia","code":"AML","color":"LightSalmon","mainType":"Leukemia","level":3,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2322,"hugoSymbol":"FLT3","oncogene":true,"grch37Isoform":"ENST00000241453","grch37RefSeq":"NM_004119.2","grch38Isoform":"ENST00000241453","grch38RefSeq":"NM_004119.2","geneAliases":["STK1","FLK-2","CD135","FLK2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"572_630ins","name":"Internal tandem duplication","refResidues":null,"proteinStart":572,"proteinEnd":630,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C68936","drugName":"Quizartinib","uuid":"58ca4d1c-3ea7-4dec-a0b6-036021d0a859","synonyms":["\"(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide","AC-220","N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] benzothiazol 2-yl]phenyl}urea","Quizartinib\"","Quizartinib","AC010220","AC220","QUIZARTINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572245213000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29875101","title":"Phase 2b study of 2 dosing regimens of quizartinib monotherapy in <i>FLT3</i>-ITD-mutated, relapsed or refractory AML.","journal":"Blood","pubDate":"2018 Aug 9","volume":"132","issue":"6","pages":"598-607","authors":"Cortes JE et al","elocationId":"doi: 10.1182/blood-2018-01-821629","link":null,"reference":"Cortes JE et al. Blood. 2018 Aug 9;132(6)598-607.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://learningcenter.ehaweb.org/eha/2018/stockholm/218882/jorge.cortes.quizartinib.significantly.prolongs.overall.survival.in.patients.html","reference":"null. null. .","abstract":"Cortes, J. et al. Abstract# LB2600, EHA 2017"},{"pmid":"29859851","title":"Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.","journal":"The Lancet. Oncology","pubDate":"2018 Jul","volume":"19","issue":"7","pages":"889-903","authors":"Cortes J et al","elocationId":"doi: 10.1016/S1470-2045(18)30240-7","link":null,"reference":"Cortes J et al. The Lancet. Oncology. 2018 Jul;19(7)889-903.","abstract":null},{"pmid":"31175001","title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.","journal":"The Lancet. Oncology","pubDate":"2019 Jul","volume":"20","issue":"7","pages":"984-997","authors":"Cortes JE et al","elocationId":"doi: 10.1016/S1470-2045(19)30150-0","link":null,"reference":"Cortes JE et al. The Lancet. Oncology. 2019 Jul;20(7)984-997.","abstract":null}]},{"id":6591,"uuid":"39af03b5-6aff-430d-aca9-7b4391dd54d0","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_deletion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that deletes bases from the coding sequence"},"alteration":"E709_T710delinsD","name":"E709_T710delinsD","refResidues":null,"proteinStart":709,"proteinEnd":710,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C66940","drugName":"Afatinib","uuid":"e1f45ae7-33ae-428c-9e77-da4a9b7270b6","synonyms":["BIBW 2992","Afatinib","BIBW2992","AFATINIB","(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1582154110000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"26206867","title":"EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2015 Dec 1","volume":"21","issue":"23","pages":"5305-13","authors":"Kobayashi Y et al","elocationId":"doi: 10.1158/1078-0432.CCR-15-1046","link":null,"reference":"Kobayashi Y et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Dec 1;21(23)5305-13.","abstract":null},{"pmid":"31686847","title":"Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report.","journal":"OncoTargets and therapy","pubDate":"2019","volume":"12","issue":"","pages":"7399-7404","authors":"An N et al","elocationId":"doi: 10.2147/OTT.S221638","link":null,"reference":"An N et al. OncoTargets and therapy. 2019;12()7399-7404.","abstract":null},{"pmid":"28625646","title":"EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.","journal":"Lung cancer (Amsterdam, Netherlands)","pubDate":"2017 Jun","volume":"108","issue":"","pages":"45-47","authors":"Ibrahim U et al","elocationId":"doi: 10.1016/j.lungcan.2017.02.023","link":null,"reference":"Ibrahim U et al. Lung cancer (Amsterdam, Netherlands). 2017 Jun;108()45-47.","abstract":null},{"pmid":"31187861","title":"Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.","journal":"Japanese journal of clinical oncology","pubDate":"2019 Aug 1","volume":"49","issue":"8","pages":"786-788","authors":"Iwamoto Y et al","elocationId":"doi: 10.1093/jjco/hyz086","link":null,"reference":"Iwamoto Y et al. Japanese journal of clinical oncology. 2019 Aug 1;49(8)786-788.","abstract":null}]},{"id":6655,"uuid":"70011042-4c0a-477a-b733-21a854fd5e7f","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"762_823ins","name":"Exon 20 insertion","refResidues":null,"proteinStart":762,"proteinEnd":823,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C98838","drugName":"Poziotinib","uuid":"db1cb478-a788-4fce-a8d6-7e97188b7114","synonyms":["POZIOTINIB","HM781-36B","Poziotinib","NOV120101"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1550526798000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://wclc2018.iaslc.org/wp-content/uploads/2018/09/WCLC2018-Abstract-Book_vF-LR-REV-SEPT-25-2018.pdf","reference":"null. null. .","abstract":"Heymach et al. Abstract# OA02.06, WCLC 2018"},{"pmid":"29686424","title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.","journal":"Nature medicine","pubDate":"2018 May","volume":"24","issue":"5","pages":"638-646","authors":"Robichaux JP et al","elocationId":"doi: 10.1038/s41591-018-0007-9","link":null,"reference":"Robichaux JP et al. Nature medicine. 2018 May;24(5)638-646.","abstract":null},{"pmid":"27188206","title":"A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (<i>EGFR</i>)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.","journal":"Cancer research and treatment : official journal of Korean Cancer Association","pubDate":"2017 Jan","volume":"49","issue":"1","pages":"10-19","authors":"Han JY et al","elocationId":"doi: 10.4143/crt.2016.058","link":null,"reference":"Han JY et al. Cancer research and treatment : official journal of Korean Cancer Association. 2017 Jan;49(1)10-19.","abstract":null}]},{"id":3652,"uuid":"9ac68ba7-844f-49b6-a4d2-6e485be86817","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":180,"subtype":"Pancreatic Adenocarcinoma","code":"PAAD","color":"Purple","mainType":"Pancreatic Cancer","level":2,"tissue":"Pancreas","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C137800","drugName":"Rucaparib","uuid":"75ceadf8-0171-4f62-97ff-b008b15effb3","synonyms":["Rucaparib\"","8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one","Rucaparib","RUCAPARIB","\"6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1580105288000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"30051098","title":"Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation.","journal":"JCO precision oncology","pubDate":"2018","volume":"2018","issue":"","pages":"","authors":"Shroff RT et al","elocationId":"doi: 10.1200/PO.17.00316","link":null,"reference":"Shroff RT et al. JCO precision oncology. 2018;2018().","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://cancerres.aacrjournals.org/content/79/13_Supplement/CT234","reference":"null. null. .","abstract":"Reiss Binder et al. Abstract# CT234, AACR 2019"},{"pmid":"17444865","title":"Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.","journal":"Journal of gastroenterology and hepatology","pubDate":"2007 May","volume":"22","issue":"5","pages":"738-48","authors":"Jacob DA et al","elocationId":"","link":null,"reference":"Jacob DA et al. Journal of gastroenterology and hepatology. 2007 May;22(5)738-48.","abstract":null}]},{"id":3653,"uuid":"6949ec0b-750e-41c8-ac0e-d0dcd1f10a73","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":180,"subtype":"Pancreatic Adenocarcinoma","code":"PAAD","color":"Purple","mainType":"Pancreatic Cancer","level":2,"tissue":"Pancreas","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":675,"hugoSymbol":"BRCA2","oncogene":false,"grch37Isoform":"ENST00000380152","grch37RefSeq":"NM_000059.3","grch38Isoform":"ENST00000380152","grch38RefSeq":"NM_000059.3","geneAliases":["FANCD1","BROVCA2","XRCC11","FAD1","BRCC2","GLM3","PNCA2"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1598246257000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"31157963","title":"Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer.","journal":"The New England journal of medicine","pubDate":"2019 Jul 25","volume":"381","issue":"4","pages":"317-327","authors":"Golan T et al","elocationId":"doi: 10.1056/NEJMoa1903387","link":null,"reference":"Golan T et al. The New England journal of medicine. 2019 Jul 25;381(4)317-327.","abstract":null},{"pmid":"32444418","title":"Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2020 Jul 1","volume":"26","issue":"13","pages":"3239-3247","authors":"Park W et al","elocationId":"doi: 10.1158/1078-0432.CCR-20-0418","link":null,"reference":"Park W et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Jul 1;26(13)3239-3247.","abstract":null}]},{"id":2759,"uuid":"adfc8217-494f-4e67-8207-3b25d0e60821","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":180,"subtype":"Pancreatic Adenocarcinoma","code":"PAAD","color":"Purple","mainType":"Pancreatic Cancer","level":2,"tissue":"Pancreas","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":672,"hugoSymbol":"BRCA1","oncogene":false,"grch37Isoform":"ENST00000357654","grch37RefSeq":"NM_007294.3","grch38Isoform":"ENST00000357654","grch38RefSeq":"NM_007294.3","geneAliases":["RNF53","IRIS","BRCAI","PNCA4","PSCP","BROVCA1","BRCC1","FANCS","PPP1R53"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":672,"hugoSymbol":"BRCA1","oncogene":false,"grch37Isoform":"ENST00000357654","grch37RefSeq":"NM_007294.3","grch38Isoform":"ENST00000357654","grch38RefSeq":"NM_007294.3","geneAliases":["RNF53","IRIS","BRCAI","PNCA4","PSCP","BROVCA1","BRCC1","FANCS","PPP1R53"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C71721","drugName":"Olaparib","uuid":"578af76a-2e8a-463a-b7bd-0494c91ad2a1","synonyms":["OLAPARIB","AZD-2281","olaparib","AZD2281","Olaparib","KU-0059436","PARP Inhibitor AZD2281","AZD 2281","Lynparza","PARP inhibitor AZD2281"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1598246148000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"31157963","title":"Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer.","journal":"The New England journal of medicine","pubDate":"2019 Jul 25","volume":"381","issue":"4","pages":"317-327","authors":"Golan T et al","elocationId":"doi: 10.1056/NEJMoa1903387","link":null,"reference":"Golan T et al. The New England journal of medicine. 2019 Jul 25;381(4)317-327.","abstract":null},{"pmid":"32444418","title":"Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2020 Jul 1","volume":"26","issue":"13","pages":"3239-3247","authors":"Park W et al","elocationId":"doi: 10.1158/1078-0432.CCR-20-0418","link":null,"reference":"Park W et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Jul 1;26(13)3239-3247.","abstract":null}]},{"id":16841,"uuid":"61145287-acde-4be9-8495-bedacf211353","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":934,"subtype":"","code":"","color":"LightSalmon","mainType":"Histiocytosis","level":0,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","oncogene":true,"grch37Isoform":"ENST00000369535","grch37RefSeq":"NM_002524.4","grch38Isoform":"ENST00000369535","grch38RefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C68923","drugName":"Cobimetinib","uuid":"eb357145-3b18-4aca-b75a-5e18dd2bf4f9","synonyms":["Cotellic","Cobimetinib","XL518","COBIMETINIB","GDC-0973","MEK Inhibitor GDC-0973"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1564635621000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29236635","title":"Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.","journal":"The New England journal of medicine","pubDate":"2017 Dec 14","volume":"377","issue":"24","pages":"2398-2399","authors":"Jacobsen E et al","elocationId":"doi: 10.1056/NEJMc1713676","link":null,"reference":"Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.","abstract":null},{"pmid":"30867592","title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms.","journal":"Nature","pubDate":"2019 Mar","volume":"567","issue":"7749","pages":"521-524","authors":"Diamond EL et al","elocationId":"doi: 10.1038/s41586-019-1012-y","link":null,"reference":"Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.","abstract":null}]},{"id":13194,"uuid":"b28c1b8f-366a-4572-a886-a9ec190e52be","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":934,"subtype":"","code":"","color":"LightSalmon","mainType":"Histiocytosis","level":0,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C68923","drugName":"Cobimetinib","uuid":"eb357145-3b18-4aca-b75a-5e18dd2bf4f9","synonyms":["Cotellic","Cobimetinib","XL518","COBIMETINIB","GDC-0973","MEK Inhibitor GDC-0973"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1564941340000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29236635","title":"Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.","journal":"The New England journal of medicine","pubDate":"2017 Dec 14","volume":"377","issue":"24","pages":"2398-2399","authors":"Jacobsen E et al","elocationId":"doi: 10.1056/NEJMc1713676","link":null,"reference":"Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.","abstract":null},{"pmid":"30867592","title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms.","journal":"Nature","pubDate":"2019 Mar","volume":"567","issue":"7749","pages":"521-524","authors":"Diamond EL et al","elocationId":"doi: 10.1038/s41586-019-1012-y","link":null,"reference":"Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.","abstract":null}]},{"id":13579,"uuid":"ea6122cf-a19e-4c5c-b3a8-d29f1a342fb1","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":934,"subtype":"","code":"","color":"LightSalmon","mainType":"Histiocytosis","level":0,"tissue":"Myeloid","tumorForm":"LIQUID"},{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"},{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"},{"id":141,"subtype":"Low-Grade Serous Ovarian Cancer","code":"LGSOC","color":"LightBlue","mainType":"Ovarian Cancer","level":4,"tissue":"Ovary/Fallopian Tube","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5604,"hugoSymbol":"MAP2K1","oncogene":true,"grch37Isoform":"ENST00000307102","grch37RefSeq":"NM_002755.3","grch38Isoform":"ENST00000307102","grch38RefSeq":"NM_002755.3","geneAliases":["MKK1","PRKMK1","MEL","MEK1","MAPKK1","CFC3"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":5604,"hugoSymbol":"MAP2K1","oncogene":true,"grch37Isoform":"ENST00000307102","grch37RefSeq":"NM_002755.3","grch38Isoform":"ENST00000307102","grch38RefSeq":"NM_002755.3","geneAliases":["MKK1","PRKMK1","MEL","MEK1","MAPKK1","CFC3"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C77908","drugName":"Trametinib","uuid":"fb2bb01c-c0ec-4641-abf7-87f486075022","synonyms":["Mekinist","\"GSK1120212","Trametinib\"","TRAMETINIB","JTP-74057","MEK Inhibitor GSK1120212","N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","Trametinib"],"priority":1}]},{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C68923","drugName":"Cobimetinib","uuid":"eb357145-3b18-4aca-b75a-5e18dd2bf4f9","synonyms":["Cotellic","Cobimetinib","XL518","COBIMETINIB","GDC-0973","MEK Inhibitor GDC-0973"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1596222560000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"26566875","title":"Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.","journal":"Cancer discovery","pubDate":"2016 Feb","volume":"6","issue":"2","pages":"154-65","authors":"Diamond EL et al","elocationId":"doi: 10.1158/2159-8290.CD-15-0913","link":null,"reference":"Diamond EL et al. Cancer discovery. 2016 Feb;6(2)154-65.","abstract":null},{"pmid":"25370473","title":"Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2015 Jan 1","volume":"21","issue":"1","pages":"98-105","authors":"Carlino MS et al","elocationId":"doi: 10.1158/1078-0432.CCR-14-0759","link":null,"reference":"Carlino MS et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan 1;21(1)98-105.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://ascopubs.org/doi/full/10.1200/PO.16.00070","reference":"null. null. .","abstract":"Papapanagiotou et al. JCOPO, 2017"},{"pmid":"26324360","title":"Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2015 Dec 1","volume":"33","issue":"34","pages":"4099-105","authors":"Grisham RN et al","elocationId":"doi: 10.1200/JCO.2015.62.4726","link":null,"reference":"Grisham RN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Dec 1;33(34)4099-105.","abstract":null},{"pmid":"30867592","title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms.","journal":"Nature","pubDate":"2019 Mar","volume":"567","issue":"7749","pages":"521-524","authors":"Diamond EL et al","elocationId":"doi: 10.1038/s41586-019-1012-y","link":null,"reference":"Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.","abstract":null},{"pmid":"25351745","title":"MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2015 Apr 15","volume":"21","issue":"8","pages":"1935-43","authors":"Arcila ME et al","elocationId":"doi: 10.1158/1078-0432.CCR-14-2124","link":null,"reference":"Arcila ME et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Apr 15;21(8)1935-43.","abstract":null}]},{"id":9614,"uuid":"997c0971-b8cd-4132-b5b3-750ce2129d12","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":873,"subtype":"","code":"","color":"HotPink","mainType":"Breast Cancer","level":0,"tissue":"Breast","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2099,"hugoSymbol":"ESR1","oncogene":true,"grch37Isoform":"ENST00000206249","grch37RefSeq":"NM_001122740.1","grch38Isoform":"ENST00000206249","grch38RefSeq":"NM_001122740.1","geneAliases":["ESR","ESTRR","Era","ER","ESRA","NR3A1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2099,"hugoSymbol":"ESR1","oncogene":true,"grch37Isoform":"ENST00000206249","grch37RefSeq":"NM_001122740.1","grch38Isoform":"ENST00000206249","grch38RefSeq":"NM_001122740.1","geneAliases":["ESR","ESTRR","Era","ER","ESRA","NR3A1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C122834","drugName":"AZD9496","uuid":"90affda7-d416-4e37-9152-0a1531578dea","synonyms":["\"(E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid","AZD-9496","AZD 9496","Selective Estrogen Receptor Degrader AZD9496\"","Selective Estrogen Receptor Degrader AZD9496","SERD AZD9496"],"priority":1}]},{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C1379","drugName":"Fulvestrant","uuid":"b25af9e9-2195-4f16-90ea-7c21fcf3882d","synonyms":["ICI 182,780","ICI 182780","FULVESTRANT","Faslodex(ICI 182,780)","ZD9238","\"7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol","Faslodex","fulvestrant\"","Fulvestrant"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1578466308000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"31563959","title":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.","journal":"JAMA oncology","pubDate":"2019 Sep 29","volume":"","issue":"","pages":"","authors":"Sledge GW Jr et al","elocationId":"doi: 10.1001/jamaoncol.2019.4782","link":null,"reference":"Sledge GW Jr et al. JAMA oncology. 2019 Sep 29;().","abstract":null},{"pmid":"27986707","title":"Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists.","journal":"Cancer discovery","pubDate":"2017 Mar","volume":"7","issue":"3","pages":"277-287","authors":"Toy W et al","elocationId":"doi: 10.1158/2159-8290.CD-15-1523","link":null,"reference":"Toy W et al. Cancer discovery. 2017 Mar;7(3)277-287.","abstract":null},{"pmid":"27269946","title":"Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2016 Sep 1","volume":"34","issue":"25","pages":"2961-8","authors":"Fribbens C et al","elocationId":"doi: 10.1200/JCO.2016.67.3061","link":null,"reference":"Fribbens C et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Sep 1;34(25)2961-8.","abstract":null}]},{"id":10062,"uuid":"a818b112-6279-466f-acb8-398b9bd9f7f8","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":466,"subtype":"Lung Squamous Cell Carcinoma","code":"LUSC","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":3,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2260,"hugoSymbol":"FGFR1","oncogene":true,"grch37Isoform":"ENST00000425967","grch37RefSeq":"NM_001174067.1","grch38Isoform":"ENST00000425967","grch38RefSeq":"NM_001174067.1","geneAliases":["FLG","N-SAM","FLT2","ECCL","CEK","HBGFR","HRTFDS","BFGFR","FGFR-1","FLT-2","OGD","FGFBR","HH2","bFGF-R-1","CD331","KAL2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2260,"hugoSymbol":"FGFR1","oncogene":true,"grch37Isoform":"ENST00000425967","grch37RefSeq":"NM_001174067.1","grch38Isoform":"ENST00000425967","grch38RefSeq":"NM_001174067.1","geneAliases":["FLG","N-SAM","FLT2","ECCL","CEK","HBGFR","HRTFDS","BFGFR","FGFR-1","FLT-2","OGD","FGFBR","HH2","bFGF-R-1","CD331","KAL2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Amplification","name":"Amplification","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C88302","drugName":"BGJ398","uuid":"dcbc3088-5056-487b-bc2f-da930840dfff","synonyms":["\"3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea","BGJ-398","Infigratinib\"","INFIGRATINIB","Infigratinib"],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C111988","drugName":"Debio1347","uuid":"91859b88-74e8-4c71-98ce-70746997d61b","synonyms":["CH5183284","Debiopharm 1347","FF284","FGFR Inhibitor Debio 1347","debio 1347","debio 1347-101"],"priority":1}]},{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C103273","drugName":"Erdafitinib","uuid":"f2e41d69-c383-4e33-ba25-0bf5f837db11","synonyms":["\"1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-","Balversa","Erdafitinib","JNJ-42756493\"","ERDAFITINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1610322606000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"23082000","title":"Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2012 Dec 15","volume":"18","issue":"24","pages":"6658-67","authors":"Zhang J et al","elocationId":"doi: 10.1158/1078-0432.CCR-12-2694","link":null,"reference":"Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.","abstract":null},{"pmid":"21160078","title":"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.","journal":"Science translational medicine","pubDate":"2010 Dec 15","volume":"2","issue":"62","pages":"62ra93","authors":"Weiss J et al","elocationId":"doi: 10.1126/scitranslmed.3001451","link":null,"reference":"Weiss J et al. Science translational medicine. 2010 Dec 15;2(62)62ra93.","abstract":null},{"pmid":"27870574","title":"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Jan 10","volume":"35","issue":"2","pages":"157-165","authors":"Nogova L et al","elocationId":"","link":null,"reference":"Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.","abstract":null},{"pmid":"30745300","title":"A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 May 1","volume":"25","issue":"9","pages":"2699-2707","authors":"Voss MH et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-1959","link":null,"reference":"Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.","abstract":null}]},{"id":6608,"uuid":"b0768fa7-14d7-4226-ad60-187c8491a27f","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"729_761ins","name":"Exon 19 insertion","refResidues":null,"proteinStart":729,"proteinEnd":761,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C65530","drugName":"Erlotinib","uuid":"83754311-3f3b-4782-bfbf-08e71c790b9a","synonyms":["Erlotinib","erlotinib","ERLOTINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1582153104000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"29340050","title":"Molecular characteristics and clinical outcomes of <i>EGFR</i> exon 19 indel subtypes to EGFR TKIs in NSCLC patients.","journal":"Oncotarget","pubDate":"2017 Dec 19","volume":"8","issue":"67","pages":"111246-111257","authors":"Su J et al","elocationId":"doi: 10.18632/oncotarget.22768","link":null,"reference":"Su J et al. Oncotarget. 2017 Dec 19;8(67)111246-111257.","abstract":null},{"pmid":"23387505","title":"Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.","journal":"Cancer science","pubDate":"2013 May","volume":"104","issue":"5","pages":"584-9","authors":"Furuyama K et al","elocationId":"doi: 10.1111/cas.12125","link":null,"reference":"Furuyama K et al. Cancer science. 2013 May;104(5)584-9.","abstract":null},{"pmid":"28336552","title":"Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.","journal":"Cancer discovery","pubDate":"2017 Jun","volume":"7","issue":"6","pages":"596-609","authors":"Jordan EJ et al","elocationId":"doi: 10.1158/2159-8290.CD-16-1337","link":null,"reference":"Jordan EJ et al. Cancer discovery. 2017 Jun;7(6)596-609.","abstract":null},{"pmid":"31562956","title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.","journal":"Seminars in cancer biology","pubDate":"2020 Apr","volume":"61","issue":"","pages":"167-179","authors":"Harrison PT et al","elocationId":"doi: 10.1016/j.semcancer.2019.09.015","link":null,"reference":"Harrison PT et al. Seminars in cancer biology. 2020 Apr;61()167-179.","abstract":null},{"pmid":"22190593","title":"EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2012 Mar 15","volume":"18","issue":"6","pages":"1790-7","authors":"He M et al","elocationId":"doi: 10.1158/1078-0432.CCR-11-2361","link":null,"reference":"He M et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Mar 15;18(6)1790-7.","abstract":null},{"pmid":"21841502","title":"Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2011 Nov","volume":"6","issue":"11","pages":"1895-901","authors":"De Pas T et al","elocationId":"doi: 10.1097/JTO.0b013e318227e8c6","link":null,"reference":"De Pas T et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Nov;6(11)1895-901.","abstract":null},{"pmid":"24389445","title":"An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","pubDate":"2013 Dec","volume":"8","issue":"12","pages":"e107-8","authors":"Chan AW et al","elocationId":"doi: 10.1097/JTO.0b013e3182a471e0","link":null,"reference":"Chan AW et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Dec;8(12)e107-8.","abstract":null},{"pmid":"25279299","title":"Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib.","journal":"SpringerPlus","pubDate":"2014","volume":"3","issue":"","pages":"507","authors":"Agbarya A et al","elocationId":"doi: 10.1186/2193-1801-3-507","link":null,"reference":"Agbarya A et al. SpringerPlus. 2014;3()507.","abstract":null}]},{"id":9425,"uuid":"49381d96-d806-4f46-9710-ec93e8a5d4e0","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":900,"subtype":"","code":"","color":"Yellow","mainType":"Bladder Cancer","level":0,"tissue":"Bladder/Urinary Tract","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2068,"hugoSymbol":"ERCC2","oncogene":false,"grch37Isoform":"ENST00000391945","grch37RefSeq":"NM_000400.3","grch38Isoform":"ENST00000391945","grch38RefSeq":"NM_000400.3","geneAliases":["EM9","TTD","TTD1","COFS2","XPD"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":2068,"hugoSymbol":"ERCC2","oncogene":false,"grch37Isoform":"ENST00000391945","grch37RefSeq":"NM_000400.3","grch38Isoform":"ENST00000391945","grch38RefSeq":"NM_000400.3","geneAliases":["EM9","TTD","TTD1","COFS2","XPD"],"genesets":[],"tsg":true},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C376","drugName":"Cisplatin","uuid":"8560cf52-1857-41cb-8d37-e10a597d47b3","synonyms":["Cisplatyl","Cisplatina","Cis-platinum","Platosin","Plastistil","Platinol","Platiblastin","\"(SP-4-2)-Diamminedichloroplatinum","Cis-diammine-dichloroplatinum","Citoplatino","Cis-diamminedichloro Platinum (II)","Placis","Cismaplat","Platiblastin-S","Platinum, Diaminedichloro-, cis- (8CI)","Platistin","Neoplatin","Platinol-AQ VHA Plus","cisplatin\"","DDP","Peyrone's Salt","Platinum Diamminodichloride","CISPLATIN","Platinum","Lederplatin","Platinol- AQ","Briplatin","Abiplatin","Platamine","Metaplatin","Blastolem","Cysplatyna","Platinoxan","Cis-platinum II Diamine Dichloride","Cisplatin","Cisplatinum","Cis-diamminedichloridoplatinum","CDDP","Citosin","Cis-platinum II","Cis-platinous Diamine Dichloride","Platinol-AQ","Peyrone's Chloride","Cis-dichloroammine Platinum (II)","Platiran","Cis-diamminedichloroplatinum","Platinex"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1556061485000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"29980530","title":"<i>ERCC2</i> Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 Feb 1","volume":"25","issue":"3","pages":"977-988","authors":"Li Q et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-1001","link":null,"reference":"Li Q et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Feb 1;25(3)977-988.","abstract":null},{"pmid":"25096233","title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.","journal":"Cancer discovery","pubDate":"2014 Oct","volume":"4","issue":"10","pages":"1140-53","authors":"Van Allen EM et al","elocationId":"doi: 10.1158/2159-8290.CD-14-0623","link":null,"reference":"Van Allen EM et al. Cancer discovery. 2014 Oct;4(10)1140-53.","abstract":null},{"pmid":"12208738","title":"Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells.","journal":"Cancer research","pubDate":"2002 Sep 1","volume":"62","issue":"17","pages":"4899-902","authors":"Furuta T et al","elocationId":"","link":null,"reference":"Furuta T et al. Cancer research. 2002 Sep 1;62(17)4899-902.","abstract":null},{"pmid":"27310333","title":"Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.","journal":"JAMA oncology","pubDate":"2016 Aug 1","volume":"2","issue":"8","pages":"1094-6","authors":"Liu D et al","elocationId":"doi: 10.1001/jamaoncol.2016.1056","link":null,"reference":"Liu D et al. JAMA oncology. 2016 Aug 1;2(8)1094-6.","abstract":null}]},{"id":6609,"uuid":"e6471870-a4b5-461a-a9c1-24e5d0ddbc93","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":1956,"hugoSymbol":"EGFR","oncogene":true,"grch37Isoform":"ENST00000275493","grch37RefSeq":"NM_005228.3","grch38Isoform":"ENST00000275493","grch38RefSeq":"NM_005228.3","geneAliases":["PIG61","ERBB1","mENA","ERBB","HER1","NISBD2"],"genesets":[],"tsg":false},"consequence":{"term":"inframe_insertion","isGenerallyTruncating":false,"description":"An inframe non synonymous variant that inserts bases into in the coding sequence"},"alteration":"729_761ins","name":"Exon 19 insertion","refResidues":null,"proteinStart":729,"proteinEnd":761,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C1855","drugName":"Gefitinib","uuid":"b76d7b2b-b5fb-4561-892f-6b00bfaf0dfa","synonyms":["GEFITINIB","Iressa","N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine","ZD 1839","gefitinib","Gefitinib","4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline","ZD1839"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1582153186000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"29340050","title":"Molecular characteristics and clinical outcomes of <i>EGFR</i> exon 19 indel subtypes to EGFR TKIs in NSCLC patients.","journal":"Oncotarget","pubDate":"2017 Dec 19","volume":"8","issue":"67","pages":"111246-111257","authors":"Su J et al","elocationId":"doi: 10.18632/oncotarget.22768","link":null,"reference":"Su J et al. Oncotarget. 2017 Dec 19;8(67)111246-111257.","abstract":null},{"pmid":"22190593","title":"EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2012 Mar 15","volume":"18","issue":"6","pages":"1790-7","authors":"He M et al","elocationId":"doi: 10.1158/1078-0432.CCR-11-2361","link":null,"reference":"He M et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Mar 15;18(6)1790-7.","abstract":null},{"pmid":"28089594","title":"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer.","journal":"Clinical lung cancer","pubDate":"2017 May","volume":"18","issue":"3","pages":"324-332.e1","authors":"Lin YT et al","elocationId":"doi: 10.1016/j.cllc.2016.12.014","link":null,"reference":"Lin YT et al. Clinical lung cancer. 2017 May;18(3)324-332.e1.","abstract":null},{"pmid":"20075572","title":"Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis.","journal":"Internal medicine (Tokyo, Japan)","pubDate":"2010","volume":"49","issue":"2","pages":"103-7","authors":"Uruga H et al","elocationId":"","link":null,"reference":"Uruga H et al. Internal medicine (Tokyo, Japan). 2010;49(2)103-7.","abstract":null}]},{"id":2259,"uuid":"e569bfd4-15f5-421d-9d4e-31dfb7a82903","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":880,"subtype":"","code":"","color":"LightBlue","mainType":"Ovarian Cancer","level":0,"tissue":"Ovary/Fallopian Tube","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C68923","drugName":"Cobimetinib","uuid":"eb357145-3b18-4aca-b75a-5e18dd2bf4f9","synonyms":["Cotellic","Cobimetinib","XL518","COBIMETINIB","GDC-0973","MEK Inhibitor GDC-0973"],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C77908","drugName":"Trametinib","uuid":"fb2bb01c-c0ec-4641-abf7-87f486075022","synonyms":["Mekinist","\"GSK1120212","Trametinib\"","TRAMETINIB","JTP-74057","MEK Inhibitor GSK1120212","N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","Trametinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1596220727000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"24345920","title":"BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2013 Dec 15","volume":"19","issue":"24","pages":"6696-702","authors":"Hutchinson KE et al","elocationId":"doi: 10.1158/1078-0432.CCR-13-1746","link":null,"reference":"Hutchinson KE et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Dec 15;19(24)6696-702.","abstract":null},{"pmid":"26324360","title":"Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2015 Dec 1","volume":"33","issue":"34","pages":"4099-105","authors":"Grisham RN et al","elocationId":"doi: 10.1200/JCO.2015.62.4726","link":null,"reference":"Grisham RN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Dec 1;33(34)4099-105.","abstract":null}]},{"id":2261,"uuid":"cec96519-6479-4b9e-9d89-42e3b2a2bc94","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Fusions","name":"Fusions","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C68923","drugName":"Cobimetinib","uuid":"eb357145-3b18-4aca-b75a-5e18dd2bf4f9","synonyms":["Cotellic","Cobimetinib","XL518","COBIMETINIB","GDC-0973","MEK Inhibitor GDC-0973"],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C77908","drugName":"Trametinib","uuid":"fb2bb01c-c0ec-4641-abf7-87f486075022","synonyms":["Mekinist","\"GSK1120212","Trametinib\"","TRAMETINIB","JTP-74057","MEK Inhibitor GSK1120212","N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","Trametinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1596226241000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"26072686","title":"Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.","journal":"Pigment cell & melanoma research","pubDate":"2015 Sep","volume":"28","issue":"5","pages":"607-10","authors":"Menzies AM et al","elocationId":"doi: 10.1111/pcmr.12388","link":null,"reference":"Menzies AM et al. Pigment cell & melanoma research. 2015 Sep;28(5)607-10.","abstract":null},{"pmid":"24345920","title":"BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2013 Dec 15","volume":"19","issue":"24","pages":"6696-702","authors":"Hutchinson KE et al","elocationId":"doi: 10.1158/1078-0432.CCR-13-1746","link":null,"reference":"Hutchinson KE et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Dec 15;19(24)6696-702.","abstract":null},{"pmid":"26314551","title":"The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.","journal":"International journal of cancer","pubDate":"2016 Feb 15","volume":"138","issue":"4","pages":"881-90","authors":"Ross JS et al","elocationId":"doi: 10.1002/ijc.29825","link":null,"reference":"Ross JS et al. International journal of cancer. 2016 Feb 15;138(4)881-90.","abstract":null}]},{"id":10518,"uuid":"15a7fa9e-f08e-4278-ab11-716d09ce4e20","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":900,"subtype":"","code":"","color":"Yellow","mainType":"Bladder Cancer","level":0,"tissue":"Bladder/Urinary Tract","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2261,"hugoSymbol":"FGFR3","oncogene":true,"grch37Isoform":"ENST00000260795","grch37RefSeq":"NM_000142.4","grch38Isoform":"ENST00000440486","grch38RefSeq":"NM_000142.4","geneAliases":["JTK4","HSFGFR3EX","ACH","CEK2","CD333"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2261,"hugoSymbol":"FGFR3","oncogene":true,"grch37Isoform":"ENST00000260795","grch37RefSeq":"NM_000142.4","grch38Isoform":"ENST00000440486","grch38RefSeq":"NM_000142.4","geneAliases":["JTK4","HSFGFR3EX","ACH","CEK2","CD333"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"K650","name":"K650","refResidues":"K","proteinStart":650,"proteinEnd":650,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2261,"hugoSymbol":"FGFR3","oncogene":true,"grch37Isoform":"ENST00000260795","grch37RefSeq":"NM_000142.4","grch38Isoform":"ENST00000440486","grch38RefSeq":"NM_000142.4","geneAliases":["JTK4","HSFGFR3EX","ACH","CEK2","CD333"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"G380R","name":"G380R","refResidues":"G","proteinStart":380,"proteinEnd":380,"variantResidues":"R","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2261,"hugoSymbol":"FGFR3","oncogene":true,"grch37Isoform":"ENST00000260795","grch37RefSeq":"NM_000142.4","grch38Isoform":"ENST00000440486","grch38RefSeq":"NM_000142.4","geneAliases":["JTK4","HSFGFR3EX","ACH","CEK2","CD333"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"S371C","name":"S371C","refResidues":"S","proteinStart":371,"proteinEnd":371,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C88302","drugName":"BGJ398","uuid":"dcbc3088-5056-487b-bc2f-da930840dfff","synonyms":["\"3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea","BGJ-398","Infigratinib\"","INFIGRATINIB","Infigratinib"],"priority":1}]},{"approvedIndications":[],"priority":3,"drugs":[{"ncitCode":"C103273","drugName":"Erdafitinib","uuid":"f2e41d69-c383-4e33-ba25-0bf5f837db11","synonyms":["\"1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-","Balversa","Erdafitinib","JNJ-42756493\"","ERDAFITINIB"],"priority":1}]},{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C111988","drugName":"Debio1347","uuid":"91859b88-74e8-4c71-98ce-70746997d61b","synonyms":["CH5183284","Debiopharm 1347","FF284","FGFR Inhibitor Debio 1347","debio 1347","debio 1347-101"],"priority":1}]},{"approvedIndications":[],"priority":4,"drugs":[{"ncitCode":"C88272","drugName":"AZD4547","uuid":"ea736f8d-c242-45d0-96d2-225a6553bd89","synonyms":["FGFR Inhibitor AZD4547"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1608334088000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"27870574","title":"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2017 Jan 10","volume":"35","issue":"2","pages":"157-165","authors":"Nogova L et al","elocationId":"","link":null,"reference":"Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://meetinglibrary.asco.org/record/160559/abstract","reference":"null. null. .","abstract":"Siefker-Radtke et al. Abstract#4503, ASCO 2018"},{"pmid":"30745300","title":"A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 May 1","volume":"25","issue":"9","pages":"2699-2707","authors":"Voss MH et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-1959","link":null,"reference":"Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.","abstract":null},{"pmid":"21119661","title":"Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.","journal":"British journal of cancer","pubDate":"2011 Jan 4","volume":"104","issue":"1","pages":"75-82","authors":"Lamont FR et al","elocationId":"doi: 10.1038/sj.bjc.6606016","link":null,"reference":"Lamont FR et al. British journal of cancer. 2011 Jan 4;104(1)75-82.","abstract":null},{"pmid":"31088831","title":"Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2019 Aug 15","volume":"25","issue":"16","pages":"4888-4897","authors":"Bahleda R et al","elocationId":"doi: 10.1158/1078-0432.CCR-18-3334","link":null,"reference":"Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.","abstract":null},{"pmid":"26324363","title":"Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2015 Oct 20","volume":"33","issue":"30","pages":"3401-8","authors":"Tabernero J et al","elocationId":"doi: 10.1200/JCO.2014.60.7341","link":null,"reference":"Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.","abstract":null},{"pmid":"29848605","title":"Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations.","journal":"Cancer discovery","pubDate":"2018 Jul","volume":"8","issue":"7","pages":"812-821","authors":"Pal SK et al","elocationId":"doi: 10.1158/2159-8290.CD-18-0229","link":null,"reference":"Pal SK et al. Cancer discovery. 2018 Jul;8(7)812-821.","abstract":null}]},{"id":1111,"uuid":"8cbf590d-fda9-4403-a27e-08fd50123452","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":369,"hugoSymbol":"ARAF","oncogene":true,"grch37Isoform":"ENST00000377045","grch37RefSeq":"NM_001654.4","grch38Isoform":"ENST00000377045","grch38RefSeq":"NM_001654.4","geneAliases":["ARAF1","A-RAF","RAFA1","PKS2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":369,"hugoSymbol":"ARAF","oncogene":true,"grch37Isoform":"ENST00000377045","grch37RefSeq":"NM_001654.4","grch38Isoform":"ENST00000377045","grch38RefSeq":"NM_001654.4","geneAliases":["ARAF1","A-RAF","RAFA1","PKS2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C61948","drugName":"Sorafenib","uuid":"b20f2bb4-5a53-40ff-8e26-acbd42df4e8b","synonyms":["BA4 43 9006","sorafenib","Bay-439006","Sorafenib","SORAFENIB","BAY 43-9006"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1517438341000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"24569458","title":"Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.","journal":"The Journal of clinical investigation","pubDate":"2014 Apr","volume":"124","issue":"4","pages":"1582-6","authors":"Imielinski M et al","elocationId":"doi: 10.1172/JCI72763","link":null,"reference":"Imielinski M et al. The Journal of clinical investigation. 2014 Apr;124(4)1582-6.","abstract":null}]},{"id":1113,"uuid":"6e24e8cf-fb38-4166-a540-5827b59779ac","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":934,"subtype":"","code":"","color":"LightSalmon","mainType":"Histiocytosis","level":0,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":369,"hugoSymbol":"ARAF","oncogene":true,"grch37Isoform":"ENST00000377045","grch37RefSeq":"NM_001654.4","grch38Isoform":"ENST00000377045","grch38RefSeq":"NM_001654.4","geneAliases":["ARAF1","A-RAF","RAFA1","PKS2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":369,"hugoSymbol":"ARAF","oncogene":true,"grch37Isoform":"ENST00000377045","grch37RefSeq":"NM_001654.4","grch38Isoform":"ENST00000377045","grch38RefSeq":"NM_001654.4","geneAliases":["ARAF1","A-RAF","RAFA1","PKS2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C61948","drugName":"Sorafenib","uuid":"b20f2bb4-5a53-40ff-8e26-acbd42df4e8b","synonyms":["BA4 43 9006","sorafenib","Bay-439006","Sorafenib","SORAFENIB","BAY 43-9006"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1517438364000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"26566875","title":"Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.","journal":"Cancer discovery","pubDate":"2016 Feb","volume":"6","issue":"2","pages":"154-65","authors":"Diamond EL et al","elocationId":"doi: 10.1158/2159-8290.CD-15-0913","link":null,"reference":"Diamond EL et al. Cancer discovery. 2016 Feb;6(2)154-65.","abstract":null},{"pmid":"24569458","title":"Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.","journal":"The Journal of clinical investigation","pubDate":"2014 Apr","volume":"124","issue":"4","pages":"1582-6","authors":"Imielinski M et al","elocationId":"doi: 10.1172/JCI72763","link":null,"reference":"Imielinski M et al. The Journal of clinical investigation. 2014 Apr;124(4)1582-6.","abstract":null}]},{"id":2073,"uuid":"483bc890-60e3-4c65-96e5-94f5412df6dc","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":934,"subtype":"","code":"","color":"LightSalmon","mainType":"Histiocytosis","level":0,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C68923","drugName":"Cobimetinib","uuid":"eb357145-3b18-4aca-b75a-5e18dd2bf4f9","synonyms":["Cotellic","Cobimetinib","XL518","COBIMETINIB","GDC-0973","MEK Inhibitor GDC-0973"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1567665374000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29236635","title":"Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.","journal":"The New England journal of medicine","pubDate":"2017 Dec 14","volume":"377","issue":"24","pages":"2398-2399","authors":"Jacobsen E et al","elocationId":"doi: 10.1056/NEJMc1713676","link":null,"reference":"Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.","abstract":null},{"pmid":"30718231","title":"Clinical responses and persistent <i>BRAF</i> V600E<sup>+</sup> blood cells in children with LCH treated with MAPK pathway inhibition.","journal":"Blood","pubDate":"2019 Apr 11","volume":"133","issue":"15","pages":"1691-1694","authors":"Eckstein OS et al","elocationId":"doi: 10.1182/blood-2018-10-878363","link":null,"reference":"Eckstein OS et al. Blood. 2019 Apr 11;133(15)1691-1694.","abstract":null},{"pmid":"30867592","title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms.","journal":"Nature","pubDate":"2019 Mar","volume":"567","issue":"7749","pages":"521-524","authors":"Diamond EL et al","elocationId":"doi: 10.1038/s41586-019-1012-y","link":null,"reference":"Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.","abstract":null}]},{"id":1114,"uuid":"4883b824-954f-4da1-a09a-ea5e39951301","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":934,"subtype":"","code":"","color":"LightSalmon","mainType":"Histiocytosis","level":0,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":369,"hugoSymbol":"ARAF","oncogene":true,"grch37Isoform":"ENST00000377045","grch37RefSeq":"NM_001654.4","grch38Isoform":"ENST00000377045","grch38RefSeq":"NM_001654.4","geneAliases":["ARAF1","A-RAF","RAFA1","PKS2"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":369,"hugoSymbol":"ARAF","oncogene":true,"grch37Isoform":"ENST00000377045","grch37RefSeq":"NM_001654.4","grch38Isoform":"ENST00000377045","grch38RefSeq":"NM_001654.4","geneAliases":["ARAF1","A-RAF","RAFA1","PKS2"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"Oncogenic Mutations","name":"Oncogenic Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":2,"drugs":[{"ncitCode":"C68923","drugName":"Cobimetinib","uuid":"eb357145-3b18-4aca-b75a-5e18dd2bf4f9","synonyms":["Cotellic","Cobimetinib","XL518","COBIMETINIB","GDC-0973","MEK Inhibitor GDC-0973"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1572033759000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"29236635","title":"Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.","journal":"The New England journal of medicine","pubDate":"2017 Dec 14","volume":"377","issue":"24","pages":"2398-2399","authors":"Jacobsen E et al","elocationId":"doi: 10.1056/NEJMc1713676","link":null,"reference":"Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.","abstract":null},{"pmid":"30867592","title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms.","journal":"Nature","pubDate":"2019 Mar","volume":"567","issue":"7749","pages":"521-524","authors":"Diamond EL et al","elocationId":"doi: 10.1038/s41586-019-1012-y","link":null,"reference":"Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.","abstract":null}]},{"id":27,"uuid":"eb9c6197-152f-4a34-94a1-3c4f269f0695","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":560,"subtype":"Chronic Myelogenous Leukemia","code":"CML","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":25,"hugoSymbol":"ABL1","oncogene":true,"grch37Isoform":"ENST00000318560","grch37RefSeq":"NM_005157.4","grch38Isoform":"ENST00000318560","grch38RefSeq":"NM_005157.4","geneAliases":["v-abl","bcr/abl","JTK7","BCR-ABL","c-ABL1","c-ABL","ABL","CHDSKM"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"BCR-ABL1 Fusion","name":"BCR-ABL1 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C114494","drugName":"Asciminib","uuid":"1e3c2981-4cc6-43e7-be76-b479050ebdca","synonyms":["ABL001","ASCIMINIB","Asciminib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1578465399000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"31826340","title":"Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.","journal":"The New England journal of medicine","pubDate":"2019 Dec 12","volume":"381","issue":"24","pages":"2315-2326","authors":"Hughes TP et al","elocationId":"doi: 10.1056/NEJMoa1902328","link":null,"reference":"Hughes TP et al. The New England journal of medicine. 2019 Dec 12;381(24)2315-2326.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"http://abstracts.asco.org/214/AbstView_214_220317.html","reference":"null. null. .","abstract":"Mauro, M. et al. Abstract# TPS7081, ASCO 2018"}]},{"id":15964,"uuid":"772760b5-05f2-448a-972a-0a49886c31aa","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":875,"subtype":"","code":"","color":"Orange","mainType":"Renal Cell Carcinoma","level":0,"tissue":"Kidney","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2475,"hugoSymbol":"MTOR","oncogene":true,"grch37Isoform":"ENST00000361445","grch37RefSeq":"NM_004958.3","grch38Isoform":"ENST00000361445","grch38RefSeq":"NM_004958.3","geneAliases":["FRAP1","RAFT1","FRAP2","FRAP","SKS","RAPT1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2475,"hugoSymbol":"MTOR","oncogene":true,"grch37Isoform":"ENST00000361445","grch37RefSeq":"NM_004958.3","grch38Isoform":"ENST00000361445","grch38RefSeq":"NM_004958.3","geneAliases":["FRAP1","RAFT1","FRAP2","FRAP","SKS","RAPT1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L1460P","name":"L1460P","refResidues":"L","proteinStart":1460,"proteinEnd":1460,"variantResidues":"P","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2475,"hugoSymbol":"MTOR","oncogene":true,"grch37Isoform":"ENST00000361445","grch37RefSeq":"NM_004958.3","grch38Isoform":"ENST00000361445","grch38RefSeq":"NM_004958.3","geneAliases":["FRAP1","RAFT1","FRAP2","FRAP","SKS","RAPT1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L2427Q","name":"L2427Q","refResidues":"L","proteinStart":2427,"proteinEnd":2427,"variantResidues":"Q","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2475,"hugoSymbol":"MTOR","oncogene":true,"grch37Isoform":"ENST00000361445","grch37RefSeq":"NM_004958.3","grch38Isoform":"ENST00000361445","grch38RefSeq":"NM_004958.3","geneAliases":["FRAP1","RAFT1","FRAP2","FRAP","SKS","RAPT1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"L2209V","name":"L2209V","refResidues":"L","proteinStart":2209,"proteinEnd":2209,"variantResidues":"V","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C1844","drugName":"Temsirolimus","uuid":"234f5a9c-00e4-4447-8389-53e9b3fe4a26","synonyms":["CCI-779 Rapamycin Analog","temsirolimus","42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin","CCI-779","Torisel","TEMSIROLIMUS","Rapamycin Analog CCI-779","Temsirolimus","Rapamycin Analog","Cell Cycle Inhibitor 779"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1598903192000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"26831717","title":"Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2016 May 15","volume":"22","issue":"10","pages":"2445-2452","authors":"Kwiatkowski DJ et al","elocationId":"doi: 10.1158/1078-0432.CCR-15-2631","link":null,"reference":"Kwiatkowski DJ et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 May 15;22(10)2445-2452.","abstract":null}]},{"id":13213,"uuid":"fbf3c505-3024-480d-99b1-e6df9c49e451","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":876,"subtype":"","code":"","color":"Gainsboro","mainType":"Non-Small Cell Lung Cancer","level":0,"tissue":"Lung","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3845,"hugoSymbol":"KRAS","oncogene":true,"grch37Isoform":"ENST00000311936","grch37RefSeq":"NM_004985","grch38Isoform":"ENST00000311936","grch38RefSeq":"NM_004985","geneAliases":["KI-RAS","RALD","NS","c-Ki-ras2","RASK2","CFC2","K-RAS2B","K-RAS2A","K-RAS4B","NS3","K-RAS4A","K-Ras","c-Ki-ras","C-K-RAS","K-Ras 2","OES","'C-K-RAS","KRAS2","KRAS1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"G12C","name":"G12C","refResidues":"G","proteinStart":12,"proteinEnd":12,"variantResidues":"C","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C154287","drugName":"AMG-510","uuid":"7d507726-ed2e-4f65-a35a-0e1e88984278","synonyms":["AMG510","KRAS Mutant-targeting AMG 510","AMG 510"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1605237942000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"31666701","title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.","journal":"Nature","pubDate":"2019 Nov","volume":"575","issue":"7781","pages":"217-223","authors":"Canon J et al","elocationId":"doi: 10.1038/s41586-019-1694-1","link":null,"reference":"Canon J et al. Nature. 2019 Nov;575(7781)217-223.","abstract":null},{"pmid":"32955176","title":"KRAS<sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors.","journal":"The New England journal of medicine","pubDate":"2020 Sep 24","volume":"383","issue":"13","pages":"1207-1217","authors":"Hong DS et al","elocationId":"doi: 10.1056/NEJMoa1917239","link":null,"reference":"Hong DS et al. The New England journal of medicine. 2020 Sep 24;383(13)1207-1217.","abstract":null},{"pmid":null,"title":null,"journal":null,"pubDate":null,"volume":null,"issue":null,"pages":null,"authors":null,"elocationId":null,"link":"https://oncologypro.esmo.org/Meeting-Resources/ESMO-2019-Congress/Phase-1-Study-of-AMG-510-a-Novel-Molecule-Targeting-KRAS-G12C-Mutant-Solid-Tumors","reference":"null. null. .","abstract":"Govindan et al. Abstract# ESMO 2019"}]},{"id":15967,"uuid":"0f9318ac-c6d9-4a0c-b19a-b650a3dc840d","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":900,"subtype":"","code":"","color":"Yellow","mainType":"Bladder Cancer","level":0,"tissue":"Bladder/Urinary Tract","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":2475,"hugoSymbol":"MTOR","oncogene":true,"grch37Isoform":"ENST00000361445","grch37RefSeq":"NM_004958.3","grch38Isoform":"ENST00000361445","grch38RefSeq":"NM_004958.3","geneAliases":["FRAP1","RAFT1","FRAP2","FRAP","SKS","RAPT1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":2475,"hugoSymbol":"MTOR","oncogene":true,"grch37Isoform":"ENST00000361445","grch37RefSeq":"NM_004958.3","grch38Isoform":"ENST00000361445","grch38RefSeq":"NM_004958.3","geneAliases":["FRAP1","RAFT1","FRAP2","FRAP","SKS","RAPT1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E2014K","name":"E2014K","refResidues":"E","proteinStart":2014,"proteinEnd":2014,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]},{"gene":{"entrezGeneId":2475,"hugoSymbol":"MTOR","oncogene":true,"grch37Isoform":"ENST00000361445","grch37RefSeq":"NM_004958.3","grch38Isoform":"ENST00000361445","grch38RefSeq":"NM_004958.3","geneAliases":["FRAP1","RAFT1","FRAP2","FRAP","SKS","RAPT1"],"genesets":[],"tsg":false},"consequence":{"term":"missense_variant","isGenerallyTruncating":false,"description":"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved"},"alteration":"E2419K","name":"E2419K","refResidues":"E","proteinStart":2419,"proteinEnd":2419,"variantResidues":"K","referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":["Advanced kidney cancer, unresectable pancreatic neuroendocrine carcinomas, subependymal giant cell astrocytomas in the context of tuberous sclerosis and certain breast cancers."],"priority":1,"drugs":[{"ncitCode":"C48387","drugName":"Everolimus","uuid":"dacd7256-8305-466d-af04-bfd1c4e5dad5","synonyms":["RAD 001","everolimus\"","EVEROLIMUS","42-O-(2-Hydroxy)ethyl Rapamycin","Zortress","\"(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone","Certican","Votubia","Afinitor","RAD001","Everolimus"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1598901932000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"24625776","title":"Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.","journal":"Cancer discovery","pubDate":"2014 May","volume":"4","issue":"5","pages":"546-53","authors":"Wagle N et al","elocationId":"doi: 10.1158/2159-8290.CD-13-0353","link":null,"reference":"Wagle N et al. Cancer discovery. 2014 May;4(5)546-53.","abstract":null},{"pmid":"23551593","title":"Phase II study of everolimus in metastatic urothelial cancer.","journal":"BJU international","pubDate":"2013 Aug","volume":"112","issue":"4","pages":"462-70","authors":"Milowsky MI et al","elocationId":"doi: 10.1111/j.1464-410X.2012.11720.x","link":null,"reference":"Milowsky MI et al. BJU international. 2013 Aug;112(4)462-70.","abstract":null}]},{"id":19423,"uuid":"734c8867-d5fb-4385-a227-98c91e945bc7","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":865,"subtype":"","code":"","color":"Gray","mainType":"Embryonal Tumor","level":0,"tissue":"CNS/Brain","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":5727,"hugoSymbol":"PTCH1","oncogene":false,"grch37Isoform":"ENST00000331920","grch37RefSeq":"NM_000264.3","grch38Isoform":"ENST00000331920","grch38RefSeq":"NM_000264.3","geneAliases":["NBCCS","PTC1","BCNS","PTCH"],"genesets":[],"tsg":true},"alterations":[{"gene":{"entrezGeneId":5727,"hugoSymbol":"PTCH1","oncogene":false,"grch37Isoform":"ENST00000331920","grch37RefSeq":"NM_000264.3","grch38Isoform":"ENST00000331920","grch38RefSeq":"NM_000264.3","geneAliases":["NBCCS","PTC1","BCNS","PTCH"],"genesets":[],"tsg":true},"consequence":{"term":"feature_truncation","isGenerallyTruncating":true,"description":"A sequence variant that causes the reduction of a genomic feature, with regard to the reference sequence"},"alteration":"Truncating Mutations","name":"Truncating Mutations","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C82385","drugName":"Sonidegib","uuid":"6fd6144e-0186-4f5e-be60-4b16bc14b4b3","synonyms":["LDE-225","\"(1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- methyl-4'-(trifluoromethoxy)-, rel-","Smoothened Antagonist LDE225","Erismodegib","Sonidegib\"","Sonidegib","LDE225","SONIDEGIB","Odomzo"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1554443927000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"24900187","title":"Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.","journal":"ACS medicinal chemistry letters","pubDate":"2010 Jun 10","volume":"1","issue":"3","pages":"130-4","authors":"Pan S et al","elocationId":"doi: 10.1021/ml1000307","link":null,"reference":"Pan S et al. ACS medicinal chemistry letters. 2010 Jun 10;1(3)130-4.","abstract":null},{"pmid":"24523439","title":"A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2014 Apr 1","volume":"20","issue":"7","pages":"1900-9","authors":"Rodon J et al","elocationId":"doi: 10.1158/1078-0432.CCR-13-1710","link":null,"reference":"Rodon J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Apr 1;20(7)1900-9.","abstract":null}]},{"id":12064,"uuid":"1623c261-51cb-4d24-8b60-4035db438525","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":545,"subtype":"Chronic Eosinophilic Leukemia, NOS","code":"CELNOS","color":"LightSalmon","mainType":"Myeloproliferative Neoplasms","level":4,"tissue":"Myeloid","tumorForm":"LIQUID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":3717,"hugoSymbol":"JAK2","oncogene":true,"grch37Isoform":"ENST00000381652","grch37RefSeq":"NM_004972.3","grch38Isoform":"ENST00000381652","grch38RefSeq":"NM_004972.3","geneAliases":["JTK10"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"PCM1-JAK2 Fusion","name":"PCM1-JAK2 Fusion","refResidues":null,"proteinStart":-1,"proteinEnd":100000,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C77888","drugName":"Ruxolitinib","uuid":"25899e16-a7c3-4b60-bbca-77a64c85f28a","synonyms":["Ruxolitinib","Oral JAK Inhibitor INCB18424","\"(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile","INCB18424","Ruxolitinib\"","INCB-18424","RUXOLITINIB"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1517506085000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"NO","liquidPropagationLevel":"NO","articles":[{"pmid":"25207766","title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.","journal":"The New England journal of medicine","pubDate":"2014 Sep 11","volume":"371","issue":"11","pages":"1005-15","authors":"Roberts KG et al","elocationId":"doi: 10.1056/NEJMoa1403088","link":null,"reference":"Roberts KG et al. The New England journal of medicine. 2014 Sep 11;371(11)1005-15.","abstract":null},{"pmid":"25515960","title":"The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.","journal":"Blood","pubDate":"2015 Feb 19","volume":"125","issue":"8","pages":"1282-91","authors":"Schinnerl D et al","elocationId":"doi: 10.1182/blood-2014-04-570960","link":null,"reference":"Schinnerl D et al. Blood. 2015 Feb 19;125(8)1282-91.","abstract":null},{"pmid":"23630205","title":"Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubDate":"2013 Jun 10","volume":"31","issue":"17","pages":"e269-71","authors":"Rumi E et al","elocationId":"doi: 10.1200/JCO.2012.46.4370","link":null,"reference":"Rumi E et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jun 10;31(17)e269-71.","abstract":null},{"pmid":"23400675","title":"Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.","journal":"Annals of hematology","pubDate":"2013 Jun","volume":"92","issue":"6","pages":"759-69","authors":"Patterer V et al","elocationId":"doi: 10.1007/s00277-013-1695-3","link":null,"reference":"Patterer V et al. Annals of hematology. 2013 Jun;92(6)759-69.","abstract":null},{"pmid":"22875628","title":"Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements.","journal":"Haematologica","pubDate":"2013 Mar","volume":"98","issue":"3","pages":"404-8","authors":"Chase A et al","elocationId":"doi: 10.3324/haematol.2012.067959","link":null,"reference":"Chase A et al. Haematologica. 2013 Mar;98(3)404-8.","abstract":null},{"pmid":"26202607","title":"Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.","journal":"Annals of hematology","pubDate":"2015 Nov","volume":"94","issue":"11","pages":"1927-8","authors":"Rumi E et al","elocationId":"doi: 10.1007/s00277-015-2451-7","link":null,"reference":"Rumi E et al. Annals of hematology. 2015 Nov;94(11)1927-8.","abstract":null},{"pmid":"25260694","title":"Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.","journal":"Annals of hematology","pubDate":"2015 Feb","volume":"94","issue":"2","pages":"233-8","authors":"Schwaab J et al","elocationId":"doi: 10.1007/s00277-014-2221-y","link":null,"reference":"Schwaab J et al. Annals of hematology. 2015 Feb;94(2)233-8.","abstract":null},{"pmid":"22899477","title":"Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.","journal":"Blood","pubDate":"2012 Aug 16","volume":"120","issue":"7","pages":"1529-31","authors":"Lierman E et al","elocationId":"doi: 10.1182/blood-2012-06-433821","link":null,"reference":"Lierman E et al. Blood. 2012 Aug 16;120(7)1529-31.","abstract":null}]},{"id":2081,"uuid":"af5ea563-3d74-49e1-b931-ebb6f3fdeb43","evidenceType":"INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY","cancerTypes":[{"id":453,"subtype":"Melanoma","code":"MEL","color":"Black","mainType":"Melanoma","level":2,"tissue":"Skin","tumorForm":"SOLID"}],"relevantCancerTypes":[],"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"alterations":[{"gene":{"entrezGeneId":673,"hugoSymbol":"BRAF","oncogene":true,"grch37Isoform":"ENST00000288602","grch37RefSeq":"NM_004333.4","grch38Isoform":"ENST00000646891","grch38RefSeq":"NM_004333.4","geneAliases":["NS7","B-raf","BRAF1","RAFB1","B-RAF1"],"genesets":[],"tsg":false},"consequence":{"term":"NA","isGenerallyTruncating":false,"description":"NA"},"alteration":"L597","name":"L597","refResidues":"L","proteinStart":597,"proteinEnd":597,"variantResidues":null,"referenceGenomes":["GRCh38","GRCh37"]}],"description":"","additionalInfo":null,"treatments":[{"approvedIndications":[],"priority":1,"drugs":[{"ncitCode":"C77908","drugName":"Trametinib","uuid":"fb2bb01c-c0ec-4641-abf7-87f486075022","synonyms":["Mekinist","\"GSK1120212","Trametinib\"","TRAMETINIB","JTP-74057","MEK Inhibitor GSK1120212","N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","Trametinib"],"priority":1}]}],"knownEffect":"Sensitive","lastEdit":1555913141000,"lastReview":null,"levelOfEvidence":"LEVEL_3A","solidPropagationLevel":"LEVEL_3B","liquidPropagationLevel":"NO","articles":[{"pmid":"24933606","title":"Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.","journal":"Melanoma research","pubDate":"2014 Oct","volume":"24","issue":"5","pages":"504-8","authors":"Bowyer SE et al","elocationId":"doi: 10.1097/CMR.0000000000000099","link":null,"reference":"Bowyer SE et al. Melanoma research. 2014 Oct;24(5)504-8.","abstract":null},{"pmid":"22798288","title":"BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.","journal":"Cancer discovery","pubDate":"2012 Sep","volume":"2","issue":"9","pages":"791-7","authors":"Dahlman KB et al","elocationId":"","link":null,"reference":"Dahlman KB et al. Cancer discovery. 2012 Sep;2(9)791-7.","abstract":null},{"pmid":"29903896","title":"Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","pubDate":"2018 Dec 15","volume":"24","issue":"24","pages":"6483-6494","authors":"Dankner M et al","elocationId":"doi: 10.1158/1078-0432.CCR-17-3384","link":null,"reference":"Dankner M et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Dec 15;24(24)6483-6494.","abstract":null}]}]}